<SEC-DOCUMENT>0000950123-19-005898.txt : 20190920
<SEC-HEADER>0000950123-19-005898.hdr.sgml : 20190920
<ACCEPTANCE-DATETIME>20190607212644
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-19-005898
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		27
FILED AS OF DATE:		20190610
<PUBLIC-REL-DATE>20190920
DATE AS OF CHANGE:		20190607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02690
		FILM NUMBER:		19887431

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the United States
Securities and Exchange Commission and all information herein remains strictly confidential. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the
United States Securities and Exchange Commission on June 7, 2019. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">F-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES ACT
OF&nbsp;1933</B><B><I> </I></B><B> </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Innate Pharma S.A. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>France</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Primary Standard Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Classification Code Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(I.R.S.&nbsp;Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Identification&nbsp;Number)</P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Innate Pharma S.A. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>117 Avenue de Luminy&#151;BP 30191 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>13009 Marseille, France </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+
33 (0) 4 30 30 30 30 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive
offices) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Corporation Service Company </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1180 Avenue of the Americas, Suite 210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10036-8401 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(800) <FONT STYLE="white-space:nowrap">927-9801</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies of all communications, including communications sent to agent for service, should be sent to: </I></B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Richard Segal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Yvan-Claude Pierre</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Divakar
Gupta</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Brandon Fenn</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>500 Boylston
Street, 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02116</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+1 617 937 2300</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bertrand S&eacute;n&eacute;chal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Linklaters LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>25 rue de
Marignan</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>75008 Paris, France</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+33 1 56 43 56 43</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deanna L. Kirkpatrick</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Davis Polk&nbsp;&amp; Wardwell LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>450 Lexington Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New
York, NY 10017</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+1 212 450 4000</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Arnaud Duhamel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Th&eacute;ophile Strebelle</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gide&nbsp;Loyrette&nbsp;Nouel&nbsp;A.A.R.P.I.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>15 rue de Laborde</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>75008
Paris, France</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+33 1 40 75 60 00</B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public</B>: As soon as practicable after this Registration Statement becomes
effective. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act, check the following box:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or revised financial accounting standards&#134; provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Registration Fee </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of Securities to be Registered<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering&nbsp;Price<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration&nbsp;Fee<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ordinary shares, &#128;0.05 nominal value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All ordinary shares in the U.S. offering will be in the form of American Depositary Shares, or ADSs, with each ADS representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary share. ADSs
issuable upon deposit of the ordinary shares registered hereby are being registered pursuant to a separate registration statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes ordinary shares (which may be in the form of ADSs) that the underwriters have an option to purchase. See &#147;Underwriting.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes ordinary shares that are being offered in a private placement in Europe and other countries outside of the United States, but which may be resold from time to time in the United States in transactions requiring
registration under the Securities Act of 1933, as amended, or the Securities Act, or an exemption therefrom. The total number of ordinary shares (including shares in the form of ADSs) in the U.S. offering and the European private placement is
subject to reallocation between them to the extent permitted under applicable laws and regulations. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&nbsp;5, 2012.
</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in
any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>SUBJECT TO COMPLETION, DATED
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019 </B></FONT></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>PRELIMINARY
PROSPECTUS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ORDINARY SHARES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>(Including Ordinary Shares in the Form of American Depositary Shares) </I></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g14p44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per American Depositary Share
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Ordinary Share </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">We are offering an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in a global offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in the form of American Depositary Shares, or ADSs, in the
United States, referred to herein as the U.S. offering. Each ADS represents the right to receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary share and the ADSs may be evidenced by American Depositary Receipts, or
ADRs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">We are concurrently offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in Europe and
countries outside of the United States in a private placement, referred to herein as the European private placement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">This is our initial
public offering of our ADSs in the United States. We intend to apply to list our ADSs on the Nasdaq Global Market under the symbol &#147;IPHA.&#148; Our ordinary shares are listed on Euronext Paris under the symbol &#147;IPH.&#148; The final
offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros will be determined through negotiations between us and the representatives of the underwriters for the U.S. offering, and by reference to the
prevailing market prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors. On
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, the last reported sale price of our ordinary shares on Euronext Paris was
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, equivalent to a price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, assuming an exchange rate of &#128;1.00 = $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
the exchange rate on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">The closings of the U.S. offering and the European private placement, which are together referred to as the global offering, will occur
substantially simultaneously. The number of ordinary shares (including ordinary shares in the form of ADSs) in the U.S. offering and the European private placement is subject to reallocation between these offerings to the extent permitted under
applicable laws and regulations. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:11pt; font-family:Times New Roman"><B>Investing in our ADSs and ordinary shares involves a high degree of risk. See &#147;<A HREF="#toc752656_4">Risk Factors</A>&#148; beginning
on page 13 of this prospectus. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD style="width:31pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:31pt"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD style="width:17pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:17pt"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD style="width:14pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:14pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER&nbsp;ORDINARY</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Underwriting discounts<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; beginning on page 231 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable within 30 days from the date of this prospectus, to purchase up to an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares (which may be in the form of ADSs) at the offering price, less underwriting discounts. If the underwriters exercise this option in full, the total underwriting discounts
payable by us will be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) and the total proceeds to us, before expenses, will be
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">We are an &#147;emerging
growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission, or SEC, nor any U.S. state securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">The
underwriters expect to deliver the ADSs to the purchasers in the U.S. offering on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 through the book-entry facilities of The Depository
Trust Company. The underwriters expect to deliver the ordinary shares to purchasers in the European private placement on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 through the book-entry facilities of Euroclear France. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:20pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:20pt">
<TD VALIGN="top"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_1">PROSPECTUS SUMMARY</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_2">THE GLOBAL OFFERING</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_4">RISK FACTORS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_5">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_6">USE OF PROCEEDS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_7">DIVIDEND POLICY</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_8">CAPITALIZATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_9">DILUTION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_10">SELECTED CONSOLIDATED FINANCIAL DATA</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_11">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_12">BUSINESS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_13">MANAGEMENT</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_15">PRINCIPAL SHAREHOLDERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_16">DESCRIPTION OF SHARE CAPITAL</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_17">LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY</A></B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_18">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_19">SHARES AND ADSS ELIGIBLE FOR FUTURE SALE</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_20">MATERIAL UNITED STATES FEDERAL INCOME AND FRENCH TAX
CONSIDERATIONS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_21">ENFORCEMENT OF CIVIL LIABILITIES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_22">UNDERWRITING</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_23">EXPENSES RELATING TO THE GLOBAL OFFERING</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_24">LEGAL MATTERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_25">EXPERTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_26">WHERE YOU CAN FIND MORE INFORMATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_27">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>We are responsible for the information contained in this prospectus and any free-writing prospectus we prepare or authorize. We and the
underwriters have not authorized anyone to provide you with different information, and we and the underwriters take no responsibility for any other information others may give you. We are not, and the underwriters are not, making an offer to sell
these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than its date. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>For investors outside the United States: neither we nor any of the underwriters have done anything that would permit this offering or
possession or distribution of this prospectus or any free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this
prospectus or any free writing prospectus must inform themselves about, and observe any restrictions relating to, the global offering of the ADSs and ordinary shares and the distribution of this prospectus and any free writing prospectus outside the
United States. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated in France, and a majority of our outstanding securities are owned by <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> residents. Under the rules of the U.S. Securities and Exchange Commission, we are currently eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we will not be
required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements included in this prospectus are presented in euro and, unless
otherwise specified, all monetary amounts are in euro. All references in this prospectus to &#147;$,&#148; &#147;U.S. dollars,&#148; and &#147;dollars&#148; means U.S. dollars and all references to &#147;&#128;&#148; and &#147;euro,&#148; mean euro,
unless otherwise noted. Throughout this prospectus, references to ADSs mean ADSs or ordinary shares represented by such ADSs, as the case may be. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market, Industry and Other Data </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity and market size estimates, is based on information
from independent industry analysts, third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well as data from our
internal research, and are based on assumptions made by us based on such data and our knowledge of such industry and market, which we believe to be reasonable. In addition, while we believe the market opportunity information included in this
prospectus is reliable and is based on reasonable assumptions, such data involves risks and uncertainties and is subject to change based on various factors, including those discussed under the heading &#147;Risk Factors.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trademarks and Service Marks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Innate Pharma,&#148; the Innate Pharma logo and other trademarks or service marks of Innate Pharma S.A. appearing in this prospectus are
the property of Innate Pharma S.A. or its subsidiaries. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus are listed without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their right thereto. All other
trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. We do not intend to use or display other companies&#146; trademarks and trade names to imply any relationship with, or endorsement or
sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information you should consider
before investing in our ordinary shares (including ordinary shares in the form of ADSs). You should read the entire prospectus carefully, including &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements&#148;,
&#147;Business,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes appearing elsewhere in this prospectus before making an investment
decision. Unless otherwise indicated or the context otherwise requires, &#147;Innate Pharma&#148; &#147;the company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Innate Pharma S.A. and its consolidated
subsidiaries, taken as a whole. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company focused on discovering, developing and commercializing <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. We have a
<FONT STYLE="white-space:nowrap">20-year</FONT> history of research and development in immuno-oncology, having been pioneers in the understanding of natural killer cell, or NK cell, biology, and later expanding our expertise in the tumor
microenvironment, tumor antigens and antibody engineering fields. We have built, internally and through our business development strategy, a broad and diversified portfolio including an approved product, three clinical product candidates and a
robust preclinical pipeline. We have entered into collaborations with leaders in the biopharmaceutical industry, such as AstraZeneca and Sanofi, to leverage their development capabilities and expertise, and we have received upfront and milestone
payments and equity investments from our collaborations of an aggregate of approximately $550&nbsp;million over the last ten years. We may be eligible to receive an aggregate of approximately $5.5 billion in future contingent payments from existing
collaboration agreements and potential license agreements. We believe our product candidates and clinical development approach are differentiated from current immuno-oncology therapies and have the potential to significantly improve the clinical
outcome for patients with cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The immune system is the body&#146;s natural defense against invading organisms and pathogens and is
comprised of two arms: the innate immune system and adaptive immune system. Recent immunotherapy developments have focused on generating a tumor antigen-specific T cell response and have led to an unprecedented change in the treatment paradigm of
many solid tumor cancers. Despite these successes, the breadth and durability of the clinical benefit achieved has been limited to a subset of patients and tumor types. Our innovative approach to immuno-oncology aims to broaden and amplify
anti-tumoral immune responses by leveraging both the adaptive and the innate immune systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The innate immune system is comprised of a
variety of cells, including NK cells, which are involved in anti-cancer immunosurveillance through a variety of modalities. Activation of the innate immune system also helps trigger the adaptive immune system to elicit a response directed against
specific antigens and can provide durable immune memory. Our scientific expertise, strategic collaborations and discovery engine are focused on harnessing the potential of the innate immune system across three pillars. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g14i22.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a pipeline of innovative immunotherapies that we believe have the
potential to provide a significant clinical benefit to cancer patients. The following table summarizes our commercial, clinical and preclinical pipeline. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g59g66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&#147;SCCHN&#148; denotes Squamous Cell Carcinoma of the Head and Neck; &#147;CRC&#148; denotes Colorectal Cancer;
&#147;MF&#148; denotes Mycosis Fungoides; &#147;PTCL&#148; denotes Peripheral T-cell Lymphomas; &#147;NSCLC&#148; denotes Non-Small Cell Lung Cancer; and &#147;HCC&#148; denotes Hepatocellular Carcinoma. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development efforts are guided by our three pillars. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Broad spectrum immune checkpoint inhibitors</B>. We are targeting checkpoints expressed on NK cells and
myeloid cells, rather than focusing solely on T cells, in order to increase the pool of anti-tumor effector cells and potentially mount a larger anti-tumor response. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tumor antigen targeting</B>. We are developing antibodies that target tumor antigens in the form of
(i)&nbsp;antibody-drug conjugates, or ADCs, (ii)&nbsp;antibody-dependent cellular cytotoxicity, or ADCCs, inducing antibodies and (iii)&nbsp;antibody-based multi-specific NK cell engagers, or NKCEs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Suppressive factors of the TME</B>. We are developing product candidates that target suppressive pathways of
the TME in order to relieve the immunosuppression of the innate and adaptive immune responses. We are developing IPH5401, an anti-C5aR antibody that disrupts the complement pathway. In addition, we are developing product candidates that disrupt the
adenosine pathway, including IPH5201, an anti-CD39 antibody, and IPH5301, an anti-CD73 antibody. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our key competitive strengths are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our lead product candidate, monalizumab, which we are developing in collaboration with AstraZeneca for the
treatment of SCCHN, CRC and other solid tumors, is a novel, dual-targeting checkpoint</I></B> <B><I>inhibitor that has shown promising clinical data.</I></B> Monalizumab is a humanized antibody that is capable of acting on NK cells and CD8+ T cells
in order to activate both innate and adaptive immune responses. We believe these properties may allow monalizumab, in combination with other therapies, to address some of the limitations of current therapies that only target T cells and potentially
provide a chemotherapy free therapeutic alternative in earlier lines of treatment. Preliminary data from a Phase II expansion cohort of 40 patients with R/M SCCHN previously treated with chemotherapy alone or chemotherapy followed by <FONT
STYLE="white-space:nowrap">PD-1/L1</FONT> checkpoint inhibitors, showed an overall response rate to monalizumab in combination with cetuximab of 27.5%, including one complete response (2.5%) and 10 partial responses (25%), and a disease control rate
at 24 weeks of 35%. Median progression-free survival and overall survival were 5.0 months and 10.3 months, respectively. In addition, we observed that there were three (18%) responders among the 17 patients who had been previously treated with <FONT
STYLE="white-space:nowrap">PD-1/L1</FONT> checkpoint inhibitors. Following these preliminary results, in 2018, AstraZeneca expanded its agreement with us by exercising its option to gain exclusive rights to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize monalizumab in oncology. Since then we initiated two additional expansion cohorts evaluating monalizumab in combination with cetuximub in IO experienced (Cohort 2) and monalizumab
in combination with cetuximab and an anti-PD-(L)1 in IO na&iuml;ve patients (Cohort 3). We expect to present follow-up data from the first expansion cohort in the second half of 2019 and preliminary efficacy data from the second expansion cohort in
2020. AstraZeneca is also evaluating monalizumab in a Phase I/II clinical trial in combination with durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in patients with advanced solid tumors, including colorectal cancer, or CRC. Under our
collaboration agreement with AstraZeneca, we are eligible to receive a $100&nbsp;million milestone payment at the start of the first Phase III clinical trial for monalizumab. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our proprietary product candidate, IPH4102, has shown single agent activity for the treatment of relapsed
or refractory S&eacute;zary syndrome</I></B>. In our Phase I clinical trial evaluating IPH4102 in CTCL, in the subgroup of 35 patients with S&eacute;zary syndrome, we observed an overall response rate of 42.9%, median duration of response of 13.8
months and median progression-free survival of 11.7 months. IPH4102 has also been granted orphan drug designation in the European Union and in the United States for the treatment of CTCL. In January 2019, the FDA granted Fast Track designation to
IPH4102 for the treatment of adults with R/R S&eacute;zary syndrome who have received two prior systemic therapies. The results of the dedicated S&#233;zary syndrome cohort may support a future Biologics License Application, or BLA, to the FDA.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>We believe that by targeting C5a receptors, IPH5401 has potential as a novel target in cancer treatment and
as a scientifically validated pathway to reduce inflammation.</I></B> IPH5401 binds to and blocks C5a receptors expressed on subsets of myeloid derived suppressor cells, or MDSCs, and neutrophils, cells that impair anti-tumor T cell response and
chemotherapy efficacy. We are currently conducting a Phase I clinical trial of IPH5401 in combination with durvalumab, initially in patients with select advanced solid tumors, and plan to initiate a subsequent cohort expansion trial to evaluate
IPH5401 in combination with durvalumab in patients with NSCLC or HCC. We also plan to explore the potential of IPH5401 in inflammation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our commercial stage product, Lumoxiti, is the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
treatment for hairy cell leukemia in over 20 years</I></B>. Lumoxiti was approved by the FDA under priority review in September 2018 based on positive data in a Phase II clinical trial. In this trial, 75% of patients receiving Lumoxiti achieved an
overall response, 30% had a durable complete response and 34% achieved a complete response with a negative minimal residual disease. A negative minimal residual disease complete response has been shown to be a surrogate for long-term disease control
and potentially survival in several hematological malignancies. Following our <FONT STYLE="white-space:nowrap">in-licensing</FONT> of Lumoxiti in the United States and the European Union from AstraZeneca, we are leveraging AstraZeneca&#146;s
capabilities to advance commercialization efforts through a transition period while we build our commercial organization. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>We believe that our broad, early stage pipeline of innovative immunotherapies targeting innate immunity
pathways provides us with multiple opportunities for future value creation</I></B>. Our rich heritage and leadership in the field of innate immunity has allowed us to create a diversified and differentiated portfolio in immuno-oncology<B><I>.
</I></B>We have developed a large panel of molecular and cellular assays and <I>in</I> <I>vivo</I> models for assessing the pharmacodynamics, toxicology and the therapeutic activity of product candidates targeted towards the innate immune system. In
many cases, our product candidates are among a limited number of therapeutic antibodies in development for a given biological target. As a result, our differentiated approach has allowed us to forge collaborations with the leading academic
institutions, cancer centers and industry partners to evaluate and advance our product candidates either alone or in combination with other investigational or approved therapies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our diversified business model provides us with a strong financial base and strategic flexibility</I></B>.
In addition to our internally developed pipeline, we have a track record of acquiring the rights to product candidates at different stages of development, including monalizumab, Lumoxiti, IPH5401 and our IPH52 program assets. We have already derived
substantial value from these acquisitions and subsequent business development transactions relating to these assets. Our collaborations have also allowed us to leverage development capabilities and financial resources of leading biopharmaceutical
companies, while retaining optionality to <FONT STYLE="white-space:nowrap">co-develop</FONT> and potentially <FONT STYLE="white-space:nowrap">co-promote</FONT> certain assets. At the same time, we have retained or acquired exclusive development and
commercialization rights to other product candidates. We believe that our strategic collaborations, our current financial position and the proceeds from this offering will position us to continue to develop our proprietary portfolio of assets and
build our commercial infrastructure, while maintaining our leadership in the development of novel immunotherapies. As of June&nbsp;30, 2019, we had
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million in cash, cash equivalents, short term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets.<B><I> </I></B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Experienced management team with a track record in the development and commercialization of cancer
therapeutics. </I></B>Our management team and board of directors have substantial experience in the biopharmaceutical industry, including in drug discovery, clinical development and commercialization. Our Chief Executive Officer, Mondher Mahjoubi,
MD, has 28 years of oncology development, product strategy and commercial management experience.&nbsp;Previously, he was the Oncology Global Manager at AstraZeneca and had tenures at Genentech and Roche. Pierre Dodion, MD, MBA, Chief Medical
Officer, has 24 years of experience in clinical and regulatory development efforts and medical affairs. He previously held positions at ARIAD Pharmaceuticals, Pfizer, Novartis and Aventis.&nbsp;Our Chief Scientific Officer, Eric Vivier, DVM, PhD,
has over 25 years of immuno-oncology experience and a substantial track record of publications in key scientific journals.&nbsp;Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S., Inc., has over 20 years of
experience in&nbsp;strategic marketing and commercial leadership expertise across several therapeutic areas. Ms.&nbsp;Butler has led and built multiple global and US commercial teams, including the product launch of durvalumab, while serving at
AstraZeneca.<B><I> </I></B><B><I></I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to harness the immune system for the treatment of conditions with serious unmet medical needs in oncology. By leveraging our 20
years of experience in immuno-oncology research and development, we strive to continue to internally discover, externally identify and develop a broad and diversified portfolio of first and <FONT STYLE="white-space:nowrap">best-in</FONT> class
immunotherapies across various therapeutic modalities. The key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Deliver our clinical programs and improve patient outcomes in indications with high unmet medical need by
building on our scientific discoveries. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete our ongoing clinical trial of monalizumab for the treatment of SCCHN, which, together with the data from
the CRC clinical trial, will inform further development and the potential path to market. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Execute the clinical development of our wholly owned product candidate, IPH4102, for the treatment of patients
with S&eacute;zary syndrome, MF and PTCL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Progress the clinical development of our wholly owned product candidate, IPH5401, for the treatment of patients
with cancer and explore its potential to treat inflammation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance our pipeline of other proprietary product candidates, including IPH5301. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Build a commercial stage oncology-focused biotechnology company. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build a commercial infrastructure for Lumoxiti in the United States and, if approved, in the European Union.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage our commercial infrastructure for future approved products in order to build a hemato-oncology focused
commercial franchise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Retain optionality to <FONT STYLE="white-space:nowrap">co-promote</FONT> product candidates in strategic regions
for select partnered assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to invest in our proprietary and partnered portfolio by leveraging our strong financial position and
revenue from our existing collaborations. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the value of our partnered product candidates under existing collaborations and potential license
agreements, under which we may be eligible to receive up to an aggregate of approximately $5.5&nbsp;billion in future contingent payments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to explore opportunities to accelerate the development of our proprietary pipeline programs through
additional collaborations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combine our disciplined business development strategy with our immuno-oncology research and development
capabilities to further expand our product portfolio. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand our pipeline of proprietary product candidates that target novel pathways in immuno-oncology using our
internal development engine. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Associated with our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our ordinary shares (including ordinary shares in the form of ADSs) involves a high degree of risk. Any of the factors set
forth under &#147;Risk Factors&#148; may limit our ability to successfully execute our business strategy. You should carefully consider all of the information set forth in this prospectus and, in particular, should evaluate the specific factors set
forth under &#147;Risk Factors&#148; in deciding whether to invest in our securities. Among these important risks are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Biopharmaceutical development involves a high degree of uncertainty and most of our product candidates are in
early stages of development, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend upon our existing collaboration partners, AstraZeneca, Sanofi and other third parties, and may depend
upon future collaboration partners to commit to the research, development, manufacturing and marketing of our drugs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will become fully responsible for the commercialization of Lumoxiti by mid 2020, but we currently have no
sales, marketing or commercial product distribution organization and have no experience in marketing or managing the manufacturing of products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to establish sales, marketing and distribution capabilities for Lumoxiti on a timely basis, we
may not be successful in commercializing Lumoxiti. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The scientific evidence to support the feasibility of developing product candidates is both preliminary and
limited. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be successful in our efforts to develop additional products that receive regulatory approval and are
successfully commercialized. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred and may in the future incur significant operational losses related to our research and
development activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may need to raise additional funding to complete the development and any commercialization of our product
candidates, which may not be available on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we do not achieve our product development or commercialization objectives in the timeframes we expect, we may
not receive product revenue, milestones or royalty payments and we may not be able to conduct our operations as planned. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is
expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory processes that will govern the approval of our product candidates are complex and changes in
regulatory requirements could result in delays or discontinuation of development or unexpected costs in obtaining regulatory approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We intend to develop monalizumab, IPH5401 and other product candidates in combination with other therapies, which
exposes us to additional risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have no manufacturing capabilities and rely on third-party manufacturers for Lumoxiti and our product
candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter difficulties in managing our growth, which could disrupt our operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There are material weaknesses and significant deficiencies in our internal controls over financial reporting and
if we are unable to maintain effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could hurt our business, lessen investor confidence and depress the market
price of our securities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to compete may be adversely affected if we do not adequately obtain, maintain, protect and enforce
our intellectual property or proprietary rights, or if the scope of intellectual property protection we obtain is not sufficiently broad. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There has been no prior market for our ADSs and an active and liquid market for our securities may fail to
develop, which could harm the market price of the ADSs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The rights of shareholders in companies subject to French corporate law differ in material respects from the
rights of shareholders of corporations incorporated in the United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are
permitted to file less information with the SEC than a U.S. company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information about the risks we
face, please see the section of this prospectus titled &#147;Risk Factors.&#148; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to present only two years of audited financial statements in addition to any required interim
financial statements and correspondingly reduced disclosure in management&#146;s discussion and analysis of financial condition and results of operations in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the
Sarbanes-Oxley Act, in the assessment of our internal controls over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements and (ii)&nbsp;exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, including golden
parachute compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such time that we are no longer an emerging
growth company. We will cease to be an emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large
accelerated filer&#148; with at least $700&nbsp;million of equity securities; (iii)&nbsp;the issuance, in any three year period, by our company of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities
held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> and (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of our initial public offering of our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take advantage of some but not all of these reduced burdens. For example, we have presented only two years of audited
financial statements and only two years of related &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus, and intend to take advantage of the exemption from auditor
attestation on the effectiveness of our internal control over financial reporting. Accordingly, the information that we provide shareholders and holders of our ADSs may be different than you might obtain from other public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in
Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Given that we currently report and expect to continue to report under International Financial Reporting Standards, or IFRS, as issued by the
International Accounting Standards Board, or IASB, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of
such standards is required by the IASB. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Implications of Being a Foreign Private Issuer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also considered a &#147;foreign private issuer&#148; under U.S. securities laws. In our capacity as a foreign private issuer, we are
exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&nbsp;14 of the Exchange Act. In addition, members of our Executive Board and Supervisory
Board and our principal shareholders are exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our
securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to
comply with Regulation FD, which restricts the selective disclosure of material information. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such time as we are no longer a foreign
private issuer. We will remain a foreign private issuer until such time that more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of our members of
the Executive Board or Supervisory Board are U.S. citizens or residents; (ii)&nbsp;more than 50% of our assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken advantage of certain reduced reporting and other requirements in this prospectus. Accordingly, the information contained herein
may be different than the information you receive from other public companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated on September&nbsp;23, 1999 as a <I>soci&eacute;t&eacute; par actions simplifi&eacute;e</I> and converted into a
<I>soci&eacute;t&eacute; anonyme</I>, or S.A., on June&nbsp;13, 2005. Our principal executive offices are located at 117, Avenue de Luminy, 13009 Marseille, France. We are registered at the Marseille Business and Company Registry (<I>Registre du
commerce et des soci&eacute;t&eacute;s</I>) under the number SIREN 424 365 336 RCS Marseille. Our telephone number at our principal executive offices is +33 4 30 30 30 30. We have two wholly owned subsidiaries&#151;Innate Pharma, Inc., a Delaware
corporation created in 2008, and Innate Pharma France SAS, a French <I>soci&eacute;t&eacute; par actions simplifi&eacute;e</I> created in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agent for service of process in the United States is Corporation Service Company. Our website address is www.innate-pharma.com. The
reference to our website is an inactive textual reference only and information contained in, or that can be assessed through, our website is not part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to make our reports and other information filed with or furnished to the SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange
Act available, free of charge, through our website, as soon as reasonably practicable after those reports and other information are electronically filed with or furnished to the SEC. Information on our website or any other website is not
incorporated by reference into this prospectus and does not constitute a part of this prospectus. The SEC maintains an internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with
the SEC. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_2"></A>THE GLOBAL OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>Innate Pharma S.A. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Global offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares offered by us, consisting of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the form of
ADSs offered in the U.S. offering and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares offered in the European private placement. The closings of the U.S. offering and the European private placement will occur
substantially simultaneously. The total number of ordinary shares (including ordinary shares in the form of ADSs) in the U.S. offering and the European private placement is subject to reallocation between these offerings to the extent permitted
under applicable laws and regulations. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">U.S. offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs, each representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary share </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">European private placement </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering price </P></TD>
<TD>The offering price is expected to be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, the closing price of our ordinary shares on Euronext Paris
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. The final offering price per ADS in U.S. dollars and the corresponding offering price in euro will be determined by
reference to the prevailing market prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares (including ordinary shares <BR>in the form of ADSs) to be outstanding after <BR>the global
offering </P></TD>
<TD><BR><BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional ordinary shares (including ordinary shares in the form of ADSs) <BR>in the
global offering </P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have agreed to issue, at the option of the underwriters, within 30&nbsp;days from the date of this prospectus, up to an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares (which may be in the form of ADSs). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">American Depositary Shares </P></TD>
<TD>Each ADS represents&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary share, nominal value &#128;0.05 per share. You will have the rights of an ADS holder as provided in the deposit agreement
among us, the depositary and all holders and beneficial owners of ADSs issued thereunder. To better understand the terms of the ADSs, you should carefully read the section in this prospectus titled &#147;Description of American Depositary
Shares.&#148; We also encourage you to read the deposit agreement, which is filed as an exhibit to the Registration Statement that includes this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Depositary </P></TD>
<TD>Citibank, N.A. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We estimate that we will receive net proceeds from the global offering of approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), based on an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, the closing
price of our ordinary shares on Euronext Paris </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, after deducting estimated underwriting discounts and estimated offering expenses payable
by us. We intend to use the net proceeds from the global offering, together with our existing resources, to (i)&nbsp;advance the clinical development of our lead product candidate, monalizumab, in collaboration with AstraZeneca, (ii) advance the
clinical development of IPH4102 for the treatment of S&#233;zary syndrome, MF and PTCL, (iii) advance the clinical development of IPH5401 for the treatment of solid tumors, including NSCLC and HCC, (iv) build our commercial capabilities for
Lumoxiti; (v) expand and advance our preclinical programs pipeline and (vi) the remainder for working capital and other general corporate purposes. See &#147;Use of Proceeds&#148; for more information. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dividend policy </P></TD>
<TD>We do not expect to pay any dividends on the ordinary shares or ADSs in the foreseeable future. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in the ordinary shares or ADSs. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol for our ADSs </P></TD>
<TD>&#147;IPHA&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Euronext Paris trading symbol for our ordinary shares </P></TD>
<TD>&#147;IPH&#148;. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares (including ordinary shares in the form of ADSs) that will be outstanding
after the global offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of June&nbsp;30, 2019 and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June&nbsp;30, 2019, assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June&nbsp;30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019, assuming all performance conditions are met; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future
issuance under our share-based compensation plans and other delegations of authority from our shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
otherwise noted, the information in this prospectus assumes no exercise by the underwriters of their option to purchase additional ordinary shares (which may be in the form of ADSs). </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our historical consolidated financial and other data. We derived the summary consolidated statement of income
(loss) data for the years ended December&nbsp;31, 2018 and 2017 from our audited consolidated financial statements included elsewhere in this prospectus. Our audited consolidated financial statements have been prepared in accordance with
International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, as of and for the years ended December&nbsp;31, 2018 and 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical results are not necessarily indicative of the results that may be expected in the future. The following summary financial data
for the periods and as of the dates indicated are qualified by reference to, and should be read in conjunction with, our consolidated financial statements and related notes beginning on <FONT STYLE="white-space:nowrap">page&nbsp;F-1</FONT> of this
prospectus, as well as the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Income (Loss) Data: &nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue and other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">93,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">44,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net financial loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares outstanding used for computing basic and diluted net income (loss) per
share<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 reflect the impacts of the adoption of IFRS 9 and IFRS 15 that became applicable on January&nbsp;1, 2018. The comparative
consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. The impact on the consolidated statement of income (loss) of the adoption of IFRS 9 is non material and the impact of the adoption of IFRS
15 and transition measures are presented in Note 2.a to our consolidated financial statements appearing elsewhere in this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the year ended December&nbsp;31, 2018, the dilutive effect of warrants granted but not yet exercised and unallocated free shares is not material. As we were in a net loss position for the year ended
December&nbsp;31, 2017, warrants granted but not yet exercised and unallocated free shares do not have a dilutive effect. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Financial Position Data: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, short-term investments and non-current financial assets<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">202,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial debt and defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As adjusted to give effect to the issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (including ordinary shares in the form of ADSs) in
the global offering at the assumed initial offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported closing price of our ordinary shares
on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, after deducting estimated underwriting commissions and estimated offering expenses payable by us,
assuming no exercise of the underwriters&#146; option to purchase additional ordinary shares (which may be in the form of ADSs). The as adjusted information presented above is illustrative only and will adjust based on the actual public offering
price, the actual number of ordinary shares (including ordinary shares in the form of ADSs) offered by us, and the other terms of the global offering determined at pricing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Non-current assets account for &#128;35.2 million. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed initial offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), the last reported closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, would increase or decrease each of as adjusted cash and cash equivalents, total assets and total shareholders&#146;
equity by approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming that the number of ordinary shares (including ordinary shares in the form of ADSs) offered by
us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including
ordinary shares in the form of ADSs) we are offering. Each increase or decrease of 1,000,000 in the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease each of as adjusted cash and cash
equivalents, total assets and total shareholders&#146; equity by approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the initial offering price
remains the same, and after deducting estimated underwriting discounts and estimated offering expenses payable by us. The as adjusted information discussed above is illustrative only and will adjust based on the actual initial offering price, the
actual number of ordinary shares (including ordinary shares in the form of ADSs) offered by us and other terms of the global offering determined at pricing. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our ordinary shares and ADSs involves a high degree of risk. You should carefully consider the risks and uncertainties
described below, together with all of the other information in this prospectus, including our consolidated financial statements and related notes, before deciding whether to purchase our ordinary shares or ADSs. If any of the following risks are
realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the market price of our ordinary shares and ADSs could decline, and you could lose part or all of your
investment. Please also see &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development and Commercialization
of Lumoxiti and Our Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Biopharmaceutical development involves a high degree of uncertainty and most of our
product candidates are in early stages of development, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company with one commercial product, Lumoxiti, which we recently acquired from AstraZeneca and which we have not yet
begun to commercialize on our own. The rest of our portfolio consists of product candidates, some of which we are <FONT STYLE="white-space:nowrap">co-developing,</FONT> in the early stages of clinical development and preclinical programs. Although
we have generated limited revenue from product sales from our only product approved by regulatory authorities, Lumoxiti, we do not expect to have any other significant product sales or related revenue unless our additional product candidates or any
future product candidates are approved for sale and successfully commercialized. Accordingly, our ability to predict our future operating results or business prospects is more limited than if we had a longer history of approved products on the
market or later-stage clinical product candidates. Although Lumoxiti has been approved by the U.S. Food and Drug Administration, or the FDA, it has only been marketed for a short period of time and, to date, AstraZeneca has been responsible for its
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to mature and expand our portfolio of proprietary and partnered product candidates to
address unmet medical needs in immuno-oncology. Although our research and development efforts to date have resulted in a pipeline of product candidates, all of our product candidates require additional development, regulatory review and approvals,
substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before they can be commercialized and before we can generate any revenue from product sales or royalties. If we or our collaboration
partners are unable to successfully develop and market these product candidates, our business, prospects, financial condition and results of operations may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aside from our acquisition of Lumoxiti, our operations to date have been limited to developing our product candidates and undertaking
preclinical studies and clinical trials of our product candidates, including monalizumab, through our partnership with AstraZeneca, IPH4102 and IPH5401, our most advanced product candidates. The success in development of our current and future
product candidates by us or our collaborators will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining positive results in clinical trials including by demonstrating efficacy, safety and durability of
effect of such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completing preclinical studies and receiving regulatory approvals or clearance for conducting clinical trials for
our preclinical programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receiving and maintaining approvals for commercialization of such product candidates from regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing or overseeing the manufacturing of our product candidates in acceptable quantities and at an
acceptable cost; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter, and
performing our obligations pursuant to such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including
patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">avoiding and defending against third-party interference, infringement or other intellectual property claims; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and growing an organization of scientists, medical professionals, marketing, distribution and sales
personnel and executives who can develop our product candidates and commercialize any approved products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
if we are unable to reduce our dependence on Lumoxiti and our current clinical and preclinical product candidates, either by <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring new product candidates, developing our other product
candidates or discovering new product candidates, we may be similarly adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will become fully responsible for the
commercialization of Lumoxiti by mid 2020 but we currently have no sales, marketing or commercial product distribution organization and have no experience in marketing or managing the manufacturing of products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company with one commercial product, Lumoxiti, which we recently acquired and have not yet begun to commercialize on
our own. AstraZeneca is currently responsible for all aspects of the commercialization and manufacturing of Lumoxiti in the United States, and we will begin transitioning these activities in the United States in the second half of 2019 and
thereafter be fully responsible for its commercialization and manufacturing by mid 2020. We currently have no sales, marketing or commercial product distribution capabilities and have no experience in managing the manufacturing of or marketing
products. We plan to develop <FONT STYLE="white-space:nowrap">in-house</FONT> marketing and sales capabilities and infrastructure, which will require significant expenses, management resources and time. If we are able to achieve this goal, we will
compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing, sales and distribution personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable or decide not to establish or expand internal sales, marketing and commercial distribution capabilities for Lumoxiti or any
of the products we may develop, we will likely pursue contractual arrangements for the sale, marketing and distribution of such products. However, there can be no assurance that we will be able to establish or maintain such arrangements, and if we
do, we may have little or no control over the sales, marketing and commercial distribution efforts of such third parties. Any revenue we receive will depend upon the efforts of these third parties, and their efforts may not be successful. Our
revenue from product sales may be lower than if we had commercialized Lumoxiti or any future product candidates we may develop, if approved, ourselves. We will also face competition in our search for third parties to assist us with the sales,
marketing and distribution efforts of Lumoxiti or any of our product candidates that receive regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no
assurance that we will be able to develop <FONT STYLE="white-space:nowrap">in-house</FONT> sales and commercial distribution capabilities or establish or maintain relationships with third-party partners to successfully commercialize any product in
the United States, Europe or elsewhere and, as a result, we may not be able to generate product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to
establish sales, marketing and distribution capabilities for Lumoxiti on a timely basis, we may not be successful in commercializing Lumoxiti. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have a sales, marketing or distribution infrastructure and have no experience in the sale, marketing or distribution of
pharmaceutical products. To achieve commercial success for any approved product, including our approved product, Lumoxiti, we must either develop a sales and marketing organization or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outsource these functions to third parties. Lumoxiti has only been commercially available for a very short period of time and, to date, the responsibilities of commercialization have been handled
by AstraZeneca. We will begin transitioning activities in the United States in the second half of 2019 and thereafter be fully responsible for its commercialization by mid 2020. We plan to use a combination of
<FONT STYLE="white-space:nowrap">focused&nbsp;in-house&nbsp;sales</FONT> and marketing capabilities and third-party collaboration, licensing and distribution arrangements to sell any of our products that receive marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming, could delay the
continued commercialization of Lumoxiti and could delay any other potential product launch. If the commercial launch of a product for which we recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur
for any reason, we could have prematurely or unnecessarily incurred these commercialization costs. This may be costly, and our investment could be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be
able to hire or retain a sales force that is sufficient in size or has adequate expertise in the medical markets that we plan to target. If we are unable to establish or retain a sales force and marketing and distribution capabilities, our operating
results may be adversely affected. If a potential partner has development or commercialization expertise that we believe is particularly relevant to one of our product candidates, we may seek to collaborate with that potential partner even if we
believe we could otherwise develop and commercialize the product independently. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The scientific evidence to support the feasibility
of developing product candidates is both preliminary and limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our innovative approach to immuno-oncology aims to activate both
the innate and adaptive immune systems against abnormal or cancerous cells and restore the body&#146;s ability to disrupt their proliferation, potentially leading to durable responses in patients. This approach is focused on developing checkpoint
inhibitors, tumor-targeting antibodies and antibodies that affect the tumor microenvironment, and several of our product candidates rely on novel mechanisms of action for which we have limited scientific evidence and preclinical and clinical data.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not ultimately be able to provide the FDA, European Medicines Agency, or EMA, or other regulatory authorities with substantial
clinical evidence to support a claim of efficacy and durability of response to enable the applicable regulators to approve our product candidates for any indication. This may occur because later clinical trials fail to reproduce favorable data
obtained in earlier clinical trials, because the applicable regulator disagrees with how we interpret the data from these clinical trials or because the applicable regulator does not accept these therapeutic effects as valid endpoints in pivotal
clinical trials that are sufficient to grant marketing approval. Additionally, because product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical
studies and earlier clinical trials our collaborators in earlier stages of clinical trials may eventually choose to discontinue later stage trials. For example, following initial promising results assessing the safety and efficacy of our product
candidate lirilumab for the treatment of various cancer indications, our collaborator decided not to continue development after receiving Phase II clinical trial data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the safety and efficacy traits of any product candidate, clinical trial failures may result from a multitude of factors
including flaws in trial design, dose selection, placebo effect and patient enrollment criteria. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse
safety profiles, notwithstanding promising results in earlier trials, and it is possible that we will as well. Based upon negative or inconclusive results, we or our collaborators may decide, or regulators may require us, to conduct additional
clinical trials or preclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also need to demonstrate that our product candidates are safe and well tolerated. We do not have significant data on
possible harmful long-term effects of our product candidates and do not expect to have this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data in the near future. As a result, our ability to generate clinical safety and efficacy data sufficient to support submission of a marketing application or commercialization of our product
candidates is uncertain and is subject to significant risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We intend to develop monalizumab, IPH5401 and other product candidates
in combination with other therapies, which exposes us to additional risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently developing monalizumab and IPH5401,
and may develop other product candidates, in combination with one or more currently approved cancer therapies. Specifically, with AstraZeneca, we are currently evaluating monalizumab in an ongoing open-label Phase Ib/II trial in combination with
cetuximab, an epidermal growth factor receptor, or EGFR, inhibitor. AstraZeneca is also currently evaluating monalizumab in ongoing Phase I and II trials in combination with durvalumab, an anti-PD-L1 immune checkpoint inhibitor. Additionally, we are
currently conducting a Phase I clinical trial of IPH5401 in combination with durvalumab, initially in patients with select advanced solid tumors. Patients may not be able to tolerate our product candidates in combination with other therapies. Even
if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory
authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the
treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other therapies or for indications other than cancer. This could result in our own products, if approved, being
removed from the market or being less successful commercially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also evaluate monalizumab, IPH5401 or any other future product
candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities. We will not be able to market and sell monalizumab, IPH5401 or any other
product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA, EMA or other comparable foreign regulatory authorities do not approve, revoke their approval of, or if safety, efficacy,
manufacturing or supply issues arise with, the products or product candidates we choose to evaluate in combination with monalizumab, IPH5401 or any other product candidate we develop, we may be unable to obtain approval of or market monalizumab,
IPH5401 or any other such product candidate we develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We and our collaborators rely on third parties to conduct some of our
preclinical studies and clinical trials and perform other clinical development tasks. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, it may not be
possible to obtain regulatory approval for, or commercialize, our product candidates and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third parties to conduct clinical trials of our product candidates or product candidates
that we have licensed to them. For example, under our license and collaboration agreements with AstraZeneca, AstraZeneca is responsible for a number of clinical trials relating to monalizumab and IPH5201, which are subject to such agreements. In
addition, we and our collaborators are responsible for and are supporting several clinical trials that are sponsored by academic or research institutions, known as investigator-sponsored trials. By definition, the financing, design and conduct of an
investigator-sponsored trial are the sole responsibility of the sponsor, and we or our collaborators, as applicable, have limited control over these aspects of these clinical trials, or the timing and reporting of the data from these trials. We and
our collaborators also depend on independent clinical investigators and Contract Research Organizations, or CROs, to conduct clinical trials. CROs may also assist in the collection and analysis of data. There are a limited number of CROs that have
the expertise to run clinical trials of our product candidates. Identifying, qualifying and managing performance of third-party service providers can be difficult and time consuming and can cause delays
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in our development programs. These investigators and CROs are not our employees and we are not able to control, other than by contract, the amount of resources, including the amount of time, that
they devote to our product candidates and clinical trials. If the investigators sponsoring trials of our product candidates, independent investigators participating in clinical trials that we or our collaborators are sponsoring or CROs fail to
devote sufficient resources to our clinical trials and development of our product candidates or product candidates we have licensed to others, or if their performance is substandard, it may delay or compromise the prospects for approval and
commercialization of any product candidates that we or our collaborators develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this
information will be misappropriated, and we may not be able to obtain adequate remedies for such disclosure or misappropriation. Further, the FDA, EMA and other regulatory authorities require that we comply with standards, commonly referred to as
current Good Clinical Practice, or cGCP, and other local legal requirements, including data privacy regulations, for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the
rights, integrity and confidentiality of clinical trial subjects are protected. If clinical investigators or CROs fail to meet their obligations to us or comply with cGCP procedures or other applicable legal requirements, the data generated in these
trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that all of our clinical trials comply with cGCP regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our
clinical trials must be conducted with product produced under current Good Manufacturing Practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval
process. If clinical investigators or CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the
failure to adhere to our protocol or regulatory requirements, or for other reasons, our clinical trials or those of our collaborators may be extended, delayed or terminated, and we or our collaborators may not be able to obtain regulatory approval
for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of our current clinical-stage product candidates and we cannot be certain that we or our
collaborators will be able to obtain regulatory approval for, or successfully commercialize, these product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business and future success depend on receiving regulatory approval for, and the commercial success of, our proprietary and partnered product candidates. We have agreements with AstraZeneca with respect to the advanced development, clinical trial
collaboration and potential future registration and marketing of several of our product candidates, including monalizumab and IPH5201, and with Sanofi for the research and development of IPH61. Our near-term prospects depend heavily on
AstraZeneca&#146;s successful clinical development and commercialization of monalizumab as well as the successful clinical development of our other product candidates. The clinical success of these product candidates will depend on a number of
factors, including the ability and willingness of AstraZeneca and our other collaborators to complete ongoing clinical trials for monalizumab, our ability to complete the clinical trials for which we are responsible, and the safety, tolerability and
efficacy of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to develop additional products that receive regulatory
approval and are successfully commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than our commercial product, Lumoxiti, our pipeline consists of various
product candidates at different phases of preclinical and clinical development. The development of a product candidate is a long, costly and uncertain process, aimed at demonstrating the therapeutic benefit of a product candidate that competes with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
existing products or those being developed. There is no guarantee that we or our collaborators will be able to demonstrate a sufficient degree of clinical efficacy or safety of one or more of our
proprietary or licensed product candidates in order to gain regulatory approval or to become commercially viable. The degree of uncertainty associated with clinical development and the risks associated with developing new product candidates may make
it difficult to evaluate our current business and our future prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to continue to develop our product candidates that are
currently in clinical trials, including monalizumab, IPH4102 and IPH5401. Monalizumab is currently being investigated in multiple Phase I and Phase II clinical trials under a <FONT STYLE="white-space:nowrap">co-development</FONT> agreement with
AstraZeneca. IPH4102 is currently being investigated in an open-label, multi-cohort Phase II clinical trial. IPH5401 is currently being evaluated in Phase I and Phase II clinical trials. While we believe that we will eventually have the <FONT
STYLE="white-space:nowrap">in-house</FONT> capabilities to complete the development of monalizumab, IPH4102 and IPH5401, we have not yet completed the clinical trials for these or other product candidates, and there can be no assurance that these or
other product candidates will gain regulatory approval or become commercially viable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in the preclinical development of a product
candidate could lead to delays in initiating its clinical development. A failure in the preclinical development of a product candidate could lead to abandoning its development. Further delays or failures at the various clinical stages for a given
indication could result in delay or halt the development of the product candidate in such indication or in other indications. Moreover, disappointing results during the initial phases of development are often not a sufficient basis for deciding
whether or not to continue a project. At these early stages, sample sizes, the duration of studies and the parameters examined may not be sufficient to enable a definitive conclusion to be drawn, in which case further investigations are required.
Conversely, promising results during the initial phases, and even after advanced clinical trials have been conducted, do not guarantee that a product candidate or an approved drug, such as Lumoxiti, will be successfully commercialized and marketed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risks related to the failure of a product candidate&#146;s development are highly related to the stage of maturity of the product
candidate. Given the relatively early stage of the product candidates in our pipeline, there is a substantial risk that some or all of our product candidates will not obtain regulatory approval or be commercialized, which would have an adverse
impact on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to
identify, discover or develop additional product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are seeking to develop a broad and innovative pipeline of product
candidates in addition to monalizumab, IPH4102 and IPH5401. We may not be successful in identifying additional product candidates for clinical development for a number of reasons. For example, our research methodology may be unsuccessful in
identifying potential product candidates or the potential product candidates we identify may have harmful side effects, lack of efficacy or other characteristics that make them unmarketable or unlikely to receive regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research programs to pursue the development of our product candidates for additional indications and to identify new product candidates and
disease targets require substantial technical, financial and human resources. Our research programs may initially show promise in identifying potential indications or product candidates, yet fail to yield results for clinical development for a
number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential indications or product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may, after further study, be shown to have harmful adverse effects or other
characteristics that indicate they are unlikely to be effective drugs; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may take greater human and financial resources to identify additional therapeutic opportunities for our
product candidates or to develop suitable potential product candidates through internal research programs than we will possess, thereby limiting our ability to diversify and expand our product portfolio. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance that we will ever be able to identify additional
indications for our product candidates or to identify and develop new product candidates through internal research programs. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to
be unsuccessful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter substantial delays in our clinical trials, or may be unable to conduct our clinical trials on the
timelines we expect. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any
clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful
or timely completion of clinical development include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the
initiation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or failure in reaching a consensus with regulatory agencies on clinical trial design;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs and investigational sites, the terms of
which can be subject to extensive negotiation and may vary significantly among different CROs and investigational sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a temporary or permanent clinical hold by regulatory agencies, including as a result of a new
safety finding that presents unreasonable risk to clinical trial participants, a negative finding from an inspection of our clinical trial operations or investigational sites, developments in trials conducted by competitors for related technology
that raise regulators&#146; concerns about risk to patients of the technology broadly or if a regulatory body finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable patients to participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us, our CROs or other third parties, including our collaborators, to adhere to clinical trial
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having patients complete participation in a clinical trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients withdrawing from a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of adverse events associated with a product candidate that are viewed to outweigh its potential
benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical trial protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory feedback requiring us to amend the protocols of ongoing clinical trials in response to safety
considerations, as we have previously been required to; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or
additional clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates being greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our
deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer of manufacturing processes to larger-scale facilities operated by either a contract manufacturing
organization, or CMO, or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">batch recalls, recalls of manufactured product candidates or delays in manufacturing, testing, releasing,
validating, or importing or exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to
generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical
study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates
and may harm our business and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti or our product candidates in development may cause undesirable side
effects or have other properties that could halt or delay their clinical development, prevent their regulatory approval, limit their commercialization or result in other negative consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Use of our approved product, Lumoxiti, or our product candidates in development could be associated with side effects or adverse events which
can vary in severity and in frequency. Undesirable side effects or unacceptable toxicities caused by our products or product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials. The FDA or European
regulatory authorities could delay or deny approval of our product candidates for any or all targeted indications and negative side effects could result in a more restrictive label for any drug that is approved. Side effects such as toxicity or
other safety issues associated with the use of our product candidates could also require us or our collaborators to perform additional studies or halt development of product candidates or sale of approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or could
result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, as toxicities resulting from immunotherapy are not normally encountered in the
general patient population and by medical personnel. Inadequate training in recognizing or managing the potential side effects of our product candidates or our approved product, Lumoxiti, could result in adverse effects to patients, including death.
Any of these occurrences may have an adverse impact on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We
face substantial competition from companies with significantly greater resources and experience. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical market, and notably the immuno-oncology field, is characterized by rapidly advancing technologies, products protected by intellectual property rights and intense competition and is subject to significant and rapid change as
researchers learn more about diseases and develop new technologies and treatments. We face potential competition from many different sources, including major pharmaceutical companies, specialty pharmaceutical and biotechnology companies, academic
institutions and governmental agencies and public and private research institutions. Any product candidates that we or our collaborators successfully develop will compete with existing therapies and new therapies that may become available in the
future. If competing products are marketed before ours, or at lower prices, or cover a wider therapeutic spectrum, or if they prove to be more effective or better tolerated, our business, prospects, financial condition and results of operations
could be affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors who are developing immuno-oncology and anti-cancer therapies have considerably greater
resources and experience in research, access to patients for clinical trials, drug development, finance, manufacturing, marketing, technology and personnel than we do. In particular, large pharmaceutical companies have substantially more experience
than we do in conducting clinical trials and obtaining regulatory authorizations. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of
our competitors. Smaller or early-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors are also likely to compete
with us to recruit and retain scientific and management personnel, acquire rights for promising product candidates and other complementary technologies, establish clinical trial sites and patient registration for clinical trials and acquire
technologies complementary to, or necessary for, our programs, as well as to enter into collaborations with partners who have access to innovative technologies. If we cannot successfully compete with new or existing products, our marketing and sales
will suffer and we may never be profitable. Should any of these risks materialize, our business, prospects, financial condition and results of operations may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that our product candidates or our approved product, Lumoxiti, will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain regulatory authorizations or become commercially available before those of our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">remain competitive in the face of other products developed by our competitors, which may prove to be safer, are
more effective, have fewer or less severe side effects, are more convenient, have a broader label, have more robust intellectual property protection or are less expensive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">remain competitive in the face of products of competitors that are more efficient in their manufacturing or more
effective in their marketing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not become obsolete or unprofitable due to technological progress or other therapies developed by our
competitors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while our approved product and any future product candidates that are approved may compete
with many existing drugs or other therapies, to the extent they are solely used in combination with these therapies, our product candidates will not be competitive with such therapies but any sales of such products could be limited to sales of the
combination therapy. In this case, we would be exposed to the same competitive risks as the product used in combination with our product, such as a product that is marketed before the combination therapy, has lower prices, covers a wider therapeutic
spectrum or proves to be more effective or better tolerated. For additional information regarding competition to our business see &#147;Business&#151;Competition.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on enrollment of patients in our clinical trials for our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful and timely completion of clinical trials will require that we or our subcontractors enroll a sufficient number of suitable patients.
Clinical trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. Patient enrollment depends on many factors, including the size and nature of the patient population, eligibility
criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating,
and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. For example, we are developing IPH4102 for the treatment of cutaneous <FONT
STYLE="white-space:nowrap">T-cell</FONT> lymphoma, or CTCL. CTCL is an orphan disease, which means that the potential patient population is limited. In addition, there are several other product candidates potentially in development for the
indications for which we are developing product candidates, and we may compete for patients with the sponsors of trials for those drugs. These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely
and cost-effective manner. Delays in the completion of any clinical trial of any of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to
commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the inability to obtain regulatory approval of our product
candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and reimbursement may be limited or unavailable in certain market segments
for our approved product, Lumoxiti, and product candidates, if approved, which could make it difficult for us to sell our product or product candidates profitably. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful sales of Lumoxiti and our product candidates, if approved, will depend, in part, on the availability of adequate coverage and
reimbursement from government authorities and third-party payors, such as private health insurers and health maintenance organizations. Patients who are provided medical treatment for their conditions generally rely on third-party payors to
reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States or the Social Security in France, and commercial payors
are critical to new product acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination
that use of a product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Policies for coverage and reimbursement for products vary among third-party payors. No uniform policy of coverage and reimbursement for
products exists among third-party payors, and third-party payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of approved drugs and medical services, in addition to questioning their
safety and efficacy. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us or our partners to provide to each payor
supporting scientific, clinical and cost-effectiveness data for the use of our products on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate
reimbursement will be obtained. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available.
Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find
unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluations required following the use of our product candidates or approved
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our product candidates and our approved product, Lumoxiti, represent new approaches to the treatment of cancer and
accordingly, may have a higher cost than conventional therapies and may require long-term follow-up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be elevated. There are currently a
limited number of immunotherapy products that are designed to treat cancer on the market and, accordingly, there is less experience or precedent for the reimbursement of such treatments by governmental entities or third-party payors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Government restrictions on pricing and reimbursement and other healthcare cost-containment initiatives may negatively affect our ability
to generate revenues for Lumoxiti and other product candidates for which we obtain regulatory approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities and
other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, including by limiting coverage and the amount of reimbursement for particular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medications. Increasingly, third-party payors are requiring that pharmaceutical and biotechnology companies provide them with predetermined discounts from list prices as a condition of coverage,
are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes and are challenging the prices charged for medical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the European Union and other foreign jurisdictions, there have been a number of legislative and regulatory changes to
the healthcare system that could affect our or our partners&#146; ability to sell our products profitably. By way of example, in the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act, which we collectively refer to as the ACA, was enacted in March 2010 and is having a significant impact on the provision of, and payment for, healthcare in the United States. The ACA was intended to broaden access to health
insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and
impose additional health policy reforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the provisions of the ACA of importance to our product candidates are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and
biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to
23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been judicial and Congressional
challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal and replace certain aspects of the ACA, and we expect such challenges to continue. Since January 2017, President Trump has signed two executive
orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and
replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision
that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year
that is commonly referred to as the &#147;individual mandate.&#148; Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implementation of certain fees mandated by the ACA, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance
plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Further, the Bipartisan Budget Act of 2018, or the
BBA, among other things, amended the ACA, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; In July 2018, CMS published a final rule permitting further
collections and payments to and from certain ACA qualified health plans and health insurance issuers under its risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this
risk adjustment. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by the U.S. Congress as part of the Tax Cuts and Jobs Act of
2017 Act. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and
other efforts to repeal and replace the ACA will impact the ACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA
was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2027 unless additional Congressional action is taken. Both the
Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012, or ATRA, further reduced Medicare payments to several providers and the ATRA increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. Additional legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and reduce demand and
prices for our product candidates, if approved. This could harm our or our partners&#146; ability to market any drugs and generate revenues. Cost containment measures that healthcare payors and providers are instituting and the effect of further
healthcare reform could significantly reduce potential revenues from the sale of any of our product candidates approved in the future, and could cause an increase in our compliance, manufacturing, or other operating expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United States, federal programs impose penalties on drug manufacturers in the form of mandatory additional rebates and/or
discounts if commercial prices increase at a rate greater than the U.S. Bureau of Labor Statistics consumer price index, and these rebates or discounts, which can be substantial, may affect our ability to raise commercial prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and
manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#146;s budget proposal for fiscal year 2019 contains
additional drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part
B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. The Trump administration also released a &#147;Blueprint&#148; to lower
drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of
their products and reduce the out of pocket costs of drug products paid by consumers. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January&nbsp;1,
2019. On January&nbsp;31, 2019, the Office of Inspector General of the United States Department of Health and Human Services proposed modifications to the U.S. Anti-Kickback Statute safe harbors which, among other things, will affect rebates paid by
manufacturers to Medicare Part D plans, the purpose of which is to further reduce the cost of drug products to consumers. Additionally, the Centers for Medicare &amp; Medicaid Services, or CMS, issued a final rule, effective on July 9, 2019, that
requires direct-to-consumer television advertisements of prescription drugs and biological products, for which payment is available </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater than $35 for
a monthly supply or usual course of treatment. Prescription drugs and biological products that are in violation of these requirements will be included on a public list. The U.S. Congress and the Trump administration have each indicated that it will
continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some countries, the proposed pricing for a biopharmaceutical product must be approved before it may be lawfully
marketed. In addition, in certain foreign markets, the pricing of biopharmaceutical product is subject to government control and reimbursement may in some cases be unavailable. The requirements governing drug pricing vary widely from country to
country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for
human use. An EU member state may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by the manufacturer or it may instead adopt a system of direct or indirect controls on the profitability of
the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for
any of our products. Historically, biopharmaceutical products launched in the European Union do not follow price structures of the United States and generally tend to have significantly lower prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that pricing pressures will continue and may increase, which may make it difficult for us to sell Lumoxiti or any of our product
candidates that may be approved in the future at a price acceptable to us or any of our existing or future collaborators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti
and any of our other product candidates, if approved and commercialized, may fail to achieve market acceptance by physicians, patients, third-party payors or the medical community to a degree that is necessary for commercial success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the medical community accepts a product as safe and efficacious for its indicated use, physicians may choose to restrict the use of the
product if we are unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our drug is preferable to any existing drugs or treatments. We cannot predict the degree of market acceptance of Lumoxiti or
any product candidate that receives marketing authorization, which will depend on a number of factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demonstration of the clinical efficacy and safety of the drug; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approved labeling for the drug and any required warnings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevalence and severity of adverse side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the advantages and disadvantages of the drug compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ease of the drug&#146;s use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to educate the medical community about the safety and effectiveness of the drug;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of any approval provided by the FDA or foreign regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity about our product or about competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the coverage and reimbursement policies of government and commercial third-party payors pertaining to the drug;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price of our drugs relative to competing treatments. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Poor market penetration could have an adverse effect on our business, prospects, financial
condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if some of our other product candidates receive marketing authorization, the terms of
such approval, ongoing regulation and potential post-marketing restrictions or withdrawal from the market may limit how the drug may be marketed and may subject us to penalties for failure to comply with regulatory requirements, which could impair
our ability to generate revenues. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if any of our other product candidates receives marketing authorization, such approval may
carry conditions that limit the market for the drug or put the drug at a competitive disadvantage relative to alternative therapies. Regulators may limit the marketing of products to particular indications or patient populations. Regulators may
require warning labels and drugs with warnings are subject to more restrictive marketing regulations than drugs without such warnings. These restrictions could make it more difficult to market any drug effectively. Marketing restrictions may reduce
the revenue that we are able to obtain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of our product candidates for which we obtain marketing authorization, and the manufacturing
processes, post-approval studies and measures, labeling, advertising and promotional activities for such products, among other things, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities. These
requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records
and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing authorization of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the
product may be marketed or to the conditions of approval, including the FDA requirement to implement a risk evaluation and mitigation strategy to ensure that the benefits of a drug or biological product outweigh its risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA, EMA and other national authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance
to monitor the safety or efficacy of a product, such as long-term observational studies on natural exposure. The FDA and other agencies, including the U.S. Department of Justice, closely regulate and monitor the post-approval marketing and promotion
of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. Later discovery of previously unknown problems with our product candidates
or with manufacturing processes, including adverse events of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of
post-market studies or clinical studies to assess new safety risks, or the imposition of distribution or other restrictions including suspension of production and/or distribution and withdrawal of regulatory approvals. Failure to comply with these
requirements may lead to financial penalties, compliance expenditures, total or partial suspension of production and/or distribution, product seizure or detention, refusal to permit the import or export of products, suspension of the applicable
regulator&#146;s review of a company&#146;s submissions, enforcement actions, product recalls, injunctions and even criminal prosecution, any of which could materially and adversely affect our business, financial condition and results of operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are exposed to a number of regulatory and commercial risks relating to the United Kingdom&#146;s potential exit from the
European Union. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, a majority of the eligible members of the electorate in the U.K. voted to withdraw from the European
Union in a national referendum, commonly referred to as &#147;Brexit.&#148; Pursuant to Article 50 of the Treaty on European Union, the U.K. will cease to be an EU Member State either on the effective date of a withdrawal agreement (entry into such
a withdrawal agreement will require U.K. parliamentary approval) or, failing that, two years following the U.K.&#146;s notification of its intention to leave the EU (the &#147;Brexit Date&#148;), unless the European Council (together with the U.K.)
unanimously decides to extend the two year period. On March&nbsp;29, 2017, the U.K. formally notified the European Council of its intention to leave the EU. It is unclear how long it will take to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
negotiate a withdrawal agreement, but it appears likely that Brexit will continue to involve a process of lengthy negotiations between the U.K. and EU Member States to determine the future terms
of the U.K.&#146;s relationship with the EU.&nbsp;For example, in March 2018, the U.K. reached a provisional agreement (the &#147;Withdrawal Agreement&#148;) with the EU on transitional arrangements following Brexit (which are intended to enable the
U.K. to remain within the EU single market and customs union for a transitional period through 2020), but this Withdrawal Agreement needs to be formally agreed as part of the withdrawal arrangements currently under negotiation.&nbsp;Given that no
formal withdrawal arrangements have been agreed, there have been several extensions to the Brexit Date and the U.K. has yet to formally leave the EU. On April&nbsp;11, 2019, the EU granted the U.K. a further extension to the Brexit Date until
October&nbsp;31, 2019. The purpose of this extension is to allow for the ratification of the Withdrawal Agreement by the U.K. House of Commons.&nbsp;If the Withdrawal Agreement is ratified, the U.K. will leave the EU earlier than October&nbsp;31,
2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2019, the U.K. Prime Minister, Theresa May, announced that she would formally resign from the role of Prime
Minister on June&nbsp;7, 2019.&nbsp;Following the resignation of Mrs.&nbsp;May, a leadership contest amongst Conservative party candidates will begin, and a new Prime Minister is set to be appointed by
<FONT STYLE="white-space:nowrap">mid-July.&nbsp;Any</FONT> new Prime Minister may choose to renegotiate the Withdrawal Agreement, or leave the EU on October&nbsp;31, 2019 with no formal withdrawal arrangements in place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical trials in the U.K. are subject to the UK Medicines and Healthcare Products Regulatory Agency, or MHRA and EMA regulations. If the
U.K. proceeds to leave the EU without any formal withdrawal arrangements, there could be considerable uncertainty as to the continued applicability of such regulations in the U.K. We are currently conducting clinical trials of IPH4102 in the U.K.
and we cannot be certain such trials will not be affected if the U.K. leaves the EU without any formal withdrawal arrangements. IPH4102 received an orphan drug designation in the EU, which provides for an exclusive
<FONT STYLE="white-space:nowrap">10-year</FONT> marketing period during which no similar product may apply for a marketing authorization in the EU for the same indication, as well as an exemption from regulatory fees and other advantages. We may
lose this designation and benefits for IPH4102 in the U.K. in the event that the U.K. exits the EU without any formal withdrawal arrangements. Furthermore, if we obtain an MA in the EU, such authorization may not permit us to engage in commercial
sales of our product candidates in the U.K. and we may not be able to obtain the required authorization from the U.K. regulator. If we are required to obtain additional authorizations in the U.K., we will incur additional costs to obtain such
authorizations, which may be significant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred and may in the future incur significant operational losses related to our research and development activities.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses in each year since our inception except for the years ended December&nbsp;31, 2016 and 2018. Our net
income (loss) was &#128;3.0&nbsp;million and &#128;(48.4)&nbsp;million for the years ended December&nbsp;31, 2018 and 2017, respectively. Substantially all of our net losses resulted from costs incurred in connection with our development programs
and from general and administrative expenses associated with our ongoing operations. We expect to incur significant expenses and operating losses for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently only have one product, Lumoxiti, that has received regulatory approval for sale or has generated revenues from commercial sales,
and none of our other product candidates have received regulatory approval. Unless this happens, the likelihood and amount of our future operational losses will depend, in part, on the commercialization of our approved product, Lumoxiti, the pace
and amount of our future expenditures and our ability to obtain funding through milestone or royalty payments under our license and collaboration agreements, equity or debt financings, strategic collaborations and government grants and tax credits.
We expect that our main source of income for the near- and medium-term will be: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revenue from the commercialization of Lumoxiti; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments received under our license and collaboration agreements with third parties, including AstraZeneca and
Sanofi; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government grants and research tax credits. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interruption of one of those sources of income could have a material adverse effect on our business, prospects, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to be profitable in the future will depend on our ability to generate revenue from sales relating to
our sole commercial product, Lumoxiti, and other product candidates, if approved, and our ability to obtain regulatory approval for marketing our product candidates. If our product candidates receive regulatory approval, our future revenues will
depend upon the size of any markets in which our product candidates have received approval, and market acceptance, reimbursement from third-party payors and market share. Any of these factors could have a material adverse effect on our business,
prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may need to raise additional funding to complete the development and
any commercialization of our product candidates, which may not be available on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently advancing our product candidates through preclinical and clinical development, and anticipate relying
on partners less as we develop into a commercial stage biopharmaceutical company with research, development and commercial capabilities. We currently retain the full development and marketing rights to IPH4102 and IPH5401 and may retain rights to
additional proprietary product candidates in the future. The development of immunotherapy product candidates is expensive, and we expect our research and development expenses to increase as we advance our product candidates through clinical trials
and regulatory approvals. If clinical trials are successful and obtain regulatory approval for product candidates that we develop, we expect to incur commercialization expenses before these product candidates are marketed and sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research, preclinical and clinical development of our product candidates if our current
collaboration partners cease their collaborations with us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the scope of our current clinical trials for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate additional preclinical, clinical or other studies for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop manufacturing processes for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add additional manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory and marketing authorizations for our product candidates that successfully complete clinical
studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize Lumoxiti and any other products for
which we may obtain marketing authorization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify and validate additional product candidates that may result in additional preclinical, clinical
or other product studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone or other payments under any <FONT STYLE="white-space:nowrap">in-license</FONT> agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, protect, defend and expand our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain new and existing skilled personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create additional infrastructure to support our operations as a public company in the United States following the
completion of this global offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter issues with any of the above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had cash, cash equivalents, short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT>
financial assets of &#128;202.7&nbsp;million. We believe our cash, cash equivalents, short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets, together with the net proceeds of the global offering and our cash
flow from operations (including payments we expect to receive pursuant to our collaboration agreements) and government funding of research programs will be sufficient to fund our operations for at
least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, in order to
complete the development process, obtain regulatory approval and, if approved, commercialize our product candidates that we are developing <FONT STYLE="white-space:nowrap">in-house,</FONT> including IPH4102 and IPH5401, develop our proprietary
technology and develop a pipeline of additional product candidates, we will require additional funding. Our existing resources and the net proceeds from the global offering may not be sufficient to cover any additional financing needs, in which case
new funding would be required. The conditions and arrangements for such new financing would depend, among other factors, on economic and market conditions that are beyond our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing
will be available in sufficient amounts or on terms acceptable to us, if at all. Under French law, our share capital may be increased only with shareholders&#146; approval at an extraordinary general shareholders&#146; meeting on the basis of a
report from the Executive Board. In addition, the French Commercial Code imposes certain limitations on our ability to price certain offerings of our share capital without preferential subscription rights (<I>droit pr&eacute;f&eacute;rentiel de
souscription</I>), which limitation may prevent us from successfully completing any such offering. See &#147;Description of Share Capital&#151;Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional
securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary shares or the ADSs to decline. The sale of additional equity or convertible securities would dilute our shareholders. We may
seek funds through arrangements with collaborative partners or otherwise at an earlier stage of product development than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or
otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we need and are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more
of our research or development programs or the commercialization of any product or product candidate or we may be unable to expand our operations or otherwise capitalize on our business opportunities as desired, which could impair our growth
prospects. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our product development or commercialization objectives in the timeframes we expect, we may not receive product
revenue, milestones or royalty payments and we may not be able to conduct our operations as planned. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received and expect
to continue to receive payments from our collaborators when we satisfy certain <FONT STYLE="white-space:nowrap">pre-specified</FONT> milestones in our licensing or collaboration agreements. We currently depend to a large degree on these milestone
payments from our existing collaborators in order to fund our operations and we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enter into new collaboration agreements that also provide for milestone payments. These milestone payments are generally dependent on the accomplishment of various scientific, clinical,
regulatory, sales and other product development objectives, and the successful or timely achievement of many of these milestones is outside of our control, in part because some of these activities are being conducted by our collaborators. If we or
our collaborators fail to achieve the applicable milestones, we may not receive such milestone payments. A failure to receive any such milestone payment may cause us to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, reduce or terminate certain research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce headcount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raise funds through additional equity or convertible debt financings that could be dilutive to our shareholders
and holders of our ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain funds through collaboration agreements that may require us to assign rights to technologies or products
that we would have otherwise retained; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sign new collaboration or license agreements that may be less favorable than those we would have obtained under
different circumstances; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consider strategic transactions or engaging in a joint venture with a third party. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to receive milestone or royalty payments and the occurrence of any of the events above may have a material adverse impact on our
business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The revenues generated from our collaboration and license
agreements have contributed and are expected to contribute a large portion of our revenue for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
entered into collaboration and license agreements with pharmaceutical companies, including AstraZeneca. The cash payments received from our partners were &#128;40.3&nbsp;million and &#128;14.0&nbsp;million for the years ended December&nbsp;31, 2018
and 2017, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also enhance our research efforts by establishing collaborations with academic or <FONT
STYLE="white-space:nowrap">non-profit</FONT> research institutions and other biopharmaceutical companies. The participation in these collaborations may generate revenue and funding in the form of operating grants or the reimbursement of research and
development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to renew or maintain our license agreements or collaborative research contracts or may be unable
to sign new agreements with new collaborators on reasonable terms or at all. The early termination of a contract, the <FONT STYLE="white-space:nowrap">non-renewal</FONT> of a contract or our inability to find new collaborators would adversely affect
our business. Should any of these risks materialize, this could have an adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We benefit from tax credits in France that could be reduced or eliminated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a French biopharmaceutical company, we benefit from certain tax advantages, including the Research Tax Credit (<I>Cr&eacute;dit Imp&ocirc;t
Recherche</I>), which is a French tax credit aimed at stimulating research and development. The Research Tax Credit is calculated based on our claimed amount of eligible research and development expenditures in France and represented
&#128;13.5&nbsp;million and &#128;11.0&nbsp;million for the years ended December&nbsp;31, 2018 and 2017, respectively. The Research Tax Credit is a source of financing to us that could be reduced or eliminated by the French tax authorities or by
changes in French tax law or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Research Tax Credit can be offset against French corporate income tax due by the company
with respect to the year during which the eligible research and development expenditures have been made. The portion of tax credit in excess which is not being offset, if any, represents a receivable against the French Treasury which can in
principle be offset against the French corporate income tax due by the company with respect to the three following years. The remaining portion of tax credit not being offset upon expiry of such a period may then be refunded to the company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, since we currently qualify as a small- and
<FONT STYLE="white-space:nowrap">medium-size</FONT> business, the French Treasury refunded each of our 2016 and 2017 Research Tax Credit claims immediately (meaning that, in practice, we receive the refund during the year following the year in which
the eligible research and development expenditures are made). We expect that in the future we will no longer qualify as a small- and <FONT STYLE="white-space:nowrap">medium-size</FONT> business and therefore would no longer be entitled to the
immediate reimbursement of the Research Tax Credit but instead would be reimbursed within the expiry of the period of three years mentioned above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The French tax authorities, with the assistance of the Higher Education and Research Ministry, may audit each research and development program
in respect of which a Research Tax Credit benefit has been claimed and assess whether such program qualifies in their view for the Research Tax Credit benefit. The French tax authorities may challenge our eligibility for, or our calculation of,
certain tax reductions or deductions in respect of our research and development activities (and therefore the amount of Research Tax Credit claimed), or the accelerated reimbursement allowed for small- and
<FONT STYLE="white-space:nowrap">medium-size</FONT> businesses and our credits may be reduced, which would have a negative impact on our revenue and future cash flows. Furthermore, the French Parliament may decide to eliminate, or to reduce the
scope or the rate of, the Research Tax Credit benefit, either of which it could decide to do at any time. If we fail to receive future Research Tax Credit amounts or if our calculations are challenged, even if we comply with the current requirements
in terms of documentation and eligibility of its expenditure, our business, prospects, financial condition and results of operations could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to carry forward existing tax losses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have accumulated tax loss carry forwards of &#128;220.1&nbsp;million as of December&nbsp;31, 2018. Applicable French law provides that, for
fiscal years ending after December&nbsp;31, 2012, the use of these tax losses is limited to &#128;1.0&nbsp;million, plus 50% of the portion of net earnings exceeding this amount. The unused balance of the tax losses in application of such rule can
be carried forward to future fiscal years, under the same conditions and without time restriction. There can be no assurance that future changes to applicable tax law and regulation will not eliminate or alter these or other provisions in a manner
unfavorable to us, which could have an adverse effect on our business, prospects, financial condition, cash flows or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Changes to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws could materially adversely affect our company.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, the Tax Cuts and Jobs Act was signed into law and significantly revised the Internal Revenue Code of
1986, as amended, or the Code. The Tax Cuts and Jobs Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the
tax deduction for interest expense to 30% of adjusted taxable income (except for certain small businesses), implementation of a &#147;base erosion anti-abuse tax,&#148; which requires U.S. corporations to make an alternative determination of taxable
income without regard to tax deductions for certain payments to affiliates, taxation of certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporations&#146; earnings considered to be &#147;global intangible low taxed income,&#148; which is
also referred to as GILTI, repeal of the alternative minimum tax, or AMT, for corporations and changes to a taxpayer&#146;s ability to either utilize or refund the AMT credits previously generated, changes to the limitation on deductions for certain
executive compensation particularly with respect to the removal of the previously allowed performance based compensation exception, changes in the attribution rules relating to shareholders of certain &#147;controlled foreign corporations,&#148;
limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, <FONT STYLE="white-space:nowrap">one-time</FONT> taxation of offshore earnings at reduced rates regardless
of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or
repealing many business deductions and credits. Notwithstanding the reduction in the U.S. corporate income tax rate, the overall impact of the Tax Cuts and Jobs Act is uncertain and our business and financial condition could be adversely affected.
The impact of the Tax Cuts and Jobs Act on holders of our ordinary shares or ADSs is also uncertain and could be adverse. For example, recent changes in U.S. federal income tax law resulting in additional taxes owed by U.S. holders (as described
under &#147;Material United States Federal Income Tax and French Tax Considerations&#151;Material U.S. Federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Income Tax Considerations&#148;) under the new GILTI tax rules or related to &#147;controlled foreign corporations&#148; may discourage U.S. investors from owning or acquiring 10% or greater of
our outstanding ordinary shares or ADSs, which other shareholders may have viewed as beneficial or may otherwise negatively impact the trading price of our ordinary shares or ADSs. We are unable to predict what federal tax law may be proposed or
enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices, could affect our effective tax rates in the future in countries
where we have operations and have an adverse effect on our overall tax rate in the future, along with increasing the complexity, burden and cost of tax compliance. We urge our shareholders and holders of our ADSs to consult with their legal and tax
advisors with respect to this legislation and the potential tax consequences of investing in or holding our ordinary shares or ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes
or <FONT STYLE="white-space:nowrap">non-realization</FONT> of expected benefits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A tax authority may disagree with tax positions
that we have taken, which could result in increased tax liabilities. For example, the French tax authorities, the U.S. Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts
paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject
to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#147;permanent establishment&#148; under international tax treaties, and such an assertion, if successful, could increase our expected
tax liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an
assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the result could increase our anticipated effective tax rate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval and Marketing of Our Product Candidates and Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming
and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, in particular in the
United States or the European Union, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research and development of pharmaceutical products is governed by complex regulatory requirements. The regulatory agencies that oversee
these requirements have the authority to permit the commencement of clinical trials or to temporarily or permanently halt a study. They are entitled to request additional clinical data before authorizing the commencement or resumption of a study,
which could result in delays or changes to our product development plan. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with all applicable guidelines, rules and regulations. If we fail
to do so, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our
ability to generate sufficient product revenue to maintain our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical trials of our product candidates are, and the
manufacturing and marketing of our one approved product, Lumoxiti, and our other product candidates will be, subject to regulation by numerous government authorities in the United States, in the European Union and in other countries where we intend
to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate, with substantial evidence gathered in well-controlled clinical trials, and, with
respect to approval in the United States, to the satisfaction of the FDA, with respect to approval in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
European Union, to the satisfaction of the EMA or, with respect to approval in other countries, similar regulatory authorities in those countries, that the product candidate is safe and effective
for use in each target indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, we expect that the requisite regulatory submission to seek marketing
authorization for our product candidates will be a Biologic License Application, or BLA, and the competent regulatory authority is the FDA. In the European Union, the requisite approval is a Marketing Authorization, or MA, which for products
developed by the means of antibody-based therapeutics, gene or cell therapy products as well as tissue engineered products, is issued through a centralized procedure involving the EMA (see &#147;Business&#151;Regulation&#148;). Satisfaction of these
and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval,
may subject an applicant to administrative or judicial sanctions. These sanctions could include, for example, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product
recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data from preclinical and clinical studies are likely to give rise to different interpretations, which could delay regulatory authorization,
restrict the scope of any such authorization or force us to repeat trials in order to meet the requirements of the various regulators. Regulatory requirements and processes vary widely among countries, and we may be unable to obtain authorization
within each relevant country in a timely manner. Regulatory authorities may prevent us from starting clinical trials or continuing clinical development if the data were not produced according to applicable regulations or if they consider that the
balance between the expected benefits of the product and its possible risks is not sufficient to justify the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite our efforts,
our product candidates may not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer improvement over existing, comparable products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be proven safe and effective in clinical trials; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meet applicable regulatory standards. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of substantial
resources beyond our existing cash on hand and the net proceeds we expect to raise in this offering. Of the large number of drugs in development globally, only a small percentage successfully complete the regulatory approval process and not all
approved drugs are successfully commercialized. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary for us or our partners to bring a potential product candidate to market could have a material adverse
effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory processes that will govern the
approval of our product candidates are complex and changes in regulatory requirements could result in delays or discontinuation of development or unexpected costs in obtaining regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates are based on new technologies that are constantly evolving and have not been extensively tested on humans. The
applicable regulatory requirements vary between jurisdictions and are also complex, potentially difficult to apply and subject to significant modifications. Modifications to regulations during the course of clinical development and regulatory review
may lead to delays or the refusal of authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, the United States and other countries, regulations can potentially: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significantly delay or increase the cost of development, testing, manufacturing and marketing of our products;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the indications for which we will be authorized to market our products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose new, more stringent, requirements, suspend marketing authorizations, or request the suspension of clinical
trials or the marketing of our products if unexpected results are obtained during trials performed by other researchers on products similar to our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing authorization in one jurisdiction does not ensure marketing authorization in another, but a failure or delay in obtaining marketing
authorization in one jurisdiction may have a negative effect on the regulatory process in others. Failure to obtain marketing authorization in other countries or any delay or setback in obtaining such approval would impair our ability to develop
additional markets for our product, Lumoxiti, or any additional product candidates that are approved. This would reduce our target market and limit the full commercial potential of our product or product candidates. Should any of these risks
materialize, this could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to obtain marketing approval in jurisdictions other than the United States
and Europe would prevent our product candidates from being marketed in these other jurisdictions, and any approval we are granted for our product candidates in the United States and Europe would not assure approval of product candidates in other
jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market and sell our other product candidates in jurisdictions other than the United States and Europe,
we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval process varies among countries and can involve additional testing. The time required to obtain approval may differ from that
required to obtain FDA approval or approvals from regulatory authorities in the European Union. The regulatory approval process outside the United States and Europe generally includes all of the risks associated with obtaining FDA approval or
approvals from regulatory authorities in the European Union. In addition, some countries outside the United States and Europe require approval of the sales price of a product before it can be marketed. In many countries, separate procedures must be
followed to obtain reimbursement and a product may not be approved for sale in the country until it is also approved for reimbursement. We may not obtain marketing, pricing or reimbursement approvals outside the United States and Europe on a timely
basis, if at all. Approval by the FDA or regulatory authorities in the European Union does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States and
Europe does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA or regulatory authorities in the European Union. We may not be able to file for marketing approvals and may not receive necessary approvals
to commercialize our products in any market. Marketing approvals in countries outside the United States and Europe do not ensure pricing approvals in those countries or in any other countries, and marketing approvals and pricing approvals do not
ensure that reimbursement will be obtained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Side effects that appear following the launch of a drug on the market may result in the
product being taken off the market or additional warnings being added to the label despite having obtained all regulatory approvals. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A drug&#146;s launch in the market may expose a large number of patients to potential risks associated with the treatment with a new
pharmaceutical product. Certain side effects, which may not have been identified during clinical trials, can subsequently appear. For these reasons, regulatory agencies require companies to implement post-approval monitoring. Depending on the
occurrence of serious undesirable effects, the agencies may require that we or a collaboration partner of ours take a drug off the market temporarily or permanently, even if it is effective and has obtained all the necessary marketing
authorizations. Such an action would negatively impair our ability to generate revenue from such product and could more generally negatively affect our ability to develop, obtain regulatory approval for, and commercialize our other product
candidates and our reputation generally, each of which could have a material adverse effect on our business and results of operations. In addition, if the product candidates we develop receive marketing authorization and we or others identify
undesirable side effects caused by Lumoxiti or any other products after the approval, a number of potentially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant negative consequences could result, including that regulatory authorities may require the addition of labeling statements, such as a &#147;boxed&#148; warning or a contraindication,
we may be required to create a medication guide outlining the risks of such side effects for distribution to patients and our reputation may suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti and any other product candidate for which we obtain marketing approval will be subject to strict enforcement of post-marketing
requirements and we could be subject to substantial penalties, including withdrawal of our product from the market, if we fail to comply with all regulatory requirements or if we experience unanticipated problems with our product and product
candidates, when and if any of them are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lumoxiti and any product candidate for which we obtain marketing approval, will
be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities, including requirements relating to manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such
product. These requirements include, but are not limited to, restrictions governing promotion of an approved product, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements
relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. In addition, even if marketing approval of
a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed, restrictions for specified age groups, warnings, precautions or contraindications or to the conditions of
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other federal and state agencies, including the U.S. Department of Justice, or DOJ, closely regulate compliance
with all requirements governing prescription products, including requirements pertaining to marketing and promotion of products in accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP
requirements. The FDA and DOJ impose stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we do not market our products for their approved indications, we may be subject
to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. Prescription products may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may also
share truthful and not misleading information that is otherwise consistent with the labeling. Violations of such requirements may lead to investigations alleging violations of the Food, Drug and Cosmetic Act and other statutes, including the False
Claims Act and other federal and state health care fraud and abuse laws as well as state consumer protection laws. Our failure to comply with all regulatory requirements, and later discovery of previously unknown adverse events or other problems
with our products, manufacturers or manufacturing processes, may yield various results, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation involving patients taking our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on such products, manufacturers or manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage to relationships with any potential collaborators; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable press coverage and damage to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-compliance</FONT> by us or any future collaborator with the FDA, EMA or other regulatory requirements
regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with regulatory
requirements regarding the protection of personal information can also lead to significant penalties and sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our future
growth depends, in part, on our ability to penetrate multiple markets, in which we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future profitability will depend, in part, on our ability to commercialize Lumoxiti and our product candidates, if approved, in markets in
Europe, the United States and other countries where we maintain commercialization rights. If we commercialize Lumoxiti and any of our product candidates, if approved, in multiple markets, we would be subject to additional risks and uncertainties,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency exchange rate fluctuations and currency controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially adverse and/or unexpected tax consequences, including penalties due to the failure of tax planning or
due to the challenge by tax authorities on the basis of transfer pricing and liabilities imposed from inconsistent enforcement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the burden of complying with complex and changing regulatory, tax, accounting and legal requirements, many of
which vary between countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different medical practices and customs in multiple countries affecting acceptance of drugs in the marketplace;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing payor reimbursement regimes, governmental payors or patient
<FONT STYLE="white-space:nowrap">self-pay</FONT> systems and price controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tariffs, trade barriers, import or export licensing requirements or other restrictive actions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced or loss of protection of intellectual property rights in some foreign countries, and related prevalence
of generic alternatives to therapeutics; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">becoming subject to the different, complex and changing laws, regulations and court systems of multiple
jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other risks
associated with international operations may adversely affect our ability to attain or maintain profitable operations. Future sales of Lumoxiti or our product candidates, if they are approved, will be dependent on purchasing decisions of and
reimbursement from government health administration authorities, distributors and other organizations. As a result of adverse conditions affecting the global economy and credit and financial markets, including disruptions due to political
instability or otherwise, these organizations may defer purchases, may be unable to satisfy their purchasing or reimbursement obligations, or may affect milestone payments or royalties for Lumoxiti, monalizumab or any of our product candidates that
are approved for commercialization in the future. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product candidates obtain regulatory approval, they will be subject to
continuous regulatory review. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If marketing authorization is obtained for any of our product candidates, the candidate will remain
subject to continuous review and therefore authorization could be subsequently withdrawn or restricted. We will be subject to ongoing obligations and oversight by regulatory authorities, including adverse event reporting requirements, marketing
restrictions and, potentially, other post-marketing obligations, all of which may result in significant expense and limit our ability to commercialize such products. For example, we will be responsible for the completion of an FDA required
post-marketing trial of Lumoxiti. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If there are changes in the application of legislation or regulatory policies, or if problems are
discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or <FONT STYLE="white-space:nowrap">co-marketers</FONT> fails to comply with regulatory requirements, the regulators could take various
actions. These include imposing fines on us, imposing restrictions on the product or its manufacture and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations,
requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur
substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if one of our product candidates has orphan drug designation, we may not be able to obtain any benefit from such designation.
Furthermore, if a product is granted orphan drug exclusivity in the same indication for which we are developing IPH4102 or our other product candidates that is granted orphan drug designation, we may not be able to have our product candidate
approved by the applicable regulatory authority for a significant period of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some jurisdictions,
including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare
disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. In the European Union, the European Commission may designate a product candidate as an orphan medicinal product if it is
a medicine for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affects not more than five in 10,000 persons in the European Union, or it is unlikely that marketing of the medicine would generate sufficient
returns to justify the investment needed for its development. Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a
period of marketing exclusivity, which, subject to certain exceptions, precludes the FDA from approving the marketing application of another drug for the same indication for that time period or precludes the EMA, and other national drug regulators
in the European Union, from accepting the marketing application for another medicinal product for the same indication. The applicable period is seven years in the United States and ten years in the European Union. The European Union period can be
reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost in the United States if
the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. The granting of a request
for orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IPH4102 has
been granted orphan drug designation for CTCL in Europe and in the United States and we may pursue orphan drug designation for another product candidate that we may develop in the future in the United States and/or Europe. However, there is no
assurance we will be able to receive orphan drug designation for other product candidates that we may develop in the United States and/or Europe or for any other product candidate in any jurisdiction. Even if we are successful in obtaining orphan
drug designation, orphan drug status </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not ensure that we have market exclusivity in a particular market. Even if we obtain orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect
the product from competition because exclusivity can be suspended under certain circumstances. In the United States, even after an orphan drug is approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes
that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the European Union, orphan exclusivity will not prevent a marketing authorization being granted for a
similar medicinal product in the same indication if the new product is safer, more effective or otherwise clinically superior to the first product or if the marketing authorization holder of the first product is unable to supply sufficient
quantities of the product. In addition, if another product is granted marketing approval and orphan drug exclusivity in the same indication for which we are developing a product candidate with orphan drug designation, we may not be able to have our
product candidate approved by the applicable regulatory authority for a significant period of time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>A fast track, breakthrough
therapy or other designation by the FDA may not actually lead to a faster development. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek fast track,
breakthrough&nbsp;therapy or similar designation for our product candidates. If a product is intended for the treatment of a serious or life threatening condition and the product demonstrates the potential to address unmet medical need for this
condition, the sponsor may apply for FDA fast track designation. We have received fast track designation for IPH4102 for the treatment of adult patients with relapsed or refractory S&eacute;zary syndrome who have received at least two prior systemic
therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may in the future seek a breakthrough therapy designation for some of our product candidates that reach the
regulatory review process. A breakthrough therapy is a drug candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and that, as indicated by preliminary clinical
evidence, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies by
the FDA are eligible for accelerated approval and increased interaction and communication with the FDA designed to expedite the development and review process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, these designations do not ensure that we will experience a faster development process, review or approval compared to conventional
FDA procedures. In addition, the FDA may withdraw a designation if it believes that the designation is no longer supported by data from our clinical development program. A designation alone does not guarantee qualification for the FDA&#146;s
priority review procedures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Priority review designation by the FDA may not lead to a faster regulatory review or approval process
and, in any event, does not assure FDA approval of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA determines that a product candidate offers
major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six
months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if
we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any
advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the <FONT STYLE="white-space:nowrap">six-month</FONT> review cycle or thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to anti-corruption laws, as well as export control laws, customs laws,
sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of
operations and financial condition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to other laws and regulations governing our international operations, including
regulations administered by the governments of the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange
regulations, collectively referred to as the trade control laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S.
individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign
entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to
maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the
FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in
connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">French anti-corruption laws also prohibit acts of bribery and influence peddling: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 433-1 1&deg; and 432-11 1&deg; of the French Criminal Code (bribery of domestic public officials);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 433-1 2&deg; and 432-11 2&deg; of the French Criminal Code (influence peddling involving domestic public
officials ); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article 434-9 of the French Criminal Code (bribery of domestic judicial staff); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article 434-9-1 of the French Criminal Code (influence peddling involving domestic judicial staff);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 445-1 and 445-2 of the French Criminal Code (bribery of private individuals); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article 433-2 of the French Criminal Code (influence peddling involving private individuals);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 435-1 and 435-3 of the French Criminal Code (bribery of foreign or international public officials);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 435-7 and 435-9 of the French Criminal Code (bribery of foreign or international judicial staff);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 435-2, 435-4, 435-8 and 435-10 of the French Criminal Code (active and passive influence peddling
involving foreign or international public officials and foreign or international judicial staff); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">French Law of December 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2017 on Transparency, the Fight
Against Corruption and the Modernization of the Economy (Sapin 2 Law). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that we will be effective
in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the French anti-corruption laws or other legal requirements, including trade control laws. If we are not in compliance with the FCPA, the French anti-corruption
laws and other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial
condition, results of operations and liquidity. Likewise, any investigation of any potential violations of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the FCPA, the French anti-corruption laws, other anti-corruption laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, results
of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to healthcare laws and regulations which may require substantial compliance
efforts and could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and others will play a primary role in the recommendation and prescription of our products, if approved. Our
arrangements with such persons and third-party payors and our operations will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we research, market, sell and distribute our products, if we obtain marketing authorization. Restrictions under applicable U.S. federal, state and foreign healthcare laws and regulations include, but are not limited to, the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and
willfully soliciting, offering, receiving or providing remuneration, including any kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the
purchase or lease, order or recommendation of, any item, good, facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False
Claims Act, which impose criminal and civil penalties, including those from civil whistle-blower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment that
are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that impose criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering up a material
fact or making false statements relating to healthcare matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing
regulations, which impose certain requirements on covered entities and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health
information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the ACA,
that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to track and annually
report to CMS payments and other transfers of value provided to physicians and teaching hospitals, and certain ownership and investment interests held by physicians or their immediate family members; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state or foreign laws and regulations, such as state anti-kickback and false claims laws, including the
French &#147;Bertrand Law&#148;, French Ordinance <FONT STYLE="white-space:nowrap">n&deg;2017-49</FONT> of 19&nbsp;January 2017, and the UK&#146;s Bribery Act 2010, which may apply to items or services reimbursed by any third-party payor, including
commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements, state laws that require biopharmaceutical companies to comply with the biopharmaceutical
industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state laws that require the reporting of information relating to drug and biologic pricing; state and local laws that require
the registration of pharmaceutical sales representatives and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect as
HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our business arrangements with third parties comply with applicable healthcare
laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If our operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,
fines, disgorgement, imprisonment, possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar
agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could
substantially disrupt our operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions,
including exclusions from government funded healthcare programs. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer of
personal information. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may collect, process, use or transfer personal information from individuals located in the European Union
in connection with our business, including in connection with conducting clinical trials in the European Union. Additionally, we intend to commercialize Lumoxiti, and any of our product candidates that receive marketing approval, in the European
Union. The collection and use of personal health data in the European Union is governed by the provisions of the General Data Protection Regulation ((EU) 2016/679), or the GDPR. This legislation imposes requirements relating to having legal bases
for processing personal information relating to identifiable individuals and transferring such information outside of the European Economic Area, or EEA, including to the United States, providing details to those individuals regarding the processing
of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#146; requests to exercise their rights in respect of their personal
information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments and record-keeping. The
GDPR imposes additional responsibilities and liabilities in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. Failure to comply with the
requirements of the GDPR and related national data protection laws of the member states of the European Union may result in substantial fines, other administrative penalties and civil claims being brought against us, which could have a material
adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend upon our existing collaboration partners, AstraZeneca, Sanofi and other third parties, and may depend upon future collaboration
partners to commit to the research, development, manufacturing and marketing of our drugs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have significant collaborations with
AstraZeneca for the commercialization of Lumoxiti and the development of monalizumab, IPH5201 and other product candidates. We also collaborate with Sanofi for the development of IPH61, and we may enter into additional collaborations for other of
our product candidates or technologies in development. We cannot control the timing or quantity of resources that our existing or future collaborators will dedicate to research, preclinical and clinical development, manufacturing or marketing of our
products. Our collaborators may not perform their obligations according to our expectations or standards of quality. Our collaborators could terminate our existing agreements for a number of reasons, including that they may have other, higher
priority products in development or because our partnered programs may no longer be a priority for them. If any of our collaboration agreements were to be terminated, we could encounter significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delays in developing our product candidates, lose the opportunity to earn any revenues we expected to generate under such agreements, incur unforeseen costs, and suffer damage to the reputation
of our product, product candidates and as a company generally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to optimize the launch and market penetration of certain of our
future product candidates, we may enter into distribution and marketing agreements with pharmaceutical industry leaders. For these product candidates, we would not market our products alone once they have obtained marketing authorization. The risks
inherent in entry into these contracts are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the negotiation and execution of these agreements is a long process that may not result in an agreement being
signed or that can delay the development or commercialization of the product candidate concerned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">these agreements are subject to cancellation or <FONT STYLE="white-space:nowrap">non-renewal</FONT> by our
collaborators, or may not be fully complied with by our collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of a license granted by us, we lose control of the development of the product candidate licensed; in
such cases we would have only limited control over the means and resources allocated by our partner for the commercialization of our product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly obtain, maintain, enforce, or defend our intellectual property or proprietary
rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these risks materialize, or should we fail to find suitable collaborators, this could have a material adverse effect on our
business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The late-stage development and marketing of our product
candidates may partially depend on our ability to establish collaborations with major biopharmaceutical companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to
develop and market some of our product candidates, we rely on collaboration, research and license agreements with pharmaceutical companies to assist us in the development of product candidates and the financing of their development. For our most
advanced clinical product candidate, monalizumab, we entered into an agreement with AstraZeneca, in part because of their late-stage development and marketing capabilities. As we identify new product candidates, we will determine the appropriate
strategy for development and marketing, which may result in the need to establish collaborations with major biopharmaceutical companies. We may also enter into agreements with institutions and universities to participate in our other research
programs and to share intellectual property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may fail to find collaboration partners and to sign new agreements for our other
product candidates and programs. The competition for partners is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new
collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic
transaction, may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or
business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#146;s time and attention in order to manage a collaboration or
develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs,
write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key
suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on
our business, financial condition, results of operations and prospects. Conversely, any failure to enter any additional collaboration or other strategic transaction that would be beneficial to us could delay the development and potential
commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to supply key materials used in our research and development, to provide services to us and to assist with
clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make considerable use of third-party suppliers for the key materials used in our business. The failure of
third-party suppliers to comply with regulatory standards could result in the imposition of sanctions on us. These sanctions could include fines, injunctions, civil penalties, refusal by regulatory organizations to grant approval to conduct clinical
trials or marketing authorization for our products, delays, suspension or withdrawal of approvals, license revocation, seizure or recalls of our products, operating restrictions and legal proceedings. Furthermore, the presence of <FONT
STYLE="white-space:nowrap">non-conformities,</FONT> as detected in regulatory toxicology studies, could result in delays in the development of one or more of our product candidates and would require further tests to be financed. Although we are
involved in establishing the protocols for the production of these materials, we do not control all the stages of production and cannot guarantee that the third parties will fulfil their contractual and regulatory obligations. In particular, a
partner&#146;s failure to comply with protocols or regulatory constraints, or repeated delays by a partner, could compromise the development of our products or limit its liability. Such events could also inflate the product development costs
incurred by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also use third parties to provide certain services such as scientific, medical or strategic consultancy services.
These service providers are generally selected for their specific expertise, as is the case with the academic partners with whom we collaborate. To build and maintain such a network under acceptable terms, we face intense competition. Such external
collaborators may terminate, at any time, their involvement. We can exert only limited control over their activities. We may not be able to obtain the intellectual property rights to the product candidates or technologies developed under
collaboration, research and license agreements under acceptable terms or at all. Moreover, our scientific collaborators may assert intellectual property rights or other rights beyond the terms of their engagement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, we use third-party investigators to assist with conducting clinical trials. All clinical trials are subject to strict regulations and
quality standards. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We do not and will not have access to all information regarding our product candidates that are subject to collaboration and license
agreements. Consequently, our ability to inform our shareholders about the status of product candidates that are subject to these agreements, and our ability to make business and operational decisions, may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not and will not have access to all information regarding our product candidates that are subject to our license and collaboration
agreements with AstraZeneca, Sanofi and other third parties, including potentially material information about clinical trial design, execution and timing, safety and efficacy, clinical trial results, regulatory affairs, manufacturing, marketing and
other areas known by our collaborators. In addition, we have confidentiality obligations under our collaboration and license agreements. Therefore, our ability to keep our shareholders informed about the status of product candidates subject to such
agreements will be limited by the degree to which our collaborators keep us informed and allow us to disclose information to the public or provide such information to the public themselves. If our collaborators do not inform us about our product
candidates subject to agreements with them, we may make operational and investment decisions that we would not have made had we been fully informed, which may have an adverse impact on our business, prospects, financial condition and results of
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Manufacture of Lumoxiti and Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have no manufacturing capabilities and rely on third-party manufacturers for Lumoxiti and our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates that are tested during our preclinical and clinical trials are manufactured by third parties. We have no production
capabilities and rely on third parties to manufacture our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This strategy means that we do not directly control certain key
aspects of our product development, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality of the product manufactured; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the delivery times for drugs for a given clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical and commercial quantities that can be supplied; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with applicable laws and regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on third-party manufacturers creates risks that may not exist if we had our own manufacturing capabilities. These risks include:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of third-party manufacturers to comply with regulatory and quality-control standards;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production of insufficient quantities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage during transport and/or storage of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach of agreements by third-party manufacturers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the agreements for reasons beyond our
control. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should our third-party manufacturers breach their obligations or should we fail to renew our contracts with
them, we cannot guarantee that we will be able to find new suppliers within a timeframe and under conditions that would not be detrimental. We could also be faced with delays or interruptions in our supplies, which could result in a delay in the
clinical trials and, ultimately, a delay in the commercialization of the product candidates that we are developing or a loss of product sales. Should any of these risks materialize, this could have a material adverse effect on our business,
prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are reliant upon third parties to manufacture and supply components of
certain substances necessary to manufacture Lumoxiti and our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently independently conduct
manufacturing activities for Lumoxiti or our product candidates in development, and we are reliant on several third-party CMOs for the manufacture and supply of components and substances for all of the product candidates we are developing. In
addition, certain component materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or
another company that is not interested in continuing to manufacture these materials for us. We cannot assure you that, if required, we will be able to identify alternate sources with the desired scale and capability and establish relationships with
such sources. A loss of any CMO or component supplier and delay in establishing a replacement could delay our clinical development and regulatory approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing facilities and clinical trial sites are subject to significant government regulations and approvals and if our or our
partners third-party manufacturers fail to comply with these regulations or maintain these approvals, our business could be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third-party manufacturers are subject to ongoing regulation and periodic inspection by national authorities, including the EMA, FDA and
other regulatory bodies to ensure compliance with cGMP, when </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
producing batches of Lumoxiti and our product candidates for clinical trials. CROs and other third party research organizations must also comply with GLP when carrying out regulatory toxicology
studies. Any failure to follow and document our or their adherence to such GMP and GLP regulations or other regulatory requirements may lead to significant delays in the availability of products for commercial sale or clinical trials, may result in
the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications for our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with applicable regulations could also result in national authorities, the EMA, FDA or other applicable regulatory
authorities taking various actions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">levying fines and other civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposing consent decrees or injunctions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to suspend or put on hold one or more of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspending or withdrawing regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delaying or refusing to approve pending applications or supplements to approved applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to suspend manufacturing activities or product sales, imports or exports; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to communicate with physicians and other customers about concerns related to actual or potential
safety, efficacy, and other issues involving our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandating product recalls or seizing products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposing operating restrictions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking criminal prosecutions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the foregoing actions could be detrimental to our reputation, business, financial condition or operating results. Furthermore, our key
suppliers may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all. In addition, before any additional
products would be considered for marketing authorization in Europe, the United States or elsewhere, our suppliers will have to pass an inspection by the applicable regulatory agencies. We are dependent on our suppliers&#146; cooperation and ability
to pass such inspections, and the inspections and any necessary remediation may be costly. Failure to pass such inspections by us or any of our suppliers would affect our ability to commercialize Lumoxiti or our product candidates in Europe, the
United States or elsewhere. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our production costs may be higher than we currently estimate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lumoxiti and our product candidates are manufactured according to manufacturing best practices applicable to drugs for clinical trials and to
specifications approved by the applicable regulatory authorities. If any of our products were found to be <FONT STYLE="white-space:nowrap">non-compliant,</FONT> we would be required to manufacture the product again, which would entail additional
costs and may prevent delivery of the product to patients on time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other risks inherent in the production process may have the same
effect, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contamination of the controlled atmosphere area; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unusable premises and equipment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new regulatory requirements requiring a partial and/or extended stop to the production unit to meet the
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unavailable qualified personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">power failure of extended duration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">logistical error. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these risks materialize, this could have a material adverse effect our business, prospects, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may use hazardous chemicals and biological materials in our business and any claims relating to improper handling,
storage or disposal of these materials could be time-consuming and costly. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development processes involve the
controlled use of hazardous materials, including chemicals, biological and radioactive materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We also handle genetically
recombined material, genetically modified species and pathological biological samples. Consequently, in France and in the jurisdictions where we conduct clinical trials, we are subject to environment and safety laws and regulations governing the
use, storage, handling, discharge and disposal of hazardous materials, including chemical and biological products and radioactive materials. We impose preventive and protective measures for the protection of our workforce and waste control
management in accordance with applicable laws, including part four of the French Labor Code, relating to occupational health and safety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In France, we are required to comply with a number of national, regional and local legislative or regulatory provisions regarding radiation
and hazardous materials, including specific regulations regarding the use, handling and storage of radioactive materials and the potential exposure of employees to hazardous materials and radiation. We must also comply with French regulations
concerning the use and handling of genetically modified organisms, or GMOs, in confined spaces. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable
regulations, we could be subject to fines and may have to suspend all or part of our operations. Compliance with environmental, health and safety regulations involves additional costs, and we may have to incur significant costs to comply with future
laws and regulations in relevant jurisdictions. Compliance with environmental laws and regulations could require us to purchase equipment, modify facilities and undertake considerable expenses. We could be liable for any inadvertent contamination,
injury or damage, which could negatively affect its business, although we have subscribed to an insurance policy covering certain risks inherent to its business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Organization and Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy involves continuing to grow our business internally. However, we may also grow externally through selective acquisitions of
complementary products and technologies, or of companies with such assets, although no such plan is currently contemplated. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our
operations, particularly in the areas of research, drug development, regulatory affairs and sales, marketing and distribution for our approved product, Lumoxiti. To manage our anticipated future growth, we must continue to implement and improve our
managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company
with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management may need to divert a disproportionate amount of its attention away from its <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a substantial amount of time to managing internal or external growth. We may not be able to effectively manage the expansion of our operations which may result in weaknesses
in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional
product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business
strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to acquire assets or companies, the success of such an acquisition would depend on our capacity to carry out such
acquisitions and to integrate such assets or companies into our existing operations. The implementation of such a strategy could impose significant constraints, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">human resources: recruiting, integrating, training, managing, motivating and retaining a growing number of
employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial and management system resources: identification and management of appropriate financing and management
of our financial reporting systems; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">infrastructure: expansion or transfer of our laboratories or the development of our information technology
system. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to manage internal growth or have difficulty integrating any acquisitions, it could have a
material adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will need to hire new
employees and expand our use of service providers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2019, we had 208 employees. As our development and
commercialization plans and strategies develop, we must add a significant number of additional managerial, operational, sales, marketing, financial and other personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely, and for the foreseeable future will continue to rely, in part on certain independent organizations, advisors and
consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified
replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or
terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside
contractors and consultants on economically reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our organization by
hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize Lumoxiti and our product candidates and, accordingly, may not achieve
our research, development and commercialization goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on qualified management personnel and our business could be harmed
if we lose key personnel and cannot attract new personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to retain key persons in our organization and to recruit
qualified personnel is crucial for our success. In particular, our success depends heavily on its ability to retain key people in our organization, including key scientific and medical personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should we be unable to retain the individuals who form our team of key managers and key scientific advisors, it could have a material adverse
effect on our business and development and could consequently affect our business, prospects, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to recruit qualified scientific and medical personnel to carry out our clinical
trials and expand into new areas that require specialized skills, such as regulatory matters, marketing and manufacturing. We compete with other companies, research organizations and academic institutions in recruiting and retaining highly qualified
scientific, technical and management personnel. Competition for such personnel is very intense in the biopharmaceutical field and there can be no assurance that we will be successful in attracting or retaining such personnel and the failure to do so
could harm our operations and our growth prospects. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our business may be exposed to foreign exchange risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur some of our expenses, and derive certain of our revenues, in currencies other than the euro. In particular, as we expand our
operations and conduct additional clinical trials in the United States, we will incur additional expenses in U.S. dollars. As a result, we are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to
fluctuations in foreign currency exchange rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not engage in hedging transactions to protect against uncertainty in
future exchange rates between particular foreign currencies and the euro. Therefore, an unfavorable change in the value of the euro against the U.S. dollar could have a negative impact on our revenue and earnings growth. We cannot predict the impact
of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows. The ADSs being offered in the U.S. offering will be quoted in U.S. dollars on
Nasdaq, while our ordinary shares trade in euro on Euronext Paris. Our financial statements are prepared in euro. Therefore, fluctuations in the exchange rate between the euro and the U.S. dollar will also affect, among other matters, the value of
our ordinary shares and ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our license and collaboration agreements with AstraZeneca, the payments we receive are in U.S.
dollars. In the future, we could generate part of our sales in the United States and part in Europe and could therefore be subject to an unfavorable euro/dollar exchange rate. Therefore, for example, an increase in the value of the euro against the
U.S. dollar could be expected to have a negative impact on our revenue and earnings growth as U.S. dollar revenue and earnings, if any, would be translated into euro at a reduced value. We could also sign contracts denominated in other currencies,
which would increase our exposure to currency risk. In accordance with our business decisions, our exposure to this type of risk could change depending on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currencies in which we receive our revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currencies chosen when agreements are signed, such as licensing agreements, or
<FONT STYLE="white-space:nowrap">co-marketing</FONT> or <FONT STYLE="white-space:nowrap">co-</FONT> development agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the location of clinical trials on product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our policy for insurance cover. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, we have not put any specific hedging arrangements in place to address these risks. Should any of these risks materialize, this
could have a material adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Product liability
and other lawsuits could divert our resources, result in substantial liabilities, reduce the commercial potential of Lumoxiti or our product candidates and damage our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that we develop therapeutic products intended to be tested on humans and used to treat humans, the risk that we may be sued on product
liability claims is inherent in our business. Side effects of, or manufacturing defects in, products that we develop could result in the deterioration of a patient&#146;s condition, injury or even death. For example, our liability could be sought
after by patients participating in the clinical trials in the context of the development of the therapeutic products tested and unexpected side effects resulting from the administration of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these products. Once a product is approved for sale and commercialized, the likelihood of product liability lawsuits increases. Criminal or civil proceedings might be filed against us by
patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing our products. These actions could include claims resulting from acts by our partners, licensees and subcontractors, over which we have little
or no control. These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities, may be forced to limit or
forgo further commercialization of the affected products and may suffer damage to our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the clinical trial process is
designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical
trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use Lumoxiti or our
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained liability insurance coverage for each of our clinical trials in compliance with local legislation
and rules. In the United States, our aggregate insurance coverage for our ongoing clinical trials is &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million in the aggregate. Our insurance coverage may not be
sufficient to cover any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect
us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in
our favor, could be substantial. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have obtained product liability insurance with a coverage amount of &#128;10&nbsp;million per year. Our product
liability insurance will need to be adjusted in connection with the commercial sales of Lumoxiti and our product candidates, and may be unavailable in meaningful amounts or at a reasonable cost. If we are the subject of a successful product
liability claim that exceeds the limits of any insurance coverage we obtain, we would incur substantial charges that would adversely affect our earnings and require the commitment of capital resources that might otherwise be available for the
development and commercial launch of our product programs. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>There are material weaknesses and significant deficiencies in our internal controls over financial reporting and if we are unable to
maintain effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could hurt our business, lessen investor confidence and depress the market price of our
securities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must maintain effective internal control over financial reporting in order to accurately and timely report our
results of operations and financial condition. In addition, as a public company listed in the United States, the Sarbanes-Oxley Act will require, among other things, that we assess the effectiveness of our internal control over financial reporting
at the end of each fiscal year starting with the end of the first full fiscal year after the completion of the global offering. However, our independent registered public accounting firm will not be required to attest to the effectiveness of our
internal controls over financial reporting for so long as we are an &#147;emerging growth company,&#148; which may be up to five fiscal years following the date of this global offering. An independent assessment of the effectiveness of our internal
controls could detect problems that our management&#146;s assessment might not. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has not completed an assessment of the
effectiveness of our internal control over financial reporting, and our independent registered public accounting firm has not conducted an audit of our internal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
control over financial reporting. In the course of auditing the consolidated financial statements as of and for the year ended December&nbsp;31, 2018, a material weakness in our internal controls
related to the recognition of the revenue from our collaboration and licensing agreement with AstraZeneca on monalizumab was identified. The specific weakness in our internal controls involved insufficient review of the calculation of the
transaction price and percentage of completion of costs incurred, leading to an incorrect amount of revenue recognized for the year ended December&nbsp;31, 2018, which was corrected prior to the issuance of our audited financial statements. In the
course of auditing the consolidated financial statements as of and for the year ended December&nbsp;31, 2017, three material weaknesses in our internal controls were identified. The material weaknesses related to (i)&nbsp;the accounting for
subcontracting clinical costs for which there was insufficient control on the input data from clinical studies (termination date of the study and/or number of expected visits), (ii) stock-based compensation with insufficient control surrounding the
valuation of AGAP by external valuators, and (iii)&nbsp;a risk of management override of controls on manual journal entries due to insufficient supporting documentation for certain entries. Errors not detected in relation to topics (i)&nbsp;and (ii)
have led to incorrect amounts of research and development expenses and personnel expenses for the year ended December&nbsp;31, 2017, which were corrected prior to the issuance of our audited financial statements. A number of significant deficiencies
in our internal controls have also been identified for the years ended December 31, 2018 and December 31, 2017. A number of significant deficiencies in our internal controls have also been identified for the years ended December&nbsp;31, 2018 and
December&nbsp;31, 2017. Over the course of 2019, we continue to work to remediate these material weaknesses and significant deficiencies and strengthen our controls in these areas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken and are taking steps to remediate the foregoing weaknesses and deficiencies. However, if we do not successfully remediate these
issues or if we fail to design and operate effective internal controls in the future, it could result in material misstatements in our financial statements, result in the loss of investor confidence in the reliability of our financial statements and
subject us to regulatory scrutiny and sanctions, which in turn could harm the market value of our ordinary shares and ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules
governing the standards that will have to be met for our management to assess our internal control over financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act are complex and require significant documentation, testing and
possible remediation. These stringent standards require that our audit committee be advised and regularly updated on management&#146;s review of internal control over financial reporting. We have begun the process of designing, implementing, and
testing the internal control over financial reporting required to comply with this obligation. This process is time-consuming, costly, and complicated. Our management may not be able to effectively and timely implement controls and procedures that
adequately respond to the increased regulatory compliance and reporting requirements that will be applicable to us as a public company listed in the United States. If we fail to staff our accounting and finance function adequately or maintain
internal control over financial reporting adequate to meet the demands that will be placed upon us as a public company listed in the United States, our business and reputation may be harmed and the price of our ordinary shares and ADSs may decline.
In addition, undetected material weaknesses in our internal control over financial reporting could lead to restatements of financial statements and require us to incur the expense of remediation. Any of these developments could result in investor
perceptions of us being adversely affected, which could cause a decline in the market price of our securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our internal
computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have implemented a security policy intended to secure our data against impermissible access and to preserve the integrity and
confidentiality of the data. Despite the implementation of security measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural
disasters, terrorism, war, telecommunication and electrical failures, and other sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If such an event were to occur and cause interruptions in our operations, it could result in
a material disruption of our programs. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. To
the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary
information, we could incur liabilities, including penalties under data privacy laws such as the GDPR and other regulations, and the further development of our product candidates could be delayed. Should any of these risks materialize, this could
have a material adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage
in misconduct or other improper activities, including violating applicable regulatory standards and requirements, engaging in insider trading or violate the terms of their confidentiality agreements, which could significantly harm our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to
comply with legal requirements or the requirements of national authorities, the EMA, FDA and other government regulators, provide accurate information to applicable government authorities, comply with fraud and abuse and other healthcare laws and
regulations in the United States, Europe and elsewhere, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to
extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales
commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory
sanctions and serious harm to our reputation. We have a Code of Ethics that applies to all employees and consultants, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this
activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our partners, employees,
consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized
disclosure of confidential information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our
competitive business position. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire businesses or products in the future and we may not realize the benefits of such acquisitions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although our current strategy involves continuing to grow our business internally, we may grow externally through selective acquisitions of
complementary products and technologies, or of companies with such assets. If such acquisitions were to become necessary or attractive in the future, we may not be able to identify appropriate targets or make acquisitions under satisfactory
conditions, in particular, satisfactory price conditions. In addition, we may be unable to obtain the financing for these acquisitions under favorable conditions, and could be led to finance these acquisitions using cash that could be allocated to
other purposes in the context of existing operations. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from an acquisition that delay or prevent us from realizing their expected benefits or
enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction, which could have a material adverse effect on our business, financial conditions, earnings and
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to compete may be adversely affected if we do not adequately obtain, maintain, protect and enforce our intellectual property
or proprietary rights, or if the scope of intellectual property protection we obtain is not sufficiently broad. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success
depends, in large part, on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to Lumoxiti and our product candidates. However, we may not be able to obtain,
maintain or enforce our patents and other intellectual property rights which could affect our ability to compete effectively. For example, we cannot guarantee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we will file all necessary or desirable patent applications or that we will obtain the patents that we have
applied for and that are under review; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we will be able to develop new patentable product candidates or technologies or obtain patents to protect
such new product candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we or our licensing or collaboration partners were the first to make the product candidates or technologies
covered by the issued patents or pending patent applications that we license or own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we will be able to obtain sufficient rights to all necessary or desirable patents or other intellectual
property rights, whether at all or on reasonable terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the scope of any issued patents that we own or license will be broad enough to protect Lumoxiti or our
product candidates or effectively prevent others from commercializing competitive technologies and product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that there is no risk of our owned and licensed patents being challenged, invalidated or circumvented by a third
party. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file,
prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time
to obtain patent protection. Although we enter into confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, consultants, CROs, outside scientific
collaborators, sponsored researchers, and other advisors, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Given the amount of
time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not
provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. In addition, in some circumstances, we may not have the right to control the preparation, filing, prosecution, maintenance,
enforcement and defense of patents and patent applications covering technology that we license to or from third parties. For example, pursuant to our license agreement with AstraZeneca for monalizumab, AstraZeneca retains control of such activities
for certain patents that we license to it under the agreement and patents that arise under the collaboration. We cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in
a manner consistent with the best interest of our business. If any third party that controls our patents and patent applications fails to maintain our patents or such third party loses rights to our patents or patent applications, our rights to
those patents and underlying technology may be reduced or eliminated and our right to develop and commercialize our product candidates that are subject to such rights could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, some of our patents and patent applications are, and may in the future be, <FONT STYLE="white-space:nowrap">co-owned</FONT> with
third parties. If we are unable to obtain an exclusive license to any such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT>
may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We may also need the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted
after issuance. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will
provide us with any meaningful protection, prevent competitors or other third parties from circumventing our patents by developing similar or alternative technologies or products in a noninfringing manner, or otherwise provide us with any
competitive advantage. Challenges from competitors or other third parties could reduce the scope of our patents or render them invalid or unenforceable, which could limit our ability to stop others from using or commercializing similar or identical
technology and product candidates, or limit the duration of the patent protection for Lumoxiti and our product candidates. The legal proceedings that we may then have to enter into in order to enforce and defend our intellectual property could be
very costly and could distract our management and other personnel from their normal responsibilities, notably in the case of lawsuits in the United States. The probability of disputes arising over our intellectual property will increase
progressively as patents are granted and as the value and appeal of the inventions protected by these patents are confirmed. The occurrence of any of these events concerning any of our patents or intellectual property rights could have a material
adverse effect our business, prospects, financial condition and results of operations. These risks are even higher for us, because of our limited financial and human resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions,
and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in
patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. Furthermore, our owned and
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our owned and licensed patent rights and technology was funded in
part by the U.S. government. As a result, the government may have certain rights, or <FONT STYLE="white-space:nowrap">march-in</FONT> rights, to such patent rights and technology. When new technologies are developed with government funding, the
government generally obtains certain rights in any resulting patents, including a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license authorizing the government to use the invention for
<FONT STYLE="white-space:nowrap">non-commercial</FONT> purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights to use or allow
third parties to use our licensed technology. The government can exercise its <FONT STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because we fail to achieve practical application of the government-funded
technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to
manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may allege that we or our partners infringe, misappropriate or otherwise violate such third parties&#146; intellectual
property rights, which could prevent or delay our development efforts, stop us from commercializing Lumoxiti or our product candidates, or increase the costs of commercializing Lumoxiti or our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends on our ability and the ability of our partners to develop, manufacture, market and sell Lumoxiti and our product
candidates, and use our proprietary technologies, without infringing, misappropriating or otherwise violating any intellectual property or proprietary rights of third parties. The field of biopharmaceuticals involves significant patent and other
intellectual property litigation, which can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth of claims allowed in some patents covering biopharmaceutical compositions also may be uncertain and
difficult to determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be aware of all third-party intellectual property rights potentially relating to
our product candidates. In general, in the United States patent applications are not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot be sure that we were the first to make the inventions claimed in any
owned or licensed patents or pending patent applications, or that we were the first to file for patent protection for such inventions. If we were not the first to invent such inventions or first to file any patent or patent application for such
inventions, we may need to obtain licenses from third parties (which may not be available under commercially reasonable terms, or at all), delay the launch of product candidates, or cease the production and sale of certain product candidates or
develop alternative technologies that are the subject of such patents or patent applications, any of which could have a material adverse effect on our business, prospects, financial condition and results of operations. For example, third parties may
claim that IPH4102 uses technology protected by their patents. Although we believe that our current activities and our planned development of IPH4102 does not and will not infringe on such patents, which expire in the near term, third parties may
disagree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may allege that we or our partners infringe, misappropriate or otherwise violate any such third party&#146;s
patents or other intellectual property rights and assert infringement claims against us, regardless of their merit. A court of competent jurisdiction could hold that these third party patents are valid, enforceable and infringed, which could
materially and adversely affect our ability to commercialize Lumoxiti and any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the
validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is
no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#146;s intellectual property rights, and we are unsuccessful in demonstrating that such rights are
invalid or unenforceable, we could be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bear the potentially significant costs of proceedings brought against us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay damages, which may include treble damages and attorney&#146;s fees if we are found to have willfully
infringed a third party&#146;s patent rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cease developing, manufacturing and commercializing the infringing technology or product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire a license to such third-party intellectual property rights, which may not be available on commercially
reasonable terms, or at all, and may be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other intellectual property proceedings may cause us to incur significant expenses and could
distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares or ADSs. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Should one or more of the
foregoing risks materialize, this could have a material adverse effect on our reputation, business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our patents could be found invalid or unenforceable if challenged and we may not be able to protect our intellectual property.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our and our licensors&#146; patents and patent applications, if issued, may be challenged, invalidated or circumvented by third
parties. U.S. patents and patent applications may also be subject to interference proceedings, <FONT STYLE="white-space:nowrap">re-examination</FONT> proceedings, derivation proceedings, post-grant review or <I>inter partes</I> review in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States Patent and Trademark Office, or USPTO, challenging our or our licensors&#146; patent rights. Foreign patents may be subject also to opposition or comparable proceedings in the
corresponding foreign patent office. For example, two of our European patents with claims covering a class of anti-NKG2A antibodies defined by characteristics shared with monalizumab have been challenged in oppositions at the European Patent Office,
or the EPO. Although the Opposition Division of the EPO issued a decision that some claims covering such class of anti-NKG2A antibodies are valid, the Opposition Division&#146;s decisions for both patents are currently under appeal. We have also
received notices that third parties filed oppositions challenging our <FONT STYLE="white-space:nowrap">in-licensed</FONT> European patents covering certain of our CD39 technology, and these oppositions are currently pending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may allege that third parties infringe our or our licensors&#146; patents and the defendant could counterclaim that such
patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several
statutory requirements, including lack of novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent
withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we
cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such patent litigation or proceeding could result in the loss of our or our licensors&#146; patents, denial of our or our licensors&#146;
patent applications or loss or reduction in the scope of one or more of the claims of such patents or patent applications. Accordingly, our or our licensors&#146; rights under any issued patents may not provide us with sufficient protection against
competitive product candidates or processes, we could become unable to manufacture or commercialize Lumoxiti or our product candidates without infringing third-party patent rights, and the duration of the patent protection of Lumoxiti or our product
candidates could be limited. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation. Even if we are successful, such litigation or proceedings may be costly and may distract our management and other personnel from their normal responsibilities. Any of the foregoing could have a material adverse effect
on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends
on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT>
with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or
applications will be due to be paid to the USPTO, and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or patent applications and any patent rights we may own in the future. In
certain circumstances, we may rely on our licensing partners to pay these fees. The USPTO and various foreign patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent
application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT>
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or
identical products or technology, which could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Developments in patent law could have a negative impact on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws could increase the uncertainties and costs surrounding the prosecution
of patent applications and the enforcement or defense of issued patents. For example, from time to time, the U.S. Congress, the USPTO or similar foreign authorities may change the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standards of patentability and any such changes could have a negative impact on our business. In addition, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into
law in September 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> system to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, changes to the way issued patents are challenged and changes to the way patent applications are disputed during the examination process such
as allowing third-party submission of prior art to the USPTO during patent prosecution. These changes may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. Under a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system, assuming that other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on
an invention regardless of whether another inventor made the invention earlier. The USPTO has developed new regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law
associated with the America Invents Act, and, in particular, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> provisions, became effective in March 2013. Substantive changes to patent law associated
with the America Invents Act, or any subsequent U.S. legislation regarding patents, may affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America Invents Act will
have on the cost of prosecuting our U.S. patent applications, our ability to obtain U.S. patents based on our discoveries and our ability to enforce or defend any patents that may issue from our patent applications, all of which could have a
material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changes to or different interpretations of patent laws in the United States and
other countries may permit others to use our or our partners&#146; discoveries or to develop and commercialize our technology and product candidates without providing any compensation to us, or may limit the number of patents or claims we can
obtain. The patent positions of companies in the biotechnology and pharmaceutical market are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of U.S. patent protection available in certain circumstances and weakened
the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts,
and the USPTO, as well as similar bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and
enforce our intellectual property in the future, which could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
legislation for extending the term of patents covering Lumoxiti and each of our product candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and conditions of FDA marketing authorization of Lumoxiti and our product candidates, one or more of our
U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments
permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the
remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended.
However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, fail to exercise due diligence during the testing phase or regulatory review process or otherwise fail
to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can
enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from Lumoxiti or an applicable product could be reduced, possibly materially, which
could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will not seek to protect our intellectual property rights in all jurisdictions
throughout the world and we may not be able to adequately enforce our intellectual property rights in all jurisdictions where we seek intellectual property protection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, maintaining, prosecuting and defending patents on Lumoxiti and our product candidates in all countries and jurisdictions throughout the
world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. Consequently, we may not be able to prevent third parties from using
our product candidates or technologies in all countries outside the United States, or from selling or importing products made using our product candidates or technologies in and into the United States or other jurisdictions. Competitors may use our
technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, and enforcement is not as strong as
that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in
particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the federal and state laws
in the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not
favor the enforcement of patents and other intellectual property protection, especially those relating to biopharmaceuticals or biotechnologies. This could make it difficult for us to stop the infringement of our patents, if obtained, or the
misappropriation or other violation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the
enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain
countries, and we will not have the benefit of patent protection in such countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal
decisions by courts in the United States and other countries may affect our ability to obtain adequate protection for our technology and the enforcement of our intellectual property. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Should any of these risks materialize, this could have a material adverse effect on our business,
prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert ownership or commercial rights to products,
product candidates or technologies that we develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties have made, and may in the future make, claims challenging the
inventorship or ownership of our intellectual property, which may result in the imposition of additional obligations on us, such as development, royalty and milestone payments. We have written agreements with partners or other third parties that
provide for the ownership of intellectual property arising from our collaborations and our other work with such third parties. These agreements provide that we must negotiate certain commercial rights with partners and other third parties with
respect to joint inventions or inventions made by our partners or such third parties that arise from the results of the collaboration or other work with such third parties. In some instances, there may not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be adequate written provisions to address clearly the resolution of intellectual property rights that may arise under our agreements. If we cannot successfully negotiate sufficient ownership and
commercial rights to the inventions that result from our use of a third party&#146;s materials where required, or if disputes otherwise arise with respect to the intellectual property developed with the use of a third party&#146;s samples, we may be
limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us
are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the
commercial value of such inventions. We also may be unsuccessful in executing assignment agreements with each party who, in fact, conceives or develops intellectual property that we regard as our own, or such agreements might not be self-executing
or might be breached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from
using certain intellectual property, may lose our exclusive rights in such intellectual property or may be required to acquire a license to such intellectual property, which may not be available on commercially reasonable terms or at all. Any of the
foregoing could have a material adverse impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations under license or
technology agreements with third parties, we could lose license rights that are critical to our business, and we may not be successful in obtaining necessary intellectual property rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We license intellectual property from third parties that is critical to our business through license agreements, including but not limited to
licenses related to the manufacture, composition, use and sale of our product candidates, and in the future we may enter into additional agreements that provide us with licenses to valuable intellectual property or technology. For example, we depend
on our license agreement with AstraZeneca for the commercialization of Lumoxiti and our license agreement with Novo Nordisk A/S for the development and commercialization of monalizumab. Our license agreements impose various obligations on us, which
may include development, royalty and milestone payments. If we fail to comply with any of these obligations, our licensors may have the right to terminate the agreements. If our license agreements with AstraZeneca or Novo Nordisk A/S or any other
current or future licensors terminate, we would lose valuable rights and may be required to cease our development, manufacture or commercialization of Lumoxiti or our product candidates, including monalizumab. In addition, our business would suffer
if our licensors fail to abide by the terms of the agreements, if our licensors fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable. Should any of these risks
materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, disputes may arise regarding intellectual property subject to a license agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of the counterparty that is
not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship or ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our counterparties and us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreements under which we currently license intellectual property from third parties are complex, and certain provisions in such
agreements may be susceptible to multiple interpretations. The resolution of any contract dispute that may arise could narrow what we believe to be the scope of our rights to the relevant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intellectual property, or modify in a manner adverse to us what we believe to be our or our counterpart&#146;s financial or other obligations under the relevant agreement, any of which could have
material adverse effect on our business, financial condition, results of operations and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current license agreement on acceptable
terms, we may be unable to unsuccessfully develop and commercialize the affected product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the growth of our
business may depend, in part, on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use proprietary rights held by third parties. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT>
intellectual property rights from third parties that we identify as necessary for our product candidates on reasonable terms or at all. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more
established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, capital resources,
and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual
property rights on terms that would allow us to make an appropriate return on our investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our business, we collaborate
with <FONT STYLE="white-space:nowrap">non-profit</FONT> and academic institutions to accelerate our preclinical research or development under agreements with these institutions. Typically, these institutions provide us with an option to negotiate a
license to any of the institution&#146;s or its employees&#146; rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are
acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our applicable development or commercialization program. If we are unable to
successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon the development and commercialization of the relevant program and our business,
financial conditions, results of operations and prospects could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert that our employees,
consultants or independent contractors have wrongfully used or disclosed confidential information or misappropriated trade secrets of their current or former employers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ individuals who are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their
work for us, and no such claims against us are currently pending, we may be subject to claims that we or our employees, consultants or independent contractors have used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such individual&#146;s current or former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Should any of these risks
materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be materially harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, because we operate in the highly technical field of biopharmaceutical drug development, we rely
in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our
employees, consultants, CROs, outside scientific collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confidential and not disclose to third parties all confidential information developed by such party or made known to such party by us during the course of such party&#146;s relationship with us.
However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets and confidential information and these agreements may be breached, and we may not have adequate remedies for
any breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical
and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our
security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect
trade secrets. Moreover, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed to or
misappropriated by a third party, or if any such information was independently developed by a third party, our competitive position could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our trade and technical secrets include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain unpatented technical expertise that we believe provides us with an advantage in conducting research and
development work in our field; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain scientific knowledge generated by the work we carry out; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain information relating to the product candidates we are currently developing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain information relating to the agreements signed between us and third parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unauthorized disclosure or misappropriation of certain of these secrets could allow third parties to offer products or services to compete
with ours or generally have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The structures put in place to protect our trade and technical
secrets do not constitute a guarantee that one or more of our trade and technical secrets will not be disclosed or misappropriated. The agreements or other arrangements to protect our trade secrets may fail to provide the protection sought, or are
breached, or that our trade secrets are disclosed to, or developed independently by, our competitors. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Unauthorized use of our trademarks may generate confusion and result in costs and delays to the detriment of our
marketing efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our trademarks are a key component of our identity and our products. Although the key components of our
trademarks have been registered, notably in France and the United States, other companies in the pharmaceutical sector might use or attempt to use similar trademarks or components of our trademarks, and thereby create confusion in the minds of third
parties. Our registered trademarks may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. In addition, there could be potential trademark infringement claims brought by owners of other
trademarks that incorporate variations of our registered or unregistered trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we develop trademarks for products that
conflict with intellectual property rights of third parties, we would then have to redesign or rename our products in order to avoid encroaching on the intellectual property rights of third parties. This could prove to be impossible or costly in
terms of time and financial resources and could be detrimental to our marketing efforts. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights
have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are the same as or similar to Lumoxiti and our product candidates or
utilize similar technology but that are not covered by the claims of the patents that we license or may own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our license partners or current or future collaborators, might not have been the first to make the
inventions covered by the issued patent or pending patent application that we license or may own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our license partners or current or future collaborators, might not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or licensed intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our owned or licensed pending patent applications will not lead to issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Ownership of Our Ordinary Shares and the ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>There has been no prior market for our ADSs and an active and liquid market for our securities may fail to develop, which could harm the
market price of the ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this global offering, while our ordinary shares have been listed on Euronext Paris since 2006,
there has been no public market on a U.S. national securities exchange for our ordinary shares or ADSs. Although we anticipate that the ADSs will be approved for listing on Nasdaq, an active trading market for the ADSs may never develop or be
sustained following this global offering. The initial offering price of the ADSs will be determined through negotiations between us and the underwriters. This offering price may not be indicative of the market price of our ordinary shares or ADSs
after this global offering. In the absence of an active trading market for the ADSs, investors may not be able to sell their ADSs at or above the offering price or at the time that they would like to sell. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of our equity securities may be volatile, and purchasers of our ordinary shares or ADSs could incur substantial
losses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is likely that the price of our ordinary shares and ADSs will be significantly affected by events such as announcements
regarding scientific and clinical results concerning product candidates currently being developed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by us, our collaboration partners or our main competitors, changes in market conditions related to our sector of activity, announcements of new contracts, technological innovations and
collaborations by us or our main competitors, developments concerning intellectual property rights, as well as the development, regulatory approval and commercialization of new products by us or our main competitors and changes in our financial
results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity markets are subject to considerable price fluctuations, and often, these movements do not reflect the operational and
financial performance of the listed companies concerned. In particular, biotechnology companies&#146; share prices have been highly volatile and may continue to be highly volatile in the future. As we operate in a single industry, we are especially
vulnerable to these factors to the extent that they affect our industry. Fluctuations in the stock market as well as the macro-economic environment could significantly affect the price of our ordinary shares. As a result of this volatility,
investors may not be able to sell their ordinary shares or ADSs at or above the price originally paid for the security. The market price for our ordinary shares and ADSs may be influenced by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in our financial condition and operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in our growth rate relative to our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition from existing products or new products that may emerge; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures,
collaborations or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results of delays in our or any of our competitors&#146; preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval for any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination of a strategic alliance or the inability to establish additional strategic alliances;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuance of new or updated research or reports by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary share and ADS price and volume fluctuations attributable to inconsistent trading volume levels of our
ordinary shares and ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">price and volume fluctuations in trading of our ordinary shares on Euronext Paris; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key management or scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments related to proprietary rights, including patents, litigation matters and our
ability to obtain patent and other intellectual property protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to coverage policies or reimbursement levels by commercial third-party payors and government payors and
any announcements relating to coverage policies or reimbursement levels; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional debt or equity financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our ordinary shares or ADSs by us, our insiders or our other shareholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and market conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other market and industry factors may cause the market price and demand for our ordinary shares and ADSs to fluctuate substantially,
regardless of our actual operating performance, which may limit or prevent investors from readily selling their ordinary shares or ADSs and may otherwise negatively affect the liquidity of the trading market for the ordinary shares and ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or
unfavorable research about our business, the price of the ordinary shares or ADSs and their trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
trading market for the ADSs and ordinary shares depends in part on the research and reports that securities or industry analysts publish about us or our business. As a public company in France since 2006, our equity securities are currently subject
to coverage by a number of analysts. If fewer securities or industry analysts cover our company, the trading price for the ADSs and ordinary shares would be negatively impacted. If one or more of the analysts who covers us downgrades our equity
securities or publishes incorrect or unfavorable research about our business, the price of the ordinary shares and ADSs would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us
regularly, or downgrades our securities, demand for the ordinary shares and ADSs could decrease, which could cause the price of the ordinary shares and ADSs or their trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently intend to pay dividends on our securities and, consequently, your ability to achieve a return on your investment
will depend on appreciation in the price of the ordinary shares and ADSs. In addition, French law may limit the amount of dividends we are able to distribute. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our ordinary shares and do not currently intend to do so for the foreseeable future. We
currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your ADSs for the foreseeable future and the success of an investment in the ADSs will depend upon any future
appreciation in its value. Consequently, investors may need to sell all or part of their holdings of the ADSs after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is no guarantee
that the ADSs will appreciate in value or even maintain the price at which our shareholders have purchased them. Investors seeking cash dividends should not purchase the ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, under French law, the determination of whether we have been sufficiently profitable to pay dividends is made on the basis of our
statutory financial statements prepared and presented in accordance with accounting standards applicable in France. Moreover, pursuant to French law, we must allocate 5% of our unconsolidated net profit for each year to our legal reserve fund before
dividends, should we propose to declare any, may be paid for that year, until the amount in the legal reserve is equal to 10% of the aggregate nominal value of our issued and outstanding share capital. In addition, payment of dividends may subject
us to additional taxes under French law. Therefore, we may be more restricted in our ability to declare dividends than companies that are not incorporated in France. See &#147;Description of Share Capital&#151;Key Provisions of Our Bylaws and French
Law Affecting Our Ordinary Shares&#148; for further details on the limitations on our ability to declare and pay dividends and the taxes that may become payable by us if we elect to pay a dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, exchange rate fluctuations may affect the amount of euro that we are able to distribute, and the amount in U.S. dollars that our
shareholders receive upon the payment of cash dividends or other distributions we declare and pay in euro, if any. These factors could harm the value of the ADSs, and, in turn, the U.S. dollar proceeds that holders receive from the sale of the ADSs.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase ADS in this global offering, you will experience substantial and immediate dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase ADS in this global offering, you will experience substantial and immediate dilution of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per ordinary share in the net tangible book value after giving effect to the global offering at an assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (based on &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, the closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019), because the price that you pay will be substantially greater than the net tangible book value per ordinary share that
you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the initial offering price when they purchased their ordinary shares. You will experience additional dilution upon exercise of any
outstanding warrants to purchase ordinary shares or if we otherwise issue additional ordinary shares or ADSs below the offering price. For a further description of the dilution that you will experience immediately after this global offering, see
&#147;Dilution.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this global offering and
may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have broad discretion in the application of the net proceeds that we receive from this
offering as well as of our existing cash, cash equivalents short-term investments and non-current financial assets, and we may spend or invest these funds in a way with which our shareholders or holders of our ADSs disagree. Our failure to apply
these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from the offering in a manner that does not produce income or that loses value. These investments may not yield a favorable
return to our investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of ordinary shares or ADSs by existing shareholders could depress the market price of the
ordinary shares or ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing shareholders sell, or indicate an intent to sell, substantial amounts of ordinary shares
or ADSs in the public market after the <FONT STYLE="white-space:nowrap">90-day</FONT> contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the trading price of the
ADSs could decline significantly and could decline below the offering price. Upon completion of the global offering, we will have outstanding &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary
shares, including ordinary shares represented by ADSs, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of which are subject to a contractual restriction on selling for up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; days, subject to customary exceptions. As of the date of this prospectus, the exercise of all our instruments convertible into ordinary shares would enable the subscription of new ordinary shares,
representing approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the diluted share capital. The underwriters may permit our members of the Executive Board and of the Supervisory Board, employees and current shareholders to sell ordinary shares prior to the
expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. See &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering expire, and based on the number of ordinary shares outstanding upon completion of this global offering, including ordinary shares represented by ADSs, additional
ordinary shares will be eligible for sale in the public market, all of which ordinary shares are held by members of the Executive Board and of the Supervisory Board and other affiliates and will be subject to volume limitations under Rule 144 under
the Securities Act of 1933, as amended, or the Securities Act. In addition, the ordinary shares subject to subscription under our instruments convertible under shares will become eligible for sale in the public market in the future, subject to
certain legal and contractual limitations. Sales of a large number of the ordinary shares in the public market could have an adverse effect on the market price of the ADSs. See &#147;Shares and ADSs Eligible for Future Sale&#148; for a more detailed
description of sales that may occur in the future. If these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of the ordinary shares and ADSs could decline substantially. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The dual listing of our ordinary shares and the ADSs following this global offering may adversely affect the liquidity and value of the
ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this global offering and after the ADSs begin trading on Nasdaq, our ordinary shares will continue to be listed on
Euronext Paris. Trading of the ADSs or ordinary shares in these markets will take place in different currencies (U.S. dollars on Nasdaq and euro on Euronext Paris), and at different times (resulting from different time zones, different trading days
and different public holidays in the United States and France). The trading prices of our ordinary shares on these two markets may differ due to these and other factors. Any decrease in the price of our ordinary shares on Euronext Paris could cause
a decrease in the trading price of the ADSs on Nasdaq. Investors could seek to sell or buy our ordinary shares to take advantage of any price differences between the markets through a practice referred to as arbitrage. Any arbitrage activity could
create unexpected volatility in both our share prices on one exchange, and the ordinary shares available for trading on the other exchange. In addition, holders of ADSs will not be immediately able to surrender their ADSs and withdraw the underlying
ordinary shares for trading on the other market without effecting necessary procedures with the depositary. This could result in time delays and additional cost for holders of ADSs. We cannot predict the effect of this dual listing on the value of
our ordinary shares and the ADSs. However, the dual listing of our ordinary shares and the ADSs may reduce the liquidity of these securities in one or both markets and may adversely affect the development of an active trading market for the ADSs in
the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The rights of shareholders in companies subject to French corporate law differ in
material respects from the rights of shareholders of corporations incorporated in the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a French company with
limited liability. Our corporate affairs are governed by our bylaws and by the laws governing companies incorporated in France. The rights of shareholders and the responsibilities of members of our Executive Board and of our Supervisory Board are in
many ways different from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. For example, in the performance of its duties, our Executive Board is required by French law to consider the interests of
our company, its shareholders, its employees and other stakeholders, rather than solely our shareholders and/or creditors. It is possible that some of these parties will have interests that are different from, or in addition to, your interests as a
shareholder or holder of ADSs. See &#147;Management&#151;Corporate Governance Practices&#148; and &#147;Description of Share Capital.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. investors may have difficulty enforcing civil liabilities against our company and members of the Executive Board and the
Supervisory Board. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of the members of our Executive Board and Supervisory Board and the experts named in this prospectus are <FONT
STYLE="white-space:nowrap">non-residents</FONT> of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such
persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. Additionally, it may be difficult to assert U.S. securities law
claims in actions originally instituted outside of the United States. Foreign courts may refuse to hear a U.S. securities law claim because foreign courts may not be the most appropriate forums in which to bring such a claim. Even if a foreign court
agrees to hear a claim, it may determine that the law of the jurisdiction in which the foreign court resides, and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be
proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the law of the jurisdiction in which the foreign court resides. In particular, there is some doubt as to whether French
courts would recognize and enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the
United States or elsewhere may be unenforceable in France. An award for monetary damages under the U.S. securities laws would be considered punitive if it does not seek to compensate the claimant for loss or damage suffered but is intended to punish
the defendant. French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of a corporation in the corporation&#146;s interest if it fails to bring such legal action
itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action may be borne by the relevant shareholder or the group of shareholders. The enforceability of any judgment in France will depend on
the particular facts of the case as well as the laws and treaties in effect at the time. The United States and France do not currently have a treaty providing for recognition and enforcement of judgments, other than arbitration awards, in civil and
commercial matters. See &#147;Enforcement of Civil Liabilities.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our bylaws and French corporate law contain provisions that
may delay or discourage a takeover attempt. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions contained in our bylaws and French corporate law could make it more
difficult for a third party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of our bylaws impose various procedural and other requirements, which could make it more difficult for shareholders to
effect certain corporate actions. These provisions include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, the owner of 90% of the share capital or voting rights of a public company listed on a
regulated market in a Member State of the European Union or in a state party to the EEA Agreement, including from the main French stock exchange, has the right to force out minority shareholders following a tender offer made to all shareholders;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a non-resident of France as well as any French entity controlled by non-residents of France may
have to file a declaration for statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such
filings are required in connection with investments exceeding &#128;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. See &#147;Limitations Affecting Shareholders of a French
Company&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, certain investments in a French company relating to certain strategic industries by individuals
or entities not residents in a Member State of the EU are subject to prior authorization of the Ministry of Economy. See &#147;Limitations Affecting Shareholders of a French Company&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger (i.e., in a French law context, a share for share exchange following which our company would be
dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our Executive Board as well as a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger of our company into a company incorporated outside of the European Union would require 100% of our
shareholders to approve it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a cash merger is treated as a share purchase and would require the consent of each
participating shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders may in the future grant our Executive Board broad authorizations to increase our share capital
or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have preferential subscription rights on a <I>pro rata </I>basis on the issuance by us of any
additional securities for cash or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts, which rights may only be waived by the extraordinary general meeting (by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote) of our
shareholders or on an individual basis by each shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board appoints the members of the Executive Board and shall fill any vacancy within two months;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board has the right to appoint members of the Supervisory Board to fill a vacancy created by the
resignation or death of a member of the Supervisory Board for the remaining duration of such member&#146;s term of office, and subject to the approval by the shareholders of such appointment at the next shareholders&#146; meeting, which prevents
shareholders from having the sole right to fill vacancies on our Supervisory Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Executive Board can be convened by the chairman of the Executive Board or other members of the Executive
Board delegated for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board can be convened by the chairman or the vice-chairman of the Supervisory Board. A member of
the Executive Board or one-third of the members of the Supervisory Board may send a written request to the chairman to convene the Supervisory Board. If the chairman does not convene the Supervisory Board 15 days following the receipt of such
request, the authors of the request may themselves convene the Supervisory Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board meetings can only be regularly held if at least half of its members attend either
physically or by way of videoconference or teleconference enabling the members&#146; identification and ensuring their effective participation in the Supervisory Board&#146;s decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by
mail at the relevant ordinary shareholders&#146; general meeting is required to remove members of the Executive Board and/or members of the Supervisory Board with or without cause; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the crossing of certain ownership thresholds has to be disclosed and can impose certain obligations; see the
section of this prospectus titled &#147;Description of Share Capital&#151;Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice is required for nominations to the Supervisory Board or for proposing matters to be acted upon at
a shareholders&#146; meeting, except that a vote to remove and replace a member of the Supervisory Board can be proposed at any shareholders&#146; meeting without notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares shall comply with applicable insider trading rules and regulations, and in particular with
the Market Abuse Regulation 596/2014 of April&nbsp;16, 2014; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to French law, our bylaws, including the sections relating to the number of members of the Executive and
Supervisory Boards, and election and removal of members of the Executive and Supervisory Boards from office may only be modified by a resolution adopted by <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes of our shareholders present,
represented by a proxy or voting by mail at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers of ADSs in the U.S. offering will not be
directly holding our ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of ADSs will not be treated as one of our shareholders and will not have direct
shareholder rights. French law governs our shareholder rights. The depositary, through the custodian or the custodian&#146;s nominee, will be the holder of the ordinary shares underlying ADSs held by purchasers of ADSs in the U.S. offering.
Purchasers of ADSs in the U.S. offering will have ADS holder rights. The deposit agreement among us, the depositary and purchasers of ADSs in the U.S. offering, as an ADS holder, and all other persons directly and indirectly holding ADSs, sets out
ADS holder rights, as well as the rights and obligations of us and the depositary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Your right as a holder of ADSs to participate in
any future preferential subscription rights offering or to elect to receive dividends in shares may be limited, which may cause dilution to your holdings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to French law, if we issue additional securities for cash, current shareholders will have<B><I> </I></B>preferential subscription
rights for these securities on a pro rata basis unless they waive those rights at an<B><I> </I></B>extraordinary meeting of our shareholders (by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote) or individually by each<B><I>
</I></B>shareholder. However, our ADS holders in the United States will not be entitled to exercise or sell such<B><I> </I></B>rights unless we register the rights and the securities to which the rights relate under the Securities Act or<B><I>
</I></B>an exemption from the registration requirements is available. In addition, the deposit agreement provides<B><I> </I></B>that the depositary will not make rights available to you unless the distribution to ADS holders of both the<B><I>
</I></B>rights and any related securities are either registered under the Securities Act or exempted from registration<B><I> </I></B>under the Securities Act. Further, if we offer holders of our ordinary shares the option to receive<B><I>
</I></B>dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory<B><I> </I></B>assurances from us that extending the offer to holders of ADSs does not require registration of any<B><I>
</I></B>securities under the Securities Act before making the option available to holders of ADSs. We are under<B><I> </I></B>no obligation to file a registration statement with respect to any such rights or securities or to endeavor to<B><I>
</I></B>cause such a registration statement to be declared effective. Moreover, we may not be able to establish an<B><I> </I></B>exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to<B><I>
</I></B>participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in<B><I> </I></B>their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not
distributed<B><I> </I></B>or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you<B><I> </I></B>will receive no value for these rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>You may not be able to exercise your right to vote the ordinary shares underlying your ADSs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions
of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute
to the holders as of the record date (i)&nbsp;the notice of the meeting or solicitation of consent or proxy sent by us and (ii)&nbsp;a statement as to the manner in which instructions may be given by the holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may instruct the depositary of your ADSs to vote the ordinary shares underlying your ADSs. Otherwise, you will not be able to exercise
your right to vote, unless you withdraw the ordinary shares underlying the ADSs you hold. However, you may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for your instructions, the depositary, upon
timely notice from us, will notify you of the upcoming vote and arrange to deliver our voting materials to you. We cannot guarantee you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your
ordinary shares or to withdraw your ordinary shares so that you can vote them yourself. If the depositary does not receive timely voting instructions from you, it may give a proxy to a person designated by us to vote the ordinary shares underlying
your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote, and
there may be nothing you can do if the ordinary shares underlying your ADSs are not voted as you requested. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>You may be subject to
limitations on the transfer of your ADSs and the withdrawal of the underlying ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your ADSs are transferable on the
books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of
your ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the
deposit agreement, or for any other reason subject to your right to cancel your ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because
the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#146; meeting or we are paying a dividend on our ordinary shares. In addition, you may
not be able to cancel your ADSs and withdraw the underlying ordinary shares when you owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that
apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. See the section of this prospectus titled &#147;Description of American Depositary Shares.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less
information with the SEC than a U.S. company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer, as defined in the SEC&#146;s rules and regulations
and, consequently, we are not subject to all of the disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations
and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section&nbsp;14 of the Exchange Act. In addition, our
Executive Board and Supervisory Board members are exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act and related rules with respect to their purchases and sales of our securities.
Moreover, while we currently make annual and semi-annual filings with respect to our listing on Euronext Paris and expect to file financial reports on an annual and semi-annual basis, we will not be required to file periodic reports and financial
statements with the SEC as frequently or as promptly as U.S. public companies and will not be required to file quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or current reports on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> under the Exchange Act. In addition, foreign private issuers are not required to file their annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F</FONT> until four months after the end of each
fiscal year. Accordingly, there will be less publicly available information concerning our company than there would be if we were not a foreign private issuer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer, we are permitted to adopt certain home country practices
in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards and these practices may afford less protection to shareholders than they would enjoy if we complied fully with Nasdaq corporate
governance listing standards. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer listed on Nasdaq, we will be subject to their corporate governance
listing standards. However, Nasdaq rules permit foreign private issuers to follow the corporate governance practices of its home country. Some corporate governance practices in France may differ significantly from Nasdaq corporate governance listing
standards. For example, neither the corporate laws of France nor our bylaws require a majority of our Supervisory Board members to be independent and although the corporate governance code to which we currently refer (the AFEP/MEDEF code) recommends
that, in a widely-held company like ours, a majority of the Supervisory Board members be independent (as construed under such code), this code only applies on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;comply-or-explain&#148;</FONT></FONT> basis and we may in the future either decide not to apply this recommendation or change the corporate code to which we
refer.&nbsp;Furthermore, we could include <FONT STYLE="white-space:nowrap">non-independent</FONT> members of the Supervisory Board as members of our compensation and nomination committee, and our independent Supervisory Board members would not
necessarily hold regularly scheduled meetings at which only independent members of the Supervisory Board are present. Currently, we intend to follow home country practice to the maximum extent possible. Therefore, our shareholders may be afforded
less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers. For an overview of our corporate governance practices, see &#147;Management&#151;Corporate Governance Practices.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; under the JOBS Act and will be able to avail ourselves of reduced disclosure
requirements applicable to emerging growth companies, which could make our ordinary shares ADSs less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth
companies,&#148; including not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation
and shareholder approval of any golden parachute payments not previously approved. In addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in
Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. We will not take advantage of the extended transition period provided under Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new
or revised accounting standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find the ordinary shares or ADSs less attractive because we may rely
on these exemptions. If some investors find the ordinary shares or ADSs less attractive as a result, there may be a less active trading market for the ordinary shares or ADSs and the price of the ordinary shares or ADSs may be more volatile. We may
take advantage of these exemptions until such time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of (1)&nbsp;the last day of the fiscal year in which we have more than
$1.07&nbsp;billion in annual revenue; (2)&nbsp;the date we qualify as a &#147;large accelerated filer&#148; with at least $700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (3)&nbsp;the issuance,
in any three year period, by our company of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> and (4)&nbsp;the last day of the
fiscal year ending after the fifth anniversary of our initial public offering of the ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may lose our foreign private issuer
status in the future, which could result in significant additional cost and expense. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we currently qualify as a foreign
private issuer, the determination of foreign private issuer status is made annually on the last business day of an issuer&#146;s most recently completed second fiscal quarter and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordingly, the next determination will be made with respect to us on June&nbsp;30, 2019. In the future, we would lose our foreign private issuer status if we to fail to meet the requirements
necessary to maintain our foreign private issuer status as of the relevant determination date. For example, if more than 50% of our securities are held by U.S. residents and more than 50% of the members of our Executive Board or Supervisory Board
are residents or citizens of the United States, we could lose our foreign private issuer status. Immediately following the closing of this global offering, approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares (including
ordinary shares in the form of ADSs) will likely be held by U.S. residents (assuming that all purchasers in the U.S. offering are residents of the United States). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we incur
as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than
the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, rather than IFRS, and modify certain of
our policies to comply with corporate governance practices required of U.S. domestic issuers. Such conversion of our financial statements to U.S. GAAP would involve significant time and cost. In addition, we may lose our ability to rely upon
exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers such as the ones described above and exemptions from procedural requirements related to the solicitation of proxies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our analysis of our income, assets, activities and market capitalization for our taxable year ending December&nbsp;31, 2018, we
believe that we were not classified as a passive foreign investment company, or PFIC, for the taxable year ending December&nbsp;31, 2018. Based on the expected nature and composition of our income, assets, activities and market capitalization for
our taxable year ending December&nbsp;31, 2019, we believe that we will not be classified as a PFIC for the taxable year ending December&nbsp;31, 2019. However, there can be no assurance that we will not be considered a PFIC in the current year or
for any future taxable year. Under the Code, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company will be considered a PFIC for any taxable year in which (1) 75% or more of its gross income consists of passive income or (2) 50% or more of the
average quarterly value of its assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment
property and certain rents and royalties. In addition, for purposes of the above calculations, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation that directly or indirectly owns at least 25% by value of the shares of another corporation
is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a PFIC for any taxable year during which a U.S. holder (as defined below under
&#147;Material United States Federal Income Tax and French Tax Considerations&#151;Material U.S. Federal Income Tax Considerations&#148;) holds our ordinary shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. holder in
all succeeding years during which the U.S. holder owns the ordinary shares or ADSs, regardless of whether we continue to meet the PFIC test described above, unless the U.S. holder makes a specified election once we cease to be a PFIC. If we are
classified as a PFIC for any taxable year during which a U.S. holder holds our ordinary shares or ADSs, the U.S. holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for
any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements. For further discussion of the PFIC rules and the adverse U.S. federal income tax
consequences in the event we are classified as a PFIC, see the section of this prospectus titled &#147;Material United States Federal Income Tax and French Tax Considerations&#151;Material U.S. Federal Income Tax Considerations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If a United States person is treated as owning at least 10% of our ordinary shares,
such holder may be subject to adverse U.S. federal income tax consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. holder is treated as owning, directly,
indirectly or constructively, at least 10% of the value or voting power of our ordinary shares or ADSs, such U.S. holder may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our
group, if any. Our group currently includes one U.S. subsidiary and, therefore, under current law our current <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiary and any future newly formed or acquired
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries will be treated as controlled foreign corporations, regardless of whether we are treated as a controlled foreign corporation. A United States shareholder of a controlled foreign
corporation may be required to annually report and include in its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income&#148; and investments in U.S.
property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or
foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with controlled foreign corporation reporting obligations may subject a United States shareholder to significant monetary
penalties. We cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the controlled foreign corporation rules of
the Code. U.S. holders should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares or ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, particularly the sections of this prospectus titled &#147;Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business,&#148; contains forward-looking statements. All statements other than present and historical facts and conditions contained in this prospectus,
including statements regarding our future results of operations and financial position, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this prospectus, the words
&#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;is designed to,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148;
&#147;predict,&#148; &#147;objective,&#148; &#147;should,&#148; or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prospects of attaining, maintaining and expanding marketing authorization for monalizumab, IPH4102 and our
other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our preclinical studies and clinical trials and those conducted
by third parties, including our collaborator AstraZeneca; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully develop and advance our pipeline of product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization of Lumoxiti, including the expected transitioning of commercialization activities in the
United States from AstraZeneca to us commencing in mid 2019, and any of our product candidates, if approved, for which we retain commercialization rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future agreements with third parties in connection with the commercialization of our product candidates and any
other approved product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop sales and marketing capabilities and transition into a commercial-stage company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of Lumoxiti and our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of increased competition as well as innovations by new and existing competitors in our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain, maintain, protect and enforce our intellectual property rights and propriety technologies
and to operate our business without infringing the intellectual property rights and proprietary technology of third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States, Europe and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not
limited to, tax regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and stock
performance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected use of proceeds of the global offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed in the section of this prospectus titled &#147;Risk
Factors.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the section of this prospectus titled &#147;Risk Factors&#148; for a discussion of
important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus
will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any
other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act do not protect any forward-looking statements that we make in connection with the global offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the
Registration Statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. We qualify all of our
forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds from the global offering of approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming an offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, after deducting estimated underwriting discounts and estimated offering expenses payable by us, and assuming no exercise
of the underwriters&#146; option to purchase additional ordinary shares (including ordinary shares in the form of ADSs). If the underwriters exercise their option in full, we estimate that we will receive net proceeds from the global offering of
approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million) after deducting estimated underwriting discounts and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of the global offering are to increase our financial flexibility in order to advance our proprietary and partnered
pipeline and build out our commercial capabilities. We currently expect to use the net proceeds from the offering, together with a portion of our cash, cash equivalents, short-term investments, and non-current financial assets (in aggregate ) as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the clinical development of
our lead product candidate, monalizumab, in collaboration with AstraZeneca, which is currently being evaluated for the treatment of patients with R/M SCCHN and in patients with advanced solid tumors, including CRC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the clinical development of
IPH4102 for the treatment of patients with S&#233;zary syndrome, MF and PTCL, and approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the clinical development of IPH5401 in patients with solid tumors, including NSCLC
and HCC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to build our commercial capabilities for
Lumoxiti in the U.S. and, if approved, in the European Union; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to expand and advance our preclinical
pipeline, including transitioning IPH5301 into clinical development. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use the remainder of any net proceeds
from the global offering, together with a portion of our cash, cash equivalents, short-term investments and non-current financial assets, for general corporate purposes. We may also use a portion of the net proceeds to in-license, acquire or invest
in complementary technologies, products, businesses or assets, either alone or in collaboration with a partner. However, we have no current plans, commitments or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no specific plans as to how the net proceeds from the global offering will be allocated beyond the uses specified above and
therefore management will retain discretion with respect to the use of the net proceeds of the global offering. We may also use a portion of the net proceeds to acquire, license or invest in complementary technologies or businesses. However, we
currently have no agreements or commitments to complete any such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had cash, cash
equivalents, short-term investments and non-current financial assets of &#128;202.7&nbsp;million. We believe our cash, cash equivalents, short-term investments and non-current financial assets, together with the net proceeds of the global offering
and our cash flow from operations (including payments we expect to receive pursuant to our collaboration agreements) and government funding of research programs, will be sufficient to fund our operations for at least
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected use of the net proceeds from the global offering and time horizon
for the use of our funds represent our intentions based upon our current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the
completion of the global offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors,
including the progress of our development efforts, the status of and results from preclinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies and any ongoing clinical trials or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates and
any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from the global offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from the global offering, we intend to invest the net proceeds in a variety of capital preservation
investments, including short-term, investment-grade, interest-bearing instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed initial offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ADS) would increase or decrease our net proceeds from the global offering by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming the number of ordinary shares
(including ordinary shares in the form of ADSs), as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and estimated offering expenses payable by us. We may also increase or decrease
the number of ordinary shares (including ordinary shares in the form of ADSs) we are offering. An increase or decrease of 1,000,000 ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease the net
proceeds to us by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the assumed initial offering price remains the same and after deducting estimated
underwriting discounts and estimated offering expenses payable by us. The actual net proceeds payable to us will adjust based on the actual number of ordinary shares (including ordinary shares in the form of ADSs) sold by us, the actual initial
offering price and other terms of the global offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our ordinary shares. We do not anticipate paying cash dividends on our equity securities in
the foreseeable future and intend to retain all available funds and any future earnings for use in the operation and expansion of our business, given our state of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirements of French law and our bylaws, dividends may only be distributed from our distributable profits, plus any amounts
held in our available reserves which are reserves other than legal and statutory and revaluation surplus. Dividend distributions, if any in the future, will be made in euro and converted into U.S. dollars with respect to the ADSs, as provided in the
deposit agreement. See &#147;Description of Share Capital&#148; for more information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our current assets and capitalization as of December&nbsp;31, 2018 on an actual and on an as adjusted basis to
reflect the issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (including ordinary shares in the form of ADSs) in the global offering at an assumed initial offering
price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported closing price of
our ordinary shares on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, after deducting estimated underwriting discounts and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our capitalization following the global offering will be adjusted based on the actual initial offering price and other terms of the global
offering determined at pricing, including the amount by which actual offering expenses are higher or lower than estimated. The table should be read in conjunction with the information contained in &#147;Use of Proceeds,&#148; &#147;Summary
Consolidated Financial Data,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; as well as our consolidated financial statements and the related notes included elsewhere in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary and preferred shares, &#128;0.05 nominal value: 63,932,655 ordinary shares and 6,931
preferred shares issued and outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preferred shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">167,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">171,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed initial offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported
closing price of our ordinary shares on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, would increase or decrease each of as adjusted cash and cash equivalents, total
shareholders&#146; equity and total capitalization by approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us, as set forth on the cover page of
this prospectus, remains the same and after deducting estimated underwriting discounts and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including ordinary shares in the form of ADSs) we
are offering. Each increase or decrease of 1,000,000 ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease each of as adjusted cash and cash equivalents, total shareholders&#146; equity and total
capitalization by approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million),
assuming that the assumed offering price remains the same, and after deducting estimated underwriting discounts and estimated offering expenses payable by us. The as adjusted information discussed above is illustrative only and will adjust based on
the actual initial offering price, the actual number of ordinary shares (including ordinary shares in the form of ADSs) offered by us and other terms of the global offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares (including ordinary shares in the form of ADSs) that will be
outstanding after the global offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of June 30, 2019 and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June 30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June 30, 2019 assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June&nbsp;30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019 assuming all performance conditions are met; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future
issuance under our share-based compensation plans and other delegations of authority from our shareholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in the ordinary shares or ADSs in this global offering, your ownership interest will be diluted to the extent of the difference
between the offering price per ordinary share or ADS paid by you and the as adjusted net tangible book value per share after the global offering. Our net tangible book value as of December&nbsp;31, 2018 was &#128;82.7 million ($94.8 million), or
&#128;1.29 per ordinary share (equivalent to $1.48 per ADS), based on the exchange rate in effect as of December&nbsp;31, 2018. Net tangible book value per share is determined by dividing (i)&nbsp;our total assets less our intangible assets and our
total liabilities by (ii)&nbsp;the number of ordinary shares outstanding as of December&nbsp;31, 2018, or 63,932,655 ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to our sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary
shares (including ordinary shares in the form of ADSs) in the global offering, assuming an offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, and after deducting estimated underwriting discounts and estimated offering expenses payable by us, our as adjusted net tangible book value at
December&nbsp;31, 2018 would have been approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share (equivalent to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS). This amount represents an immediate increase in net tangible book value of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS) to our existing
shareholders and an immediate dilution in net tangible book value of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS) to new investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table illustrates this dilution on a per ordinary share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Ordinary<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per ordinary share or ADS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per ordinary share or ADS attributable to new investors
participating in the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per ordinary share or ADS after the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in as adjusted net tangible book value per ordinary share or ADS to new investors
participating in the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed initial offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported
closing price of our ordinary shares on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, would increase or decrease our as adjusted net tangible book value by approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in this global offering would be approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), assuming that the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us, as set forth on the cover page of
this prospectus, remains the same, and after deducting estimated underwriting discounts and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including ordinary shares in the form of ADSs) we
are offering. An increase in the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us by 1,000,000 would increase the as adjusted net tangible book value by approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in this global offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), assuming that the initial offering price remains the same, and after deducting estimated underwriting discounts and estimated offering
expenses payable by us. Similarly, a decrease in the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us by 1,000,000 would decrease the as adjusted net tangible book value by approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in this global offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share ($&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; per ADS), assuming that the initial offering price remains the same, and after deducting estimated underwriting discounts and estimated
offering expenses payable by us. The as adjusted information discussed above is illustrative only and will be adjusted based on the actual offering price, the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us
and other terms of this global offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase additional
ordinary shares (which may be in the form of ADSs), the as adjusted net tangible book value after the global offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the increase in the as adjusted net tangible book value to existing shareholders would be
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in this global offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets
forth consideration paid to us in cash for ordinary shares purchased from us by our existing shareholders (translated into U.S. dollars at an exchange rate of $1.00 =
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ) and by new investors participating in this global offering based on an assumed offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported
closing price of our ordinary shares on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, and before deducting estimated underwriting discounts and estimated offering expenses
payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares or<BR>ADSs&nbsp;Purchased&nbsp;from&nbsp;Us</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price<BR>per Ordinary<BR>Share/ADS</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Number&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Percent&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Amount&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Percent&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00 ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed
initial offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), the last reported closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, would increase or decrease the total consideration paid by new investors participating in this global offering by
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us, as set forth on the
cover page of this prospectus, remains the same and before deducting estimated underwriting discounts. We may also increase or decrease the number of ordinary shares (including ordinary shares in the form of ADSs) we are offering. An increase or
decrease by 1,000,000 in the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease the total consideration paid by new investors participating in this global offering by
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the initial offering price remains the same and before deducting estimated underwriting discounts. The
information discussed in the table above is illustrative only and will be adjusted based on the actual offering price, the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us and the other terms of this global
offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the underwriters exercise their option to purchase additional ordinary shares (which may
be in the form of ADSs) in full, the number of ordinary shares held by the existing shareholders after this global offering would be reduced to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding
after the global offering, and the number of ordinary shares (including ordinary shares in the form of ADSs) held by new investors participating in this global offering would increase to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , or &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding after the global
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares (including ordinary shares in the form of ADSs) that will be outstanding after the global
offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of June 30, 2019 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June 30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June 30, 2019 assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June 30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019 assuming all performance conditions are met; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future
issuance under our share-based compensation plans and other delegations of authority from our shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
otherwise noted, the information in this prospectus assumes no exercise by the underwriters of their option to purchase additional ordinary shares (including ordinary shares in the form of ADSs). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_10"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derived the selected consolidated statement of income (loss) data for the years ended December&nbsp;31, 2018 and 2017 and the selected
consolidated statement of financial position data as of December&nbsp;31, 2018 and 2017 from our audited consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements have been prepared in accordance
with IFRS as issued by the IASB. Our historical results are not necessarily indicative of the results that may be expected in the future. The following selected financial data for the periods and as of the dates indicated are qualified by reference
to and should be read in conjunction with our consolidated financial statements and related notes beginning on page <FONT STYLE="white-space:nowrap">F-1</FONT> of this prospectus and the section of this prospectus titled &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Income
(Loss) Data: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue and other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">93,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">44,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Operating income (loss)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net financial loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Net income (loss)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares outstanding used for computing basic and diluted net income (loss) per
share<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 reflect the impacts of the adoption of IFRS 9 and IFRS 15 that became applicable on January&nbsp;1, 2018. The comparative
consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. The impact on the consolidated statement of income (loss) of the adoption of IFRS 9 is non material and the impact of the adoption of IFRS
15 and transition measures are presented in Note 2.a to our consolidated financial statements appearing elsewhere in this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the year ended December&nbsp;31, 2018, the dilutive effect of warrants granted but not yet exercised and unallocated free shares is not material. As we were in a net loss position for the year ended
December&nbsp;31, 2017, warrants granted but not yet exercised and unallocated free shares do not have a dilutive effect. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated
Statement of Financial Position Data: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, short-term investments and non-current financial assets<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">202,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial debt and defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Non-current assets account for &#128;35.2&nbsp;million. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion of our financial condition and results of operations in conjunction with the &#147;Selected
Consolidated Financial Data&#148; and our audited consolidated financial statements and the related notes thereto included elsewhere in this prospectus. In addition to historical information, the following discussion and analysis contains
forward-looking statements that reflect our plans, estimates and beliefs. Our actual results and the timing of events could differ materially from those anticipated in the forward-looking statements. Factors that could cause or contribute to these
differences include those discussed below and elsewhere in this prospectus, particularly in sections titled &#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements.&#148; Our consolidated financial statements have been
prepared in accordance with IFRS as issued by the IASB, which may differ in material respects from generally accepted accounting principles in other jurisdictions, including the United States. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company
focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. We have a 20-year history of research
and development in immuno-oncology, having been pioneers in the understanding of natural killer cell, or NK cell, biology, and later expanding our expertise in the tumor microenvironment, tumor antigens and antibody engineering fields. We have
built, internally and through our business development strategy, a broad and diversified portfolio including an approved product, three clinical product candidates and a robust preclinical pipeline. We have entered into collaborations with leaders
in the biopharmaceutical industry, such as AstraZeneca and Sanofi, to leverage their development capabilities and expertise. We believe our product candidates and clinical development approach are differentiated from current immuno-oncology
therapies and have the potential to significantly improve the clinical outcome for patients with cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have
devoted substantially all of our financial resources to research and development efforts, including conducting preclinical studies and clinical trials of our product candidates, providing general and administrative support for our operations and
protecting our intellectual property. Our marketed product, Lumoxiti, was approved by the U.S. Food and Drug Administration, or FDA, under priority review in September 2018 and was commercially launched by AstraZeneca AB, or AstraZeneca, in November
2018. We have not yet generated any material revenue from product sales. We have funded our operations to date primarily through private and public offerings of ordinary shares, payments from our collaborators and research tax credits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had &#128;202.7&nbsp;million in cash, cash equivalents, short-term investments and <FONT
STYLE="white-space:nowrap">non-current</FONT> financial assets. Since our inception, we have raised a total of &#128;240.4&nbsp;million through the sale of equity securities, including &#128;33.7&nbsp;million in the initial public offering of our
ordinary shares on Euronext Paris in 2006. We have also received $475.0&nbsp;million (&#128;415.9&nbsp;million) in payments from our collaborators, including AstraZeneca, since 2011, excluding payments received for purchases of our equity securities
by our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have significant agreements with AstraZeneca pursuant to which we have the right to earn milestone and royalty
payments. We have other license agreements pursuant to which we have acquired intellectual property and under which we will be required to make payments to the counterparty upon the achievement of certain milestone events and commercial sales
related to our product candidates. See &#147;&#151;Our Strategic Collaborations and Licensing Agreements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net
losses in each year since our inception except for the years ended December&nbsp;31, 2018 and December&nbsp;31, 2016. Our net results were a &#128;3.0&nbsp;million net income and a &#128;48.4&nbsp;million net loss for the years
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ended December&nbsp;31, 2018 and 2017, respectively. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from
general and administrative expenses associated with our operations. As we continue our intensive research and development programs and invest in the commercialization of Lumoxiti, we expect to continue to incur significant expenses and may again
incur operating losses in future periods. We anticipate that such expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the research and development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate clinical trials for, or additional preclinical development of, our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop and refine the manufacturing processes for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add manufacturers or suppliers of biological materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory and marketing authorizations for any of our product candidates that successfully complete
development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize Lumoxiti and any other products for
which we may obtain marketing authorization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify and validate additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or license other product candidates, technologies or biological materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty or other payments under any current or future license agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">secure manufacturing arrangements for commercial production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to attract and retain new and existing skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create additional infrastructure to support our operations as a U.S. public company and incur increased legal,
accounting, investor relations and other expenses; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience delays or encounter issues with any of the above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will need to raise additional funding, in addition to the net proceeds of the global offering, prior to completing
clinical development of any of our product candidates. Until such time that we can generate substantial revenues from sales of Lumoxiti our product candidates, if approved, we expect to finance our operating activities through a combination of
milestone payments received pursuant to our strategic alliances, equity offerings, debt financings, government or other third-party funding and collaborations, and licensing arrangements. However, we may not receive milestone payments when expected,
or at all, and we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or
terminate our development programs or commercialization efforts or grant to others rights to develop or market product candidates that we would otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us to
cease operations, in part or in full. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation of Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audited consolidated financial statements included herein for the years ended December&nbsp;31, 2018 and 2017 have been prepared in
accordance with IFRS as issued by the IASB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the listing of our ordinary shares on Euronext Paris and in accordance with the
European Union&#146;s regulation No.&nbsp;1606/2002 of July&nbsp;19, 2002, we also prepare and publish our consolidated financial statements in accordance with IFRS as adopted by the European Union, or EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All the standards published by the IASB that are mandatorily applicable in the years ended December&nbsp;31, 2018 and 2017 are endorsed by the
EU and are mandatorily applicable in the EU. Therefore, our audited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consolidated financial statements for the years ended December&nbsp;31, 2018 and 2017 are compliant with both IFRS as issued by the IASB and IFRS as adopted by the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in accordance with IFRS requires us to make significant judgments and estimates which are presented
below in &#147;&#151;Critical Accounting Policies and Significant Judgments and Estimates.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Principal Collaboration and Licensing Agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreements related to monalizumab with Novo Nordisk A/S and with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2014 Novo Nordisk A/S monalizumab agreement</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;5, 2014, we in-licensed from Novo
Nordisk A/S full development and commercialization rights to monalizumab. Novo Nordisk A/S received &#128;2.0&nbsp;million in cash and 600,000 of our ordinary shares at a price of &#128;8.33 per share (&#128;5.0 million) and is eligible to receive
up to &#128;20.0&nbsp;million in potential regulatory milestones and tiered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-high</FONT></FONT> single-digit percentage royalties on net sales. The agreement with Novo Nordisk
A/S included a right to additional consideration in the event of an <FONT STYLE="white-space:nowrap">out-licensing</FONT> agreement. Consequently, following the agreement signed with AstraZeneca in April 2015 as described below, we paid Novo Nordisk
A/S additional consideration of &#128;6.5&nbsp;million. In addition, as a result of AstraZeneca&#146;s exercise of its option under our agreement in October 2018, Novo Nordisk A/S became entitled to a second and final additional payment amounting to
$15.0&nbsp;million (&#128;13.1 million), which is recognized as a liability as of December&nbsp;31, 2018 and was paid in February 2019. These amounts of additional consideration were added to the net book value of the intangible asset and are
amortized according to the same amortization plan as the initial &#128;7.0&nbsp;million payment recognized in 2014. The net book value of the license amounted to &#128;12.7&nbsp;million as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2015 AstraZeneca monalizumab agreements</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Under co-development and option agreements signed with
AstraZeneca in 2015, we granted to AstraZeneca an exclusive license, subject to certain exclusions, to certain of our patents and know-how to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis,
prevention and treatment of oncology diseases and conditions. We further granted to AstraZeneca a worldwide, non-exclusive license to certain of our other patents to develop, manufacture and commercialize licensed products, including monalizumab, in
the field of diagnosis, prevention and treatment of oncology diseases and conditions. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received an initial payment of $250 million under
these agreements on June 30, 2015, of which $100 million was paid to us as an initial payment for the co-development agreement and $150 million was paid to us as consideration for the option agreement. In connection with AstraZeneca&#146;s exercise
of its option under the option agreement, we received an upfront payment of $100 million in January 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the option exercise,
AstraZeneca is the lead party in developing the licensed products and must use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize each licensed product in certain major markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the initial payment and option exercise payment, AstraZeneca is obligated to pay us up to $925 million in the aggregate upon
the achievement of certain development and regulatory milestones ($500 million) and commercialization milestones ($425 million). We are eligible to receive tiered royalties ranging from a low double-digit to mid-teen percentage on net sales of
licensed products outside of Europe. We are required for a defined period of time to co-fund 30% of the Phase III clinical trials of licensed products, subject to an aggregate cap, in order to receive 50% of the profits and losses in Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we opt out of our <FONT STYLE="white-space:nowrap">co-funding</FONT> obligations, we would forfeit the option to co-promote licensed
products under the agreement, and our right to share in 50% of such profits would terminate and sales in Europe will instead be factored into net sales used to calculate royalty and milestone payments to us. Additionally, Phase III and regulatory
milestone payments that may be payable to us will be reduced and AstraZeneca will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsible for the promotion of licensed products worldwide, subject to our option to co-promote the licensed products in certain European countries. Should we elect not to co-promote, our share
of profits in Europe will be reduced by a specified amount of percentage points not to exceed the mid-single digits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement
related to Lumoxiti with AstraZeneca </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we obtained an exclusive license from AstraZeneca under certain patents and
know-how of AstraZeneca to develop, manufacture and commercialize Lumoxiti for all uses in humans and animals in the United States, the European Union and Switzerland. Under this Agreement, AstraZeneca is obligated to provide support for the
continued development and commercialization of Lumoxiti in the European Union and Switzerland prior to regulatory submission and approval as well as support for the continued commercialization of Lumoxiti in the United States for a specified period.
We are scheduled to transition to full commercialization responsibilities by <FONT STYLE="white-space:nowrap">mid-2020.</FONT> Under the agreement, we were obligated to pay a $50.0&nbsp;million initial payment (&#128;43.8 million), which we paid in
January 2019, and are obligated to pay conditional payments up to $25.0&nbsp;million in the aggregate upon the achievement of certain commercial and regulatory milestones. We will reimburse AstraZeneca for the development, production and
commercialization costs it incurs during the transition period, subject to certain limitations for the year ending December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement related to IPH5201 with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we signed a collaboration and option agreement with AstraZeneca for <FONT STYLE="white-space:nowrap">co-development</FONT> and
<FONT STYLE="white-space:nowrap">co-commercialization</FONT> of IPH5201. Under the agreement, AstraZeneca paid us a $50.0&nbsp;million upfront payment ($26.0 million paid in October 2018 and $24.0&nbsp;million paid in January 2019), and is obligated
to pay us up to an aggregate of $10.0&nbsp;million upon the achievement of certain development milestones. Upon exercise of its option under the agreement, AstraZeneca is committed to pay an option exercise fee of $25.0&nbsp;million and up to
$800.0&nbsp;million in the aggregate upon the achievement of certain development and regulatory milestones ($300 million) and commercialization milestones ($500 million). The arrangement also provides for a 50% profit share in Europe if we do not
opt out of co-promoting and late stage co-funding obligations. We would be eligible to receive tiered royalties ranging from a high-single digit to mid-teen percentage on net sales of IPH5201, or from a mid-single digit to low-double digit
percentage on net sales of other types of licensed products, outside of Europe. The royalties payable to us under the agreement may be reduced under certain circumstances, including loss of exclusivity or lack of patent protection. We recognized
&#128;15.6&nbsp;million as revenue from proceeds related to this agreement for the year ended December&nbsp;31, 2018, and were also reimbursed by AstraZeneca for certain research and development expenses related to IPH5201. We have the option to <FONT
STYLE="white-space:nowrap">co-fund</FONT> 30% of the shared development expenses related to the Phase III clinical trials in order to acquire <FONT STYLE="white-space:nowrap">co-promotion</FONT> rights and to share in 50% of the profits and losses
of licensed products in Europe. If we opt out of our co-funding obligations, among other things, our right to share in 50% of the profits and losses in Europe and right to co-promote in certain European countries will terminate and will be replaced
by rights to receive royalties on net sales at the rates applicable to outside of Europe. Additionally, certain milestone payments that may be payable to us would be reduced. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement related to additional preclinical molecules with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we granted to AstraZeneca four exclusive options that are exercisable until IND approval to obtain a worldwide,
royalty-bearing, exclusive license to certain of our patents and know-how relating to certain specified pipeline candidates to develop and commercialize optioned products in all fields of use. Pursuant to the agreement, AstraZeneca paid us a
$20.0&nbsp;million upfront payment (&#128;17.5 million) do not take in October 2018. We recognize this upfront payment in the consolidated statement of financial position as deferred revenue as of December&nbsp;31, 2018, until the exercise or the
termination of each option, at the earliest. Upon exercise of an option, we would be entitled to an option exercise payment of $35 million, as well as development and regulatory milestone payments ($320 million) and commercialization milestone
payments ($500 million) and tiered, mid-single digit to mid-teen percentage royalties on net sales of the applicable product. The royalties payable to us may be reduced under certain circumstances, including loss of exclusivity, lack of patent
protection or the specific nature of the compound included within the applicable product. Additionally, we would have rights to co-fund certain development costs in order to obtain profit and loss sharing in Europe. So long as we elect to co-fund
such development costs, we also will have a right to co-promote optioned products in Europe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreements related to IPH5401 with Novo Nordisk A/S and with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2017 IPH5401 <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement with Novo Nordisk
A/S</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>In July 2017, we signed an exclusive license agreement with Novo Nordisk A/S relating to IPH5401. Under the agreement, Novo Nordisk A/S granted us a worldwide, exclusive license to develop, manufacture and
commercialize pharmaceutical products that contain or comprise an anti-C5aR antibody, including IPH5401. We made an upfront payment of &#128;40.0&nbsp;million, &#128;37.2&nbsp;million of which was contributed in new shares and &#128;2.8&nbsp;million
of which in cash. We are obligated to pay up to an aggregate of &#128;370.0&nbsp;million upon the achievement of development, regulatory and sales milestones and tiered royalties ranging from a low double-digit to low-teen percentage of net sales.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 IPH5401 AstraZeneca agreement</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>On January&nbsp;1, 2018, we entered into a clinical trial
collaboration agreement with AstraZeneca to sponsor a Phase I/II clinical trial <FONT STYLE="white-space:nowrap">(STELLAR-001)</FONT> to evaluate the safety and efficacy of durvalumab, an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> immune checkpoint inhibitor, in combination with IPH5401, as a treatment for patients with select solid tumors. We are the sponsor of the trial and the costs are equally shared between us and
AstraZeneca. This collaboration agreement is a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> agreement and does not include any licensing rights on IPH5401 to AstraZeneca. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Bristol-Myers Squibb licensing agreement in relation to lirilumab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our agreement with Bristol-Myers Squibb Company, or BMS, related to the licensing of lirilumab, a product candidate that we
discontinued developing in 2017, we received an upfront payment of $35.3&nbsp;million (&#128;24.9 million) in July 2011 and were eligible to receive additional payments of up to an aggregate of $430.0&nbsp;million depending on the achievement of <FONT
STYLE="white-space:nowrap">pre-specified</FONT> milestones during the development and commercialization period. We received a milestone payment of $5.0&nbsp;million (&#128;4.5 million) in October 2015, which was fully recognized as revenue in the
year ended December&nbsp;31, 2015, and another milestone payment of $15.0&nbsp;million (&#128;14.0 million) in January 2017, which was fully recognized as revenue in the year ended December&nbsp;31, 2016. We were also entitled to receive <FONT
STYLE="white-space:nowrap">pre-specified</FONT> tiered, low double-digit to <FONT STYLE="white-space:nowrap">mid-teen</FONT> percentage royalty payments on worldwide net sales. We do not expect to receive any additional proceeds from this agreement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue and other income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue and other income mainly consists of revenues from collaboration and licensing agreements and government financing for research
expenditure in the form of the research tax credits, as well as other grants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue from collaboration and licensing agreements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently derive substantially all our revenues from payments pursuant to our licensing and collaboration agreements with
AstraZeneca relating to monalizumab and IPH5201, consisting of (i)&nbsp;upfront payments, (ii)&nbsp;milestone payments based upon the achievement of <FONT STYLE="white-space:nowrap">pre-determined</FONT> development, regulatory and commercial events
and (iii)&nbsp;research and development fees related to charges for full time equivalents, or FTEs, at contracted rates and reimbursement of research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any revenue from product sales since our inception, with the exception in 2018 of Lumoxiti sales, which are classified
in the net income (loss) from distribution agreements during the transition period with AstraZeneca. Our ability to generate significant product revenue and to become profitable will depend upon our ability to successfully commercialize Lumoxiti and
our ability to successfully develop, obtain regulatory approval for and commercialize any other product candidates. Because of the numerous risks and uncertainties associated with product development and regulatory approval, we are unable to predict
the amount, timing or whether we will be able to obtain product revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2018, IFRS 15 <I>Revenue from contracts with customers</I>, or IFRS 15,
became mandatorily applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS 15 supersedes IAS 11 <I>Construction contracts</I>, IAS 18 <I>Revenue</I>, or IAS 18, and related
interpretations, and changes the accounting treatment of the revenue relating to our agreement with AstraZeneca. Under IFRS 15, our <FONT STYLE="white-space:nowrap">co-funding</FONT> share of research and development expenses incurred by AstraZeneca
is no longer recorded as research and development expense, but rather is deducted from the recognition of the upfront payment received by us upon execution of the agreement. The amount of our <FONT STYLE="white-space:nowrap">co-funding</FONT>
obligation is now recognized as a collaboration liability and is no longer recorded as deferred revenue in the consolidated statement of financial position. When the collaboration liability is in a foreign currency, which is the case in the context
of this agreement, it is translated at each reporting date using the closing exchange rate, which generates foreign exchange gains or losses in our consolidated statement of income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have opted for the modified retrospective approach without any of the practical expedients allowed by IFRS 15. Accordingly, the comparative
information is not restated and the cumulative impact of the first application is presented as an adjustment of the opening equity as of January&nbsp;1, 2018. Consequently, the first application of IFRS 15&nbsp;may affect the comparability of our
revenue and research and development expenses for the years ended December&nbsp;31, 2018 and 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2018, agreements
are analyzed according to IFRS 15. For our agreements relating to monalizumab and IPH5201, we have concluded that the license is not distinct from the research and development services because those services increase the utility of the license. As a
result, the estimated transaction price is spread over the period when we are engaged to deliver services to AstraZeneca based on the percentage of completion of the costs to be incurred, and <FONT STYLE="white-space:nowrap">non-refundable</FONT>
initial payments received are deferred and recognized as revenue over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Variable consideration can be included in the estimated
transaction price only if it is highly probable that the related revenue will not reversed in the future. According to the level of uncertainty relating to the results of preclinical studies and clinical trials and the decisions relating to
regulatory approvals, related payments are excluded from the transaction price as long as the triggering event is not certain. If and when the triggering event occurs, the corresponding milestone is added to the transaction price and revenue is
recognized relative to the percentage of completion related to the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a collaboration contract grants to the collaborator
an option to acquire a license, we exercise judgment to determine the beginning date of transfer of the control of the license. Depending on the situation, the recognition of the revenue begins from the date of the contract, with the payment
relating to the exercise of the option being therefore considered as variable consideration, or the recognition is deferred until the exercise or expiration of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the agreements with AstraZeneca relating to IPH5201 and IPH5401, we are reimbursed for some of our internal and external
costs. We recognize these reimbursements as revenue in our consolidated statement of income (loss) when the related costs are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue recognition involves significant judgments and estimates by management. See &#147;&#151;Critical Accounting Policies and Significant
Judgments and Estimates.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to 2018, revenue was recognized in accordance with IAS 18, which resulted in a difference in revenue
recognition accounting policies used for the audited consolidated financial statements for the year ended December&nbsp;31, 2018 and 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Government financing for research expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our government financing for research expenditures consists of research tax credits (<I>cr&eacute;dit d</I><I>&#146;</I><I>imp&ocirc;t
recherche</I>) and grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research tax credit is granted to companies by the French tax authorities in order to
encourage them to conduct technical and scientific research. Companies demonstrating that they have expenses that meet the required criteria, including research expenses located in France or, since January&nbsp;1, 2005, within the EU or in another
state that is a party to the agreement in the European Economic Area that has concluded a tax treaty with France that contains an administrative assistance clause, receive a tax credit which can be used against the payment of the corporate tax due
for the fiscal year in which the expenses were incurred and during the next three fiscal years, or, as applicable, can be reimbursed for the excess portion. The expenditures taken into account for the calculation of the research tax credit involve
only research expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main characteristics of the research tax credit are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research tax credit results in a cash inflow to us from the tax authorities, i.e., it is used to offset the
payment of corporate tax or is paid directly to us for the portion that remains unused the year after the date of its record as a tax credit in the income statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our corporate income tax liability does not limit the amount of the research tax credit&#151;if we do not pay any
corporate income tax, we can request direct cash payment of the research tax credit the year following its record in the income statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research tax credit is not included in the determination of the corporate income tax. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the research tax credit is not deductible from taxes payable by us, it is usually reimbursed by the French government during the fourth
fiscal year following the period for which it was booked in the consolidated statement of income (loss). Since 2010, companies classified as small- and medium-sized, according to the European Union criteria, have been eligible for early
reimbursement of the research tax credit. We qualified for early reimbursement of the research tax credit and received the amount corresponding to 2016 and 2017 in July 2017 and September 2018, respectively. Since 2008, repayable grants have been
deducted from the basis of calculation of the research tax credit. We also conduct studies outside of the EU, notably in the United States, and these research expenses are not eligible for the research tax credit calculation. We expect that our
status as a small or medium size company may be lost at the end of the fiscal year ending December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have concluded that
the research tax credit meets the definition of a government grant as defined in IAS 20 <I>Accounting for government grants and disclosure of government assistance</I>, or IAS 20, and that the classification as &#147;Revenue and other income&#148;
in our consolidated statement of income (loss) is appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also from time to time receive government grants, which are recognized
in our consolidated statement of income (loss) when we comply with the conditions attached to the grants and they are <FONT STYLE="white-space:nowrap">non-repayable</FONT> grants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, our operating expenses have consisted primarily of research and development expenses and general and administration expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We engage in substantial research and development efforts to develop innovative product candidates. Research and development expense consists
primarily of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel costs, including salaries, related benefits and share-based compensation, for our employees engaged in
scientific research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of third-party contractors and academic institutions involved in preclinical studies or clinical trials that
we may conduct, or third-party contractors involved in field trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases of biological raw materials, real estate leasing costs as well as conferences and travel costs; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other expenses, such as expenses for use of laboratories and facilities for our research and development
activities as well as depreciation and amortization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development efforts are focused on our existing
product candidates and preclinical programs, including the advancement of our lead product candidates, monalizumab, IPH4102 and IPH5401. Our direct research and development expenses consist principally of external costs associated with
subcontracting of preclinical and clinical operations to third parties, which we track on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. We also use our employee and infrastructure
resources across multiple research and development programs, and do not track these indirect expenses on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to
completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical studies or other services performed. Significant judgment and estimates are made in determining the accrued
expense balances at the end of any reporting period. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for research and development goods or services to be received in the future from third parties are deferred and capitalized.
The capitalized amounts are expensed as the related goods are delivered or the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development
activities are central to our business. As product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of
later-stage clinical trials, we expect that our research and development costs will increase in the foreseeable future. Such cost increases are expected to occur as we conduct existing clinical trials and initiate future clinical trials, manufacture
<FONT STYLE="white-space:nowrap">pre-commercial</FONT> clinical trial and preclinical study materials, expand our research and development efforts, seek regulatory approvals for our product candidates that successfully complete clinical trials,
access and develop additional technologies and hire additional personnel to support our research and development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot
determine with certainty the duration and total costs of our future clinical trials of our product candidates or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our product candidates, or those of
our collaborators, that might obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will
depend on a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress and expense of our ongoing clinical trials as well as any additional preclinical
studies, clinical trials conducted by our collaborators and other research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial and preclinical study results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expense of filing, maintaining, prosecuting, defending and enforcing patent claims and other intellectual
property rights; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to market, commercialize and achieve market acceptance for any products that receive regulatory
approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of monalizumab, IPH4102 and
IPH5401 or any other product candidate or preclinical program that we are developing or could develop in the future could mean a significant change in the costs and timing associated with the development of such product candidates or preclinical
programs. For example, if the FDA, the European Medicines Agency, or EMA, or another regulatory authority were to require us to conduct preclinical studies and clinical trials beyond those that we currently anticipate will be required for the
completion of clinical development, or if we experience significant delays in enrollment in any clinical trials, we could be required to spend significant additional financial resources and time on the completion of clinical development. For a
discussion of the risks associated with completing the development projects on schedule, see &#147;Risk Factors&#151;Risks Related to the Development and Commercialization of Lumoxiti and Our Product Candidates.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel costs and share-based compensation for personnel other than research and
development staff. General and administrative expenses also consist of fees for professional services, mainly related to audit, IT, accounting, recruitment and legal services, communication and travel costs, real-estate leasing costs, office
furniture and equipment costs, allowance for amortization and depreciation, director&#146;s attendance fees and insurance costs and overhead costs, such as postal and telecommunications expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expense will increase in the future as we grow our support functions for the expected
increase in our research and development activities and the commercialization of Lumoxiti. Our share of Lumoxiti operational expenses are included in net income (loss) from distribution agreements because AstraZeneca has been responsible for
commercialization activities to date. However, we expect that we will directly incur operational expenses related to Lumoxiti in the fiscal year ending December&nbsp;31, 2019 and future periods, which will be included in general and administrative
expenses. We also anticipate increased expenses associated with being a public company in the United States, including costs related to strengthening our support functions and hiring additional staff as well as our audit, legal, regulatory and <FONT
STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with Nasdaq listing and SEC requirements, director and officer insurance premiums and investor relations costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net income (loss) from distribution agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When commercialization activities related to a product that we own or license are performed by a third-party under a collaboration or
transition agreement, we must determine if the collaborator acts as an agent or a principal. With respect to our agreement with AstraZeneca related to Lumoxiti, we concluded that AstraZeneca acted as principal during the periods presented because
AstraZeneca controls the commercialization activities and is the holder of the applicable regulatory marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
result, we recognize on a single line the net income (loss) from our Lumoxiti distribution agreement in an amount equal to the sales for the period (which were immaterial for each of the periods presented), net of the administrative and selling
expenses associated with the sales revenue allocated to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net financial loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial loss primarily consists of (a)&nbsp;realized and unrealized foreign exchange gains and losses primarily related to the purchase
of services as well as deposit accounts denominated in U.S.&nbsp;dollars and (b)&nbsp;gains and losses and interest received in relation to cash and cash equivalents that have been deposited in cash accounts, short-term fixed deposits and short-term
highly liquid investments with original maturities of three months or less. Our cash and cash equivalents generate a modest amount of interest income. We expect to continue this investment philosophy in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Comparisons for the years ended December&nbsp;31, 2018 and 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our consolidated statements of income (loss) for the periods presented. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018(1)&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">32,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue and other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,983</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,016</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 reflect the impacts of the adoption of IFRS 9 and IFRS 15 that became applicable on January&nbsp;1, 2018. The comparative
consolidated financial statements as of and for the year ended December&nbsp;31 2017 have not been restated. The impact on the consolidated statement of income (loss) of the adoption of IFRS 9 is non material and the impact of the adoption of IFRS
15 is presented in &#147;Principal Components of Our Results of Operations&#151;Revenue from Collaboration and Licensing Agreements.&#148; See Note 2.a to our consolidated financial statements appearing elsewhere in this prospectus for more details
on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below provides a reconciliation of our consolidated statement of income (loss) as
published for the year ended December&nbsp;31, 2018 and our consolidated statement of income (loss) without the application of IFRS&nbsp;15, which reflects the application of the same accounting principles as for the year ended December&nbsp;31,
2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15&nbsp;Impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Excluding&nbsp;IFRS&nbsp;15<BR>Impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">100,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114,985</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(15,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(103,293</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income/(loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,637</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(569</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,349</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,067</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>7,349</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue and other income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue and other income resulted from collaboration and licensing agreements and government financing for research expenditure. Revenue and
other income increased by &#128;49.9&nbsp;million, or 113.4%, to &#128;94.0&nbsp;million for the year ended December&nbsp;31, 2018, as compared to revenue and other income of &#128;44.0&nbsp;million for the year ended December&nbsp;31, 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborations and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">32,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue and other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>44,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenues from collaboration and licensing agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from collaboration and licensing agreements increased by &#128;47.3&nbsp;million, or 144.8%, to &#128;79.9&nbsp;million for the year
ended December&nbsp;31, 2018, as compared to revenues from collaboration and licensing agreements of &#128;32.6&nbsp;million for the year ended December&nbsp;31, 2017. These revenues were derived principally under our agreements with AstraZeneca and
are set forth in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from collaboration and licensing agreements:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Monalizumab agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">61,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">32,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>IPH5201 agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invoicing of research and development (IPH5201 and IPH5401 agreements)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange gains on collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue from collaboration and licensing agreements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>79,892</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>32,631</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proceeds related to monalizumab.&nbsp;&nbsp;&nbsp;&nbsp;</I>Revenue related to monalizumab increased by
&#128;29.2&nbsp;million, or 90.3%, to &#128;61.5&nbsp;million for the year ended December&nbsp;31, 2018, as compared to &#128;32.3&nbsp;million for the year ended December&nbsp;31, 2017. This change is primarily due to (i)&nbsp;the exercise of the
option by AstraZeneca in October 2018, which resulted in revenue of &#128;32.0&nbsp;million in the year ended December&nbsp;31, 2018 and (ii)&nbsp;an increase of &#128;18.3&nbsp;million in revenue recognized in the period based on the percentage of
completion of development work, partially offset by (iii)&nbsp;the impact of the adoption of IFRS 15, which had a negative impact of &#128;21.0&nbsp;million on revenue for the year ended December&nbsp;31, 2018 . As of December&nbsp;31, 2018, the
deferred revenue related to monalizumab is &#128;104.9&nbsp;million (&#128;54.2&nbsp;million as &#147;Deferred revenue&#151;Current portion&#148; and &#128;50.7&nbsp;million as &#147;Deferred
<FONT STYLE="white-space:nowrap">revenue&#151;Non-current</FONT> portion&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proceeds related to
IPH5201.&nbsp;&nbsp;&nbsp;&nbsp;</I>Revenue related to IPH5201 for the year ended December&nbsp;31, 2018 was &#128;15.6&nbsp;million compared to nil for the year ended December&nbsp;31, 2017. Revenue related to the partial recognition of the
$50.0&nbsp;million <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment received from AstraZeneca in 2018, which has been recognized as revenue based on the percentage of completion of the development work. As of December&nbsp;31,
2018, the amount not yet recognized in revenue amounted to &#128;27.9&nbsp;million, classified as &#147;Deferred revenue&#151;Current portion.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Invoicing of research and development costs.&nbsp;&nbsp;&nbsp;&nbsp;</I>Revenue from invoicing of research and development costs for the
year ended December&nbsp;31, 2018 was &#128;2.2&nbsp;million compared to nil for the year ended December&nbsp;31, 2017. Pursuant to<I> </I>our agreements with AstraZeneca, research and development costs related to IPH5401 are equally shared between
us and AstraZeneca and research and development costs related to IPH5201 are fully borne by AstraZeneca, resulting in periodic settlement invoices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Government financing for research expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures increased by &#128;2.7&nbsp;million, or 23.3%, to &#128;14.1&nbsp;million for the year ended
December&nbsp;31, 2018, as compared to &#128;11.4&nbsp;million for the year ended December&nbsp;31, 2017. This change is primarily a result of an increase in the research tax credit of &#128;2.5&nbsp;million, which is mainly due to an increase in
eligible research and development personnel expenses and an increase in amortization of the monalizumab intangible asset following the additional consideration due to Novo Nordisk A/S in 2018. The table below details government funding for research
expenditures for the years ended December&nbsp;31, 2018 and 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Government financing for research expenditure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>14,060</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>11,402</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research tax credit is calculated as 30% of the amount of research and development expenses, net of grants
received, eligible for the research tax credit for the years ended December&nbsp;31, 2018 and 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents our operating expenses for the years ended December&nbsp;31, 2018 and 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">69,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>84,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses in the periods presented primarily relate to activities for our monalizumab, IPH4102 and IPH5401
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses are broken down as set forth in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monalizumab(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPH4102</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPH5401</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lumoxiti(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discovery projects and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total direct research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>42,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses (including share-based payments)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Personnel and other expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,409</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>69,555</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>67,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As a result of the adoption of IFRS 15 as of January&nbsp;1, 2018, monalizumab expenses do not include our <FONT STYLE="white-space:nowrap">co-funding</FONT> share of research and development work performed by
AstraZeneca, which amounted to &#128;15.5&nbsp;million and is recorded as a reduction to the transaction price, which is to be recorded as a revenue based on the percentage of completion. See the table appearing on Page 93 of this Prospectus for
reconciliation to IFRS 15. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lumoxiti research and development expenses mainly relate to the generation of additional data for regulatory purposes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development increased by &#128;2.6&nbsp;million, or 3.8%, to &#128;69.6&nbsp;million for the year ended December&nbsp;31, 2018,
as compared to research and development of &#128;67.0&nbsp;million for the year ended December&nbsp;31, 2017. The increase is mainly explained by: (i) an increase of &#128;9.6 million in expenses related to IPH5401 following our acquisition of the
related rights from Novo Nordisk in June 2017, (ii) an increase of &#128;8.3 million in expenses related to the progress of our monalizumab program (excluding the IFRS 15 impact), partially offset by (iii) a decrease of &#128;15.5 million related to
the impact of IFRS 15. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel expenses including share-based compensation to our employees and consultants decreased by
&#128;0.5&nbsp;million, or 3.2%, to &#128;14.2&nbsp;million for the year ended December&nbsp;31, 2018, as compared to &#128;14.7&nbsp;million for the year ended December&nbsp;31, 2017. This decrease is the cumulative impact of (i)&nbsp;the decrease
of &#128;3.0&nbsp;million in share-based payments partially offset by (ii)&nbsp;the increase in wages and salaries of &#128;2.8&nbsp;million due to increases in employee headcount and bonuses paid. As of December&nbsp;31, 2018 and 2017, we had 154
and 147 employees engaged in research and development activities, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by &#128;1.1&nbsp;million, or 6.6%, to &#128;18.1&nbsp;million for the year ended
December&nbsp;31, 2018, as compared to general and administrative expenses of &#128;17.0&nbsp;million for the year ended December&nbsp;31, 2017. General and administrative expenses represented a total of 20.7% and 20.3% of the total operating
expenses for the years ended December&nbsp;31, 2018 and 2017, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents our general and administrative
expenses by nature for the years ended December&nbsp;31, 2018 and 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses (including share-based payments)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non scientific advisory and consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total general and administrative</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>18,142</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>17,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Other expenses are related to intellectual property, maintenance costs for laboratory equipment and our headquarters, depreciation and amortization and other general and administrative expenses. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel expenses includes the compensation paid to our employees and consultants, and decreased by &#128;2.9&nbsp;million, or 27.3%, to
&#128;7.6&nbsp;million for the year ended December&nbsp;31, 2018, as compared to personnel expenses of &#128;10.5&nbsp;million for the year ended December&nbsp;31, 2017. This decrease results from a decrease in share-based payments of
&#128;4.3&nbsp;million, partially offset by the increase in wages and salaries of &#128;1.4&nbsp;million. As of December&nbsp;31, 2018, we had 41 employees in general and administrative functions, which was stable compared to December&nbsp;31, 2017.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-scientific</FONT> advisory and consulting expenses mostly consist of auditing, accounting, taxation
and legal fees as well as consulting fees in relation to business strategy and operations and hiring services. <FONT STYLE="white-space:nowrap">Non-scientific</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advisory and consulting expenses increased by &#128;1.5&nbsp;million, or 39.7%, to &#128;5.3&nbsp;million for the year ended December&nbsp;31, 2018 as compared to &#128;3.8&nbsp;million for the
year ended December&nbsp;31, 2017, primarily as a result of our agreement with AstraZeneca entered into in October 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net income
(loss) from distribution agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognized a net loss of &#128;1.1&nbsp;million from the Lumoxiti distribution agreement in
the year ended December&nbsp;31, 2018, which reflected immaterial revenue from sales of Lumoxiti in the period, less administrative and selling expenses associated with the sales revenue allocated to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Financial income (loss), net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net financial loss decreased by &#128;5.6&nbsp;million, or 69.8%, to &#128;2.4&nbsp;million for the year ended December&nbsp;31, 2018, as
compared to &#128;8.0&nbsp;million for the year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents the components of our net
financial loss for the years ended December&nbsp;31, 2018 and 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange gains</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,002</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized losses on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,535</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(8,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2018 and 2017, the foreign exchange gains and losses mainly result from
the variance of the exchange rate between the Euro and the U.S. dollar on U.S. dollar-denominated cash and cash equivalents and financial assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unrealized losses on financial assets relate to unquoted instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
liquidity and capital resources discussion that follows contains certain estimates as of the date of this prospectus of our estimated future sources and uses of liquidity (including estimated future capital resources and capital expenditures) and
future financial and operating results. These estimates reflect numerous assumptions made by us with respect to industry performance, general business, economic, regulatory, market and financial conditions and other future events, and matters
specific to our businesses, all of which are difficult or impossible to predict and many of which are beyond our control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Sources
and uses of liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have primarily financed our operations through our receipt of $475.0 million (&#128;415.9&nbsp;million)
in payments from our collaborators, including AstraZeneca, since 2011, excluding payments received for purchases of our equity securities by our collaborators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also financed our operations since our inception through several rounds of public
and private financings. Since our inception, we have raised a total of &#128;240.4 million through the sale of equity securities, including &#128;33.7 million in the initial public offering of our ordinary shares on Euronext Paris in 2006. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have received an aggregate of &#128;67.1&nbsp;million in research tax credits received to date. As a French biopharmaceutical
company, we have benefited from certain tax advantages, including, for example, the research tax credit. The research tax credit can be offset against French corporate income tax due and the portion in excess, if any, may be refunded. The research
tax credit is calculated based on our claimed amount of eligible research and development expenditures in France. The research tax credit increased by &#128;2.5&nbsp;million, or 22.5%, to &#128;13.5&nbsp;million for the year ended December&nbsp;31,
2018, as compared to a research tax credit of &#128;11.0&nbsp;million for the year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently qualify as
a small or medium size business. Therefore, the French Treasury refunded our 2016 research tax credit claims during the following year and we received reimbursement of the 2017 research tax credit in compliance with the applicable regulatory rules
in September 2018. We expect our status as a small or medium size business will be lost at the end of the fiscal year 2019 and, therefore, we would no longer be entitled to the immediate reimbursement of the Research Tax Credit but instead would be
reimbursed within the expiry of a three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are potentially eligible to earn a significant amount of milestone payments and
royalties under our agreements with AstraZeneca in the event that we satisfy certain <FONT STYLE="white-space:nowrap">pre-specified</FONT> milestones. We may enter into new collaboration agreements that also provide milestone payments. These
milestone payments are dependent on the accomplishment of various development, regulatory and commercialization objectives, and the achievement of many of these milestones is outside of our control. However, our ability to earn these payments and
their timing will, in part, be dependent upon the outcome of our research activities which is uncertain at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;3,
2017, we borrowed from the bank Soci&eacute;t&eacute; G&eacute;n&eacute;rale in order to finance the construction of our future headquarters. This loan, amounting to a maximum of &#128;15.2&nbsp;million, can be drawn down during the period of the
construction in order to pay supplier payments as they become due, but in any event no later than August&nbsp;30, 2019. We have decided to postpone this construction. Until this construction begins, the proceeds of the loan will be used to finance
several projects, such as extension of our current building, improvement of our information systems and development of our commercial infrastructure. Repayment of any amounts drawn down are payable over a
<FONT STYLE="white-space:nowrap">12-year</FONT> term beginning on August&nbsp;30, 2019 and ending on August&nbsp;30, 2031. As security for the loan, we pledged collateral in the form of financial instruments held at Soci&eacute;t&eacute;
G&eacute;n&eacute;rale amounting to &#128;15.2&nbsp;million. The security interest on the pledged financial instruments will be released in accordance with the following schedule: &#128;4.2&nbsp;million in July 2024, &#128;5.0&nbsp;million in July
2027 and &#128;6.0&nbsp;million in July 2031. As of December&nbsp;31, 2018, we had drawn down &#128;1.3&nbsp;million under the loan. The loan bears a fixed interest rate of 2.01%. Under the loan, we are subject to a covenant that our total cash,
cash equivalents and current and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets as of each fiscal year end will be at least equal to the amount of outstanding principal under the loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease our headquarters in Luminy, Marseille, France under a finance lease agreement. The present value of the minimum lease payments until
2021, which is the term of the lease, is recognized as a financial liability of &#128;1.1&nbsp;million at December&nbsp;31, 2018. In addition, we obtained a &#128;1.5&nbsp;million PTZI loan (<I>Pr&ecirc;t &agrave; Taux Z&eacute;ro
Innovation</I>&#151;interest-free loan for innovation) from <I>Banque Publique d&#146;Investissement</I>, or BPI France, in 2013. The loan is repayable beginning in September 2016 over five years. Lastly, during the years ended December&nbsp;31,
2016 and 2017, we also used lease-financing and bank loans to finance the acquisition of laboratory equipment and to set up new laboratories. The debt related to these loans amounts to &#128;1.4&nbsp;million at December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity position </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments increased by &#128;51.4&nbsp;million, or 44.3%, to &#128;167.5&nbsp;million for the year
ended December&nbsp;31, 2018, as compared to cash, cash equivalents and short-term investments of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#128;116.1&nbsp;million for the year ended December&nbsp;31, 2017. The cash assets that we hold consist of current accounts and fixed term accounts. Short-term investments primarily consist of
shares of money market funds and mutual funds. Their purpose is to finance our activities, including our research and development costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Excluding share options, we have received a total of &#128;240.4&nbsp;million from capital increases, before deducting the costs associated
with capital increases, between 1999 and December&nbsp;31, 2018. The table below summarizes the main capital increases between 1999 and December&nbsp;31, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;Proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2002</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2006</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2006</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.7&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2009</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.3&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.3&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.6&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B><B></B><B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>240.4</B><B></B><B>&nbsp;million</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth cash flow data for the years ended December&nbsp;31, 2018 and 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from / (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from / (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from / (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of the exchange rate changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase / (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,947</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(76,539</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows from / (used in) operating activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash flow used in operations decreased by &#128;15.5&nbsp;million to &#128;32.5&nbsp;million for the year ended December&nbsp;31, 2018
as compared net cash flows used in operations of &#128;48.1&nbsp;million for the year ended December&nbsp;31, 2017. This improvement of our operating cash flows results from the collection of &#128;40.3&nbsp;million of proceeds relating to the
agreements signed with AstraZeneca in October 2018, partially offset by an increase of outflows in relation to our research and development activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows from / (used in) investing activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash flows from investing activities for the year ended December&nbsp;31, 2018 were &#128;24.3&nbsp;million and mainly consisted of
(i)&nbsp;acquisitions of net financial assets for &#128;24.2&nbsp;million, (ii)&nbsp;interest received on financial assets for &#128;1.4&nbsp;million, less (iii)&nbsp;acquisitions of property and equipment for &#128;0.8&nbsp;million and
(iv)&nbsp;acquisition of intangible assets for &#128;0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash flows used in investing activities for the year ended
December&nbsp;31, 2017 were &#128;29.5&nbsp;million and mainly consisted of (i)&nbsp;acquisitions of net financial assets for &#128;25.7&nbsp;million, (ii)&nbsp;interest received on financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets for &#128;1.4&nbsp;million,&nbsp;less (iii)&nbsp;the IPH5401 acquired rights from Novo Nordisk A/S resulting in a cash out flows of &#128;2.8&nbsp;million, as the remaining part of the
upfront payment of &#128;40.0&nbsp;million was contributed in kind through a capital increase of &#128;37.2&nbsp;million, (iv)&nbsp;acquisitions of property and equipment for &#128;3.0&nbsp;million (mainly related to the acquisition of the land
attached to our headquarters and certain pieces of laboratory equipment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The acquisitions of current financial assets consist of
purchases of current marketable securities that do not meet the conditions under IAS 7 <I>Statement of cash flows</I> to be considered as cash equivalents. See Note 4 to our consolidated financial statements for the year ended December&nbsp;31, 2018
appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows from / (used in) financing activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash flows from financing activities for the year ended December&nbsp;31, 2018 increased by &#128;60.3&nbsp;million to
&#128;61.2&nbsp;million as compared to net cash flows from financing activities of &#128;0.9&nbsp;million for the year ended December&nbsp;31, 2017. On October&nbsp;22, 2018, AstraZeneca acquired 9.8% of our capital through the issuance of 6,260,500
new shares at &#128;10 per share, generating a &#128;62.6&nbsp;million cash inflow.<B><I> </I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Funding requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds of this global offering, together with our existing cash, cash equivalents, short-term
investments and non-current financial assets, will enable us to fund our operating expenses and capital expenditure requirements for at least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months. We
have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate a sufficient amount of revenue from sale of approved products, if ever, we expect to finance our operating activities
through our existing liquidity, the proceeds of this global offering and expected milestone payments from collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our present and
future funding requirements will depend on many factors, including, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size, progress, timing and completion of our clinical trials and preclinical studies for any current or
future product candidates, including our lead product candidates, monalizumab and IPH4102, IPH5401; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of potential new product candidates we identify and decide to develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with our payment obligations to third parties in connection with our development and potential
commercialization of certain of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with expanding our organization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against
claims of infringement raised by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may
encounter as a result of evolving regulatory requirements or adverse results with respect to any of these product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selling and marketing activities undertaken in connection with the commercialization of Lumoxiti and any other
current or future product candidates, including monalizumab, IPH4102, IPH5401 and IPH5201 and other product candidates, together with the costs involved in the creation of a sales and marketing organization; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenues, if any, we may derive either directly, or in the form of milestone or royalty payments
from any future potential partnership agreements, from monalizumab, IPH5201, or relating to our other product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information as to the risks associated with our future funding needs, see &#147;Risk Factors&#151;We may need to raise additional
funding to complete the development and any commercialization of our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, which may not be available on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development
efforts or other operations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Capital expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations mainly require investment in intangible assets. We acquired the rights of IPH5401 from Novo Nordisk A/S in 2017. We paid an
upfront of &#128;40.0&nbsp;million, of which &#128;37.2&nbsp;million was contributed in new ordinary shares and &#128;2.8&nbsp;million in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, we paid to AstraZeneca an initial payment for the license related to Lumoxiti ($50.0&nbsp;million, or &#128;43.8 million,
using the foreign exchange rate of 1.1422 at the date of payment), and in February 2019, we paid to Novo Nordisk A/S additional consideration relating to monalizumab ($15.0&nbsp;million, or &#128;13.1&nbsp;million as of December&nbsp;31, 2018). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations generally require little investment in tangible assets because we outsource most of the manufacturing and research activities
to third parties. We lease some of our computer equipment under operating lease agreements. We account for our payments for these items as operating expenses in the consolidated statement of income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our capital expenditures in the year ended December&nbsp;31, 2018 and 2017 primarily related to laboratory equipment. Clinical research and
development costs are not capitalized until marketing authorizations are obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate office in Luminy, Marseille, France is
leased under a finance lease agreement signed in 2008 with Sogebail, a subsidiary of Soci&eacute;t&eacute; G&eacute;n&eacute;rale, for an aggregate of &#128;6.6&nbsp;million. The lease-financing agreement has a 12-year term. We have a purchase
option for all of the buildings and land for the lump sum of &#128;1 at the end of the term of the contract in June 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since July
2017, we also rent office space in Marseille, France under a commercial lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations at December&nbsp;31, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI France PTZI interest-free loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;real estate(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down payment&#151;real estate(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease&#151;Building &#147;Le Virage&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease&#151;Vehicles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,688</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,862</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>678</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,061</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,289</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lease finance obligations&#151;real estate relate primarily to real estate property in relation to our acquisition of our headquarters and main laboratories and are presented in the above table net of the cash
collateral paid to Sogebail, the lessor. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We paid a guarantee to Sogebail for our real estate lease in the form of a down payment. This down payment amounted to &#128;0.2&nbsp;million at December&nbsp;31, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commitment amounts in the table above are associated with contracts that are enforceable
and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. The table does not include
obligations under agreements that we can cancel without a significant penalty as well as obligations under our employment benefit plans, which amounted to &#128;3.7&nbsp;million as of December&nbsp;31, 2018. Also, this table does not include the
undrawn part of the building loan amounting to &#128;13.9&nbsp;million that we are committed to fully draw before August&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2018, we have non-cancellable purchase commitments for a total of &#128;10.6 million with various CMOs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of a supply of scientific equipment, we were committed towards a supplier to minimum annual purchases of consumables. As of
December&nbsp;31, 2018, the overall commitment was amounting to &#128;0.3&nbsp;million for the period from January 2019 to June 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, we have certain obligations under the terms of research, collaboration and licensing agreements which usually require us to bear all expenses relating to the procurement, examination and extension procedures of patents, as well as to
uphold and defend the patents and will require, according to certain milestones, the payment of lump sums and royalties on sales to the licensor. The timing of the obligations depends on when related milestones are reached, which cannot be
anticipated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also signed option agreements which require us to (i)&nbsp;bear all expenses relating to the procurement, examination and
extension procedures of patents, as well as to uphold and defend the patents, (ii)&nbsp;pay a lump sum of money as option payment and (iii)&nbsp;if we decide to later <FONT STYLE="white-space:nowrap">opt-in,</FONT> to pay to the licensor of lump
sums (milestone payments) and royalties on sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, we signed certain agreements with collaborators, which defined the rules of
joint-ownership and the granting of rights regarding certain aspects of intellectual property. Under these contracts, we usually bear all expenses relating to the procurement, examination and extension procedures of the patents and to any procedure
required to uphold and defend the patents. These agreements also usually require, in exchange for a license over the share of rights owned by the <FONT STYLE="white-space:nowrap">co-owner,</FONT> and according to certain milestones, the payment of
lump sums and royalties on sales to the <FONT STYLE="white-space:nowrap">co-owner.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet
Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not, and we do not currently, engage in
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet financing arrangements as defined under SEC rules, such as relationships with other entities or financial partnerships, which are often referred to as structured finance or special purpose
entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our consolidated statement of financial position. In addition, we do not engage in trading activities involving <FONT
STYLE="white-space:nowrap">non-exchange</FONT> traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we did engage in these relationships. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has not completed an assessment of the effectiveness of our internal control over financial reporting, and our independent
registered public accounting firm has not conducted an audit of our internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the audit of our
consolidated financial statements as of and for the years ended December 31, 2018 and 2017, we identified material weaknesses in our internal control over financial reporting. A company&#146;s internal control over financial reporting is a process
designed by, or under the supervision of, a company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#146;s board of directors, management and other personnel to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Under standards established by the Public Company Accounting Oversight
Board, a material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement in our annual or interim financial statements will not
be prevented or detected and corrected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of auditing the consolidated financial statements as of and for
the year ended December 31, 2018, a material weakness in our internal controls related to the recognition of the revenue from our collaboration and licensing agreement with AstraZeneca on monalizumab was identified. The specific weakness in our
internal controls involved insufficient review of the calculation of the transaction price and percentage of completion of costs incurred, leading to an incorrect amount of revenue recognized for the year ended December 31, 2018, which was corrected
prior to the issuance of our audited financial statements. In the course of auditing the consolidated financial statements as of and for the year ended December 31, 2017, three material weaknesses in our internal controls were identified. The
material weaknesses related to (i) the accounting for subcontracting clinical costs for which there was insufficient control on the input data from clinical studies (termination date of the study and/or number of expected visits), (ii) stock-based
compensation with insufficient control surrounding the valuation of AGAP by external valuators, and (iii) a risk of management override of controls on manual journal entries due to insufficient supporting documentation for certain entries. Errors
not detected in relation to topics (i) and (ii) have led to incorrect amounts of R&amp;D expenses and personnel expenses for the year ended December 31, 2017, which were subsequently corrected prior to the issuance of our audited financial
statements. A number of significant deficiencies in our internal controls have also been identified for the years ended December&nbsp;31, 2018 and December&nbsp;31, 2017. Over the course of 2019, we continue to work to remediate these material
weaknesses and strengthen our controls in these areas. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were not required to perform an evaluation of our internal control over
financial reporting in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified all, or that we will not in the future have additional, material weaknesses. Material weaknesses may still
exist when we report on the effectiveness of our internal control over financial reporting as required by reporting requirements under Section 404 after the completion of this global offering. See &#147;Risk factors&#151;There are material
weaknesses and significant deficiencies in our internal controls over financial reporting and if we are unable to maintain effective controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected,
which could hurt our business, less investor confidence and depress the market price of our securities.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and
Significant Judgments and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with IFRS. Some of the accounting
methods and policies used in preparing the financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the facts
and circumstances. The actual value of our assets, liabilities and shareholders&#146; equity as well as our income and expenses could differ from the value derived from these estimates if conditions changed and these changes had an impact on the
assumptions adopted. See Note 2 to our consolidated financial statements for the years ended December&nbsp;31, 2018 and 2017 appearing elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the most significant management judgments and assumptions in the preparation of our consolidated financial statements are
described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Accounting for collaboration and licensing arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, our revenue has been generated primarily from payments received in relation to research, collaboration and licensing agreements signed
with pharmaceutical companies. These contracts generally provide for components such as upfront payments, milestone payments upon reaching certain predetermined development objectives, research and development funding, as well as payment of
royalties on future sales of products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-refundable</FONT> upfront payments are deferred and
recognized as revenue over the period we are engaged to deliver services to the third party. Revenue is recognized based on completion of the underlying work. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestone payments represent amounts received from our collaborators, the receipt of which is dependent upon the achievement of certain
scientific, regulatory, or commercial milestones. We recognize milestone payments when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no right to
refund of the payment. The triggering event may be scientific results achieved by us or another party to the arrangement, regulatory approvals, or the marketing of products developed under the arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of the subcontracting costs relating to clinical trial costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expense accruals for clinical trials are based on estimates of the fees associated with services provided by clinical trial investigational
sites and clinical research organizations. Payments under some of the contracts we have with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing
service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we
may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activity or fees associated with a study or service at a given point in time, adjustments to research and development
expenses may be necessary in future periods. Historically, our estimated accrued expenses have approximated actual expense incurred. However, due to the nature of such estimates, we cannot assure you that we will not make changes to our estimates in
the future as we become aware of additional information about the status or conduct of our clinical trials and other research activities. &nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of AstraZeneca invoices under the monalizumab and Lumoxiti agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The quarterly invoices submitted under these agreements are based on estimates made by AstraZeneca on the basis of its accounting work, which
requires AstraZeneca to make estimates regarding the advancement of clinical programs and associated costs. AstraZeneca provides us with an update on their budgets, which provides us with visibility into variations and allows us to identify
potential deviations. These invoices have a significant impact on our operating expenses and trade payables. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of the fair value of share options, warrants and free shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2018, we have granted share-based compensation under several plans to certain employees and members of our executive and
supervisory boards in the form of free shares (<I>Attributions gratuites d&#146;actions</I>, or AGA), free preferred shares convertible into ordinary shares (<I>Attributions gratuites d&#146;actions de pr&eacute;f&eacute;rence convertibles en
actions ordinaires</I>, or AGAP) and free performance shares (<I>Attributions gratuites d&#146;actions de performance</I>, or AGA Perf) as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Types</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>warrants<BR>outstanding<BR>as of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>number of<BR>shares&nbsp;to&nbsp;be<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>price<BR>per<BR>share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>date<BR>share&nbsp;fair<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGAP <FONT STYLE="white-space:nowrap">2017-1</FONT> (Employees)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGAP Management&nbsp;2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGA Employees 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGA Bonus 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGA Perf Employees 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGA&nbsp;Perf&nbsp;Management&nbsp;2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for share-based compensation in accordance with the authoritative guidance on share-based
compensation, IFRS 2 <I>Share-based payment</I>, or IFRS 2. Pursuant to IFRS 2, the awards are measured at their fair value on the date of grant. The fair value is calculated with the most relevant formula regarding the conditions and the settlement
of each plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Determining the fair value of share-based awards at the grant date requires judgment. We use the Black-Scholes option and
Monte Carlo approach pricing models to determine the fair value of share-based compensation. Free preference shares plans includes performance conditions that are based on the market price of our ordinary shares. Holders of free preference shares
may also benefit from accelerated vesting triggered by the achievement of internal goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of the grant date fair value
of warrants and free shares is affected by assumptions regarding a number of complex and subjective variables. These variables include the fair value of our ordinary shares on the date of grant, the expected term of the awards, our share price
volatility, the employee turnover weighted average probability, risk-free interest rates, expected dividends, and performance conditions when applicable. We estimate these items as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Fair value of our ordinary shares.</B> As our ordinary shares are publicly traded on Euronext Paris, for purposes of determining the fair
value of our ordinary shares we have established a policy of using the closing sales price per ordinary share as quoted on Euronext Paris on the date of the grant by the management board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Volatility.</B> We use the historical volatility of our ordinary shares on Euronext Paris, made on the basis of a Capital Asset
Pricing model of the share price using a Monte Carlo approach. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Employee turnover weighted average probability</B>. This rate is based
on the historical data from our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Risk-Free Interest Rate</B>. The risk-free interest rate is based on the Euribor swap. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Dividend Yield.</B> We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable
future. Consequently, we have used an expected dividend yield of zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the assumptions used in the Black-Scholes and
Monte-Carlo models change significantly, share-based compensation for future awards may differ materially compared to the awards granted previously. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of employee-benefit obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of defined benefit obligation is measured according to actuarial valuations. Inherent in these valuations are key actuarial
assumptions such as the discount rate, mortality tables and rates of turnover in employee personnel. These assumptions are provided in Note 10 to our consolidated financial statements appearing elsewhere in this prospectus. Any change in these
actuarial assumptions could have a significant impact on our consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of contingencies and
loss provision </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our activities, we may be exposed to contractual commitment risk. Management exercises its judgment to
estimate the probability and amount of cash outflows, as well as the information to disclose regarding contingent liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Estimate of the recoverable amount of the acquired and under progress licenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairment tests are performed on a yearly basis for the intangible assets which are not amortized (such as intangible assets in progress). We
test amortizable intangible assets for impairment when there is an indicator of impairment. Impairment tests involve comparing the recoverable amount of the licenses to their net book value. The recoverable amount of an asset is the higher of its
fair value less costs to sell and its value in use. If the carrying amount of any asset is below its recoverable amount, we recognize an impairment loss to reduce the carrying amount to the recoverable amount. The main assumptions used for the
impairment test include (a)&nbsp;the amount of cash flows that are set on the basis of the development and commercialization plans and budgets approved by Management, (b)&nbsp;assumptions related to the achievement of the clinical trials and the
launch of the commercialization, (c)&nbsp;the discount rate, (d)&nbsp;assumptions on risk related to the development and (e)&nbsp;for the commercialization, selling price and volume of sales, and are provided in Note 6 to our consolidated financial
statements which are included elsewhere in this prospectus. Any change in these assumptions could lead to the recognition of an impairment charge that could have a significant impact on our consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of failure of the clinical trials in progress, we may have to fully depreciate the intangible asset. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Estimate of the useful life of the acquired licenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets are amortized on a straight line basis over their anticipated useful life. The estimated useful life is the period over which
the asset provides future economic benefits. It is estimated by management and is regularly revised by taking into consideration the period of development over which it expects to receive economic benefits such as collaboration revenues, royalties
and product of sales. However, given the uncertainty surrounding the duration of the research and development activities for the programs in development and their likelihood to generate future economic benefits to the company, the estimated useful
life of the rights related to these programs is rarely longer than the actual development phase of the product candidate. When a program is in commercialization phases, the useful life takes into account the protection of the exclusivity rights and
the anticipated period of commercialization without taking into account any extension or additional patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures
about Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our activities are exposed to liquidity risk, foreign currency exchange risk, interest rate risk and credit risk.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not believe that we are exposed to short-term liquidity risk, considering our cash and cash equivalents of &#128;152.3&nbsp;million as of
December&nbsp;31, 2018, which consist primarily of cash and money market funds and term deposits that are convertible into cash immediately without penalty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign currency exchange rate risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to foreign exchange risk inherent in certain subcontracting activities related to our operations in the United States, which are
invoiced in U.S. dollars. We do not currently have material recurring revenues in euro, dollars or in any other currency. As we further increase our business, particularly in the United&nbsp;States, we expect to face greater exposure to exchange
rate risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue denominated in U.S. dollars has represented approximately 100% of revenue in the years ended December&nbsp;31,
2018 and 2017, respectively. Our payments in U.S. dollars represented approximately 31.9% and 15.1% of our payments in the years ended December&nbsp;31, 2018 and 2017, respectively. In order to cover this foreign currency exchange rate risk in part,
we kept in U.S. dollars a part of the consideration received from AstraZeneca in June 2015 and January 2019. We do not use hedging instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited exposure to interest rate risk. Our exposure primarily relates to money market funds and time deposit accounts. Changes in
interest rates have a direct impact on the rate of return on these investments and the cash flows generated. We do not have any credit facilities bearing variable interest rates. The repayment of the advances from BPI France<B> </B>is not subject to
interest rate risk. The effect of an increase or decrease in interest rates would have an immaterial effect on profit or loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Credit risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
credit risk related to our cash equivalents, short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets is not significant in light of the quality of the issuers. We deemed that no instrument of its portfolio is
exposed to credit risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Exemptions and Foreign Private Issuer
Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>JOBS Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with an annual revenue under $1.07&nbsp;billion, we qualify as an &#147;emerging growth company&#148; as defined in the JOBS Act.
As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to present only two years of audited financial statements in addition to any required interim
financial statements and correspondingly reduced disclosure in management&#146;s discussion and analysis of financial condition and results of operations in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the
Sarbanes-Oxley Act, in the assessment of our internal controls over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements and (ii)&nbsp;exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, including golden
parachute compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions for up to five years or until such earlier time that
we are no longer an emerging growth company. We will cease to be an emerging growth company upon the earliest to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue, (ii)&nbsp;the date we qualify as a &#147;large accelerated filer&#148; with at
least $700&nbsp;million of equity securities; (iii)&nbsp;the issuance, in any three year period, by our company of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities held by <FONT
STYLE="white-space:nowrap">non-affiliates;</FONT> and (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of our initial public offering of our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take advantage of some but not all of these reduced burdens. For example, we have presented only two years of audited
financial statements and only two years of related &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus, and intend to take advantage of the exemption from auditor
attestation on the effectiveness of our internal control over financial reporting. Accordingly, the information that we provide stockholders may be different than you might obtain from other public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in
Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Given that we currently report and expect to continue to report under IFRS as issued by the IASB, we have irrevocably elected not to avail
ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB. Since IFRS makes no distinction between public and
private companies for purposes of compliance with new or revised accounting standards, the requirements for our compliance as a private company and as a public company are the same. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Private Issuer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon consummation of this global offering, we will report under the Exchange Act as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company
with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are
applicable to U.S. domestic public companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of
a security registered under the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading
activities and liability for insiders who profit from trades made in a short period of time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> containing unaudited financial and other specified information, or current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> upon the occurrence of specified significant events; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulation FD, which regulates selective disclosures of material information by issuers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company
focused on discovering, developing and commercializing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutic antibodies designed to harness the immune system for the treatment of oncology
indications with significant unmet medical need. We have a <FONT STYLE="white-space:nowrap">20-year</FONT> history of research and development in immuno-oncology, having been pioneers in the understanding of natural killer cell, or NK cell, biology,
and later expanding our expertise in the tumor microenvironment, tumor antigens and antibody engineering fields. We have built, internally and through our business development strategy, a broad and diversified portfolio including an approved
product, three clinical product candidates and a robust preclinical pipeline. We have entered into collaborations with leaders in the biopharmaceutical industry, such as AstraZeneca and Sanofi, to leverage their development capabilities and
expertise, and we have received upfront and milestone payments and equity investments from our collaborations of an aggregate of approximately $550&nbsp;million over the last ten years. We believe our product candidates and clinical development
approach are differentiated from current immuno-oncology therapies and have the potential to significantly improve the clinical outcome for patients with cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The immune system is the body&#146;s natural defense against invading organisms and pathogens and is comprised of two arms: the innate immune
system and adaptive immune system. Recent immunotherapy developments have focused on generating a tumor antigen-specific T cell response and have led to an unprecedented change in the treatment paradigm of many solid tumor cancers. Despite these
successes, the breadth and durability of the clinical benefit achieved has been limited to a subset of patients and tumor types. Our innovative approach to immuno-oncology aims to broaden and amplify anti-tumoral immune responses by leveraging both
the adaptive and the innate immune systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The innate immune system is comprised of a variety of cells, including NK cells, which are
involved in anti-cancer immunosurveillance through a variety of modalities. Activation of the innate immune system also helps trigger the adaptive immune system to elicit a response directed against specific antigens and can provide durable immune
memory. Our scientific expertise, strategic collaborations and discovery engine are focused on harnessing the potential of the innate immune system across three pillars. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g14i22.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a pipeline of innovative immunotherapies that we believe have the
potential to provide a significant clinical benefit to cancer patients. The following table summarizes our commercial, clinical and preclinical pipeline. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g59g66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&#147;SCCHN&#148; denotes Squamous Cell Carcinoma of the Head and Neck; &#147;CRC&#148; denotes Colorectal Cancer;
&#147;MF&#148; denotes Mycosis Fungoides; &#147;PTCL&#148; denotes Peripheral T-cell Lymphomas; &#147;NSCLC&#148; denotes Non-Small Cell Lung Cancer; and &#147;HCC&#148; denotes Hepatocellular Carcinoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these product candidates, we have an active development pipeline with programs in the discovery and preclinical stages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development efforts are guided by our three pillars. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Broad spectrum immune checkpoint inhibitors</B>. We are targeting checkpoints expressed on NK cells and
myeloid cells, rather than focusing solely on T cells, in order to increase the pool of anti-tumor effector cells and potentially mount a larger anti-tumor response. Our most advanced checkpoint inhibitor product candidate, monalizumab, is a
potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> dual checkpoint inhibitor designed to activate both tumor-infiltrating NK cells and CD8+ T cells, potentially resulting in increased effector
functions and greater killing of tumor cells by the immune system. By activating NK cells, which are potent producers of cytokines, monalizumab may also favor dendritic cell maturation, which may in turn increase the generation of a T cell response
against the tumor. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">We and AstraZeneca AB, or AstraZeneca, are currently evaluating monalizumab in an open-label Phase
Ib/II clinical trial in combination with cetuximab, an epidermal growth factor receptor, or EGFR, inhibitor in patients&nbsp;with relapsed or metastatic squamous cell carcinoma of the head and neck, or R/M SCCHN. In addition to unleashing
tumor-infiltrating NK and CD8+ T cells, the combination of cetuximab and monalizumab may activate NK cells through the recognition of cetuximab-coated tumor cells via the CD16 activating receptor. In 2018, we presented data from a first expansion
cohort from this trial, including efficacy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">
data and have since then expanded to two additional expansion cohorts evaluating monalizumab in combination with cetuximab in patients who had been previously treated with chemotherapy alone or
in patients who had been treated with chemotherapy followed by checkpoint inhibitors. We expect to present follow-up data from the first expansion cohort in the second half of 2019 and preliminary efficacy data from the second expansion cohort in
2020. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">AstraZeneca is also evaluating monalizumab in a Phase I/II clinical trial in combination with durvalumab, an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> immune checkpoint inhibitor, in patients with advanced solid tumors, including colorectal cancer, or CRC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">We are also exploring the possibility of developing an antibody designed to reduce the effects of
<FONT STYLE="white-space:nowrap">Siglec-9</FONT> receptors, expressed on NK cells and myeloid cells, for the treatment of cancer. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tumor antigen targeting</B>. We are developing antibodies that target tumor antigens in the form of
(i)&nbsp;antibody-drug conjugates, or ADCs, (ii)&nbsp;antibody-dependent cellular cytotoxicity, or ADCCs, inducing antibodies and (iii)&nbsp;antibody-based multi-specific NK cell engagers, or NKCEs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>ADCs</I></B>. One approach is to directly kill tumor cells using either an ADC, such as with our IPH43
program, or an immunotoxin, such as with our commercial-stage product Lumoxiti. Lumoxiti is a marketed, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> CD22-directed immunotoxin, which was approved by
the FDA under priority review in September 2018 for the treatment of adult patients with relapsed or refractory, or R/R, hairy cell leukemia, or HCL, who have received at least two prior systemic therapies, including treatment with a purine
nucleoside analog, or PNA. Lumoxiti is the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> treatment for HCL in over 20 years. IPH43 is as an ADC targeting MICA/B that we are developing for the treatment of oncology indications.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>ADCCs.</I></B> Another approach is to develop antibodies that activate cells of the innate immune system,
such as NK cells, in order to induce ADCC. Our most advanced product candidate utilizing this approach is IPH4102, a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody targeting
KIR3DL2, a receptor not expressed on healthy tissues except on a subset of NK cells and T cells. We are developing IPH4102 for the treatment of various forms of T cell lymphomas, or TCL, including cutaneous T cell lymphoma, or CTCL, and peripheral T
cell lymphoma, or PTCL. Mycosis fungoides, or MF, is the most common form of CTCL, and S&eacute;zary syndrome is an aggressive form of CTCL. In January 2019, the FDA granted IPH4102 Fast Track designation for the treatment of adults with R/R,
S&eacute;zary syndrome who have received at least two prior systemic therapies. IPH4102 has also been granted orphan drug designation in the European Union and in the United States for the treatment of CTCL. In May 2019, we initiated a Phase II
clinical trial evaluating IPH4102 in different subtypes of TCL. We expect to announce the outcome of the first stage of the MF and PTCL cohorts in the second half of 2020 and report first efficacy data for the different cohorts beginning in 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Antibody-based multi-specific NKCEs</I></B>. We are also developing a pipeline of multi-specific NKCEs that
engage an activating checkpoint, NKp46, on NK cells, in order to direct NK cells to the tumor. We believe this innovative approach may allow for immuno-oncology treatments with a more favorable safety profile than T cell engagers.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Suppressive factors of the TME</B>: We are developing product candidates that target suppressive pathways of
the TME in order to relieve the immunosuppression of the innate and adaptive immune responses. We are developing IPH5401, an anti-C5aR antibody that disrupts the complement pathway. In January 2018, we entered into a non-exclusive clinical trial
collaboration with AstraZeneca for IPH5401. As part of this collaboration, we are conducting a Phase I/II clinical trial to evaluate the safety and efficacy of IPH5401 in combination with durvalumab as a treatment for patients with solid tumors,
including NSCLC and HCC. We expect to report preliminary safety data from this dose-escalation clinical trial in the second half of 2019. In addition, we are developing product candidates that disrupt the adenosine pathway, including IPH5201, an
anti-CD39 antibody, and IPH5301, an anti-CD73 antibody. In October 2018, we entered into a collaboration and option agreement for IPH5201 with AstraZeneca. We expect to file INDs for IPH5201 and IPH5301 in the second half of 2019 and the first half
of 2020, respectively. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaborations allow us to leverage the expertise and resources of large pharmaceutical
companies and research institutions with the goal of accelerating the development of several of our product candidates while providing financing to expand the development of our proprietary product candidates. Over the last ten years we have
received an aggregate of approximately $550&nbsp;million in upfront and milestone payments and equity investments from our collaborations and may be eligible to receive an aggregate of approximately $5.5&nbsp;billion in future contingent payments
from existing collaboration agreements and potential license agreements. In April 2015, we entered into a collaboration with AstraZeneca relating to monalizumab, and in October 2018, AstraZeneca expanded this collaboration to gain full oncology
rights for monalizumab and options to acquire development rights to IPH5201 and four of our other preclinical programs. Concurrently, we acquired U.S. and EU commercial rights to Lumoxiti, and AstraZeneca acquired a 9.8% equity stake in our company.
We have also entered into a collaboration agreement with Sanofi Aventis Recherche&nbsp;&amp; D&eacute;veloppement, or Sanofi, which includes two programs based on our multi-specific, NKCE technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Competitive Strengths </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our
key competitive strengths are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our lead product candidate, monalizumab, which we are developing in collaboration with AstraZeneca for the
treatment of SCCHN, CRC and other solid tumors, is a novel, dual-targeting checkpoint inhibitor that has shown promising clinical data.</I></B> Monalizumab is a humanized antibody that is capable of acting on NK cells and CD8+ T cells in order to
activate both innate and adaptive immune responses. We believe these properties may allow monalizumab, in combination with other therapies, to address some of the limitations of current therapies that only target T cells and potentially provide a
chemotherapy free therapeutic alternative in earlier lines of treatment. Preliminary data from a Phase II expansion cohort of 40 patients with R/M SCCHN previously treated with chemotherapy alone or chemotherapy followed by <FONT
STYLE="white-space:nowrap">PD-1/L1</FONT> checkpoint inhibitors, showed an overall response rate to monalizumab in combination with cetuximab of 27.5%, including one complete response (2.5%) and 10 partial responses (25%), and a disease control rate
at 24 weeks of 35%. Median progression-free survival and overall survival were 5.0 months and 10.3 months, respectively. In addition, we observed that there were three (18%) responders among the 17 patients who had been previously treated with <FONT
STYLE="white-space:nowrap">PD-1/L1</FONT> checkpoint inhibitors. Following these preliminary results, in 2018, AstraZeneca expanded its agreement with us by exercising its option to gain exclusive rights to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize monalizumab in oncology. Under our collaboration agreement with AstraZeneca, we are eligible to receive a $100&nbsp;million milestone payment at the start of the first Phase III
clinical trial for monalizumab. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our proprietary product candidate, IPH4102, has shown single agent activity for the treatment of relapsed
or refractory S&eacute;zary syndrome</I></B>. In our Phase I clinical trial evaluating IPH4102 in CTCL, in the subgroup of 35 patients with S&eacute;zary syndrome, we observed an overall response rate of 42.9%, median duration of response of 13.8
months and median progression-free survival of 11.7 months. IPH4102 has also been granted orphan drug designation in the European Union and in the United States for the treatment of CTCL. In January 2019, the FDA granted Fast Track designation to
IPH4102 for the treatment of adults with R/R S&eacute;zary syndrome who have received two prior systemic therapies. The results of the dedicated S&#233;zary syndrome cohort may support a future Biologics License Application, or BLA, submission to
the FDA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>We believe that by targeting C5a receptors, IPH5401 has potential as a novel target in cancer treatment and
as a scientifically validated pathway to reduce inflammation.</I></B> IPH5401 binds to and blocks C5a receptors expressed on subsets of myeloid derived suppressor cells, or MDSCs, and neutrophils, cells that impair anti-tumor T cell response and
chemotherapy efficacy. We are currently conducting a Phase I clinical trial of IPH5401 in combination with durvalumab, initially in patients with select advanced solid tumors, and plan to initiate a subsequent cohort expansion trial to evaluate
IPH5401 in combination with durvalumab in patients with NSCLC or HCC. We also plan to explore the potential of IPH5401 in inflammation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our commercial stage product, Lumoxiti, is the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
treatment for HCL in over 20 years</I></B>. Lumoxiti was approved by the FDA under priority review in September 2018 based on positive data in a Phase II clinical trial. In this trial, 75% of patients receiving Lumoxiti achieved an overall response,
30% had a durable complete response and 34% achieved a complete response with a negative minimal residual disease. A negative minimal residual disease complete response has been shown to be a surrogate for long-term disease control and potentially
survival in several hematological malignancies. Following our <FONT STYLE="white-space:nowrap">in-licensing</FONT> of Lumoxiti in the United States and the European Union from AstraZeneca, we are leveraging AstraZeneca&#146;s capabilities to advance
commercialization efforts through a transition period while we build our commercial organization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>We believe that our broad, early stage pipeline of innovative immunotherapies targeting innate immunity
pathways provides us with multiple opportunities for future value creation</I></B>. Our rich heritage and leadership in the field of innate immunity has allowed us to create a diversified and differentiated portfolio in immuno-oncology<B><I>.
</I></B>We have developed a large panel of molecular and cellular assays and <I>in vivo</I> models for assessing the pharmacodynamics, toxicology and the therapeutic activity of product candidates targeted towards the innate immune system. In many
cases, our product candidates are among a limited number of therapeutic antibodies in development for a given biological target. As a result, our differentiated approach has allowed us to forge collaborations with the leading academic institutions,
cancer centers and industry partners to evaluate and advance our product candidates either alone or in combination with other investigational or approved therapies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our diversified business model provides us with a strong financial base and strategic flexibility</I></B>.
In addition to our internally developed pipeline, we have a track record of acquiring the rights to product candidates at different stages of development, including monalizumab, Lumoxiti, IPH5401 and our IPH52 program. We have already derived
substantial value from these acquisitions and subsequent business development transactions relating to these assets. Our collaborations have also allowed us to leverage development capabilities and financial resources of leading biopharmaceutical
companies, while retaining optionality to <FONT STYLE="white-space:nowrap">co-develop</FONT> and potentially <FONT STYLE="white-space:nowrap">co-promote</FONT> certain assets. At the same time, we have retained or acquired exclusive development and
commercialization rights to other product candidates. We believe that our strategic collaborations, our current financial position and the proceeds from this global offering will position us to continue to develop our proprietary portfolio of assets
and build our commercial infrastructure, while maintaining our leadership in the development of novel immunotherapies. As of June&nbsp;30, 2019, we had
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million in cash, cash equivalents, short term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets.<B><I> </I></B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Experienced management team with a track record in the development and commercialization of cancer
therapeutics. </I></B>Our management team and board of directors have substantial experience in the biopharmaceutical industry, including in drug discovery, clinical development and commercialization. Our Chief Executive Officer, Mondher Mahjoubi,
MD, has 28 years of oncology development, product strategy and commercial management experience.&nbsp;Previously, he was the Oncology Global Manager at AstraZeneca and had tenures at Genentech and Roche. Pierre Dodion, MD, MBA, Chief Medical
Officer, has 24 years of experience in clinical and regulatory development efforts and medical affairs. He previously held positions at ARIAD Pharmaceuticals, Pfizer, Novartis and Aventis.&nbsp;Our Chief Scientific Officer, Eric Vivier, DVM, PhD,
has over 25 years of immuno-oncology experience and a substantial track record of publications in key scientific journals.&nbsp;Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S., Inc., has over 20 years of
experience in&nbsp;strategic marketing and commercial leadership expertise across several therapeutic areas. Ms.&nbsp;Butler has led and built multiple global and US commercial teams, including the product launch of durvalumab, while serving at
AstraZeneca.<B><I> </I></B><B><I></I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to harness the immune system for the treatment of conditions with serious unmet medical needs in oncology. By leveraging our 20
years of experience in immuno-oncology research and development, we strive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to continue to internally discover, externally identify and develop a broad and diversified portfolio of first and <FONT STYLE="white-space:nowrap">best-in</FONT> class immunotherapies across
various therapeutic modalities. The key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Deliver our clinical programs and improve patient outcomes in indications with high unmet medical need by
building on our scientific discoveries. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete our ongoing clinical trial of monalizumab for the treatment of SCCHN, which, together with the data from
the CRC clinical trial, will inform further development and the potential path to market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Execute the clinical development of our wholly owned product candidate, IPH4102, for the treatment of patients
with S&eacute;zary syndrome, MF and PTCL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Progress the clinical development of our wholly owned product candidate, IPH5401, for the treatment of patients
with cancer and explore its potential to treat inflammation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance our pipeline of other proprietary product candidates, including IPH5301. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Build a commercial stage oncology-focused biotechnology company. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build a commercial infrastructure for Lumoxiti in the United States and, if approved, in the European Union.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage our commercial infrastructure for future approved products in order to build a hemato-oncology focused
commercial franchise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Retain optionality to <FONT STYLE="white-space:nowrap">co-promote</FONT> product candidates in strategic regions
for select partnered assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to invest in our proprietary and partnered portfolio by leveraging our strong financial position and
revenue from our existing collaborations. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the value of our partnered product candidates under existing collaborations and potential license
agreements, under which we may be eligible to receive up to an aggregate of approximately $5.5&nbsp;billion in future contingent payments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to explore opportunities to accelerate the development of our proprietary pipeline programs through
additional collaborations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combine our disciplined business development strategy with our immuno-oncology research and development
capabilities to further expand our product portfolio. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand our pipeline of proprietary product candidates that target novel pathways in immuno-oncology using our
internal development engine. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Activating Innate Immunity: Harnessing the Power of Immunotherapy to Treat Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The Innate Immune System: Gatekeeper of the Adaptive Immune System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The immune system is the body&#146;s defense against invading organisms and pathogens and is comprised of two arms: the innate immune system
and adaptive immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The innate immune system represents the first barrier of immune defense because it reacts almost immediately
against threats and serves as a catalyst to mobilize other components of the immune system. The innate immune system functions to identify, attack and kill pathogens or cancer cells, produce cytokines and activate the complement cascade and the
adaptive immune system through antigen presentation. These functions involve a variety of cells, including NK cells, dendritic cells, monocytes, macrophages and neutrophils. These cells then launch adaptive immune responses while also mounting their
own effector responses. Throughout the body, cells of the innate immune system play a critical role in the immunosurveillance and detection of the formation of cancer cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once activated, the adaptive immune system responds with large numbers of cells directed
against specific antigens and can provide durable immune memory. An adaptive immune response is highly specific to particular antigens expressed by pathogens or cancer cells, but it requires time to develop in a process known as priming. Key
components of the adaptive immune system include antibodies, which are produced by B cells and that bind to antigens and mark them for destruction by other immune cells, and T&nbsp;cells, which recognize antigens on diseased cells and then attack
and eliminate them. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g25l94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The graphic above shows the interaction of the cells in the innate immune system and adaptive immune system
in the presence of microbial infections and tumors. The various cells in the innate immune system rapidly launch their own effector response to fight the infection or tumor while also activating the B cells and T cells in the adaptive immune system.
Once activated, the adaptive immune system launches a slower but more targeted effector response against the infection or tumor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Key Elements to Modulating the Activity of Immune Cells to Treat Cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cells implicated in innate and adaptive immunity can have different impacts on the treatment of cancer. While cytotoxic CD8+ T cells and NK
cells help eliminate tumors, subsets of T cells, such as regulatory T cells, and subsets of myeloid cells, such as myeloid-derived suppressor cells (MDSCs), can be harmful to the host by contributing to an immunosuppressive environment and promoting
tumor growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immune cell activity is controlled by many activating and inhibitory factors, including activating receptors and inhibitory
receptors, called checkpoints, which are expressed at the surface of these cells. <FONT STYLE="white-space:nowrap">PD-1,</FONT> <FONT STYLE="white-space:nowrap">LAG-3,</FONT> TIGIT and NKG2A are examples of inhibitory checkpoints while <FONT
STYLE="white-space:nowrap">OX-40,</FONT> CD137, NKG2D and NKp46 are examples of activating checkpoints. When engaged, the inhibitory checkpoints can impair anti-tumor immunity of adaptive and innate immune cells such as CD8+ T cells or NK cells,
thereby contributing to tumor escape from immune control. Inhibitory checkpoints are potential therapeutic targets for restoring anti-cancer immunosurveillance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The Role of the Innate Immune System as a Modality for Cancer Therapies with Significant Potential </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer has historically been treated with surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy or a combination of these
treatments that are directed at the tumor itself. More recently, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advances in the understanding of the immune system&#146;s role in cancer have led to immunotherapy becoming an important therapeutic modality, shifting the therapeutic target from the tumor to
the host and focusing on the immune system and the TME in order to reactivate its immunosurveillance against cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer immunotherapy
began with treatments that nonspecifically activated the immune system, such as <FONT STYLE="white-space:nowrap">IL-2</FONT> and IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> cytokines therapies, which had limited efficacy, significant toxicity
or both. More recent immunotherapy developments have instead focused on the generation of a tumor antigen-specific T cell response, in particular by modulating the activity of inhibitory receptors expressed by T cells. This modulation can limit T
cells expansion, such as with <FONT STYLE="white-space:nowrap">anti-CTLA-4</FONT> therapy, or limit their effector properties, such as with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> therapies. The therapeutic targeting of inhibitory receptors controlling T cell function has led to an unprecedented change in the treatment paradigm of many
cancers in solid tumors, such as melanoma, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and renal cell carcinoma, and in hematopoietic malignancies, such as Hodgkin lymphoma. Despite these successes, the breadth and durability
of clinical benefit achieved has been limited to a subset of patients and tumor types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The onset, maintenance and development of
long-lasting, protective T cell responses are dependent on innate immune cells and NK cells in particular. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Harnessing Innate
Immunity in Cancer: NK Cells as a Key Player in the Anti-Tumor Immune Response </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NK cells are part of the innate immune system and
represent a significant fraction of the total number of cytotoxic cells in the body. They are active in many hematological and solid tumors and play a key role in the initiation of the T&nbsp;cell response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Checkpoints expressed on NK cells include inhibitory cell surface receptors, such as NKG2A, and activating NK cell receptors, such as NKp46.
NKp46 is the most specific NK cell marker identified to date across organs and species. Other receptors, such as NKG2A, are more prevalent in certain subsets of NK cells, including NK cells infiltrating the tumor, and are also present on tumor
infiltrating CD8+ T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NK cells are involved in the anti-cancer immunosurveillance through a variety of direct and indirect effects.
The figure below provides an illustration of anti-cancer functions of NK cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g752656g07h45.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">NK cells are able to directly and selectively kill cells undergoing stress caused by a cancerous transformation or pathogen
infection, a process called natural cytotoxicity.</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3" ALIGN="center">


<IMG SRC="g752656g01x34.jpg" ALT="LOGO">
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">


<IMG SRC="g752656g78x43.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">NK cells can also kill target cells when they are coated by antibodies in a process called antibody-dependent cellular cytotoxicity (ADCC).</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g752656g14z14.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NK cells are also potent producers of cytokines, which are soluble
molecules that recruit and activate an adaptive immune response by T&nbsp;cells through dendritic or other antigen-presenting cells, which in turn may enable the generation of immune memory against tumor cells.</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By providing the initial catalyst for the multilayered immune response, the activation of the innate immune
system through the targeting of NK cells could potentially result in an enhanced anti-tumoral T cell response. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The Tumor and its
Host: The Immune System and the Tumor Microenvironment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, the pursuit of understanding the resistance to immune
checkpoint inhibitors has led to an increased focus on the TME, which plays an important role in the inhibition of both the innate and adaptive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immune system. The TME contains a complex interplay of immunosuppressive biological pathways, cells and other components surrounding the tumor that often act together to profoundly suppress the
body&#146;s anticancer immune response, thereby allowing tumors to evade the immune system. More specifically, the TME can inhibit immune responses through the following means: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlling oxygen availability to cells, resulting in hypoxia; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing or degrading key metabolites regulating cell survival or activation, such as PGE2, adenosine,
tryptophan and <FONT STYLE="white-space:nowrap">L-Arginine;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing cytokines, such as <FONT STYLE="white-space:nowrap">TGF-&szlig;;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruiting suppressive cells such as MDSCs and regulatory T cells. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical data has shown that targeting the TME and neutralizing its immunosuppressive, cancer-promoting effects could play a key role
in the fight against cancer in combination with other immunotherapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach: Three Pillars to Harness the Potential of the
Innate Immune System </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-tumor immune response results from complex interactions between many different cells, including innate
immune cells, adaptive immune cells and cancer cells. While T cells, particularly CD8+ T cells, are critical to many protective anti-tumor immune responses, they do not act autonomously and require the activation of innate immune cells to achieve
full potential. More specifically, T cells expand upon the presentation of antigens by activated dendritic cells, a process that can be enhanced by the activation of NK cells through the production of development factors, chemokines or cytokines. In
addition, innate immune cells can also have anti-tumor activity independent of their impact on T cells and other adaptive immune cells, including for example, the cytotoxic activity of NK cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our scientific expertise, strategic collaborations and discovery engine allow us to harness the potential of the innate immune system across
three pillars: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Broad spectrum immune checkpoint inhibitors</B>. We are targeting checkpoints expressed on several immune
system cell types including NK cells and myeloid cells, rather than focusing solely on T cells, in order to increase the pool of anti-tumor effector cells and potentially mount a larger anti-tumor response. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tumor antigen targeting</B>. We are developing antibodies designed to target tumor antigens, in either
ADCC-inducing or ADC formats, and unique antibody-based multi-specific NKCEs, with the goal of combining the direct effect of tumor cell killing with the indirect priming and amplification of the T cell response by releasing tumor antigens and
mobilizing innate immune cells such as NK cells. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Suppressive factors of the TME</B>. We are developing product candidates that relieve the immunosuppression of
the innate and adaptive immune responses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g05q01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pipeline is balanced between these three pillars and each pillar is designed to harness the potential
of the innate immune system. More specifically, for each of these pillars, we are advancing the following innovative approaches: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"><B><I>The targeting of inhibitory checkpoints includes the generation of broad-spectrum immune checkpoint inhibitors, such as monalizumab, that have been designed
to unleash several immune cell types such as NK cells and CD8+ T cells. By unleashing both types of cells, broad spectrum immune checkpoint inhibitors may provide a more effective anti-tumor response when combined with other
therapies.</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the greatest advances in immuno-oncology has been the development of antibodies that target T cell
checkpoints, most notably the <FONT STYLE="white-space:nowrap">CTLA-4</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> pathways. These treatments have shown an ability to activate T cells, shrink
tumors and improve patient survival in a broad range of tumors. In 2011, Yervoy (ipilimumab, anti-CTLA4) became the first checkpoint inhibitor approved by the FDA, followed by Opdivo (nivolumab, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1)</FONT></FONT> in 2014 and Keytruda (pembrolizumab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1)</FONT></FONT> in 2015. Other recently approved checkpoint inhibitors include
Tecentriq (atezolizumab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1),</FONT></FONT> Bavencio (avelumab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1),</FONT></FONT> Imfinzi
(durvalumab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1)</FONT></FONT> and Libtayo (cemiplimab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1).</FONT></FONT> However, the breadth and
durability of clinical benefit achieved has been limited to a subset of patients and tumor types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing broad spectrum
checkpoint inhibitors targeting inhibitory checkpoints expressed on several cell types in order to potentially increase the breadth and quality of anti-tumor response. Our most advanced checkpoint inhibitor product candidate, monalizumab, is a
potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> dual checkpoint inhibitor designed to activate both tumor-infiltrating NK cells and CD8+ T cells, potentially resulting in increased effector
functions and greater killing of the tumor by the immune system. Our preclinical data provide evidence for this dual mechanism of action, the potential of this approach to induce long-lasting anti-tumoral immunity when combined with <FONT
STYLE="white-space:nowrap">PD-(L)1</FONT> blockers and the ability to increase the activity of ADCC inducing tumor-targeting antibodies such as cetuximab. Our preclinical checkpoint inhibitor programs include a program targeting <FONT
STYLE="white-space:nowrap">Siglec-9</FONT> receptors, which is expressed on tumor-infiltrating T cells, NK cells and innate myeloid cells. We also plan to continue to discover and explore the potential of developing other novel broad spectrum
checkpoint inhibitors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"><B><I>Targeting tumor antigens, including innovative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
antibody-derived drug candidates such as NKCEs, to harness the anti-tumor activity of NK cells.</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Antigen-targeting antibody development is highly dependent upon several factors, including the pattern of
expression of the target and the intended mechanism of action. For example, to be effective through ADCC, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
antibodies should be used in an immunocompetent setting, whereas to be effective by disrupting a signal, antibodies should target a driver of the oncogenic process. We are targeting tumor
antigens that are generally highly-expressed in tumor tissues but poorly-expressed in healthy tissues in order to develop product candidates through three approaches: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The first approach is to directly kill tumor cells using either an ADC, such as with our IPH43 program or an
immunotoxin, such as our commercial-stage product Lumoxiti. This approach is particularly well suited when the tumor bed is not sufficiently infiltrated by immune cells. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The second approach is to develop antibodies that activate cells of the innate immune system, such as NK cells,
that favor an immune-mediated mechanism of action. Our most advanced product candidate that utilizes this approach is IPH4102, a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody
targeting KIR3DL2. IPH4102 seeks to induce tumor killing through ADCC, and we are developing IPH4102 for the treatment of various forms of TCL, such as CTCL, including its aggressive subtype, S&eacute;zary syndrome, and PTCL. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The third approach is to develop multi-specific antibodies that leverage an activating checkpoint, NKp46. Our
multi-specific antibodies co-engage both NKp46, with or without CD16, and the tumor antigen. This approach has the potential to more effectively mobilize NK cells because, in the TME of many solid tumors, CD16, the receptor mediating the ADCC of
antibodies, can be downregulated on NK cells and whereas NKp46 expression is conserved on tumor-infiltrating NK cells. We are currently pursuing this innovative approach for two undisclosed targets with Sanofi and for one undisclosed target with
AstraZeneca. We believe that bridging innate effector cells with the tumor antigen through a multi-specific molecule has the potential to overcome limitations of current strategies focused on artificially redirecting T cells towards the tumors,
either with chimeric antigen receptor (CAR) T cells or T cell engagers. Although these current strategies have had significant success in certain hematologic malignancy indications, they are often associated with serious adverse events including
cytokine release syndrome and neurologic complications. Data from our preclinical studies suggest that NKCEs are not associated with inflammatory cytokine release and exhibit anti-tumoral activity in solid tumor mouse models, providing a rationale
to investigate the impact of NKCE in patients beyond hematologic malignancies. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"><B><I>Targeting the immunosuppressive TME to render it more immuno-competent through the disruption of the adenosine pathway, such as with IPH5201, an
anti-CD39, and with IPH5301, an anti-CD73, and the complement pathway, such as with IPH5401, an anti-C5aR.</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also focusing our development on the role of the TME in suppressing anti-tumoral immunity. The TME can
inhibit both innate and adaptive immune responses by producing or degrading key metabolites or by recruiting suppressive cells, or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adenosine is one of the components of the TME that most broadly affects immune response. It is produced by the sequential degradation of
extracellular adenosine triphosphate, or ATP, by two enzymes: first CD39 and then CD73. For this reason, this pathway has attracted significant development efforts that have been focused primarily on the downstream part of the adenosine degradation
cascade, CD73 and the adenosine receptors. We are developing a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> anti-CD73 antibody, and have also focused on the upstream part of the cascade,
CD39, in order to block the production of immunosuppressive adenosine and increase the pool of immuno-stimulatory extracellular ATP. We believe this approach is also potentially mechanistically synergistic with many therapies, particularly with our
checkpoint inhibitor and tumor-targeting product candidates and programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the most abundant cell populations within the TME is the
myeloid cell subset. Increasing evidence shows that MDSCs accumulate in most individuals with cancer, where they promote tumor progression, inhibit anti-tumor immunity and are an obstacle to many cancer immunotherapies. Additionally, data from mouse
models suggests that chronic inflammation and complement pathway activation eventually promotes an immuno-suppressive TME through MDSCs that impair anti-tumor T cell response and chemotherapy efficacy. In
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
particular, one of the complement proteins, referred to as C5a, can be produced at the tumor bed where it attracts and activates MDSCs. Our anti-C5aR program, designed to block the migration and
activation of MDSCs, is an opportunity to test a differentiated approach targeting this cell population in cancer. In inflammation, the role of the C5a/C5aR pathway is well established and other companies are currently exploring the efficacy of
blockers in several rare, inflammatory diseases. Other neutrophil-driven more frequent diseases such as sepsis, acute lung injury, ischemia-reperfusion injury and asthma, offer the possibility of exploring a scientifically validated pathway in these
conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Monalizumab, a Dual Checkpoint Inhibitor Targeting T Cells and NK Cells </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview and Mechanism of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing monalizumab, a humanized IgG4 monoclonal antibody targeting NKG2A, in collaboration with AstraZeneca. Monalizumab is being
investigated for the treatment of SCCHN, CRC and other tumor types. NKG2A is an inhibitory receptor that is expressed on a subset of peripheral and tumor-infiltrating NK cells and tumor-infiltrating cytotoxic CD8+ T cells. Monalizumab acts to block
the binding of NKG2A to its ligand, <FONT STYLE="white-space:nowrap">HLA-E,</FONT> which is overexpressed in many tumors and is often associated with a poor prognosis. Monalizumab enables NK cells and CD8+ T cells to kill cancer cells despite
expression of <FONT STYLE="white-space:nowrap">HLA-E,</FONT> thereby promoting effector T cell responses in combination with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> antibody and enhancing NK
cell effector functions and ADCC. The following illustration provides an overview of monalizumab&#146;s mechanism of action: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g19q99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As depicted above, in the absence of a blockade by monalizumab, the inhibitory receptor NKG2A recognizes
its ligand, <FONT STYLE="white-space:nowrap">HLA-E,</FONT> on the tumor cell. This recognition inhibits or diminishes the activity of the NK cell and CD8+ T cell against the tumor cell because the inhibitory signal from the NKG2A receptor
counterbalances the signal of the activating receptors, shown in green in the illustration above. When NKG2A is blocked from recognizing its ligand by monalizumab, the signal from the activating receptors can prevail and thereby trigger the NK cell
and CD8+ T&nbsp;cell to eliminate the cancerous cells. Activation of NK cells at the tumor site appears to initiate the sequence of immune events that allows tumors to be detected and killed by CD8+ T cells through a combination of direct
cytotoxicity and the promotion of adaptive responses by inducing recruitment of dendritic cells that present tumor antigens via <FONT STYLE="white-space:nowrap">MHC-I</FONT> on the surface of those cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Development Strategy and Opportunity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expression of <FONT STYLE="white-space:nowrap">HLA-E</FONT> in several cancer types suggests that it plays a key role in suppressing or
inhibiting an immune response to the tumor, thereby allowing tumor progression. <FONT STYLE="white-space:nowrap">HLA-E</FONT> is expressed in <FONT STYLE="white-space:nowrap">70-90%</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of patients with SCCHN, CRC, cancers of the ovary, endometrium, cervix and lung, and various types of leukemia and lymphoma, as well as in up to 50% of all cases of melanoma and esophageal
cancers. We are evaluating monalizumab in clinical trials in collaboration with AstraZeneca in multiple advanced solid tumors. Currently, the most advanced clinical programs are for the treatment of SCCHN and CRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SCCHN accounts for approximately 4% of all cancers in the United States. The American Cancer Society estimates that in 2019, over 65,000
Americans will develop head and neck cancer and over 14,500 will die from the disease. The survival rate in patients with SCCHN varies greatly depending on the stage of the cancer at diagnosis. Among patients with more advanced disease (stages III
and IV), up to 50% develop locoregional relapses and/or distant metastases. Once this occurs, the five-year survival rate drops significantly. Cetuximab (marketed as Erbitux), an EGFR inhibitor, and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> checkpoint inhibitors, including nivolumab (marketed as Opdivo) and pembrolizumab (marketed as Keytruda), have been approved by the FDA for the treatment of SCCHN in the second line setting.
However, many patients continue to fail to respond to these treatments and patients with SCCHN who have received prior immuno-oncology treatments have few treatment options and represent a group with a significant unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRC is the third most common cancer in men and the second most common cancer in women globally. The American Cancer Society estimates that in
2019, over 145,000 Americans will develop CRC and over 51,000 will die from the disease. The five-year survival rate varies greatly depending on the stage of the cancer: for localized colorectal cancer, the five-year survival rate is as high as 90%,
but if the cancer has metastasized, the five-year survival rate drops to 14%. Patients with metastatic CRC typically receive multi-agent chemotherapy with or without antiangiogenic therapy. Approximately 50% of CRC patients have a mutation of the
KRAS oncogene. Patients without this mutation typically receive an EGFR inhibitor. With these regimens, median overall survival reaches 30 months, but the five-year survival rate is less than 15%. If these treatments fail, patients may receive third
and later lines of treatment, such as regorafenib (marketed as Stivarga) and the trifluridine/tipiracil combination (marketed as Lonsurf). While both of these drugs have been approved by the FDA, their response rate is less than 15% and overall
survival was observed to be longer than placebo by less than two months. More substantial activity has been reported for checkpoint inhibitors in patients with the microsatellite instable, or MSI, subtype of CRC, referred to as <FONT
STYLE="white-space:nowrap">MSI-CRC.</FONT> However, the MSI subtype comprises only <FONT STYLE="white-space:nowrap">5-15%</FONT> of all CRC cases. Among the <FONT STYLE="white-space:nowrap">85-95%</FONT> of CRC patients with the microsatellite
stable, or MSS, subtype of CRC, referred to as <FONT STYLE="white-space:nowrap">MSS-CRC,</FONT> patients in the third and later lines of treatment represent a significant unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are primarily focused on investigating monalizumab in combination with other approved anti-cancer agents, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cetuximab</B>, an antibody directed against EGFR, is used for the treatment of metastatic CRC and SCCHN. In
preclinical models, cetuximab has been observed to bind to EGFR on tumor cells and thereby trigger ADCC by NK cells. However, the efficacy of ADCC is inhibited by NKG2A engagement with <FONT STYLE="white-space:nowrap">HLA-E.</FONT> Our preclinical
data support our hypothesis that monalizumab, by blocking the binding of NKG2A to <FONT STYLE="white-space:nowrap">HLA-E,</FONT> could enhance the therapeutic activity of cetuximab. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Durvalumab</B> is an antibody directed against <FONT STYLE="white-space:nowrap">PD-L1.</FONT> <FONT
STYLE="white-space:nowrap">PD-L1</FONT> and <FONT STYLE="white-space:nowrap">HLA-E</FONT> are both <FONT STYLE="white-space:nowrap">up-regulated</FONT> on many cancer cells, and they have both been observed to suppress tumor immune response and
contribute to tumor progression. Our preclinical data support our hypothesis that a monalizumab and durvalumab combination therapy may result in a greater anti-tumor immune response than durvalumab alone by blocking both the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> and the <FONT STYLE="white-space:nowrap">NKG2A/HLA-E</FONT> inhibitory pathways. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specificity of the combination of cetuximab and monalizumab is produced by the dual targeting of both activating receptors and inhibitory
receptors. Immune checkpoint inhibitors unleash lymphocytes by blocking inhibitory receptors and rely on endogenous activating receptors expressed on these lymphocytes to mediate the attack of the tumor cells. In contrast, we believe the combination
of cetuximab and monalizumab will not only unleash NK cells by blocking the inhibitory function of NKG2A, but also trigger NK cell cytotoxicity via the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognition of cetuximab-coated tumor cells through the CD16 receptor. The following illustration depicts the way in which monalizumab, in combination with cetuximab or durvalumab, is designed to
result in greater anti-tumor activity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g19r54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rationale for these combinations is further supported by the favorable tolerability profile of
monalizumab that we observed in preclinical studies and earlier clinical trials, suggesting that monalizumab is generally not expected to negatively impact the safety profile of the combination partner drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of monalizumab was investigated by Novo Nordisk in two Phase I trials in patients with rheumatoid arthritis and one Phase I/II
dose-ranging monotherapy trial in advanced, heavily pretreated ovarian cancer patients. Although short in duration and in a different patient population, the rheumatoid arthritis trial provided valuable dose escalation data that we were able to
leverage in order to accelerate development of monalizumab in oncology indications. In the ovarian cancer dose-ranging trial, 18 patients were randomized to three monalizumab treatments groups: 1 mg/kg, 4 mg/kg and 10 mg/kg. Monalizumab was well
tolerated in each of the three groups with no dose limiting toxicities, or DLTs, and no serious adverse events, or SAEs, reported. The most frequent adverse events, or AEs, were headache, fatigue, dry mouth, nausea/vomiting, hot flashes and
arthromyalgia. In a dose-ranging trial performed by NCIC in patients with ovarian cancer, the only AEs equal or above grade 3 were two cases of fatigue, three cases of nausea/vomiting and one case of dehydration. There was no observed dose
relationship between AEs and dosage of monalizumab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development of Monalizumab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of the ongoing clinical trials that we or our collaborator, AstraZeneca, are conducting, as well as investigator-sponsored
trials evaluating monalizumab. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trial</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sponsor</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of<BR>Patients<BR>Receiving<BR>Monalizumab</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase Ib/II clinical trial in combination with cetuximab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Innate&nbsp;Pharma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 140</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">R/M SCCHN</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase I/II clinical trial in combination with durvalumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AstraZeneca</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 501</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Advanced&nbsp;Solid&nbsp;Tumors, including CRC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase II clinical trial in combination with durvalumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AstraZeneca</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 60</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Unresectable, Stage III NSCLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase II clinical trial in combination with durvalumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AstraZeneca</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 40</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Resectable, Early-Stage NSCLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">PIONeeR Phase II clinical trial in combination with durvalumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Not&nbsp;yet&nbsp;recruiting</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Marseille&nbsp;Public&nbsp;University Hospital System</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 30</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">NSCLC with <FONT STYLE="white-space:nowrap">PD-1</FONT> Resistance</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase II clinical trial</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European Organisation for Research and Treatment of&nbsp;Cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 76</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">R/M SCCHN</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase I clinical trial</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Innate Pharma and Institut Paoli-Calmettes</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Post-Allogenic Stem Cell Transplantation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase II clinical trial</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Recruitment completed;&nbsp;ongoing <FONT STYLE="white-space:nowrap">follow-up</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European Organisation for Research and Treatment of&nbsp;Cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 34</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">R/M SCCHN</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our collaboration agreement with AstraZeneca, we are eligible to receive a $100 million milestone
payment at the start of a Phase III clinical trial for monalizumab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase Ib/II Clinical Trial in Relapsed/Metastatic SCCHN (in combination with cetuximab)
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and AstraZeneca are currently evaluating monalizumab in an open-label, Phase Ib/II clinical trial in combination with cetuximab in
patients with R/M SCCHN. The trial is currently being conducted at five sites in the United States pursuant to an investigational new drug application, or IND, that was accepted by the FDA in August 2015, and in nine sites in France, where it was
approved by the <I>Agence Nationale de la S&eacute;curit&eacute; du M&eacute;dicament et des Produits de Sant&eacute;</I>, or ANSM, in September 2015. The trial is expected to enroll up to 140 patients. The following graphic shows the trial design:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g95n92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase Ib dose-escalation portion of the clinical trial, 17 patients with R/M SCCHN were evaluated
across five dose levels of monalizumab (0.4, 1.0, 2.0, 4.0 and 10.0 mg/kg), administered every two weeks, in combination with cetuximab, administered intravenously with an initial dose of 400
mg/m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> and subsequent doses of 250 mg/m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>. For the Phase Ib dose-escalation portion of the trial, the primary endpoint was to assess the
occurrence of DLTs in order to determine the recommended dose level of monalizumab for the Phase II portion of the trial. The secondary endpoint was objective response rate, which is measured as the rate of patients who had a complete or partial
response according to RECIST 1.1, a widely used guideline to measure anti-tumor response in oncology. The response categories defined under RECIST 1.1 are summarized in the table below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="71%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Response category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Definition according to RECIST 1.1</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Definitions&nbsp;of&nbsp;measurable&nbsp;and <FONT STYLE="white-space:nowrap">non-measurable</FONT> disease; numbers and site of target disease</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Measurable lesions are 10 mm or more in long diameter (15 mm for nodal lesions); maximum of 5 lesions (2 per organ). All other disease considered <FONT STYLE="white-space:nowrap">non-target</FONT> (must be 10 mm or longer in short
axis for nodal disease).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR, PR or SD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cannot have met criteria for PD prior to CR, PR or SD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confirmation of CR, PR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Only required for <FONT STYLE="white-space:nowrap">non-randomized</FONT> trials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confirmation of SD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New lesions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Results in PD. Recorded but not measured.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confirmation of PD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not required (unless equivocal).</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seventeen patients were enrolled in the dose escalation portion of the Phase Ib trial. Two patients were not evaluable for DLTs as they
withdrew from the trial within three weeks of first treatment for reasons other than DLTs. In the 15 evaluable patients, no DLTs, infusion-related reactions or immune-related disorders were observed,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and no discontinuations from the trial attributable to treatment-related AEs or treatment-related deaths occurred. The combination was reported to be well tolerated with no AEs beyond those
observed with monalizumab or cetuximab administered as monotherapies. The most common treatment-related AEs were asthenia/fatigue (24%) and headache (18%). All AEs related to treatment with monalizumab were grade 1 or 2 except for one case of grade
3 fatigue experienced by a patient in the 0.4 mg/kg treatment group. Based on the results observed in the Phase Ib dose- escalation portion of the trial, the recommended Phase II dose of monalizumab, in combination with cetuximab, was established as
10 mg/kg, administered intravenously every two weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint for the Phase II portion of the trial is objective response
rate, which is measured as the rate of patients who had a complete or partial response according to RECIST 1.1. Secondary endpoints for the Phase II portion of the trial include duration of response, progression-free survival and overall survival.
The Phase II portion of the trial is comprised of three expansion cohorts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expansion Cohort 1,</U> which enrolled 40 patients, evaluated the combination of monalizumab and cetuximab in
patients with R/M SCCHN who had been previously treated with chemotherapy alone or chemotherapy followed by checkpoint inhibitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expansion Cohort 2</U>, which is expected to enroll 40 patients, began recruiting in September 2018 and is
evaluating the combination of monalizumab and cetuximab in patients with R/M SCCHN who have received a maximum of two prior systemic regimens in the R/M setting and with prior exposure to a <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitor
(who we refer to as <FONT STYLE="white-space:nowrap">IO-pretreated</FONT> patients); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expansion Cohort 3</U>, which is expected to enroll up to 40 patients, began recruiting in April 2019 and is
evaluating the combination of monalizumab, cetuximab and a <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitor in patients with R/M SCCHN who have not received prior systemic regimens in the R/M setting and without prior exposure to <FONT
STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitors (who we refer to as <FONT STYLE="white-space:nowrap">IO-na&iuml;ve</FONT> patients). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary clinical efficacy data from the first expansion cohort was presented at the American Association for Cancer Research, or AACR,
2018 annual meeting and at the European Society for Medical Oncology, or ESMO, 2018 annual meeting. Further subset analyses were presented at the 2018 annual meeting of the Society for Immunotherapy of Cancer. As of August&nbsp;31, 2018, a total of
40 patients with R/M SCCHN were evaluable for safety. Thirty-nine patients were evaluable for efficacy, while one patient was not evaluable for efficacy because of fatal tumor progression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the efficacy results as of August&nbsp;31, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Best overall response</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>n=40,&nbsp;n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete Response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(2.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial Response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;(25.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stable Disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22 (55.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Progressive Disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6 (15.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subtotal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39 (97.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Early death from progression</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (2.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Outcome Measure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Patients&nbsp;(n=40)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">IO-Na&iuml;ve&nbsp;Patients</FONT></B><br><B>(n=23)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">IO-Pretreated&nbsp;Patients</FONT></B><br><B>(n=17)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overall Response Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">27.5%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">35.0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18.0%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Progression-Free Survival</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0&nbsp;months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.0 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0 months</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Overall Survival</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10.3&nbsp;months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10.3&nbsp;months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12.8&nbsp;months</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disease Control Rate at 24 Months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">35%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">39%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">29%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Time to Response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.6 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.7 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.6&nbsp;months</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Duration of Response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.6 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.3 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.6 months</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Progression-Free Survival (PFS) and Overall Survival (OS) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g77y86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although preliminary, the activity of the monalizumab and cetuximab combination appears to occur across
Human Papillomavirus, or HPV, status, tumor burden and <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> expression. We believe our preliminary results of the monalizumab and cetuximab combination are encouraging when viewed in light of the clinical
results of currently approved treatment options for R/M SCCHN: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cetuximab was approved by the FDA for patients previously treated with platinum-based chemotherapy on the basis
of a <FONT STYLE="white-space:nowrap">single-arm</FONT> Phase II clinical trial in which patients treated with cetuximab achieved an overall response rate of 12.6%, median time to progression of 2.3 months and overall survival of 5.8 months.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pembrolizumab was approved by the FDA for the treatment of patients previously treated with platinum-based
chemotherapy on the basis of a <FONT STYLE="white-space:nowrap">single-arm</FONT> Phase II clinical trial <FONT STYLE="white-space:nowrap">(KEYNOTE-012)</FONT> in which patients treated with pembrolizumab achieved an overall response rate of 16%.
The median <FONT STYLE="white-space:nowrap">follow-up</FONT> time was 8.9 months. Among the 28 responding patients, the median duration of response had not been reached (range: 2.4+ to 27.7+ months), with 23 patients having responses of six months
or longer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nivolumab was approved by the FDA for the treatment of patients previously treated with platinum-based
chemotherapy on the basis of a randomized, active-controlled, open-label clinical trial <FONT STYLE="white-space:nowrap">(CHECKMATE-141).</FONT> Patients were randomized to receive nivolumab or the investigator&#146;s choice of cetuximab,
methotrexate or docetaxel. Patients treated with nivolumab achieved an overall response rate of 13.3%. Median overall survival was 7.5 and 5.1 months in the nivolumab and investigator&#146;s choice arms, respectively. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe the preliminary results of this trial are promising, no definitive conclusions regarding safety or effectiveness can be
drawn between this trial and those of the approved drugs discussed above due to the development stage of monalizumab, differences in trial designs and other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the 40 patients evaluable for safety in the first expansion cohort of our Phase II trial, all experienced one or more treatment-emergent
adverse events, or TEAEs, of which half were grade 3 or 4. Thirty (75%) of TEAEs were deemed to be related to treatment with monalizumab, and of these, seven (18%) were grade 3 or 4. Of the 40 evaluable patients, 16 (40%) patients experienced SAEs,
12 (30%) of which were grade <FONT STYLE="white-space:nowrap">3-4.</FONT> Of these SAEs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
three (8%) were deemed to be related to treatment with monalizumab and were grade 3 or 4. These SAEs consisted of colitis, interstitial lung disease and hypophosphatemia, each experienced by one
separate patient. Only one patient discontinued participation in the trial due to an AE. Cetuximab monotherapy is associated with significant toxicity. In the pivotal clinical trial of cetuximab in SCCHN, AEs were reported for 99% of the patients
and SAEs, mostly grade 3 or 4, were reported in 46% of the 47 patients. The most common cetuximab-related AEs were rash, acne and asthenia. In our trial investigating the monalizumab and cetuximab combination, there has been no indication to date
that the addition of monalizumab has a negative impact on the tolerability of cetuximab or vice-versa, consistent with the favorable tolerability profile of monotherapy observed in prior preclinical studies and clinical trials to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to report <FONT STYLE="white-space:nowrap">follow-up</FONT> data from the first expansion cohort in the second half of 2019 and
preliminary data from the second expansion cohort in 2020. We believe that data from the second cohort expansion testing monalizumab in combination with cetuximab in patients having been treated by a previous line of
<FONT STYLE="white-space:nowrap">PD-(L)1</FONT> will inform the next steps of the development of the combination.<I> </I>We estimate that there are approximately 15,000 patients that have received at least two prior lines of treatment in the United
States, Europe, Japan and China. We also believe that there will be a paradigm shift in the frequency and stage of use for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> treatments, which we believe will
be utilized more frequently in earlier lines of treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third expansion cohort was initiated in April 2019 and will provide
initial data in <FONT STYLE="white-space:nowrap">IO-na&iuml;ve</FONT> patients. We believe these data will inform the design of potential future clinical trials in early settings, such as the first line or locally advanced setting. We estimate that
in the United States, Europe, Japan and China, there are approximately 65,000 and 40,000 patients in the first line and locally advanced settings, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase I/II Clinical Trial in Solid Tumors, including Colorectal Cancer (in combination with durvalumab) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca is evaluating monalizumab in a Phase I/II, multi-center, <FONT STYLE="white-space:nowrap">single-arm,</FONT> 3+3 dose-escalation
and cohort expansion clinical trial in combination with durvalumab in up to 501 adults with advanced solid tumor malignancies, including CRC. This trial, which commenced in February 2016, is being conducted at 28 sites in the United States pursuant
to an IND that was accepted by the FDA in January 2016, as well as over 40 sites in Australia, Belgium, Brazil, Canada, France, Hungary, Italy, South Korea, New Zealand, Spain and the United Kingdom. The primary endpoint of the trial is safety, with
anti-tumor efficacy being a key secondary endpoint. Other secondary endpoints include response duration, progression-free survival, overall survival, pharmacokinetics, pharmacodynamics, and immunogenicity of a monalizumab and durvalumab combination.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, at the annual meeting of the American Society of Clinical Oncology, or ASCO, the trial investigators presented clinical
data showing preliminary anti-tumor activity in patients with R/M <FONT STYLE="white-space:nowrap">MSS-CRC,</FONT> a population historically unresponsive to <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> blockade. At the most recent measurement
date in April of 2018, 40 patients were evaluable for safety and 39 were evaluable for efficacy. Thirty-five (88%) patients had two or more prior lines of therapy. The key efficacy data from this Phase I/II clinical trial are summarized in the table
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Efficacy parameter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;patients&nbsp;(%)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of patients</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">39&nbsp;(100%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0&nbsp;(0%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3&nbsp;(8%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stable disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11&nbsp;(28%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Progression</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">22&nbsp;(56%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not evaluable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3&nbsp;(8%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overall response rate (95% Confidence interval)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">3&nbsp;(8%)&nbsp;(2-22)</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disease control rate at 16 weeks (95% Confidence interval)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">12&nbsp;(31%)&nbsp;(17-48)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Efficacy parameter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weeks&nbsp;(range)</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median duration of response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">16.1&nbsp;weeks&nbsp;(15.9-not&nbsp;estimable)</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical results of the currently approved treatment options for R/M <FONT
STYLE="white-space:nowrap">MSS-CRC,</FONT> regorafenib and trifluridine, are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regorafenib (marketed as Stivarga) was approved by the FDA for the treatment of patients who have been previously
treated with chemotherapy, an anti-vascular endothelial growth factor, or VEGF, therapy and, if KRAS wild type, an anti-EGFR therapy, based on a randomized, placebo-controlled Phase III clinical trial. In this trial, patients with metastatic CRC who
were treated with regorafenib achieved an overall response rate of 1%. Median overall survival was 6.4 months in the regorafenib group versus 5.0 months in the placebo group. Progression-free survival was 2.0 months in the regorafenib group versus
1.7 months in the placebo group, and 41% of patients in the regorafenib group achieved disease control compared to 15% in the placebo group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Trifluridine/tipiracil combination (marketed as Lonsurf) was approved by the FDA for the treatment of patients
who have been previously treated with the same prior treatments as regorafenib, based on a randomized, placebo-controlled Phase III clinical trial. Patients treated with trifluridine/tipiracil combination achieved an overall response rate of 1.6%.
Median overall survival was 7.2 months in the trifluridine/tipiracil combination group versus 5.2 months in the placebo group. Progression-free survival was 2.0 months in the trifluridine/tipiracil combination group compared to 1.7 months in the
placebo group. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data indicate that there remains a significant medical need for metastatic CRC in the third or
later line setting with response rates to available treatments of less than 5% and median overall survival only minimally exceeding that seen with placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety results of the monalizumab and durvalumab combination from this trial have been consistent with the monotherapy profiles of each
agent. Dose-escalation was completed with no DLTs and the maximum tolerated dose was not reached. No fatal AEs or AEs leading to treatment discontinuation were reported. In the <FONT STYLE="white-space:nowrap">MSS-CRC</FONT> expansion cohort, the
most common treatment-related AEs included arthralgia (7.5%), increased levels of alkaline phosphatase, or AST (7.5%), hypothyroidism (7.5%), pruritus (7.5%) and rash (7.5%). Grade 3 or 4 AEs that occurred in three patients were limited to one case
each of sepsis (grade 4) and increased lipase (grade 3), that both were resolved, and increased AST (grade 3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based in part on the
clinical trial results observed to date, AstraZeneca has decided to pursue additional expansion cohorts to assess the safety and efficacy of monalizumab in combination with durvalumab in first and third line settings in treating metastatic CRC.
These additional expansion cohorts are ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca will use clinical trial data observed to date to inform the design of
potential future clinical trials in CRC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Additional Exploratory Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Monalizumab is also being evaluated by us, AstraZeneca and investigator sponsors in several exploratory trials: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>AstraZeneca&#146;s two clinical trials in NSCLC</I>. AstraZeneca is conducting two separate Phase II clinical
trials assessing the efficacy and safety of durvalumab monotherapy as compared to durvalumab in combination with various novel agents, including monalizumab, in NSCLC. The first trial is expected to enroll up 60 patients with unresectable, stage III
NSCLC and the second trial is expected to enroll 40 patients with resectable NSCLC. The primary endpoint of the first trial is objective response rate at 16 weeks according to RECIST 1.1, and secondary endpoints include incidence of AEs, duration of
response, disease control and progression-free survival. The primary endpoint of the second trial is major pathological response rate and key secondary endpoints include safety and pathological complete response rate. These trials began in January
2019 and are being conducted in the United States, Canada, France, Hong Kong, Italy, Poland, Portugal, Spain, Switzerland and Taiwan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>The PIONeeR clinical trial</I>, <I>a Phase II clinical trial sponsored by Marseille Public University Hospital
System</I>. The purpose of this trial is to assess how to overcome resistance to immune checkpoint inhibitor monotherapies with experimental precision immunotherapies combined with durvalumab in third or fourth line treatment, in patients with
advanced NSCLC. The PIONeeR trial includes multiple trial arms, each testing a different therapy in combination with durvalumab. In the monalizumab arm, up to 30 patients will receive durvalumab in combination with 750 mg of monalizumab every four
weeks. The <FONT STYLE="white-space:nowrap">12-week</FONT> disease control rate is the primary endpoint, and there are multiple key secondary endpoints including overall response rate, progression-free survival, overall survival and duration of
response. The trial is being conducted in France. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase I clinical trial evaluating monalizumab as a single agent in patients with hematological malignancies in
a post-transplantation setting sponsored by Institut Paoli-Calmettes.</I> The objective of this trial is to identify the maximum tolerated dose, if any, and to select a recommended Phase II dose in this particular population. The trial will enroll
up to 18 patients and will include patients who have received allogenic hematopoietic stem cell transplantation. Four sequential cohorts of patients will receive a single escalating dose of monalizumab 75 to 100 days after stem cell transplantation.
The primary endpoint is the occurrence ratio of DLTs within four weeks of treatment. Secondary endpoints include incidence of acute and chronic graft-versus-host disease, probabilities of <FONT STYLE="white-space:nowrap">non-relapse</FONT>
mortality, cumulative incidence of relapse, probability of disease-free survival and probability of overall survival, each measured at one year after administration of monalizumab. This trial began in December 2016<I> </I>and is being conducted in
France. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase II clinical trial evaluating monalizumab in patients with R/M SCCHN sponsored by the European
Organisation for Research and Treatment for Cancer</I>. The objective of this trial is to evaluate biomarker-based treatment of patients with R/M SCCHN. The trial groups patients into different biomarker-driven cohorts, each receiving a different
study drug. Monalizumab will be evaluated in a single arm Phase II cohort of approximately 40 patients who are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> na&iuml;ve or resistant. The primary
endpoints of the trial are progression-free survival at 16 weeks and objective response rate at six months. Secondary endpoints include progression-free survival, response duration, overall survival and toxicity, each measured at 54 months after
first patient in, as well as objective response rate measured at 48 months after first patient in. The trial began in March 2017 and is being conducted in Belgium, France, Italy and the United Kingdom. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class,</FONT></FONT> Marketed Product <FONT
STYLE="white-space:nowrap">In-Licensed</FONT> from AstraZeneca for the Treatment of Hairy Cell Leukemia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lumoxiti (moxetumomab
pasudotox-tdfk) is a marketed, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> CD22-directed cytotoxin for the treatment of HCL which was approved by the FDA under priority review in September 2018 as a
treatment for adult patients with R/R HCL who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog, or PNA. Lumoxiti has been granted orphan drug designation by the FDA for the treatment of HCL.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HCL is a rare, chronic and slow-growing leukemia in which the bone marrow over-produces abnormal B cell lymphocytes. Untreated, HCL can
result in serious conditions, including infections, bleeding, anemia and potentially may lead to death. Approximately 1,000 people are diagnosed with HCL in the United States each year. HCL accounts for up to 3% of all adult leukemias. While many
patients initially respond to treatment, approximately <FONT STYLE="white-space:nowrap">30-40%</FONT> will relapse within five to ten years after their first treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PNAs, such as cladribine and pentostatin, are the established first line treatments for patients with HCL. Up to 90% of the patients treated
with PNAs achieve a complete remission. However, PNAs are associated with AEs linked to myelosuppression, which is a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, and immunosuppression. Most patients who
relapse more than two years after their initial treatments receive a second course of PNAs with a similar overall response rate to initial therapy but with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shorter duration. Patients who relapse earlier often receive PNAs combined with rituximab. When a patient relapses a second time, reaching the third line setting, PNAs are less effective, with a
significantly lower response rate and shortened duration of response. The third and later line setting represents a significant medical challenge, with no established standard of care and very few treatment options available. The National
Comprehensive Cancer Network, or NCCN, guidelines for HCL, updated in January 2019, recommend that patients who are third line or later in treatment be considered for Lumoxiti or participate in clinical trials of vemurafenib, with or without
rituxan, or ibrutinib. Vemurafenib and ibrutinib have shown limited activity. The third and later line setting represents a significant medical challenge, with no established standard of care and very few treatment options available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The approval of Lumoxiti was based on data from the open-label &#145;1053&#146; trial, which was a
<FONT STYLE="white-space:nowrap">single-arm,</FONT> multi-center Phase II clinical trial assessing the efficacy, safety, immunogenicity and pharmacokinetics of Lumoxiti monotherapy in patients with R/R HCL who had received at least two prior
therapies, including one PNA. The trial enrolled 80 patients and was conducted at 34 sites in 14 countries. The primary endpoint was durable complete response, defined as complete response with hematologic remission (blood count normalization) for
more than 180 days. Secondary endpoints included overall response rate, relapse-free survival, progression-free survival, time to response, safety, pharmacokinetics and immunogenic potential. In this trial, of the patients treated with Lumoxiti, 75%
achieved an overall response, 30% had a durable complete response and 34% achieved a complete response with no minimal residual disease. The following table summarizes initial efficacy results of the trial at the primary readout: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Efficacy measure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Result %, (95% CI)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Durable complete response rate<SUP STYLE="font-size:85%; vertical-align:top">a,b</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">30% (20, 41)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overall response rate<SUP STYLE="font-size:85%; vertical-align:top">c</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">75% (64, 84)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete response rate<SUP STYLE="font-size:85%; vertical-align:top">d</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">41% (30, 53)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial response rate<SUP STYLE="font-size:85%; vertical-align:top">e</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">34% (24, 45)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haematologic remission rate<SUP STYLE="font-size:85%; vertical-align:top">b</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">80%</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">a</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Durable complete response is defined as patients who achieved complete response with haematologic remission for a duration of more than 180 days </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">b</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Haematologic remission is defined as haemoglobin &gt; 11g/dL, neutrophils &gt; 1500/mm<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>, platelets
&gt;&nbsp;100,000/mm<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> without transfusions or growth factor for at least 4 weeks </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">c</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Overall response rate is defined as best overall response of complete response or partial response </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">d</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Complete response is defined as clearing of the bone marrow of hairy cells by routine haematoxylin and eosin stain, radiologic resolution of pre-existing lymphadenopathy and/or organomegaly, and haematologic remission
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">e</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Partial response is defined as <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 50% decrease or normalisation (&lt; 500/mm<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>) in peripheral blood lymphocyte count,
reduction of pre-existing lymphadenopathy and/or organomegaly, and haematologic remission </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this trial, Lumoxiti had an acceptable tolerability profile, with low rates of
treatment-related AEs leading to discontinuation. Grade 3 and 4 capillary leak syndrome and hemolytic uremic syndrome were seen in 5% and 2.5% of the patients, respectively. These AEs were reported to be manageable and reversible with close
monitoring and best supportive care. We expect additional <FONT STYLE="white-space:nowrap">follow-up</FONT> data to be available in the second half of 2019 and to be presented at an upcoming conference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We <FONT STYLE="white-space:nowrap">in-licensed</FONT> commercial rights to Lumoxiti in the United States and European Union from AstraZeneca
in 2018. As part of our agreement with AstraZeneca, we have a collaborative and staged transition for the Lumoxiti program. AstraZeneca is currently conducting all aspects of the distribution, sales and marketing in the United States on our behalf.
We are establishing a specialized medical and commercial teams in the United States and will transition to full commercialization responsibilities by <FONT STYLE="white-space:nowrap">mid-2020.</FONT> We plan to leverage the commercial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infrastructure that we are developing for Lumoxiti to commercialize our other product candidates targeting rare cancers, including IPH4102 in S&eacute;zary syndrome, MF and PTCL, if approved.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, in collaboration with AstraZeneca, plan to file for regulatory approval of Lumoxiti for the treatment of patients R/R HCL in the
European Union by the first quarter of 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH4102, A Tumor Targeting Anti-KIR3DL2 Antibody </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview and Mechanism of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing our wholly owned product candidate IPH4102 for the treatment of certain subtypes of TCLs, including CTCL and PTCL. IPH4102 is
designed to bind to the KIR3DL2 receptor and to kill cancer cells by ADCC, as illustrated in the following figure. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g36n86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KIR3DL2 is a receptor of the KIR family. In our preclinical studies, we have observed that KIR3DL2 is not
expressed on healthy tissues, except on a subset of NK cells and T cells. In addition, KIR3DL2 is expressed in <FONT STYLE="white-space:nowrap">T-cell</FONT> lymphoma. In particular, 65% of CTCL patients express KIR3DL2 and KIR3DL2 is also expressed
in approximately 50% of patients with MF, the most common type of CTCL. This frequency increases to 85% for the most aggressive CTCL subtypes, including S&eacute;zary syndrome. KIR3DL2 is also expressed by approximately 50% of patients with PTCL.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, the FDA granted IPH4102 Fast Track Designation for the treatment of adults with R/R S&eacute;zary syndrome who have
received at least two prior systemic therapies. IPH4102 has also been granted orphan drug designation in the European Union and in the United States for the treatment of CTCL. In May 2019, we initiated a Phase II clinical trial evaluating IPH4102 in
different subtypes of TCL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cutaneous T Cell Lymphoma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CTCL is a heterogeneous group of <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphomas that are characterized by the abnormal
accumulation of malignant T cells, primarily in the skin. CTCL accounts for approximately 4% of all <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphomas and has a median age at diagnosis of 55 to 65 years. There are approximately
6,000 new CTCL cases diagnosed per year in Europe and the United States combined. The most common type of CTCL is mycosis fungoides, or MF, accounting for approximately half of all CTCLs. S&eacute;zary syndrome, characterized by the presence of
lymphoma cells in the blood, is a CTCL subtype with a particularly poor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prognosis. The following table outlines the most common CTCL types, their frequency as a percentage of all cases of CTCL, and prognosis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>CTCL Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Frequency&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">5-year&nbsp;disease-specific</FONT></B><br><B>survival (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mycosis fungoides</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary cutaneous CD30+ lympho-proliferative disorders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">95-99</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary cutaneous CD4+ small/medium <FONT STYLE="white-space:nowrap">T-cell</FONT>
lymphoproliferative disorder</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mycosis fungoides variants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S&eacute;zary syndrome</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with advanced CTCL have a poor prognosis with few therapeutic options and no standard of care.
Treatment generally includes skin-directed therapies, such as topical corticosteroids, and systemic treatments, such as steroid drugs and interferon, for patients with more advanced disease or for whom skin-directed therapies failed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two new drugs have recently been approved for the treatment of CTCL: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Brentuximab vedotin (marketed as Adcetris), has been approved by the FDA for treatment of patients with primary
cutaneous anaplastic large cell lymphoma, or pcALCL, or CD30-expressing MF who have received prior systemic therapy. In Europe, brentuximab vedotin is indicated for the treatment of adult patients with CD30+ CTCL who require systemic therapy. The
response rate to brentuximab vedotin was 67% compared to 20% in the control group (physician&#146;s choice of either methotrexate or bexarotene) and the median progression-free survival was 16.7 months compared to 3.5 months for the control group.
Brentuximab vedotin was associated with a 45% risk of peripheral neuropathy, which led to treatment discontinuation in 12% of the patients and inclusion of a boxed warning on the label. Brentuximab vedotin is not approved in S&eacute;zary syndrome.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mogamulizumab, marketed as Poteligeo, has been approved by the FDA and the EMA for the treatment of adult
patients with R/R MF or S&eacute;zary syndrome after at least one prior systemic therapy. The response rate to mogamulizumab was 28%, compared to 5% in the control group (vorinostat), and the median progression-free survival was 7.6 months compared
to 3.1 months for the control group. The most common AEs were rash, infusion-related reactions, fatigue, diarrhea, upper respiratory tract infection and musculoskeletal pain. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although these new treatments represent progress in the treatment of CTCL, they are still associated with the safety and efficacy limitations
observed in their respective clinical trials. Further, even with these options, the vast majority of these treated patients eventually relapse and overall survival remains poor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Peripheral <FONT STYLE="white-space:nowrap">T-Cell</FONT> Lymphoma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PTCL is a diverse group of aggressive <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphomas that develop from mature T cells and
NK cells. PTCL arises in the lymphoid tissues outside of the bone marrow, such as in the lymph nodes, spleen, gastrointestinal tract and skin. The various PTCL types, their frequency as a percentage of all TCL cases, and prognosis are shown in the
following table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>PTCL Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Frequency&nbsp;(%)</B><br><B>Europe&nbsp;&amp; U.S.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">5-year&nbsp;overall&nbsp;survival&nbsp;(%)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PTCL not otherwise specified</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Angioimmunoblastic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">16-28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anaplastic large cell lymphoma, or ALCL, ALK positive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">6-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anaplastic large cell lymphoma, ALK negative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irrespective of the specific regimen used (single agent chemotherapy or combination
chemotherapy including GemOx), patients with R/R PTCL typically experience a poor outcome, with a median progression-free survival and overall survival of 3.1 months and 5.5 months, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Multi-agent chemotherapy is the recommended first line treatment for the majority of patients with PTCL. Brentuximab vedotin is approved in
combination with first line chemotherapy for patients with CD30-positive PTCL. For patients who are eligible, subsequent stem cell transplantation is a potentially curative option but it is limited to a minority of patients. Despite these
treatments, a high proportion of patients need second line therapy. Belinostat (marketed as Beleodaq), pralatrexate (marketed as Folotyn) and romidepsin (marketed as Istodax) have each been approved by the FDA in this setting, but efficacy is
generally limited. In the respective <FONT STYLE="white-space:nowrap">non-randomized</FONT> clinical registration trials, the response rate to belinostat, pralatrexate and romidepsin were each less than 30%, and the median duration of response was
approximately 10 months for belinostat and pralatrexate. None of these treatments have been approved by the EMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In fact, despite these
approvals, current treatment guidelines recommend participation in a clinical trial as a preferred option for patients with relapsed PTCL after first line. If clinical trials are not available, a chemotherapy combination of gemcitabine and
oxaliplatin, or GemOx, is listed as one of the preferred treatment combinations. Several studies have been published on the role of GemOx in patients with relapsed lymphoma and it is one of the most widely used regimens for this patient population
in the United States, Europe and Asia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development of IPH4102 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of our ongoing clinical trials of IPH4102. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trial</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sponsor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Patients in</B><br><B>Trial</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Indication(s)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Phase II clinical trial (TELLOMAK)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Innate&nbsp;Pharma</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">up&nbsp;to&nbsp;250</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">S&eacute;zary&nbsp;syndrome,&nbsp;MF&nbsp;and&nbsp;PTCL</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Phase I clinical trial</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Recruitment&nbsp;completed,&nbsp;initial<BR>data reported and <FONT STYLE="white-space:nowrap">follow-up</FONT><BR>ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Innate Pharma</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">44</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CTCL&nbsp;(including&nbsp;35&nbsp;patients&nbsp;with<BR>S&eacute;zary syndrome)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase II Clinical Trial (TELLOMAK) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, we initiated a global, open-label, multi-cohort Phase II clinical trial, known as TELLOMAK. This clinical trial is being conducted
at more than 10 sites in the United States, pursuant to an IND accepted by the FDA in January 2019, and at 11 sites in France, pursuant to approval by ANSM in February 2019, and in Germany, Italy and the United Kingdom. In this trial, we are
evaluating IPH4102 alone and in combination with GemOx in patients with advanced TCL. We expect to recruit up to 250 patients, with IPH4102 evaluated as a single agent in approximately 60 patients with S&eacute;zary syndrome who have received at
least two prior treatments, including mogamulizumab, as a single agent in approximately 90 patients with MF who have received at least two prior systemic therapies, and as combination with standard chemotherapy in approximately 100 patients with
PTCL who have received at least one prior treatment. The MF and PTCL arms will be comprised of two cohorts each, testing IPH4102 in KIR3DL2 expressing and <FONT STYLE="white-space:nowrap">non-expressing</FONT> patients. These cohorts will follow a
Simon <FONT STYLE="white-space:nowrap">2-stage</FONT> design that will terminate if treatment is considered futile. The following graphic depicts the trial design: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g61j66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint of the trial is objective response rate, measured using the 2011 Olsen criteria for
CTCL or the Lugano criteria for PTCL, respectively. Key secondary measures include incidence of treatment-emergent AEs, the effect of skin disease on quality of life as measured by the Skindex29 questionnaire, pruritus as measured by the Visual
Analog Scale, progression-free survival and overall survival. We expect to announce the outcome of the first stage of the MF and PTCL cohorts in the second half of 2020 and report first data from the different cohorts beginning in 2021. The results
of the dedicated S&eacute;zary syndrome cohort may support a future BLA submission to the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase I Clinical Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2015, we began a Phase I dose-escalating and cohort expansion clinical trial to evaluate IPH4102 for the treatment of advanced
CTCL. The trial enrolled 44 patients, including 35 patients with S&eacute;zary syndrome. The primary objective of the trial was to evaluate IPH4102 safety, and to identify DLTs and the maximum tolerated dose. Data from this trial were presented at
the 2018 meeting of the American Society of Hematology. We reported clinical activity in the subgroup of 35 S&eacute;zary syndrome patients, including an observed overall response rate of 42.9%, median duration of response of 13.8 months and median
progression-free survival of 11.7 months. The overall response rate appeared to be higher (53.6%) in the 28 patients with no histologic evidence of large cell transformation. Clinical activity was associated with a substantial improvement in quality
of life as assessed by the Skindex29 and Pruritus Visual Analog Scale scores. IPH4102 was generally well tolerated, consistent with previous observations. The most common AEs were peripheral edema (29%), asthenia
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(26%) and fatigue (23%), all of which were grade 1 or 2. Possibly treatment-related, grade 3 or above adverse events were observed in four patients (11%) and only three patients (9%) stopped
treatment as a result of an adverse event. One patient stopped treatment because of peripheral neuropathy, one patient stopped treatment because of general malaise and one patient stopped treatment because of several adverse events, including renal
injury, respiratory failure, dysphagia and sepsis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5401, An Anti-C5aR Antibody Acting on Immunosuppressive Cells in the Tumor
Microenvironment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview and Mechanism of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced antibody targeting the tumor microenvironment is IPH5401, which is designed to bind to and block the C5a receptor, or C5aR, a
receptor that is expressed on MDSCs and neutrophils. Part of the innate immune system, these types of cells promote tumor growth by secreting inflammatory and angiogenic factors that promote blood vessel growth, potently suppress T cells and NK
cells and hamper the activities of <FONT STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitors. C5a, a factor in the complement cascade, is often overexpressed in tumors, where it attracts and activates MDSCs and neutrophils in the tumor
microenvironment, promoting an immunosuppressive environment at the tumor bed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The image below depicts the mechanism of action of
IPH5401. IPH5401 is designed to bind to C5aR, thereby blocking its ability to bind to C5a. This blocking allows the CD8+ or CD4 T cells and NK cells, which would otherwise be suppressed by MDSC and neutrophils, to target and kill the tumor. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g13f27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical studies support development of IPH5401 in combination with
<FONT STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitors or other immunotherapies in cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development of
IPH5401 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trial</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sponsor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Patients</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Indication(s)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase I/II clinical trial <FONT STYLE="white-space:nowrap">(STELLAR-001)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Innate&nbsp;Pharma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">up&nbsp;to&nbsp;100</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Solid&nbsp;Tumors,&nbsp;NSCLC,&nbsp;HCC</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2018, we entered into a non-exclusive clinical trial collaboration with AstraZeneca with respect to
IPH5401. As part of this collaboration, we are conducting a multi-center, open label, dose-escalation and dose-expansion Phase I/II clinical trial <FONT STYLE="white-space:nowrap">(STELLAR-001)</FONT> to evaluate the safety and efficacy of IPH5401
in combination with durvalumab, an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> immune checkpoint inhibitor, as a treatment for patients with solid tumors, including
<FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung carcinoma, or NSCLC, with secondary resistance to prior immuno-oncology treatment and <FONT STYLE="white-space:nowrap">IO-na&iuml;ve</FONT> hepatocellular carcinoma, or HCC. The trial is
being conducted at two sites in the United States pursuant to an IND accepted by the FDA in May 2018 and at two sites in France pursuant to approval by ANSM. The first patient in this clinical trial was enrolled in September 2018, and we expect to
enroll up to 100 patients in total. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This trial consists of a dose-escalation part and two expansion cohorts. In the
dose-escalation part, patients receive IPH5401 in combination with 1,500 mg of durvalumab every 4 weeks. The first expansion cohort will evaluate the IPH5401 and durvalumab combination in patients with NSCLC who are
<FONT STYLE="white-space:nowrap">IO-pretreated</FONT> and the second expansion cohort will evaluate the IPH5401 and durvalumab combination in patients with HCC who are <FONT STYLE="white-space:nowrap">IO-na&iuml;ve.</FONT> The primary endpoints of
this trial are assessment of DLTs for up to six weeks after treatment and AEs from screening through up to 30 days after the last dose of trial medication. Secondary endpoints include objective response rate according to RECIST 1.1, duration of
response and progression-free survival. The graphic below depicts the trial design: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g90m90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to report preliminary safety data from this clinical trial in the second half of 2019. Pursuant
to our agreement, we and AstraZeneca are sharing the costs of this clinical trial on a 50/50 basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IPH5401 for the Treatment of Inflammation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The complement system consists of a network of more than 50 different plasma and membrane associated proteins. It is a part of the innate
immune system and plays a key role in host defense against pathogens as well as in tissue homeostasis. The anaphylatoxin C5a is formed upon cleavage of C5 during the process of complement activation. C5a is the most potent chemoattractant and
induces recruitment and activation of different immune cells to inflamed tissue, among which are neutrophils, eosinophils, monocytes, basophils, and mast cells. In addition, release of C5a increases blood vessel permeability, chemokine release from
neutrophils, and expression of adhesion molecules on endothelial cells. All of these processes facilitate further immune cell recruitment into inflamed tissue and local inflammation. Unsuitable activation of the complement cascade and production of
C5a are associated with inflammatory conditions including several types of vasculitis, systemic lupus erythematous, rheumatoid arthritis, ischemia/reperfusion injury, hydradenitis suppurativa,<U></U>&nbsp;psoriasis, acne, and urticaria. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5201, An Anti-CD39 Antibody Targeting the Immunosuppressive Adenosine Pathway </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a CD39-blocking monoclonal antibody known as IPH5201. In preclinical models using both primary human cells and tumor mouse
models, we observed that the blockade of CD39 could stimulate anti-tumor immunity across a wide range of tumors by preventing the production of adenosine and by promoting the accumulation of extracellular adenosine triphosphate, or ATP, in the tumor
microenvironment. CD39 is a membrane-bound extracellular enzyme that is overexpressed on the surface of regulatory T&nbsp;cells, myeloid cells and several types of tumor cells. CD39 suppresses the immune system by degrading ATP into adenosine
monophosphate, or AMP, that is then further degraded into adenosine by CD73. Within the tumor microenvironment, ATP promotes immune-cell mediated killing of cancer cells, and accumulation of ATP is beneficial for enhancing anti-tumor immune
responses. However, ATP degradation and adenosine accumulation causes immune suppression and dysregulation of immune cells, which results in the spreading of tumors. By promoting the accumulation of immune-stimulating ATP, and preventing the
production of immune-suppressive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adenosine, we believe that the blockade of CD39 may stimulate anti-tumor activity across a wide range of tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This rationale is supported by our preclinical data for IPH5201 in mouse tumor models and by the analysis of anti-tumor immune responses in
tumor-challenged CD39 <FONT STYLE="white-space:nowrap">knock-out</FONT> mice. In this model, significant tumor responses were observed in response to treatment with <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors and ADCC-inducing
antibodies, as well as with immunogenic chemotherapy, compared to responses to these agents in wild-type mice. The following images show the results of human CD39 <FONT STYLE="white-space:nowrap">knock-in</FONT> mouse tumor model. The four graphs on
the left show changes in tumor volume over time depending on the type of treatment group, which included a control group (gray), an IPH5201 (mouse version) group (blue), an oxaliplatin group (orange) and an oxaliplatin and IPH5201 combination group
(purple). The diagram below outlines survival among these four treatment groups. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g24u24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data were presented at the AACR 2018 annual meeting and were published in May 2019. We expect to file
an IND for IPH5201 in the second half of 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5301, An Anti-CD73 Antibody Targeting the Immunosuppressive Adenosine Pathway
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a CD73 blocking antibody for immuno-oncology known as IPH5301. CD73 plays a significant role in promoting
immunosuppression through the pathway degrading ADP into adenosine. CD73 blockade promotes anti-tumor immunity by reducing adenosine accumulation. We have generated a panel of novel anti-CD73 antibodies and, in the first half of 2018, selected a
lead product candidate from this program, IPH5301, due to a combination of parameters including affinity for CD73, inhibition of CD73 enzymatic activity and its chemistry, manufacturing and control profile. We presented preclinical data further
supporting the rationale of developing IPH5301, including in combination with IPH5201, at the AACR 2018 annual meeting. These data were also published in May 2019. IPH5301 has been observed to have a differentiated and superior activity compared to
benchmark antibodies that are currently in clinical development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IPH5301 is more potent in restoring CD4+ and CD8+ T cell proliferation in an <FONT
STYLE="white-space:nowrap">ATP-suppression</FONT> assay, than the most advanced clinical candidates </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g01o95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to file an IND for IPH5301 in the first half of 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Additional Preclinical Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a robust pipeline of additional preclinical product candidates across our three development pillars. Within our preclinical pipeline,
four programs are being developed under an option agreement with AstraZeneca including IPH43, the anti-Siglec-9 program and one multi-specific NKp46 NKCE program. Another NKCE program, IPH61, is developed in collaboration with Sanofi. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IPH43: Anti-MICA/B Antibody and Tumor Targeting Antibody Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing IPH43 as an antibody-drug conjugate targeting MICA/B for the treatment of oncology indications. MICA/B molecules bind to the
NKG2D activating receptor and are specifically expressed on several highly prevalent solid tumors types including in the breast, colon and lung. We believe an antibody that kills <FONT STYLE="white-space:nowrap">MICA/B-expressing</FONT> tumor cells
could potentially treat these cancers by eliminating tumor cells. Because MICA/B molecules are highly polymorphic and therefore frequently subject to genetic variation, we have generated a series of high affinity antibodies recognizing equivalently
the most frequent genetic variants of MICA/B. We chose to target MICA/B using an ADC format because it allows the elimination of tumor cells in the condition in which the tumor is not infiltrated by immune cells, known as an immune desert. This
program is in preclinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Anti-Siglec-9</FONT> &#150; Checkpoint Inhibitor Program
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exploring the possibility of developing an antibody designed to reduce the effects of the
<FONT STYLE="white-space:nowrap">Siglec-9</FONT> receptor for the treatment of cancer. <FONT STYLE="white-space:nowrap">Siglec-9</FONT> is an inhibitory checkpoint that is expressed on a broad range of immune cells, including NK cells and myeloid
cells such as dendritic cells, monocytes and neutrophils. <FONT STYLE="white-space:nowrap">Siglec-9</FONT> can interact with sialic acids expressed by tumors, leading to a reduced immune cell function that allows tumors to proliferate. In our
preclinical studies, we observed that&nbsp;antibodies designed to block <FONT STYLE="white-space:nowrap">Siglec-9&#146;s</FONT> interaction with its ligands enhanced NK cell cytotoxicity. We have also observed in our preclinical studies that <FONT
STYLE="white-space:nowrap">Siglec-9</FONT> is highly expressed on monocytes and dendritic cells and upregulated on T cells in cancer patients, suggesting a potential additional role as an inhibitory checkpoint agent. This program is in preclinical
development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>NKp46 NK Cell Engagers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Multispecific monoclonal antibodies, or multispecifics, are antibody-derived formats that can simultaneously bind to two or more different
types of molecules. A number of studies of bispecific antibodies are currently underway, such as those assessing the safety and efficacy of bispecific T cell engagers, such as BiTEs, which engage T cells via the antigen receptor on <FONT
STYLE="white-space:nowrap">one-side</FONT> of the bispecific T cell engager, and a tumor antigen on the other side of the BiTE. These molecules have demonstrated the ability to reduce or slow the growth of tumors in cancer patients, but also carry a
significant toxicity risk. This toxicity risk occurs by engaging all T cells, irrespective of their specificity and development status, potentially leading to an overt production of cytokines by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these T cells, referred to as a cytokine storm. In parallel, bispecific killer cell engagers, or BiKEs, that engage CD16 receptors found on NK cells, and trispecific killer cell engagers, or
TriKEs, that engage CD16 receptors and contain <FONT STYLE="white-space:nowrap">IL-15,</FONT> a cytokine that promotes NK cell activation and survival, have also been developed to target antigens expressed on solid tumors. BiKEs and TriKEs can be
effective both in vitro and in vivo preclinical models. These multifunctional molecules that engage NK cells could reduce the risks associated with toxicity, as NK cell counts only represent approximately 10% of T cell counts, thereby potentially
limiting the likelihood of inducing a cytokine storm. However, it remains unclear whether these multifunctional CD16 engager antibodies can activate NK cells in solid tumors since they often express low levels of CD16. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed trifunctional NKCEs to <FONT STYLE="white-space:nowrap">co-engage</FONT> NKp46 and CD16 on NK cells together with a tumor
antigen. In our preclinical studies, we observed that NKp46 NKCEs have stronger anti-tumor activity as compared to preclinical findings from other approved anti-tumor therapeutic antibodies, such as rituximab,
<FONT STYLE="white-space:nowrap">Fc-enhanced</FONT> obinutuzumab and cetuximab. We believe these results support the clinical development of NKCEs for cancer immunotherapy, as a complement to existing immuno-oncology approaches. The following images
depict the mechanism of action of these multifunctional NK cell engagers and our preclinical results. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g752656g29k88.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g752656g73c07.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IPH61 is a NKp46 NKCE developed as part of our research collaboration and licensing agreement with Sanofi for
the generation and evaluation of up to two NKp46 NKCEs, using Sanofi&#146;s technology and tumor targets and our NK cell engager technology. Under the terms of the agreement, Sanofi&nbsp;is responsible for the development, manufacturing and
commercialization of products resulting from the research collaboration. We are eligible to receive payments of up to &#128;400.0&nbsp;million primarily upon the achievement of development and commercial milestone as well as royalties on net sales.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical industry, and notably the cancer field, is characterized by rapidly advancing technologies, products protected by intellectual property rights and intense competition and is subject to significant and rapid changes as researchers
learn more about diseases and develop new technologies and treatments. While we believe that our technology, knowledge, experience, collaborations and scientific resources provide us with competitive advantages, we face potential competition from
many different sources, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any approved product that
we commercialize will compete with existing therapies and new therapies that may become available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a large number
of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Many of our competitors have significantly greater experience, personnel and resources as it relates to research, drug
development, manufacturing and marketing. In particular, large pharmaceutical laboratories have substantially more experience than we do in conducting clinical trials and obtaining regulatory authorizations. Mergers and acquisitions in the
pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These competitors are also likely to compete with us to recruit and retain top qualified scientific and management personnel, acquire rights for promising product candidates
and technologies, establish clinical trial sites and patient registration for clinical trials, acquire technologies complementary to, or necessary for, our programs and enter into collaborations with potential partners who have access to innovative
technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are
more effective, have a better safety profile, are more convenient, have a broader label, have more robust intellectual property protection or are less expensive than any products that we may develop. Our competitors also may obtain regulatory
approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our competitors could be more efficient
in manufacturing or more effective in marketing their own products than we or our partners may be in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our lead
product candidate, monalizumab, a novel dual-targeting checkpoint inhibitor, there are several pharmaceutical companies marketing and developing treatments for either SCCHN or <FONT STYLE="white-space:nowrap">MSS-CRC.</FONT> For SCCHN, Erbitux
(cetuximab), marketed by Eli Lilly, and checkpoint inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab), marketed by Bristol-Myers Squibb and Merck, respectively, have all been approved in the second line setting. For CRC, Stivarga
(regorafenib), marketed by Bayer, and Lonsurf (trifluridine/tipiracil), marketed by Taiho Oncology, are both approved in the third line or later setting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to Lumoxiti, our marketed product for the treatment of HCL, there is currently no established standard of care and very few
treatment options available in the third line and later setting. The National Comprehensive Cancer Network, or NCCN, guidelines for HCL, updated in January 2019, recommend that patients who are third line or later in treatment be considered for
Lumoxiti as well as participation in clinical trials of vemurafenib, with or without rituxan, or ibrutinib. Vemurafenib, rituxan and ibrutinib have not been approved by the FDA for the treatment of HCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to IPH4102, our monoclonal antibody product candidate targeting KIR3DL2, we are aware of several pharmaceutical companies
marketing and developing products for the treatment of patients with CTCL, including MF and S&eacute;zary syndrome, and PTCL. Two new drugs have been recently approved by the FDA for CTCL: Adcetris (brentuximab vedotin), marketed by Seattle Genetics
and approved for treatment of patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing MF who have received prior systemic therapy, and Poteligeo (mogamulizumab), marketed by Kyowa Kirin and approved for the
treatment of adult patients with R/R MF or S&eacute;zary syndrome after at least one prior systemic therapy. Zolinza (vorinostat) is the only drug approved by the FDA for CTCL patients after two prior failures. In the second line setting of PTCL,
Beleodaq (belinostat), Folotyn (pralatrexate) and Istodax (romidepsin) have all been approved by the FDA; however, none of these treatments have been approved by the EMA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also several pharmaceutical and biotechnology companies that are focused on the tumor microenvironment, including the complement and
the adenosine pathways. The C5a and C5aR pathways have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attracted efforts mainly in inflammation, but we are aware of some companies targeting C5a or C5aR in the oncology settings as well, such as MorphoSys AG and InflaRx N.V. Many companies are
active in the adenosine pathway, targeting CD73, CD39 or the adenosine receptors. For example, Bristol-Myers Squibb and AstraZeneca each have anti-CD73 product candidates in clinical development, and several other biotechnology companies are active
in this area, including Corvus Pharmaceuticals, Inc., Arcus Biosciences, Inc. and Surface Oncology, Inc.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NK cells
have been increasingly researched and we are aware of many companies addressing NK cells through different approaches such as cell therapies (Fate Therapeutics, Inc., NantKwest, Inc.) and multispecifics (Affimed N.V., Dragonfly Therapeutics, Inc.)
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategic Collaborations and License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2015 Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
April 2015, we entered into two agreements with MedImmune, a wholly owned subsidiary of AstraZeneca, which we refer to as AstraZeneca. The first agreement was a co-development and license agreement relating to certain combination products containing
monalizumab, or the Original Co-Development Agreement, and the second agreement was a development and option agreement for products containing monalizumab, including products using monalizumab as a monotherapy, or the 2015 Option Agreement. We
received an initial payment of $250 million under these agreements on June 30, 2015, of which $100 million was paid to us as an initial payment for the Original Co-Development Agreement and $150 million was paid to us as consideration for the 2015
Option Agreement described below. In October 2018, AstraZeneca exercised its option under the 2015 Option Agreement, which resulted in the automatic termination of both the Original Co-Development Agreement and the 2015 Option Agreement, and a new
co-development and license agreement relating to all products containing monalizumab, or the 2015 Co-Development Agreement, automatically came into effect. In connection with AstraZeneca&#146;s exercise of its option under the 2015 Option Agreement,
an upfront payment of $100 million was due under the 2015 Co-Development Agreement, which it paid in January 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2015
Co-Development Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2015 Co-Development Agreement, we granted to AstraZeneca a worldwide, exclusive license,
subject to certain exclusions, to certain of our patents and know-how to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology diseases and conditions. We
further granted to AstraZeneca a worldwide, non-exclusive license to certain of our other patents to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology
diseases and conditions. We retain the rights under the licensed patents and know-how to, among other things, co-promote licensed products in certain European countries, pursuant to our option to co-promote, and exploit the licensed patents and
know-how to research, develop and commercialize the licensed products outside of the field of diagnosis, prevention and treatment of oncology diseases and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2015 Co-Development Agreement, we are required to collaborate with AstraZeneca to develop and commercialize licensed products.
AstraZeneca will be the lead party in developing the licensed products and must use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize each licensed product in certain major markets. Each party will have to
use commercially reasonable efforts to complete certain development activities in accordance with a specified development plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
required for a defined period of time to co-fund 30% of the Phase III clinical trials of licensed products, subject to an aggregate cap, in order to receive 50% of the profits in Europe. We have the option to withdraw from such co-funding
requirements, in which case we would forfeit the option to co-promote licensed products under the agreement, and our right to share in 50% of such profits would terminate and sales </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in Europe will instead be factored into net sales used to calculate royalty and milestone payments to us. Additionally, certain Phase III and regulatory milestone payments that may be payable to
us will be reduced or extinguished entirely. AstraZeneca will be responsible for the promotion of licensed products worldwide, subject to our option to co-promote the licensed products in certain European countries. Should we elect not to
co-promote, our share of profits in Europe will be reduced by a specified amount of percentage points not to exceed the mid-single digits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development by AstraZeneca of a licensed product under the 2015 Co-Development Agreement is subject to certain reciprocal non-compete
obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca is obligated to pay us up to $925 million in the aggregate upon the achievement of certain development and
regulatory milestones ($500 million) and commercialization milestones ($425 million). As described above, the arrangement also provides for a 50% profit share and, subject to certain deferrals of reimbursement, loss share of licensed products in
Europe if we do not opt out of our co-funding and co-promoting obligations. In addition, we will be eligible to receive tiered royalties ranging from a low double-digit to mid-teen percentage on net sales of licensed products outside of Europe. The
royalties payable to us under the 2015 Co-Development Agreement may be reduced under certain circumstances, including loss of exclusivity or lack of patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our right to receive royalties under the 2015 Co-Development Agreement expires, on a licensed product-by-licensed product and
country-by-country basis, on the latest of: (i) the tenth anniversary of the first commercial sale of such licensed product in such country, or in the case of European countries, in any European country, (ii)&nbsp;the expiration of regulatory
exclusivity for such licensed product in such country and (iii) the expiration of the last-to-expire valid licensed patent claim subject to the agreement that covers such licensed product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the term of the 2015 Co-Development Agreement will expire on the date on which all of AstraZeneca&#146;s payment
obligations have expired. We may terminate the 2015 Co-Development Agreement if AstraZeneca challenges any patent licensed to it under the agreement. AstraZeneca may terminate the 2015 Co-Development Agreement in its entirety for convenience at any
time effective upon 120 days&#146; prior written notice to us. Either party may terminate the 2015 Co-Development Agreement in the event of an uncured material breach by the other party or for certain bankruptcy or insolvency events involving the
other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the 2015 Co-Development Agreement is terminated by AstraZeneca for convenience or by us for AstraZeneca&#146;s material
breach, insolvency or a patent challenge by AstraZeneca, all licenses and rights granted under the agreement terminate, however, upon any such termination, AstraZeneca would grant us an exclusive, worldwide, royalty-bearing right and license, with
the right to grant sublicenses, under technology developed by AstraZeneca and incorporated into or necessary for the exploitation of licensed products, except for certain manufacturing technology that would require a separate agreement. If the 2015
Co-Development Agreement is terminated by AstraZeneca for our material breach or insolvency, AstraZeneca has the right to continue the agreement by providing written notice to us. If AstraZeneca provides us with such written notice, among other
things, our rights under the co-promote option will terminate and we must cease any development, manufacture or commercialization activities under the agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into three additional agreements with AstraZeneca. The first agreement is a collaboration and option agreement
relating to IPH5201, or the 2018 CD39 Option Agreement. We received an initial payment of $50 million under this agreement, $26 million of which was received in October 2018 and $24&nbsp;million of which was received in January 2019. The second
agreement is an option agreement relating to four pre-clinical programs, which we refer to as the 2018 Future Programs Option Agreement. We received an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initial payment of $20 million under this agreement in October 2018. The third agreement is a license agreement with AstraZeneca relating to Lumoxiti, or the Lumoxiti Agreement. We made an
initial payment to AstraZeneca of $50 million under this agreement in January 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 CD39 Option Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2018 CD39 Option Agreement, we granted to AstraZeneca an exclusive option to obtain an exclusive license to certain of our
patents and know-how to develop and commercialize licensed products, including IPH5201 in the field of the diagnosis, prevention and treatment of all diseases and conditions in humans or animals, subject to certain limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2018 CD39 Option Agreement, we must collaborate with AstraZeneca to develop CD39 option products. Prior to the expiration of the
option period, we and AstraZeneca are subject to certain non-compete obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca is responsible for funding the research and
development costs of CD39 option products contemplated in the joint development plan. Additionally, we may conduct certain exploratory clinical studies at our own cost, subject to reimbursement by AstraZeneca with a premium under certain
circumstances related to subsequent development by AstraZeneca. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2018 CD39 Option Agreement, AstraZeneca is obligated to
pay us up to $10 million in the aggregate upon the achievement of certain development milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the term of
the 2018 CD39 Option Agreement will expire on the earlier of exercise of the option or expiration of the option period in the event that AstraZeneca does not exercise the option. We may terminate the 2018 CD39 Option Agreement if AstraZeneca
challenges any option patent. AstraZeneca may terminate the 2018 CD39 Option Agreement in its entirety for convenience at any time effective upon three months&#146; prior written notice to us. Either party may terminate the 2018 CD39 Option
Agreement in the event of an uncured material breach by the other party or for certain bankruptcy or insolvency events involving the other party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>CD39 Co-Development and License Agreement Upon Option Exercise by AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon exercise of the option under the 2018 CD39 Option Agreement, we would enter into a co-development and license agreement with AstraZeneca,
or the CD39 Potential License Agreement. Under the CD39 Potential License Agreement, we would grant to AstraZeneca a worldwide, exclusive license, subject to certain exclusions, to certain of our patents and know-how regarding, among other things,
our IPH5201 candidate, to develop, manufacture and commercialize licensed products in the field of diagnosis, prevention and treatment of diseases and conditions in humans and in animals, subject to certain limitations. We would retain certain
rights under the licensed patents and know-how to, among other things, co-promote licensed products in certain European countries, pursuant to our option to co-promote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CD39 Potential License Agreement provides for a payment of $25 million upon exercise. Additionally, AstraZeneca would be obligated to pay
us up to $800 million in the aggregate upon the achievement of certain development and regulatory milestones ($300 million) and commercialization milestones ($500 million). The arrangement also provides for a 50% profit share in Europe if we do not
opt out of co-promoting and late stage co-funding obligations. In addition, we would be eligible to receive tiered royalties ranging from a mid-single digit to mid-teen percentage on net sales of licensed products outside of Europe. The royalties
payable to us under the CD39 Potential License Agreement may be reduced under certain circumstances, including loss of exclusivity, lack of patent protection or the specific nature of the compound included within the licensed product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CD39 Potential License Agreement, unless we have elected not to co-fund, we would be required to collaborate with AstraZeneca to
develop and commercialize licensed products. AstraZeneca would be the lead </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party in developing and commercializing the licensed products and each party must use commercially reasonable efforts to develop, obtain regulatory approval and commercialize at least one
licensed product in certain major markets. Each party would have to use commercially reasonable efforts to complete its development activities in accordance with a specified development plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We would have the option to co-fund 30% of the Phase III clinical trials of licensed products in order to share in 50% of the profits and
losses of licensed products in Europe. If we do not exercise this co-funding option, among other things, our right to share in 50% of the profits and losses in Europe and right to co-promote in certain European countries will terminate and will be
replaced by rights to receive royalties on net sales at the rates applicable to outside of Europe. Additionally, certain milestone payments that may be payable to us would be reduced. AstraZeneca would be responsible for the promotion of licensed
products worldwide, subject to our option to co-promote the licensed products in certain European countries if we elect to co-fund. Additionally, we would have a right of first negotiation in the event that AstraZeneca wishes to grant a third party
the right to commercialize licensed products in Europe or the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development by AstraZeneca of a licensed product under
the Potential License Agreement is subject to certain reciprocal non-compete obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our right to receive royalties under the CD39
Potential License Agreement expires, on a licensed product-by-licensed product and country-by-country basis, on the latest of: (i) the tenth anniversary of the first commercial sale of such licensed product in such country, or, in the case of
European countries, in any European country, (ii) the expiration of regulatory exclusivity for such licensed product in such country and (iii) the expiration of the last-to-expire valid licensed patent claim subject to the agreement that covers such
licensed product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the term of the CD39 Potential License Agreement would expire on the date on
which all of AstraZeneca&#146;s payment obligations have expired. We may terminate the CD39 Potential License Agreement if AstraZeneca challenges any patent licensed to it under the agreement. AstraZeneca may terminate the CD39 Potential License
Agreement in its entirety for convenience at any time effective upon 120 days&#146; prior written notice to us. Either party may terminate the CD39 Potential License Agreement in the event of an uncured material breach by the other party or for
certain bankruptcy or insolvency events involving the other party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Future Programs Option Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2018 Future Programs Option Agreement, we granted to AstraZeneca four exclusive options that are exercisable until IND approval
to obtain a worldwide, royalty-bearing, exclusive license to certain of our patents and know-how relating to certain specified pipeline candidates to develop and commercialize optioned products in all fields of use. Upon exercise of an option, we
would be entitled to an option exercise payment of $35 million, as well as development and regulatory milestone payments ($320 million) and commercialization milestone payments ($500 million) and tiered, mid-single digit to mid-teen percentage
royalties on net sales of the applicable product. The royalties payable to us may be reduced under certain circumstances, including loss of exclusivity, lack of patent protection or the specific nature of the compound included within the applicable
product. Additionally, we would have rights to co-fund certain development costs in order to obtain profit and loss sharing in Europe. So long as we elect to co-fund such development costs, we also will have a right to co-promote optioned products
in Europe. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement for Lumoxiti </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Lumoxiti Agreement, we obtained an exclusive license under certain patents and know-how of AstraZeneca to develop, manufacture
and commercialize Lumoxiti for all uses in humans and animals in the United States, the European Union and Switzerland. We are obligated to pay AstraZeneca up to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$25&nbsp;million in the aggregate upon the achievement of certain regulatory and commercial milestones. In connection with the Lumoxiti Agreement, we also obtained an exclusive sublicense from
AstraZeneca under certain third-party intellectual property rights. In consideration for such sublicense we are obligated to pay a low single digit royalty on our net sales of Lumoxiti, as well as milestone payments up to approximately
$1&nbsp;million in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Lumoxiti Agreement, AstraZeneca is obligated to provide support for the continued development
and commercialization of Lumoxiti in the European Union and Switzerland prior to regulatory submission and approval as well as support for the continued commercialization of Lumoxiti in the United States for a specified period. We will reimburse
AstraZeneca for the development, production and commercialization costs it will incur during the transition period, subject to certain limitations for the year ending December 31, 2019. In addition, pursuant to the Lumoxiti Agreement we will enter
into a supply agreement with AstraZeneca for the continued supply of Lumoxiti for sale in the United States, the European Union and Switzerland. Under the Lumoxiti Agreement, each party is obligated to use commercially reasonable efforts to conduct
a number of activities under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Lumoxiti Agreement, we have a right of first negotiation in the event that
AstraZeneca intends to grant rights to commercialize Lumoxiti outside of the United States, the European Union and Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Lumoxiti Agreement will expire on a country-by-country basis upon the latest of (i) the expiry of the last exclusively licensed patent in such country, (ii) expiration of any regulatory exclusivity in such country, and (iii) the fifteenth
anniversary of the first commercial sale of Lumoxiti in such country. Either party may terminate the Lumoxiti Agreement upon any uncured material breach of such party&#146;s obligations under the agreement or upon a bankruptcy or insolvency of the
other party. Additionally, AstraZeneca may terminate the agreement in the event we challenge any patent exclusively licensed under the agreement or cease to perform all commercial activities with respect to Lumoxiti in the United States or the
European Union for a specified period of time. We may terminate the Lumoxiti Agreement upon certain prior notice to AstraZeneca. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Additional agreements related to Monalizumab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Novo Nordisk A/S </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2014, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the full development and commercialization rights to
monalizumab relating to the modulation of the activity of isolated NK cells from Novo Nordisk A/S. In consideration for these rights, we paid Novo Nordisk A/S &#128;2&nbsp;million in cash and 600,000 of our ordinary shares at a price of &#128;8.33
per share. Novo Nordisk A/S is eligible to receive a total of &#128;20&nbsp;million in potential regulatory milestones and tiered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-high</FONT></FONT> single-digit percentage
royalties on future net sales. The agreement with Novo Nordisk A/S included a right to additional consideration in the event of an <FONT STYLE="white-space:nowrap">out-licensing</FONT> agreement. Consequently, following the agreement signed with
AstraZeneca in April 2015, we paid Novo Nordisk A/S an additional consideration amount of &#128;6.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018
AstraZeneca exercised its option under the 2015 Option Agreement to acquire an exclusive license to monalizumab. Pursuant to this option exercise, AstraZeneca paid $100&nbsp;million to us and, as a result, Novo Nordisk A/S became entitled to a
second and final payment amounting to $15.0 million (&#128;13.1 million). If the AstraZeneca agreement is terminated for any reason, we will pay to Novo Nordisk A/S a portion of any amounts that have been budgeted but have not been spent or will not
be spent under the initial research and development budget. In light of current development plans and research and development costs incurred to date, we do not currently expect any amounts to be paid pursuant to this provision. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Novo Nordisk for IPH5401 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July of 2017 we entered into an exclusive license agreement with Novo Nordisk A/S relating to IPH5401, or the 2017 Novo Agreement, pursuant
to which we obtained a worldwide, exclusive license under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain patents and know-how of Novo Nordisk A/S to develop, manufacture and commercialize pharmaceutical products that contain or comprise an Anti-C5aR antibody. We made an initial payment to
Novo Nordisk A/S of &#128;40.0 million under the 2017 Novo Agreement which was offset against Novo Nordisk A/S&#146;s subscription in new shares. We are obligated to pay Novo Nordisk A/S in the aggregate up to &#128;370.0 million upon achievement of
certain development, regulatory and sales milestones and tiered royalties ranging from a low double-digit to low teen percentage on net sales. Our royalty payment obligations are subject to certain reductions and expire on a product-by-product and
country-by-country basis upon the later of the date the exploitation of a licensed product is no longer covered by a claim of a licensed patent in such country, loss of data or regulatory exclusivity in such country, and the twelfth anniversary of
the first commercial sale of such product in such country. In connection with the 2017 Novo Agreement, we obtained an exclusive sublicense from Novo Nordisk A/S under certain third-party intellectual property rights. In consideration for such
sublicense we may be obligated to pay a mid-single digit royalty on our net sales of a licensed product, however, we will be entitled to offset such payments against royalties payable to Novo Nordisk A/S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2017 Novo Agreement, we are obligated to use commercially reasonable efforts to develop and seek regulatory approval for a licensed
product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2017 Novo Agreement shall expire upon expiration of the last royalty payment obligation under the agreement. Either party
may terminate the 2017 Novo Agreement upon any uncured material breach of the agreement by the other party or upon a bankruptcy or insolvency of the other party. Additionally, Novo Nordisk A/S may terminate the agreement in the event we challenge
any patent licensed under the agreement. We may terminate the 2017 Novo Agreement upon prior notice to Novo Nordisk A/S. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration and licensing agreement with Sanofi </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a research collaboration and licensing agreement with Sanofi in January 2016 to apply our proprietary technology to the
development of bispecific antibody formats engaging NK cells to kill tumor cells through the activating receptor NKp46. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will work
together with Sanofi on the generation and evaluation of up to two bispecific NK cell engagers, using our technology and Sanofi&#146;s tumor targets. Under the terms of the license agreement, Sanofi will be responsible for the development,
manufacturing and commercialization of products resulting from the research collaboration. We will be eligible for up to &#128;400.0&nbsp;million in payments, primarily upon the achievement of development and commercial milestones, as well as
royalties on net sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on obtaining and maintaining patent, trade secret and other intellectual property and proprietary
protection of our technology, current and future products and product candidates and methods used to develop and manufacture them. We cannot be sure that patents will be granted with respect to any of our pending patent applications or to any patent
applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be sufficient to protect our technology or will not be challenged, invalidated or circumvented.
Our success also depends on our ability to operate our business without infringing, misappropriating or otherwise violating any patents and other intellectual property or proprietary rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to
protect our trade secrets, in part, by confidentiality agreements with our employees, consultants, scientific advisors and contractors. These agreements may not provide meaningful protection or may be breached, and we may not have an adequate remedy
for any such breach. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.
Notwithstanding these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measures, these agreements and systems may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently
discovered by competitors, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or drug candidates or
obtain or use information that we regard as proprietary. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. To the extent that our employees, consultants, contractors or partners use intellectual
property owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. For more information regarding the risks related to intellectual property,
please see &#147;Risk Factors&#151;Risks Related to Intellectual Property Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file patent applications to protect our product candidates, technical processes and the processes used to prepare our product candidates,
the compounds or molecules contained in these product candidates and medical treatment methods. We also license rights to patents owned by third parties, academic partners or other companies in our field. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Moxetumab pasudotox-tdfk (Lumoxiti) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;31, 2019, the intellectual property rights related to Lumoxiti<I> </I>are <FONT STYLE="white-space:nowrap">in-licensed</FONT>
from AstraZeneca and include three families of U.S. and certain selected foreign patents, with statutory expiration dates ranging from 2022 to 2033, not including patent term adjustment or any potential patent term extension. U.S. Patent
No.&nbsp;10,072,083 covers the composition of matter of Lumoxiti, and its counterpart European application EP 2&nbsp;613 857 B1 covers the manufacture of Lumoxiti. This U.S. patent has, and any patents that issue from such European application would
have, a statutory expiration date in 2031, not including patent term adjustment or any potential patent term extension. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Monalizumab/IPH22 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;31, 2019, the principal intellectual property rights related to the monalizumab compound are
<FONT STYLE="white-space:nowrap">in-licensed</FONT> from Novo Nordisk A/S and include U.S. Patent Nos. 8,206,709 and 8,901,283, European patents EP&nbsp;2&nbsp;038&nbsp;306 B1 and EP 2&nbsp;426&nbsp;150 B1 and counterpart patents in certain other
countries. These patents cover the composition of matter of monalizumab and have a statutory expiration date in 2027, not including patent term adjustment or any potential patent term extension. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IPH4102/Anti-KIR3DL2 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;31, 2019, the principal intellectual property rights related to IPH4102 are wholly owned by us and include U.S. Patent
No.&nbsp;10,280,222, European patent application EP 3 116 908 A1 and counterpart patent applications in certain other countries. These patents and patent applications cover the composition of matter of IPH4102, and such patents have, and any patents
that issue from such applications would have, a statutory expiration date in 2035, not including patent term adjustment or any potential patent term extension. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5401/Anti-C5aR </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;31, 2019, the principal intellectual property rights related to IPH5401 are <FONT STYLE="white-space:nowrap">in-licensed</FONT>
from Novo Nordisk A/S and include U.S. Patent Nos. 8,613,926, 8,846,045 and 10,323,097, European patent EP 2 718 322 B1 and counterpart patents and patent applications in certain other countries. These patents and patent applications cover the
composition of matter of IPH5401, and such patents have, and any patents that issue from such applications would have, a statutory expiration date in 2032, not including patent term adjustment or any potential patent term extension. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5201/Anti-CD39 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;31, 2019, we own two families of patent applications containing
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> claims directed to IPH5201. These families include one PCT application and one U.S. provisional patent application that are wholly owned by us. If
a patent covering IPH5201 issues from a <FONT STYLE="white-space:nowrap">non-provisional</FONT> U.S. patent application timely filed from such PCT or U.S. provisional application, it would have a statutory expiration date in 2038 or 2039,
respectively, not including patent term adjustment or any potential patent term extension. The U.S. provisional patent application is not eligible to become an issued patent until, among other things, we file a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of filing the related provisional patent application. If we do not timely file any <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent
application, we may lose our priority date with respect to our provisional patent application and any patent protection on the inventions disclosed in our provisional patent application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of patents in the countries in which they are obtained. In most countries,
including the United States, the patent term is 20 years from the earliest claimed filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application or its foreign equivalent in the applicable country. In the United States,
a patent&#146;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed
over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. In the United States, a patent may also be eligible for limited patent term extension under the Drug Price Competition and Patent Term
Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend
the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it, or a
method for manufacturing it may be extended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own the mark INNATE PHARMA in the United States, Australia and Europe (EU community trademark), and INNATE in Europe (EU community
trademark). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and
development work, preclinical tests, clinical studies, facilities, and the manufacture and sale of our products are and will continue to be subject to the complex legislative and regulatory provisions implemented by the various public authorities in
Europe, the United States and other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EMA, FDA and the various national regulatory authorities impose considerable
constraints on the development, manufacture and sale of products that we develop and clinical trials we conduct. In case of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these regulations, the regulatory authorities may impose fines,
seize or remove products from the market or even partially or totally suspend their production. They may also revoke previously granted marketing authorizations, reject authorization applications. These regulatory constraints are important in
considering whether an active ingredient can ultimately become a drug, as well as for recognizing the time and investments necessary for such development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are differences from one country to another, the development of therapeutic products for human use is subject to similar
procedures and must comply with the same types of regulations in all ICH&nbsp;countries (countries part of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). In order to obtain
marketing authorization for a product, proof of its efficacy and safety should be provided by the applicant, along with detailed information on its composition and manufacturing process. This entails significant pharmaceutical and preclinical
developments, clinical trials and laboratory tests. The development of a new drug from fundamental research to marketing comprises five&nbsp;steps: (i)&nbsp;research, (ii) preclinical trials, (iii)&nbsp;clinical trials in humans, (iv)&nbsp;marketing
authorization and (v)&nbsp;marketing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of the purity and stability of the manufactured substance or active pharmaceutical ingredient
and the formulated product, as well as in vitro and animal studies to assess the safety and activity of the product candidate for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is
subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies,
among other things, are submitted to the applicable regulatory agency in connection with the application to begin human testing. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and
long-term toxicity studies, may continue after submission of the application. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of clinical trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In humans, clinical trials are usually carried out in three phases that are generally sequential, but under unique circumstances phases of
trials can overlap or even be skipped, following a specific review and determination by regulatory agencies. Clinical trials are sometimes necessary after marketing authorization to explain certain side-effects, investigate a specific
pharmacological effect, obtain more accurate or additional data. Additional trials are also commonly conducted to explore new indications. Regulatory authorization is needed to carry out clinical trials. The regulatory authorities may block, suspend
or require significant modifications to the clinical study protocols submitted by companies seeking to test products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical
trial authorization in the European Union </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current regulation relating to clinical trials is governed by European Directive
2001/20/EC of 4&nbsp;April 2001 on clinical trials, which has been transposed into national legislation by all European Union Member States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2001 Directive cited above has been revised and replaced by the Clinical Trials Regulation&nbsp;EU No.&nbsp;536/2014 of 16&nbsp;April
2014, which aims at harmonizing and streamlining the clinical trials authorization process. The Clinical Trial Regulation&nbsp;EU No.&nbsp;536/2014 of 16&nbsp;April 2014 entered into force on 16&nbsp;June 2014. However, the regulation will not
become applicable until the publicly available EU database and EU portal are fully functional and have been confirmed through an independent audit. The new regulation will become applicable six months after the European Commission publishes notice
of this confirmation. Due to technical difficulties with the development of the IT systems, the portal&#146;s <FONT STYLE="white-space:nowrap">go-live</FONT> date had to be postponed and therefore the Clinical Trials Regulation will come into
application in the course of 2020 instead of October 2018, as previously scheduled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When it will become applicable, the Clinical Trials
Regulation will be directly applicable (for instance under French law). Some national provisions specifying the national rules will remain applicable. It will apply to interventional clinical trials on medicinal products and to clinical trials
authorized under the current 2001 Directive still ongoing three years after the Clinical Trial Regulation has come into operation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Clinical Trial Regulation will allow better consistency throughout EU Member States: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Single submission of the clinical trial application dossier through the EU Portal (Article 5) including a common
part assessed jointly by all participating EU Member States, and a national part covering the ethical and operational aspects of the trial assessed by each EU Member State independently. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A clinical trial authorization will be issued in the form of a single decision by each EU Member State concerned
(Article 4). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This new regulation will also increase transparency of authorized clinical trials in the European Union:
the European Union database will serve as the source of public information, without prejudice of personal data </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protection, commercially confidential information protection, and protection of confidential communication between Member State and trial supervision between Member States. Public information
will include clinical trial authorization information, protocol data, and a summary of the results 12 months after the end of the trial (or six months in case of pediatric clinical trials). The regulation will apply in the Member States without the
requirement for separate implementing legislation by each Member State. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trial authorization in the United States
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, an Investigational New Drug application, or IND, must be submitted to the FDA and accepted before clinical
trials can start on humans. An IND is an exemption from the Federal Food, Drug, and Cosmetic Act, or FDCA, that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request
for FDA authorization to administer an investigational product to humans. This application contains early research data as well as the pharmaceutical dossier, preclinical and clinical data (if any) and includes the clinical protocol. If there is no
objection from the FDA, the IND application becomes valid 30 days after it is received by the FDA. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health
risks. At any time during or subsequent to this <FONT STYLE="white-space:nowrap">30-day</FONT> period, the FDA may request the suspension of clinical trials, whether such trials are planned or in progress, and request additional information. This
temporary suspension continues until the FDA receives the information it has requested. Furthermore, any ethics committee with authority over a clinical site may delay or suspend clinical trials, either temporarily or definitively, if it believes
that patient safety is not ensured or in case of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to the foregoing IND requirements, an independent institutional review board, or IRB, representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that
institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must
operate in compliance with FDA regulations An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements
or if the product candidate has been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s primary objectives in reviewing
an IND are to assure the safety and rights of patients and to help assure that the quality of the investigation will be adequate to permit an evaluation of the biological product&#146;s safety, purity and potency. The decision to terminate
development of an investigational biological product may be made by either a health authority body such as the FDA, an IRB or ethics committee, or by us for various reasons. Additionally, some trials are overseen by an independent group of qualified
experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to
available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for
suspension or termination may be made by us based on evolving business objectives and/or competitive climate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Good clinical
practices </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In most countries, clinical trials must comply with the cGCP standards as defined by the International Council for
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, or ICH. Directive 2005/28/EC dated 8&nbsp;April 2005 adopted the cGCP principles in the context of strengthening the regulatory structure specified by
Directive 2001/20/EC. The competent authority designated in each Member Country to authorize clinical trials must take into consideration, among other factors, the scientific value of the study, the safety of the participants and the possible
responsibility of the clinical site. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conducting clinical trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials must be carried out in compliance with complex regulations throughout the various phases of the process, based on the principle
of informed consent by the patient to whom the products will be administered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trial phases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials may be conducted in the United States, in Europe or in other parts of the world as long as such trials have been approved by
health authorities and ethics committees in each country where the trial is conducted. There are three well-established and internationally-recognized clinical phases: Phase I, II and III. This classification is used by the FDA and the EMA as well
as other regulatory agencies. Each of these clinical phases is described below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase I:&nbsp;The product candidate is initially introduced into healthy human subjects and tested for safety,
dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy
volunteers, the initial human testing is often conducted in patients. Sponsors sometimes designate their Phase I trials as Phase Ia or Phase Ib. Phase Ib trials are typically aimed at confirming dosing, pharmacokinetics and safety in larger number
of patients. Some Phase Ib studies evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase II:&nbsp;This phase involves clinical trials in a limited patient population to identify possible adverse
effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase III:&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an
expanded patient population at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product
labeling. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase IV studies, may be conducted after initial marketing
approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the applicable regulator may mandate the performance of Phase IV clinical trials as a
condition of approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In specific situations, certain phases of development can be merged or even skipped when clear signs of efficacy
emerge in the early phases of development and the product candidate is designed for patients with major unmet medical needs. However, these deviations from the standard pattern of development must be discussed and approved by health authorities.
Given the high unmet medical need for certain cancer patients, deviations from the typical phases of development are frequent in oncology and in particular, in the field of immunotherapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of clinical trial information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> drugs are required to register and disclose certain
clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made
public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has
been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Regulations concerning marketing authorizations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to be marketed, a drug product must have regulatory authorization (known as approval of a New Drug Application, or NDA, or a Biologics
License Application, or BLA, in the United States and a Marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Authorization, or MA, in the European&nbsp;Union). The competent authorities are the FDA in the United States and the EMA in Europe. Companies apply for an NDA/BLA or an MA based on quality,
safety and efficacy. In Europe, the United States and Japan, the dossier is a standard dossier referred to as a CTD, or Common Technical Document. The file relating to the NDA/MA describes the manufacturing of the active substance, the manufacturing
of the final product and the clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United States review and
approval process for biological products </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA approves complex biological products under the Public
Health Service Act, or PHSA. In order to obtain approval to market a biological product in the United States, a marketing application must be submitted to the FDA that provides data establishing the safety, purity and potency of the proposed
biological product for its intended indication. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed
information relating to the product&#146;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or
from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity and potency of the biological product to
the satisfaction of the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLA is thus a vehicle through which applicants formally propose that the FDA approve a new product for
marketing and sale in the United States for one or more indications. Every new product candidate must be the subject of an approved BLA before it may be commercialized in the United States. Under federal law, the submission of most BLAs is subject
to an application user fee and the sponsor of an approved BLA is also subject to annual program user fees. These fees are typically increased annually. Certain exceptions and waivers are available for some of these fees, such as an exception from
the application fee for products with orphan designation and a waiver for certain small businesses, an exception from the establishment fee when the establishment does not engage in manufacturing the product during a particular fiscal year, and an
exception from the product fee for a product that is the same as another product approved under an abbreviated pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following
submission of a BLA, the FDA conducts a preliminary review of the application generally within 60 calendar days of its receipt and strives to inform the sponsor by the 74th day after the FDA&#146;s receipt of the submission to determine whether the
application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the additional information. The
resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA has agreed to
specified performance goals in the review process of BLAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which FDA accepts the application
for filing, and 90% of applications for NMEs that have been designated for &#147;priority review&#148; are meant to be reviewed within six months of the filing date. For applications seeking approval of products that are not NMEs, the <FONT
STYLE="white-space:nowrap">ten-month</FONT> and <FONT STYLE="white-space:nowrap">six-month</FONT> review periods run from the date that FDA receives the application. The review process and the Prescription Drug User Fee Act goal date may be extended
by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an application, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with a BLA submission, including component manufacturing, finished product manufacturing, and control testing laboratories. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a
BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. In addition, as a condition of approval, the FDA may require an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicant to develop a Risk Evaluation and Mitigation Strategy, or REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh
the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known
or potential adverse events, and whether the product is a new molecular entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel product to
an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to
whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the FDA&#146;s evaluation of the application and accompanying information, including the results of the inspection of the
manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response
letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#146;s
satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA
approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be
conducted to further assess the product&#146;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management
mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After
approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Registration procedures in Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To access the European markets through community procedures, drug products must be submitted through the Centralized Procedure, the Mutual
Recognition Procedure or the Decentralized Procedure. The process for doing this depends, among other things, on the nature of the medicinal product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31&nbsp;March 2014 provides for the Centralized Procedure. The
Centralized Procedure results in a single marketing authorization (MA), granted by the European Commission that is valid across the European Economic Area or EEA (<I>i.e.</I>, the European Union as well as Iceland, Liechtenstein and Norway). The
Centralized Procedure is compulsory for human drugs that are: (i)&nbsp;derived from biotechnology processes, such as genetic engineering, (ii)&nbsp;contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS,
cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii)&nbsp;officially designated orphan medicines and (iv)&nbsp;advanced-therapy medicines, or ATMPs, such as gene therapy, somatic cell
therapy or tissue-engineered medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Article 3 of the Regulation (EC) No 726/2004, the Centralized Procedure is optional for any
medicinal product not appearing in the Annex if: (1)&nbsp;the medicinal product contains a new active substance which, on the date of entry into force of this Regulation, was not authorized in the EU; or (2)&nbsp;the applicant shows that the
medicinal product constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization in accordance with this Regulation is in the interests of patients or animal health at EU level. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Centralized Procedure in the European Union, the European Medicines Agency, or
EMA, shall ensure that the opinion of the Committee for Medicinal Products for Human Use, or CHMP, is given within 210 days (Article 6.3). This excludes <FONT STYLE="white-space:nowrap">so-called</FONT> clock stops, during which additional written
or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human Use, or CHMP (Article 7). At the end of the review period, the CHMP provides an opinion to the European
Commission. If this is opinion favorable, the Commission may then adopt a decision to grant an MA. When an application is submitted for a MA in respect of medicinal products for human use which are of major interest from the point of view of public
health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure. The request shall be duly substantiated. If the CHMP accepts the request, the time-limit laid down in Article 6(3),
first subparagraph, shall be reduced to 150 days (Article 14(9)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">National MAs, issued by the competent authorities of the member states
of the EEA, are also available; however these only cover their respective territory. National MAs may be applied for through the Mutual Recognition Procedure or Decentralized Procedure in order that multiple competent authorities in different member
states of the EEA may each issue a national MA in their territory for the same product on the back of the same application. National MAs are only available for products not falling within the mandatory scope of the Centralized Procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since 2008, as a consequence of a European directive, a marketing authorization is now renewed only once, five years after the initial
registration (Article 14, paragraph 2). The marketing authorization shall be then valid for an unlimited period, unless the Commission decides, on justified grounds, relating to pharmacovigilance, to proceed with one additional five-year renewal in
accordance with paragraph 2 (Article 14, paragraph 3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible for a drug to be withdrawn from the market, upon the request of the
health authorities, if a serious problem arises, in particular a safety-related problem. The marketing authorization is then cancelled. There can be various reasons for the withdrawal of drugs from the market, with the main reasons being public
health, major undesirable side effects and <FONT STYLE="white-space:nowrap">non-compliance</FONT> with manufacturing rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Non-standard</FONT> registration procedures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aside from the standard procedure of granting a marketing
authorization, as described above, there are <FONT STYLE="white-space:nowrap">non-standard</FONT> registration procedures that allow a shorter <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-market</FONT></FONT> for new
medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, <FONT STYLE="white-space:nowrap">non-standard</FONT> registration procedures under the Centralized Procedures are
as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Conditional approval: valid only one year instead of five. It is granted only if the benefit / risk ratio is
positive, that is if the product responds to unmet medical needs, and if the benefits to public health outweigh the risks associated with uncertainty because of an incomplete evaluation of the drug (for instance, because of clinical trials still
ongoing at the time of the evaluation, or when additional clinical trials are needed). This temporary character may be renewed if an appropriate report to support this is provided by the sponsor. Once the pending studies are provided, it can become
a &#147;normal&#148; marketing authorization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval in exceptional circumstances: a marketing authorization may be granted in exceptional cases, reviewed
each year to reassess the risk-benefit balance when the initial dossier for assessment of the drug cannot contain all required data, when for instance the condition to be treated is rarely encountered. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Accelerated approval: the evaluation process is accelerated (150 days instead of 210 days) when a drug is of
major interest from the standpoint of public health. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following expedited approval programs are in place in the
United States: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Accelerated Approval is a program<B> </B>that is intended to make promising products for life threatening
diseases available on the market on the basis of preliminary evidence prior to formal demonstration of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
patient benefit. The FDA evaluation is performed on the basis of a surrogate marker (a measurement intended to substitute for the clinical measurement of interest) that is considered likely to
predict patient benefit. A result of substitution or marker (&#147;surrogate endpoint&#148;) is a result of laboratory or physical sign that is not in itself a direct measure of the patient&#146;s feelings, its functions or survival, but which
allows to anticipate a therapeutic benefit. The approval that is granted may be considered as a provisional approval with a written commitment to complete clinical studies that formally demonstrate patient benefit. This procedure is equivalent to
the &#147;conditional approval&#148; in Europe. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Priority&nbsp;Review is given to drugs that offer major advances in treatment, or provide a treatment where
no adequate therapy exists. A Priority&nbsp;Review means that the time it takes FDA to review a new drug application is reduced to six months rather than 10 months. This procedure is equivalent to the &#147;accelerated approval&#148; in Europe.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Fast Track&nbsp;Program&nbsp;refers to a process for interacting with FDA to facilitate the development and
expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. The advantages of this process include scheduled meetings to seek FDA input into
clinical development plans and to collect appropriate data that will be needed to support approval. Fast Track designation does not necessarily lead to a Priority Review or Accelerated Approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Breakthrough Therapy Designation is aimed at accelerating the development and examination of drugs which are
intended to treat serious illnesses and where the preliminary clinical evidence indicates that the drug may exhibit a substantial improvement over the available therapies with regard to clinically significant criterion (criteria).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A drug which is given the designation &#147;Breakthrough Therapy&#148; can benefit from the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All of the features of the designation &#147;Fast Track&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intensive support on a program for the development of effective drugs, from Phase I onwards; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Organizational commitment involving &#147;FDA senior managers.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If research or additional studies show that a product presents a risk when it is marketed, the FDA may require its immediate withdrawal. In
addition, FDA may withdraw approval for placing on the market for other reasons, especially if the studies after approval are not made with due care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan drugs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan
drugs are drugs used for the prevention or treatment of deadly or serious rare conditions. A special authorization procedure is used for orphan drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the 1983 Orphan Drug Act is intended to encourage the development of treatments for orphan diseases. The FDA grants the
status of orphan drug to any drug aimed at treating diseases affecting fewer than 200,000 people a year in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a product available in
the United States for treatment of the disease or condition will be recovered from sales of the product. The Orphan Drug Act also provides the possibility of obtaining grants from the American government to cover clinical trials, tax credits to
cover research costs, a possible exemption from application fees when filing for registration with the FDA, and a seven-year exclusivity if a marketing authorization is granted. If a product with orphan designation receives the first FDA approval
for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity
means that the FDA may not approve another sponsor&#146;s marketing application for the same drug for the same indication for seven years, except in certain limited circumstances. Orphan exclusivity does not block the approval of a different product
for the same rare disease or condition, nor does it block the approval of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
same product for different indications. If a biologic designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug
application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same biologic for the same indication is shown to be clinically
superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, equivalent legislation has been adopted to promote treatments for rare diseases. Under Article 8 of the Regulation (EC) No
141/2000, products receiving orphan designation in the European Union can receive ten years of market exclusivity, during which time no similar medicinal product may be placed on the market for the same therapeutic indication. Under Article 37 of
the Regulation (EC) No 1901/2006, an orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies (in this case for orphan drugs no extension to any supplementary protection certificate can
be granted, see further detail below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of Article 3 of Regulation 141/2000/EC of 16&nbsp;December 1999, as amended by
Regulation 847/2000/EC of 27&nbsp;April 2000, a medicinal product may be designated as orphan if: (1) (a) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than
five in 10,000 persons in the European Union when the application is made, or (b)&nbsp;that is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union
and that without incentives it is unlikely that the marketing of the medicinal product in the European Union would generate sufficient return to justify the necessary investment; and (2)&nbsp;for either of these conditions, the applicant must
demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicinal product will be of significant benefit to those
affected by that condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and scientific assistance for study proposals (Articles 6 and 9 of the above-mentioned regulation). The application
for orphan drug designation must be submitted before the application for marketing authorization (Article 5). The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but
not if the designation is still pending at the time the marketing authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the product obtains orphan drug status, it is granted an exclusive <FONT STYLE="white-space:nowrap">10-year</FONT> marketing period during
which no similar product may apply for a marketing authorization in the European Union for the same indication, as well as an exemption from regulatory fees and other advantages. The <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity
may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market
exclusivity (Article 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, marketing authorization may be granted to a similar medicinal product for the same indication at any
time if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder of the MA for the original orphan medicinal product has given its consent to the second applicant;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder of the MA for the original orphan medicinal product cannot supply sufficient quantities of the orphan
medicinal product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the second applicant can establish in the application that its product, although similar to the orphan medicinal
product already authorized, is safer, more effective or otherwise clinically superior. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing authorization may also
be granted to a similar medicinal product with the same orphan indication if the product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently
profitable not to justify maintenance of market exclusivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Registration procedures outside of Europe and the United States
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulation in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial
sales and distribution of drugs. Pharmaceutical firms who wish to market their medicinal drugs outside the European Union and the United States must submit marketing authorization application to the national authorities of the concerned countries,
such as the Pharmaceutical and Medical Device Agency, or PMDA in Japan. The approval process varies from jurisdiction to jurisdiction and the time to approval may be longer or shorter than that required by the FDA or European Commission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval regulation in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biologics manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such
as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as
well as new application fees for supplemental applications with clinical data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers and other entities involved in
the manufacture and distribution of approved products are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP
requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain
cGMP compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards
is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure
to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other
restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, or complete withdrawal
of the product from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved BLAs, or suspension or revocation
of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted
only for the approved indications and in accordance with the provisions of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Prescription products may
be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may also share truthful and not misleading information that is otherwise consistent with the labeling. A company that is
found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, and its implementing regulations, as well as the Drug Supply Chain Security Act, or DSCA, which regulate the distribution
and tracing of prescription drug samples at the federal level, and set minimum standards for the regulation of distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical
product samples, and the DSCA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Patent term restoration and extension in the United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A patent claiming a new biologic product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent
restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted on a patent covering a product is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time
between the effective date a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term extension cannot
be used to extend the remaining term of a patent past a total of 14 years from the product&#146;s approval date. Only one patent applicable to an approved product is eligible for the extension, the application for the extension must be submitted
prior to the expiration of the patent in question, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. A patent that covers multiple products for which approval is sought can
only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA. For more information regarding the risks related to patent term
restoration and extension, please see &#147;Risk Factors&#151;Risks Related to Intellectual Property Rights&#151;If we do not obtain protection under the Hatch-Waxman Amendments and similar <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Healthcare law and regulation in the United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of biologic products that are granted
marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, transparency laws and patient data privacy laws and regulations and
other healthcare laws and regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and
willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service,
for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties
laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to
made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective
implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on covered entities and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy,
security and transmission of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient
Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as
ownership and investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to healthcare items or services that are reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the
relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Certain state laws require
the reporting of information relating to drug and biologic pricing; and some state and local laws require the registration of pharmaceutical sales representatives. State and foreign laws also govern the privacy and security of health information in
some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with these laws or any other governmental regulations as applicable, could result in the imposition of significant civil,
criminal and administrative penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional integrity reporting requirements and oversight, as well as
contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Healthcare reform in
the United States </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A primary trend in the United States healthcare industry and elsewhere is cost containment. There have been a number
of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for biologics and other medical products, government control and other changes to
the healthcare system in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By way of example, the United States and state governments continue to propose and pass
legislation designed to reduce the cost of healthcare. In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs. Among the
provisions of the ACA of importance to potential product candidates are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription biologic
agents, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded manufacturers&#146; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum
rebate for both branded and generic products and revising the definition of &#147;average manufacturer price,&#148; or AMP, for calculating and reporting Medicaid rebates on outpatient prescription product prices and extending rebate liability to
prescriptions for individuals enrolled in Medicare Advantage plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for products that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded the types of entities eligible for the 340B drug discount program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to now provide a 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale-discount</FONT></FONT> off the negotiated price of applicable brand products to eligible beneficiaries during their coverage gap period as a condition for the
manufacturers&#146; outpatient products to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service
delivery models to lower Medicare and Medicaid spending, potentially including prescription product spending. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There
have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal and replace certain aspects of the ACA, and we expect such challenges to continue. Since January 2017,
President Trump has signed two executive orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered
legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts
and Jobs Act of 2017 includes a provision that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying
health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed
the implementation of certain fees mandated by the ACA, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health
insurance providers based on market share, and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA,
effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; In July 2018, CMS published a final rule permitting further collections and payments to and from certain ACA
qualified health plans and health insurance issuers under its risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December&nbsp;14, 2018, a Texas
U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by the U.S. Congress as part of the Tax Cuts and Jobs Act of 2017 Act. While the Texas U.S. District Court
Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will
impact the ACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in
August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several
government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2027 unless additional Congressional action is taken. In
January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further,
there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state
legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement
methodologies for drugs. At the federal level, the Trump administration&#146;s budget proposal for fiscal year 2019 contains additional drug price control measures that could be enacted during the 2019 budget process or in other future legislation,
including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for <FONT
STYLE="white-space:nowrap">low-income</FONT> patients. The Trump administration also released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer
competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. For example, in September
2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January&nbsp;1, 2019. On January&nbsp;31, 2019, the Office of Inspector General of the United States Department of Health and
Human Services proposed modifications to the U.S. Anti-Kickback Statute safe harbors which, among other things, will affect rebates paid by manufacturers to Medicare Part D plans, the purpose of which is to further reduce the cost of drug products
to consumers. Additionally, CMS issued a final rule, effective on July 9, 2019, that requires direct-to-consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or
Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of treatment. Prescription drugs and biological
products that are in violation of these requirements will be included on a public list. The U.S. Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug
costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pharmacovigilance system in Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of a European MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for
pharmacovigilance, or QPPV, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new European MA applications must include a risk management plan, or RMP, describing the risk management system that the company will put
in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization
obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access,
subject to limited redactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Advertising regulation in Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and
therefore all <FONT STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in
the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each European Union Member State and can differ from
one country to another. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical coverage, pricing and reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European Union </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional
studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides
options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a
specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor
and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries
attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has
become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after
reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices.
There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the United States, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Significant uncertainty
exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors,
including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. The process for
determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly
challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved
list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for
sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals.
Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product candidate could reduce physician utilization once the product is approved and have a material
adverse effect on sales, results of operations and financial condition. Additionally, a payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s
determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of products have been
a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved products. Coverage policies and
third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies
and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-corruption, anti-kickback and transparency regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Arrangements with healthcare providers, physicians, third-party payors and customers can expose pharmaceutical manufactures to broadly
applicable anti-bribery, fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More specifically, each of the above-mentioned steps of the development of therapeutic products for human use is heavily regulated and
therefore involves significant interaction with public officials which is likely to cause a risk of corruption or bribery. For instance, in many countries, hospitals are operated by the government, and doctors and other hospital employees are
considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to enforcement actions. That is why business activity may be
subject to anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including without limitation the Foreign Corrupt Practices Act, the U.K. Bribery Act or the French Sapin 2 Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All these statutes generally prohibit offering, promising, giving, or authorizing others to give anything of value, either directly or
indirectly, to a government or a foreign government official or employees of public international organizations in order to influence official action, or otherwise obtain or retain business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implementation of these statutes may also impose to develop internal compliance programs, procedures and guidelines to detect and report
any suspicious activities and to mitigate any risks of noncompliance which may occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to specific
healthcare regulations, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the French &#147;transparency&#148; provisions, or &#147;French Sunshine Act&#148; (Articles L. <FONT
STYLE="white-space:nowrap">1453-1</FONT> and D. <FONT STYLE="white-space:nowrap">1453-1</FONT> and seq. of the French Public Health Code or PHC), which contains provisions regarding transparency of fees received by some healthcare professionals from
industries, i.e. companies manufacturing or marketing healthcare products (medicinal products, medical devices, etc.) in France. According to the provisions, these companies shall publicly disclose (on a specific public website available at
www.entreprises-</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
transparence.sante.gouv.fr) the advantages and fees paid to healthcare professionals amounting to &#128;10 or above, as well as the agreements concluded with the latter, along with detailed
information about each agreement (the precise subject matter of the agreement, the date of signature of the agreement, its end date, the total amount paid to the healthcare professional, etc.); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the French &#147;anti-gift&#148; provisions (Articles <FONT STYLE="white-space:nowrap">L.1453-3</FONT> to <FONT
STYLE="white-space:nowrap">L.1453-12</FONT> PHC), setting out a general prohibition of payments and rewards from industries, i.e. companies manufacturing or marketing health products, to healthcare professionals, with limited exceptions and strictly
defines the conditions under which such payments or awards are lawful. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Data protection rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Regulation 2016/679, known as the General Data Protection Regulation, or GDPR, as well as EU Member State implementing legislations, apply
to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located
in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws impose strict obligations on the ability to process personal data, including health-related information, in
particular in relation to their collection, use, disclosure and transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, in certain countries, in particular France, the conduct
of clinical trials is subject to compliance with specific provisions of the Act <FONT STYLE="white-space:nowrap">No.78-17</FONT> of 6&nbsp;January 1978 on Information Technology, Data Files and Civil Liberties, as amended, and in particular Chapter
IX relating to the processing of personal data in the health sector. These provisions require, among others, the filing of compliance undertakings with &#147;standard methodologies&#148; adopted by the French Data Protection Authority (the CNIL),
or, if not complying, obtaining a specific authorization from the CNIL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common standard methodologies are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Decision <FONT STYLE="white-space:nowrap">No.&nbsp;2018-154</FONT> of May&nbsp;3, 2018 concerning the approval of
a standard methodology for processing personal data in the context of research in the field of health, which does not require the express consent of the person involved (methodology <FONT STYLE="white-space:nowrap">MR-003);</FONT> and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Decision <FONT STYLE="white-space:nowrap">No.&nbsp;2018-153</FONT> of May&nbsp;3, 2018 concerning the approval of
a standard methodology for the processing of personal data carried out within the context of research in the field of clinical trials, which requires the express consent of the person involved (standard methodology
<FONT STYLE="white-space:nowrap">MR-001).</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain specific cases, entities processing health personal data
may have to comply with article <FONT STYLE="white-space:nowrap">L1111-8</FONT> of the French Public Health Code which imposes certain certifications for the hosting service providers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Raw Materials and Supplies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
dependent on specialized third parties, who are subject to cGMP requirements and regulations, for the supply and control of various biological materials. We do not have any internal manufacturing and control capabilities. We source the materials for
our product candidates and preclinical programs on a purchase order basis but will also have long-term supply contracts in place for one commercial-stage product and for one clinical-stage product candidate, in preparation for the supply we will
need for a clinical pivotal trial. However, we believe that competitive pricing is achieved because there are a number of potential long-term replacements for each of our suppliers. Generally, the prices of the principal biological raw materials
that we purchase are stable. To the extent that we are exposed to price fluctuations, we generally do not expect, in the near term, to be able to pass on cost increases because of the early development stage of our product candidates and because our
commercial product is marketed for a rare disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2019, we had 208 full-time employees. None of our employees are represented by collective bargaining agreements. We
believe that we maintain good relations with our employees. As of April&nbsp;30, 2019, of our 208 full-time employees, 206 were based in France and two were based in the United States. The following chart shows the number of employees as of
April&nbsp;30, 2019 broken out by department: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Full-time equivalent employees</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;April&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate offices and laboratories are located in Luminy, near Marseille, France. In 2008, we signed a lease-financing agreement with
SOGEBAIL, a subsidiary of Soci&eacute;t&eacute; G&eacute;n&eacute;rale, for &#128;6.6&nbsp;million to finance the acquisition of our offices. The lease-financing agreement has a 12-year term. We have a purchase option for all of the buildings and
land for the lump sum of &#128;1 at the end of the term of the contract. We believe that our existing facilities are adequate to meet our current needs and that suitable additional alternative facilities will be available in the future on
commercially reasonable terms to meet our future needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not
currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement
costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth information concerning the members of our Executive Board and Supervisory Board and our other executive officers as of June 1, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Board Members</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mondher Mahjoubi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman&nbsp;of&nbsp;the&nbsp;Executive&nbsp;Board,&nbsp;Chief&nbsp;Executive&nbsp;Officer, Member of the Executive Committee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yannis Morel, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Board, EVP, Product Portfolio Strategy &amp; Business Development, Member of the Executive Committee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Board, EVP, Chief Financial Officer, Member of the Executive Committee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supervisory Board Members</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Herv&eacute; Brailly, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Irina Staatz-Granzer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member and Vice Chairman of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Yves Blay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilles Brisson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">67</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V&eacute;ronique Chabernaud, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ma&iuml;lys Ferrere<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Langlois, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">73</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcus Schindler, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Executive Officers</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pierre Dodion, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Committee, EVP, Chief Medical Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Odile Belzunce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Committee, VP Compliance, IT and Portfolio Management</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Butler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Committee, EVP, U.S. General Manager of Innate Pharma US Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Vivier, D.V.M., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Permanent Guest to the Executive Committee, SVP, Chief Scientific Officer</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As representative of Bpifrance Participations, the legal entity that holds this Supervisory Board seat. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As representative of Novo Nordisk A/S, the legal entity that holds this Supervisory Board seat. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Executive Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mondher Mahjoubi, M.D.</I>, Chief Executive Officer and Chairman of our Executive Board, was appointed as our Chief Executive Officer and
Chairman of our Executive Board on December&nbsp;30, 2016. Prior to joining us, Dr.&nbsp;Mahjoubi led the Oncology area at AstraZeneca beginning in November 2013 where he focused on the cancer pipeline and global strategy before becoming
AstraZeneca&#146;s Oncology Global Manager in August 2016. In that role, he had direct responsibility for oncology global medical affairs and United States medical affairs. Prior to AstraZeneca, he was the Senior Vice President of Global Product
Strategy in Oncology at Genentech and he previously held positions in marketing and medical affairs for Sanofi-Aventis. Dr.&nbsp;Mahjoubi holds a M.D. from the University of Tunis (Tunisia) and certifications in Medical Oncology from the University
of Tunis and University of Paris Sud (France) and in Clinical Research and Methodology from the University of Lariboisiere-Saint Louis (France). He is trained as a medical oncologist and is a member of the American Society of Clinical Oncology and
European Society of Medical Oncology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Yannis Morel, Ph.D.</I>, member of the Executive Board and EVP, Product Portfolio
Strategy and Business Development, joined us in 2001 and has held his current position since 2007 and was appointed as a member of our Executive Board on May&nbsp;25, 2015. He was employed in various positions in our Research and Development
Department, including immunology researcher and program manager, from 2001 to 2007. He received a Ph.D. in Oncology from <FONT STYLE="white-space:nowrap">Aix-Marseille</FONT> University (France) and a B.S. in Molecular Physical Chemistry from Ecole
Normale Sup&eacute;rieure de Cachan (France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier</I>, member
of the Executive Board and Chief Financial Officer, joined us in 2007, was appointed Chief Financial Officer on December&nbsp;30, 2016 and was appointed as a member of our Executive Board on January&nbsp;31, 2019. Prior to her current position,
Ms.&nbsp;Mercier served as Executive Vice President Finance and was previously our Director of Investor Relations. Prior to joining us, Ms.&nbsp;Mercier held positions as an equity analyst at Oddo Securities and Natexis Bleichroeder. She has a MSc.
(DEA) in Neurosciences from Universit&eacute; <FONT STYLE="white-space:nowrap">Aix-Marseille</FONT> (France) and a M.B.A. from ESSEC Business School (France). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Herv&eacute; Brailly, Ph.D.</I>, Chairman of the Supervisory Board, is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and chaired
our Executive Committee from the time of our founding in 1999 until we were converted into a <I>soci&eacute;t&eacute; anonyme</I> with an executive board and supervisory board on June&nbsp;13, 2005. Dr.&nbsp;Brailly served as our Chief Executive
Officer until December&nbsp;30, 2016. Prior to joining us, he spent his entire career at Immunotech SA, a biotechnology company acquired in 1995 by Beckman-Coulter, where he held various leadership positions. Dr.&nbsp;Brailly also serves as a member
of the bureau and as the treasurer of EuroBioMed association and is a <FONT STYLE="white-space:nowrap">co-founder</FONT> and Partner of Asajes Ventures (Tokyo). Dr.&nbsp;Brailly has served on the boards of directors of Deinove SA (ALDEI) since May
2017. Dr.&nbsp;Brailly received a Ph.D.&nbsp;in Immunology, with a specialization in immuno-pharmacology, from the Ecole des Mines de Paris (France). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Irina Staatz-Granzer, Ph.D.</I>, Vice Chairman and member of the Supervisory Board, has served on our Supervisory Board since 2009.
Dr.&nbsp;Staatz-Granzer has held business development positions at Hermal, Boots Healthcare International, Knoll, Scil Biomedicals and was CEO of Scil Technology Gmbh and U3 Pharma AG. She founded and is currently CEO of Staatz Business
Development&nbsp;&amp; Strategy. Dr.&nbsp;Staatz-Granzer also serves as Chairman of Talix Therapeutics NV and Blink Biomedicals SAS and as President of PLCD (German Pharma Licensing Club). Dr.&nbsp;Staaz-Granzer received a degree in pharmacy from
Philipps-Universit&auml;t Marburg (Germany) and a Ph.D. from the University of T&uuml;bingen (Germany). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jean-Yves Blay, Ph.D.</I>,
member of the Supervisory Board, has served on our Supervisory Board since 2017. Prof. Blay has held the post of General Director of the Centre L&eacute;on B&eacute;rard in Lyon, France, since 2014 and in 2016 became Secretary of the Oncology
Commission of the French Academy of Medicine. Previously, he held the position of President of the European Organization for Research and Treatment of Cancer. Prof. Blay is a trained medical oncologist and received a Ph.D. from the University Claude
Bernard in Lyon (France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Gilles Brisson</I>, member of the Supervisory Board, has served on our Supervisory Board since 2007 and was
the Chairman until December&nbsp;30, 2016. Mr.&nbsp;Brisson has worked in management positions at <FONT STYLE="white-space:nowrap">Rh&ocirc;ne-Poulenc</FONT> and then at Aventis Pharma, where he served as Chairman of the Executive Board, Chairman of
the Supervisory Board and Europe Manager. Mr.&nbsp;Brisson also serves as Chairman of the Supervisory Board of Ethypharm SA and Financiere Verdi III and member of the Board of Directors of LFB SA. He received a degree from Hautes Etudes Commerciales
de Paris (France).<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>V&eacute;ronique Chabernaud, M.D.</I>, member of the Supervisory Board, has served on our Supervisory Board
since 2015. Dr.&nbsp;Chabernaud is an oncologist and has worked for 20 years in the pharmaceutical industry. In particular, she was the Director of the French Oncological Operational Unit at Sanofi Aventis, a Vice President of Marketing and Sales at
Aventis Intercontinental and Europe, and Director of Oncology Global Medical Affairs at Rh&ocirc;ne Poulenc Rorer. She has also consulted with companies in France and abroad. Such companies include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Genomic Health, BioSystems International, MaunaKea Technologies and Ariana Pharma. In 2007, Dr.&nbsp;Chabernaud founded Cr&eacute;er la Vitalit&eacute;, which helps companies and organizations in
the development of a global health approach. Dr.&nbsp;Chabernaud also founded the association &#147;Enfance et Vitalit&eacute;&#148; which offers health workshops to children. She is a graduate of ESSEC Business School (France) and has a M.D. in
Medicine, Oncology and Cancer Biology from Facult&eacute; Xavier Bichat in Paris (France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ma&iuml;lys Ferrere</I>, member of the
Supervisory Board, has served on our Supervisory Board since 2017 when she was appointed after being proposed by our shareholder Bpifrance. Ms.&nbsp;Ferrere has been Director of the Large Venture Investment team, Innovation Division of Bpifrance
since 2012. Previously, Ms.&nbsp;Ferrere was an Investment Director at the Strategic Investment Fund between 2009 and 2012 and served as a member of the Board of Pixium Vision and Gensight Biologics. Ms.&nbsp;Ferrere also serves as member of the
supervisory board of Valneva SE and member of the Board of DBV Technologies SA, Sequans Communications SA and Euronext Paris. She received a Bachelor degree in Business Law from Pantheon-Sorbonne University, Paris (France) and graduated from IEP
(School of Higher Education for Political Studies), France and the French Society for Financial Analysts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Patrick Langlois, Ph.D.</I>,
member of the Supervisory Board, has served on our Supervisory Board since 2010. Dr.&nbsp;Langlois has been Associate Managing Director of PJL Conseils since 2005. Dr.&nbsp;Langlois worked for the
<FONT STYLE="white-space:nowrap">Rh&ocirc;ne-Poulenc</FONT> group starting in 1975 and was appointed the Financial Director in 1997, where he served until 1999. From 2000 through 2004, he worked at Aventis. Dr.&nbsp;Langlois also serves as the
chairman of the board of directors of French company Sensorion SA and also serves as a director of Newron (Italy). He received a Ph.D. in Economics from the University of Rennes (France). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Marcus Schindler, Ph.D.</I>, member of the Supervisory Board, has served on our Supervisory Board since 2018 when he was appointed after
being proposed by our shareholder Novo Nordisk A/S. Dr.&nbsp;Schindler has been Senior Vice President and Head of Global Drug Discovery at Novo Nordisk A/S since April 2018. Dr.&nbsp;Schindler has close to 20 years of experience in leadership roles
in the pharmaceutical industry, working both in international large pharma and biotechnology companies, including Astra Zeneca (Sweden), Boehringer Ingelheim (Germany) and (OSI) Prosidion (UK). He received a Ph.D. in Pharmacology from the University
of Cambridge. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pierre Dodion, M.D.</I>, Member of the Executive Committee, Executive Vice President and Chief Medical Officer, joined us in that role in
2014. Prior to joining us, Dr.&nbsp;Dodion served as Senior Vice President, Chief Medical Officer and later as Senior Vice President of Corporate Development and Operations at Nasdaq-listed ARIAD Pharmaceuticals from 2007 until 2013. He previously
held positions at Pfizer, Novartis and Aventis. Dr.&nbsp;Dodion received a M.D. from Free University of Brussels (Belgium) and a M.B.A. from Saint Joseph University in Philadelphia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Odile Belzunce</I>, Member of the Executive Committee, Senior Vice President, Compliance, IT and Portfolio Management, was appointed as a
member of our Executive Committee on January&nbsp;31, 2019. During the ten years prior to Ms.&nbsp;Belzunce joining our Executive Committee, Ms.&nbsp;Belzunce served as our Quality Manager and Head of Compliance. Ms.&nbsp;Belzunce received a DESS
&#147;Analyse&nbsp;&amp; Qualit&eacute;&#148; from <FONT STYLE="white-space:nowrap">Aix-Marseille</FONT> University (France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jennifer
Butler</I>, Member of the Executive Committee, Executive Vice President and U.S. General Manager, joined us in that role in 2019. Prior to joining us, Ms.&nbsp;Butler served as Chief Business Officer, Chief Commercial Officer and Head of U.S.
Operations at Tessa Therapeutics from July 2017 until March 2019. Prior to Tessa Therapeutics, Ms.&nbsp;Butler served for more than ten years in various commercial roles with increasing responsibility at AstraZeneca and MedImmune. Ms.&nbsp;Butler
received a B.A. Biological Basis of Behavior with a concentration in the Physiology of Neural Systems from University of Pennsylvania. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eric Vivier, D.V.M., Ph.D.</I>, Permanent guest to the Executive Committee, Senior Vice
President, Chief Scientific Officer, joined us in that role in 2018. Prior to joining us, Dr.&nbsp;Vivier joined the Center of Immunology at Marseille-Luminy (CIML) in 1993, becoming its Director in 2008 until 2017. Dr.&nbsp;Vivier received a Doctor
of Veterinary Medicine from Ecole Nationale V&eacute;t&eacute;rinaire de Maisons-Alfort (France) and holds a Ph.D. in Immunology from the Paris University (Paris XI) (France). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Supervisory Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board
is made up of a minimum of three members and a maximum of eighteen. The members of the Supervisory Board are appointed for a renewable term of two years at the general meeting of shareholders. The general meeting of shareholders may revoke the
appointments of the members of the Supervisory Board at any time during the meeting by a simple majority vote. The appointees are selected by the shareholders and may be individuals or companies. Each member must own at least one of our ordinary
shares for the entire term of the appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The age limit for being a member of the Supervisory Board and the limitations on holding
such an appointment concurrently with an appointment in another company are subject to the applicable legal and regulatory provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the
Supervisory Board in Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Supervisory Board is primarily responsible for the oversight of our risk management activities
and has delegated to the audit committee the responsibility to assist our Supervisory Board in this task. While our Supervisory Board oversees our risk management, our management, through the Executive Board is responsible for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> risk management processes. Our Supervisory Board expects our management to consider risk and risk management in each business decision, to proactively develop and
monitor risk management strategies and processes for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and to effectively implement risk management strategies adopted by the Supervisory Board. We
believe this division of responsibilities is the most effective approach for addressing the risks we face. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Supervisory Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board has established an audit committee, a compensation and nomination committee and a transactions committee, which operate
pursuant to rules of procedure adopted by our Supervisory Board. Subject to available exemptions, the composition and functioning of all of our committees will comply with all applicable requirements of the French Commercial Code, the Exchange Act,
the Nasdaq listing rules and SEC rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with French law, committees of our Supervisory Board will only have
an advisory role and can only make recommendations to our Supervisory Board. As a result, decisions will be made by our Supervisory Board taking into account <FONT STYLE="white-space:nowrap">non-binding</FONT> recommendations of the relevant
Supervisory Board committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee assists our Supervisory Board in its oversight of our corporate accounting and financial reporting and oversees the
selection of our auditors, their remuneration and independence and keeps the Supervisory Board informed on control systems, key processes and procedures, security and risks. From the Supervisory Board of May&nbsp;22, 2019, the members of the audit
committee as of the date of this prospectus are Patrick Langlois, Irina Staatz-Granzer and Mailys Ferrere as representative of Bpifrance Participations. Dr.&nbsp;Langlois is the Chairman of the audit committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Supervisory Board has determined that Dr.&nbsp;Langlois and Dr.&nbsp;Staatz-Granzer are
independent within the meaning of the applicable listing rules and the independence requirements contemplated by Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. Our Supervisory Board has further determined that
Dr.&nbsp;Langlois is an &#147;audit committee financial expert&#148; as defined by the Nasdaq listing rules and that each of the members qualifies as financially sophisticated under the Nasdaq listing rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal responsibility of our audit committee is to monitor the existence and efficacy of our financial audit and risk control
procedures on an ongoing basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Supervisory Board has specifically assigned the following duties to the audit committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal control of the half-year and annual accounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating internal control practices, risk analysis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supervising the creation of the financial statements published by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessing accounting methods; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting statutory auditors, negotiating their fees, reviewing of their conclusions and reviewing their
independence. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews and approves the report from the Chairman of the Supervisory Board on
internal control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation and Nomination Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation and nomination committee assists our Supervisory Board in reviewing and making recommendations to our Supervisory Board with
respect to the appointment and the compensation of the members of our Executive Board, Supervisory Board and Executive Committee and other key employees. In accordance with operating rules adopted by the Supervisory Board, the nomination and
compensation committee is composed of at least two members appointed by the Supervisory Board. Following the Supervisory Board on May&nbsp;22, 2019, the members of the committee are Patrick Langlois, Herv&eacute; Brailly and V&eacute;ronique
Chabernaud. Currently, Dr.&nbsp;Langlois and Dr.&nbsp;Chabernaud are independent members of the compensation and nomination committee. Dr.&nbsp;Chabernaud is the Chairman of the committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Supervisory Board has specifically assigned the following duties to the compensation and nomination committee: reviewing our remuneration
policy, in particular the description of our collective objectives (applicable company-wide) and individual objectives (for members of the Executive Board and the Executive Committee), reviewing the compensation of the members of our Executive Board
and the Executive Committee, the policy concerning the distribution of equity such as warrants, stock options, grants and capital increases reserved for members of our savings plan, examining the amount of attendance fees (<I>jetons de
pr&eacute;sence</I>) among the Supervisory Board and the committees members, assisting the Supervisory Board in the selection of the members of the Executive Board and committees, making recommendations with respect to the independence of the
members of the Supervisory Board and committees and preventing conflicts of interest within the Supervisory Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Transactions
Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our transactions committee assists our Supervisory Board in examining the business and corporate development
opportunities available to us, which may include the acquisition of rights to products or the acquisition of other companies as well as <FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities. The members of this committee are Irina
Staatz-Granzer, Herv&eacute; Brailly and Marcus Schindler. Currently, Dr.&nbsp;Staatz-Granzer is an independent member and Chairman of the transactions committee. Our Supervisory Board has specifically assigned the following
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
duties to the transactions committee: to analyze the fundamentals of the products and/or companies targeted by us, the feasibility of targeted acquisitions and to participate in the selection of
investment bankers and/or consultants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Observer to the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Olivier Martinez is an observer to the Supervisory Board. Dr.&nbsp;Martinez is a Senior Investments Director for Bpifrance
Participations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The Strategic Advisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have a Strategic Advisory Board composed of six external consultants, consisting of three individuals from the medical community and
three individuals from the scientific community. The Strategic Advisory Board is not a committee of the Supervisory Board within the meaning of Article <FONT STYLE="white-space:nowrap">R.225-29</FONT> of the French Commercial Code; its members are
chosen by the Executive Board. This kind of advisory committee is common in French companies in the biotechnology sector. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Strategic
Advisory Board&#146;s role is to assist us in our strategic choices in scientific and technical fields. Its main missions are to evaluate the relevance of our choices in terms of product development and to propose, if necessary, changes to strategic
or technical approaches; to advise management and guide our scientific direction in identifying strategies and selecting product candidates, based, in particular, on the scientific results obtained by us, including new targets and new compounds and
to promote and advise us in our alliance strategies, such as external growth supporting synergies, including acquisition of new competences, purchase of operating rights, product candidates and innovative technologies. The Strategic Advisory Board
is comprised of Sebastian Amigorena, Aur&eacute;lien Marabelle, Ruslan Medzhitov, Miriam Merad, Tanguy Seiwert and Mario Sznol. Dr.&nbsp;Merad is the Chairman of the Strategic Advisory Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sebastian Amigorena, Ph.D.</I>, is the &#147;Directeur de Recherche de Classe Exceptionnelle&#148; at the Centre National de la Recherche
Scientifique. He also leads the Immunology Department and the newly created Cancer Immunotherapy Center at Institut Curie in Paris (France). Dr.&nbsp;Amigorena has made significant contributions to immunology and cell biology at every stage of his
career. His findings have helped advance the understanding of antigen presentation and T cell priming by dendritic cells, with applications in the fields of cancer immunotherapy and vaccination. Dr.&nbsp;Amigorena has received numerous national and
international prizes and awards, including the prestigious senior European Research Council award in 2008 and in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Aur&eacute;lien
Marabelle, MD, Ph.D.</I>, is the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. Dr.&nbsp;Marabelle&#146;s clinical practice is dedicated to early phase clinical trials in cancer
immunotherapy and his translational research is focused on mechanisms of action of immune checkpoint monoclonal antibodies. He works as a senior medical oncologist and an investigator in the Drug Development Department. He is coordinating a team
focused on cancer immunotherapy translational research projects at INSERM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ruslan Medzhitov, Ph.D.</I>, is a Sterling Professor at
Yale University School of Medicine in New Haven, Connecticut and an Investigator of the Howard Hughes Medical Institute. His research interests include biology of inflammation, biological bases of diseases and evolutionary design of biological
systems. Dr.&nbsp;Medzhitov is a member of the National Academy of Sciences, National Academy of Medicine and European Molecular Biology Organization. He is a fellow of the American Academy of Microbiology and a foreign member of the Russian Academy
of Sciences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Miriam Merad, M.D., Ph.D.</I>, is the Mount Sinai Chair professor in Cancer Immunology and the Director of the Precision
Immunology Institute at Mount Sinai School of Medicine in New York. Dr.&nbsp;Merad&#146;s laboratory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies the contribution of macrophages and dendritic cells to Cancer and Inflammatory diseases in mice and humans. She has shown that tissue macrophages have unique functional attributes that
contribute to tumor outcome and response to treatment. Dr.&nbsp;Merad pioneered mapping the regulatory network of dendritic cells resulting in the identification of a lineage of dendritic cells, the CD103+ DC, that is now considered to be a key
target to improve antiviral and antitumor immunity. Dr.&nbsp;Merad receives generous funding from the National Institutes of Health, or NIH, for her research on innate immunity and their contribution to human disease and belongs to several NIH
consortia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tanguy Seiwert, M.D.</I>, is Assistant Professor of Medicine, Section of Hematology and Oncology in the Department of
Medicine at the University of Chicago. Dr.&nbsp;Seiwert&#146;s research focuses on the biology of head and neck cancer and lung cancer. In the laboratory, he studies targeted therapies that disrupt specific pathways vital to cancer growth and
metastasis. More specifically, he focuses on which novel drugs appear most promising, which individual tumors are more likely to respond to these treatments and how to successfully combine therapies. Dr.&nbsp;Seiwert uses this preclinical knowledge
to develop new treatments for use in clinical trials, and to ultimately improve patient care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mario Sznol, M.D.</I>, is a Professor of
Medicine, Leader, Melanoma/RCC Disease-Associated Research Team, and <FONT STYLE="white-space:nowrap">co-leader,</FONT> Cancer Immunology Program at the Yale Cancer Center in New Haven, Connecticut. Recently, he was appointed the incoming President
of the Society for Immunotherapy of Cancer. Dr.&nbsp;Sznol&#146;s interests include cancer immunotherapy, drug development for cancer and treatment of patients with melanoma and renal cell carcinoma. After completing a fellowship in medical oncology
at Mount Sinai College of Medicine in New York in 1987, he joined the National Cancer Institute, or NCI, as a Senior Investigator in the Investigational Drug Branch, or IDB, Cancer Therapy Evaluation Program, or CTEP. He was Head of the Biologics
Evaluation Program, IDB, CTEP, from 1994 to 1999, and in 1999, was appointed Vice President of Clinical Development for Vion Pharmaceuticals in New Haven, Connecticut. He joined the Yale faculty in medical oncology in 2004. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Executive Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have an Executive Committee composed of members with significant experience in strategy, financial management, medical research,
research and development project management, the negotiation of industrial and commercial agreements in the field of innovative companies, including biotechnology companies, compliance and regulations and in business development. The Executive
Committee meets at least once a month and deals with all subject regarding the activities and the management of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current
members of the Executive Committee are Mondher Majoubi, Yannis Morel, Laure-H&eacute;l&egrave;ne Mercier, Pierre Dodion, Odile Belzunce and Jennifer Butler. Eric Vivier, our Senior Vice President, Chief Scientific Officer, is a permanent guest to
the meetings of the Executive Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance Practices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a French <I>soci&eacute;t&eacute; anonyme</I>, we are subject to various corporate governance requirements under French law. We are a
&#147;foreign private issuer&#148; under the U.S. federal securities laws and the Nasdaq listing rules. The foreign private issuer exemption will permit us to follow home country corporate governance practices instead of certain Nasdaq listing
requirements. A foreign private issuer that elects to follow a home country practice instead of Nasdaq listing requirements must submit to Nasdaq a written statement from an independent counsel in such issuer&#146;s home country certifying that the
issuer&#146;s practices are not prohibited by the home country&#146;s laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply the AFEP/MEDEF code, which recommends that a
majority of the members of the Supervisory Board be independent (as such term is defined under the code). Neither the corporate laws of France nor our bylaws requires that (i)&nbsp;our compensation committee include only independent members of the
Supervisory Board, (ii)&nbsp;each committee of the Supervisory Board have a formal written charter or (iii)&nbsp;our independent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
members of the Supervisory Board hold regularly scheduled meetings at which only independent members of the Supervisory Board are present. We intend to follow French corporate governance
practices in lieu of Nasdaq listing requirements for each of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These exemptions do not modify the independence requirements
for the audit committee, and we intend to comply with the requirements of the Sarbanes-Oxley Act and the Nasdaq listing rules, which require that our audit committee be composed of at least three independent members. Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act provides that the audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control over the performance of their duties,
management of complaints made, and selection of consultants. Under Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> if the laws of a foreign private issuer&#146;s home country require that any such matter be approved by the board of directors or
the shareholders of the Company, the audit committee&#146;s responsibilities or powers with respect to such matter may instead be advisory. Under French law, the audit committee may only have an advisory role and appointment of our statutory
auditors, in particular, must be decided by our shareholders at our annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Nasdaq rules require that a listed
company specify that the quorum for any meeting of the holders of share capital be at least 33 1/3% of the outstanding shares of the company&#146;s ordinary voting shares. We intend to follow our French home country practice, rather than complying
with this Nasdaq rule. Consistent with French Law, our bylaws provide that when first convened, general meetings of shareholders may validly convene only if the shareholders present or represented hold at least (1) 20% of the voting shares in the
case of an ordinary general meeting or of an extraordinary general meeting where shareholders are voting on a capital increase by capitalization of reserves, profits or share premium, or (2) 25% of the voting shares in the case of any other
extraordinary general meeting. If such quorum required by French law is not met, the meeting is adjourned. There is no quorum requirement under French law when an ordinary general meeting or an extraordinary general meeting is reconvened where
shareholders are voting on a capital increase by capitalization of reserves, profits or share premium, but the reconvened meeting may consider only questions that were on the agenda of the adjourned meeting. When any other extraordinary general
meeting is reconvened, the required quorum under French law is 20% of the shares entitled to vote. If a quorum is not met at a reconvened meeting requiring a quorum, then the meeting may be adjourned for a maximum of two months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a Code of
Ethics applicable to all of our employees and members of our Executive Board and Supervisory Board. Following the completion of this global offering, the Code of Ethics will be available on our website. We expect that any amendments to the Code of
Ethics, or any waivers of its requirements, will be disclosed on our website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the members of our Executive Board and Supervisory Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Members of the Executive and Supervisory Boards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the entry into force of the Sapin 2 Law (French law no. 2016-1691 of December 9, 2016), the payment of any variable or exceptional
compensation attributed for a financial year to the Chairman of the Supervisory Board, the Chairman of the Executive Board and members of the Executive Board, is subject to approval at the next ordinary general meeting (ex-post vote). The payments
of the below variable compensations, for the year ending December 31, 2018, were approved by the ordinary and extraordinary shareholder meeting held on May 22, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of Members of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Attendance Fees </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
pay attendance fees to the members of the Supervisory Board, except for the permanent representatives of Novo Nordisk A/S and Bpifrance Participations and the Chairman of the Supervisory Board. At our general
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting of shareholders held on May&nbsp;29, 2018, shareholders set the total attendance fees to be distributed among the members of the Supervisory Board at &#128;200,000. The attendance fees
consist of a fixed portion and a variable portion based on attendance at meetings of the Supervisory Board and its committees. The following table shows the framework for our attendance fees for the year ended December&nbsp;31, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Member Role</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attendance&nbsp;Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fixed Portion</B> (annual fee)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Supervisory&nbsp;Board&nbsp;Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Supervisory Board Member</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&#128;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable Portion</B> (attendance fee at
each<BR>meeting of the Supervisory Board)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Committee Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Other&nbsp;Members&nbsp;of&nbsp;the&nbsp;Supervisory&nbsp;Board</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&#128;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable Portion</B> (attendance fee at each<BR>meeting of a committee of the
Supervisory Board)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Committee Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Other Committee Members</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the attendance fees earned by members of the Supervisory
Board during the year ended December&nbsp;31, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Member</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attendance&nbsp;Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilles Brisson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">43,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Langlois</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">43,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Irina Staatz-Granzer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V&eacute;ronique Chabernaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Yves Blay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our general meeting of shareholders held on May&nbsp;22, 2019, shareholders set the total attendance fees
to be distributed among the members of the Supervisory Board at &#128;240,000. The following table shows the framework for our attendance fees for the year ending December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Member Role</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attendance&nbsp;Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fixed Portion</B> (annual fee)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Supervisory Board Member</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&#128;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable Portion</B> (attendance fee at
each meeting of the Supervisory Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Supervisory Board Chairman and Committee Chairman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Other Members of the Supervisory Board</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&#128;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"> 2,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable Portion</B> (attendance fee at each meeting of a committee of the
Supervisory Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Committee Chairman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Other Committee Members</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Chairman Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2016, the Supervisory Board decided that Herv&eacute; Brailly, the Chairman of the Supervisory Board, would receive
specific compensation pursuant to article <FONT STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code for his duties as Chairman of the Supervisory Board. During the year ended December&nbsp;31, 2018, we paid Mr.&nbsp;Brailly
&#128;50,000 as specific compensation for his performance of these duties. The Supervisory Board of January&nbsp;31, 2019 decided to increase the fixed compensation of Mr.&nbsp;Brailly by &#128;50,000 to a total of &#128;100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on December&nbsp;14, 2016, we entrusted Mr.&nbsp;Brailly with a specific mission pursuant to article <FONT
STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code. This mission, renewed by the Supervisory Board on December&nbsp;13, 2017, consists of ensuring the transition to our new executive team and providing strategic advice. This
agreement expired on December 31, 2018. During the year ended December&nbsp;31, 2018, we paid Mr.&nbsp;Brailly &#128;100,000 for his performance of these additional duties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Jean-Yves Blay </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2018, we entrusted Jean-Yves Blay, a member of our Supervisory Board, with a specific mission pursuant to article <FONT
STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code. Based on Mr.&nbsp;Blay&#146;s scientific and medical qualifications, we have agreed that he will attend meetings of our Strategic Advisory Board consisting of at least one
meeting that he attends <FONT STYLE="white-space:nowrap">in-person</FONT> and approximately two conference calls per year. Mr.&nbsp;Blay will participate in these Strategic Advisory Board meetings and then present a report to the Supervisory Board,
at least once a year, on his opinions of the Strategic Advisory Board&#146;s proceedings. This agreement will remain in place for the duration of Mr.&nbsp;Blay&#146;s term of office as a member of the Supervisory Board, including any renewal terms.
We have agreed to pay Mr.&nbsp;Blay &#128;10,000 in compensation for his performance of these additional duties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of
Members of the Executive Board </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Framework for Executive Board Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, the Executive Board consisted of Mondher Mahjoubi and Yannis Morel. Dr.&nbsp;Mahjoubi served as
Chairman of the Executive Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation of members of the Executive Board is decided by the Supervisory Board upon
recommendation by the compensation and nomination committee. The compensation of Dr.&nbsp;Mahjoubi, the Chairman of the Executive Board, is paid under his social mandate, whereas the compensation of Dr.&nbsp;Morel is paid under his employment
contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation of members of the Executive Board includes the following components: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fixed Compensation</I>. The members of the Executive Board receive fixed compensation pursuant to their
employment agreement or, in the case of the Chairman, his social mandate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Annual Variable Compensation</I>. The members of the Executive Board are eligible to receive annual variable
compensation upon the recommendation of the compensation and nomination committee based on the achievement of <FONT STYLE="white-space:nowrap">pre-specified</FONT> objectives. For the year ended December&nbsp;31, 2018, such objectives were
Scientific Leadership, Financial Discipline, Organization Readiness and Great Place to Work, which were divided for each member of the Executive Board into <FONT STYLE="white-space:nowrap">sub-criteria</FONT> with an achievement percentage. The
members of the Executive Board are able to opt to receive a portion of their annual variable compensation in the form of free shares, increased by a 30% premium. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Performance Free Shares</I>. The members of the Executive Board are able to receive, upon authorization of the
Supervisory Board and upon recommendation of the compensation and nomination committee, equity compensation in the form of performance free shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Benefits</I>. The members of the Executive Board receive other benefits consisting of a supplementary
pension plan, <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits and, for the Chairman of the Executive Board, unemployment insurance. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Compensation of Mondher Mahjoubi </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the compensation earned by Dr.&nbsp;Mahjoubi during the year ended December&nbsp;31, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Type of Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount of<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">470,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gross fixed compensation pursuant to Dr.&nbsp;Mahjoubi&#146;s social mandate.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Cash </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">155,100</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">This amount represents 50% of Dr.&nbsp;Mahjoubi&#146;s annual variable compensation, based on his achievement of 100% of the annual
objectives increased by 5% over-performance. Dr.&nbsp;Mahjoubi elected to receive the other 50% of his variable compensation in the form of free shares.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Free Shares</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">269,152</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mahjoubi opted for the payment of 50% of his annual variable compensation in free shares, increased by a 30% premium. The
Executive Board of July 3, 2018 attributed 36,225 free shares (AGA Bonus 2018) to Dr.&nbsp;Mahjoubi. The number of free shares was calculated on the basis of the weighted-average price per ordinary share for the 20 trading days preceding July 3,
2018, amounting to &#128;5.06 per share. These 36,225 free shares are valued at &#128;269,152 on the basis of the stock price on December 31, 2018, or &#128;7.43 per ordinary share.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Exceptional Premium</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">116,129</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board granted this amount as an exceptional premium to Dr.&nbsp;Mahjoubi based on his crucial role during the
company&#146;s development collaboration with AstraZeneca in October 2018.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance Free Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">233,100</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">This amount was calculated in accordance with the IFRS&nbsp;2 valuation of the grant to Dr.&nbsp;Mahjoubi of 70,000 performance free shares.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits in Kind</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">21,302</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Primarily represents amounts paid for unemployment insurance and use of a company car, among other benefits.</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"><B>&#128;</B></TD>
<TD VALIGN="middle" ALIGN="right"><B>1,264,783</B></TD>
<TD NOWRAP VALIGN="middle"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Compensation of Yannis Morel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the compensation earned by Dr.&nbsp;Morel during the year ended December&nbsp;31, 2018: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Type of Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount of<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">216,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Gross fixed compensation pursuant to Dr.&nbsp;Morel&#146;s employment contract.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Cash </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">35,510</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">This amount represents 50% of Dr.&nbsp;Morel&#146;s annual variable compensation, based on his achievement of 100% of the annual
objectives increased by 4.8% over-performance. Dr.&nbsp;Morel elected to receive the other 50% of his variable compensation in the form of free shares.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Free Shares</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">61,847</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Morel opted for the payment of 50% of his annual variable compensation in free shares, increased by a 30% premium. The Executive
Board of July 3, 2018 attributed 8,324 free shares (AGA Bonus 2018) to Dr. Morel. The number of free shares was calculated on the basis of the weighted-average price per ordinary share for the 20 trading days preceding July 3, 2018, amounting to
&#128;5.06 per share. These 8,324 free shares are valued at &#128;61,847 on the basis of the stock price on December 31, 2018, or &#128;7.43 per ordinary share.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Exceptional Premium</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">27,450</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board granted this amount as an exceptional premium to Dr.&nbsp;Morel based on his crucial role during the company&#146;s
development collaboration with AstraZeneca in October 2018.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance Free Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">166,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">This amount was calculated in accordance with the IFRS&nbsp;2 valuation of the grant to Dr.&nbsp;Morel of 50,000 performance free shares.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits in Kind</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Primarily represents amounts paid for use of a company car, among other benefits.</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"><B>&#128;</B></TD>
<TD VALIGN="middle" ALIGN="right"><B>511,229</B></TD>
<TD NOWRAP VALIGN="middle"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2019 Executive Board Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our general meeting of shareholders held on May&nbsp;22, 2019, shareholders approved the compensation of the members of the Executive Board
set forth in the following table for the year ending December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Type of Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Mondher&nbsp;Mahjoubi</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Yannis&nbsp;Morel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne&nbsp;Mercier</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">216,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maximum Annual Variable Compensation if 100% of the objectives are reached<I> </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">282,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">64,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">54,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maximum Annual Variable Compensation if case of over-performance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">352,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">82,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">68,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier was appointed as a member of the Executive Board on January&nbsp;31, 2019. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variable compensation for the year ending December&nbsp;31, 2019 is based on the achievement of the following <FONT
STYLE="white-space:nowrap">pre-specified</FONT> objectives, which are divided for each member of the Executive Board into <FONT STYLE="white-space:nowrap">sub-criteria</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with an achievement percentage: Scientific Leadership, Finance, Commercial Performance, Preparation and Adequacy of the Organization and Great Place to Work. Members of the Executive Board may
opt for the payment of 50% of their annual variable compensation in free shares, in which case it will be increased by a 30% premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
our general meeting of shareholders held on May&nbsp;22, 2019, shareholders also approved the allocation of free performance shares subject to stock market value and internal conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, provisions of bylaws that limit the liability of the members of Executive and Supervisory Boards are prohibited. However,
French law allows <I>soci&eacute;t&eacute;s anonymes</I> to contract for and maintain liability insurance against civil liabilities incurred by members of Executive and Supervisory Boards involved in a third-party action, provided that they acted in
good faith and within their capacities as members of such board of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have liability insurance for our Executive and Supervisory Board members, and intend to obtain insurance coverage for liability under the
Securities Act. We also intend to enter into agreements with our Executive and Supervisory Board members to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification under French law, these agreements
will provide for indemnification for damages and expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding arising out of his or her actions
in that capacity. We believe that this insurance and these agreements are necessary to attract qualified Executive and Supervisory Board members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These agreements may discourage shareholders from bringing a lawsuit against our Executive and Supervisory Board members for breach of their
fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our Executive and Supervisory Board members, even though such an action, if successful, might otherwise benefit us and our
shareholders. Furthermore, a shareholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our Executive and Supervisory Board members pursuant to these insurance agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentives </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our ability
to grant equity incentives is a valuable and necessary compensation tool that allows us to attract and retain the best personnel for positions of substantial responsibility, provides additional incentives to employees and promotes the success of our
business. Due to French corporate law and tax considerations, we have historically granted several different equity incentive instruments to our Executive Board and Supervisory Board members, employees and consultants, including (i)&nbsp;BSAs, which
have historically only been granted to independent members of the Supervisory Board and consultants, (ii)&nbsp;BSAARs and (iii)&nbsp;free shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Executive Board&#146;s authority to grant these warrants and free shares and the aggregate amount authorized to be granted must be
approved by a majority of the shareholders present at the relevant extraordinary shareholders&#146; meeting. Once approved by our shareholders, our Executive Board can continue to grant such awards for a specified period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have various compensation plans for our Executive Board members, Supervisory Board members, employees and consultants that have been
approved by our shareholders. The last allocation in 2015 of BSAARs no longer continue to vest following termination of the employment, office or service of the holder within the first two years and all vested warrants must be exercised within
post-termination exercise periods set forth in the grant documents. In the event of certain changes in our share capital structure, such as a consolidation or share split or dividend, French law and applicable grant documentation provides for
appropriate adjustments of the numbers of ordinary shares issuable and/or the exercise price of the outstanding warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2019, we had the following equity awards, warrants and free shares
outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June 30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June 30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June 30, 2019 assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June 30, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019, assuming all performance conditions are met. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Equity Warrants and Redeemable Share Subscription Warrants </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Share Warrants (BSA) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share warrants, or BSA, are granted at a <I>de minimis</I> price and entitle the holder of one BSA to exercise the warrant for one underlying
share, at an exercise price per share determined by our Executive Board at the time of grant by reference to the then prevailing share price. We have granted BSA to Supervisory Board members and certain consultants of the Company. Our share warrants
plans include provisions that allow for the adjustment of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> exercise ratio to compensate for certain modifications of our share capital, such as rights
issues, stock splits, mergers and other events affecting all existing shareholders. None of those events have occurred yet. Our BSA have an exercise period of 10 years &#150; BSA not exercised after that time lapse and are automatically cancelled.
Our share warrants cannot be sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the BSA outstanding as of June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Plan title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA 2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA <FONT STYLE="white-space:nowrap">2015-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA <FONT STYLE="white-space:nowrap">2015-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA 2017</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">General assembly meeting date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29,&nbsp;2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;28,&nbsp;2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27,&nbsp;2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27,&nbsp;2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,&nbsp;2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;29, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;17, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;16, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;20,&nbsp;2017</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total number of BSA authorized</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">350,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">300,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">150,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">150,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">25,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">150,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total number of BSA granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">225,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">237,500</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">150,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14,200</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">37,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Start date of the exercise period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;29, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;17, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;16, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;20,&nbsp;2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">End date of the exercise period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;29, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;17, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;16, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;26, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;30, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;20,&nbsp;2027</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise price per BSA/share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;1.77</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;2.36</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;8.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;9.59</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;14.05</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Number of BSA exercised as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">BSA cancelled or lapsed as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">BSA remaining as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Share Warrants (BSAAR) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redeemable share warrants, or BSAAR, are identical to our share warrants of BSA (including the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> exercise ratio, its potential adjustment for certain modifications of our share capital and the exercise period of 10 years), except for the following features: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BSAAR are initially purchased by the beneficiary at their fair value, as determined by an expert, and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BSAAR plans include a &#147;forcing&#148; clause making it possible to encourage holders to exercise their
BSAAR when the market price exceeds the exercise price and reaches a threshold defined in the BSAAR plan. We can then, subject to a time period for notifying the holders that will permit them to exercise their BSAAR, decide to purchase the
unexercised BSAAR at a unit price equal to the BSAAR acquisition price initially paid by its holder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our redeemable
share warrants cannot be sold. Our BSAAR have been granted to certain of our executive officers and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows
the BSAAR outstanding as of June&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Plan title</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSAAR 2011</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSAAR 2012</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSAAR 2015</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General assembly meeting date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;28,&nbsp;2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;9,&nbsp;2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;1, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of BSAAR granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">650,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">146,050</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,050,382</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Start date of the exercise period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;9, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;1, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">End date of the exercise period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;9, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;30, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR initial purchase price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;0.05</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;0.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;1.15</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price per BSAAR/share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;2.04</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;2.04</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;7.20</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of BSAAR exercised as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR cancelled or lapsed as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR remaining as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Free Shares (AGA) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Free shares, or AGA, are employee equity incentive instruments pursuant to which the beneficiaries are granted, for free, the possibility to
receive our ordinary shares under certain conditions. Upon grant by our Executive Board, the AGA are subject to an acquisition, or vesting, period of at least one year. At the end of this period, the free shares vest and the beneficiary becomes a
full shareholder. However, if the vesting period is less than a certain period set by law of currently two years (but three years under previous law), it must be followed by a <FONT STYLE="white-space:nowrap">lock-up</FONT> period, so that the sum
of the two periods is equal to a minimum total period also set by law of currently two years (but three years under previous law). Vesting can be conditional or not. The vesting of all or our AGA is subject to a presence condition at the end of the
vesting period. Some of our AGA are also subject to performance conditions. Over the years, we have established several AGA plans, for all of our employees or for management only, sometimes as a &#147;welcome package&#148; (with no performance
conditions). Our free share plans include provisions that allow for the adjustment of the number of ordinary shares to which a beneficiary is entitled at the end of the vesting period to compensate for certain modifications of our share capital,
such as rights issues, stock splits, mergers and other events affecting all existing shareholders, during the vesting period. Certain of our plans also provide for an accelerated vesting in case of a tender offer on the Company during the vesting
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One particular AGA plan, the &#147;AGA Bonus&#148; entitles our management to opt for the payment of up to 50% of their annual
variable compensation in free shares. Those who take this option benefit from a matching compensation equal to 30% of the corresponding portion of the annual variable compensation, also payable in free shares. The AGA Bonus are subject to the same
performance conditions, after a <FONT STYLE="white-space:nowrap">one-year</FONT> vesting period, as the annual variable compensation. The number of AGA Bonus is determined by dividing the euro amount of the annual variable compensation for which the
election is made and of the matching contribution, by an average of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the trading price of our shares. Once vested, the AGA Bonus are subject to the minimum <FONT STYLE="white-space:nowrap">one-year</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the AGAs outstanding as of June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" NOWRAP><B>Plan title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Employees<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Employees<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA Bonus<BR><FONT STYLE="white-space:nowrap">2017-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Employees<BR><FONT STYLE="white-space:nowrap">2017-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>New<BR>Members<BR><FONT STYLE="white-space:nowrap">2017-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Bonus<BR><FONT STYLE="white-space:nowrap">2018-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Employees<BR><FONT STYLE="white-space:nowrap">2018-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA Perf<BR>Employees<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA Perf<BR>Management<BR>2018</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">General assembly meeting date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;29,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;29,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;29,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;29,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2018</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;30,<BR>2017<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;3,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;29,<BR>2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;3,<BR>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">January&nbsp;14,<BR>2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November&nbsp;20,<BR>2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November&nbsp;20,<BR>2018</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Vesting Period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Lock-up</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Performance Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Number of AGA granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">99,932</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">250,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">149,943</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">28,556</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">114,500</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">25,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">67,028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">90,650</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">327,500</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">260,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Number of AGA vested as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Number of AGA lapsed as of June&nbsp;30,
2019<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Number of AGA remaining to be vested as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The annual variable compensation performance conditions are determined on or about the beginning of the fiscal year and executives make their election at about that time. However, because we need the shareholders&#146;
to vote on the envelope of free shares available for granting AGA Bonus (like all other free shares), we wait until our annual shareholders meeting (generally during the second half of the second quarter of the year) to grant the AGA Bonus &#150;
hence a granting, vesting and <FONT STYLE="white-space:nowrap">lock-up</FONT> calendar different from that of the payment of the annual variable compensation, which takes place towards the end of the fiscal year or at the beginning of the next
fiscal year. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Usually after the end of the vesting period, the Executive Board will convene and acknowledge the number of free shares that have vested and the number of those that have not, because the presence condition and, as
applicable, the performance condition, has not been met. For the purpose of computing the amount of share-based compensation in our consolidated financial statements, AGA that have lapsed because the presence condition has not bene met, are excluded
from the computation, even though the Executive Board has not met yet and formally acknowledged this fact. As a result, certain of the numbers above are different from those in our consolidated financial statements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general assembly held on May&nbsp;22, 2019 authorized the allocation of (i) up to 50,000 free shares without performance condition to the
benefit of new executives (employees and/or executive officers), (ii) up to 75,000 free shares to the benefit of employed members of the Executive Committee, employed senior executives and/or corporate officers (AGA Bonus), (iii) up to 400,000 free
shares with performance condition to the benefit of executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers and (iv) up to 675,000 free shares with performance condition to the benefit of
employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Free Preferred Shares (AGAP) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Free preferred shares, or AGAP, are another employee equity incentive instrument similar to the free shares or AGA, except that, after a <FONT
STYLE="white-space:nowrap">one-year</FONT> vesting period, the beneficiaries receive a preferred shares (shares B) which will become convertible into ordinary shares following a <FONT STYLE="white-space:nowrap">lock-up</FONT> period of two
additional years, if the performance conditions (and a presence condition) are met at the end of this <FONT STYLE="white-space:nowrap">lock-up</FONT> period. Each free preferred share is convertible into a number of our ordinary shares &#150; which
number depends upon the degree of fulfilment of the performance conditions. The free preferred shares remain convertible into ordinary shares for a period of six years and six months. Free preferred shares not converted at the end of this conversion
period can be repurchased by us and cancelled. Our AGAP cannot be sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established several AGAP plans in 2016 and 2017 for all
of our employees or for management only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the acquisition and <FONT STYLE="white-space:nowrap">lock-up</FONT> periods,
beneficiaries of the 2016 AGAP are not entitled to vote at our shareholders&#146; meetings, to dividends or to preferential subscription rights. On the contrary, during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, beneficiaries of the
2017 AGAP are entitled to vote at our shareholders&#146; meetings, to dividends and to preferential subscription rights, as if they held the same number of ordinary shares as their number of vested AGAP. After the end of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, holders of all of our AGAP that have not yet converted them into our ordinary shares, are entitled to vote at our shareholders&#146; meetings, to dividends and to preferential subscription rights, on
the basis of the number of ordinary shares to which they are entitled if they convert their AGAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our free preferred share plans include
provisions that allow for the adjustment of the number of ordinary shares to which a beneficiary is entitled upon conversion of his or her AGAP at the end of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, to compensate for certain
modifications of our share capital, such as rights issues, stock splits, mergers and other events affecting all existing shareholders. The 2017 AGAP plan provides for an accelerated vesting with a waiver of the performance conditions in case of a
tender offer on the Company during the vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the AGAPs outstanding as of June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Plan title</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP Management<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP Employees<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR>2017-1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Employees<BR>2017-1</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">General assembly meeting date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,&nbsp;2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,&nbsp;2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;21,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;30,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;21,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;3, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;3, 2018</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Number of AGAP granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,486</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,600</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,725</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Maximum number of ordinary shares into which each AGAP can be converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Number of AGAP vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,550</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,381</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,581</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Number of AGAP lapsed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">450</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">105</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">400</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">166</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Since January&nbsp;1, 2016, we have engaged in the following transactions with members of our Executive and Supervisory Boards and holders
of more than 5% of our outstanding voting securities, and their respective affiliates, which we refer to as our related parties. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions With
Our Principal Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2015, we entered into two agreements with MedImmune, a wholly owned subsidiary of AstraZeneca, which we refer to as AstraZeneca. The
first agreement was a <FONT STYLE="white-space:nowrap">co-development</FONT> and license agreement relating to certain combination products containing monalizumab, or the Original <FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement, and
the second agreement was a development and option agreement for products containing monalizumab, including products using monalizumab as a monotherapy, or the 2015 Option Agreement. In October 2018, AstraZeneca exercised its option under the 2015
Option Agreement, which resulted in the automatic termination of both of the Original <FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement and the 2015 Option Agreement, and a new <FONT STYLE="white-space:nowrap">co-development</FONT>
and license agreement relating to all products containing monalizumab, or the 2015 <FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement, automatically came into effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into additional agreements with AstraZeneca. The first agreement is a collaboration and option agreement relating
to IPH5201, or the 2018 CD39 Option Agreement. The second agreement is an option agreement relating to four preclinical programs, which we refer to as the 2018 Future Programs Option Agreement. On October&nbsp;25, 2018, we issued an aggregate of
6,260,500 ordinary shares to MedImmune Limited, at a purchase price of &#128;10.00 per share, pursuant to an equity investment agreement. As in connection with this agreement, AstraZeneca agreed to a five-year standstill, which can be waived by us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Business&#151;Our Strategic Collaborations and License Agreements&#151;AstraZeneca&#148; for more detailed information about
our agreements with AstraZeneca. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Novo Nordisk A/S </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have entered into several agreements with Novo Nordisk A/S, including as described in detail in &#147;Business&#151;Our
Strategic Collaborations and License Agreements&#151;Additional agreements related to Monalizumab&#151;Novo Nordisk A/S&#148; and &#147;Business&#151;Our Strategic Collaborations and License Agreements&#151;License Agreement with Novo Nordisk for
IPH5401.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>AstraZeneca <FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement Payment Resolution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, we and Novo Nordisk A/S agreed on the amounts owed by us to Novo Nordisk A/S as a result of the
<FONT STYLE="white-space:nowrap">co-development</FONT> agreement entered into with AstraZeneca in April 2015. Under such agreement, we paid to Novo Nordisk A/S &#128;6,500,000. In addition, we agreed that if AstraZeneca pays us the $100,000,000
pursuant to the exercise of its licensing option, we would pay an additional $15,000,000 to Novo Nordisk&nbsp;A/S. This $15,000,000 was paid to Novo Nordisk A/S in February 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contribution In Kind Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2017, we entered into a contribution in kind agreement with Novo Nordisk&nbsp;A/S under which Novo Nordisk A/S agreed to transfer
shares to us by way of contribution, which contribution relates to all the shares held by Novo Nordisk A/S in a company named NN&nbsp;C5aR&nbsp;S.A.S, set up for the purpose of acquiring the exclusive development and commercial rights in the
anti-C5aR antibody by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the transaction described above, we entered into the following agreements
with Novo Nordisk A/S: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exclusive license agreement dated July&nbsp;4, 2017; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Side letter dated June&nbsp;23, 2017 pursuant to which we and Novo Nordisk A/S agreed on the transaction terms
and the payment by us of specified external advisory costs and other costs relating to the manufacturing of a first batch; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An indemnity agreement dated July&nbsp;13, 2017, relating to the reimbursement of certain tax credits.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrangements with the Members of our Executive and Supervisory Boards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Director and Executive Officer Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Management&#151;Compensation of Members of the Executive and Supervisory Boards&#148; for information regarding compensation of the
members of our Supervisory and Executive Boards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Jean-Yves Blay </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2018, we entrusted Jean-Yves Blay, a member of our Supervisory Board, with a specific mission pursuant to article <FONT
STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code. Based on Mr.&nbsp;Blay&#146;s scientific and medical qualifications, we have agreed that he will attend meetings of our Strategic Advisory Board consisting of at least one
meeting that he attends <FONT STYLE="white-space:nowrap">in-person</FONT> and approximately two conference calls per year. Mr.&nbsp;Blay will participate in these Strategic Advisory Board meetings and then present a report to the Supervisory Board,
at least once a year, on his opinions of the Strategic Advisory Board&#146;s proceedings. This agreement will remain in place for the duration of Mr.&nbsp;Blay&#146;s term of office as a member of the Supervisory Board, including any renewal terms.
We have agreed to pay Mr.&nbsp;Blay &#128;10,000 in compensation for his performance of these additional duties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with
Herv&eacute; Brailly </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2016, we entrusted Mr.&nbsp;Brailly with a specific mission pursuant to article <FONT
STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code. This mission, renewed by the Supervisory Board on December&nbsp;13, 2017, consists of ensuring the transition to our new executive team and providing strategic advice. This
agreement expired on December&nbsp;31, 2018. During the year ended December&nbsp;31, 2018, we paid Mr.&nbsp;Brailly &#128;100,000 for his performance of these additional duties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this global offering, we intend to enter into indemnification agreements with each of our Executive Board and Supervisory
Board members. See the section of this prospectus titled &#147;Management&#151;Limitations on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction with Related Companies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From
time to time, in the ordinary course of our business, we may contract for services from companies or institutions in which certain members of our Executive Board or Supervisory Board may serve as a director or advisor. The cost and provision of
these services are negotiated on an arms-length basis and none of these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We comply with French law regarding approval of transactions with related parties. Prior to the closing of this global offering, we expect to
adopt a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. The policy will become effective immediately upon the execution of
the underwriting agreement for this offering. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any
related person are, were or will be participants and the amount involved in the transaction exceeds $120,000. Transactions involving compensation for services provided to us as an employee or members of the Executive Board and the Supervisory Board
are not covered by this policy. A related person is any member of the Executive Board or Supervisory Board or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity
owned or controlled by such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including
any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the
related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our Executive Board, for review, consideration and approval or ratification. The presentation must include a
description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from,
as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each member of our Executive Board and Supervisory Board and, to the extent
feasible, significant shareholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under our Code of Business Conduct and Ethics, which we intend to adopt in connection with this global offering, our employees
and Executive and Supervisory Board members have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering related person transactions, our audit committee, or other independent body of our Supervisory Board, will take into account
the relevant available facts and circumstances including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on the independence of a member of the Executive Board or Supervisory Board in the event that the
related person is a member of the Executive Board or Supervisory Board, immediate family member of a member of the Executive Board or Supervisory Board or an entity with which a member of Executive Board or Supervisory Board is affiliated;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit
committee, or other independent body of our Supervisory Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our audit committee, or
other independent body of our Supervisory Board, determines in the good faith exercise of its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the transactions
described above were entered into prior to the adoption of the written policy, but all were approved by our Executive Board considering similar factors to those described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_15"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes sets forth, as of May&nbsp;1, 2019 and following the completion of the global offering,
information regarding beneficial ownership of our ordinary shares by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our Executive Board and Supervisory Board members individually; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our Executive Board and Supervisory Board members as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To our knowledge, as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our ordinary shares were held of record by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; residents of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security
if he, she or it possesses sole or shared voting or investment power of that security, including free shares that vest within 60 days of May&nbsp;1, 2019 and options and warrants that are currently exercisable or exercisable within 60 days of
May&nbsp;1, 2019. Ordinary shares subject to free shares, options and warrants currently exercisable or exercisable within 60 days of May&nbsp;1, 2019 are deemed to be outstanding for computing the percentage ownership of the person holding these
free shares, options or warrants and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage of any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage ownership information shown in the table prior to the global offering is based upon
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of May&nbsp;1, 2019. The percentage ownership information shown in the table after the global offering is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding, assuming the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ordinary shares (including ordinary shares in the form of ADSs) by us in the global offering and no exercise of the underwriters&#146; option to purchase additional ordinary shares (including ordinary shares in the form of ADSs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons named in the table below
have sole voting and investment power with respect to all ordinary shares shown that they beneficially own, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other
purpose, including for purposes of Sections 13(d) and 13(g) of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each beneficial owner listed in the table below
is c/o Innate Pharma S.A., 117, Avenue de Luminy &#150; BP 30191, 13009 Marseille, France. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD style="width:132pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:132pt"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD style="width:39pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:39pt"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD style="width:40pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:40pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Ordinary<BR>Shares&nbsp;Beneficially&nbsp;Owned<BR>Before Global Offering</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Ordinary&nbsp;Shares<BR>Beneficially Owned</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before Global<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After Global<BR>Offering</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Shareholders</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MedImmune Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bpifrance Participations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Board and Supervisory Board members and other executive officers</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mondher Mahjoubi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yannis Morel, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Herv&eacute; Brailly, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Irina Staatz-Granzer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Yves Blay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilles Brisson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V&eacute;ronique Chabernaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ma&iuml;lys Ferrere</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Langlois</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcus Schindler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pierre Dodion, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Odile Belzunce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Butler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Vivier, D.V.M.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All members of our Executive Board and Supervisory Board and other executive officers as a
group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_16"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our
share capital summarizes certain provisions of our bylaws. Such summaries do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of our bylaws, a copy of which has been filed as
an exhibit to the Registration Statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2019, our outstanding share capital
consisted of a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares with a nominal value of &#128;0.05 per share and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preferred shares with a nominal value of &#128;0.05 per share. As of June&nbsp;30, 2019, we had the following equity warrants, redeemable share subscription warrants, and free
shares and convertible preferred shares outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June&nbsp;30, 2019 assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June&nbsp;30, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019 assuming all performance conditions are met. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, our bylaws set forth only our issued and outstanding share capital as of the date of the bylaws. Our fully diluted share
capital represents all issued and outstanding ordinary shares, as well as all potential ordinary shares which may be issued upon exercise of outstanding equity warrants and redeemable share subscription warrants and following the vesting of free
shares, as approved by our shareholders and granted by our Executive Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2018, our share capital as set forth in
our bylaws is &#128;3,196,979.30, representing 63,932,655 ordinary shares with a nominal value of &#128;0.05 per share and 6,931 preferred shares with a nominal value of &#128;0.05. An increase of our share capital may only be approved by an
extraordinary meeting of shareholders or as delegated to the Executive Board by an extraordinary meeting of shareholders. At an extraordinary meeting of shareholders held May&nbsp;22, 2019, our shareholders delegated authority to our Executive
Board, subject to certain conditions and approvals of the Supervisory Board, to authorize an increase of our share capital of up to 23,620,445 ordinary shares. This authorization includes a global authorization for an issuance of up to 22,420,445
ordinary shares and issuance of up to 1,200,000 ordinary shares as free shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon closing of the global offering, our outstanding
share capital will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, nominal value &#128;0.05 per share (or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the underwriters exercise their option to purchase in full). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of the Ordinary Shares Outstanding Prior to This Global Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the reconciliation of the number of ordinary shares issued and outstanding as of December&nbsp;31, 2016, 2017 and
2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares outstanding at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,921,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with purchase by Novo Nordisk A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the vesting of free shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares outstanding at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,600,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the vesting of free shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with purchase by MedImmune Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,260,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares outstanding at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,932,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of warrants and vesting of free
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares outstanding at May&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,043,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>History of Securities Issuances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From January&nbsp;1, 2016 through May&nbsp;1, 2019, the following events have changed the number of our issued and outstanding ordinary shares:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;6, 2016, we issued an aggregate of 2,700 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;5,508. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On May&nbsp;30, 2016, we issued an aggregate of 58,940 ordinary shares to employees and executive managers in
connection with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;138,248. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 4,486 free preferred shares (AGAP <FONT
STYLE="white-space:nowrap">2016-1)</FONT> to employees and executive managers, convertible into 897,200 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 99,932 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 50,000 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;3, 2016, we issued an aggregate of 25,650 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;52,326. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 250,000 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-2)</FONT> to an executive manager. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 149,943 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-2)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 3,000 free preferred shares (AGAP <FONT
STYLE="white-space:nowrap">2016-2)</FONT> to an executive manager, convertible into 600,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;24, 2017, we issued an aggregate of 38,950 ordinary shares to executive managers in connection
with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;327,144. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On February&nbsp;10, 2017, we issued an aggregate of 50,500 ordinary shares to employees and executive managers
in connection with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;119,020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On June&nbsp;14, 2017, we issued an aggregate of 1,850 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;3,774. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;13, 2017, we issued an aggregate of 3,343,748 ordinary shares to Novo Nordisk A/S, at a purchase
price of &#128;11.12 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2017, we issued an aggregate of 28,556 bonus free shares (AGA Bonus <FONT
STYLE="white-space:nowrap">2017-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2017, we issued an aggregate of 37,000 share warrants (BSA
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to members of the Supervisory Board, convertible into 37,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2017, we issued an aggregate of 98,770 ordinary shares and 3,931 free preferred shares to
employees and executive managers in connection with the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2016-1</FONT> and AGAP <FONT STYLE="white-space:nowrap">2016-1),</FONT> for aggregate gross proceeds of &#128;5,135.05.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2017, we issued an aggregate of 144,978 ordinary shares and 3,000 free preferred shares to
employees and executive managers in connection with the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2016-2</FONT> and AGAP <FONT STYLE="white-space:nowrap">2016-2),</FONT> for aggregate gross proceeds of &#128;7,398.90.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 5,725 free preferred shares (AGAP
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to employees convertible into 572,500 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 2,400 free preferred shares (AGAP
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to executive managers convertible into 240,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 114,500 free shares (AGA
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November 20, 2018, we issued an aggregate of 327,500 performance free shares (AGA Performance <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November 20, 2018, we issued an aggregate of 260,000 performance free shares (AGA Performance <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;3, 2018, we issued an aggregate of 67,028 bonus free shares (AGA Bonus <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2018, we issued an aggregate of 22,055 ordinary shares to executive managers in connection
with the vesting of free shares (AGA Bonus <FONT STYLE="white-space:nowrap">2017-1),</FONT> for aggregate gross proceeds of &#128;1,102.75. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;25, 2018, we issued an aggregate of 6,260,500 ordinary shares to MedImmune Limited, at a purchase
price of &#128;10.00 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;29, 2018, we issued an aggregate of 50,000 ordinary shares to employees and executive managers
in connection with the exercise of share warrants, for aggregate gross proceeds of &#128;2,500. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;18, 2019, we issued an aggregate of 111,250 ordinary shares and 7,581 preferred shares to employees
and executive managers in connection with the exercise of redeemable share warrants and the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2017-1</FONT> and AGAP <FONT STYLE="white-space:nowrap">2017-1),</FONT> for aggregate gross
proceeds of &#128;5,941.55. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January&nbsp;1, 2016 through May&nbsp;1, 2019, an aggregate of 66,140 redeemable share warrants (BSAAR) were
exercised at prices ranging from &#128;2.04 to &#128;7.20 per ordinary share. Pursuant to these exercises, we issued an aggregate of 66,140 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January&nbsp;1, 2016 through May&nbsp;1, 2019, an aggregate of 163,200 share warrants (BSA) were exercised
at prices ranging from &#128;1.77 to &#128;8.65 per ordinary share. Pursuant to these exercises, we issued an aggregate of 163,200 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January&nbsp;1, 2016 through May&nbsp;1, 2019, an aggregate of 14,512 free preferred shares (AGAP) were
vested. Pursuant to these free preferred shares vesting, we issued an aggregate of 6,931 preferred shares 2016 and 7,581 preferred shares 2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January&nbsp;1, 2016 through May&nbsp;1, 2019, an aggregate of 376,303 free shares (AGA) were vested.
Pursuant to these free shares vesting, we issued an aggregate of 376,303 ordinary shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description below reflects the terms of our bylaws and summarizes the material rights of holders of our ordinary shares under French law.
Please note that this is only a summary and is not intended to be exhaustive. For further information, please refer to the full text of our bylaws, a copy of which has been filed as an exhibit to the Registration Statement of which this prospectus
forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Purpose (Article 4 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business purpose, directly or indirectly, in France or other countries is to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perform, for our self or on behalf of third parties, any and all operations involving research, development,
studies, perfecting of production processes and marketing products of pharmaceutical interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register or grant any patents or licenses relating directly or indirectly to our business; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more generally, perform any operation of any kind, whether economic, legal, financial, civil or commercial, which
may be directly or indirectly related to our business purpose or any similar, associated or complementary purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Board
(Articles 14 to 16 of the Bylaws) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Board is responsible for our management and is composed of a minimum of two members
and a maximum of five members who perform their duties under the supervision of the Supervisory Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Members of the Executive
Board </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the Executive Board are appointed or have their appointments renewed by the Supervisory Board. The members of
the Executive Board must be individuals. They are not required to be shareholders. They may be French citizens or citizens of other countries. Members of the Executive Board cannot be members of the Supervisory Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum age for being a member of the Executive Board and the limitations on having such an appointment concurrently with an appointment
in another company are subject to the applicable legal and regulatory provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of office for the members of the Executive
Board is three years and may be renewed. If there is a vacancy, the Supervisory Board must fill the vacancy within two months. The replacement is appointed for the time remaining until the Executive Board is up for renewal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the Executive Board may be removed from office, with or without cause and without notice, by the Supervisory Board or at any
General Meeting of shareholders, by a simple majority vote of the shareholders present and voting at the meeting in person or by proxy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Chairman of the Executive Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board elects a Chairman from among the members of the Executive&nbsp;Board to serve for the duration of his appointment as a
member of the Executive Board. The Chairman of the Executive Board represents us in our relations with third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory
Board may assign this power of representation to one or more other members of the Executive Board. Assignees have the title of General Manager. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Meetings and Powers of the Executive Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Board meets as often as is in our interest, but at least once per quarter. Meetings are called by the Chairman or a member of the
Executive Board appointed for this purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At least half of the members of the Executive Board must be present to constitute a quorum
and decisions are made by a majority of the members of the Executive Board present or represented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Board has broad power to
act under all circumstances on our behalf. It exercises this power within the limits of our business purpose and subject to any powers expressly given to the Supervisory Board and Shareholders&#146; Meetings by law and according to our bylaws, and
abiding by any restrictions on powers decided by the Supervisory Board. There are currently no limits imposed on the amounts of loans or borrowings that the Executive Board may approve. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of the Executive Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The method and amount of compensation for each member of the Executive Board is determined by the Supervisory Board when appointing such
member. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Supervisory Board (Articles 17 to 21 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Members of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Board is supervised by a Supervisory Board made up of a minimum of three members and a maximum of eighteen. The members of the
Supervisory Board are appointed for a renewable term of two years at the General Meeting of shareholders, which may revoke their appointments at any time. The appointees are selected from among the shareholders and may be individuals or companies.
Each member must own at least one of our ordinary shares for the entire term of the appointment. Members of the Supervisory Board cannot be members of the Executive Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of members of the Supervisory Board who have reached the age of seventy years cannot be higher than a third of the members of the
Supervisory Board. If the age limitation is exceeded, the eldest member is deemed to have resigned automatically. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Chairman of the
Supervisory Board </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board appoints from its members who are individuals a Chairman and a Vice-Chairman, who are in
charge of convening the Supervisory Board and leading the debates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a report to the General Meeting of shareholders attached to the
Executive Board&#146;s Management Report, the Chairman of the Supervisory Board reports on the conditions for preparing and organizing the work of the Supervisory Board as well as the internal control procedures set up by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Meetings and Powers of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board meets as often as is in our interests but least once per quarter. Meetings are called by the Chairman or Vice-Chairman,
or by a member of the Executive Board or <FONT STYLE="white-space:nowrap">one-third</FONT> of the members of the Supervisory Board, under the circumstances and according to the conditions set forth in the bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At least half of the members of the Supervisory Board must be present to constitute a quorum and decisions are made by a majority of the
members of the Supervisory Board present or represented, it being specified that in a case of a split-vote, the Chairman of the Supervisory Board shall have the deciding vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board exercises permanent control over our management by the Executive Board
and the powers explicitly conferred on it by the French laws. It alone has the authority to authorize certain significant transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, any agreement entered into, directly or through an intermediary, between us and one of the members of the Executive Board or
Supervisory Board, or a shareholder that holds over 10% of the voting rights, or, if such shareholder is a company, the controlling company thereof, must be subject to prior authorization from the Supervisory Board. The interested member cannot vote
on such decision. The same applies to agreements in which a person referred above has an indirect interest. Such prior authorization also applies to agreements between us and another company if one of the members of our Executive Board or
Supervisory Board is the owner, a partner with unlimited liability, manager, director, managing director, member of the Executive Board or of the Supervisory Board, or, in a general manner is in a position of responsibility within the other company.
These provisions are not applicable to agreements concerning <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations entered into under normal conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation for attendance at board meetings (<I>jetons de pr&eacute;sence</I>) is determined at the annual ordinary General Meeting. The
General Meeting of shareholders may allocate an annual fixed sum and our Supervisory Board allocates this sum among its members as it sees fit. In addition, the Supervisory Board may allocate exceptional compensation (<I>r&eacute;mun&eacute;ration
exceptionnelle</I>) for missions or mandates entrusted to its members; in this case, this remuneration is subject to the provisions regarding related-parties agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Committees </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Supervisory Board may decide to establish committees responsible for reviewing matters which the Supervisory Board or its Chairman wish to submit to them for examination and advice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Observers (Article 23 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the General Meeting of shareholders, one or more shareholders&#146; observers may be appointed, at the discretion of the shareholders for a
term of office expiring at the shareholders meeting convened to decide on the financial statements for the preceding financial year after the first anniversary date of their appointment. Shareholders&#146; observers may be individuals or companies
and are not required to be shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The observers attend all Supervisory Board meetings, with the right to speak but not to vote.
They hold the same information and communication rights than the Supervisory Board&#146;s members and they are bound to the same confidentiality obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights and Obligations Attached to Ordinary Shares (Articles 12 and 41 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our ordinary shares gives the right to a share of the profits and assets in proportion to the amount of capital it represents. It also
gives the right to vote and be represented in the General Meeting of shareholders under the conditions set forth by the law and the bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are liquidated, any assets remaining after payment of the debts, liquidation expenses and all of the remaining obligations will first be
used to repay in full the par value of our ordinary shares. Any surplus will be distributed pro rata among shareholders in proportion to the number of ordinary shares respectively held by them, taking into account, where applicable, of the rights
attached to ordinary shares of different classes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders are liable for corporate liabilities only up to the par value of the
ordinary shares they hold; they are not liable to further capital calls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not issued any ordinary shares giving holders privileged rights compared to those
attached to other ordinary shares. See the section of this prospectus titled &#147;Management&#151;Equity Incentives&#148; for a description of the Free Preferred Shares (AGAP) granted to the Company&#146;s management and employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders&#146; rights may be modified as allowed by French law. Only the extraordinary shareholders&#146; meeting is<I> </I>authorized to
amend any and all provisions of our bylaws. It may not, however, increase shareholder commitments<I> </I>without the prior approval of each shareholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights (Article 12 of the Bylaws) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting rights attached to the ordinary shares are in proportion to the amount of capital they represent and each share gives the right to
one vote. There is no double voting right attached to the ordinary shares. The ownership of a share implies, ipso facto, the acceptance of our bylaws and any decision of our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, treasury shares or ordinary shares held by entities controlled by us are not entitled to voting rights and do not count for
quorum purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">They is no limitation on voting rights in our bylaws nor limit the right of
<FONT STYLE="white-space:nowrap">non-residents</FONT> of France or <FONT STYLE="white-space:nowrap">non-French</FONT> persons to own or, where applicable, to vote our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, the holders of warrants of the same class (i.e., warrants that were issued at the same time and with the same rights),
including founders&#146; warrants, are entitled to vote as a separate class at a general meeting of that class of warrant holders under certain circumstances, principally in connection with any proposed modification of the terms and conditions of
the class of warrants or any proposed issuance of preferred shares or any modification of the rights of any outstanding class or series of preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends (Article 41 of the Bylaws) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may only distribute dividends out of our distributable profits, plus any amounts held in our reserves that the shareholders decide to make
available for distribution, other than those reserves that are specifically required by law. The conditions for payment of dividends in cash shall be set at the shareholders&#146; meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Distributable Profits&#148; consist of our statutory net profit in each fiscal year, calculated in accordance with accounting standards
applicable in France, as increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts. Pursuant to French law, we must allocate at least 5% of our statutory net profit for each year to
our legal reserve fund before dividends may be paid with respect to that year. Such allocation is compulsory until the amount in the legal reserve is equal to 10% of the aggregate par value of our issued and outstanding share capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends are distributed to shareholders pro rata according to their respective holdings of ordinary shares. In the case of interim
dividends, distributions are made to shareholders on the date set by our Executive Board during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an ordinary
general shareholders&#146; meeting or by our Executive Board in the absence of such a decision by the shareholders. Shareholders that own ordinary shares on the actual payment date are entitled to the dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to French law, dividends must be paid within a maximum of nine months after the close of the relevant fiscal year, unless extended by
court order. Dividends not claimed within five years after the payment date shall be deemed to expire and revert to the French state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders may be granted an option to receive dividends in cash or in ordinary shares, in accordance with legal conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in Share Capital (Article 7 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any change to the capital or the rights attached to the ordinary shares is subject to legal provisions, as our bylaws do not set forth any
particular requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Increase in Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to French law, our share capital may be increased only with shareholders&#146; approval at an extraordinary general shareholders&#146;
meeting following the recommendation of our Executive Board. The shareholders may delegate to our Executive Board either the authority (<I>d&eacute;l&eacute;gation de comp&eacute;tence</I>) or the power (<I>d&eacute;l&eacute;gation de pouvoir</I>)
to carry out any increase in share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increases in our share capital may be effected by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuing additional shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing the nominal value of existing shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">creating a new class of equity securities (preference shares); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercising the rights attached to securities giving access to the share capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increases in share capital by issuing additional securities may be effected through one or a combination of the following issuances: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for cash; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for assets contributed in kind; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through an exchange offer or merger; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by conversion of previously issued debt instruments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by exercise of the rights attached to securities giving access to the share capital; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by capitalization of profits, reserves or share premium; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain conditions, by way of offset against debt incurred by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Decisions to increase the share capital through the capitalization of reserves, profits and/or share premium require shareholders&#146;
approval at an extraordinary general shareholders&#146; meeting, acting under the quorum and majority requirements applicable to ordinary shareholders&#146; meetings. Increases effected by an increase in the nominal value of shares require unanimous
approval of the shareholders, unless effected by capitalization of reserves, profits or share premium. All other capital increases require shareholders&#146; approval at an extraordinary general shareholders&#146; meeting acting under the regular
quorum and majority requirements for such meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Reduction in Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to French law, any reduction in our share capital requires shareholders&#146; approval at an extraordinary general shareholders&#146;
meeting following the recommendation of our Executive Board. The share capital may be reduced either by decreasing the nominal value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be
reduced by the repurchase and cancellation of shares. Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise, depending on the contemplated operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Preferential Subscription Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to French law, if we issue additional securities for cash, current shareholders will have preferential subscription rights to these
securities on a pro rata basis. Preferential subscription rights entitle the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual or entity that holds them to subscribe pro rata based on the number of shares held by them to the issuance of any securities increasing, or that may result in an increase of, our share
capital by means of a cash payment or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts. Pursuant to French law, the preferential subscription rights are transferable during a period equivalent to the subscription period relating to a
particular offering but starting two days prior to the opening of the subscription period and ending two days prior to the closing of the subscription period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferential subscription rights with respect to any particular offering may be waived at an extraordinary general meeting by a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> vote of our shareholders or individually by each shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Executive Board and our
independent auditors are required by French law to present reports to the shareholders&#146; meeting that specifically address any proposal to waive the preferential subscription rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current shareholders waived their preferential subscription rights with respect to this global offering at an extraordinary general
shareholders&#146; general meeting held on May&nbsp;22, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Holding and Transfer of Shares (Articles 9 and 10 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Form of Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ordinary shares are nominative or bearer, if the legislation so permits, according to the shareholder&#146;s choice. The Free Preferred Shares (AGAP) are nominative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in accordance with applicable laws, we may request at any time from the central depository responsible for holding our Shares, the
information referred to in Article L. <FONT STYLE="white-space:nowrap">228-2</FONT> of the French Commercial Code. Thus, we are, in particular and at any time, entitled to request the name and year of birth or, in the case of a legal entity, the
name and the year of incorporation, nationality and address of holders of securities conferring immediate or long-term voting rights at its shareholders&#146; meeting and the amount of securities owned by each of them and, where applicable, the
restrictions that the securities could be affected by. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Holding of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with French law concerning the &#147;dematerialization&#148; of securities, the ownership rights of shareholders are represented
by book entries instead of share certificates. Shares issued are registered in individual accounts opened by us or any authorized intermediary, in the name of each shareholder and kept according to the terms and conditions laid down by the legal and
regulatory provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Ownership of Shares by <FONT STYLE="white-space:nowrap">Non-French</FONT> Persons </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Limitations Affecting Shareholders of a French Company.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Assignment and Transfer of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares are freely negotiable, subject to applicable legal and regulatory provisions. French law notably provides for standstill obligations and
prohibition of insider trading. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repurchase and Redemption of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, we may acquire our own ordinary shares. Such acquisition may be challenged on the ground of market abuse regulations.
However, Market Abuse Regulation 596/2014 of April&nbsp;16, 2014 and its delegated regulations, or MAR, provides for safe harbor exemptions when the acquisition is made (i)&nbsp;under a <FONT STYLE="white-space:nowrap">buy-back</FONT> program to be
authorized by the shareholders in accordance with the provisions of Article L. <FONT STYLE="white-space:nowrap">225-209</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the French Commercial Code and with the General Regulations of the French Financial Markets Authority, or AMF and (ii)&nbsp;for the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to decrease our share capital, with the approval of the shareholders at an extraordinary general meeting; in this
case, the ordinary shares repurchased must be cancelled within one month from the expiry of the purchase offer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to meet obligations arising from debt securities that are exchangeable into equity instruments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide ordinary shares for distribution to employees or managers under a profit-sharing, free share or share
option plan; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we benefit from a simple exemption when the acquisition is made under a liquidity contract complying with the
General Regulations of, and market practices accepted by, the AMF. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All other purposes, and especially share <FONT
STYLE="white-space:nowrap">buy-backs</FONT> made for external growth operations in pursuance of Article L. <FONT STYLE="white-space:nowrap">225-209</FONT> of the French Commercial Code, while not forbidden, must be pursued in strict compliance of
market manipulation and insider dealing rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under MAR and in accordance with the General Regulations of the AMF, a corporation shall
report to the competent authority of the trading value on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all the
transactions relating to the <FONT STYLE="white-space:nowrap">buy-back</FONT> program, in a detailed form and in an aggregated form.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No
such repurchase of ordinary shares may result in us holding, directly or through a person acting on our behalf, more than 10% of our issued share capital. Ordinary shares repurchased by us continue to be deemed &#147;issued&#148; under French law
but are not entitled to dividends or voting rights so long as we hold them directly or indirectly, and we may not exercise the preemptive rights attached to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sinking Fund Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws do
not provide for any sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Meeting of Shareholders (Articles 26 to 37 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Calling Meetings and Conditions for Admission (Articles 27 to 30 of the Bylaws) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General Meetings of shareholders are called by the Executive Board, or failing that, by the Supervisory Board. They can also be called by the
auditor(s) or an officer appointed by a court upon request, by any interested party or by the Works Council in an emergency, by one or more shareholders holding at least five percent of the ordinary shares or by an association of our shareholders.
Meetings are held at our registered offices or at any other location indicated in the convening notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The meeting is published in the
French Bulletin of Mandatory Legal Notices (<I>Bulletin des Annonces L&eacute;gales Obligatoires </I>or BALO) at least 35 days prior to the date of a General Meeting of shareholders. In addition to the information concerning us, the notice indicates
in particular the agenda of the General Meeting of shareholders and the draft resolutions that will be presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the 21 days
preceding the meeting, we will publish the information and documents relating to the meeting on our web site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The General Meeting of
shareholders must be announced at least 15 days beforehand, by a notice placed in a journal that publishes legal announcements in the department where the headquarters are located, and in the BALO. Holders of registered ordinary shares who have
owned them for at least one month as of the date on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the latest notice is published receive individual notices. When a General Meeting of shareholders is unable to take action because the requisite quorum is not present, a second meeting is
called at least ten days in advance using the same procedure as the first one. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The General Meeting of shareholders may only take action
on items on the agenda. However, it may dismiss and replace one or more members of the Supervisory Boards at any time. The General Meeting may also dismiss the members of the Executive Board. One or more shareholders representing at least the
percentage of share capital fixed by law, and acting according to the legally required conditions and deadlines, are allowed to request that items and/or draft resolutions be added to the agenda of the General Meeting of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each shareholder has the right to attend the meetings and take part in deliberation (i)&nbsp;personally; (ii) by granting proxy to another
shareholder, his or her spouse or partner in a civil union or any other natural or legal person of his or her choice; (iii)&nbsp;by sending a proxy to the company without indication of the beneficiary; (iv)&nbsp;by voting by correspondence; or
(v)&nbsp;by videoconference or another means of telecommunication, including internet, in accordance with applicable laws and regulations that allow identification; by presenting proof of identity and ownership of ordinary shares, subject to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for holders of registered ordinary shares, an entry in the shareholder registry at least two business days before
the General Meeting of shareholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for holders of bearer ordinary shares, filing, under the conditions provided by law, of a certificate of
participation issued by an authorized intermediary two days before the date of the General Meeting of shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
final date for returning voting ballots by correspondence is set by the Executive Board and disclosed in the notice of meeting published in the BALO. This date cannot be earlier than three days prior to the meeting as provided in the bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder who has voted by correspondence will no longer be able to participate directly in the meeting or to be represented. In the case
of returning the proxy form and the voting by correspondence form, the proxy form is taken into account, subject to the votes cast in the voting by correspondence form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder may be represented at meetings by any individual or legal entity by means of a proxy form which we send to such shareholder
either at the shareholder&#146;s request or at our initiative. A shareholder&#146;s request for a proxy form must be received at the registered office at least five days before the date of the meeting. The proxy is only valid for a single meeting,
for two meetings (an ordinary and an extraordinary meeting convened for the same day or within 15 days) or for successive meetings convened with the same agenda. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder may vote by correspondence by means of a voting form, which we send to such shareholder either at the shareholder&#146;s request
or at our initiative, or which we include in an appendix to a proxy voting form under the conditions provided for by current laws and requirements. A shareholder&#146;s request for a voting form must be received at the registered office at least six
days before the date of the meeting. The voting form is also available on our website at least 21 days before the date of the meeting. The voting by correspondence form addressed by a shareholder is only valid for a single meeting or for successive
meetings convened with the same agenda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Bylaws and French Corporate Law Contain Provisions that May Delay or Discourage a Takeover Attempt
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions contained in our bylaws and French corporate law could make it more difficult for a third-party to acquire us, even if
doing so might be beneficial to our shareholders. In addition, provisions of our bylaws </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impose various procedural and other requirements, which could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, the owner of 90% of the share capital or voting rights of a public company listed on a
regulated market in a Member State of the European Union or in a state party to the European Economic Area, or EEA, Agreement, including from the main French stock exchange, has the right to force out minority shareholders following a tender offer
made to all shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a non-resident of France as well as any French entity controlled by non-residents of France may
have to file a declaration for statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such
filings are required in connection with investments exceeding &#128;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. See &#145;&#145;Limitations Affecting Shareholders of a
French Company&#146;&#146;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, certain investments in a French company relating to certain strategic industries by individuals
or entities not residents in a Member State of the EU are subject to prior authorization of the Ministry of Economy. See &#145;&#145;Limitations Affecting Shareholders of a French Company&#146;&#146;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger (i.e., in a French law context, a share for share exchange following which our company would be
dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our Executive Board as well as a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger of our company into a company incorporated outside of the European Union would require 100% of our
shareholders to approve it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a cash merger is treated as a share purchase and would require the consent of each
participating shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders may grant in the future our Executive Board broad authorizations to increase our share capital
or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have preferential subscription rights on a <I>pro rata </I>basis on the issuance by us of any
additional securities for cash or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts, which rights may only be waived by the extraordinary general meeting (by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote) of our
shareholders or on an individual basis by each shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board appoints the members of the Executive Board and shall fill any vacancy within two months;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board has the right to appoint members of the Supervisory Board to fill a vacancy created by the
resignation or death of a member of the Supervisory Board for the remaining duration of such member&#146;s term of office, and subject to the approval by the shareholders of such appointment at the next shareholders&#146; meeting, which prevents
shareholders from having the sole right to fill vacancies on our Supervisory Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Executive Board can be convened by the chairman of the Executive Board or other members of the Executive
Board delegated for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board can be convened by the chairman or the vice-chairman of the Supervisory Board. A member of
the Executive Board or one-third of the members of the Supervisory Board may send a written request to the chairman to convene the Supervisory Board. If the chairman does not convene the Supervisory Board 15 days following the receipt of such
request, the authors of the request may themselves convene the Supervisory Board; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board meetings can only be regularly held if at least half of its members attend either
physically or by way of videoconference or teleconference enabling the members&#146; identification and ensuring their effective participation in the Supervisory Board&#146;s decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by
mail at the relevant ordinary shareholders&#146; general meeting is required to remove members of the Executive Board and/or members of the Supervisory Board with or without cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the crossing of certain ownership thresholds has to be disclosed and can impose certain obligations; see the
section of this prospectus titled &#147;Description of Share Capital&#150;Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice is required for nominations to the Supervisory Board or for proposing matters to be acted upon at
a shareholders&#146; meeting, except that a vote to remove and replace a member of the Supervisory Board can be proposed at any shareholders&#146; meeting without notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares shall comply with applicable insider trading rules and regulations, and in particular with
the Market Abuse Regulation 596/2014 of April&nbsp;16, 2014; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to French law, our bylaws, including the sections relating to the number of members of the Executive and
Supervisory Boards, and election and removal of members of the Executive and Supervisory Boards from office may only be modified by a resolution adopted by <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes of our shareholders present,
represented by a proxy or voting by mail at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder Identification (Article 9 of the Bylaws)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinary Shares may be registered or bearer ordinary shares, at the option of the shareholder, subject to the applicable legal
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To identify the holders of bearer ordinary shares, we are authorized to ask in accordance with current legal and regulatory
requirements, the central depositary that maintains the records of the issue of these ordinary shares, in exchange for a fee, for the holders&#146; name or business name, year of birth or year of incorporation, address and nationality, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address, number of securities held giving immediate or future access to the capital and any restrictions to which the securities are subject. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Modification of the Bylaws (Article 36 of the Bylaws) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws may only be amended by approval at an extraordinary shareholders&#146; meeting. Our bylaws may not, however, be amended to increase
shareholder commitments without the approval of each shareholder. Decisions are made by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy, or voting by mail. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Crossing the Threshold Set in the Bylaws (Article 11 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without prejudice to the legal or regulatory stipulations, any natural person or legal entity who goes above or below, directly or indirectly,
acting alone or in concert (<I>de concert</I>), a percentage of the share capital or voting rights equal to or higher than 1% or a multiple of this percentage, must inform us of the total number of ordinary shares, voting rights and securities
giving access to capital or voting rights that it, he or she owns immediately or eventually, within five trading days of the date on which such ownership threshold is crossed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If shareholders fail to comply with these obligations, shares or voting rights exceeding the fraction that should have been declared are
deprived of voting rights at General Meetings of Shareholders for any meeting that would be held until the expiry of a period of two years from the date of regularization of the notification in accordance with Article L. <FONT
STYLE="white-space:nowrap">233-14</FONT> of the Commercial Code, if the failure to declare has been determined and one or several shareholders holding at least 5% of the capital make a request thereof, as recorded in the minutes of the General
Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These requirements are without prejudice to the threshold crossing declarations provided for
under French law in Articles L. 233-7, L. 233-9 and L. 233-10 of the French Commercial Code, which impose a declaration to us and to the French Financial Markets Authority (AMF) upon crossing of the following thresholds in share capital or voting
rights no later than the fourth trading day following the crossing: 5%, 10%, 15%, 20%, 25%, 30%, 33.33%, 50%, 66.66%, 90% and 95%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, any shareholder crossing, alone or acting in concert, these 10%, 15%, 20% or 25% thresholds shall file a declaration pursuant to
which it shall set out its intention for the following 6 months, including notably whether it intends to continue acquiring shares of the company or to acquire control over the company and its intended strategy for the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, and subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 30% threshold shall file a mandatory
public tender offer. Also, any shareholder holding directly or indirectly a number between 30% and 50% of the capital or voting rights and who, in less than 12 consecutive months, increases their holding of capital or voting rights by at least 1% of
the company&#146;s capital or voting rights, shall file a mandatory public tender offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities Exercisable for Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Equity Incentives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section of this prospectus titled &#147;Management&#151;Equity Incentives&#148; for a description of securities granted by our
Executive Board to our members of Executive Board and of Supervisory Board, employees and consultants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differences in Corporate Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a <I>soci&eacute;t&eacute; anonyme &agrave; directoire et conseil de surveillance</I>, or S.A., incorporated under the laws of France.
The laws applicable to French S.A.s differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the French Commercial Code applicable to us and the Delaware
General Corporation Law, the law under which many public companies in the United States are incorporated. This summary is not intended to be a complete discussion of the respective rights. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of the members of the Executive Board and of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, a <I>soci&eacute;t&eacute; anonyme &agrave; directoire et conseil de surveillance</I> must have at least three and may have up to eighteen members of the Supervisory Board. The number of members of the Executive
Board can be raised to seven if the Company is listed on a regulated exchange. Otherwise, such number cannot be greater than five. In addition, the composition of the Executive Board endeavors to seek a balanced representation of women and men. The
number of members of the Executive Board and of the Supervisory Board is fixed by or in the manner provided in the bylaws. Since January&nbsp;1, 2017, the number of members of</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the certificate of incorporation or, if the certificate is silent, in the
bylaws.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the Supervisory Board of each gender may not be less than 40%. Any appointment made in violation of this limit that is not remedied will be null and void as well as the deliberations taken by the Supervisory Board member irregularly
appointed. The members of the Supervisory Board are appointed at the shareholders&#146; general meetings.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Members of the Executive Board and of the Supervisory Board Qualifications</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, a corporation may prescribe qualifications for the members of the Executive Board and of the Supervisory Board under its bylaws. In addition, under French law, members of a supervisory board of a corporation may be
legal entities (with the exception of the chairman of the supervisory board), and such legal entities may designate an individual to represent them and to act on their behalf at meetings of the supervisory board.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or bylaws.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Removal of members of the Executive Board and of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, the members of the Executive Board and of the Supervisory Board may be removed from office, with or without cause and without notice, at any shareholders&#146; meeting, by a simple</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation whose board is classified, unless otherwise</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">majority vote of the shareholders present and voting at the meeting in person or by proxy. In addition, the members of the Executive Board may be removed by the Supervisory Board if provided in the bylaws. Our bylaws provide this
possibility.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">provided in the certificate of incorporation, stockholders may effect such removal only for cause.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vacancies on the Executive Board and on the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, vacancies on the Executive Board resulting from death or a resignation have to be filled by the Supervisory Board within two months. Vacancies on the Supervisory Board resulting from death or a resignation, may be
filled by the remaining members of the Supervisory Board pending ratification by the shareholders by the next shareholders&#146; meeting.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, vacancies on a corporation&#146;s board of directors, including those caused by an increase in the number of directors, unless otherwise provided in the certificate of incorporation, may be filled by a majority
of the remaining directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual General Meeting</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, the annual general meeting of shareholders shall be held at such place, on such date and at such time as decided</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be provided by</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">each year by the Executive Board and notified to the shareholders in the convening notice of the annual meeting, within six months after the close of the relevant fiscal year unless such period is extended by court order.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the certificate of incorporation or by the bylaws, or by the board of directors if neither the certificate of incorporation or the bylaws so provide.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">General Meeting</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, general meetings of the shareholders may be called by the Executive Board or, failing that, by the statutory auditors, or by a court appointed agent (<I>mandataire ad hoc</I>) or liquidator in certain
circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the Executive Board or the relevant person. General meetings of
the shareholders may also be called by the Supervisory Board.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice of General Meetings</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">A first convening notice is published in the French Bulletin of Mandatory Legal Notices (BALO) at least 35 days prior to a meeting and made available on the website of the company at least 21 days prior to the meeting. Subject to
special legal provisions, the meeting notice is sent out at least 15 days prior to the date of the meeting, by means of a notice inserted both in a legal announcement bulletin (<I>journal d&#146;annonces l&eacute;gales</I>) of the registered office
department and in the BALO. Further, the holders of registered ordinary shares for at least a month at the time of the latest of the insertions of the notice of meeting shall be summoned individually, by regular letter (or by registered letter if
they request it and include an advance of expenses) sent to their last known address. This notice to registered shareholders may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting
it beforehand by registered letter with acknowledgment of receipt in</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than 10 nor
more than 60 days before the date of the meeting and shall specify the place, date, hour, means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote, the record date for voting if it
is different from the record date determining notice and, in the case of a special meeting, purpose or purposes for which the meeting is called.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">accordance with legal and regulatory requirements, specifying his <FONT STYLE="white-space:nowrap">e-mail</FONT> address. When the shareholders&#146; meeting cannot deliberate due to lack of required quorum, the second meeting must
be called at least ten calendar days in advance in the same manner as used for the first notice. The convening notice shall specify the name of the company, its legal form, share capital, registered office address, registration number with the
French Registry of Commerce and Companies (<I>registre du commerce et des soci&eacute;t&eacute;s</I>), the place, date, hour and agenda of the meeting and its nature (ordinary and/or extraordinary meeting). The convening notice must also indicate
the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can obtain voting forms by mail.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proxy</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Each shareholder has the right to attend the meetings and participate in the discussions (i)&nbsp;personally, or (ii)&nbsp;by granting proxy to another shareholder, his/her spouse, his/her partner with whom he/she has entered into a
civil union or to any natural or legal person of his/her choice; or (iii)&nbsp;by sending a proxy to the company without indication of the beneficiary (in which case, such proxy shall be cast in favor of the resolutions supported by the Executive
Board), or (iv)&nbsp;by voting by correspondence, or (v)&nbsp;by video conference or another means of telecommunication in accordance with applicable laws that allow identification. The proxy is only valid for a single meeting, for two meetings (an
ordinary and an extraordinary meeting convened for the same day or within 15 days) or for successive meetings convened with the same agenda.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy
provides for a longer period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder action by written consent</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, shareholders&#146; action by written consent is not permitted in a <I>soci&eacute;t&eacute; anonyme</I>.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation&#146;s certificate of incorporation (1)&nbsp;may permit</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">stockholders to act by written consent if such action is signed by all stockholders, (2)&nbsp;may permit stockholders to act by written consent signed by stockholders having the minimum number of votes that would be necessary to
take such action at a meeting or (3)&nbsp;may prohibit actions by written consent.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preemptive Rights</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, in case of issuance of additional ordinary shares or other securities for cash or <FONT STYLE="white-space:nowrap">set-off</FONT> against cash debts, the existing shareholders have preferential subscription rights
to these securities on a <I>pro rata</I> basis unless such rights are waived by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present at the extraordinary meeting deciding or authorizing the
capital increase, voting in person or represented by proxy or voting by mail. In case such rights are not waived by the extraordinary general meeting, each shareholder may individually either exercise, assign or not exercise its preferential
subscription rights. Preferential subscription rights may only be exercised during the subscription period. In accordance with French law, the exercise period shall not be less than five trading days. Preferential subscription rights are
transferable during a period equivalent to the subscription period but starting two business days prior to the opening of the subscription period and ending two business days prior to the closing of the subscription period.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in a corporation&#146;s certificate of incorporation, a stockholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the
corporation&#146;s stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sources of Dividends</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, dividends may only be paid by a French <I>soci&eacute;t&eacute; anonyme</I> out of &#147;distributable profits,&#148; plus any distributable reserves and &#147;distributable premium&#148; that the shareholders
decide to make available for distribution, other than those reserves that are specifically required by law. &#147;Distributable profits&#148; consist of the</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, dividends may be paid by a Delaware corporation either out of (1)&nbsp;surplus as defined in and computed in accordance with Delaware law or (2)&nbsp;in case there is no such surplus, out of its net profits for
the fiscal year in which the dividend is declared and/or the preceding fiscal year, except when the capital is diminished by depreciation in the</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward
from prior years.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Distributable premium&#148; refers to the contribution paid
by the shareholders in addition to the par value of their ordinary shares for their subscription that the shareholders decide to make available for distribution.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Except in case of a share capital reduction, no distribution can be made to the shareholders when the net equity is, or would become, lower than the amount of
the share capital plus the reserves which cannot be distributed in accordance with the law or the bylaws.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">value of its property, or by losses, or otherwise, to an amount less than the aggregate amount of capital represented by issued and outstanding stock having a preference on the distribution of assets.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Repurchase of Ordinary Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, a corporation may acquire its own ordinary shares. Such acquisition may be challenged on the ground of market abuse
regulations. However, Market Abuse Regulation 596/2014 of April&nbsp;16, 2014 provides for safe harbor exemptions when the acquisition is made for the following purposes:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to decrease its share capital, with the approval of the shareholders at the extraordinary general
meeting;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to meet
obligations arising from debt securities that are exchangeable into equity instruments; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;with a view to distributing the relevant shares to employees or managers under a profit-sharing,
restricted free share or share option plan.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">All other purposes, and especially share
<FONT STYLE="white-space:nowrap">buy-backs</FONT> made for external growth operations in pursuance of Article L. <FONT STYLE="white-space:nowrap">225-209</FONT> of the French Commercial Code, while not forbidden, must be pursued in strict compliance
of market manipulation and insider dealing rules.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the capital of the corporation is impaired or such redemption or repurchase would impair the capital of the
corporation.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Market Abuse Regulation 596/2014 of April&nbsp;16, 2014
(MAR) and in accordance with the General Regulations of the AMF, a corporation shall report to the competent authority of the trading value on which the shares have been admitted to trading or are traded, no later than by the end of the seventh
daily market session following the date of the execution of the transaction, all the transactions relating to the <FONT STYLE="white-space:nowrap">buy-back</FONT> program, in a detailed form and in an aggregated form.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">No such repurchase of ordinary shares may result in the company holding, directly or
through a person acting on its behalf, more than 10% of its issued share capital.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liability of members of the Executive Board and of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, the bylaws may not include any provisions limiting the liability of members of the Executive Board. Civil liabilities of the members of the Executive Board and of the Supervisory Board may be sought for (1)&nbsp;an
infringement of laws and regulations applicable to a company, (2)&nbsp;breach of the bylaws and (3)&nbsp;management failure. Civil liabilities of the members of the Supervisory Board may be sought for the infractions committed by the members of the
Executive Board if, by knowing it, they did not reveal it to the shareholders&#146; meeting.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a corporation&#146;s certificate of incorporation may include a provision eliminating or limiting the personal liability
of a director to the corporation or its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any breach of the
director&#146;s duty of loyalty to the corporation or its stockholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation
of law;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;intentional or
negligent payment of unlawful dividends or stock purchases or redemptions; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any transaction from which the director derives an improper personal benefit.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Voting Rights</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">French law provides that, unless otherwise provided in the bylaws, each shareholder is entitled to one vote for each share of capital stock held by such shareholder. As from April 2016, double voting rights are automatically granted
to the shares held in registered form for more</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such
stockholder.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">than two years, unless provided otherwise in the bylaws. Our bylaws provide that double voting rights are not applicable to our shareholders.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Vote on Certain Transactions</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under French law, completion of merger, dissolution, sale, lease or exchange of all or substantially all of a corporation&#146;s
assets requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the
approval of the Executive Board; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the
shareholders present, represented by proxy or voting by mail at the relevant meeting or, in the case of a merger with a <FONT STYLE="white-space:nowrap">non-European</FONT> Union company, approval of all shareholders of the corporation (by
exception, the extraordinary general meeting of the acquiring company may delegate to the Executive Board authority to decide a merger-absorption or to determine the terms and conditions of the merger plan).</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of
a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#146;s assets or dissolution requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the approval of the board of directors; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by the vote of the
holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dissent or Dissenters&#146; Appraisal Rights</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">French law does not provide for any such right but provides that a merger is subject to shareholders&#146; approval by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote as stated above.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or
consolidation by demanding payment in cash for the stockholder&#146;s shares equal to the fair value of those shares, as determined by the Delaware Chancery Court in an action timely brought by the corporation or a dissenting stockholder. Delaware
law grants these appraisal rights only in the case of mergers or consolidations and not in the case of a sale or transfer of assets or a purchase of assets for stock.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Further, no appraisal rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more than
2,000 stockholders, unless the agreement of a merger or consolidation</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">requires the holders to accept for their shares anything other than:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of stock of the surviving corporation;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of stock of another
corporation that are either listed on a national securities exchange or held of record by more than 2,000 stockholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;cash in lieu of fractional shares of the stock described in the two preceding bullet points;
or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any combination of the
above.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In addition,
appraisal rights are not available to holders of shares of the surviving corporation in specified mergers that do not require the vote of the stockholders of the surviving corporation.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Standard of Conduct for members of the Executive Board and of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">French law does not contain specific provisions setting forth the standard of conduct of a member of the Executive Board and of the Supervisory Board. However, members of the Executive Board and of the Supervisory Board have a duty
to act without self-interest, on a well informed basis and they cannot make any decision against a corporation&#146;s corporate interest (<I>int&eacute;r&ecirc;t social</I>). In addition, members of the Executive Board shall take into account social
and environmental issues arising out of the Company&#146;s activity.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general,
directors have a duty to act without self-interest, on a well informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Suits</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the Executive
Board (but not from the Supervisory Board) of a corporation in the corporation&#146;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such
action are borne by the relevant shareholder or the group of shareholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The
plaintiff must remain a shareholder through the duration of the legal action.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce
the right itself. The complaint must:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff
complains or that the plaintiff&#146;s shares thereafter devolved on the plaintiff by operation of law; and allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and
the</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no other case where shareholders may initiate a derivative
action to enforce a right of a corporation.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A shareholder may alternatively or
cumulatively bring individual legal action against the members of the Executive Board only, provided he has suffered distinct damages from those suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant
shareholder.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">reasons for the plaintiff&#146;s failure to obtain the action; or</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state the reasons for not
making the effort.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Additionally, the plaintiff must remain a stockholder through the
duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, corporations are not required to file a certificate of incorporation with the French Registry of Commerce and Companies (<I>registre du commerce et des soci&eacute;t&eacute;s</I>) and only have bylaws
(<I>statuts</I>) as organizational documents.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, generally a corporation may amend its certificate of incorporation if:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;its board of directors has
adopted a resolution setting forth the amendment proposed and declared its advisability; and</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the amendment is adopted by the affirmative votes of a majority (or greater
percentage as may be specified by the corporation) of the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be specified by the corporation) of the outstanding shares of each class or series of stock,
if any, entitled to vote on the amendment as a class or series.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of Bylaws</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, only the extraordinary shareholders&#146; meeting is authorized to adopt or amend the bylaws.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal bylaws. A corporation may also confer, in its certificate of incorporation, that power upon the board of directors.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Name; Formation; Registered Office </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our legal name and commercial name is Innate Pharma S.A. We were incorporated on September&nbsp;23, 1999 as a <I>soci&eacute;t&eacute; par
actions simplifi&eacute;e</I> and converted into a <I>soci&eacute;t&eacute; anonyme</I>, or S.A., on June&nbsp;13, 2005. Our headquarters are located at 117, Avenue de Luminy, 13009 Marseille, France. We are registered at the Marseille Business and
Company Registry (<I>Registre du commerce et des soci&eacute;t&eacute;s</I>) under the number SIREN 424 365 336 RCS Marseille. Our telephone number at our principal executive offices is +33 4 30 30 30 30. Our agent for service of process in the
United States is Corporation Service Company. Our website address is www.innate-pharma.com. The reference to our website is an inactive textual reference only and information contained in, or that can be assessed through, our website is not part of
this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to have our ADSs listed on the Nasdaq Global Market under the symbol &#147;IPHA.&#148; Our ordinary shares are currently
listed on Euronext Paris under the symbol &#147;IPH.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this global offering, the transfer agent and registrar for our ADSs will be Citibank, N.A. Soci&eacute;t&eacute;
G&eacute;n&eacute;rale Securities Services is our transfer agent and registrar for our ordinary shares and currently maintains our share register for our ordinary shares. The share register reflects only record owners of our ordinary shares. Holders
of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our share register. The depositary, the custodian or their nominees will be the holder of the shares underlying the ADSs. Holders of our ADSs
have a right to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder rights, see &#147;Description of American Depositary Shares&#148; in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_17"></A>LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ownership of ADSs by <FONT STYLE="white-space:nowrap">Non-French</FONT> Residents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the French Commercial Code nor our bylaws currently impose any restrictions on the right of
<FONT STYLE="white-space:nowrap">non-French</FONT> residents or <FONT STYLE="white-space:nowrap">non-French</FONT> shareholders to own and vote shares. However, <FONT STYLE="white-space:nowrap">non-French</FONT> residents must file a declaration for
statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection
with investments exceeding &#128;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a
fine of up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, certain foreign investments in companies incorporated under French laws are subject to the prior authorization from the French
Minister of the Economy, where all or part of the target&#146;s business and activity relate to a strategic sector, such as energy, transportation, public health, telecommunications, etc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Exchange Controls </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current
French foreign exchange control regulations there are no limitations on the amount of cash payments that we may remit to residents of foreign countries. Laws and regulations concerning foreign exchange controls do, however, require that all payments
or transfers of funds made by a French resident to a <FONT STYLE="white-space:nowrap">non-resident</FONT> such as dividend payments be handled by an accredited intermediary. All registered banks and substantially all credit institutions in France
are accredited intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Preferential Subscription Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our current shareholders waived their preferential subscription rights with respect to this global offering at a shareholders&#146;
general meeting held on May&nbsp;22, 2019, in the future our shareholders will have preferential subscription rights. Under French law, shareholders have preferential rights to subscribe for cash issues of new ordinary shares or other securities
giving rights to acquire additional ordinary shares on a pro rata basis. Holders of our securities in the United States (which may be in the form of ordinary shares or ADSs) may not be able to exercise preferential subscription rights for their
securities unless a registration statement under the Securities Act is effective with respect to such rights or an exemption from the registration requirements imposed by the Securities Act is available. We may, from time to time, issue new ordinary
shares or other securities giving rights to acquire additional ordinary shares (such as warrants) at a time when no registration statement is in effect and no Securities Act exemption is available. If so, holders of our securities in the United
States will be unable to exercise any preferential subscription rights and their interests will be diluted. We are under no obligation to file any registration statement in connection with any issuance of new ordinary shares or other securities. We
intend to evaluate at the time of any rights offering the costs and potential liabilities associated with registering the rights, as well as the indirect benefits to us of enabling the exercise by holders of ADSs in the United States of the
subscription rights, and any other factors we consider appropriate at the time, and then to make a decision as to whether to register the rights. We cannot assure you that we will file a registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For holders of our ordinary shares in the form of ADSs, the depositary may make these rights or other distributions available to ADS holders.
If the depositary does not make the rights available to ADS holders and determines that it is impractical to sell the rights, it may allow these rights to lapse. In that case the holders will receive no value for them. The section of this prospectus
titled &#147;Description of American Depositary Shares&#148; explains in detail the depositary&#146;s responsibility in connection with a rights offering. See also &#147;Risk Factors&#151;Risks Related to Ownership of Our Ordinary Shares and the
ADSs.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_18"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citibank, N.A. has agreed to act as the depositary bank for the ADSs. Citibank&#146;s depositary offices are located at 388 Greenwich Street,
New York, New York 10013. ADSs represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be represented by certificates that are commonly known as American Depositary Receipts, or ADRs. The depositary bank
typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank N.A., Milan Branch, via dei Mercanti, 12, 20121 Milan, Italy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will appoint Citibank as depositary bank pursuant to a deposit agreement. A copy of the deposit agreement will be filed with the SEC under
cover of a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> (Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ). You may obtain a copy of the deposit agreement from the SEC&#146;s website at
www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of
ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this
summary. We urge you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary share<B> </B>that is on deposit with the depositary bank and/or custodian. An ADS also represents the right to receive, and to exercise the
beneficial interests in, any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and
the depositary bank may agree to change the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-Share</FONT></FONT> ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable
by ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the
depositary bank, the custodian or their nominees. <B></B>Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary bank, the custodian and their
respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. <B></B>A beneficial owner of ADSs may or may not be the holder of ADSs.
Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners)
only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit
agreement.<B></B><B>&nbsp;</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be
bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary bank. As an ADS holder
you appoint the depositary bank to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of
France, which may be different from the laws in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, applicable laws and regulations may require you to
satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or any of
their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>As an owner of ADSs, we will not treat you as one of our shareholders and you will not
have direct shareholder rights. The depositary bank will hold on your behalf the shareholder rights attached to the</I><B><I> </I></B><I>ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights
for the</I><B><I> </I></B><I>ordinary shares represented by your ADSs through the depositary bank only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an
ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manner in which you own the ADSs
(e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary bank&#146;s services are made
available to you. As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary bank in your name reflecting the
registration of uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the &#147;direct registration system&#148; or &#147;DRS&#148;). The direct registration system reflects the uncertificated (book-entry)
registration of ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary bank to the holders of the ADSs. The direct registration system includes
automated transfers between the depositary bank and The Depository Trust Company (&#147;DTC&#148;), the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your
brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The
procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held
through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#147;holder.&#148; When we
refer to &#147;you,&#148; we assume the reader owns ADSs and will own ADSs at the relevant time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of the ordinary shares
in the name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights
and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights
in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends
and Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited
with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number
of ADSs held as of the specified record date, after deduction of the applicable fees, taxes and expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions of Cash
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the
custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S.
dollars to the holders, subject to French laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion into U.S. dollars will take place only if practicable and
if the U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on
deposit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of cash will be made net of the fees, expenses, taxes and governmental
charges payable by holders under the terms of the deposit agreement. The depositary bank will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the
applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number
of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will <U>either</U> distribute to holders new ADSs representing the ordinary shares deposited <U>or</U> modify the
<FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT> shares ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional
entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of
new ADSs or the modification of the <FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT> shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms
of the deposit agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new ordinary shares so distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No such distribution of new ADSs will be made if it would violate a law (<I>e.g.</I>, the U.S. securities laws) or if it is not operationally
practicable. If the depositary bank does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a
distribution of cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions of Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary bank and we
will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to
exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the
transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to establish procedures to facilitate the distribution and
exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will <I>not</I>
distribute the rights to you if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not timely request that the rights be distributed to you or we request that the rights not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We fail to deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The
proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Elective Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior
notice thereof to the depositary bank and will indicate whether we wish the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elective distribution to be made available to you. In such case, we will assist the depositary bank in determining whether such distribution is lawful and reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all of the
documentation contemplated in the deposit agreement. In such case, the depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in France would
receive upon failing to make an election, as more fully described in the deposit agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will
notify the depositary bank in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it is reasonably practicable to distribute such property to you and if we provide to the depositary bank all of the documentation
contemplated in the deposit agreement, the depositary bank will distribute the property to the holders in a manner it deems practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit
agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will <I>not</I> distribute the property to you and will sell the property if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not request that the property be distributed to you or if we request that the property not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank determines that all or a portion of the distribution to you is not reasonably practicable.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we decide to redeem
any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the
redemption to the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable
redemption price. The depositary bank will convert into U.S. dollars upon the terms of the deposit agreement the redemption funds received in a currency other than U.S. dollars and will establish procedures to enable holders to receive the net
proceeds from the redemption upon surrender of their ADSs to the depositary bank. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be
retired will be selected by lot or on a <I>pro rata</I> basis, as the depositary bank may determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes Affecting Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, <FONT
STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive
the property received or exchanged in respect of the ordinary shares held on deposit. The depositary bank may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form <FONT
STYLE="white-space:nowrap">F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the Shares. If the depositary bank may not lawfully
distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of ADSs upon Deposit of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the global offering, the ordinary shares being offered pursuant to the prospectus will be deposited by us with the
custodian.&nbsp;Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in the prospectus. After the completion of the global offering, the ordinary shares that are being offered for sale pursuant
to the prospectus will be deposited by us with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the closing of the offer, the depositary bank may create ADSs on your behalf if you or your broker deposit ordinary shares with the
custodian. The depositary bank will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit
ordinary shares and receive ADSs may be limited by U.S. and French legal considerations applicable at the time of deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance
of ADSs may be delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary bank will only issue ADSs in
whole numbers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the
depositary bank. As such, you will be deemed to represent and warrant that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares are duly authorized, validly issued, fully paid,
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or
exercised. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You are duly authorized to deposit the ordinary shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge,
mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit have not been stripped of any rights or entitlements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the representations or warranties are incorrect in any way, we and the depositary bank may, at your cost and
expense, take any and all actions necessary to correct the consequences of the misrepresentations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer, Combination and Split Up of ADRs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you
will have to surrender the ADRs to be transferred to the depositary bank and also must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide such proof of identity and genuineness of signatures as the depositary bank deems appropriate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide any transfer stamps required by the State of New York or the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to
the terms of the deposit agreement, upon the transfer of ADRs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To have your ADRs either combined or split up, you must
surrender the ADRs in question to the depositary bank with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a
combination or split up of ADRs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Ordinary shares Upon Cancellation of ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number of
underlying ordinary shares<B> </B>at the custodian&#146;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and French law considerations applicable at the time of withdrawal. In order to
withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery
of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold
ADSs registered in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of the
ordinary shares represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for
cancellation that represent a whole number of securities on deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will have the right to withdraw the securities represented by
your ADSs at any time except for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed,
or (ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obligations to pay fees, taxes and similar charges. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on
deposit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your
ADSs except to comply with mandatory provisions of law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the
ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in<B> </B>the section of this prospectus entitled &#147;Description of Share Capital&#151;Voting Rights (Article 12 of the Bylaws).&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the depositary bank will distribute to you any notice of shareholders&#146;
meeting received from us together with information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary bank may distribute to
holders of ADSs instructions on how to retrieve such materials upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary bank timely receives voting instructions
from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#146;s ADSs in accordance with such voting instructions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities for which no voting instructions have been received will not be voted (except as otherwise contemplated in the deposit agreement).
Please note that the ability of the depositary bank to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to
enable you to return voting instructions to the depositary bank in a timely manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Charges </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Fees</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADSs-to-ordinary</FONT></FONT> shares ratio, or for any other
reason), excluding ADS issuances as a result of distributions of ordinary shares)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS issued</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the <FONT STYLE="white-space:nowrap">ADSs-to</FONT> ordinary shares ratio, or for any other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS cancelled</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of ADSs pursuant to (i)&nbsp;stock dividends or other free stock distributions, or (ii)&nbsp;exercise of rights to purchase additional ADSs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a <FONT STYLE="white-space:nowrap">spin-off)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ADS Services</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary bank</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and <I>vice versa</I>, or for any other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely
transferable ADSs, and <I>vice versa</I>).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS holder you will also be responsible to pay certain charges such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taxes (including applicable interest and penalties) and other governmental charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share
register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain cable, telex and facsimile transmission and delivery expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fees, expenses, spreads, taxes and other charges of the depositary bank and/or service providers (which may
be a division, branch or affiliate of the depositary bank) in the conversion of foreign currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reasonable and customary
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements applicable to
ordinary shares, ADSs and ADRs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fees, charges, costs and expenses incurred by the depositary bank, the custodian, or any nominee in
connection with the ADR program. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADS fees and charges for (i)&nbsp;the issuance of ADSs, and (ii)&nbsp;the cancellation
of ADSs are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS
issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may
be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees
and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being
distributed. In the case of (i)&nbsp;distributions other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from
distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in
accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. In the case of (i)&nbsp;registration of ADS transfers,
the ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii)&nbsp;conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be
payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of refusal to pay
the depositary bank fees, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS
holder. Certain depositary fees and charges (such as the ADS services fee) may become payable shortly after the closing of the ADS offering.<B> </B>Note that the fees and charges you may be required to pay may vary over time and may be changed by us
and by the depositary bank. You will receive prior notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of
the ADR program or otherwise, upon such terms and conditions as we and the depositary bank agree from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments and Termination
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may agree with the depositary bank to modify the deposit agreement at any time without your consent. We undertake to give holders
30 days&#146; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or
supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we
may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be bound by the modifications to the deposit agreement if you continue to hold your
ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right to direct the depositary bank to terminate the deposit agreement. Similarly, the depositary bank may in certain
circumstances on its own initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least &nbsp;&nbsp;&nbsp;&nbsp; days before termination. Until termination, your rights under the deposit
agreement will be unaffected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After termination, the depositary bank will continue to collect distributions received (but will not
distribute any such property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of
ADSs in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding
(after deduction of applicable fees, taxes and expenses). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with any termination of the deposit agreement, the depositary
bank may make available to owners of ADSs a means to withdraw the ordinary shares represented by ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the depositary bank. The
ability to receive unsponsored American depositary shares upon termination of the deposit agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American depositary shares and the
payment of applicable depositary fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Books of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular
business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will maintain in New York facilities to record and process the issuance, cancellation, combination, <FONT
STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Obligations and Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement limits our obligations and the depositary bank&#146;s obligations to you. Please note the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement
without negligence or bad faith. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in
which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any
action, for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary
shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our
failure to give notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the
deposit agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank disclaim any liability if we or the depositary bank are prevented or forbidden from or
subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by
reason of present or future provision of any provision of our Articles of Incorporation, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any
discretion provided for in the deposit agreement or in our Articles of Incorporation<B> </B>or in any provisions of or governing the securities on deposit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or
information received from legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice
or information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank also disclaim liability for the inability by a holder to benefit from any
distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank may rely without any liability upon any written notice, request or other document
believed to be genuine and to have been signed or presented by the proper parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of
the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary
relationship, among us, the depositary bank and you as ADS holder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which
parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to
account for any payment received as part of those transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the
depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable
for any deficiency if the sale proceeds do not cover the taxes that are due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank may refuse to issue ADSs, to deliver,
transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced
tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may
require to fulfill legal obligations. You are required to indemnify us, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Conversion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable
at a reasonable cost or within a reasonable period, the depositary bank may take the following actions in its discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders
for whom the conversion and distribution is lawful and practical. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Distribute the foreign currency to holders for whom the distribution is lawful and practical.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hold the foreign currency (without liability for interest) for the applicable holders. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law/Waiver of Jury Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
deposit agreement, the ADRs and the ADSs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including<B> </B>ordinary shares represented by ADSs) is governed by the laws of France.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>AS A PARTY TO THE DEPOSIT AGREEMENT, YOU IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, YOUR RIGHT TO TRIAL BY
JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND/OR THE DEPOSITARY BANK. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit
agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement,
including any claim under U.S. federal securities laws. <I>If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in
accordance with applicable case law. However, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations
promulgated thereunder.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_19"></A>SHARES AND ADSs ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the global offering, while our ordinary shares have been listed on Euronext Paris since 2006, there has been no public market on a
U.S. national securities exchange for our ordinary shares or ADSs and we cannot assure you that a significant public market in the United States for the ordinary shares or ADSs will be sustained after this global offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future sales of ADSs in the U.S. public market after this global offering, and the availability of ADSs for future sale, could adversely
affect the market price of the ADSs prevailing from time to time. As described below, a significant number of currently outstanding ordinary shares will not be available for sale shortly after this global offering due to contractual restrictions on
transfers of ordinary shares and ADSs. However, sales of substantial amounts of ADSs or ordinary shares, or the perception that these sales could occur, could adversely affect prevailing market prices for the ADSs and could impair our future ability
to raise equity capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of ordinary shares outstanding on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019, upon completion of the global offering, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ordinary shares (including ordinary shares in the form of ADSs) will be outstanding (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise in full their option to
purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares, which may be in the form of ADSs, in connection with the global offering), assuming no outstanding warrants
or options are exercised and assuming no free shares become vested. All of the ADSs sold in the U.S. offering will be freely tradable without restrictions or further registration under the Securities Act, except for any ADSs sold to our
&#147;affiliates,&#148; as that term is defined under Rule 144 under the Securities Act. The ordinary shares held by existing shareholders are &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act.
Restricted securities may be sold in the United States on the Nasdaq Global Market only if registered or if their resale qualifies for exemption from registration described below under Rule 144 or Rule 701 promulgated under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a person who has
beneficially owned restricted ordinary shares for at least six months would be entitled to sell their securities pursuant to Rule 144 under the Securities Act provided that (1)&nbsp;such person is not deemed to have been one of our affiliates at the
time of, or at any time during the 90 days preceding, a sale and (2)&nbsp;we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted ordinary shares
for at least six months, but who are our affiliates at the time of, or at any time during the 90 days preceding a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a
number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1.0% of the number of ordinary shares (including ordinary shares in the form of ADSs) then outstanding, which
will equal approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately after the completion of the global offering based on the number of ordinary shares outstanding as
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of the ADSs on the Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, in each case, that we have been subject to the
Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and
notice provisions of Rule 144. <FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales of restricted shares under Rule 144 also are subject to the availability of current public information about us until a period of one year has elapsed since
the securities were acquired from the issuer or an affiliate of the issuer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities Act permits resales of shares in reliance upon Rule 144 but without compliance with certain restrictions of Rule
144, including the holding period requirement. Most of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees or members of the Supervisory and Executive Boards who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule 701, but
all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares subject also to French law, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has indicated that Rule 701 will apply to typical stock options granted by an issuer before it becomes subject to the reporting
requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the members of our Executive and Supervisory Board and certain of our shareholders have agreed that, without the prior written consent of
Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group L.L.C., or, collectively, the Representatives, on behalf of the underwriters, we and they will not, during the period ending 90 days after the date of this prospectus (i)&nbsp;offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any ordinary shares,
ADSs or any securities convertible into or exercisable or exchangeable for our ordinary shares or ADSs; or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of the ordinary shares or ADSs. In addition, we have agreed that, without the prior written consent of the Representatives on behalf of the underwriters, we will not, during the restricted period, file any registration statement with the
SEC relating to the offering of any ordinary shares or ADSs or any securities convertible into or exercisable or exchangeable for ordinary shares or ADSs. The restrictions described in this paragraph are subject to certain exceptions. See <FONT
STYLE="white-space:nowrap">&#147;Underwriting&#151;Lock-up</FONT> Agreements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Representatives, in their sole discretion, may
release the ADSs and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently expect any release of ordinary shares or ADSs subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements prior
to the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> periods. Upon the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> periods, substantially all of the ordinary shares and ADSs subject to
such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>French
Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, and notably under the General Regulation (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) issued by the AMF, as
well as under Market Abuse Regulation 596/2014 of 16&nbsp;April 2014, or MAR, any person that holds inside information shall, until such information is made public, refrain from (1)&nbsp;carrying out any transactions relating to securities issued by
the company, (2)&nbsp;recommending that another person engage in insider dealing or induce another person to engage in insider dealing, (3)&nbsp;unlawfully disclosing inside information outside of the normal exercise of an employment, a profession
or duties. The use of inside information by cancelling or amending an order concerning a financial instrument to which the information relates where the order was placed before the person concerned possessed the inside information, shall also be
considered to be insider dealing. These rules apply to all persons who hold inside information as a result of (1)&nbsp;their status as board member, executive officer, manager, employee of the company, third parties acting on behalf of the company
and having access to privileged information as party of their professional relations with the company during the preparation or the completion of a particular transaction, such as investor services providers, lawyers or public relations agencies,
(2)&nbsp;their holding of securities in the share capital of the company, and/or (3)&nbsp;their access to information because of their employment, profession or duties or their participation in the preparation of a financial transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under MAR and the General Regulation of the AMF, it is also prohibited for a person to engage or attempt to engage in market manipulation.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prohibited transactions include all transactions related to securities: stocks, securities
convertible, options, warrants, bonds, and in particular, (1)&nbsp;transfer of securities, (2)&nbsp;exercise of options, warrants or any securities giving access to the capital, (3)&nbsp;transfer of free shares and (4)&nbsp;acquisition of
securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation S </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation
S provides generally that sales made in offshore transactions are not subject to the registration or prospectus delivery requirements of the Securities Act. Accordingly, restricted securities may be sold in offshore transactions in compliance with
Regulation S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_20"></A>MATERIAL UNITED STATES FEDERAL INCOME AND FRENCH TAX
CONSIDERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following describes material U.S. federal income tax considerations relating to the acquisition, ownership and disposition of our ordinary
shares or ADSs by a U.S. holder (as defined below). This summary addresses these tax considerations only for U.S. holders that are initial purchasers of our ordinary shares or ADSs pursuant to the global offering and that will hold such ordinary
shares or ADSs as capital assets (generally, property held for investment). This summary does not address all U.S. federal income tax matters that may be relevant to a particular U.S. holder. This summary does not address tax considerations
applicable to a holder of our ordinary shares or ADSs that may be subject to special tax rules including, without limitation, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions or insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities, currencies, commodities, or notional principal contracts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities or organizations, including an &#147;individual
retirement account&#148; or &#147;Roth IRA&#148; as defined in Section&nbsp;408 or 408A of the Code (as defined below), respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts, regulated investment companies or grantor trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our ordinary shares or ADSs as part of a &#147;hedging,&#148; &#147;integrated,&#148;
&#147;wash sale&#148; or &#147;conversion&#148; transaction or as a position in a &#147;straddle&#148; for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal
income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that received our ordinary shares or ADSs as compensation for the performance of services;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons acquiring our ordinary shares or ADSs in connection with a trade or business conducted outside of the
United States, including a permanent establishment or a fixed base in France; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders that own directly, indirectly, or through attribution 10% or more of the voting power or value of our
ordinary shares or ADSs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders that have a &#147;functional currency&#148; other than the U.S. dollar. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our ordinary shares or ADSs who fall within one of the categories above are advised to consult their tax advisor regarding the
specific tax consequences which may apply to their particular situation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this description, a &#147;U.S. holder&#148;
is a beneficial owner of our ordinary shares or ADSs that is (or is treated as), for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United
States, any state therein or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust, if a court within the United States is able to exercise primary supervision over its administration and
one or more U.S. persons have the authority to control all of the substantial decisions of such trust, or if such trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds our ordinary shares or ADSs, the
tax consequences relating to an investment in our ordinary shares or ADSs will depend in part upon the status of the partner and the activities of the partnership. Such a partner or partnership should consult its tax advisor regarding the specific
tax considerations of acquiring, owning and disposing of our ordinary shares or ADSs in its particular circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion in this section is based in part upon the representations of the depositary
and the assumption that each obligation in the deposit agreement and any related agreement will be performed in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Persons considering an investment in our ordinary shares or ADSs should consult their own tax advisors as to the particular tax
consequences applicable to them relating to the acquisition, ownership and disposition of our ordinary shares or ADSs, including the applicability of U.S. federal, state and local tax laws, French tax laws and other
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description does not address the U.S. federal estate, gift, or
alternative minimum tax considerations, or any U.S. state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax considerations of the acquisition, ownership and disposition of our ordinary shares or ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing, proposed and temporary U.S. Treasury
Regulations promulgated thereunder and administrative and judicial interpretations thereof, in each case as in effect and available on the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to differing
interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U.S. Internal Revenue Service, or the IRS, will not take a position concerning the tax consequences of the acquisition, ownership
and disposition of our ordinary shares or ADSs or that such a position would not be sustained by a court. We have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax considerations in the purchase,
ownership or disposition of our ordinary shares or ADSs. Accordingly, holders should consult their own tax advisors concerning the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of acquiring, owning
and disposing of our ordinary shares or ADSs in their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As indicated below, this discussion is subject to U.S.
federal income tax rules applicable to a &#147;passive foreign investment company,&#148; or a PFIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, and taking into account
the earlier assumptions, for U.S. federal income tax purposes, a U.S. holder holding ADSs will be treated as the owner of the ordinary shares represented by the ADSs. Exchanges of ordinary shares for ADSs, and ADSs for ordinary shares, generally
will not be subject to U.S. federal income tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions</I></B>. Subject to the discussion under &#147;&#151;Passive Foreign
Investment Company Considerations,&#148; below, the gross amount of any distribution (including any amounts withheld in respect of foreign tax) actually or constructively received by a U.S. holder with respect to our ordinary shares or ADSs will
generally be taxable to the U.S. holder as a dividend to the extent of the U.S. holder&#146;s pro rata share of our current or accumulated earnings and profits as determined under U.S. federal income tax principles. Distributions in excess of
earnings and profits will generally be <FONT STYLE="white-space:nowrap">non-taxable</FONT> to the U.S. holder to the extent of, and will be applied against and reduce, the U.S. holder&#146;s adjusted tax basis in our ordinary shares or ADSs.
Distributions in excess of earnings and profits and such adjusted tax basis will generally be taxable to the U.S. holder as either long-term or short-term capital gain depending upon whether the U.S. holder has held our ordinary shares or ADSs for
more than one year as of the time such distribution is received. However, since we do not calculate our earnings and profits under U.S. federal income tax principles, it is expected that any distribution will be reported as a dividend, even if that
distribution would otherwise be treated as a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital or as capital gain under the rules described above. <FONT STYLE="white-space:nowrap">Non-corporate</FONT> U.S. holders may qualify for
the preferential rates of taxation with respect to dividends on our ordinary shares or ADSs applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year) and qualified dividend income (as discussed
below) if we are a &#147;qualified foreign corporation&#148; and certain other requirements (discussed below) are met. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation (other than a corporation that is classified as a PFIC for the
taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a)&nbsp;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the
Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provision, or (b)&nbsp;with respect to any dividend it pays on ADSs which are readily tradable on an established securities market in the United States. We have applied to list our ADSs on the
Nasdaq Global Market, which is an established securities market in the United States, and we expect the ADSs to be readily tradable on the Nasdaq Global Market. There can be no assurance that the ADSs will be considered readily tradable on an
established securities market in the United States in later years. The Company, which is incorporated under the laws of France, believes that it qualifies as a resident of France for purposes of, and is eligible for the benefits of, the Convention
between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital, signed on August&nbsp;31, 1994,
as amended and currently in force, or the U.S.-France Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-France Tax Treaty is satisfactory for purposes of the qualified dividend rules and
that it includes an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">exchange-of-information</FONT></FONT> program. Therefore, subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations,&#148;
below, such dividends will generally be &#147;qualified dividend income&#148; in the hands of individual U.S. holders, provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss, during the <FONT
STYLE="white-space:nowrap">121-day</FONT> period beginning 60 days before the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date) and certain other requirements are met. The dividends will not be eligible for the dividends-received deduction
generally allowed to corporate U.S. holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder generally may claim the amount of any French withholding tax as either a
deduction from gross income or a credit against its U.S. federal income tax liability. The foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual basis. Generally, the credit cannot exceed
the proportionate share of a U.S. holder&#146;s U.S. federal income tax liability that such U.S. holder&#146;s taxable income bears to such U.S. holder&#146;s worldwide taxable income. In applying this limitation, a U.S. holder&#146;s various items
of income and deduction must be classified, under complex rules, as either &#147;foreign source&#148; or &#147;U.S. source.&#148; In addition, the creditability of foreign taxes could be affected by actions taken by intermediaries in the chain of
ownership between the holders of our ordinary shares or ADSs and our company if, as a result of such actions, the holders of our ordinary shares or ADSs are not properly treated as beneficial owners of the underlying ordinary shares. Each U.S.
holder should consult its own tax advisors regarding the foreign tax credit rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, the amount of a distribution paid to a
U.S. holder in a foreign currency will be the U.S. dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the depositary receives the distribution, in the case of the ADSs, or on the day the distribution is
received by the U.S. holder, in the case of ordinary shares, regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S. holder realizes on a subsequent conversion of foreign
currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in a foreign currency are converted into U.S. dollars on the day they are received, a U.S. holder should not be required to recognize foreign currency gain
or loss in respect of the dividend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sale, Exchange or Other Taxable Disposition</I></B>. A U.S. holder will generally recognize
gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of our ordinary shares or ADSs in an amount equal to the difference between the U.S. dollar value of the amount realized from such sale or
exchange and the U.S. holder&#146;s adjusted tax basis in those ordinary shares or ADSs, determined in U.S. dollars. Subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations&#148; below, this gain or loss will
generally be a capital gain or loss. The adjusted tax basis in our ordinary shares or ADSs generally will be equal to the cost of such ordinary shares or ADSs. Capital gain from the sale, exchange or other taxable disposition of our ordinary shares
or ADSs by a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder is generally eligible for a preferential rate of taxation applicable to capital gains, if the <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder&#146;s
holding period determined at the time of such sale, exchange or other taxable disposition for such ordinary shares or ADSs exceeds one year (i.e., such gain is long-term taxable gain). The deductibility of capital losses for U.S. federal income tax
purposes is subject to limitations. Any such gain or loss that a U.S. holder recognizes generally will be treated as U.S. source gain or loss for foreign tax credit limitation purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a cash basis taxpayer, units of foreign currency paid or received are translated into
U.S. dollars at the spot rate on the settlement date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between the trade date and the settlement date of such a purchase or sale.
An accrual basis taxpayer, however, may elect the same treatment required of cash basis taxpayers with respect to purchases and sales of our ordinary shares or ADSs that are traded on an established securities market, provided the election is
applied consistently from year to year. Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units of foreign currency paid or received are translated into U.S. dollars at
the spot rate on the trade date of the purchase or sale. Such an accrual basis taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign currency gain or loss a U.S.
holder realizes will be U.S. source ordinary income or loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Medicare Tax</I></B>. Certain U.S. holders that are individuals,
estates or trusts are subject to a 3.8% tax on all or a portion of their &#147;net investment income,&#148; which may include all or a portion of their dividend income and net gains from the disposition of our ordinary shares or ADSs. Each U.S.
holder that is an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our ordinary shares or ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Considerations</I></B>. If we are classified as a PFIC in any taxable year, a U.S. holder will be
subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. holder could derive from investing in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company that does not
distribute all of its earnings on a current basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be classified as a PFIC for U.S. federal income tax purposes in any taxable
year in which, after applying certain look-through rules with respect to the income and assets of our subsidiaries, either: (1)&nbsp;at least 75% of the gross income is &#147;passive income&#148; or (2)&nbsp;at least 50% of the average quarterly
value of our total gross assets (which would generally be measured by fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the market value of the ADSs and our ordinary shares, which are
subject to change) is attributable to assets that produce &#147;passive income&#148; or are held for the production of &#147;passive income.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions,
the excess of gains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of our ordinary shares or ADSs. If a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> corporation owns directly or indirectly at least 25% by value of the stock of another corporation, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is treated for purposes of the PFIC tests
as owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate share of the other corporation&#146;s income. The determination of whether we are a PFIC is a fact-intensive determination made on
an annual basis and the applicable law is subject to varying interpretation. If we are classified as a PFIC in any taxable year during which a U.S. holder owns our ordinary shares or ADSs, such U.S. holder will be subject to special tax rules
discussed below and could suffer adverse tax consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market value of our assets may be determined in large part by reference to
the market price of the ADSs and our ordinary shares, which is likely to fluctuate after the global offering. Therefore, fluctuations in the market price of our ordinary shares or ADSs may result in our being a PFIC for any taxable year. In
addition, the composition of our income and assets will be affected by how, and how quickly, we use the cash proceeds from the global offering in our business. Whether we are a PFIC for any taxable year will depend on income, assets, activities and
market capitalization in each year, and because this is a factual determination made annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year. We do not believe we were
characterized as a PFIC in our taxable year ended December&nbsp;31, 2018. Based on the expected nature and composition of our income, assets, activities and market capitalization for our taxable year
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ending December 31, 2019, we believe that we will not be classified as a PFIC for our taxable year ending December&nbsp;31, 2019; however, there can be no assurance that we will not be considered
a PFIC in the current year or for any future taxable year. Our U.S. counsel expresses no opinion regarding our conclusions or our expectations regarding our PFIC status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are classified as a PFIC in any year with respect to which a U.S. holder owns our ordinary shares or ADSs, we will continue to be
treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ordinary shares or ADSs, regardless of whether we continue to meet the tests described above unless we cease to be a PFIC and the U.S.
holder has made a &#147;deemed sale&#148; election under the PFIC rules or is eligible to make and makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election (as described below), with respect to
all taxable years during such U.S. holder&#146;s holding period in which we are a PFIC. If the &#147;deemed sale&#148; election is made, a U.S. holder will be deemed to have sold the ordinary shares or ADSs the U.S. holder holds at their fair market
value as of the date of such deemed sale and any gain from such deemed sale would be subject to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. holder&#146;s
ordinary shares or ADSs with respect to which such election was made will not be treated as shares in a PFIC and the U.S. holder will not be subject to the rules described below with respect to any &#147;excess distribution&#148; the U.S. holder
receives from us or any gain from an actual sale or other disposition of the ordinary shares or ADSs. U.S. holders should consult their tax advisors as to the possibility and consequences of making a deemed sale election if such election becomes
available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC, and you are a U.S. holder that does not make one of the elections described above (and below in further
detail), a special tax regime will apply to both (a)&nbsp;any &#147;excess distribution&#148; by us to you (generally, your ratable portion of distributions in any year which are greater than 125% of the average annual distribution received by you
in the shorter of the three preceding years or your holding period for our ordinary shares or ADSs) and (b)&nbsp;any gain realized on the sale or other disposition of our ordinary shares or ADSs. Under this regime, any excess distribution and
realized gain will be treated as ordinary income and will be subject to tax as if (a)&nbsp;the excess distribution or gain had been realized ratably over your holding period, (b)&nbsp;the amount deemed realized in each year had been subject to tax
in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. holder&#146;s regular ordinary
income rate for the current year and would not be subject to the interest charge discussed below), and (c)&nbsp;the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those
years. In addition, dividend distributions made to you will not qualify for the lower rates of taxation applicable to qualified dividends discussed above under &#147;Distributions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain elections may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of our ordinary
shares or ADSs. If a U.S. holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, the U.S. holder generally will recognize as ordinary income any excess of the fair market value of our
ordinary shares or ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of our ordinary shares or ADSs over their fair market value at the end of
the taxable year (but only to the extent of the net amount of income previously included as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). If a U.S. holder makes the
election, the U.S. holder&#146;s tax basis in our ordinary shares or ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of our ordinary shares or ADSs in a year in which we are a PFIC
will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only if we are a PFIC
and our ordinary shares or ADSs are &#147;regularly traded&#148; on a &#147;qualified exchange.&#148; Our ordinary shares or ADSs will be treated as &#147;regularly traded&#148; in any calendar year in which more than a de minimis quantity of our
ordinary shares or ADSs are traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of their principal purposes the meeting of the trading requirement are disregarded). The
Nasdaq Global Market is a qualified exchange for this purpose and, consequently, if the ADSs are regularly traded, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will be available to a
U.S. holder. It should be noted that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
it is intended that only the ADSs and not our ordinary shares will be listed on the Nasdaq Global Market. Consequently, our ordinary shares may not be marketable if Euronext Paris (where our
ordinary shares are listed) does not meet the applicable requirements. U.S. holders should consult their tax advisors regarding the availability of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election for ordinary shares that are not represented by ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves
&#147;marketable.&#148; As a result, even if a U.S. holder validly makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to our ordinary shares or ADSs, the U.S. holder may
continue to be subject to the PFIC rules (described above) with respect to its indirect interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. holders should consult their tax
advisors as to the availability and desirability of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, as well as the impact of such election on interests in any lower-tier PFICs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently intend to provide the information necessary for U.S. holders to make qualified electing fund elections if we were treated
as a PFIC for any taxable year. U.S. holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section would apply to indirect
distributions and gains deemed to be realized by U.S. holders in respect of any of our subsidiaries that also may be determined to be PFICs. U.S. holders should consult their tax advisors regarding the application of the PFIC rules to our
subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. holder owns our ordinary shares or ADSs during any taxable year in which we are a PFIC, the U.S. holder generally
will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally with the U.S. holder&#146;s federal income tax return for that
year. If our company were a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisors
with respect to the acquisition, ownership and disposition of our ordinary shares or ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to our ordinary shares or ADSs and the IRS information reporting
obligations with respect to the acquisition, ownership and disposition of our ordinary shares or ADSs. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Backup Withholding and
Information Reporting</I></B>. U.S. holders generally will be subject to information reporting requirements with respect to dividends on our ordinary shares or ADSs and on the proceeds from the sale, exchange or disposition of our ordinary shares or
ADSs that are paid within the United States or through U.S.-related financial intermediaries, unless the U.S. holder is an &#147;exempt recipient.&#148; In addition, U.S. holders may be subject to backup withholding on such payments, unless the U.S.
holder provides a taxpayer identification number and a duly executed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or otherwise establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding
will be allowed as a credit against a U.S. holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain Reporting Requirements With Respect to Payments of Offer Price</I></B>. U.S. holders paying more than $100,000 for our ordinary
shares or ADSs generally may be required to file IRS Form 926 reporting the payment of the offer price for our ordinary shares or ADSs to us. Substantial penalties may be imposed upon a U.S. holder that fails to comply. Each U.S. holder should
consult its own tax advisor as to the possible obligation to file IRS Form 926. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Asset Reporting</I></B>. Certain individual
U.S. holders are required to report information relating to an interest in our ordinary shares or ADSs, subject to certain exceptions (including an exception for shares held in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accounts maintained by U.S. financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return. U.S. holders are urged to
consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of our ordinary shares or ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE DISCUSSION ABOVE IS A SUMMARY OF THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs AND IS BASED
UPON LAWS AND RELEVANT INTERPRETATIONS THEREOF IN EFFECT AS OF THE DATE OF THIS PROSPECTUS, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH RETROACTIVE EFFECT. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX
CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material French Tax
Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following describes the material French income tax consequences to U.S. holders of purchasing, owning and disposing
of our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not purport to be a complete analysis or listing of all potential tax effects of the acquisition,
ownership or disposition of our ADSs to any particular investor, and does not discuss tax considerations that arise from rules of general application or that are generally assumed to be known by investors. All of the following is subject to change.
Such changes could apply retroactively and could affect the consequences described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, France introduced a comprehensive set
of tax rules applicable to French assets that are held by or in foreign trusts. These rules provide inter alia for the inclusion of trust assets in the settlor&#146;s net assets for the purpose of applying the former French wealth tax (replaced by
the French real estate wealth tax as from January&nbsp;1, 2018), for the application of French gift and death duties to French assets held in trust, for a specific tax on capital on the French assets of foreign trusts not already subject to the
former French wealth tax (replaced by the French real estate wealth tax as from January&nbsp;1, 2018) and for a number of French tax reporting and disclosure obligations. The following discussion does not address the French tax consequences
applicable to securities (including ADSs) held in trusts. If ADSs are held in trust, the grantor, trustee and beneficiary are advised to consult their own tax advisor regarding the specific tax consequences of acquiring, owning and disposing of such
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description of the French income tax and real estate wealth tax consequences set forth below is based on the double tax
treaty entered into between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital of
August&nbsp;31, 1994 (the &#147;Treaty&#148;), which came into force on December&nbsp;30, 1995 (as amended by any subsequent protocols, including the protocol of January&nbsp;13, 2009), and the tax guidelines issued by the French tax authorities in
force as of the date of this prospectus, or the Treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion applies only to investors that are entitled to Treaty benefits
under the &#147;Limitation on Benefits&#148; provisions contained in the Treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership holds ADSs, the tax treatment of the
partnership and a partner in such partnership generally will depend on the status of the partner and the activities of the partnership. Such partner or partnership is urged to consult its own tax advisor regarding the specific tax consequences of
acquiring, owning and disposing of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion applies only to investors that hold ADSs as capital assets that are entitled to
Treaty benefits under the &#147;Limitation on Benefits&#148; provision contained in the Treaty, and whose ownership of the ADSs is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectively connected to a permanent establishment or a fixed base in France. Certain U.S. holders may be subject to special rules not discussed below, and are advised to consult their usual tax
advisor regarding the specific tax consequences which may apply to their particular situation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. holders are advised to consult their
own tax advisor regarding the tax consequences of the purchase, ownership and disposition of ADSs in light of their particular circumstances, especially with regard to the &#147;Limitations on Benefits&#148; provision contained in the Treaty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Tax on Sale or other Disposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a matter of principles, under French tax law, a U.S. holder should not be subject to any French tax on any capital gain from the sale,
exchange, repurchase or redemption by us of ordinary shares or ADSs, provided such U.S. holder is not a French tax resident for French tax purposes and has not held more than 25% of our dividend rights, known as <I>&#147;droits aux benefices
sociaux,&#148; </I>at any time during the preceding five years, either directly or indirectly, and, as relates to individuals, alone or with relatives (as an exception, a U.S. holder resident, established or incorporated in certain <FONT
STYLE="white-space:nowrap">non-cooperative</FONT> States or territories as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the French tax code (<I>Code g&eacute;n&eacute;ral des imp&ocirc;ts</I>, the &#147;FTC&#148;) should be
subject to a 75% withholding tax in France on any such capital gain, regardless of the fraction of the dividend rights it holds). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
application of the Treaty, a U.S. holder who is a U.S. resident for purposes of the Treaty and entitled to Treaty benefits will not be subject to French tax on such capital gain unless the ordinary shares or the ADSs form part of the business
property of a permanent establishment or fixed base that the U.S. holder has in France. U.S. holders who own ordinary shares or ADSs through U.S. partnerships that are not resident for Treaty purposes are advised to consult their own tax advisor
regarding their French tax treatment and their eligibility for Treaty benefits in light of their own particular circumstances.&nbsp;A U.S. holder that is not a U.S. resident for Treaty purposes or is not entitled to Treaty benefits (and in both
cases is not resident, established or incorporated in certain <FONT STYLE="white-space:nowrap">non-cooperative</FONT> States or territories as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the FTC) and has held more than 25%
of our dividend rights, known as <I>&#147;droits aux benefices sociaux&#148; </I>at any time during the preceding five years, either directly or indirectly, and, as relates to individuals, alone or with relatives will be subject to a levy in France
(i)&nbsp;at the rate of 12.8% for individuals, and (ii)&nbsp;a rate corresponding to the standard corporate income tax rate set forth in Article <FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for legal persons. Special rules apply to U.S.
holders who are residents of more than one country. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Financial Transactions Tax and Registration Duties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article 235 <I>ter </I>ZD of the FTC, purchases of shares or ADSs of a French company listed on a regulated market of the European
Union or on a foreign regulated market formally acknowledged by the AMF are subject to a 0.3% French tax on financial transactions provided that the issuer&#146;s market capitalization exceeds 1&nbsp;billion euros as of December&nbsp;1 of the year
preceding the taxation year. A list of companies whose market capitalization exceeds 1&nbsp;billion euros as of December&nbsp;1 of the year preceding the taxation year, within the meaning of Article 235<I> ter</I> ZD of the FTC, is published
annually by the French tax authorities in their official guidelines. As at 1 December&nbsp;2018, our market capitalization did not exceed 1&nbsp;billion euros, pursuant to <FONT STYLE="white-space:nowrap">BOI-ANNX-000467-20181217.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, Nasdaq Global Market, on which ADSs will be listed, is not currently acknowledged by the AMF but this may change in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a consequence, neither the ADSs nor the ordinary shares are currently within the scope of the French tax on financial transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this global offering, purchases of our ADSs may be subject to such tax in the future provided that our market capitalization exceeds
1&nbsp;billion euros in the year preceding the taxation year and that the Nasdaq Global Market is acknowledged by the French AMF. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case where Article 235 <I>ter</I> ZD of the FTC is not applicable, transfers of
shares issued by a French company which are listed on a regulated or organized market within the meaning of the French monetary code (<I>Code mon&eacute;taire et financier</I>) are subject to uncapped registration duties at the rate of 0.1% if the
transfer is evidenced by a written statement (&#147;<I>acte</I>&#148;) executed either in France or outside France. As ordinary shares of our company are listed on Euronext Paris, which is an organized market within the meaning of the French
monetary code, their transfer should be subject to uncapped registration duties at the rate of 0.1% subject to the existence of a written statement (&#147;<I>acte</I>&#148;), and provided that Article 235 <I>ter</I> ZD of the FTC is not applicable.
Although there is no case law or official guidelines published by the French tax authorities on this point, transfer of ADSs should remain outside of the scope of the aforementioned 0.1% registration duties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid by a French corporation to <FONT STYLE="white-space:nowrap">non-residents</FONT> of France are generally subject to French
withholding tax at a rate of (i) 30% (to be aligned on the standard corporate income tax rate set forth in Article <FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for fiscal years beginning as from January&nbsp;1, 2020) for payment
benefiting legal persons which are not French tax residents, and (ii) 12.8% for payment benefiting individuals who are not French tax residents. Dividends paid by a French corporation in certain
<FONT STYLE="white-space:nowrap">non-cooperative</FONT> States or territories, as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the FTC, will generally be subject to French withholding tax at a rate of 75%. However, eligible
U.S. holders entitled to Treaty benefits under the &#147;Limitation on Benefits&#148; provision contained in the Treaty who are U.S. residents, as defined pursuant to the provisions of the Treaty, will not be subject to this 30% (to be aligned on
the standard corporate income tax rate set forth in Article <FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for fiscal years beginning as from January&nbsp;1, 2020) or 75% withholding tax rate, but may be subject to the withholding tax at a
reduced rate (as described below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. holder who
is a U.S. resident as defined pursuant to the provisions of the Treaty and whose ownership of the ordinary shares or ADSs is not effectively connected with a permanent establishment or fixed base that such U.S. holder has in France, is generally
reduced to 15%, or to 5% if such U.S. holder is a corporation and owns directly or indirectly at least 10% of the share capital of the issuer; such U.S. holder may claim a refund from the French tax authorities of the amount withheld in excess of
the Treaty rates of 15% or 5%, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For U.S. holders that are not individuals but are U.S. residents, as defined pursuant to the
provisions of the Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or 15% withholding tax rates contained in the &#147;Limitation on Benefits&#148; provision of the Treaty, are complex, and certain technical
changes were made to these requirements by the protocol of January&nbsp;13, 2009. U.S. holders are advised to consult their own tax advisor regarding their eligibility for Treaty benefits in light of their own particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid to an eligible U.S. holder may immediately be subject to the reduced rates of 5% or 15% provided that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holder establishes before the date of payment that it is a U.S. resident under the Treaty by completing and
providing the depositary with a treaty form (Form 5000) in accordance with French guidelines (BOI-INT-DG-20-20-20-20-20120912 dated September 12, 2012); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary or other financial institution managing the securities account in the U.S. of such holder provides
the French paying agent with a document listing certain information about the U.S. holder and its ordinary shares or ADSs and a certificate whereby the financial institution managing the U.S.&nbsp;holder&#146;s securities account in the United
States takes full responsibility for the accuracy of the information provided in the document. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Otherwise, dividends
paid to a U.S. holder, if such U.S. holder is a legal person, will be subject to French withholding tax at the rate of 30% (to be aligned on the standard corporate income tax rate set forth in Article
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for fiscal years beginning as from January&nbsp;1, 2020), or 75% if paid in certain
<FONT STYLE="white-space:nowrap">non-cooperative</FONT> States or territories (as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the FTC), and then reduced at a later date to 5% or 15%, provided that such holder duly completes
and provides the French tax authorities with the treaty forms Form 5000 and Form 5001 before December&nbsp;31 of the second calendar year following the year during which the dividend is paid. Certain qualifying pension funds and certain other <FONT
STYLE="white-space:nowrap">tax-exempt</FONT> entities are subject to the same general filing requirements as other U.S. holders except that they may have to supply additional documentation evidencing their entitlement to these benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Form 5000 and Form 5001, together with instructions, will be provided by the depositary to all U.S. holders registered with the depositary.
The depositary will arrange for the filing with the French tax authorities of all such forms properly completed and executed by U.S. holders of ordinary shares or ADSs and returned to the depositary in sufficient time so that they may be filed with
the French tax authorities before the distribution in order to immediately obtain a reduced withholding tax rate. Otherwise, the depositary must withhold tax at the full rate of 30% (to be aligned on the standard corporate income tax rate set forth
in Article <FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for fiscal years beginning as from January&nbsp;1, 2020) or 75% as applicable. In that case, the U.S. holders may claim a refund from the French tax authorities of the excess
withholding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any case, individual taxpayers who are not fiscally domiciled in France should not have to comply with these
procedures if the French withholding tax applying to them is lower than 15%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Estate and Gift Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a transfer of securities by gift or by reason of death of a U.S. holder that would otherwise be subject to French gift or
inheritance tax, respectively, will not be subject to such French tax by reason of the double tax treaty entered into between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double
Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritances and Gifts, dated November&nbsp;24, 1978, unless (i)&nbsp;the donor or the transferor is domiciled in France at the time of making the gift or at the time of
his or her death, or (ii)&nbsp;the ADSs were used in, or held for use in, the conduct of a business through a permanent establishment or a fixed base in France. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Wealth Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
from January&nbsp;1, 2018, the French wealth tax <I>(imp&ocirc;t de solidarit&eacute; sur la fortune) </I>is repealed and replaced by the French real estate wealth tax<I> (imp&ocirc;t sur la fortune immobili&egrave;re). </I>The scope of such new tax
is narrowed to real estate assets (and certain assets deemed to be real estate assets) or rights, held directly or indirectly through one or more legal entities and whose net taxable assets amount at least to &#128;1,300,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broadly, subject to provisions of double tax treaties and to certain exceptions, individuals who are not residents of France for tax purposes
within the meaning of Article 4 B of the FTC, are subject to real estate wealth tax <I>(imp&ocirc;t sur la fortune immobili&egrave;re) </I>in France in respect of the portion of the value of their shares of our company representing real estate
assets (Article 965, 2&deg; of the FTC). Some exceptions are provided by the FTC<I>. </I>For instance, any participations representing less than 10% of the share capital of an operational company and shares representing real estate for the
professional use of the company considered shall not fall within the scope of the French real estate wealth tax <I>(imp&ocirc;t sur la fortune immobili&egrave;re).</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treaty (the provisions of which should be applicable to this new real estate
wealth tax <I>(imp&ocirc;t sur la fortune immobili&egrave;re) </I>in France), the French real estate wealth tax <I>(imp&ocirc;t sur la fortune immobili&egrave;re</I>) will however generally not apply<I> </I>to securities held by an eligible U.S.
holder who is a U.S. resident, as defined pursuant to the provisions of the Treaty, provided that such U.S. holder (i)&nbsp;does not own directly or indirectly more than 25% of the issuer&#146;s financial rights and (ii)&nbsp;that the ADSs do not
form part of the business property of a permanent establishment or fixed base in France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. holders are advised to consult their own
tax advisor regarding the specific tax consequences which may apply to their particular situation with respect to such French real estate wealth tax <I>(imp&ocirc;t sur la fortune immobili&egrave;re</I>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_21"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a corporation organized under the laws of France. The majority of our members of the Executive Board and Supervisory Board are citizens
and residents of countries other than the United States, and the majority of our assets are located outside of the United States. We have appointed an agent for service of process in the United States; however, it may be difficult for investors:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to obtain jurisdiction over us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident members of the
Executive Board and Supervisory Board in U.S. courts in actions predicated on the civil liability provisions of the U.S.&nbsp;federal securities laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce judgments obtained in such actions against us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
resident members of the Executive Board and supervisory; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to bring an original action in a French court to enforce liabilities based upon the U.S. federal securities laws
against us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident members of the Executive Board and Supervisory Board; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce against us or our Executive Board in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> courts,
including French courts, judgments of U.S. courts predicated upon the civil liability provisions of the U.S. federal securities laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, a final judgment for the payment of money rendered by any federal or state court in the United States based on civil liability,
whether or not predicated solely upon the U.S. federal securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirements concerning the recognition and the
enforcement of foreign judgments and is capable of being immediately enforced in the United States. A French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits of the underlying claim, only if (1)
that judgment is enforceable in the jurisdiction of the U.S. court which rendered it, (2) that judgment was rendered by a court having jurisdiction over the dispute (the condition will be met if the dispute is clearly connected to the jurisdiction
of the U.S. court and French courts did not have exclusive jurisdiction over the matter), (3) that judgment does not contravene French international public order and public policy, including the right to due process, and (4) the U.S. judgment is not
tainted with fraud and is not incompatible with a judgment rendered by a French court in the same matter, or with an earlier judgment rendered by a foreign court in the same matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, French law guarantees full compensation for the harm suffered but is limited to the actual damages, so that the victim does not
suffer or benefit from the situation. Such system excludes damages such as, but not limited to, punitive and exemplary damages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
result, the enforcement, by U.S. investors, of any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities law against us or members of our Executive Board and Supervisory Board or
certain experts named herein who are residents of France or countries other than the United States would be subject to the above conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, there may be doubt as to whether a French court would impose civil liability on us, the members of our Executive Board and
Supervisory Board or certain experts named herein in an original action predicated solely upon the U.S. federal securities laws brought in a court of competent jurisdiction in France against us or such members, officers or experts, respectively.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_22"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This global offering consists of a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares,
consisting of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an offering of a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the form of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs in the United
States, referred to as the U.S. offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a concurrent private offering of a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in Europe (including France) and countries outside of the United States, referred to as the European private placement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group L.L.C. are acting as representatives of the
underwriters in the U.S. offering. Citigroup Global Markets Limited is acting as a representative in the European private placement. As used herein, with respect to the U.S. offering, the term &#147;underwriters&#148; refers to the underwriters
offering ordinary shares in the form of ADSs in the United States and, with respect to the European private placement, the underwriter offering ordinary shares in Europe, as the case may be. The underwriters in the U.S. offering and the underwriter
in the European private placement are collectively referred to herein as the &#147;underwriters.&#148; Under the terms and subject to the conditions of an underwriting agreement dated the date of this prospectus, the underwriters named below have
severally agreed to purchase, and we have agreed to sell to them, severally, the number of ADSs (including underlying ordinary shares) and/or ordinary shares (exclusive of ordinary shares underlying ADSs), as the case may be, indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters in each offering are offering the ADSs or ordinary shares, as the case may be, subject to
their acceptance of the ADSs and ordinary shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the ADSs or ordinary shares, as the case may
be, offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the ADSs and ordinary shares offered by this prospectus
if any such ADSs or ordinary shares, as the case may be, are taken. However, the underwriters are not required to take or pay for the ADSs and ordinary shares covered by the underwriters&#146; option to purchase additional ADSs and ordinary shares
described below. The total number of ADSs in the U.S. offering and ordinary shares in the European private placement (including any ADSs or ordinary shares purchased pursuant to the underwriters&#146; option to purchase additional ADSs and ordinary
shares described below) is subject to reallocation between these offerings to the extent permitted under applicable law and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADSs and ordinary shares sold by the underwriters will be offered at the offering price set forth on the cover of this prospectus. Any ADSs
and ordinary shares sold by the underwriters to securities dealers may be sold at a discount from the offering price not to exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS and &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ordinary share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares (which may be in the form of ADSs) at the offering price listed on the cover page of this prospectus, less underwriting discounts. To the extent the
option is exercised, each underwriter must purchase a number of additional ADSs or additional ordinary shares, as the case may be, approximately proportionate to that underwriter&#146;s initial purchase commitment. Any ADSs or ordinary shares issued
or sold under the option will be issued and sold on the same terms and conditions as the other ADSs and ordinary shares that are the subject of this global offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per ADS, per ordinary share and total offering price,
underwriting discounts, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Ordinary Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>ADSs&nbsp;and/or<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>ADSs&nbsp;and/or<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated expenses payable by us in connection with the global offering, exclusive of the underwriting
discounts, are approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for expenses relating to clearance of this global offering with the Financial Industry Regulatory Authority up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they do not intend sales to discretionary
accounts to exceed 5% of the total number of ADSs offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list the ADSs on the Nasdaq Global Market under
the trading symbol &#147;IPHA.&#148; Our ordinary shares are listed on Euronext Paris under the trading symbol &#147;IPH.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that, without the prior written consent of Citigroup Global
Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited on behalf of the respective underwriters in the global offering, we will not, during the period ending 90 days after the date of this prospectus (the
&#147;restricted period&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any ordinary shares, ADSs or any securities convertible into or exercisable or exchangeable for ADSs or ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the SEC (or the equivalent thereof in
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions) relating to the global offering of any ordinary shares, ADSs or any securities convertible into or exercisable or exchangeable for ADSs or ordinary shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of ADSs or ordinary shares, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction described above is to be settled by delivery of ADSs
or ordinary shares, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, we will not,
during the restricted period, make any demand for, or exercise any right with respect to, the registration of any ADSs or ordinary shares or any security convertible into or exercisable or exchangeable for any ADSs or ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions contained in the preceding paragraph shall not apply to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each of the members of our Supervisory Board and Executive Board and certain of our shareholders have agreed that, without the
prior written consent of Citigroup Global Markets Inc., SVB Leerink </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, on behalf of the respective underwriters in the offerings, they will not, during the restricted period, (1)&nbsp;offer, pledge,
sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any ADSs or ordinary shares
beneficially owned (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), by such person or any other securities so owned that are convertible into or exercisable or exchangeable for ordinary shares or
ADSs; or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the ordinary shares or ADSs, whether any such transaction described in clause (1)&nbsp;or (2)
above is to be settled by delivery of ordinary shares, ADSs or such other securities, in cash or otherwise. The foregoing restrictions shall not apply to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing paragraph, &#147;Change of Control&#148; means the transfer (whether by tender offer, merger, consolidation or
other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter pursuant to this global offering), of our voting securities if, after such transfer, such
person or group of affiliated persons would hold more than 50% of our outstanding voting securities (or our surviving entity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, such person has agreed that, without the prior written consent of Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, on behalf of the respective underwriters in the offerings, it
will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any ADSs, ordinary shares or any security convertible into or exercisable or exchangeable for ADSs or ordinary shares. Such
person also agrees and consents to the entry of stop transfer instructions with our transfer agent, registrar and depositary against the transfer of such person&#146;s ADSs or ordinary shares except in compliance with the foregoing restrictions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, in their sole discretion, may
release the ADSs and ordinary shares and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the ADSs and ordinary shares, the underwriters may engage in transactions that stabilize, maintain or
otherwise affect the price of the ADSs and ordinary shares. Specifically, the underwriters may sell more ADSs and ordinary shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is
covered if the short position is no greater than the number of ADSs and ordinary shares available for purchase by the underwriters under the option to purchase additional ADSs and ordinary shares. The underwriters can close out a covered short sale
by exercising the option or purchasing ADSs and ordinary shares in the open market. In determining the source of ADSs and ordinary shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of
ADSs and ordinary shares compared to the price available under the option. The underwriters may also sell ADSs and ordinary shares in excess of the option, creating a naked short position. The underwriters must close out any naked short position by
purchasing ADSs and ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs and ordinary shares in the open market after
pricing that could adversely affect investors who purchase in this global offering. As an additional means of facilitating this global offering, the underwriters may bid for, and purchase, ADSs and ordinary shares in the open market to stabilize the
price of the ADSs and ordinary shares. These activities may raise or maintain the market price of the ADS and ordinary shares above independent market levels or prevent or retard a decline in the market price of the ADS and ordinary shares. The
underwriters are not required to engage in these activities and may end any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have
agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or
more underwriters participating in this global offering. Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, on behalf of the respective underwriters in the offerings, may agree to allocate a
number of ADSs and ordinary shares to underwriters for sale to their online brokerage account holders. Such Internet distributions will be allocated to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging. financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long
and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or
express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Citibank, N.A., an affiliate of Citibank Global Markets Inc. and Citigroup Global Markets Limited, is acting as depositary in
this global offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Global Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this global offering, there has been no public market for the ADSs. The offering price of the ADSs and ordinary shares was determined
by negotiations between us and Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, on behalf of the respective underwriters in the offerings, and by reference to the prevailing market prices of
our ordinary shares on Euronext Paris after taking into account market conditions and other factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than
in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this
prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction,
except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions
relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a
solicitation is unlawful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Member State&#148;) an offer to the public of any ADSs and
ordinary shares which are the subject of the global offering contemplated by this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus may not be made in that Member State, except that an offer to the public in that Member State of any ADSs and ordinary shares may be made at any time under the following exemptions
under the Prospectus Directive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investor as defined in the Prospectus
Directive), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of ADSs and ordinary shares shall result in a requirement for the publication by the Company or any underwriter of a prospectus
pursuant to Article 3 of the Prospectus Directive or a supplement of a prospectus pursuant to Article&nbsp;16 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any ADSs and ordinary shares in any
Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ADSs and ordinary shares to be offered so as to enable an investor to decide to purchase any ADSs and ordinary shares, as
the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>MiFID II Product Governance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of each manufacturer&#146;s product approval process, the target market assessment in respect of the ADSs and ordinary
shares has led to the conclusion that: (i)&nbsp;the target market for the ADSs and ordinary shares is eligible counterparties and professional clients only, each as defined in Directive 2014/65/EU (as amended, &#147;MiFID II&#148;); and
(ii)&nbsp;all channels for distribution of the ADSs and ordinary shares to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the ADSs and ordinary shares (a
&#147;distributor&#148;) should take into consideration the manufacturers&#146; target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the ADSs and ordinary
shares (by either adopting or refining the manufacturers&#146; target market assessment) and determining appropriate distribution channels. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>France </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs
and the ordinary shares have not been and will not be offered or sold to the public in the Republic of France, and no offering or this prospectus or any marketing materials relating to the ADSs and the ordinary shares must be made available or
distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs and the
ordinary shares may only be offered or sold in the Republic of France pursuant to article&nbsp;L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">411-2-II</FONT></FONT> of the French <I>Code mon&eacute;taire et financier</I> to
(i)&nbsp;providers of third party portfolio management investment services, (ii)&nbsp;qualified investors (i<I>nvestisseurs qualifi&eacute;s</I>) acting for their own account and/or (iii)&nbsp;a limited group of investors (<I>cercle restreint
d&#146;investisseurs</I>) acting for their own account, all as defined in and in accordance with articles L. <FONT STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2</FONT> and D.
<FONT STYLE="white-space:nowrap">411-1</FONT> to <FONT STYLE="white-space:nowrap">D.411-4,</FONT> <FONT STYLE="white-space:nowrap">D.744-1</FONT> and D. <FONT STYLE="white-space:nowrap">754-1</FONT> and D.
<FONT STYLE="white-space:nowrap">764-1</FONT> of the French <I>Code mon&eacute;taire et financier</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors are informed
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus nor any other offering materials relating to the ADSs and the ordinary shares described
in this prospectus has been submitted for clearance to the French financial market authority (<I>Autorit&eacute; des march&eacute;s financiers</I>); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus, nor any offering material relating to the ADSs and the ordinary shares has been or will
be released, issued, distributed or caused to be released, issued or distributed to the public in France or used in connection with any offer for subscription or sale of the ADSs and the ordinary shares to the public in France within the meaning of
article L. 411-1 of the French <I>Code mon&eacute;taire et financier</I>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individuals or entities referred to in article L. 411-2-II of the French <I>Code mon&eacute;taire et
financier</I> may participate in the global offering, as provided under articles D.411-1, D.411-2, D.744-1, D.754-1 and D.764-1 of the French <I>Code mon&eacute;taire et financier</I>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direct and indirect distribution or sale to the public of the ADSs and the ordinary shares acquired by them
may only be made in compliance with articles L. 411-1, L. 411-2, L. 412-1 and L. 621-8 to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.&nbsp;621-8-3</FONT></FONT> of the French <I>Code mon&eacute;taire et financier</I>.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs and ordinary shares may not be offered or sold by means of any document other than (i)&nbsp;in circumstances that do not constitute an
offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules
made thereunder, or (iii)&nbsp;in other circumstances that do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating
to the ordinary shares or ADSs may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by,
the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to ordinary shares or ADSs that are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional
investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan, or the Financial Instruments and Exchange Law, and each underwriter has agreed that it will not offer or sell any securities, directly or
indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term, as used in this prospectus means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments
and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs and ordinary shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document, nor any other offering or marketing material relating
to the ADSs and ordinary shares or this global offering, may be publicly distributed or otherwise made publicly available in Switzerland. Neither this document nor any other offering or marketing material relating to this global offering, the
Company, or the ordinary shares or ADSs has been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of the ADSs and ordinary shares will not be supervised by, the
Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of the ADSs and ordinary shares has not been and will not be authorized under the Swiss Federal Act on Collective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of ordinary shares or ADSs.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United Arab Emirates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or DFSA.
This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying
any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for this prospectus. The ADSs and ordinary shares to which this prospectus
relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the ordinary shares or ADSs offered should conduct their own due diligence on the ADSs and ordinary shares. If you do not understand the contents of
this prospectus, you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the
Order (all such persons together being referred to as &#147;relevant persons&#148;).</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a
relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively
by relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs
and ordinary shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or
subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of
the ADSs and ordinary shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this global
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_23"></A>EXPENSES RELATING TO THE GLOBAL OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the costs and expenses, other than underwriting discounts, payable in connection with the sale of ordinary
shares and ADSs in the global offering. All amounts are estimated except the SEC registration fee, the Nasdaq initial listing fee and the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee. Except as otherwise noted, all the
expenses below will be paid by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be completed by amendment. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_24"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley&nbsp;LLP, Boston, Massachusetts, is representing us in connection with this global offering. The validity of the ordinary shares and
certain other matters of French law will be passed upon for us by Linklaters LLP. Legal counsel to the underwriters in connection with this global offering are Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP and Gide Loyrette Nouel A.A.R.P.I. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_25"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements as of December&nbsp;31, 2018 and 2017 and for each of the two years in the period ended
December&nbsp;31, 2018 included in this prospectus have been audited by Deloitte&nbsp;&amp; Associ&eacute;s, an independent registered public accounting firm, as stated in their report appearing herein (which report expresses an unqualified opinion
on the consolidated financial statements and includes an explanatory paragraph referring to the adoption of IFRS 15 <I>Revenue from Contracts with Customers </I>and IFRS 9 <I>Financial instruments</I>). Such consolidated financial statements are
included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offices of
Deloitte&nbsp;&amp; Associ&eacute;s are located at Les Docks &#150; Atrium 10.4, 10 place de la Joliette, 13002 Marseille, France. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_26"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under the Securities Act with respect
to the ordinary shares and ADSs offered in this prospectus. A related registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> will be filed with the SEC to register the ADSs. This prospectus, which forms a part of the Registration
Statement, does not contain all of the information included in the Registration Statement. Certain information is omitted and you should refer to the Registration Statement and its exhibits for that information. With respect to references made in
this prospectus to any contract or other document of Innate Pharma S.A., such references are not necessarily complete and you should refer to the exhibits attached to the Registration Statement for copies of the actual contract or document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this global offering, we will become subject to periodic reporting and other informational requirements of the Exchange Act
as applicable to foreign private issuers. Accordingly, we will be required to file reports, including annual reports on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> periodic reports and other information, with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are allowed four months after the end of our fiscal year to file our annual report with the SEC, and we are not required to disclose
certain detailed information regarding executive compensation that is required from U.S. domestic issuers. Also, as a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing of proxy statements to
shareholders, and the members of our Supervisory Board and Executive Board and our principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are also exempt from the requirements of Regulation FD (Fair Disclosure) which, generally, are meant to ensure
that select groups of investors are not privy to specific information about an issuer before other investors. We are, however, still subject to the anti-fraud and anti-manipulation rules of the SEC, such as Rule
<FONT STYLE="white-space:nowrap">10b-5.</FONT> Since many of the disclosure obligations required of us as a foreign private issuer are different than those required of U.S. domestic reporting companies, our shareholders, potential shareholders and
the investing public in general should not expect to receive information about us in the same amount, or at the same time, as information is received from, or provided by, other U.S. domestic reporting companies. We are only liable for violations of
the rules and regulations of the SEC that apply to us as a foreign private issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC maintains a website at www.sec.gov that
contains reports and information statements and other information regarding registrants like us that file electronically with the SEC. You also can inspect our registration statement, as well as any other information we file with or furnish to the
SEC, on this website. This reference to the SEC&#146;s website is an inactive textual reference only and is not a hyperlink. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to
make our annual reports and other information filed with or furnished to the SEC available, free of charge, through our website at www.innate-pharma.com as soon as reasonably practicable after those reports and other information are filed with or
furnished to the SEC. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A><A NAME="toc752656_27"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Consolidated Financial Statements as of and for the Years Ended December&nbsp;31, 2018 and 2017</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_1">Report&nbsp;of&nbsp;Independent&nbsp;Registered&nbsp;Public&nbsp;
Accounting&nbsp;Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_2">Consolidated Statements of Financial Position as of December&nbsp;
31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_3">Consolidated Statements of Income (Loss) for the Years Ended December&nbsp;
31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_4">Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December&nbsp;31,
 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_6">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_5">Consolidated Statements of Changes in Shareholders&#146; Equity for the Years
 Ended December&nbsp;31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_7">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin752656_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">To the shareholders and the Board of Directors of Innate Pharma S.A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated statements of financial position of Innate Pharma S.A. and subsidiaries (the &#147;Company&#148;) as of December&nbsp;31, 2018 and 2017, the related consolidated statements of income (loss), comprehensive income (loss),
changes in shareholders&#146; equity, and cash flows, for each of the two years in the period ended December&nbsp;31, 2018, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2018 and 2017, and the results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31,
2018, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board (IASB). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in
Accounting Principle </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 2a to the consolidated financial statements, the company implemented accounting changes relating to the
adoption of IFRS 15 Revenue from Contracts with Customers and IFRS 9 Financial Instruments, as adopted by the IASB and applicable to periods starting on or after January&nbsp;1, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting.
Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Associ&eacute;s </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Marseille, France </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">June 6, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as
the Company&#146;s auditor since 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_2"></A>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>319,643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>137,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>131,574</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>117,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>451,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities<B>&#151;</B>current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities<B>&#151;</B>current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue<B>&#151;</B>current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>196,737</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,909</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities<B>&#151;</B>non-current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities<B>&#151;</B><FONT STYLE="white-space:nowrap">non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue<B>&#151;</B><FONT STYLE="white-space:nowrap">non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>87,238</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>95,158</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,595</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>451,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_3"></A>CONSOLIDATED STATEMENTS OF INCOME (LOSS) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro, except per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue and other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,983</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,016</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) per share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in &#128; per share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_4"></A>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018(1)&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items which will be reclassified in the consolidated statement of income (loss):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of short-term investments and
<FONT STYLE="white-space:nowrap">non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation gain (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items which will not be reclassified in the consolidated statement of income
(loss):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and (losses) related to defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>683</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,424</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(47,702</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_6"></A>CONSOLIDATED STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018(1)&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6, 7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions for defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions for charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains (losses) on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance on financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(204</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains (losses) on assets and other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating cash flow before change in working capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(31,080</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from (used in) operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,531</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,060</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6, 8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7,&nbsp;8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of current financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of <FONT STYLE="white-space:nowrap">non-current</FONT> financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of tangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of current financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of <FONT STYLE="white-space:nowrap">non-current</FONT> financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from (used in) investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,279</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(29,460</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the exercise / subscription of equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in capital, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,222</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>915</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of the exchange rate changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,947</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(76,539</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at the end of the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>152,314</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>99,367</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Change&nbsp;in&nbsp;working&nbsp;capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15<BR>restatements(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variance<BR>excluding&nbsp;IFRS&nbsp;15<BR>restatements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others (excluding rebates related to capital expenditures)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others (excluding payables related to capital expenditures)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities&#151;current and <FONT STYLE="white-space:nowrap">non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue&#151;current and <FONT STYLE="white-space:nowrap">non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total working capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(77,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(138,085</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,584</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,488</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(47,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Change&nbsp;in&nbsp;working&nbsp;capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others (excluding payables related to capital expenditures)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Change in working capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(138,085</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(155,066</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,980</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation in change in financial liability and equity </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash-flows</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT><BR>variations</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(+)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(-)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-current</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BPI France -PTZI IPH41(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing<B>&#151;</B>Property transaction</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing<B>&#151;</B>Property transaction (down-payment)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing<B>&#151;</B>Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing<B>&#151;</B>Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing<B>&#151;</B>Property transaction</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><FONT STYLE="white-space:nowrap">Sub-total(2)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,343</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,348</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,172</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Increase in capital, net</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Subscription of equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><FONT STYLE="white-space:nowrap">Sub-total(3)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>62,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Interests</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><FONT STYLE="white-space:nowrap">Sub-total</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(102</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>62,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest-free loan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 9, &#147;Financial liabilities.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Consolidated statement of changes in shareholders&#146; equity. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_5"></A>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&#146; EQUITY
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro, except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retained<BR>earnings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>comprehensive<BR>income</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net<BR>income<BR>(loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>January&nbsp;1, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,921,304</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>187,571</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(116,235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(503</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>86,169</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of short-term investments and
<FONT STYLE="white-space:nowrap">non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Actuarial gains on defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation gain</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>683</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(47,702</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Allocation of prior period income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise and subscription of equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shares issued for the acquisition of C5aR intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11,&nbsp;1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,607,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,880</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>234,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(103,593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>180</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restatement related to the first application of IFRS&nbsp;9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; <B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restatement related to the first application of IFRS&nbsp;15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>January&nbsp;1, 2018 (after restatement)(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,607,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,880</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>234,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(89,454</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>99,444</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Actuarial losses on defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive income for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,424</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Allocation of prior period loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise and subscription of equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in capital, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,260,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63,939,586</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,197</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>299,932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(137,840</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,099</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_7"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1) The Company, significant agreements description and key events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Innate Pharma S.A. (the &#147;Company&#148; and together with its subsidiaries, referred to as the &#147;Group&#148;) is a biotechnology
company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a 20-year history of research and development in immuno-oncology, having been pioneers in the understanding of natural killer
cell, or NK cell, biology, and later expanding its expertise in the tumor microenvironment, tumor antigens and antibody engineering fields. The Company has built, internally and through its business development strategy, a broad and diversified
portfolio including an approved product, three clinical product candidates and a robust preclinical pipeline. The Company has entered into collaborations with leaders in the biopharmaceutical industry, such as AstraZeneca and Sanofi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From its inception, the Company has incurred losses due to its research and development (&#147;R&amp;D&#148;) activity. The financial year
ended December&nbsp;31, 2018 generated a &#128;3,049&nbsp;thousand net income. As of December&nbsp;31, 2018, the shareholders&#146; equity amounted to &#128;167,240&nbsp;thousand. Subject to potential new milestone payments related to its
collaboration agreements, the Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates in development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s future operations are highly dependent on a combination of factors, including: (i)&nbsp;the success of its R&amp;D;
(ii)&nbsp;regulatory approval and market acceptance of the Company&#146;s future product candidates; (iii)&nbsp;the timely and successful completion of additional financing; and (iv)&nbsp;the development of competitive therapies by other
biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to <FONT STYLE="white-space:nowrap">mid-term,</FONT> to be financed through partnership agreements for the development and commercialization of
its drug candidates and through the issuance of new equity instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s activity is not subject to seasonal
fluctuations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2018, the Company had two wholly owned subsidiaries: Innate Pharma, Inc., incorporated under the laws of
Delaware in 2009, and Innate Pharma France SAS, incorporated under the laws of France in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Innate Pharma, Inc. nor Innate
Pharma France SAS had engaged in any material operations as of December 31, 2018. Both of the Company&#146;s subsidiaries are fully consolidated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
1. Significant contracts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following paragraphs describe the key provisions of significant contracts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a) Agreements related to monalizumab with Novo Nordisk A/S and with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>2014 Novo Nordisk A/S monalizumab agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2014, the Company acquired from Novo Nordisk A/S full development and commercialization rights to monalizumab. Novo Nordisk
A/S received &#128;2.0&nbsp;million in cash and 600,000 ordinary shares at a price of &#128;8.33 per share (&#128;5.0 million). Novo Nordisk A/S is eligible to receive up to &#128;20.0&nbsp;million in potential regulatory milestones and single-digit
tiered royalties on sales of monalizumab products. The agreement with Novo Nordisk A/S included a right to additional consideration in the event of an <FONT STYLE="white-space:nowrap">out-licensing</FONT> agreement. Consequently, following the
agreement signed with AstraZeneca in April 2015 (as described below), the Company paid to Novo Nordisk A/S additional consideration of &#128;6.5&nbsp;million (paid in April 2016). Following the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of the option by AstraZeneca in October 2018 (as described below), Novo Nordisk A/S became entitled to a second and final additional payment amounting to $15.0&nbsp;million (&#128;13.1
million) which was recognized as a liability as of December&nbsp;31, 2018 and was paid in February 2019. There are no other potential additional payments due to Novo Nordisk A/S. These amounts were added to the net book value of the intangible asset
and are amortized according to the same amortization plan as the initial &#128;7.0&nbsp;million recognized in 2014. The net book value of the license amounted to &#128;12.7&nbsp;million as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.g, 2.i and 6 for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>2015 AstraZeneca monalizumab agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under co-development and option agreements signed with AstraZeneca in 2015, the Company granted to AstraZeneca an exclusive license, subject to
certain exclusions, to certain of its patents and know-how to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology diseases and conditions. The Company
further granted to AstraZeneca a worldwide, non-exclusive license to certain of its other patents to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology
diseases and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received an initial payment of $250 million under these agreements in June 2015, of which $100
million was paid to the Company as an initial payment for the co-development agreement and $150 million was paid to the Company as consideration for the option agreement. On October&nbsp;22, 2018, AstraZeneca exercised this option, triggering the
payment of $100.0&nbsp;million, which was received by the Company in January 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the option exercise, AstraZeneca became the
lead party in developing the licensed products and must use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize each licensed product in certain major markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the initial payment and option exercise payment, AstraZeneca is obligated to pay the Company up to $925 million in the
aggregate upon the achievement of certain development and regulatory milestones ($500 million) and commercialization milestones ($425 million). The Company is eligible to receive tiered royalties ranging from a low double-digit to mid-teen
percentage on net sales of licensed products outside of Europe. The Company is required for a defined period of time to co-fund 30% of the Phase III clinical trials of licensed products, subject to an aggregate cap, in order to receive 50% of the
profits in Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company opts out of its co-funding obligations, it would forfeit the option to co-promote licensed products
under the agreement, and its right to share in 50% of such profits would terminate and sales in Europe will instead be factored into net sales used to calculate royalty and milestone payments to it. Additionally, Phase&nbsp;III and regulatory
milestone payments that may be payable to the Company will be reduced and AstraZeneca will be responsible for the promotion of licensed products worldwide, subject to the Company&#146;s option to co-promote the licensed products in certain European
countries. Should the Company elect not to co-promote, its share of profits in Europe will be reduced by a specified amount of percentage points not to exceed the mid-single digits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.a, 2.o and 13.a for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Agreement related to Lumoxiti with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company obtained an exclusive license from AstraZeneca under certain patents and know-how of AstraZeneca to develop,
manufacture and commercialize Lumoxiti for all uses in humans and animals in the United States, the European Union and Switzerland. Under this Agreement, AstraZeneca is obligated to provide support for the continued development and commercialization
of Lumoxiti in the European Union and Switzerland prior to regulatory submission and approval as well as support for the continued </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization of Lumoxiti in the United States for a specified period. The Company is scheduled to transition to full commercialization responsibilities by mid-2020. Under the agreement, the
Company was obligated to pay a $50.0 million initial payment (&#128;43.8 million), which it paid in January 2019, and is obligated to pay conditional payments up to $25.0 million in the aggregate upon the achievement of certain commercial and
regulatory milestones. The Company will reimburse AstraZeneca for the development, production and commercialization costs it incurs during the transition period, subject to certain limitations for the year ending December 31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.p and 15 for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>c) Agreement related to IPH5201 with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company signed a collaboration and option agreement with AstraZeneca for co-development and co-commercialization of
IPH5201. Under the agreement, AstraZeneca paid the Company a $50.0 million upfront payment ($26.0 million paid in October 2018 and $24.0 million paid in January 2019), and is obligated to pay the Company up to an aggregate of $10.0 million upon the
achievement of certain development milestones. Upon exercise of its option under the agreement, AstraZeneca is committed to pay an option exercise fee of $25.0 million and up to $800.0 million in the aggregate upon the achievement of certain
development and regulatory milestones ($300 million) and commercialization milestones ($500 million). The arrangement also provides for a 50% profit share in Europe if the Company does not opt out of co-promoting and late stage co-funding
obligations. In addition, we would be eligible to receive tiered royalties ranging from a high-single digit to mid-teen percentage on net sales of IPH5201, or from a mid-single digit to low-double digit percentage on net sales of other types of
licensed products, outside of Europe. The royalties payable to us under the agreement may be reduced under certain circumstances, including loss of exclusivity or lack of patent protection. The Company recognized &#128;15.6 million as revenue from
proceeds related to this agreement for the year ended December 31, 2018, and was also reimbursed by AstraZeneca for certain research and development expenses related to IPH5201. The Company has the option to co-fund 30% of the shared development
expenses related to the Phase III clinical trials in order to acquire co-promotion rights and to share in 50% of the profits and losses of licensed products in Europe. If the Company opts out of its co-funding obligations, among other things, its
right to share in 50% of the profits and losses in Europe and right to co-promote in certain European countries will terminate and will be replaced by rights to receive royalties on net sales at the rates applicable to outside of Europe.
Additionally, certain milestone payments that may be payable to the Company would be materially reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.o and 13.b for
accounting description. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>d) Agreement related to additional preclinical molecules with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company granted to AstraZeneca four exclusive options that are exercisable until IND approval to obtain a worldwide,
royalty-bearing, exclusive license to certain of the Company&#146;s patents and know-how relating to certain specified pipeline candidates to develop and commercialize optioned products in all fields of use. Pursuant to the agreement, AstraZeneca
paid the Company a $20.0 million upfront payment (&#128;17.5&nbsp;million) in October 2018. The Company recognizes this upfront payment in the consolidated statement of financial position as deferred revenue as of December 31, 2018, until the
exercise or the termination of each option at the earliest. Upon exercise of an option, the Company would be entitled to an option exercise payment of $35 million, as well as development and regulatory milestone payments ($320 million) and
commercialization milestone payments ($500&nbsp;million) and tiered, mid-single digit to mid-teen percentage royalties on net sales of the applicable product. The royalties payable to the Company may be reduced under certain circumstances, including
loss of exclusivity, lack of patent protection or the specific nature of the compound included within the applicable product. Additionally, the Company would have rights to co-fund certain development costs in order to obtain profit and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
loss sharing in Europe. So long as the Company elects to co-fund such development costs, it will have a right to co-promote optioned products in Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.o and 13.c for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>e) Agreements related to IPH5401 with Novo Nordisk and with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>2017 IPH5401 <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement with Novo Nordisk A/S </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, the Company signed an exclusive license agreement with Novo Nordisk A/S relating to IPH5401. Under the agreement, Novo Nordisk
A/S granted the Company a worldwide, exclusive license to develop, manufacture and commercialize pharmaceutical products that contain or comprise an anti-C5aR antibody, including IPH5401. The Company made an upfront payment of &#128;40.0 million,
&#128;37.2 million of which was contributed in new shares and &#128;2.8 million of which in cash. The Company is obligated to pay up to an aggregate of &#128;370.0 million upon the achievement of development, regulatory and sales milestones and
tiered royalties ranging from a low double-digit to low-teen percentage of net sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.g, 2.i and 6 for accounting
description. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>2018 IPH5401 AstraZeneca agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 1, 2018, the Company entered into a clinical trial collaboration agreement with AstraZeneca to sponsor a Phase I/II clinical trial
(STELLAR-001) to evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with IPH5401, as a treatment for patients with select solid tumors. The Company is the sponsor of the trial and the costs are
equally shared between the two partners. This collaboration is a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> agreement and does not include any licensing rights on IPH5401 to AstraZeneca. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.o and 13.d for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.2 Key events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a) Key events for
the year ended December&nbsp;31, 2018 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2018, AstraZeneca exercised its option related to
monalizumab. See the description of the agreement related to monalizumab with AstraZeneca as presented in Note 1.1.a. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
several agreements were signed during the year with AstraZeneca. See the description of the agreement related to Lumoxiti, agreement related to IPH5201, agreement related to additional preclinical molecules and agreement related to IPH5401 as
presented in Note 1.1.b, Note 1.1.c, Note 1.1.d and Note 1.1.e, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;22, 2018, AstraZeneca acquired 9.8% of the
capital of the Company through the issuance by the Company of 6,260,500 new ordinary shares for a total amount of &#128;62,605&nbsp;thousand, with a nominal value of &#128;0.05 per share and an issue price of &#128;10.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This issuance was contingent upon, and concurrent with, the execution of the agreements described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Key events for the year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See 2017 IPH5401 <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement with Novo Nordisk A/S in Note 1.1.c. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February 6, 2017, the Company announced top-line results from the Effikir trial evaluating the efficacy of lirilumab as a single agent in
elderly patients with acute myeloid leukemia. The trial did not meet the primary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efficacy endpoint but confirms the tolerance profile of lirilumab as a monotherapy. On November 22, 2017, the Company published an update on the clinical study program of lirilumab, stating that
while lirilumab was shown to be well-tolerated, the assessment of efficacy from the ongoing exploration of doublet combinations did not provide clear evidence of benefit to patients or an obvious development path. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;3, 2017, the Company entered into a loan agreement with Soci&eacute;t&eacute; G&eacute;n&eacute;rale in order to finance the
construction of its planned future headquarters. The loan, amounting to a maximum of &#128;15.2&nbsp;million, will be drawn upon during the period of the construction in order to make payments to suppliers as they become due. This period during
which the Company may draw funds ends on August&nbsp;30, 2019. The repayment of the loan will occur beginning on August 30, 2019 and for a period of 12 years thereafter. In connection with this loan, the Company authorized collateral of its
financial Soci&eacute;t&eacute; G&eacute;n&eacute;rale instruments amounting to &#128;15.2&nbsp;million. The security interest on the pledge of financial instruments will be released in accordance with the following schedule: &#128;4.2&nbsp;million
in July 2024, &#128;5.0&nbsp;million in July 2027 and &#128;6.0&nbsp;million in July 2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not yet begun this
construction. Until construction begins, the proceeds of the loan will be used to finance several projects (e.g., extension of the current building, improvement of the Company&#146;s information systems and development of a commercial
infrastructure). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2) Accounting policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a) Basis of preparation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union&#146;s regulation
No.&nbsp;1606/2002 of July&nbsp;19, 2002, the consolidated financial statements of the Company for the years ended December&nbsp;31, 2018 and 2017 (the &#147;Consolidated Financial Statements&#148;) have been prepared in accordance with both
International Financial Reporting Standards (&#147;IFRS&#148;) as issued by the International Accounting Standard Board (&#147;IASB&#148;) and IFRS as approved by the European Union (&#147;EU&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comparative figures are presented as of and for the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS includes International Financial Reporting Standards, International Accounting Standards (the &#147;IAS&#148;) and the interpretations
issued by the Standing Interpretations Committee (the &#147;SIC&#148;) and the International Financial Reporting Interpretations Committee (&#147;IFRIC&#148;). The main accounting methods used to prepare the Consolidated Financial Statements are
described below. These methods were used for the two years presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Consolidated Financial Statements have been prepared under the
historical cost convention, with the exception of certain asset and liability categories and in accordance with the provisions set forth in IFRS such as employee benefits measured using the projected unit credit method, borrowings measured at
amortized cost and derivative financial instruments measured at fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumption of going concern was used given the
Company&#146;s financial position and liquidity to meet its financing needs for the 12 months following December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that are detailed in Note 2.v. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for share data and per share amounts, the Consolidated Financial Statements are presented in thousands of euro. Amounts are rounded up
or down to the nearest whole number for the calculation of certain financial data and other information contained in these accounts. Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Adoption of IFRS 15 </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS 15 <I>Revenue from contracts with customers</I>, or IFRS 15, which supersedes IAS 11 <I>Construction contracts</I>, or IAS 11, and IAS 18
<I>Revenue</I>, or IAS 18, came into effect on January&nbsp;1, 2018. The amended accounting policy applied to revenue is presented in Note 2.o. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company decided to apply the modified retrospective approach without any of the practical expedients allowed by IFRS 15. According to this
approach, the comparative information is not restated and the cumulative impact of the first application is presented as an adjustment of the opening equity of the year of first application. The modified retrospective approach does not present
comparative information, but requires a comparison for the first application year of each financial statement line item affected by the application of this standard as compared to IAS 11, IAS 18 and related interpretations that were in effect before
the change. This comparison is presented below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of the adoption of IFRS 15 is limited to the accounting treatment of the
contributions paid by the Company pursuant to its <FONT STYLE="white-space:nowrap">co-financing</FONT> under the collaboration agreement with AstraZeneca related to monalizumab. Until December&nbsp;31, 2017, under IAS 18, the Company&#146;s <FONT
STYLE="white-space:nowrap">co-financing</FONT> share of R&amp;D expenses incurred by AstraZeneca were recognized as R&amp;D expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the context of the collaboration agreement with AstraZeneca, the Company and AstraZeneca make quarterly-cost sharing payments to one another to ensure that each party <FONT STYLE="white-space:nowrap">co-finances</FONT> the R&amp;D performed by
AstraZeneca. Consequently, under IFRS 15, amounts due to the partner: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Are no longer recognized as R&amp;D expenses, but are recorded as a reduction of the transaction price recorded
as revenue following the identified performance obligation under the collaboration agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Are classified in collaboration liability in the consolidated statement of financial position (instead of a
classification in deferred revenue under IAS 18). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a collaboration liability is denominated in a foreign currency,
which is the case in the context of this AstraZeneca agreement, it is translated at each reporting date with the appropriate exchange rate, resulting in foreign exchange gains or losses recorded in the consolidated statement of income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application of IFRS 15 generated a deferred tax liability of &#128;3,098&nbsp;thousand as of January&nbsp;1, 2018. The Company recorded a
deferred tax asset equaling the amount of deferred tax liability as of January&nbsp;1, 2018 as a result of tax losses carryforward. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of the first adoption of IFRS 15 on the statement of financial position as of
January&nbsp;1, 2018 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B><br><B>as&nbsp;published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15<BR>restatement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2018</B><br><B>restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>137,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>137,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>117,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>120,599</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>258,121</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,909</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,556</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>68,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred <FONT STYLE="white-space:nowrap">revenue&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>95,158</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,834</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>90,324</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,595</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,488</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>99,444</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>258,121</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the tables below provide a comparison between the published Consolidated
Financial Statements and the figures as they would have been had the Company continued to apply IAS 18 during the 2018 financial year: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31,<BR>2018</B><br><B>as&nbsp;published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15&nbsp;impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31,<BR>2018,&nbsp;excluding<BR>IFRS&nbsp;15&nbsp;impacts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>319,643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>319,643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>131,574</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>130,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>451,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>449,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,987</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>196,095</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>204,945</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred <FONT STYLE="white-space:nowrap">revenue&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>87,890</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,272</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,139</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>161,101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>451,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>449,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,&nbsp;2018</B><br><B>as&nbsp;published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15<BR>impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,&nbsp;2018,</B><br><B>excluding&nbsp;IFRS&nbsp;15<BR>impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114,985</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(15,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(103,293</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,637</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(569</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,349</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,067</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,349</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in &#128; per share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Adoption of IFRS 9 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS 9 <I>Financial instruments</I>, or IFRS 9, which supersedes IAS 39 <I>Financial instruments: recognition and measurement</I>, or IAS 39,
came into effect on January&nbsp;1, 2018. IFRS 9 defines new principles covering the classification and measurement of financial instruments, the recognition of impairment provisions for credit risk on financial assets and hedge accounting. The
Company has applied IFRS 9 as of January&nbsp;1, 2018 by recording the cumulative impact in opening equity at this transition date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regarding financial instruments, IFRS 9 requires, for <FONT STYLE="white-space:nowrap">non-derivative</FONT> financial assets, a change of
name of the <FONT STYLE="white-space:nowrap">sub-categories</FONT> of financial assets without, however, modifying the valuation principles of these assets, which remain either at fair value or amortized cost. The valuation models used by the
Company remain unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The modification of the depreciation principles for financial assets measured at amortized cost, which now
consists of adopting an approach based on expected losses, in practice has resulted in the Company not recognizing impairment and mainly impacts trade receivables, which were nil as of January&nbsp;1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The only impact of IFRS 9 on the financial statements of the Company concerns the recognition of the variance in fair value of the mutual
funds. Under IAS 39, the variance in fair value of these financial assets was recognized in other comprehensive income. Under IFRS 9, it will be recognized in the statement of income. Following the application of the standard, the impact on the
opening statement of financial position is a reclassification from the cumulated comprehensive income to retained earnings in an amount of &#128;653&nbsp;thousand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amended accounting policy applied to financial instruments is presented in Note 2.f. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Recently issued accounting standards and interpretations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recently issued standards and interpretations whose application is mandatory as of January&nbsp;1, 2018 are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRS 9, which supersedes IAS 39; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRS 15, which supersedes IAS 11, IAS 18 and the corresponding interpretations (IFRIC 13, IFRIC 15, IFRIC 18 and
SIC 31). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New standards, amendments to existing standards and subsequent interpretations have been published but are not
applicable in 2018. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRS 16<I> Leases</I>, or IFRS 16, mandatory for financial years beginning on or after January&nbsp;1, 2019. IFRS
16 replaces the IAS 17 <I>Leases</I>, or IAS 17, and the corresponding interpretations (IFRIC 4, SIC 15 and SIC 27); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRIC 23 <I>Uncertainty over income tax treatments</I>, mandatory for financial years beginning on or after
January&nbsp;1, 2019. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not early adopted the new accounting standards, amendments and interpretations.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>IFRS 16 </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS 16 was issued in January 2016 and replaces IAS 17, IFRIC 4 Determining whether an Arrangement contains a Lease, <FONT
STYLE="white-space:nowrap">SIC-15</FONT> Operating Leases-Incentives and <FONT STYLE="white-space:nowrap">SIC-27</FONT> Evaluating the Substance of Transactions Involving the Legal Form of a Lease. IFRS 16 sets out the principles for the
recognition, measurement, presentation and disclosure of leases and requires lessees to account for all leases under a single <FONT STYLE="white-space:nowrap">on-balance</FONT> sheet model similar to the accounting for finance leases under IAS 17.
The standard includes two recognition exemptions for lessees&#151;leases of <FONT STYLE="white-space:nowrap">&#147;low-value&#148;</FONT> assets (e.g., personal computers) and short-term leases (i.e., leases with a lease term of 12 months or less).
At the commencement date of a lease, a lessee recognizes a liability to make lease payments (i.e., the lease liability) and an asset representing the right to use the underlying asset during the lease term (i.e., the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset). Lessees are required to separately recognize the interest expense on the lease liability and the depreciation expense on the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset. The change in presentation of operating lease expenses results in a corresponding increase in cash flows from operating activities and a decrease in cash
flows from financing activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the new standard, the Company determined the lease term including any lessee&#146;s
extension or termination option that is deemed reasonably certain. The assessment of such options was performed at the commencement of a lease and required judgment by the management. Measuring the lease liability at the present value of the
remaining lease payments required using an appropriate discount rate in accordance with IFRS 16. The discount rate is the interest rate implicit in the lease or if that cannot be determined, the incremental borrowing rate at the date of the lease
commencement. The incremental borrowing rate can have a significant impact on the net present value of the <FONT STYLE="white-space:nowrap">right-of</FONT> use asset and lease liability recognized and requires judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lessees remeasure the lease liability upon the occurrence of certain events (e.g., a change in the lease term, a change in future lease
payments resulting from a change in an index or rate used to determine those payments). The lessee generally recognizes the amount of the remeasurement of the lease liability as an adjustment to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Progress of work to estimate the impacts of IFRS 16 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has carried out an analysis of the impacts of IFRS 16. The contracts impacted by this new standard mainly relate to the rental of
premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the transition method, the Company will opt for the modified retrospective
approach to contracts previously reported as leases under IAS 17 or IFRIC 4, and, therefore, will only recognize leases on the balance sheet as of January&nbsp;1, 2019. Accordingly, comparative information will not be restated and the cumulative
effect of initially applying IFRS 16 will be presented as an adjustment to opening reserves. As of January&nbsp;1, 2019, the right-of-use will be recognized as assets for their net value (as if IFRS 16 had always been applied) and the present value
of the remaining payments will be recognized as a liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the following practical expedients as allowed by IFRS
16: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">apply a single discount rate to assets with similar characteristics; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">elect to use the exemption proposed by standard on lease contracts for which the lease terms end within 12 months
as of the date of initial application; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not recognize leases whose term ends within 12 months of the date of initial application. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company excludes initial direct costs from the measurement of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets at the date of initial application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates that the effect on the opening consolidated statement of financial position as of January&nbsp;1, 2019 to be between
&#128;600&nbsp;thousand and &#128;900&nbsp;thousand resulting from the recognition of the lease obligation and the right of use associated with leases contracts. The effect on equity as of January&nbsp;1, 2019 is not expected to be material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>c) Change in accounting policies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for the adoption of IFRS 9 and IFRS 15 as of January&nbsp;1, 2018, there has been no change in accounting policies for any of the years
presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>d) Translation of transactions denominated in foreign currency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to IAS 21 <I>The effects of changes in foreign exchange rates</I>, transactions performed by consolidated entities in currencies other
than their functional currency are translated at the prevailing exchange rate on the transaction date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade receivables and payables and
liabilities denominated in a currency other than the functional currency are translated at the <FONT STYLE="white-space:nowrap">period-end</FONT> exchange rate. Unrealized gains and losses arising from translation are recognized in net operating
income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign exchange gains and losses arising from the translation of inter-Group transactions or receivables or payables denominated
in currencies other than the functional currency of the entity are recognized in the line &#147;net financial income (loss)&#148; of the consolidated statements of income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign currency transactions are translated into the presentation currency using the following exchange rates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>&#128;1&nbsp;EQUALS&nbsp;TO</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPENING<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AVERAGE<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CLOSING<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AVERAGE<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CLOSING<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>USD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>e) Consolidation method </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Group applies IFRS 10 <I>Consolidated financial statements</I>, or IFRS 10. IFRS 10 presents a single consolidation model identifying
control as the criteria for consolidating an entity. An investor controls an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investee if it has the power over the entity, is exposed or has rights to variable returns from its involvement with the entity and has the ability to use its power over the entity to affect the
amount of the investor&#146;s returns. Subsidiaries are entities over which the Company exercises control. They are fully consolidated from the date the Group obtains control and are deconsolidated from the date the Group ceases to exercise control.
Intercompany balances and transactions are eliminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>f) Financial instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Financial assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets are initially measured at fair value plus directly attributable transaction costs in the case of instruments not measured at
fair value through profit or loss. Directly attributable transaction costs of financial assets measured at fair value through profit or loss are recorded in the consolidated statement of income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under IFRS 9, financial assets are classified in the following three categories: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial assets at amortized cost; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial assets at fair value through other comprehensive income (&#147;FVOCI&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial assets at fair value through profit or loss. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The classification of financial assets depends on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The characteristics of the contractual cash flows of the financial assets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The business model that the entity follows for the management of the financial asset. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financial assets at amortized cost </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets are measured at amortized cost when (i)&nbsp;they are not designated as financial assets at fair value through profit or loss,
(ii)&nbsp;they are held within a business model whose objective is to hold assets in order to collect contractual cash flows and (iii)&nbsp;they give rise to cash flows that are solely payments of principal and interest on the principal amount
outstanding (&#147;SPPI&#148; criterion). They are subsequently measured at amortized cost, determined using the effective interest method (&#147;EIR&#148;), less any expected impairment losses in relation to the credit risk. Interest income,
exchange gains and losses, impairment losses and gains and losses arising on derecognition are all recorded in the consolidated statement of income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This category primarily includes trade receivables, as well as other loans and receivables. Long-term loans and receivables that are not
interest-bearing or that bear interest at a below-market rate are discounted when the amounts involved are material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financial assets
at fair value through other comprehensive income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets at fair value through other comprehensive income is mainly comprised
is composed of debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair
value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for
the period within the line items Financial income or Financial expenses. The Company did not hold this type of instrument as of January&nbsp;1, 2018 or as of December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financial assets at fair value through profit or loss </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets at fair value through profit or loss is comprised of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instruments whose contractual cash flows represent payments of interest or repayments of principal, but which are
managed other than with a view to collecting cash flows and/or selling the asset; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instruments that management has designated as &#147;fair value through profit or loss&#148; on initial
recognition. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gains and losses arising from changes in fair value are recognized in profit or loss within the line items
financial income or financial expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Impairment of financial assets measured at amortized cost </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main assets involved are trade receivables and others. Trade receivables are recognized when the Company has an unconditional right to
payment by the customer. Impairment losses on trade receivables and others are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is
estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are
indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a
reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within Operating expenses in the consolidated statement of income (loss). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Financial liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial liabilities comprise deferred revenue, collaboration liabilities, loans and trade and other payables. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial liabilities are initially recognized on the transaction date, which is the date that the Company becomes a party to the contractual
provisions of the instrument. They are derecognized when the Company&#146;s contractual obligations are discharged, cancelled or expire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loans are initially measured at fair value of the consideration received, net of directly attributable transaction costs. Subsequently, they
are measured at amortized cost using the EIR method. All costs related to the issuance of loans, and all differences between the issuance proceeds net of transaction costs and the value on redemption, are recognized within financial expenses in the
consolidated statement of income (loss) over the term of the debt using the EIR method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other financial liabilities include trade
accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash equivalents are short-term, highly liquid investments, that are readily convertible to known amounts of cash and which are subject to an
insignificant risk of changes in value. Cash and cash equivalents comprise the cash that is held at the bank and petty cash as well as the short-term fixed deposits for which the maturity is less than three months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of establishing the statement of cash flows, cash and cash equivalents include cash in hand, demand deposits and short
fixed-term deposits with banks and short-term highly liquid investments with original maturities of three months or less, net of bank overdrafts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents are initially recognized at their purchase costs on the transaction date, and are subsequently measured at fair
value. Changes in fair value are recognized in profit or loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Fair value of financial instruments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under IFRS 13 <I>Fair value measurement</I> and IFRS 7 <I>Financial instruments: disclosures</I>, or IFRS 7, fair value measurements must be
classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 2: fair value calculated using valuation techniques based on observable market data such as prices of
similar assets and liabilities or parameters quoted in an active market; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 3: fair value calculated using valuation techniques based wholly or partly on unobservable inputs such as
prices in an inactive market or a valuation based on multiples for unlisted securities. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>g) Intangible assets
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Research and development (R&amp;D) expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with IAS 38 <I>Intangible assets</I>, or IAS 38, expenses on research activities are recognized as an expense in the period in
which it is incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An internally generated intangible asset arising from the Company&#146;s development activities is recognized only
if all of the following conditions are met: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Technically feasible to complete the intangible asset so that it will be available for use or sale;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company has the intention to complete the intangible assets and use or sell it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company has the ability to use or sell the intangible assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The intangible asset will generate probable future economic benefits, or indicate the existence of a market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adequate technical, financial and other resources to complete the development are available; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company is able to measure reliably the expenditure attributable to the intangible asset during its
development. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the risks and uncertainties related to regulatory approval, the R&amp;D process and the
availability of technical, financial and human resources necessary to complete the development phases of the product candidates, the six criteria for capitalization are usually considered not to have been met until the product candidate has obtained
marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within Research
and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule
that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an intangible asset. These related costs are
capitalized when they are incurred and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments for
separately acquired research and development are capitalized within &#147;Other intangible assets&#148; provided that they meet the definition of an intangible asset: a resource that is (i)&nbsp;controlled by the Group, (ii)&nbsp;expected to provide
future economic benefits for the Group and (iii)&nbsp;identifiable (i.e. it is either separable or arises from contractual or legal rights). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with paragraph 25 of IAS 38, the first recognition criterion, relating to the
likelihood of future economic benefits generated by the intangible asset, is presumed to be achieved for research and development activities when they are acquired separately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this context, amounts paid to third parties in the form of initial payments or milestone payments relating to product candidates that have
not yet obtained a regulatory approval are recognized as intangible assets. These rights are amortized on a straight-line basis: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">after obtaining the regulatory approval, over their useful life; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">after entering in an <FONT STYLE="white-space:nowrap">out-license</FONT> collaboration agreement with a third-party partner, over their estimated useful life. This estimated useful life takes into consideration the
period of protection of the <FONT STYLE="white-space:nowrap">out-licensed</FONT> exclusivity rights and the anticipated period over which the Company will receive the economic benefits of the asset. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unamortized rights (before marketing authorization) are subject to impairment tests in accordance with the method defined in Note 5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When intangible assets acquired separately are acquired through variable or conditional payments, these payments are recognized as an increase
of the carrying amount of the intangible asset when they become due. Royalties due by the Company related to acquired licenses are recognized as operating expenses when the Company recognizes sales subject to royalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Other intangible assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other intangible assets consist of acquired software. Costs related to the acquisition of software licenses are recognized as assets based on
the costs incurred to acquire and set up the related software. Software is amortized using the straight-line method over a period of one to three years depending on the anticipated period of use. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>h) Property and equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are carried at acquisition cost. Major renewals and improvements are capitalized while repairs and maintenance are
expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are depreciated over their estimated useful lives using the straight-line depreciation
method. Leasehold improvements are depreciated over the life of the improvement or the remaining lease term, whichever is shorter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
headquarters of the Company was split into several components (e.g., foundations, structure, electricity, heating and ventilation systems) which are depreciated over different useful lives according to the anticipated useful life of these elements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation periods are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings&nbsp;and&nbsp;improvements&nbsp;on&nbsp;buildings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20&nbsp;to&nbsp;40&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Installations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 to 20 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technical installations and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment and office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and IT equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>i) Impairment of intangible assets, property, and equipment, </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Group assesses at the end of each reporting period whether there is an indication that intangible assets, property and equipment may be
impaired. If any indication exists, the Group estimates the recoverable amount of the related asset. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not there is any indication of impairment, intangible assets not yet available
for use are tested for impairment annually by comparing their carrying amount with their recoverable amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to IAS
36&#151;<I>Impairment of Assets</I>, criteria for assessing indication of loss in value may notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or obsolescence or physical damage
of the asset not included in the amortization/depreciation schedule. The recognition of an impairment loss alters the amortizable/depreciable amount and potentially, the amortization/depreciation schedule of the relevant asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairment losses on intangible assets, property and equipment shall be reversed subsequently if the impairment loss no longer exists or has
decreased. In such case, the recoverable amount of the asset is to be determined again so that the reversal can be quantified. The asset value after reversal of the impairment loss may not exceed the carrying amount net of depreciation/amortization
that would have been recognized if no impairment loss had been recognized in prior periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Group does not have any intangible assets
with an indefinite useful life. However, as explained in Note 2.g, the Group recognized intangible assets in progress, which will be amortized once marketing authorization is received. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>j) Employee benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Long-term pension benefits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Company employees are entitled to pension benefits required by French law: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pension benefit, paid by the Company upon retirement (i.e. defined benefit plan); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pension payments from social security entities, financed by contributions from businesses and employees (i.e.
defined contribution plan&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company has implemented an additional, <FONT
STYLE="white-space:nowrap">non-mandatory,</FONT> pension plan (&#147;Article 83&#148;), initially for the benefit of executives only. This plan was extended to the <FONT STYLE="white-space:nowrap">non-executive</FONT> employees starting on
January&nbsp;1, 2014. This plan meets the definition of defined contribution plan and is financed through a contribution that corresponds to 2.2% of the employee&#146;s annual wage, with the Company paying 1.4% and the employee paying 0.8%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the defined benefit plan, the costs of the pension benefit are estimated using the &#147;projected unit credit&#148; method. According to
this method, the pension cost is accounted for in the consolidated statement of income (loss), so that it is distributed uniformly over the term of the services of the employees. The pension benefit commitments are valued using the actual present
value of estimated future payments, adopting the rate of interest of long-term bonds in the private sector (i.e. Euro zone AA or higher rated corporate bonds + 10 years). The difference between the amount of the provision at the beginning of a
period and at the close of that period is recognized in the consolidated statement of income (loss) for the portion representing the costs of services rendered and the net interest costs, and through other comprehensive income for the portion
representing the actuarial gains and losses. The Company&#146;s commitments under the defined benefit plan are not covered by any plan assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made by the Company for defined contribution plans are accounted for as expenses in the consolidated statement of income (loss) in
the period in which they are incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Other long-term benefits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company pays seniority bonuses to employees reaching 10, 15 and 20 years of seniority. These bonuses represent long-term employee benefits.
Under IAS 19R &#147;Employee benefits&#148;, they are recording as a defined benefit obligation in the consolidated statement of financial position, but their remeasurements is not recognized in the consolidated statement of other comprehensive
income (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Other short-term benefits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An accrued expense is recorded for the amount the Company expects to pay its eligible employees in relation to services rendered during the
reporting period (actual legal or implicit obligation to make to these payments on a short-term basis). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>k) Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Finance leases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leases of
property and equipment where the Company has substantially all the risks and rewards of ownership are classified as finance lease arrangements under IAS 17&#151;Leases. Property and equipment acquired under finance-leases are capitalized at the
inception of the lease at the lower of the fair value of the leased property or the present value of the minimum lease payments. Each lease payment is divided between principal repayment and interest expense so as to achieve a constant rate on the
outstanding amount due. The corresponding rental obligations, net of interest expenses, are classified as financial liabilities in the consolidated statements of financial position. Property and equipment acquired under finance leases are
depreciated over the useful life of the asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Operating leases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leases where a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating lease
arrangements under IAS 17. Payments made under operating-leases, net of any incentives received from the lessor, are recognized as expenses on the consolidated statements of income (loss) on a straight-line basis over the period of the lease. When a
lease contract includes rent-free periods or when the paid rents are not equal on the contract duration, the minimum payments are deferred on a straight-line basis over the leasing period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>l) Provisions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the course of its business, the Company could be exposed to certain risks and litigations, notably in relation to contractual arrangements. Provisions are recognized when the Company has a present legal or constructive obligation as a result of past
events, it is probable that the Company is subject to a release of outflow representatives of economic benefits to settle the obligation and a reliable estimate of the amount of the obligation can be made. Management of the Company estimates the
probability and the expected amount of a cash outflow associated with risks, together with the other information to be provided on possible liabilities. Where the Company expects a provision to be reimbursed, for example under an insurance contract,
the reimbursement is recognized as a separate asset but only when the reimbursement is certain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>m) Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinary shares are classified in shareholders&#146; equity. Costs associated with the issuance of new shares are directly accounted for in
shareholders&#146; equity in diminution of issuance premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s own shares bought in the context of a brokering/liquidity
agreement are presented as a reduction in shareholders&#146; equity until their cancellation, their reissuance or their disposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>n) Share-based compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its inception, the Company has established several plans for compensation paid in equity instruments in the form of free shares
(&#147;<I>Attributions gratuites d&#146;actions</I>,&#148; or &#147;AGA&#148;), free preferred shares convertible into ordinary shares (&#147;<I>Attributions gratuites d&#146;actions de pr&eacute;f&eacute;rence convertibles en actions
ordinaires</I>,&#148; or &#147;AGAP&#148;), free performance shares (&#147;<I>Attributions gratuites d&#146;actions de performance</I><I></I>,&#148; or &#147;AGA Perf&#148;), share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subscription warrants (&#147;<I>Bons de souscription d&#146;actions</I>,&#148; or &#147;BSA&#148;), redeemable share subscription warrants (&#147;<I>Bons de Souscription et/ou d&#146;Acquisition
d&#146;Actions Remboursables</I>,&#148; or &#147;BSAAR&#148;), granted to its employees, executives, members of the Executive Board and scientific consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to IFRS 2&#151;<I>Share-based Payment, </I>these awards are measured at their fair value on the date of grant. The fair value is
calculated with the most relevant formula regarding the conditions and the settlement of each plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For share-based compensation granted
to employees, executives, members of the Executive Board and scientific consultants, the Company uses the Black-Scholes and Monte Carlo approach pricing models to determine the fair value of the share-based compensation. For scientific consultants
providing similar services, as the Company cannot estimate reliably the fair value of the goods or services received, it measures the value of share-based compensation and the corresponding increase in equity, indirectly, by reference to the fair
value of the equity instruments granted also using the Black-Scholes option pricing model. The fair value of free shares included in the model is determined using the value of the shares at the time of their distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In calculating the fair value of share-based compensation, the Company also considers the vesting period and the employee turnover weighted
average probability as described in Note 14. Other assumptions used are also detailed in Note 14. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the fair value
of these awards as a share-based compensation expense over the period in which the related services are received with a corresponding increase in shareholders&#146; equity. Share-based compensation is recognized using the straight-line method. The
share compensation expense is based on awards ultimately expected to vest and is reduced by expected forfeitures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>o) Revenue
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Revenue from collaboration and license agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the Company&#146;s revenue results primarily from payments received in relation to research, collaboration and licensing agreements
signed with pharmaceutical companies. These contracts generally provide for components such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payments upon signature; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments for the exercise of the option to acquire licenses of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">milestones payments triggered following stages of development (scientific results obtained by the Company or by
the partner, obtaining regulatory marketing approvals); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments related to the Company&#146;s R&amp;D activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments triggered by the start of the commercialization of products resulting from development work or by
crossing cumulative thresholds of product sales, as well as the allocation of royalties on future sales of products or a sharing of profits on sales. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under collaboration and license agreements, the Company may promise its partners licenses on intellectual property, as well as research and
development services. According to IFRS 15, the Company has to determine if the promises included in the contract are distinct (therefore recognized separately as revenue) or if they have to be combined as a single performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When promises in a collaboration and license agreement are considered as a single performance obligation, the Company has to determine if the
combined performance obligation is satisfied over time or at point in time. If the combined performance obligation is satisfied over time, revenue recognition is based on the percentage of completion of the costs to be incurred. <FONT
STYLE="white-space:nowrap">Non-refundable</FONT> initial payments are deferred and recognized as revenue during the period the Company is engaged to deliver services to the customer on the basis of the corresponding costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When promises in a collaboration and license agreement are considered as separate
performance obligations, revenue is allocated to each obligation proportionally to its transaction price, which corresponds to a price each performance obligation would have been sold in the context of a separate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with IFRS 15, variable considerations cannot be included in the estimated transaction price as long as it not highly probable
that the related revenue will not reversed in the future. According to the level of uncertainty relating to the results of preclinical and clinical trials and the decisions relating to the regulatory approvals, variable considerations depending on
these events are excluded from the transaction price as long as the trigger event is not highly probable. When the trigger event occurs, the corresponding milestone is added to the transaction price. Such adjustments are recorded on a cumulative <FONT
STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and net income (loss) in the period of adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues
based on royalties, completion of commercialization steps or <FONT STYLE="white-space:nowrap">co-sharing</FONT> profit from sales are recognized when the corresponding sales of products are carried out by the partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a collaboration contract grants a partner an option to acquire a licensed intellectual property (&#147;IP&#148;), the Company determines
the date of the transfer of control over the licensed IP. Depending on the Company analysis, revenue related to the option fee will be recognized (i)&nbsp;when control over the licensed IP transfers (payment related to the exercise of the option
being therefore considered as a variable consideration), or, (ii)&nbsp;deferred until the exercise of the option or its expiration period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When an agreement only promises development services, the Company will recognize the related revenue when the costs are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Up-front</FONT> and milestones payments and fees are recorded as deferred revenue upon receipt or when due,
and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts due by the Company in relation to cost-sharing are recorded as collaboration liability. Amounts payable
to the Company are recorded as accounts receivable when the Company&#146;s right to consideration is unconditional. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 13 for
accounting description of significant agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>p) Net income (expenses) from distribution agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When product sales are made by a partner in the context of collaboration or transition agreements, the Company must determine if the partner
acts as an agent or a principal. A party is recognized as a principal when it has the ability to conduct the use of the products and to obtain all the residual economic benefits previously to the transfer of the control of the products to the
customers. If the Company is a principal, sales are recognized as revenue. If the Company is an agent, it recognizes as a gain or a loss, the part of the revenue it is entitled to, which is the case under the agreement with AstraZeneca in relation
to Lumoxiti (see Note&nbsp;15). Therefore, income (loss) under the agreement are recognized in the statement of income (loss) on the line item &#147;Net income (loss) from distribution agreements&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>q) Government financing for research expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Research tax credit </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
research tax credit (<I>Cr&eacute;dit d</I><I></I><I>&#146;Imp&ocirc;t Recherche</I>) (the &#147;Research Tax Credit&#148; or &#147;CIR&#148;) granted by the French tax authorities in order to encourage Companies to conduct technical and scientific
research. Companies that can justify that these expenses meet the required criteria receive such grants in the form of a refundable tax credit that can be used for the payment of taxes due for the period in which the expense was incurred and for the
next three years. These grants are presented under other income, in &#147;government financing for research expenditures&#148; line item in the consolidated statements of income (loss) , as soon as these eligible expenses were conducted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has benefited from a Research Tax Credit since its inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received the reimbursement of the Research Tax Credit for the year 2017 during the year 2018. It has requested the reimbursement
of the 2018 Research Tax Credit in 2019 under the European Community tax rules for small and medium sized enterprises (&#147;SME&#148;) in compliance with the applicable regulations in effect. Only companies that meet the definition of SME according
to European Union criteria are eligible for early reimbursement of their CIR. Management ensured that the Company is a SME according to European Union criteria and can therefore benefit from this early reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CIR is presented under other income, in &#147;government financing for research expenditures&#148; line item in the consolidated
statements of income (loss) as it meets the definition of government grant as defined in IAS&nbsp;20&nbsp;<I>Accounting for government grants and disclosure of government assistanc</I>e. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Subsidies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government
grants are recognized when there is a reasonable assurance that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company will comply with the conditions attached to the grants; and that </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The grants will be received. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A government grant that becomes receivable as compensation for expenses or losses already incurred, or for the purpose of providing immediate
financial support to the Company with no future related costs, is recognized as other income of the period in which it becomes receivable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government grants to subsidize capital expenditures are presented in the statement of financial position as deferred income and are recognized
as income on a straight line basis over the useful life of those assets that have been financed through the grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">non-repayable</FONT> loan from the government is treated as a government grant when there is a reasonable assurance that the Company will meet the terms for <FONT STYLE="white-space:nowrap">non-repayment</FONT> of the
loan. When there is no such assurance, the loan is recorded as a liability under borrowings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>r) Income tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and
liabilities and their carrying amounts in the financial statements. Main temporary differences are generally associated with the depreciation of property and equipment, provisions for pension benefits and tax losses carried forward and also with the
deferred tax liabilities / assets generated by the application of IFRS 15 (see Note 2.a &#147;Adoption of IFRS 15&#148;). Currently enacted tax rates are used in the determination of deferred income tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary
differences can be utilized. Due to Company&#146;s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized
up to deferred tax liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>s) Earnings (loss) per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with IAS 33 <I>Earnings per share</I>, basic income (loss) per share is calculated by dividing the income (loss) attributable to
equity holders of the Group by the weighted average number of outstanding shares for the period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted income (loss) per share is measured by dividing the income (loss) attributable to
holders of equity and dilutive instruments by the weighted average number of outstanding shares and dilutive instruments for the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If in the calculation of diluted income (loss) per share, instruments giving deferred rights to capital such as warrants generates an
antidilutive effect, then these instruments are not taken into account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>t) Other comprehensive income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Items of income and expenses for the period that are recognized directly in equity are presented under &#147;other comprehensive income.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>u) Segment information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For internal reporting purposes, and in order to comply with IFRS 8 <I>Operating segments</I>, the Company performed an analysis of operating
segments. Following this analysis, the Company considers that it operates within a single operating segment being the R&amp;D of pharmaceutical products in order to market them in the future. All R&amp;D activities of the Company are located in
France. Key decision makers (the executive committee of the Company) monitor the Company&#146;s performance based on the cash consumption of its activities. For these reasons, the Management of the Group considers it not appropriate to set up
separate business segments in its internal reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018 and 2017, revenue was entirely generated by one customer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>v) Critical accounting estimates and assumptions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the consolidated financial statements under IFRS requires management to make estimates, assumptions and judgments that
affect the reported amounts of assets, liabilities, income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under
the circumstances. The Company&#146;s actual results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
estimates and judgments involve mainly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the accounting for collaboration and licensing agreements</B>: the revenue results primarily from payments
based on several components (e.g., upfront payments, milestone payments) received in relation to research, collaboration and licensing agreements signed with pharmaceutical or other companies. When the Company is committed to perform R&amp;D
services, revenue is spread over the period the Company is engaged to deliver these services, more particularly on the basis of the Company&#146;s inputs to the satisfaction of a performance obligation relative to the total expected inputs to the
satisfaction of that performance obligation. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Milestone payments are dependent upon the achievement of certain
scientific, regulatory, or commercial milestones. These variable payments are recognized when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no
right to refund of the payment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The changes in estimate regarding the completion of the works and the variable consideration relating to
the contracts signed with customers are described in Note 13. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the measurement of the subcontracting costs relating to the clinical trial costs</B>: the completion of the
subcontracting costs related to clinical trials is based on two allocation keys: (i)&nbsp;time, for the services defined as fixed and linear and/or (ii)&nbsp;the number of visits for services resulting from the recruitment rate. If the Company is
not sponsor of the trial, the criteria &#147;visits&#148; is replaced by the criteria &#147;patients.&#148; For </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
each clinical trial, these allocation keys are applied to the budget of the clinical trial. These allocations keys required three types of estimates: (i)&nbsp;the budget and length of the
clinical trial for the allocation key &#147;time&#148;, and (ii)&nbsp;the total number of visits (or &#147;patients&#148;) for the criteria &#147;visit&#148; or (&#147;patient&#148;). These estimated data are defined by the clinical operations
department and validated by the management. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the estimation of shared development costs and transition costs under the 2015 AstraZeneca monalizumab
agreement and the AstraZeneca Lumoxiti <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement</B>: quarterly invoices submitted by AstraZeneca under these agreements are based on estimates made by AstraZeneca management as a result of its
accounting work. This implies estimates from AstraZeneca regarding the advancement of their clinical costs. AstraZeneca submits to the Company an update of their budgets which is reviewed by the Company in order to identify potential deviations.
These estimates of shared development costs and transition costs have a significant impact on the Company&#146;s operating income (loss), trade payables and collaboration liabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>measurement of the fair value of warrants</B>: the measurement of the fair value of warrants
granted to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Executive Board, scientific consultants, determined on the basis of Black-Scholes option and Monte Carlo approach pricing models; these models require the use
by the Company of certain calculation assumptions such as the expected volatility of the underlying share or the employee turnover weighted average rate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>measurement of employee benefits obligations</B>: inherent in these valuations are key actuarial
assumptions such as the discount rate, mortality tables and rates of turnover in employee personnel. These assumptions are provided in Note 10 and a change in these actuarial assumptions could have a material impact on the consolidated financial
statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>measurement of provision for risk</B>: as part of its activities, the Company may be exposed to
some risks, in particular those related to contractual commitments. It is required that the Management of the Company to exercise its judgment to estimate the probability of cash outflow and, if applicable, the amount of this cash outflow and the
information to provide on the contingent liabilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>estimate of the recoverable amount of the acquired and under progress licenses</B>: impairment
tests are performed on a yearly basis for the intangible assets which are not amortized (such as intangible assets in progress). Amortizable intangible assets are tested for impairment when there is an indicator of impairment. Impairment tests
involve comparing the recoverable amount of the licenses to their net book value. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. If the carrying amount of any asset is below its
recoverable amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount. The main assumptions used for the impairment test include (a)&nbsp;the amount of cash flows that are set on the basis of the development
and commercialization plans and budgets approved by Management, (b)&nbsp;assumptions related to the achievement of the clinical trials and the launch of the commercialization, (c)&nbsp;the discount rate, (d)&nbsp;assumptions on risk related to the
development and (e)&nbsp;for the commercialization, selling price and volume of sales, Any change in these assumptions could lead to the recognition of an impairment charge that could have a significant impact on the Company&#146;s consolidated
financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>estimate of the useful life of the acquired licenses</B>: intangible assets are amortized on a
straight line basis over their anticipated useful life. The estimated useful life is the period over which the asset provides future economic benefits. It is estimated by management and is regularly revised by taking into consideration the period of
development over which it expects to receive economic benefits such as collaboration revenues, royalties, product of sales, etc. However, given the uncertainty surrounding the duration of the R&amp;D activities for the programs in development and
their likelihood to generate future economic benefits to the Company, the estimated useful life of the rights related to these programs is rarely longer than the actual development phase of the product candidate. When a program is in
commercialization phases, the useful life takes into account the protection of the exclusivity rights and the anticipated period of commercialization without taking into account any extension or additional patents.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
The prospective amendment of the amortization plan of the monalizumab intangible asset, which is modified according to the estimate ending date of the Phase II clinical trial is described in Note
6. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3) Management of financial risks and fair value </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal financial instruments held by the Company are cash, cash equivalents and marketable securities. The purpose of holding these
instruments is to finance the ongoing business activities of the Company. It is not the Company&#146;s policy to invest in financial instruments for speculative purposes. The Company does not utilize derivatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal risks to which the Company is exposed are liquidity risk, foreign currency exchange risk, interest rate risk and credit risk.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Liquidity risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s cash management is performed by the Finance department, in charge of monitoring the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> financing and the short-term forecast and enabling the
Company to face its financial commitments by maintaining an amount of available cash consistent with the maturities of its liabilities. As of December&nbsp;31, 2018, cash, cash equivalents and short-term investments were &#128;167,531 thousand,
which represents more than a year of cash consumption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main characteristics of the financial instruments owned by the Company
(including liquidity) are presented in Note 4. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Foreign currency exchange risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is exposed to foreign exchange risk inherent in certain subcontracting activities relating to its operations in the United States,
which have been invoiced in U.S. dollars. The Company does not currently have recurring revenues in euros, dollars or in any other currency. As the Company further increases its business, particularly in the United States, it is expected to face
greater exposure to exchange rate risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The revenue denominated in U.S. dollars has represented approximately 100% of revenue in the
years ended December&nbsp;31, 2018 and 2017, respectively. Payments in U.S. dollars represented approximately 31.9% and 15.1% of the payments in the years ended December&nbsp;31, 2018 and 2017, respectively. In order to cover this risk, the Company
kept in U.S. dollars a part of the consideration received from AstraZeneca in June 2015 and January 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s foreign
exchange policy does not include the use of hedging instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Interest rate risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has very low exposure to interest rate risk. Such exposure primarily involves money market funds and time deposit accounts. Changes
in interest rates have a direct impact on the rate of return on these investments and the cash flows generated. The Company has no credit facilities. The repayment flows of the advances from <I>Banque Publique d&#146;Investissement</I> (&#147;BPI
France&#148;) and the borrowings subscribed in 2017 are not subject to interest rate risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Credit risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The credit risk related to the Company&#146;s cash equivalents, short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT>
financial assets is not significant in light of the quality of the issuers. The Company deemed that none of the instruments in its portfolio are exposed to credit risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Fair value </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of financial instruments traded on an active market is based on the market rate as of December&nbsp;31, 2018. The market prices
used for the financial assets owned by the Company are the bid prices in effect on the market as of the valuation date. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4) Cash, cash equivalents and
financial assets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents and short-term investments</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>167,531</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>116,110</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents and financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>202,712</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>176,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variation of short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial
assets for the periods 2017 and 2018 are the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acquisitions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Disposals</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation&nbsp;of<BR>fair&nbsp;value&nbsp;through<BR>the&nbsp;consolidated<BR>statement&nbsp;of<BR>income&nbsp;(loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation<BR>of&nbsp;fair<BR>value&nbsp;by<BR>OCI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation<BR>of</B><br><B>accrued</B><br><B>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Foreign<BR>currency<BR>effect</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT><B> </B>financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77,212</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24,217</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,786</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(152</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,341</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acquisitions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Disposals</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation&nbsp;of<BR>fair&nbsp;value&nbsp;through<BR>the&nbsp;consolidated<BR>statement&nbsp;of<BR>income&nbsp;(loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation<BR>of fair<BR>value&nbsp;by<BR>OCI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation<BR>of</B><br><B>accrued</B><br><B>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Currency<BR>translation<BR>difference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT><B> </B>financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54,757</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43,271</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17,541</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>447</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>261</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,943</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77,212</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts and fixed-term accounts. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at hand</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest-bearing accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed-term accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares in mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>152,314</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>99,367</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest-bearing accounts, fixed-term accounts and shares in mutual funds meet the criteria
to be considered as cash equivalents. For an investment to qualify as a cash equivalent it must be readily convertible to a known amount of cash and be subject to an insignificant risk of changes in value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets and short-term investments </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares in mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Short-term investments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,217</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,743</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medium-term notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,181</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,469</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the year ended December 31, 2017, shares in mutual funds are defined by the Company as assets available for
sale measured at fair value through other comprehensive income. From January 1, 2018 and the first application of IFRS 9, they are accounted for as financial assets at fair value through profit and loss. The Company only invests into funds with a
very low level of risk. As of December&nbsp;31, 2018, the Company owns shares of four mutual funds. The risk profiles of these funds are rated 1 to 7 by the financial institution who manages and commercializes these funds (1 being the lowest risk
profile). When the maturity of shares in mutual funds is longer than one year, they are classified as <FONT STYLE="white-space:nowrap">non-current</FONT> financial instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets generally include a guarantee of capital at the maturity date
(which is always longer than one year). These instruments are defined by the Company as financial assets at fair value through profit or loss and classified as <FONT STYLE="white-space:nowrap">non-current</FONT> due to their maturity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash, cash equivalents and financial assets per currency </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments and other <FONT STYLE="white-space:nowrap">non-current</FONT> financial
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>74,442</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>202,712</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>117,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>59,348</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>176,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The portion of the financial assets held and denominated in U.S. dollars will be used by the Company to pay
for services provided in the United States, which will be invoiced in U.S. dollars during the next years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Variance in fair value of
financial instruments </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value through profit or loss(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value through other comprehensive income(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In 2018 and 2017, change in fair value through profit or loss is made of &#128;4,248&nbsp;thousand (&#128;651 thousand) of unrealized gains, less &#128;462&nbsp;thousand (&#128;691 thousand) of unrealized losses,
respectively, which are recognized in Net financial loss, respectively (see Note 16). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In 2017, financial instruments for which change in fair value is recognized through other comprehensive income are related to mutual funds </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5) Trade receivables and others </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade
receivables and others are analyzed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued receivables excluding rebates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CIR(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other tax credits (e.g. CICE)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT refund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade account receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments made to suppliers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refund to be received (&#147;CVAE&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade receivables and others excluding rebates</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>139,012</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,412</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebate related to capital expenditures(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade receivables and others</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>152,112</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,412</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;Other receivables&#148; as of December&nbsp;31, 2018, are mainly related to AstraZeneca as a result of the exercise of the monalizumab exclusive license option ($100,000&nbsp;thousand or &#128;87,655 thousand) and
option granted on IPH5201 ($24,000&nbsp;thousand or &#128;20,961 thousand). These amounts are due in the first quarter of 2019, see Note 1.1.a and Note 1.1.c for agreements description. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The rebate refers to an estimated rebate of $15.0&nbsp;million (&#128;13.1 million) granted by AstraZeneca in connection with the acquisition of Lumoxiti rights and that will be paid in 2019, see Note 6.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In accordance with the principles described in Note 2.q, the CIR is recognized as other operating income in the year to which the eligible research expenditure relates. The Company obtained the repayment of the CIR for
the tax year 2017 in the amount of &#128;11,022&nbsp;thousand in 2018 and will apply for the refund of the CIR for the tax year 2018 of &#128;13,503&nbsp;thousand in 2019. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net book value of the receivables is considered to be a reasonable approximation of their estimated fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade receivables and others have payment terms of less than one year. No valuation allowance was recognized on trade receivables and others
as the credit risk of each of debtors was considered as not significant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6) Intangible assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets can be broken down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Purchased<BR>licenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;intangible<BR>assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>In&nbsp;Progress</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>January&nbsp;1, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,022</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions (amended)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2017 </B>(amended)(1)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,192</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>January&nbsp;1, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,192</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,801</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,184</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>84,529</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This amount is an upfront payment for acquisition of IPH5401 rights under the <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement signed in 2017 with Novo Nordisk A/S. The classification of this amount has
been amended compared to the 2017 consolidated financial statements since it is in progress and thus not amortized. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This amount mainly includes (i)&nbsp;an upfront payment of &#128;43,501&nbsp;thousand, less an accrued receivables of &#128;13,050&nbsp;thousand relating to the rights acquired from AstraZeneca in 2018 under the
Lumoxiti <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement and (ii)&nbsp;a &#128;13,050&nbsp;thousand additional consideration to be paid to Novo Nordisk A/S following the exercise of the option by AstraZeneca for the monalizumab
rights. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the agreement inception, acquired rights were recorded as intangible asset for an amount of &#128;7,000&nbsp;thousand. The Company recorded
an additional consideration of &#128;6,325&nbsp;thousand in 2015 and a last payment of $15,000&nbsp;thousand (&#128;13,050 thousand) in 2018 (see Note 1.1.a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, this asset is amortized on a straight-line basis over the anticipated residual duration of the Phase II trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net book values of the monalizumab rights were &#128;12,733&nbsp;thousand and &#128;4,513&nbsp;thousand as of December&nbsp;31, 2018 and
December&nbsp;31, 2017, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-CD39 rights acquired from Orega Biotech </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2016, the Company and Orega Biotech entered into an exclusive licensing agreement by which Orega Biotech granted the Company
full worldwide rights to its program of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> anti-CD39 checkpoint inhibitors. The undisclosed upfront payment paid by the Company to Orega Biotech has been
recognized as an intangible asset in the consolidated financial statements for the year ended December&nbsp;31, 2016. Criteria relating to the first development milestone were reached in December 2016. Consequently, the amount of this milestone was
recognized as an intangible asset in addition to the initial payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This asset is amortized on a straight-line basis since
November&nbsp;1, 2018 (corresponding to the effective beginning date of the collaboration) until the date the Company expects to fulfill its commitment (submission of an IND expected in 2019). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the agreement inception, an upfront payment of &#128;40&nbsp;million for acquired rights were recorded as intangible asset. As IPH5401 is
still in clinical trial, the acquired rights are classified as intangible asset in progress. They were subject to annual impairment test. No impairment were recorded since inception. These acquired rights will be amortized when the Company obtains
economic benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the agreement, the Company will pay additional payments according to the reach of specific steps. As of
December&nbsp;31, 2018, according to the uncertainty of these potential payments, no liability was recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development costs incurred
by the Company are recognized as research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main assumptions used for the impairment test are the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cash flows are set on the basis of the development and commercialization plans and budgets approved by
Management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A discount rate of 12%; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A risk of development is taken into consideration by applying probabilities of success of reaching future phases
of development to cash flows related to each development phases Those average probabilities of success of R&amp;D projects are based on an article published in Nature Biotechnology journal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the commercialization phase, selling price and sales volume are estimated on the basis of the potential
market and the observed performances of comparable drugs currently on the market. An attrition rate is applied to anticipated revenue once the related rights fall <FONT STYLE="white-space:nowrap">off-patent.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of failure of the clinical trials in progress, the Company may have to fully depreciate the intangible asset corresponding to the
IPH5401 rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company did not identify any reasonable potential variance in the key assumptions that may generate a depreciation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sensitivity testing regarding the actuarial assumptions and other assumptions such as: discount rate (+/- 2 points), attrition rate (+/-
2 points) and selling price <FONT STYLE="white-space:nowrap">(-50/+25</FONT> points) were performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IPH5401 does not generate economic
benefits yet for the Company. In accordance with IAS 38, it will be amortized when it generates economic benefits, which can result from: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The commercialization the drug candidate; or, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An <FONT STYLE="white-space:nowrap">out-licensed</FONT> agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company commercialize the drug product on its own, it will have to determine the amortization period of the related capitalized rights.
It will have to estimate their useful life, considering the date when they fall off patent. Those capitalized rights will be amortized on a straight line basis during the estimated useful life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company entered in an <FONT STYLE="white-space:nowrap">out-licensed</FONT> agreement, the Company will have to perform an analysis to
determine if the control of the rights are transferred to a third party, and thus will have to derecognize the capitalized rights. If the Company conclude that it keeps the control of the rights, it will determine their useful life and will amortize
them on a straight line basis during this useful life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti rights acquired from AstraZeneca under the 2018 AstraZeneca
multi-term agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As mentioned above, Lumoxiti rights are capitalized in 2018 for a total amount of &#128;30,451&nbsp;thousand
(see Note 1.1.b for agreement description). The Company will reimburse AstraZeneca for the development, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
production and commercialization costs incurred by AstraZeneca during the transition period, after deduction of an amount up to &#128;13.1&nbsp;million ($15 million) accrued receivable. Thus,
this accrued receivable is not included the value of capitalized rights and is recorded in trade receivables and others in the consolidated statement of financial position as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The license is amortized on a straight line basis until July&nbsp;31, 2031, which corresponds to the expiration of the current composition of
matter patent, not including any additional patent extensions or patents. The net book value of the asset amounts to &#128;29,987&nbsp;thousand as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development costs invoiced by AstraZeneca since the acquisition of the license mainly relate to the generation of additional data for
regulatory purposes. These costs are recognized as research and development expenses as incurred (see Note 14). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7) Property and equipment </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lands&nbsp;and<BR>buildings(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Laboratory<BR>equipment&nbsp;and&nbsp;other</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>In&nbsp;Progress</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net opening balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,900</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(987</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net closing balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,093</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,602</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,729</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net opening balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,093</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,602</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,729</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net closing balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>320</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company owns two properties. The one on which stands the buildings purchased in 2008 (gross value &#128;772 thousand), and a second one, adjacent to the first one, acquired in December 2017 (gross value &#128;491
thousand). They are not amortized. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Of which &#128;930&nbsp;thousand financed through loans (&#128;491&nbsp;thousand for a land and &#128;439&nbsp;thousand for the acquisition of R&amp;D equipment). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes assets under finance-lease agreements as broken down below: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Land and building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value of lands and buildings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,290</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,581</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value of equipment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,904</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8) Trade payables and others </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This line item is analyzed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Suppliers (excluding payables related to capital expenditures)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax and employee-related payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade payables and others (excluding payables related to capital expenditures)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,662</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables related to capital expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade payables and others</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>91,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,657</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The book value of trade payables and others is considered to be a reasonable approximation of their fair
value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9) Financial liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This line item was broken down per maturity and is analyzed as follows : </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds<BR>from<BR>borrowings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Repayments<BR>of</B><br><B>borrowings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI PTZI IPH41(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down-payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total&#151;Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,342</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest-free loan </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds<BR>from<BR>borrowings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Repayments<BR>of<BR>borrowings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI PTZI IPH41(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down-payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(530</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total&#151;Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,327</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,739</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,201</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest free loan </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI PTZI IPH41</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total&#151;Current financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,347</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,343</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI PTZI IPH41(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Total&#151;Non-Current</FONT> financial
liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, the Company was granted an interest-free loan for innovation (&#147;PTZI&#148;) by BPI France
relating to the program IPH4102 for an amount of &#128;1,500&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finance lease obligations relate primarily to real estate
property in relation to the acquisition in 2008 of the Company&#146;s headquarters and main laboratories. They are presented in the above table net of the cash collateral paid to Sogebail, the lessor. In the context of this operation, the Company
paid a guarantee in the form of a down-payment. This down-payment amounts to &#128;234&nbsp;thousand as of December&nbsp;31, 2018 (&#128;386&nbsp;thousand as of December&nbsp;31, 2017). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;3, 2017, the Company borrowed from the Bank &#147;Soci&eacute;t&eacute; G&eacute;n&eacute;rale&#148; in order to finance the
construction of its future headquarters. This loan amounting to a maximum of &#128;15,200&nbsp;thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. This period of raising is limited
to August&nbsp;30, 2019. The reimbursement of the capital will begin from August 30, 2019 to August&nbsp;30, 2031 (12 years). The Company authorized collateral over financial &#147;Soci&eacute;t&eacute; G&eacute;n&eacute;rale&#148; instruments
amounting to &#128;15,200&nbsp;thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: &#128;4,200&nbsp;thousand in July 2024, &#128;5,000&nbsp;thousand in July 2027 and
&#128;6,000&nbsp;thousand in July 2031. As of December&nbsp;31, 2018 the loan was raised at an amount of &#128;1,300&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
loan bears a fixed interest rate of 2.01%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets are at least equal to principal
as of financial year end. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the schedule for repayment of financial liabilities (principal only). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Repayment&nbsp;schedule&nbsp;(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&lt;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2&nbsp;to&nbsp;5&nbsp;years<BR>included</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&gt;&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI France&#151;IPH41</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down-payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;</B><B>&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>987</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>372</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,300</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,347</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,112</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,062</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the schedule for the contractual flows (being principal and interest
payments,): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Repayment&nbsp;schedule&nbsp;(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&lt;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2&nbsp;to&nbsp;5&nbsp;years<BR>included</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&gt;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI France&#151;PTZI IPH41</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,376</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down-payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(241</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>992</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,463</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,365</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,228</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,132</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,725</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair value of financial liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of financial liabilities, calculated on the basis of discounted future cash flow, was &#128;4,427&nbsp;thousand and
&#128;5,402&nbsp;thousand as of December&nbsp;31, 2018 and 2017, respectively, using level 3 fair value measurements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10) Employee benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Defined benefit obligations </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Defined&nbsp;benefit&nbsp;obligations&nbsp;(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for retirement defined benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for seniority awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total&#151;Defined benefit obligations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,621</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">French law requires payment of a lump sum retirement indemnity to employees based on years of service and
annual compensation at retirement. Benefits do not vest prior to retirement. The Company pays for this defined benefit plan. It is calculated as the present value of estimated future benefits to be paid, applying the projected unit credit method
whereby each period of service is seen as giving rise to an additional unit of benefit entitlement, each unit being measured separately to build up the final. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;24, 2016, the Company entered into an internal labor agreement with the employees representatives whereby the Company is
committed to paying a seniority award after 15 years and 20 years of employment. This award is paid on the anniversary date. A similar award existed for employees having a seniority of 10 years but was not booked due to its insignificant amount. As
such, in 2016 the Company recorded a provision for seniority awards and a corresponding charge included in &#147;Staff costs other than share-based payments&#148; (see Note 14) other than payments in shares. These awards meet the definition of other
long-term benefits under IAS 19. This provision is determined by an external actuary firm based on the assumptions disclosed hereafter and amounts to &#128;415&nbsp;thousand as of December&nbsp;31, 2018 (&#128;366&nbsp;thousand as of
December&nbsp;31, 2017). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main actuarial assumptions used to evaluate retirement benefits are the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Economic assumptions</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate (iBoxx Corporate AA) for retirement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual rate of increase in wages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Demographical assumptions</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Type of retirement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">At&nbsp;the&nbsp;initiative&nbsp;of<BR>the employee</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">At&nbsp;the&nbsp;initiative&nbsp;of<BR>the employee</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate of tax and social charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Age at retirement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Executives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- <FONT STYLE="white-space:nowrap">Non-executives</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mortality table</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">TH-TF</FONT> <FONT STYLE="white-space:nowrap">00-02</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">TH-TF</FONT> <FONT STYLE="white-space:nowrap">00-02</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual turnover by tranche of age</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">All personnel</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">All personnel</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">16-24</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">25-29</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">30-34</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">34-39</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">40-44</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">45-49</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+50 years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the projected benefit obligation for the periods presented were as follows (in thousands of euro):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As&nbsp;of&nbsp;January&nbsp;1,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,418</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial (gain) / loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,621</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial (gain) / loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no asset covering the defined benefit obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An increase/decrease of +/- 50 basis point of the discount rate would result in a decrease/increase of the total benefit obligation of
&#128;300&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main actuarial assumptions used to evaluate seniority awards at December&nbsp;31, 2018 are the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discount rate: 1.14% (difference with the rate used for pension benefit provision results from the difference of
maturity) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rate of annual increase in wages: 4.5% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rate of contributions: 45.20% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rate of wage costs: 23.29% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Age of retirement: 64 years for executives, 62 years for <FONT STYLE="white-space:nowrap">non-executives</FONT>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mortality Table: TH&#151;TF <FONT STYLE="white-space:nowrap">00-02</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual mobility rate: 2.1% on average </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Defined contribution plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In France, pension funds are generally financed by employer and employee contributions and are accounted for as defined contribution plans with
the employer contributions recognized as expensed as incurred. They amounted &#128;1,277&nbsp;thousand and &#128;982&nbsp;thousand in the years ended December&nbsp;31, 2018 and 2017, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11) Share capital and share base payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a) Share capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to
shareholders through the optimization of the debt and equity balance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company&#146;s share capital
amounted to &#128;3,196,979 divided into 63,939,586 shares with a par value of &#128;0.05 each, fully paid up, after taking into account the various capital increases that took place since the inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share capital does not include BSAs, BSAAR, AGAs and AGAPs that have been granted to certain investors or natural persons, both employees and <FONT
STYLE="white-space:nowrap">non-employees</FONT> of the Company, but not yet exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Group issued preferred shares (share B) which
will become convertible into ordinary shares following a vesting period of one year and a retention period of two years if the performance criteria are met at the end of the retention period. The number of ordinary shares to which the conversion of
one preferred share will be entitled will be determined according to the fulfillment of the performance criteria. The holders of preferred shares are not entitled to voting rights nor dividend payment until the date at which the preferred shares
become convertible into ordinary shares. The preferred shares give no preferential subscription right to any capital increase and are not transferrable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents the historical changes in the share capital of the Company as of December&nbsp;31, 2018 and 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Number&nbsp;of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Nature&nbsp;of&nbsp;the&nbsp;Transactions</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share&nbsp;Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nominal<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance&nbsp;as&nbsp;of&nbsp;January&nbsp;1,&nbsp;2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,880,352</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>234,874,392</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,600,100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">September&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (definitive acquisition of free shares)</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;25, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares to AstraZeneca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,291,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,260,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;25, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">November&nbsp;29, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (Exercise of shares warrants)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,706,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,196,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>299,932,221</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63,932,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Number&nbsp;of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Nature&nbsp;of&nbsp;the&nbsp;Transactions</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share&nbsp;Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nominal<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance&nbsp;as&nbsp;of&nbsp;January&nbsp;1,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,696,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>187,571,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,921,304</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">January&nbsp;24,<BR>2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (exercise of share warrants)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">February&nbsp;10,<BR>2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (exercise of share warrants)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">June&nbsp;14, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (exercise of share warrants)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;13, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Contribution in kind in the context of the acquisition of C5aR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,999,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary and preferred shares (definitive acquisition of free
shares and free preferred shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary and preferred shares (definitive acquisition of free
shares and free preferred shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,829,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;7, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Subscription of share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,880,352</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>234,874,392</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,600,100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Holding by the Company of its own shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company held 18,575 of its own shares as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Share based payments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has issued BSAs, BSAARs, stock options, AGAs and AGAPs as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Types</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants&nbsp;void<BR>as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>exercised&nbsp;as<BR>of</B><br><B>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>outstanding<BR>as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>number&nbsp;of<BR>shares&nbsp;to&nbsp;be<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercice<BR>price&nbsp;per<BR>share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sept. 9, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSAAR 2011</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">May&nbsp;27, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSAAR 2012</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSAAR 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21,&nbsp;2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP Management <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">nil</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;30,&nbsp;2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Employees <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">September&nbsp;20,&nbsp;2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Bonus 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">April&nbsp;3,2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">April&nbsp;3,2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP Management 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">April&nbsp;3,2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Bonus Management 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">November&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Perf Employees 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">November&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Perf Management 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;29, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA 2011</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 1.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;17, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;16, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA 2014</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">April&nbsp;27, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA <FONT STYLE="white-space:nowrap">2015-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA <FONT STYLE="white-space:nowrap">2015-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">September&nbsp;20, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,943,202</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,145,643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,747,038</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,862,100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Types</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>issued&nbsp;as&nbsp;of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants&nbsp;void</B><br><B>as&nbsp;of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>exercised&nbsp;as</B><br><B>of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>outstanding</B><br><B>as&nbsp;of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>number&nbsp;of<BR>shares&nbsp;to&nbsp;be<BR>issued&nbsp;as&nbsp;of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercice<BR>price&nbsp;per<BR>share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">Sept. 9, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSAAR 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">May&nbsp;27, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSAAR 2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSAAR 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGAP Management <FONT STYLE="white-space:nowrap">2016-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGAP Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Management <FONT STYLE="white-space:nowrap">2016-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGAP <FONT STYLE="white-space:nowrap">2016-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Management <FONT STYLE="white-space:nowrap">2016-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Employees <FONT STYLE="white-space:nowrap">2016-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">September&nbsp;20,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Bonus 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;29, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;17, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;16, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">April&nbsp;27,<BR>2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA <FONT STYLE="white-space:nowrap">2015-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA <FONT STYLE="white-space:nowrap">2015-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">September&nbsp;20,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,288,674</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,073,588</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,079,482</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,458,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>AGA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Details of AGA </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP</B><br><B>Employees</B><br><B><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA</B><br><B>Employees</B><br><B><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of grant (Executive Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;21,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;21,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;21,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;21,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">December&nbsp;30,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-transferability</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting&nbsp;period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting&nbsp;period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting&nbsp;period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of AGA granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per free share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">No</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">No</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected turnover (yearly basis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per AGA at grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA</B><br><B>Employees<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA&nbsp;Bonus</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Employees</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of grant (Executive Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">December&nbsp;30,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">December&nbsp;30,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;20,<BR>2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;3,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2018</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;3,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2018</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-transferability</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR><BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years<BR>after<BR>vesting<BR>period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR><BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years<BR>after<BR>vesting<BR>period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of AGA granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per free share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected turnover (yearly basis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per AGA at grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA</B><br><B>Employees</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA&nbsp;Bonus</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA&nbsp;Perf<BR>Employees</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA&nbsp;Perf<BR>Management</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of grant (Executive Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;3,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2018</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;3,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2018</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">November&nbsp;20,<BR>2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">November&nbsp;20,<BR>2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-transferability</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">1 years after<BR>vesting period<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">end</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">1 years after<BR>vesting period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number&nbsp;of&nbsp;AGA&nbsp;granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per free share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected turnover (yearly basis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.70%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per AGA at grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in Number of AGAs Outstanding </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;AGAs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>331,910</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>557,361</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(243,748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,682</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,049,466</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>331,910</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Breakdown of the Closing Balance </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;AGAs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Management <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Bonus 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Management 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Bonus 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Perf Employees 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Perf Management <FONT STYLE="white-space:nowrap">2018-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,049,466</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>331,910</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of granted free shares is based on the closing price of the Company&#146;s share at grant date,
reduced when necessary by an estimated turn-over rate. This estimated fair value is recognized as operating expenses on a straight-line basis over the vesting period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>AGA Management <FONT STYLE="white-space:nowrap">2016-1</FONT> / AGA Management <FONT STYLE="white-space:nowrap">2016-2&nbsp;/</FONT> AGA
Employees <FONT STYLE="white-space:nowrap">2016-1</FONT> / AGA Employees <FONT STYLE="white-space:nowrap">2016-2</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses
related to those plans were &#128;1,392&nbsp;thousand and &#128;4,383&nbsp;thousand for the financial years ended December&nbsp;31, 2018 and 2017, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>AGA <FONT STYLE="white-space:nowrap">2017-1</FONT> (Employees) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses were &#128;456&nbsp;thousand for the financial year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Free preferred shares convertible into ordinary shares: AGAP Management <FONT STYLE="white-space:nowrap">2016-1&nbsp;/</FONT> AGAP
Employees <FONT STYLE="white-space:nowrap">2016-1</FONT> / AGAP Management <FONT STYLE="white-space:nowrap">2016-2</FONT> / AGAP Management 2017&nbsp;/ AGAP Employees 2017 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AGAP Management <FONT STYLE="white-space:nowrap">2016-1,</FONT> <FONT STYLE="white-space:nowrap">2016-2</FONT> and AGAP Employees <FONT
STYLE="white-space:nowrap">2016-1</FONT> are subject to internal and share price conditions. AGAP Management <FONT STYLE="white-space:nowrap">2017-1</FONT> and AGAP Employees <FONT STYLE="white-space:nowrap">2017-1</FONT> are subject to share value
condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of these free preferred shares is based on a third party valuation report.
The valuation method used to estimate the fair value of these free preferred shares is presented below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a
Capital Asset Pricing (&#147;CAPM&#148;) model of the share price using a Monte Carlo approach; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjustment of the estimation by applying expected turnover rates; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in internal conditions are taken into account in the revision of the estimated number of free shares expected to vest during the
vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has recognized an expense over a period of one year on a straight-line basis, this period being the vesting
period. Expenses were &#128;567&nbsp;thousand and &#128;5,327&nbsp;thousand for the financial year ended December&nbsp;31, 2018 and 2017, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>AGA Bonus 2017 and AGA Bonus 2018 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AGA Bonus 2017 and 2018 were granted to the Executive members Committee who opted for these compensation plans. For each recipient, the number
of shares definitely acquired is equal to the cash equivalent of 50% of the annual variable compensation increased by a 30% premium. In the event of an over-performance (i.e. achieved target above 100%), the surplus is paid in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses were &#128;208&nbsp;thousand and &#128;189&nbsp;thousand for the financial years ended December&nbsp;31, 2018 and 2017, respectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Free performance shares (AGA Perf Employees 2018 / AGA Perf Management 2018) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Free performance shares granted in 2018 are subject to share price conditions and a vesting kicker triggered by the performance of an internal
condition, which is the success of certain clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of these free performance shares is based on a third party
valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a
CAPM model of the share price using a Monte Carlo approach; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjustment of the estimation by applying expected turnover rates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in internal conditions are taken into account in the revision of the estimated number of free performance shares expected to vest
during the vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses were &#128;84.0&nbsp;thousand the financial year ended 31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>BSA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Details of BSA </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA&nbsp;2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">BSA&nbsp;2015-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">BSA&nbsp;2015-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date&nbsp;of&nbsp;grant (Executive Board)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;29,&nbsp;2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;17,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;16,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;27,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;1,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;20,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plan expiration date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;29,<BR>2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;17,<BR>2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;16,<BR>2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;26,<BR>2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;30,<BR>2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;20,<BR>2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of BSA granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per BSA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation method used</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="21" ALIGN="center">Black&#151;Scholes</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.08</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average life of BSA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0,20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value per BSA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.62</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2.51</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6.59</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4.73</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.57</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in Number of BSA Outstanding </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;BSA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>334,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>384,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Breakdown of the Closing Balance </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;BSA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA <FONT STYLE="white-space:nowrap">2015-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA <FONT STYLE="white-space:nowrap">2015-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>334,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>334,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>384,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>384,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>BSAAR </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>BSAAR </B>are securities whose subscription price and exercise price are fixed at their fair value as determined by an expert. The BSAAR
subscription therefore represents an investment on the part of the beneficiary. At the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
end of the exercise period, if they have not been exercised, the BSAAR becomes void. The Company benefits from a clause called &laquo;forcing&raquo; making it possible to encourage holders to
exercise their redeemable equity warrants when the market price exceeds the exercise price and reaches a threshold defined in the BSAAR issuance agreement. The Company may, then, subject to a time period for notifying holders that will permit them
to exercise the BSAAR, decide to reimburse the warrants not exercised at a unit price equal to the BSAAR acquisition price paid by its holder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Details of BSAAR </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>BSAAR</I>. The methodology used to estimate the fair value of the BSAAR is similar to the one used to estimate the fair value of the BSA,
except for the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term</I>. Unlike the BSA, the Company does not have sufficient historical experience for the BSAAR.
Consequently, the expected term used for the valuation of the fair value is the legal maturity of the instrument (10 years). </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No
share-based payment compensation expense was recognized relating to the BSAAR since the amount paid by the beneficiaries is equal to the fair value. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSAAR 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date&nbsp;of&nbsp;grant&nbsp;(Executive&nbsp;Board)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;1,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plan expiration date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;30,&nbsp;2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of BSAAR granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per BSAAR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation method used</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">Black-Scholes</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average life of BSAAR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per BSA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in Number of BSAAR Outstanding </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;BSAAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,363,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Breakdown of the Closing Balance </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;BSAAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Breakdown of expenses per financial year </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The share-based compensation expenses are broken down as follows (in thousands of euro): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Employees <FONT STYLE="white-space:nowrap">2016-1&amp;2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-1&amp;2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Management <FONT STYLE="white-space:nowrap">2016-1&amp;2</FONT> / AGAP Employees <FONT
STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Management 2017 / AGAP Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Bonus 2018 / AGA Bonus 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Perf Management 2018 / AGA Perf Employees 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Share-based compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,707</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,830</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, employers&#146; social security contributions relating to free shares were paid
for an amount of &#128;68&nbsp;thousand (&#128;334&nbsp;thousand for the year ended December&nbsp;31, 2017). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12) Financial instruments recognized in
the statement of financial position and related effect on the income statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables show the carrying amounts and fair
values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of&nbsp;December&nbsp;31,&nbsp;2018</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Book&nbsp;value&nbsp;on&nbsp;the<BR>statement&nbsp;of<BR>financial&nbsp;position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>profit&nbsp;and&nbsp;loss(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>comprehensive<BR>income(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Receivables(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>354,824</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>200,669</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>154,155</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>354,824</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Book&nbsp;value&nbsp;on&nbsp;the<BR>statement of<BR>financial position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>profit and loss(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>comprehensive<BR>income(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Debt&nbsp;at</B><br><B>amortized&nbsp;costs(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>96,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>96,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>96,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of&nbsp;December&nbsp;31,&nbsp;2017</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Book&nbsp;value&nbsp;on&nbsp;the<BR>statement&nbsp;of<BR>financial&nbsp;position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>profit&nbsp;and&nbsp;loss(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>comprehensive<BR>income(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Receivables</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>197,990</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>125,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,135</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,458</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>197,990</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2017</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Book&nbsp;value&nbsp;on&nbsp;the<BR>statement of<BR>financial position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>profit and loss(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>comprehensive<BR>income(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Debt&nbsp;at&nbsp;amortized<BR>costs(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The fair value of financial assets classified as fair value through comprehensive income corresponds to the market value of the assets, which are primarily determined using level 1 measurements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the amendments to IFRS 7, financial instruments are presented in three categories based on a hierarchy of methods used to
determine fair value: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1: fair value determined based on quoted prices in active markets for assets or liabilities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2: fair value determined on the observable database for the asset or liability concerned either directly or indirectly; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3: fair value determined on the basis of evaluation techniques based in whole or in part on unobservable data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13) Revenue and government financing for research expenditures </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>of which monalizumab agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>61,546</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>32,346</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>of which IPH5201 agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>15,632</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invoicing of research and development costs (IPH5201 and IPH5401 agreements)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange gains on collaboration agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue from collaboration and licensing agreements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,892</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,631</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The impact of the application of the IFRS 15 standard is presented in Note 2.a. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a)
Revenue recognition related to monalizumab AstraZeneca agreements and amendments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company identified the following promises
under the monalizumab AstraZeneca agreements and amendments: (1)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license related to monalizumab restricted to two applications, with an option for an exclusive license related to
monalizumab including all applications, (2)&nbsp;the performance of certain initial studies related to phases I/II trials, and participation in certain studies of phases I/II trials and phase III clinical trials through a <FONT
STYLE="white-space:nowrap">co-financing.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considered the license has a standalone functionality and is capable of being
distinct. However the Company determined that the license is not distinct from the performance of initial studies and participation to phase III clinical trials of because they increased the utility of the licensed IP. Thus, the licensed IP, the
performance of initial studies and participation to phase III clinical trials are a combined into a single performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
performance obligation was considered as satisfied over time as AstraZeneca controls the licensed IP which is being enhanced during the agreement. The revenue is recognized over time, based on the input method (costs incurred). As a result, the
Company recognizes the price of the transaction as a revenue on the basis of the progress of studies that the Company has undertaken to carry out under the agreement. Progression is assessed following to actual costs incurred relative to the total
budgeted costs to fulfill the obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price was initially estimated to the initial payment of $250,000&nbsp;thousand,
less the amounts that the Company expected to pay to AstraZeneca for <FONT STYLE="white-space:nowrap">co-financing</FONT> Phase I/II clinical studies. The additional payment of $100,000&nbsp;thousand triggered by AstraZeneca&#146;s exercise of the
exclusivity option was treated as a change in the price estimate of the transaction. In addition, the amendment of the contract, which modified the scope and budget of the studies to be carried out by the Company a as well as the arrangements for
sharing the cost of the other studies, led to a revision of the degree of progress and the price of the transaction. Thus, the exercise of the option and the amendment of the contract resulted in the recognition of a favorable cumulative adjustment
of &#128;31,966&nbsp;thousand in revenue for the year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subsequent milestones and potential royalty
payments are excluded from the transaction price due to the uncertainties of clinical trials results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company used the most likely
amount to determine variable consideration. Variable consideration for cost-sharing payments related to certain studies of phases I/II trials and phase III clinical trials when applicable are included in the transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and AstraZeneca make quarterly cost-sharing payments to one another in amounts necessary to ensure that each party bears its
contractual share of the overall shared development costs incurred. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company accounts for cost sharing payments from AstraZeneca as increase in revenue in its consolidated statements of income (loss), while cost sharing payments to AstraZeneca are recorded as a
reduction of revenue, or contra-revenue. Costs incurred by the Company related to agreed-upon service under the agreement are recorded as research and development expenses in its consolidated statements of financial income (loss). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in monalizumab deferred revenue (in thousands of euro): </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,260</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue for the 2017 financial year <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2017, as published</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restatement related to the first application of IFRS 15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2018 restated</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,831</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue for the 2018 financial year(1)-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in deferred revenue resulting from the exercise of the $100M option.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer to collaboration liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(717</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>104,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Without exercise of the option, the amount recognized as revenue would have amounted to &#128;29,581&nbsp;thousand. The impact of the exercise on 2018 revenue amounted to &#128;31,966&nbsp;thousand. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The exercise of the $100,000&nbsp;thousand option was converted to &#128;87,002&nbsp;thousand, of which &#128;85,358&nbsp;thousand was recognized as deferred revenue and &#128;1,644&nbsp;thousand recognized in
collaboration liabilities. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in monalizumab collaboration liabilities (in thousands of euro) : </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2017,&nbsp;as&nbsp;published</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restatement related to the first application of IFRS 15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2018 restated</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deductions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,656</B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Of which &#128;20,987 thousand of current portion and &#128;10,669 of non-current portion. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Revenue recognition related to IPH5201 AstraZeneca collaboration and option agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that IPH5201 AstraZeneca collaboration and option agreement is an enforceable contract under IFRS 15 as the upfront
payment is <FONT STYLE="white-space:nowrap">non-refundable</FONT> and thus AstraZeneca will incur significant loss if it doesn&#146;t exercise its licensed option. The Company considered that the upfront payment is a variable consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company identified the following promises under the IPH5201 AstraZeneca collaboration and option agreement : (1) an option for an
exclusive license related to IPH5201 and (2) the performance of research and development services in conformity with the defined development plans, including preclinical studies and a Phase I clinical trial (which scope is still under discussion).
The Company determined that the option is not distinct from the performance of research and development services because they increased the utility of the licensed IP. Thus, the option and the performance of research and development services are
combined into a single performance obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price was initially estimated to the initial upfront payment of
$50,000&nbsp;thousand (received in October 2018 for $26,000&nbsp;thousand and in January 2019 for $24,000 thousand) and estimated quarterly payment received in relation to costs incurred by the Company for preclinical studies. Development and
commercial milestones and potential royalties payments were excluded from the transaction price due to uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance
obligation was considered as satisfied over time as the IP in development has no alternate use for the Company as it is an exclusive license and that the Company has an enforceable right to payment for completed research and development services.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applied the input method and recognized the price of the transaction as a revenue percentage of completion of the costs of
the preclinical studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in IPH5201 deferred revenue (in thousands of euro): </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variance of the <B>deferred revenue</B> relating to this agreement is presented in the following schedule (in thousands of euro): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue for the 2018 financial year <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27,869</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>c) Revenue related to collaboration and option agreement related to four
<FONT STYLE="white-space:nowrap">to-be-agreed</FONT> upon molecules (preclinical molecules) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the option
to acquire an exclusive license provides a material right to AstraZeneca that it would not receive without entering into that contract. The Company will recognize revenue when those future goods or services are transferred or when the option
expires. Thus, the upfront payment is recorded as a deferred revenue for an amount of &#128;17,400&nbsp;thousand as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>d) Revenue recognition related to IPH5401 AstraZeneca agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue as research and development expenses are incurred (see Note 1.1.c for agreement description). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>e) Schedule of variance of deferred revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variance of the global deferred revenue is presented in the following schedule: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017&nbsp;as<BR>published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Impact<BR>IFRS&nbsp;15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017&nbsp;as<BR>revised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Recognition<BR>in&nbsp;P&amp;L</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transfer&nbsp;to</B><br><B>collaboration</B><br><B>liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monalizumab</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,831</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(715</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>104,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPH5201</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27,869</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical molecules</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(1)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,083</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,831</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>146,259</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(77,180</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(715</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>150,195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(2)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Of which &#128;47,909&nbsp;thousand of current deferred revenue and &#128;87,005&nbsp;thousand of <FONT STYLE="white-space:nowrap">non-current</FONT> deferred revenue. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Of which &#128;82,096&nbsp;thousand of current deferred revenue and &#128;68,098&nbsp;thousand of <FONT STYLE="white-space:nowrap">non-current</FONT> deferred revenue. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Monalizumab</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue for the 2017 financial year <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>f) Government financing for research expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company receives grants from the European Commission and the French government and state organizations in several different forms: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investment and operating grants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research Tax Credits. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total amount for government financing for research expenditures recorded as other income in the income statement can be analyzed as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research Tax Credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Government financing for research expenditures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,060</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,402</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14) Operating expenses </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>R&amp;D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>G&amp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>R&amp;D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>G&amp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subcontracting costs(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,327</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37,996</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of supplies and consumable materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,819</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses other than share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,520</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19,121</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,995</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(15,163</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,707</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,985</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Personnel expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(14,226</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(7,601</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><I>&nbsp;</I></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><I>(21,828</I></B></TD>
<TD NOWRAP VALIGN="bottom"><B><I>)&nbsp;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(14,692</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(10,456</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><I>&nbsp;</I></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><I>(25,148</I></B></TD>
<TD NOWRAP VALIGN="bottom"><B><I>)&nbsp;</I></B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-scientific</FONT> advisory and consulting(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,301</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,794</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,357</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasing and maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,968</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel expenses and meeting attendance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(992</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,294</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketing, communication and public relations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(518</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(649</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scientific advisory and consulting(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(845</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other purchases and external expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(311</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(687</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,402</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,396</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,087</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,499</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income and (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,502</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,076</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total net operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(69,555</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,142</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(67,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company subcontracts a significant part of its preclinical (pharmaceutical development, tolerance studies and
other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
to third parties. Associated costs are recorded in subcontracting on the basis of the level of completion of the clinical trials. The increase between 2017 and 2018 is essentially due to the
progress of the preclinical and clinical programs but also for &#128;1,094&nbsp;thousand of R&amp;D costs related to Lumoxiti following the agreement signed with AstraZeneca in October 2018. In accordance with this agreement, AstraZeneca will
invoice the Company development costs during the transition. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Non-scientific</FONT> advisory and consulting are services performed to support the selling, general and administration activities of the Company, such as legal, accounting and audit
fees as well as business development support. The increase results from advisory fees in relation with the Company&#146;s structuring in a context of strong growth. The following schedule presents the breakdown per audit firm of the audit fees.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Audit&nbsp;Conseil<BR><FONT STYLE="white-space:nowrap">Expertise&nbsp;-&nbsp;PKF</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deloitte&nbsp;&amp;<BR>Associ&eacute;s</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Audit&nbsp;Conseil<BR><FONT STYLE="white-space:nowrap">Expertise&nbsp;-&nbsp;PKF</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deloitte&nbsp;&amp;<BR>Associ&eacute;s</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>800</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>867</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-audit</FONT> fees*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>205</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>605</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>810</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>166</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>731</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>897</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Non-audit</FONT> fees: these fees correspond to services performed by the auditors related to the production of certification in the context of the declaration of expenses for the
obtention of grants; to the verification report of social and environmental information, special reports within the framework of operations on the Company&#146;s capital </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Personnel expenses other than share-based compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The line item amounted to &#128;19,121&nbsp;thousand and &#128;15,163&nbsp;thousand for the years ended December&nbsp;31, 2018 and 2017
respectively. The Company had 195 employees as of December&nbsp;31, 2018, compared to 188 as of December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
benefited from the &#147;competitiveness and employment tax credit&#148; (CICE) of &#128;180.0&nbsp;thousand and &#128;233.0&nbsp;thousand for the financial year ended December&nbsp;31, 2018 and 2017, respectively. This tax credit will be mainly
used to reinforce the research teams. It is deducted from the line item &#147;Personnel expenses other than share-based compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Depreciation and amortization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The line item is mainly composed of the amortization of the monalizumab, IPH5201 and Lumoxiti intangible assets (see Note 6). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Cost of supplies and consumable materials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of supplies and consumable materials consists mainly of the cost of procurement of the Company&#146;s drug substance and/or drug product
that is manufactured by third-parties. This line item amounts to &#128;3,819&nbsp;thousand and &#128;4,287&nbsp;thousand for the years ended December&nbsp;31, 2018 and 2017, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Intellectual property expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual property expenses amounted to &#128;1,380&nbsp;thousand and &#128;1,499&nbsp;thousand for the financial years ended
December&nbsp;31, 2018 and 2017, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the acquisition of intellectual property rights from third parties, excluding the
acquisitions of patents by way of assignation, the Company has three different types of agreements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclusive option agreements, which correspond to an exclusive period during which the Company evaluates the
opportunity to acquire the licensing rights of the intellectual property subject to the option agreement. The Company generally pays an option fee and bears the past and/or present intellectual property expenses related to the invention subject to
the option agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclusive licensing agreements of which the duration varies according to contractual conditions but which is
generally the same as the life of the underlying intellectual property. The Company pays the past and/or present expenses related to the intellectual property and also costs related to access to technology, milestone payments when they are achieved
and in the case of marketing of the products/technologies covered by the intellectual property, royalties on sales; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclusive collaboration and licensing agreements including some exclusive collaboration on a specific work
program or for a specific area of which the duration is limited in time, and an exclusive license of a varying duration according to contractual conditions but which generally coincides with the life of the underlying intellectual property. The
Company agrees to bear research and development expenses for the exclusive collaboration part, and, for the exclusive license part, pays fees to access technology, intellectual property expenses, milestone payments when they are achieved and in the
case of marketing of the products/technologies covered by the intellectual property, royalties on sales. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15) Net income / (loss)
from distribution agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the transition period, Lumoxiti products are commercialized in the United States by AstraZeneca
who is the owner of the regulatory approval. As explained in Note 2.p, the Company concluded that it did not meet the criteria for being principal under IFRS 15. Consequently, the net loss resulting from all Lumoxiti marketing&#146;s operations are
disclosed in the item line &#147;Net income / (loss) from distribution agreements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized a
&#128;1,109&nbsp;thousand net loss, corresponding to production and marketing costs, net of sales proceeds, as invoiced by AstraZeneca in relation to the Lumoxiti distribution agreement for the period. Sales of Lumoxiti products in the year ended
December&nbsp;31, 2018 were not significant considering that the first commercialization in the United States happened in the last quarter of 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16) Net financial loss </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net financial
loss can be analyzed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange gains</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,002</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized losses on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,535</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the financial years ended December&nbsp;31, 2017 and 2018, the foreign exchange gains
and losses mainly result from the variance of the exchange rate between the Euro and the U.S. dollar on U.S. dollars denominated cash and cash equivalent and financial assets accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unrealized losses on financial assets relate to unquoted instruments, the fair value of which is determined using level 2 measurements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17) Income Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the Company&#146;s
early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized up to deferred tax liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Temporary differences mainly result from finance leases, provision for defined benefit obligation and tax losses carryforwards. As of
December&nbsp;31, 2018 and 2017, deferred tax liabilities and deferred tax assets each amounted to &#128;19&nbsp;thousand and &#128;250&nbsp;thousand, respectively, resulting in a net amount of zero in the consolidated statements of financial
positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the accumulated tax losses carryforwards of Innate Pharma SA were &#128;219,563&nbsp;thousand
with no expiration date (&#128;218,670&nbsp;thousand as of December&nbsp;31, 2017). As of December&nbsp;31, 2018, the accumulated tax losses carryforwards of Innate Pharma Inc. was &#128;493&nbsp;thousand, or $564&nbsp;thousand,
(&#128;446&nbsp;thousand, or $535&nbsp;thousand as of December&nbsp;31, 2017), with a <FONT STYLE="white-space:nowrap">20-year</FONT> period expiration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the financial year ended December&nbsp;31, 2017, the Company recognized a &#128;368&nbsp;thousand prior period tax adjustment for a tax
regime that was no more applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the financial year 2018, the Company opted for the carry back mechanism which gave rise to a
&#128;333&nbsp;thousand tax credit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Tax rate reconciliation </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tax benefit / (loss) calculated at statutory tax rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,016</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase/decrease in tax expense arising from:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research Tax Credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborations with customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-recognition</FONT> of deferred tax assets related to tax
losses and temporary differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carry-back</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective tax expense (a)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax income / (loss) (b)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income tax expense (a)+(b)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18) Commitments, contingencies and litigations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Commitments </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Consumable purchases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
part of a supply of scientific equipment, the Company was committed towards a supplier to minimum annual purchases of consumables. As of December&nbsp;31, 2018, the overall commitment was amounting to &#128;281 thousand for the period from January
2019 to June 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Operating lease commitments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the increase of employees, the Company signed on June&nbsp;30, 2017 a lease to rent a new building. The lease covers a period of nine
years with possibility for termination after three and six years. At December&nbsp;31, 2018, the commitment related to the rent until June&nbsp;30, 2020 (which is the end of the three-years <FONT STYLE="white-space:nowrap">non-terminable</FONT>
period) amounts to &#128;449&nbsp;thousand. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;to&nbsp;3<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;to&nbsp;5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease&#151;Building &#147;Le Virage&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease&#151;Vehicles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>769</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Loan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;17, 2017, the Company took out a loan amounting to &#128;15,200&nbsp;thousand in order to finance the acquisition of a land and
the construction of its future headquarters to be fully drawn before August&nbsp;31, 2019. As of December&nbsp;31, 2018, the Company has partially drawn an amount of &#128;1,300&nbsp;thousand, resulting in a remaining amount to be drawn of
&#128;13,900&nbsp;thousand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licensing and collaboration agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commitments related the Company&#146;s licensing and collaboration agreements are disclosed in Note 1.1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies and litigations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2012, Platine Pharma Services SAS, the Company&#146;s former subsidiary, received a tax notice suggesting that it should pay a
tax on salaries of &#128;91&nbsp;thousand. The management of Platine Pharma Services does not agree with this position on the ground that the status of Platine Pharma Services is exempt from such tax as it is a commercial company. The period subject
to the tax audit was prior to the acquisition by Transgene of an equity interest in Platine Pharma Services which was at the time a wholly-owned subsidiary. Therefore, in accordance with the liabilities guarantee clause, the contingent liability
resulting from this adjustment would be borne by the former parent company. Based on an assessment of the technical merits of this position, the Company believes that it is not probable that an outflow of resources embodying economic benefits will
be required to settle the contingency and, as a result, has not recognized a provision in the consolidated financial statements. This litigation ended as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is exposed to contingent liabilities relating to legal actions before the labor court or intellectual property issues happening in
the ordinary course of its activities. Each <FONT STYLE="white-space:nowrap">pre-litigation,</FONT> known litigation or procedure in ordinary course the Company is involved in was analyzed at the closing date after consultation of advisors. There is
no acknowledged litigation as of December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions amounted to &#128;690&nbsp;thousand and &#128;1,012&nbsp;thousand as of December&nbsp;31, 2018 and 2017, respectively. They
consisted solely of the employer contribution in respect of the grants of employee equity instruments. In accordance with IFRS 2, when a Company decides to provide its employees with shares bought back on the market, a provision has to be recognized
upon the decision to allocate free shares that are spread over the vesting period when the plan conditions actions for employees when they join the Company at the end of the plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19) Related party transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Members of the Executive Board and Executive Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the periods presented, the following compensation was granted to the members of the Executive Committee of the Company and were
recognized as expense: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses and other short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extra pension benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Committee members compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,208</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,584</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, two members of the Executive Committee were also members of the Executive Board.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel expenses and other short-term employee benefits correspond to amounts effectively paid during the calendar year to which they
relate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;31, 2018, J&eacute;r&ocirc;me Tiollier resigned from his function as a member of the Executive Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calculation of share-based compensation is detailed in Note 11.b. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Members of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized a provision of &#128;216&nbsp;thousand for attendance fees (<I>jetons de presence</I>)<I> </I>relating to the year ended
December&nbsp;31, 2018 which should be paid in 2019. This amount includes the compensation for the Chairman of the Supervisory Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Related parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S is a board member and is related to the Company by three licensing agreements related to the drug-candidates lirilumab,
monalizumab and IPH5401. Under the terms of the agreements, Novo Nordisk A/S is eligible to receive milestone payments as well as royalties on future sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company has a &#128;13,050&nbsp;thousand additional consideration to be paid to Novo Nordisk A/S relating to
the additional consideration for monalizumab following the exercise of the option by AstraZeneca and a &#128;756&nbsp;thousand liability relating to a production delivery of IPH5401. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca is a shareholder and is related to the Company through several collaboration and option licensing or license agreements for
different drug candidates (monalizumab, IPH5401, IPH5201 and preclinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
molecules) and a license agreement for the rights of the drug Lumoxiti. The payments between the two companies as well as the liabilities and receivables as of 31&nbsp;December 2018 are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assets/<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collection (AstraZeneca to the Company) / Receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments (the Company to AstraZeneca) / Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,560</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In addition, the Company recognized in the income statement a net expense of &#128;1,109&nbsp;thousand as net result from distribution agreements (see Note 15) and an R&amp;D expense of &#128;1.1&nbsp;million as
operating expenses (see Note&nbsp;14) </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BPI France is a board member and has granted the Company a &#128;1,500&nbsp;thousand
interest-free loan (<I>Pr&ecirc;t &agrave; Taux Z&eacute;ro Innovation</I>, or &#147;PTZI&#148;). This loan will be reimbursed starting September 2016 over a 5-year period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Subsidiaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
business relationships between the Company and its subsidiaries are governed by intra-group agreements, conducted at standard conditions on an arm&#146;s length basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20) Income (loss) per share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Basic
income (loss) per share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic income (loss) per share is calculated by dividing the net income (loss) attributable to equity
holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro,&nbsp;except&nbsp;for&nbsp;share&nbsp;data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares in circulation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic income (loss) per share (&#128; per share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Diluted income (loss) per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted
average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential ordinary shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro,&nbsp;except&nbsp;for&nbsp;share&nbsp;data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares in circulation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments for share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted income (loss) per share (&#128; per share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21) Events after the reporting date </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;14, 2019, the Executive Board granted 90,650 free shares to employees of the Company (AGA Employees <FONT
STYLE="white-space:nowrap">2018-1).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;18, 2019, subsequent to the definitive acquisitions of (i) 110,500 free shares
granted on April&nbsp;3, 2018 under the &#147;AGA Employees 2017&#148; plan, (ii) 5,581 free preferred shares convertible into ordinary share granted on April&nbsp;3, 2018 under the &#147;AGAP Employees 2017&#148; plan, (iii) 2,000 free preferred
shares convertible into ordinary shares granted on April&nbsp;3, 2018 under the &#147;AGAP Management 2017&#148; plan and (iv)&nbsp;the exercise of 750 &#147;2012&#148; BSAAR, the Executive Board carried out a capital increase of &#128;7,434
(including share premium). As a result, (i) 110,500 ordinary shares were created, with a nominal value of &#128;0.05, for an issue price of &#128;0.05 per share, (ii) 750 ordinary shares were created, with a nominal value of &#128;0.05, for an issue
price of &#128;2.04 per share and (iii) 7,581 &#147;2017&#148; preferred shares were created, with a nominal value of &#128;0.05, for an issue price of &#128;0.05 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 29, 2019, the Executive Board granted 25,000 free shares to an employee of the Company&#146;s subsidiary (AGA New Members 2017-1).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following these transactions, the share capital amounted to &#128;3,202,920 divided into: (i) 64,043,905 ordinary shares, each with a
nominal value of &#128;0.05; (ii) 6,931 &#147;2016&#148; preferred shares, each with a nominal value of &#128;0.05, and (iii)&nbsp;7,581 &#147;2017&#148; preferred shares, each with a nominal value of &#128;0.05, respectively, fully paid up. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;3, 2019, the Company signed an agreement with Orega Biotech amending the license agreement signed on January 4, 2016. Pursuant to
this agreement, the Company is required to pay Orega Biotech an amount of &#128;7,000 thousand as consideration following the collaboration and option agreement signed on October&nbsp;22, 2018 with AstraZeneca regarding IPH5201. The payment will be
made in June 2019 and accounted for as an increase of the Company&#146;s intangible asset related to Anti-CD39. The agreement also includes potential additional payments by the Company to Orega Biotech in connection with the completion of
milestones, as well as potential payments of parts of the sub-licensing revenues received by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Until
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 (25 days after the date of this prospectus), all dealers that buy, sell, or trade our ordinary shares, whether or not
participating in this global offering, may be required to deliver a prospectus. This is in addition to a dealers&#146; obligation to deliver a prospectus when acting as underwriter and with respect to their unsold allotments or subscriptions.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ORDINARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Including Ordinary Shares in the Form of American Depositary Shares) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g14p44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per American Depositary Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Ordinary Share </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P></center>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P></center>
<P STYLE="font-size:54pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:20pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:20pt">
<TD VALIGN="bottom"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>SVB Leerink&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="font-size:54pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;6. Indemnification of Members of the Executive and Supervisory Board. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, provisions of bylaws that limit the liability of directors are prohibited. However, French law allows
<I>soci&eacute;t&eacute;s anonymes</I> to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good faith and within
their capacities as directors or officers of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain liability insurance for the members of our Supervisory Board and Executive Board, including insurance against liability under the
Securities Act of 1933, as amended, and we intend to enter into agreements with the members of our Supervisory Board and Executive Board to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification
under French law, these agreements will provide for indemnification for damages and expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or
proceeding arising out of his or her actions in that capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the members of our Supervisory Board may, through their
relationships with their employers or partnerships, be insured and/or indemnified against certain liabilities in their capacity as members of our Supervisory Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any underwriting agreement we enter into in connection with the sale of ADSs being registered hereby, the underwriters will agree to
indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act against certain liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;7. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding share capital issued and options, warrants and free shares granted by us since January&nbsp;1, 2016.
None of the transactions described below involved any underwriters, underwriting discounts or commissions, or any public offering. Some of the transactions described below involved members of our Supervisory Board and Executive Board and 5%
shareholders and are more fully described under the section of the prospectus titled &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From January&nbsp;1, 2016 through May 1, 2019, we have issued securities in the following transactions that were not registered under the
Securities Act: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;6, 2016, we issued an aggregate of 2,700 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;5,508. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On May&nbsp;30, 2016, we issued an aggregate of 58,940 ordinary shares to employees and executive managers in
connection with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;138,248. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 4,486 free preferred shares (AGAP <FONT
STYLE="white-space:nowrap">2016-1)</FONT> to employees and executive managers, convertible into 897,200 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 99,932 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 50,000 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;3, 2016, we issued an aggregate of 25,650 ordinary shares to employees in connection with the
exercise of warrants, for aggregate gross proceeds of &#128;52,326. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 250,000 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-2)</FONT> to an executive manager. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 149,943 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-2)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 3,000 free preferred shares (AGAP <FONT
STYLE="white-space:nowrap">2016-2)</FONT> to an executive manager, convertible into 600,000 ordinary shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;24, 2017, we issued an aggregate of 38,950 ordinary shares to executive managers in connection
with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;327,144. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On February&nbsp;10, 2017, we issued an aggregate of 50,500 ordinary shares to employees and executive managers
in connection with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;119,020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On June&nbsp;14, 2017, we issued an aggregate of 1,850 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;3,774. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;13, 2017, we issued an aggregate of 3,343,748 ordinary shares to Novo Nordisk A/S, at a purchase
price of &#128;11.12 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2017, we issued an aggregate of 28,556 bonus free shares (AGA Bonus <FONT
STYLE="white-space:nowrap">2017-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2017, we issued an aggregate of 37,000 share warrants (BSA
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to members of the Supervisory Board, convertible into 37,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2017, we issued an aggregate of 98,770 ordinary shares and 3,931 free preferred shares to
employees and executive managers in connection with the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2016-1</FONT> and AGAP <FONT STYLE="white-space:nowrap">2016-1),</FONT> for aggregate gross proceeds of &#128;5,135.05.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2017, we issued an aggregate of 144,978 ordinary shares and 3,000 free preferred shares to
employees and executive managers in connection with the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2016-2</FONT> and AGAP <FONT STYLE="white-space:nowrap">2016-2),</FONT> for aggregate gross proceeds of &#128;7,398.90.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 5,725 free preferred shares (AGAP
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to employees convertible into 572,500 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 2,400 free preferred shares (AGAP
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to executive managers convertible into 240,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 114,500 free shares (AGA
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November 20, 2018, we issued an aggregate of 327,500 performance free shares (AGA Performance <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November 20, 2018, we issued an aggregate of 260,000 performance free shares (AGA Performance <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;3, 2018, we issued an aggregate of 67,028 bonus free shares (AGA Bonus <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2018, we issued an aggregate of 22,055 ordinary shares to executive managers in connection
with the vesting of free shares (AGA Bonus <FONT STYLE="white-space:nowrap">2017-1),</FONT> for aggregate gross proceeds of &#128;1,102.75. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;25, 2018, we issued an aggregate of 6,260,500 ordinary shares to MedImmune Limited, at a purchase
price of &#128;10.00 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;29, 2018, we issued an aggregate of 50,000 ordinary shares to employees and executive managers
in connection with the exercise of share warrants, for aggregate gross proceeds of &#128;2,500. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;18, 2019, we issued an aggregate of 111,250 ordinary shares and 7,581 preferred shares to employees
and executive managers in connection with the exercise of redeemable share warrants and the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2017-1</FONT> and AGAP <FONT STYLE="white-space:nowrap">2017-1),</FONT> for aggregate gross
proceeds of &#128;5,941.55. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January 1, 2016 through May 1, 2019, an aggregate of 66,140 redeemable share warrants (BSAAR) were exercised
at prices ranging from &#128;2.04 to &#128;7.20 per ordinary share. Pursuant to these exercises, we issued an aggregate of 66,140 ordinary shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January 1, 2016 through May 1, 2019, an aggregate of 163,200 share warrants (BSA) were exercised at prices
ranging from &#128;1.77 to &#128;8.65 per ordinary share. Pursuant to these exercises, we issued an aggregate of 163,200 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January 1, 2016 through May 1, 2019, an aggregate of 14,512 free preferred shares (AGAP) were vested.
Pursuant to these free preferred shares vesting, we issued an aggregate of 6,931 preferred shares 2016 and 7,581 preferred shares 2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January 1, 2016 through May 1, 2019, an aggregate of 376,303 free shares (AGA) were vested. Pursuant to
these free shares vesting, we issued an aggregate of 376,303 ordinary shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the
securities described above were exempt from registration either (a)&nbsp;under Section&nbsp;4(a)(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors or members of its senior executive management and
did not involve any public offering within the meaning of Section&nbsp;4(a)(2), (b) under Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling
efforts were made in the United States or (c)&nbsp;under Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans and contracts relating to compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;8. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;1.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;3.1**</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Bylaws (<I>statuts</I>) of the Registrant (English translation).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;4.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Deposit Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;4.2*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of American Depositary Receipt (included in Exhibit 4.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;5.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Opinion of Linklaters LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.1&#134;*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Co-Development</FONT> and License Agreement between Innate Pharma S.A. and MedImmune Limited, dated April&nbsp;24, 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.2&#134;*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Development and Option Agreement between Innate Pharma S.A. and MedImmune Limited, dated April&nbsp;24, 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.3&#134;*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lumoxiti License Agreement, between Innate Pharma S.A. and MedImmune Limited, dated October&nbsp;22, 2018.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.4&#134;*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Sub-License</FONT> Agreement, between Innate Pharma S.A. and MedImmune Limited, dated October&nbsp;22, 2018.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.5&#134;*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Option Agreement Relating to the Future Programs, between Innate Pharma S.A. and MedImmune Limited, dated October&nbsp;22, 2018.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.6&#134;*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Collaboration and Option Agreement Relating to CD39, between Innate Pharma S.A. and MedImmune Limited, dated October&nbsp;22, 2018.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.7&#134;*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Joint Research, Development, Option and License Agreement between Innate Pharma S.A. and Novo Nordisk A/S, dated March&nbsp;28, 2006, as amended to date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.8**</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Finance Lease Agreement between Innate Pharma S.A. and Sogebail S.A., dated June&nbsp;9, 2008 (English translation).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.9**</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amendment to Finance Lease Agreement between Innate Pharma S.A. and Sogebail S.A., dated September&nbsp;29, 2016 (English translation).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">21.1**</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">List of subsidiaries.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consent of Deloitte&nbsp;&amp; Associ&eacute;s.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.2*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consent of Linklaters LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Power of Attorney (included on signature page).</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Filed herein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Certain portions of this exhibit will be omitted because they are not material and would likely cause competitive harm to the registrant if disclosed. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial Statement Schedules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All schedules have been omitted because the information required to be set forth therein is not applicable or has been included in the
consolidated financial statements and notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;9. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreement certificates
in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as
indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities, other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding, is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless, in the opinion of its counsel, the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question, whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration
statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first
used after effectiveness, provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was
part of the registration statement or made in any such document immediately prior to such date of first use. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) for
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A, and contained in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act, as amended, shall be deemed to be part of this registration statement as
of the time it was declared effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) for the purpose of determining any liability under the Securities Act, each
post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) for the purpose of determining liability of the registrant under the Securities Act to any purchaser
in the initial distribution of the securities, that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the
securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed
pursuant to Rule 424; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned registrant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the portion of any other free writing
prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">F-1</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Marseille, France
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>INNATE PHARMA S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the undersigned members of the directors, officers and authorized representative of Innate Pharma S.A. hereby severally constitute and
appoint Mondher Mahjoubi and <FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier, and each of them singly, his or her true and lawful agent, proxy and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i)&nbsp;act
on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this Registration Statement together with all schedules and exhibits thereto and any subsequent registration statement
filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii)&nbsp;act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or
appropriate in connection therewith, (iii)&nbsp;act on and file any supplement to any prospectus included in this Registration Statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the
Securities Act of 1933, as amended, and (iv)&nbsp;take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming
all that such agent, proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> or any of his substitutes may lawfully do or cause to be done by virtue thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons
in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mondher Mahjoubi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Executive Officer and Chairman of the Executive Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Financial Officer and Member of the Executive Board (principal&nbsp;financial officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Herv&eacute; Brailly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Irina Staatz-Granzer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Vice-Chairman of Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jean-Yves Blay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gilles Brisson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">V&eacute;ronique Chabernaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ma&iuml;lys Ferrere</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Patrick Langlois</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Marcus Schindler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Representative in the United States</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INNATE PHARMA SA </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A
corporation with executive board and supervisory board with a share capital of EUR 3,202,920.85 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Registered Office: 117, avenue de Luminy,
13009 Marseille </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">424 365 336 Registry of Trade and Companies of Marseille </P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF ASSOCIATION <FONT STYLE="white-space:nowrap">(BY-LAWS)</FONT> </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended by the Executive Board of April&nbsp;18, 2019 </B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TITLE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM &#150; NAME &#150; REGISTERED OFFICE &#150; OBJECT &#150; DURATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 1&nbsp;&#150; Form </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was
incorporated in the form of a Simplified Share Company governed by applicable statutory provisions and by these articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was
transformed into a Corporation with a Executive Board and a Supervisory Board by a decision of the Mixed Meeting of Shareholders of 13&nbsp;June 2005. It is governed by the statutory and regulatory provisions in force and by these articles of
association. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 2&nbsp;&#150; Corporate Name </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The name of the Company is INNATE PHARMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On any instruments or
documents issued by the Company, the name of the Company must be immediately preceded or followed by the words &#147;Corporation with Executive Board and Supervisory Board&#148; and a statement of the share capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 3&nbsp;&#150; Registered Office </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
registered office is at 117, avenue de Luminy, 13009 Marseille. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It may be transferred within the same administrative department or to a neighbouring
administrative department by a decision of the Supervisory Board subject to ratification by the Ordinary Meeting of Shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE
4&nbsp;&#150; Purpose </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Company is, directly or indirectly, in France and abroad, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">carry out, on its own behalf or on behalf of third parties, any research, development, studies and development of
manufacturing or marketing procedures for pharmaceutical products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register or grant any patent or licence directly or indirectly connected with its activity; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more generally, carry out any transactions of any kind whatsoever including economic, legal, financial, civil or
commercial transactions which may be directly or indirectly related to the corporate purposes or to any similar, related or complementary objects. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 5&nbsp;&#150; Duration </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless it is
extended or wound up early, the Company shall have a duration of 99 years which starts from the day of its registration at the Registry of Trade and Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Decisions to extend the duration of the Company or to wind it up early shall be taken collectively by the shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TITLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTRIBUTION&nbsp;&#150; SHARE CAPITAL &#150; FORM OF SHARES&nbsp;&#150; RIGHTS AND OBLIGATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHED TO SHARES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE
6&nbsp;&#150; Share Capital </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The share capital is &#128;&nbsp;3,202,920.85 (three million two hundred two thousand nine hundred twenty euros and
eighty five cents). It is divided into 64,043,905 (sixty four million forty-three thousand nine hundred five) ordinary shares of zero point zero five (0.05) euro each, 6,931 (six thousand nine&nbsp;hundred thirty one) preference shares of zero point
zero five (0.05) euro each (herein referred to as &#147;<B>2016 Preference Shares</B>&#148;) and 7,581 (seven&nbsp;thousand five hundred <FONT STYLE="white-space:nowrap">eighty-one)</FONT> preference shares of zero point zero five (0.05) euro each
(herein referred to as &#147;<B>2017 Preference Shares</B>&#148;), fully subscribed and fully paid up in cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 7&nbsp;&#150; Modifications
of the Share Capital </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;The share capital may be increased by either the issue of new shares or an increase of the
nominal value of existing shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New shares are paid up either in cash, by a contribution in kind, by <FONT STYLE="white-space:nowrap">set-off</FONT>
against due and payable receivables, by incorporation of profit, reserves or issue premiums into the share capital, as a result of a merger or demerger, or further to the exercise of a right attached to securities entitling their holder to capital,
including, as the case may be, the payment of the corresponding amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New shares are issued at either their nominal amount or at such amount increased
by an issue premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A share capital increase can only be decided by an Extraordinary Meeting of Shareholders, following a report by the Executive Board
containing the information required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Extraordinary Meeting of Shareholders may, however, delegate such competence to the Executive Board
pursuant to the conditions provided by law. Within the limit of the powers so granted by an Extraordinary Meeting of Shareholders, the Executive Board shall have the powers required to increase the share capital in one or several steps, to determine
the terms and conditions thereof, to officially acknowledge the completion thereof and to make the corresponding amendments to the articles of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a share capital increase is decided by a Meeting of Shareholders, it may delegate all the powers required for the completion of the operation to the
Executive Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Executive Board is acting by virtue of a delegation of power or competence, it shall prepare a supplementary report to the
Ordinary Meeting of Shareholders held following the meeting of the Executive Board at which such action is taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the share capital is increased by
the incorporation of profits, reserves or issue premiums, the Extraordinary Meeting of Shareholders shall deliberate pursuant to the conditions of quorum and majority required for Ordinary Meeting of Shareholders. In such case, the Meeting of
Shareholders may decide that rights constituting fractional shares shall be neither negotiable nor transferable and that the corresponding securities should be sold. The&nbsp;proceeds of sale shall be allocated to the holders in proportion to their
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An increase in share capital by increasing the nominal amount of shares may only be decided by a unanimous decision of the shareholders, unless
it is the result of an incorporation of profits, reserves or issue premiums into the share capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders have a preferential right of subscription, in proportion to their shareholdings, to shares
issued by way of cash contribution in order to increase the share capital. Shares acquired pursuant to the exercise of this right shall be of the same category as that of the share from which the aforesaid right arises. This also applies to shares
resulting from the acquisition of securities other than shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders may dispose of all or part of their subscription rights during the
subscription period. Such rights are negotiable if they are detached from shares which are themselves negotiable. If this is not the case, then such subscription rights may be disposed of on the same terms as the shares themselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders may waive their preferential right on an individual basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Extraordinary Meeting of Shareholders which decides to increase the share capital may cancel the preferential right to subscription pursuant to the
conditions and within the limits set by law, and shall make such decision following the issuance of reports of the Executive Board and the Statutory Auditors, in accordance with the conditions determined by the law and regulations in force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares which have not been subscribed for on an irreducible basis may be allocated to shareholders who may have subscribed on a reducible basis for a greater
number of shares than that to which they could have subscribed on a preferential basis, in proportion to their subscription rights, and in any event, within the limit of their request, if the Extraordinary Meeting of Shareholders, or, in the case of
delegation, the Executive Board, expressly so decides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the subscriptions have not, in any respect whatsoever, covered the entire share capital
increase, the Executive Board may exercise any one or more of the options provided below, in the order it sees fit: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">limit the share capital increase to the amount of the subscriptions on the dual condition that such
subscriptions cover at least three quarters of the amount of the originally determined increase, and that such option has not been expressly prohibited by the Extraordinary Meeting of Shareholders at the time of issue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">allocate the remaining shares unless the Extraordinary Meeting of Shareholders has decided otherwise; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">opening the subscription to the public if this has been expressly authorised by the Extraordinary Meeting of
Shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the subscriptions have not covered the entire share capital increase, or three quarters of this increase in the case
of (i)&nbsp;above, after such options have been exercised, the share capital increase shall not be carried out. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the Executive Board may in any
case automatically limit the share capital increase to the amount covered by subscriptions, if unsubscribed shares represent less than 3% of the share capital increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of a share capital increase with or without a preferential right of subscription, the Extraordinary Meeting of Shareholders may provide that the
number of shares may be increased within thirty days of the closure of subscriptions by up to 15% of, and at the same price as for, the original issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the share capital increase produces fractional shares, shareholders with insufficient subscription or allocation rights shall be required personally to
acquire or dispose of the subscription rights necessary to obtain delivery of a whole number of new shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;An Extraordinary Meeting of Shareholders (or, in the case of delegation,
the Executive Board) may also (subject to the rights of creditors if relevant) authorise or decide upon a reduction of share capital for any reason and by any procedure whatsoever. A reduction in share capital may not, in&nbsp;any event, derogate
from the principle of equality between shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reduction of share capital to an amount below the legal minimum can only be decided subject to
the condition precedent of a share capital increase to at least the statutory minimum, unless the Company is transformed into a company having a different corporate form. In the event that the foregoing principle is not complied with, any interested
party may ask the courts to dissolve the Company, provided however that the dissolution of the Company cannot be ordered if, as of the date on which the court rules on the merits, the situation has been rectified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the legal and regulatory provisions in force, the Company may not either subscribe to or purchase its own shares. However, if an Extraordinary
Meeting of Shareholders has decided on a reduction of share capital for reasons other than due to losses, it can authorise the Executive Board to purchase a fixed number of shares in order to cancel them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 8&nbsp;&#150; Paying Up Shares </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At least
one quarter of the nominal value of shares subscribed for cash must be paid up on subscription together with the full amount of the issue premium, if relevant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The remainder must be paid up in one or more instalments, upon calls made by the Executive Board, within five years of the day on which the share capital
increase was completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subscribers will be informed of calls for funds by registered letter with confirmation of receipt sent at least fifteen days
prior to the date set for each payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a shareholder does not pay the amounts due with respect to the shares for which he has subscribed, on the
dates determined by the Executive Board, interest will automatically accrue on such amounts in favour of the Company at the statutory rate defined in Article&nbsp;L. <FONT STYLE="white-space:nowrap">313-2</FONT> of the Monetary and Financial Code,
as of the expiry of the month following the date on which they fall due and without the need for a court petition or formal notice. Moreover, when due payments in respect of shares have not been made within thirty days of formal notice sent to the
defaulting shareholder, such shares will no longer entitle the holder to admission to shareholders&#146; meeting and the right to vote in shareholders&#146; meetings, and shall be deducted for the calculation of the quorum. The right to dividends
and the preferential right of subscription to share capital increases attached to these shares shall be suspended. These rights shall be regained on payment of the principal and interest due in respect of the amounts due. A shareholder can then
request the payment of dividends that are not time-barred and exercise his preferential right of subscription if the exercise period for such right has not expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The share capital must be fully paid up prior to any issue of additional shares to be paid up in cash. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 9&nbsp;&#150; Form of Shares &#150; Administration of the Share Accounts </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary shares are either in registered form or, if allowed by law, in bearer form, at the shareholder&#146;s discretion. Fully
<FONT STYLE="white-space:nowrap">paid-up</FONT> 2016 Preference Shares are in registered form. Fully <FONT STYLE="white-space:nowrap">paid-up</FONT> 2017 Preference Shares are in registered form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary shares, 2016 Preference Shares and 2017 Preference Shares are registered in individual accounts opened by the Company or any authorised intermediary,
in the name of each shareholder and kept according to the conditions and procedures provided by legal and regulatory provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is authorised to rely on statutory provisions, in particular Article L. <FONT
STYLE="white-space:nowrap">228-2</FONT> of the Commercial Code, with respect to the identification of the holders of bearer shares and for such purpose it may at any time request the central depositary who administers the share account, to provide
the information referred to in Article L. <FONT STYLE="white-space:nowrap">228-2</FONT> of the Commercial Code, in exchange for payment. The Company is therefore, in particular, entitled at any time to request the name and year of birth, or
concerning a legal person, the corporate name and year of incorporation, the nationality and the post address and, if applicable, email address of holders of securities which give the right to vote in Meeting of Shareholders, either immediately or
in the future, as well as the number of shares held by each of them and, as the case may be, any restrictions which may apply to the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 10&nbsp;&#150; Transfer of Shares </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered shares may be transferred by transfer from one account to another. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary shares paid up in cash are freely transferable as from the completion of the share capital increase. Ordinary shares received in exchange for
contribution in kind are freely transferable as from the completion of the share capital increase, i.e. on the date of the Meeting of Shareholders or meeting of the Executive Board, acting under delegation, which approved the contribution, in the
case of an <FONT STYLE="white-space:nowrap">in-kind</FONT> contribution during the life of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title to ordinary shares is transferred by
registration in the buyer&#146;s account, on the date and in accordance with the conditions provided by applicable law and, as the case may be, regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary shares are freely transferable subject to legislative provisions. 2016 Preference Shares and 2017 Preference Shares are transferable under the
conditions set forth in Article 12 of these <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 11&nbsp;&#150; Crossing of Thresholds
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any natural person or legal entity referred to under Articles L. <FONT STYLE="white-space:nowrap">233-7,</FONT> L.
<FONT STYLE="white-space:nowrap">233-9</FONT> and L. <FONT STYLE="white-space:nowrap">223-10</FONT> of the Commercial Code who gains possession, directly or indirectly, alone or in concert, of a number of shares which represent a portion of the
share capital or voting rights of the Company equal to or greater than 1% or a multiple of such percentage, must inform the Company of the total number of shares, voting rights and securities granting an interest in capital or voting rights which it
owns immediately or would own in the future, by registered mail with confirmation of receipt sent to the registered office of the Company within five trading days starting from the date that the aforesaid threshold(s) were crossed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligation of information provided above also applies in the same conditions when the aforesaid thresholds are crossed downwards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares or voting rights in excess of the portion which should have been declared but which have not been declared pursuant to the aforesaid conditions, are
stripped of their rights to vote at shareholders&#146; meetings for any meeting held within two years following the date of the regularisation of the declaration in accordance with Article L. <FONT STYLE="white-space:nowrap">233-14</FONT> of the
Commercial Code, if failure to make the declaration has been observed and if one or more shareholders holding an interest of at least 5% of the share capital of the Company make such request, recorded in the minutes of the Meeting of Shareholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing obligations to declare apply in addition to the threshold crossing declarations provided by legal or regulatory provisions in force. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 12&nbsp;&#150; Rights and Obligations attached to Shares </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The share capital of the Company is divided between ordinary shares, 2016 Preference Shares and 2017 Preference Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;Rights attached to ordinary shares, 2016 Preference Shares and 2017
Preference Shares </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without prejudice to the rights attached to 2016 Preference Shares and 2017 Preference Shares, each ordinary share entitles to a
portion of the corporate profits and assets in proportion to the portion of share capital that it represents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each ordinary share gives the
right to vote and be represented at General Meetings of Shareholders pursuant to the conditions provided by law and in these articles of association. Ordinary shares, 2016 Preference Shares and 2017 Preference Shares (including shares of the Company
that might be allocated for free in the framework of a capital increase through the incorporation of reserves, issue premiums or profits) do not grant a double voting right pursuant to the last paragraph of Article L.
<FONT STYLE="white-space:nowrap">225-123</FONT> of the French Commercial Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders holding ordinary shares, 2016 Preference Shares and 2017
Preference Shares are only liable up to the nominal amount of the shares which they hold and any request for funds beyond that amount is prohibited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ownership of ordinary shares, 2016 Preference Shares and 2017 Preference Shares automatically implies agreement to be bound by the Company&#146;s <FONT
STYLE="white-space:nowrap">by-laws</FONT> and the decisions of the General Meeting of Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The heirs, creditors, successors or other
representatives of the shareholder holding ordinary shares, 2016 Preference Shares or 2017 Preference Shares cannot request seals to be placed on the Company&#146;s assets and securities or request their distribution or sale by public auction, or to
interfere with its management. In order to exercise their rights, they should rely on company records and the decisions of the General Meeting of Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever it is necessary to hold several ordinary shares, 2016 Preference Shares or 2017 Preference Shares in order to exercise a right of any kind, in the
case of an exchange, regrouping or allocation of securities, or further to a share capital increase or decrease, merger or other corporate transaction, holders of single shares or of less than the number of shares so required will only be able to
exercise such right if they themselves collect and, as the case may be, purchase or sell, the required number of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the Company may, in
the case of an exchange of securities further to a merger or demerger, a share capital reduction, the regrouping or division and mandatory conversion of bearer into registered shares, or the distribution of securities deducted from reserves or in
connection with a share capital reduction, or the distribution or allocation of free shares, pursuant to a decision of the Executive Board, sell any securities in respect of which the persons entitled thereto have not requested delivery subject to
having carried out the publicity formalities provided by regulations at least two years beforehand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As from the date of such sale, the prior securities
or rights to distribution or allocation shall be cancelled as and when required, and their holders shall only be entitled to the allocation of the net proceeds of sale of unclaimed securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;2016 Preference Shares </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;Rights attached to 2016 Preference Shares </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2016 Preference Shares and the rights of holders thereof are governed by the applicable provisions of the French Commercial Code, in particular Articles <FONT
STYLE="white-space:nowrap">228-11</FONT> et seq. thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum number of 2016 Preference Shares that may be allocated is 7,500 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only the 2016 Preference Shares convertible into ordinary shares pursuant to the terms and conditions
specified below benefit from a dividend and are entitled to the reserves, applicable only from the date at which they become convertible. The 2016 Preference Shares that have become convertible will bear rights as from the first day of the financial
year preceding the financial year during which they become convertible. The amount of the dividend (and, if applicable, of the portion of the reserves) to which each 2016 Preference Shares entitles is equal to the amount due in respect of an
ordinary share, multiplied by the number of ordinary share that can be received from the conversion of each 2016 Preference Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2016 Preference
Shares give no preferential subscription right to any capital increase or any operation granting a right on ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of an operation
taking place before the 2016 Preference Shares are converted pursuant to paragraph II.B below, the conversion ratio will be adjusted pursuant to the provisions of Article L. <FONT STYLE="white-space:nowrap">228-99,</FONT> Paragraph 2, 3&deg; and
Paragraph 5 of the French Commercial Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regards to the ownership of corporate assets, a 2016 Preference Shares gives right to a portion of the
liquidation surplus in proportion to the portion of share capital that it represents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only the 2016 Preference Shares convertible into ordinary shares
pursuant to the terms and conditions specified below grant the right to vote in the ordinary and extraordinary general meetings of holders of ordinary shares, applicable only from the date at which they become convertible. The number of voting
rights granted by each 2016 Preference Share is equal to the number of ordinary shares that can be received from the conversion of each 2016 Preference Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2016 Preference Shares grant the right to vote in the special meetings of holders of 2016 Preference Shares. Holders of 2016 Preference Shares are grouped
into a special meeting for any proposed modification of the rights attached to 2016 Preference Shares. In addition, pursuant to the provisions of Article L. <FONT STYLE="white-space:nowrap">228-17</FONT> of the French Commercial Code, any proposed
merger or demerger of the Company in which 2016 Preference Shares cannot be exchanged for shares with equivalent particular rights will be subject to the approval of any relevant special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special meetings can only make valid decisions if the holders of 2016 Preference Shares that are present or represented hold at least, when convened for the
first time, one third, and when convened for the second time, one fifth of the 2016 Preference Shares carrying the right to vote. If the capital is modified or adjusted, the rights of holders of 2016 Preference Shares are adjusted so that their
rights may be maintained pursuant to Article L. <FONT STYLE="white-space:nowrap">228-99</FONT> of the French Commercial Code. The other rights attached to 2016 Preference Shares are specified in the next paragraph. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;Conversion of 2016 Preference Shares into ordinary shares </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of 2016 Preference Shares may only be decided in the framework of an allocation of free shares in favour of the employees and/or executive
officers of the Company, pursuant to the provisions of Articles L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">225-97-1</FONT></FONT> of the French Commercial Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2016 Preference Shares will be definitively acquired by the beneficiaries after an acquisition period of one year from their allocation by the Executive Board
and subject to the beneficiary&#146;s presence in the Company or its consolidated subsidiaries as an employee, executive officer or member of an executive or supervisory body or, if applicable, of the equivalent thereof in foreign law. The
&#147;<B>Acquisition Date</B>&#148; is defined as the end of the acquisition period of the Preference Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, in the event of invalidity of the
beneficiary corresponding to classification in the second or third categories set forth by <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;341-4</FONT> of the French Social Security Code (or the equivalent thereof in an applicable foreign
law), the 2016 Preference Shares will be allocated definitively prior to the Acquisition Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2016 Preference Shares become convertible in ordinary shares, either new or existing at the
Company&#146;s option, after the above-mentioned <FONT STYLE="white-space:nowrap">one-year</FONT> vesting period from their allocation by the Executive Board, followed by a <FONT STYLE="white-space:nowrap">two-year</FONT> retention period from the
definitive allocation (the &#147;Retention Period&#148;), under the conditions set forth in Paragraphs 2 to 10 below. The &#147;<B>Expiry Date of the Retention Period</B>&#148; is defined as the end of the Retention Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, in the event of invalidity of the beneficiary corresponding to classification in the second or third categories set forth by <FONT
STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;341-4</FONT> of the French Social Security Code (or the equivalent thereof in an applicable foreign law), the 2016 Preference Shares will be allocated definitively prior to the Acquisition Date. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As from the first anniversary date of the Acquisition Date, 2016 Preference Shares will be freely transferable
to a credit institution in the framework of a pledge agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions set forth in the Article L. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">225-197-1</FONT></FONT> I., Paragraph 6 of the French Commercial Code, the 2016 Preference Shares will be&nbsp;freely transferable in the event of invalidity of the beneficiary
corresponding to classification in the second or third categories set forth by <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;341-4</FONT> of the French Social Security Code, regardless of whether such invalidity occurs before or after the
Acquisition Date. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2016 Preference Shares may only be converted for a conversion period of six years and six months from the
Expiry Date of the Retention Period (the &#147;<B>Conversion Period</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the Conversion Period, each holder of 2016 Preference Shares will have the right to convert each of his
2016 Preference Shares in ordinary&nbsp;shares, either new or existing (at the Company&#146;s option). The number of ordinary shares to which the conversion of one 2016 Preference Share will entitle will be equal to the sum of (i)&nbsp;a number of
ordinary shares determined according to the fulfilment of an internal condition (the&nbsp;&#147;<B>Internal Condition</B>&#148;) and a market condition as defined below ((the &#147;<B>Market Condition</B>&#148;) (together the &#147;<B>Performance
Criteria</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fulfilment of the Performance Criteria will give the right to convert each 2016 Preference
Share in a maximum of 200 ordinary shares, i.e.&nbsp;a&nbsp;maximum of 100 ordinary shares under the Internal Condition and a maximum of 100 ordinary shares under the Market Condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">It is specified that this conversion ratio thus determined will be adjusted in order to take into account the shares to be issued to preserve
the rights of holders of securities or other rights giving access to the share capital and holders of 2016 Preference Shares under legal and statutory requirements and Paragraph&nbsp;II. above. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Internal Condition in order to calculate the number of 2016 Preference Shares that can be converted will be
determined as a function of the highest of the following two alternative criteria: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>The first criterion is a function of the consolidated collected turnover of the Company relating to a
present or future partnership or licensing agreement, cumulated over the period from 1&nbsp;July 2016 to 30&nbsp;June 2019 (the &#147;<B>Cash Revenues</B>&#148;): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Turnover is strictly inferior to 50&nbsp;million euros, the conversion ratio under the Internal
Condition will be equal to 0; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Turnover is superior or equal to 50&nbsp;million euros and inferior to 150&nbsp;million euros, the
conversion ratio under the Price Condition will be equal to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">[(Turnover-50)/100]&times;100</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Cash Revenues are equal or superior to 150&nbsp;million Euros, the conversion ratio under the Internal
Condition will be equal to&nbsp;100; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>b)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>The second criterion is a function of the maturity of the portfolio of drug candidates developed by the
Company during the three years before the Expiry Date of the Retention Period. &#147;Drug candidates developed by the Company&#148; mean Lirilumab, Monalizumab and IPH4102. For each of these products: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of the authorization by the competent regulatory authority the United States or in Europe for the
Company or one of its partners to carry out a Phase III trial or a clinical trial with a view to register a product, the conversion ratio under the Internal Condition will be equal to 50; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of the authorization by the competent regulatory authority in the United States or in Europe for
the Company or one of its partners to carry out two Phases III trials or clinical trials with a view to register two products and/or two different indications for one product, the conversion ratio under the Internal Condition will be equal to 75;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of an acceptance from the European Medicines Agency (EMA) in Europe or the Food and Drug
Administration (FDA) in <I>the</I> United States to examine a filing by the Company or one of its partners of a marketing authorization request, the conversion ratio under the Internal Condition will be equal to 100. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Market Condition in order to calculate the conversion ratio of 2016 Preference Shares into ordinary shares
will be determined depending on the stock market price of the Innate Pharma share: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The terms &#147;<B>Initial
Price</B>&#148; mean the average closing price of the Innate Pharma share on Euronext Paris for the sixty trading days prior to the Allocation Date by the Executive Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The terms &#147;<B>Final Price</B>&#148; mean the highest average closing price of the Innate Pharma share on Euronext Paris over a period of
sixty consecutive days calculated at any time during the three years prior to the Expiry Date of the Retention Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The terms
&#147;<B>High Price</B>&#148; means the Initial Price multiplied by two. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>If the Final Price is strictly inferior to the Initial Price, the conversion ratio under the Market
Condition will be equal to 0; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>b)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>If the Final Price is between (i)&nbsp;a value equal or superior to the Initial Price and (ii)&nbsp;a
value inferior to the High Price, the conversion ratio under the Market Condition will be equal to: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">[(Final Price /
Initial Price) &#150;1/ ] x 100 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>c)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>If the Final Price is equal or superior to the High Price, the conversion ratio under the Market
Condition will be equal to 100. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The right to convert 2016 Preference Shares into ordinary shares, as well as the right to vote in the general
meetings of ordinary shares holders and the right to the dividend and to a portion of the reserves attached to 2016 Preference Shares that have become convertible pursuant to Paragraph&nbsp;II. above, are subject to the condition of the
beneficiary&#146;s presence in the Company or its consolidated subsidiaries as an employee, an executive officer or a member of an executive or supervisory body or, if applicable, of the equivalent thereof in foreign law as at the Expiry Date
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of the Retention Period. In the event that such condition ceases to be fulfilled, the Company may proceed at any moment to the redemption of 2016 Preference Shares in the conditions set forth in
Paragraph 8. below. It is specified that the provisions of this paragraph do not apply if the presence of the beneficiary in the Company or its consolidated subsidiaries ceases due to death, invalidity or retirement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fulfilment of the Performance Criteria will be recorded in a meeting of the Executive Board as soon as
practicable after the Expiry Date of the Retention Period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2016 Preference Shares that cannot be converted into ordinary shares depending on the extent to which the
Performance Criteria are fulfilled or if the presence condition as at the Expiry Date of the Retention Period is not fulfilled, and 2016 Preference Shares that can be but will not have been converted at the end of the Conversion Period, may be
bought at any time by the Company (which is under no obligation to do so) at their nominal value. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the end of the Conversion Period, the Company will have the possibility to proceed, pursuant to applicable
legal and regulatory provisions, to the cancellation of 2016 Preference Shares that will have not been converted, including those that it will have bought. The share capital will then be reduced accordingly, and creditors will have the right to
oppose such reduction in the conditions set forth in Article L. <FONT STYLE="white-space:nowrap">225-205</FONT> of the French Commercial Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New ordinary shares resulting from the conversion of 2016 Preference Shares will be assimilated to existing
ordinary shares, will bear rights as from the first day of the financial year preceding the financial year during which they become convertible, and will grant to their holders, starting from their delivery, all the rights attached to ordinary
shares. They will be subject to a request for listing on the regulated market of Euronext Paris on the same listing line as ordinary shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By way of derogation to the above, the allocation of 2016 Preference Shares can take place after the date of their allocation by the Executive Board and prior
to the Acquisition Date, in the event of invalidity of the beneficiary corresponding to classification in the second or third categories set forth by <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;341-4</FONT> of the French Social Security
Code, at the beneficiary&#146;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Executive Board will record the conversion into ordinary shares of the 2016 Preference Shares for which the
conversion fulfils the conditions set forth above, as well as the number of ordinary shares resulting from the conversions of 2016 Preference Shares that have taken place, and will modify the <FONT STYLE="white-space:nowrap">by-laws</FONT>
accordingly, in particular with regards to the breakdown of shares by category. This competence may be delegated to the Chairman of the Executive Board under the conditions set forth by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the conversion of 2016 Preference Shares into ordinary shares results in a capital increase, such increase will be fully paid up at issue through the
incorporation of reserves, profits or issue premiums for the corresponding amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders will be informed of the conversions having taken place by
the reports of the Executive Board and Statutory Auditors pursuant to <FONT STYLE="white-space:nowrap">Article&nbsp;R.&nbsp;228-18</FONT> of the French Commercial Code. These supplementary reports will be made available to the shareholders at the
Company&#146;s registered office as from the date on which each meeting is convened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>III.</B>&nbsp;&nbsp;&nbsp;&nbsp;2017 Preference Shares </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;Rights attached to 2017 Preference Shares </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2017 Preference Shares and the rights of holders thereof are governed by the applicable provisions of the French Commercial Code, in particular <FONT
STYLE="white-space:nowrap">Articles&nbsp;228-11</FONT> et seq. thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum number of 2017 Preference Shares that may be allocated is 12,500 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From their definitive acquisition until the date at which they become convertible, the 2017 Preference Shares grant the right to vote in the ordinary and
extraordinary general meetings of holders of ordinary shares on the basis of one voting right per 2017 Preference Share. As from the date on which they become convertible, the number of voting rights to which each 2017 Preferred Share entitles the
holder becomes equal to the number of ordinary shares to which the conversion of each 2017 Preferred Share entitles the holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2017 Preference Shares
grant the right to vote in the special meetings of holders of 2017 Preference Shares. Holders of 2017 Preference Shares are grouped into a special meeting for any proposed modification of the rights attached to 2017 Preference Shares. In addition,
pursuant to the provisions <FONT STYLE="white-space:nowrap">of&nbsp;Article&nbsp;L.&nbsp;228-17</FONT> of the French Commercial Code, any proposed merger or demerger of the Company in which 2017 Preference Shares cannot be exchanged for shares with
equivalent particular rights will be subject to the approval of any relevant special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special meetings can only make valid decisions if the
holders of 2017 Preference Shares that are present or represented hold at least, when convened for the first time, one third, and when convened for the second time, one fifth of the 2017 Preference Shares carrying the right to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From their definitive acquisition until the date at which they become convertible, the 2017 Preference Shares benefit from a dividend and are entitled to the
reserves. The amount of the dividend (and, if applicable, of the portion of the reserves) to which each 2017 Preference Shares entitles is equal to the amount due in respect of an ordinary share. To this end, the 2017 Preference Shares will bear
rights as from the first day of the financial year preceding the financial year during which they are definitively acquired. As from the date at which they become convertible, the amount of the dividend (and, if applicable, of the portion of the
reserves) to which each 2017 Preference Shares entitles is equal to the amount due in respect of an ordinary share, multiplied by the number of ordinary share that can be received from the conversion of each 2017 Preference Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regards to the ownership of corporate assets, a 2017 Preference Shares gives right to a portion of the liquidation surplus in proportion to the portion
of share capital that it represents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2017 Preference Shares give preferential subscription rights to any capital increase or any operation granting a
right on ordinary shares, on the basis of one preferential subscription right per 2017 Preferred Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a capital depreciation or
reduction, a change in the distribution of profits, an allocation of free shares, or the incorporation into the capital of reserves, profits or share premiums, distribution of reserves or any issue of capital securities or securities giving the
right to the allocation of capital securities with a subscription right reserved for shareholders before the 2017 Preferred Shares are convertible under the conditions provided below, the conversion ratio will be adjusted to take into account this
operation pursuant to the provisions of <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;228-99,</FONT> Paragraph&nbsp;2, 3&deg; and Paragraph&nbsp;5 of the French Commercial Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;Conversion of 2017 Preference Shares into ordinary shares </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of 2017 Preference Shares may only be decided in the framework of an allocation of free shares in favour of the employees and/or executive
officers of the Company, pursuant to the provisions of Articles L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">225-97-1</FONT></FONT> of the French Commercial Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2017 Preference Shares will be definitively acquired by the beneficiaries after an acquisition period of one year from their allocation by the Executive Board
and subject to the beneficiary&#146;s presence in the Company or its consolidated subsidiaries as an employee, executive officer or member of an executive or supervisory body or, if applicable, of the equivalent thereof in foreign law. The
&#147;<B>Acquisition Date</B>&#148; is defined as the end of the acquisition period of the 2017 Preference Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, in the event of invalidity of the beneficiary corresponding to classification in the second or third
categories set forth by <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;341-4</FONT> of the French Social Security Code (or the equivalent thereof in an applicable foreign law), the 2017 Preference Shares will be allocated definitively prior
to the Acquisition Date. In the event of the death of the beneficiary, in accordance with the provisions of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;225-197-3</FONT></FONT> of the French Commercial Code,
the heirs or successors of the beneficiary may, if they so wish, request the definitive allocation of the 2017 Preferred Shares to them within six months of the date of death. In the event of retirement, the beneficiaries will retain their right to
the definitive allocation of the 2017 Preferred Shares although they are no longer bound by an employment contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The 2017
Preference Shares become convertible in ordinary shares, either new or existing at the Company&#146;s option, after the above-mentioned <FONT STYLE="white-space:nowrap">one-year</FONT> vesting period from their allocation by the Executive Board,
followed by a <FONT STYLE="white-space:nowrap">two-year</FONT> retention period from the definitive allocation (the&nbsp;&#147;Retention Period&#148;), under the conditions set forth in Paragraphs&nbsp;2 to 13 below. The &#147;<B>Expiry Date of the
Retention Period</B>&#148; is defined as the end&nbsp;of&nbsp;the&nbsp;Retention Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an exception to the above, in the event of a public tender or
exchange offer, the final results of which are announced no later than the Expiry Date of&nbsp;the Retention Period as defined above, the 2017 Preferred Shares will become convertible no later than (i)&nbsp;the first anniversary of the Definitive
Allocation (if such an offer occurs before such anniversary and in such a way that the Retention Period lasts at least one year), or (ii)&nbsp;the date of announcement of the final results of such an offer (if such an offer occurs after the
anniversary) (the &#147;Amended Expiry Date of the Retention Period&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;As from the first anniversary date of the
Acquisition Date, 2017 Preference Shares will be freely transferable to a credit institution in the framework of a pledge agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
provisions set forth in the Article L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">225-197-1</FONT></FONT> I., Paragraph 6 of the French Commercial Code, the 2017 Preference Shares will be freely transferable in the event of
invalidity of the beneficiary corresponding to classification in the second or third categories set forth by <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;341-4</FONT> of the French Social Security Code, regardless of whether such invalidity
occurs before or after the Acquisition Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of the beneficiary&#146;s death, whether during the vesting period or the Retention Period, his
heirs will no longer be required to comply with this <FONT STYLE="white-space:nowrap">non-transferability</FONT> commitment, so that the 2017 Preferred Shares for which they have requested the definitive allocation will freely become transferable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;2017 Preference Shares may only be converted for a conversion period of six years and six months from the Expiry Date of the
Retention Period (the &#147;Conversion Period&#148;), provided however that in the event of a public tender or exchange offer whose final results are announced no later than the Expiry Date of the Retention Period, the Conversion Period shall
commence from the Amended Expiry Date of the Retention Period for such a period that, together with the Retention Period, it represents a total duration of eight years and six months from the Acquisition Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;During the Conversion Period, each holder of 2017 Preference Shares will have the right to convert each of his 2017 Preference
Shares in ordinary shares, either new or existing (at the Company&#146;s option). The number of ordinary shares to which the conversion of one 2017 Preference Share will entitle will be equal to a number of ordinary shares determined according to
the fulfilment of a market condition as defined below (the &#147;Market Condition&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;The Market Condition in order to calculate the conversion ratio of 2017 Preference
Shares into ordinary shares will be determined based on the relative performance of the Innate pharma share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Initial Price</B>&#148;
means the average closing price of the Innate Pharma share on Euronext Paris for the sixty trading days prior to the date of the General Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
term &#147;<B>Final Price</B>&#148; means (i)&nbsp;the highest average closing price of the Innate Pharma share on Euronext Paris over a period of sixty consecutive days, calculated at any time during the twelve months prior to the Expiry Date of
the Retention Period, or (ii)&nbsp;in the event of a public tender or exchange offer whose final results are announced no later than the Expiry Date of the Retention Period, the price at which this public tender offer is made (or, in the case of a
public exchange offer only, the price by transparency by applying the exchange ratio to the closing price of the bidder&#146;s share on the day before the Amended Expiry Date of the Retention Period). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>If the Final Price is inferior or equal to the Initial Price, the conversion ratio will be equal to 0;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>b)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>If the Final Price is comprised between the Initial Price and &#128;&nbsp;30, the conversion ratio will
be equal to: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">100 x [(Final Price &#150; Initial Price) / (30 &#150; Initial Price)], rounded up to the nearest whole
number </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>c)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>If the Final Price is equal or superior to &#128;&nbsp;30, the conversion ratio will be equal to 100.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, if between the date of the General Meeting and the Expiry Date of the Retention Period (or, as the case may be, the Amended
Expiry Date of the Retention Period), one of the Reference Indexes (as defined below) were to experience a Significant Variation (as defined below), then the Executive Board will have the possibility to adjust the Initial Price and/or the Final
Price to neutralize the exogenous impact of such a Significant Variation. The Executive Board shall, in this case, appoint a recognized independent expert to assist the Executive Board in the determination of such adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Reference Indexes&#148; means the following stock market indexes: SBF 120, CAC 40, Next Biotech and NBI (NASDAQ Biotechnology Index). If one of
these indexes were to be no longer available, the Executive Board can choose a replacement index. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Significant Variation&#148; means one or
the other of the following events for the relevant index: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the average of the closing value for the index over the sixty consecutive trading days prior to the Expiry Date
of the Retention Period (or, as the case may be, the Amended Expiry Date of the Retention Period) is inferior or equal to 90% of the average of the closing value for the index over the sixty consecutive trading days prior to the General Meeting ;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the average of the closing value for the index over a sixty consecutive trading days period at any time between
the date of the General Meeting and the Expiry Date of the Retention Period (or, as the case may be, the Amended Expiry Date of the Retention Period), is inferior or equal to 80% of the average of the closing value for the index over another sixty
consecutive trading days period at any time between the date of the General Meeting and the Expiry Date of the Retention Period (or, as the case may be, the Amended Expiry Date of the Retention Period). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;The right to convert 2017 Preference Shares into ordinary shares, as well as the right to vote in the general meetings of ordinary
shares holders and the right to the dividend and to a portion of the reserves attached to 2017 Preference Shares that have become convertible pursuant to Paragraph III A. above, are subject to the condition of the beneficiary&#146;s presence in the
Company or its consolidated subsidiaries as an employee, an executive officer or a member of an executive or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supervisory body or, if applicable, of the equivalent thereof in foreign law as at the Expiry Date of the Retention Period (or, as the case may be, the Amended Expiry Date of the Retention
Period). In the event that such condition ceases to be fulfilled, the Company may proceed at any moment to the redemption of 2017 Preference Shares in the conditions set forth in Paragraph 8. below. It is specified that the provisions of this
paragraph do not apply if the presence of the beneficiary in the Company or its consolidated subsidiaries ceases due to death, invalidity or retirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;The fulfilment of the Market Condition will be recorded in a meeting of the Executive Board as soon as practicable after the Expiry
Date of the Retention Period (or, as the case may be, the Amended Expiry Date of the Retention Period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;2017 Preference Shares
that cannot be converted into ordinary shares depending on the extent to which the Market Condition is fulfilled or if the presence condition as at the Expiry Date of the Retention Period (or, as the case may be, the Amended Expiry Date of the
Retention Period) is not fulfilled, and 2017 Preference Shares that can be but will not have been converted at the end of the Conversion Period, may be bought at any time by the Company (which is under no obligation to do so) at their nominal value.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;At the end of the Conversion Period, the Company will have the possibility to proceed, pursuant to applicable legal and
regulatory provisions, to the cancellation of 2017 Preference Shares that will have not been converted, including those that it will have bought. The share capital will then be reduced accordingly, and creditors will have the right to oppose such
reduction in the conditions set forth in <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;225-205</FONT> of the French Commercial Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;New ordinary shares resulting from the conversion of 2017 Preference Shares will be assimilated to existing ordinary shares, will
bear rights as from the first day of the financial year preceding the financial year during which they will be converted, and will grant to their holders, starting from their delivery, all the rights attached to ordinary shares. They will be subject
to a request for listing on the regulated market of Euronext Paris on the same listing line as ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By way of derogation to the above, the
allocation of 2017 Preference Shares can take place after the date of their allocation by the Executive Board and prior to the Acquisition Date, in the event of invalidity of the beneficiary corresponding to classification in the second or third
categories set forth by <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;341-4</FONT> of the French Social Security Code, at the beneficiary&#146;s request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;The Executive Board will record the conversion into ordinary shares of the 2017 Preference Shares for which the conversion fulfils
the conditions set forth above, as well as the number of ordinary shares resulting from the conversions of 2017 Preference Shares that have taken place, and will modify the <FONT STYLE="white-space:nowrap">by-laws</FONT> accordingly, in particular
with regards to the breakdown of shares by category. This competence may be delegated to the Chairman of the Executive Board under the conditions set forth by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;If the conversion of 2017 Preference Shares into ordinary shares results in a capital increase, such increase will be fully paid up
at issue through the incorporation of reserves, profits or issue premiums for the corresponding amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. Shareholders will be informed of the
conversions having taken place by the reports of the Executive Board and Statutory Auditors pursuant to <FONT STYLE="white-space:nowrap">Article&nbsp;R.&nbsp;228-18</FONT> of the French Commercial Code. These supplementary reports will be made
available to the shareholders at the Company&#146;s registered office as from the date on which each general meeting is convened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE
13&nbsp;&#150; Usufruct / Bare Ownership </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares are not divisible with respect to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Co-owners</FONT> of shares must arrange to be represented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-a-vis</FONT></FONT> the Company by one of them only, who will be considered as the sole holder, or by a sole agent. In the case of disagreement, a sole agent may be appointed by the
courts at the request of the most diligent <FONT STYLE="white-space:nowrap">co-owner.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the Company has been notified of an agreement to the
contrary, usufruct shareholders validly represent bare owners <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company. The right to vote is held by the usufruct shareholder in Ordinary Meeting of
Shareholders and by the bare owner in Extraordinary Meeting of Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise agreed by the parties, where shares are encumbered by a
usufruct interest, the preferential right to subscription attached thereto is held by the bare owner. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE IV </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COMPANY MANAGEMENT AND SUPERVISION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 14&nbsp;&#150; Management Structure </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company is managed by an Executive Board which exercises its duties under the supervision of a Supervisory Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 15&nbsp;&#150;
Composition of the Executive Board </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Executive Board consists of at least two members and five members at
most. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;Members of the Executive Board are appointed by the Supervisory Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of the Supervisory Board appoint one of the members of the Executive Board as Chairman of the Executive Board for the duration of his term of
office as a member of the Executive Board. The Chairman of the Executive may be dismissed by the Supervisory Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Executive Board must
be natural persons, failing which the appointment shall be null and void. They may be chosen from <FONT STYLE="white-space:nowrap">non-shareholders.</FONT> They may be French nationals or of foreign nationality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Executive Board may be dismissed by the Supervisory Board of the Meeting of Shareholders. They may resign at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a member of the Executive Board has entered into an employment contract with the Company, his dismissal, resignation or the expiry of his term of office as
a member of the Executive Board will not cause such contract to be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Executive Board is appointed for a term of three years. If a post is
vacant, the Supervisory Board must make an appointment to fill the post within two months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the terms of office of the members of the Executive
Board who were duly appointed for six years by the Supervisory Board of 13&nbsp;June 2005, pursuant to the provisions of the articles of association which were then applicable, shall continue to the end of their initial term and be renewed at the
annual meeting of shareholders called to decide on the accounts of the financial year closing 31&nbsp;December 2010. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The replacement is appointed for the
remaining term until the renewal of the Executive Board. Members of the Executive Board may be reappointed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The procedure for and amount of the
remuneration of each of the members of the Executive Board is set out in the instrument appointing them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>III.</B>&nbsp;&nbsp;&nbsp;&nbsp;No member of the Executive Board may be a member of the Supervisory Board,
the Sole Chief Executive Officer or the Chairman of the Executive Board of more than one other corporation whose registered office is in metropolitan France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Board membership may only be combined with another corporate office in another company in accordance with the statutory and regulatory restrictions
in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IV.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Executive Board meets as often as necessary in the interests of the Company and at least once a quarter,
convened by its Chairman or an Executive Board member delegated to such effect, at the place decided by the person convening the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order for
deliberations to be valid, the majority of the members of the Executive Board must be physically present. However, members of the Executive Board who attend Executive Board meetings by video-conference or any other means of telecommunication in
compliance with the statutory and regulatory provisions applicable to corporations with a Board of Directors management structure, are deemed to be present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any member of the Executive Board may be represented by another member of the Executive Board at the meetings of the Executive Board or take part in an
Executive Board meeting by video-conference or any other means of telecommunication as referred to above. Each member of the Executive Board may receive only one proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Decisions are made by a majority of those present and represented. Each member has one vote </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each meeting, the Executive Board may appoint a secretary who may be chosen from outside the members of the Executive Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>V.</B>&nbsp;&nbsp;&nbsp;&nbsp;The deliberations of the Executive Board are recorded in minutes placed or bound in a special registry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The records are signed by the Chairman and by a member of the Executive Board who is present at the meeting, or by two of the members present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Executive Board has to provide evidence of its deliberations, copies of extracts of the minutes to be submitted in evidence shall be certified by the
Chairman or by a member of the Executive Board delegated for this purpose. Following dissolution of the Company, they are certified by one of the liquidators or the sole liquidator. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 16&nbsp;&#150; Powers of the Executive Board </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Executive Board has the widest of powers to act in all circumstances in the name of the Company. It exercises its powers
within the scope of the corporate purposes, subject to the powers which are expressly granted by law to the Supervisory Board and the Meeting of Shareholders, and, as the case may be, within the limit of the restrictions on powers decided by the
Supervisory Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In its relations with third parties, the Company is bound by the actions of the Executive Board even where these are outside of the
scope of the corporate purposes, unless it proves that the third party was aware that the actions exceeded such purposes or if it could not have failed to be aware of this in view of the circumstances; publication of the articles of association not
in itself constituting sufficient evidence thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chairman of the Executive Board, or, as the case may be, the Chief Executive Officer, ,
represents the Company in its relations with third parties. The Supervisory Board may grant the same authority to represent the Company to one or more other Executive Board members, who in that case will be&nbsp;referred to as managing directors.
The Chairman of the Executive Board and the managing director (s), if any, may designate any agent which they choose to exercise specific powers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Executive Board presents a report to the Supervisory Board at least
once every quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Executive Board presents the annual financial statements to the Supervisory Board within three months of the end of each
financial year, for the purposes of verification and supervision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It must also provide the Supervisory Board with the management report which it will
present to the Annual Meeting of Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>III.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Chairman of the Executive Board represents the Company in its
relations with third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IV.</B>&nbsp;&nbsp;&nbsp;&nbsp;Members of the Executive Board may allocate corporate management tasks among themselves,
with the approval of the Supervisory Board. However, such distribution may not, under any circumstances, cause the Executive Board to lose its collegial nature with respect to the management of&nbsp;the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 17&nbsp;&#150; Composition of the Supervisory Board </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Executive Board is supervised by a Supervisory Board composed of a minimum of three members and a maximum of eighteen
members, subject to the exceptions provided by law in such respect in the event of a merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Supervisory Board are appointed from among
natural persons or legal entities that are shareholders by the Ordinary Meeting of Shareholders, which may dismiss them at any time. However, in the case of a merger or demerger, an Extraordinary Meeting of Shareholders may appoint the members of
the Supervisory Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No member of the Supervisory Board may be a member of the Executive Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of the members of the Supervisory Board who have reached seventy (70)&nbsp;years of age may not be greater than one third of the members of the
Supervisory Board in office. Where such limitation concerning the age of members of the Supervisory Board is exceeded, the most elderly member of the Supervisory Board is deemed to have automatically resigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;The duration of the terms of office of the members of the Supervisory Board is two years. It expires at the close of the
Meeting of Shareholders called to decide on the financial statements for the preceding year and which is held during the year in which their appointment expires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Supervisory Board may be reappointed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">They may
be dismissed at any time by an Ordinary Meeting of Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>III.</B>&nbsp;&nbsp;&nbsp;&nbsp;Members of the Supervisory Board may be natural
persons or legal entities. Legal entities must, at the time of their appointment, designate a permanent representative who will be subject to the same conditions and obligations and who will incur the same liabilities provided by law as if he were a
member of the Council in his own name, without prejudice to the joint and several liability of the legal entity he represents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a legal entity
dismisses its representative, it must appoint a replacement at the same time. This rule also applies in the case of the death, resignation or long-term prevention of the permanent representative from exercising his duties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A natural person who accepts an appointment and exercises as a member of the Supervisory Board thereby has
the obligation to confirm at any time on&nbsp;oath, that he satisfies the limitation required by law with respect to the combining the post of member of the Supervisory Board and member of the Executive Board of corporations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IV.</B>&nbsp;&nbsp;&nbsp;&nbsp;Appointments which are made by the Supervisory Board in accordance with the foregoing are subject to ratification by the
next following Ordinary Meeting of Shareholders. If such appointments are not ratified, the deliberations made and actions previously carried out by the Supervisory Board nevertheless remain valid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the number of the members of the Council becomes less than the statutory minimum, the Executive Board must immediately convene an Ordinary Meeting of
Shareholders to appoint members to complete the Council. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A member of the Supervisory Board appointed to replace another member shall only remain in
office for the remaining term of office of his predecessor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>V.</B>&nbsp;&nbsp;&nbsp;&nbsp;Each member of the Supervisory Board must own one share in
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a member of the Supervisory Board does not own the required number of shares on the date of his appointment or if, during his term of
office he ceases to own such number, he shall be deemed to have automatically resigned if he has not rectified this situation within six months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 18&nbsp;&#150; Chairman and Vice-Chairman of the Supervisory Board </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board appoints, from among its natural person members, a Chairman and a Vice-Chairman, who are responsible for convening the Council and
chairing the proceedings of the Council. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chairman of Supervisory Board also prepares a report presented during the annual Ordinary Meeting of
Shareholders in compliance with the conditions provided by Article L. <FONT STYLE="white-space:nowrap">225-68</FONT> paragraph 7 of the Commercial Code, providing details of the conditions in which the work of the Supervisory Board was prepared and
organised, and describing the internal supervision procedures implemented by the Company, which is attached to the Executive Board&#146; report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Chairman and Vice-Chairman exercise their duties during their term of office as members of the Supervisory Board. They may be <FONT STYLE="white-space:nowrap">re-elected.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Council may also appoint a secretary who may be selected from outside the members of the Council and determine the duration of his term of office. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 19&nbsp;&#150; Deliberations of the Supervisory Board </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Supervisory Board meets as often as necessary in the interests of the Company and at least once every quarter to review
the Executive Board&#146; report. The meeting is convened by its Chairman or Vice-Chairman either at the registered office or at any place indicated in the notice of meeting. A&nbsp;member of the Executive Board, or at least one third of the members
of the Supervisory Board, may submit a reasoned request for a Council meeting to the Chairman of the Supervisory Board by registered mail. The Chairman must convene a Council meeting not later than fifteen days from receipt of such request. If the
meeting has not been convened within this time period, the persons who made the request may convene the meeting themselves, indicating the agenda of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board cannot deliberate validly unless at least half its members are present. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Supervisory Board may participate and vote at Council meetings by video-conference or other
means of telecommunication in accordance with the statutory and regulatory provisions applicable thereto. However, voting by video-conference is not allowed for decisions concerning the verification and supervisions of financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any member of the Supervisory Board may be represented by another member of the Supervisory Board at Supervisory Board deliberations. Each&nbsp;member of the
Supervisory Board may receive only one proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Decisions are made by a majority of those present or represented, and each member has one vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a tie, the Chairman has the tiebreaking vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evidence of the number of members of the Supervisory Board in office and their appointment may be validly provided with respect to third parties on&nbsp;the
simple basis of the statement in the minutes of each meeting of the names of the members that are in attendance, represented or absent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;The deliberations of the Supervisory Board are recorded in minutes kept in a special register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such minutes are signed by the Chairman of the meeting and by at least one member of the Supervisory Board. If the Chairman of the meeting is unable to do so,
the minutes are signed by at least two members of the Supervisory Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies or extracts of such minutes are validly certified by the Chairman of
Vice-Chairman of the Supervisory Board, a member of the Executive Board or an agent duly appointed for the purpose thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the Company is wound
up, copies or extracts shall be certified by one of the liquidators of by the sole liquidator. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 20&nbsp;&#150; Powers of the Supervisory
Board </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Supervisory Board exercises constant supervision of the management of the Company by the Executive
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Supervisory Board may carry out verifications or supervision which it considers suitable at any time during
the year, and may request documents to be provided to it which it considers useful for the carrying out of its duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It receives a report from the
Executive Board at least once every quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Executive Board presents the annual financial statements and a written management report to the
Supervisory Board within three months of the end of each financial year, for the purposes of verification and supervision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board presents
the Ordinary Annual Meeting of Shareholders with its comments on the report of the Executive Board and the financial statements for the year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Supervisory Board also exercises the attributions expressly granted to it by statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board may appoint one or more of its members as
special agents for one or more determined purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board may create committees in charge of reviewing issues on which it or its Chairman
wish an opinion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 21&nbsp;&#150; Remuneration of Members of the Supervisory Board </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Meeting of Shareholders may allocate a fixed annual amount in directors&#146; fees to members of the Supervisory Board in
remuneration for their duties. The Supervisory Board may distribute such remuneration among its members as it sees fit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Supervisory Board may also allocate exceptional remuneration for missions entrusted to its members. In such case, the
remuneration is subject to the provisions of Article 22 hereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>III.</B>&nbsp;&nbsp;&nbsp;&nbsp;Members of the Supervisory Board may not receive
any other fixed or exceptional remuneration other than those referred to in paragraphs I and II above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 22&nbsp;&#150; Regulated Agreements
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;Any agreement entered into between the Company and any of the members of the Executive Board or Supervisory
Board, a shareholder with more than 10% of the voting rights or, in the case of a corporate shareholder, the company controlling it within the meaning of <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;233-3</FONT> of the Commercial Code with
more than 10% of the voting rights, is subject to the prior approval of the Supervisory Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The same rule applies to agreements in which one of the
persons referred to in the previous paragraph has an indirect interest or for which it has dealt with the Company through an intermediary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreements
between the Company and an enterprise are also subject to prior approval if one of the members of the Executive Board or the Supervisory Board of the Company is the owner, a partner with unlimited liability, a manager, director, director general,
member of the Executive Board or Supervisory Board of such enterprise, or more generally is in charge of managing such enterprise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prior approval of
the Supervisory Board is substantiated by justifying of the interest of entering the agreement for the Company, in particular by specifying the financial conditions that apply thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preceding provisions do not apply to agreements entered into in the ordinary course of business and under normal conditions, nor to agreements entered
into between two companies, one of which holds, directly or indirectly, the entire share capital of the other company, excluding if applicable the minimum number of shares necessary to comply with the requirements of Article&nbsp;1832 of the French
Civil Code or <FONT STYLE="white-space:nowrap">Articles&nbsp;L.&nbsp;225-1</FONT> and <FONT STYLE="white-space:nowrap">L.&nbsp;226-1</FONT> of the French Commercial Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The member of the Executive Board or Supervisory Board concerned must inform the Supervisory Board as soon as be becomes aware of an agreement subject to
approval. If he is a member of the Supervisory Board, he cannot take part in the vote of approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chairman of the Supervisory Board must inform the
statutory auditor of all authorised agreements to and submit them for approval to the Meeting of Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;The
statutory auditors present a special report on such agreements to the Meeting of Shareholders which will decide on these agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person concerned
cannot take part in the vote and the shares he holds are not included in the calculation of the quorum or the majority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreements entered into and
authorized in previous years and which have continued during the last year shall be reviewed annually by our Supervisory Board and must be reported to our statutory auditors for the purpose of establishing their report. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 23&nbsp;&#150; Panel of Censors </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Ordinary Meeting of Shareholders may appoint one or more censors at its discretion, who may be natural persons or legal entities, and may be shareholders or
<FONT STYLE="white-space:nowrap">non-shareholders,</FONT> for a term of office expiring at the shareholders meeting convened to decide on the financial statements for the preceding financial year after the first anniversary date of their
appointment. This appointment may be renewed an unlimited number of times. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Censors that are legal entities are represented by their legal representatives
or by any natural person duly authorised for this purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Censors are convened to and take part in all the meetings of the Supervisory Board and have a
consultative vote, according to the same methods as those that apply to members of the Supervisory Board. They are entitled to the same information and communication as members of the Supervisory Board and are bound by the same obligations of
confidentiality and discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 24&nbsp;&#150; Obligation of Confidentiality and Liability </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;Members of the Executive Board and the Supervisory Board, as well as any person convened to attend the meetings of these
bodies, are bound by complete discretion with respect to confidential information and provided as such by the Chairman of the Executive Board or as the case may be, the Supervisory Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;Members of the Executive Board and the Supervisory Board are liable towards the Company or third parties, in accordance with
their respective attributions, for breaches of statutory provisions governing limited liability companies, breaches of these articles of association and faults committed in the exercise of their duties, subject to the conditions and the sanctions
provided by the legislation in force. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE V </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STATUTORY AUDITORS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE
25&nbsp;&#150; Statutory Auditors </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One or more statutory auditors perform an audit of the Company, in the accordance with statutory requirements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Statutory Auditors are appointed by the Ordinary Meeting of Shareholders on proposal by the Supervisory Board, for six financial years. They may
always be <FONT STYLE="white-space:nowrap">re-appointed.</FONT> They may be dismissed by the aforesaid Meeting of Shareholders in the event that they commit a fault or are prevented from carrying out their duties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Meeting of Shareholders does not appoint the Statutory Auditor(s) or if one or more appointed Statutory Auditors are prevented or refuse to carry out
their duties, they, or their replacement(s), are appointed by an order of the Commercial Court with jurisdiction over the area in which the Company is based on petition of any interested person, with the Executive Board duly convened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Statutory Auditor appointed by the Meeting of Shareholders to replace another shall only remain in office for the remaining term of office of his
predecessor. If the Meeting of Shareholders appoints several Statutory Auditors, they may act together or separately but they must draft a joint report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One or more shareholder(s) with a shareholding of at least 5% may apply to the courts to dismiss one or more of the Statutory Auditors appointed by the
Meeting of Shareholders and request the appointment of one or more Statutory Auditors who will exercise their duties instead of them. If their request is granted, the Statutory Auditors so appointed shall exercise their duties until the Statutory
Auditors appointed by the Meeting of Shareholders take up their posts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Statutory Auditors certify that the annual financial statements are in due form and give a true and fair
view of the result of the operations of the preceding financial year, and of the financial situation and assets and liabilities of the Company at the end of that financial year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Their permanent role, without exercising any interference with management, is to verify the company&#146;s worth and financial documents and to ensure that
its accounting is in compliance with the rules in force. They also verify that the information contained in Executive Board management report and in the documents provided to shareholders on the financial situation and annual accounts is fair and
consistent with the annual accounts. The Statutory Auditors ensure that equality among shareholders has been complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Statutory Auditors may,
at any time during the year, carry out any verification or supervision they consider suitable and collect any information from third parties who have carried out assignments on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Statutory Auditors prepare a report for the Meeting of Shareholders on the performance of their assignment. The Statutory Auditors attach a report to the
aforesaid report, presenting their comments on the report referred to in <FONT STYLE="white-space:nowrap">Article&nbsp;L.&nbsp;225-68</FONT> paragraph&nbsp;7 of the Commercial Code with respect to internal supervision procedures relating to the
preparation and treatment of accounting and financial information. They also prepare a special report on the agreements referred to in Article 22 of these Articles of Association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Statutory Auditors are invited to attend the Executive Board meeting at which the financial statements for the preceding financial year are approved, as
well as to all Meeting of Shareholders. They may convene a Meeting of Shareholders under the conditions provided by statute. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE
VI </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SHAREHOLDERS&#146; MEETINGS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>A &#150; Provisions Applying </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>to all Meetings of Shareholders </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 26&nbsp;&#150; Meetings </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A duly constituted
Meeting of Shareholders represents all the shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Its deliberations effected in accordance with the law and the articles of association are
binding on all the shareholders, even those who were absent, dissenting or without legal standing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are three kinds of meeting, depending on the
purpose of the proposed resolutions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ordinary Meeting of Shareholders, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Extraordinary Meeting of Shareholders, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Special Meeting of Shareholders of holders of a specific category of share. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 27&nbsp;&#150; Convening Meetings </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders&#146; Meetings are convened by the Executive Board, or failing that, the Supervisory Board. They may also be convened by the Statutory Auditor(s)
or by an agent appointed by the court in accordance with the procedures and conditions provided by statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During liquidation, Shareholders&#146;
Meetings are convened by the liquidator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders&#146; Meetings are held at the registered office or in any other place indicated in the
convocation notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice of the meeting is published in the Bulletin des Annonces L&eacute;gales Obligatoires (BALO) (Mandatory Legal Notice Bulletin)
at least thirty-five days prior to which a meeting is held. In addition to the information relating to the Company, it also, in particular, sets out the agenda of the Meeting and the draft text of the resolutions which will be proposed. Subject to
particular legal requirements, requests for the inclusion of draft resolutions on the&nbsp;agenda must be sent at the latest on the publication date of the notice of the meeting and up to twenty-five days prior to the Shareholders&#146; Meeting;
this deadline is twenty days from the publication date of the notice when the notice is published more than forty-five days prior to the Shareholders&#146; Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders&#146; meetings are held at the registered office or in any other place indicated in the invitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to particular legal requirements, invitations to meetings are made at least fifteen days prior to the date of the meeting by a notice published in
both the legal notice journal of the administrative department in which the registered office is located and in the Bulletin des Annonces L&eacute;gales Obligatoires (BALO). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, holders of registered shares having held shares for at least one month as at the date of the last of the published notices must be convened
individually by ordinary letter (or by registered letter if they have requested this and advanced the costs) sent to their last known address. Such notice may also be sent by electronic communication instead of such postal dispatch, to any
shareholder who has so requested beforehand by registered mail return receipt requested, in accordance with statutory and regulatory requirements, indicating his email address. Such shareholder may send a request to the Company at any time by
registered letter with acknowledgement of receipt for the aforementioned method of telecommunication to be replaced by postal dispatch in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
invitation should contain the following information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the identity of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date, time and place of the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the nature of the meeting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the agenda of the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It must also state the conditions in which shareholders may vote by correspondence and the place and conditions pursuant to which they may procure forms for
voting by correspondence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The invitation may be sent, as the case may be, together with proxy form and a correspondence voting form, pursuant to the
conditions set out in Article&nbsp;30.&nbsp;I of these Articles of Association, or with a correspondence voting form only, pursuant to the conditions set out in Article&nbsp;30.&nbsp;II of these Articles of Association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a Shareholders&#146; Meeting has not been able to deliberate due to the required quorum not being reached, a second Shareholders&#146; Meeting is convened
with at least ten days&#146; advance notice, in the same manner as the first meeting. The invitation notice or letters for such second Shareholders&#146; Meeting state the date and agenda of the first meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 28&nbsp;&#150; Agenda </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agenda of a Meeting of Shareholders is decided by the person convening the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One or more shareholders representing at least the percentage of share capital determined by statute and acting pursuant to statutory conditions and within
statutory time periods, may request items or draft resolutions to be included on the agenda of the Meeting by registered mail with confirmation of&nbsp;receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Meeting of Shareholders cannot deliberate on an issue which has not been included on the agenda and such agenda cannot be modified on second convocation
of a Meeting of Shareholders. The Meeting of Shareholders may, however, in any circumstances, dismiss one or several members of the Supervisory Board and effect their replacement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 29&nbsp;&#150; Participation of Shareholders in Meeting of Shareholders </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All shareholders are entitled to attend Shareholders&#146; Meetings and take part in deliberations: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">either personally; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by giving a proxy to another shareholder or to his spouse; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by sending a blank proxy to the Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by voting by correspondence; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by videoconference or by another means of telecommunication in accordance with the applicable statutory and
regulatory provisions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participation in shareholders&#146; meetings in any manner is dependent on the registration or inscription of
shares under the conditions and within the deadlines set in the current regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The final date for the return of correspondence voting forms is
determined by the Executive Board and indicated in the notice of the meeting published in the Bulletin des Annonces L&eacute;gales et Obligatoires (BALO). This date cannot be prior to three days before the Shareholders&#146; Meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a shareholder is present at a Shareholders&#146; Meeting, any prior vote by correspondence will have no effect for the purposes of the aforesaid
Shareholders&#146; Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If both a proxy form and a correspondence voting form are returned, the proxy form will be taken into account, subject to the
votes expressed in the correspondence voting form. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 30&nbsp;&#150; Representation of Shareholders </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;Any shareholder may be represented at Meeting of Shareholders by another shareholder, his spouse, his partner in a civil union
or any other natural or legal person of his choice through a proxy form sent to the shareholder by the Company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">either at his request, sent to the Company by any means. This request must have been received at the registered
office at least five days prior to the Meeting of Shareholders; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the initiative of the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following must be attached to any proxy form sent to shareholders by the Company, for each Meeting of
Shareholders: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the agenda of the Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the draft resolutions presented by the Executive Board and, as the case may be, by shareholders pursuant to
statutory conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a brief summary of the Company&#146;s situation during the preceding financial year together with a table
indicating the results of the Company over the past five financial years, presented in accordance with regulatory provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a form requesting the documents to be sent as provided by the regulations in force; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a form for correspondence voting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A proxy given by a shareholder is only valid for one Meeting of Shareholders or for Meetings of Shareholders convened successively with the same agenda. A
proxy may also be given for two Meeting of Shareholders, one Ordinary and the other Extraordinary, which are held on the same day or within fifteen days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;Any shareholder may vote by correspondence through a voting form sent to him by the Company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at his request, sent to the Company by registered mail with confirmation of receipt. This request must have
been received at the registered office at&nbsp;least six days prior to the Meeting of Shareholders; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the initiative of the Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in an appendix to the proxy form in the conditions set out in Article 30. I above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following must be attached to any correspondence voting form sent to shareholders by the Company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the draft resolutions proposed together with a summary of the reasons and an indication of the author of the
resolutions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a form for sending the documents as provided by the regulations in force; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a brief summary of the Company&#146;s situation during the preceding financial year together with a table
indicating the results of the Company over the past five financial years, presented in accordance with regulatory provisions, in the case of an Ordinary Meeting of Shareholders deciding on the accounts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A correspondence voting form sent by a shareholder is only valid for one Meeting of Shareholders or for Meeting of Shareholders convened successively with the
same agenda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 31&nbsp;&#150; Attendance Register </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An attendance register is kept for each Meeting of Shareholders containing the information required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This attendance register, duly signed by the shareholders that are present, the agents and shareholders participating by video-conference or by another means
of telecommunication in compliance with statutory and regulatory requirements, and to which are attached the powers of attorney granted to each agent and, as the case may be, the correspondence voting forms, is certified by the secretariat of the
Meeting of Shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Meeting of Shareholders are chaired by the Chairman of the Supervisory Board, the Vice-Chairman or a member
of the Supervisory Board delegated for such purpose by the aforesaid Council. Failing that, the Meeting of Shareholders elects its Chairman itself. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
two shareholders present with the greatest number of votes both on in their own right and as agents, and who accept such assignment, shall act as vote tellers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The secretariat composed as such appoints a Secretary, who may be selected from outside of the shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 32&nbsp;&#150; Quorum </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Ordinary and
Extraordinary Meeting of Shareholders, the quorum is calculated on the basis of all the shares making up the share capital and, in Special Meeting of Shareholders, all the shares of the relevant category, less shares stripped of their voting rights
pursuant to statutory provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The voting rights attached to shares are proportional to the portion of share capital which they represent. Each share
entitling its holder to an interest in the capital or to beneficial enjoyment carries one vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of a vote by correspondence, only completed
forms received by the Company at least three days prior the Meeting of Shareholders shall be taken into account for the calculation of the quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forms
which do not indicate which way to vote, or which indicate an abstention, are considered as negative votes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 33&nbsp;&#150; Minutes
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deliberations of the Meeting of Shareholders are recorded in minutes drafted in a special register held at the registered office and signed by
the members of the secretariat. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies or extracts of such minutes are certified either by the Chairman of Vice-Chairman of the Supervisory Board or by a
member of the Executive Board or by the Secretary of the Meeting. If the Company is wound up, they may be validly certified by the liquidator(s). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 34&nbsp;&#150; Communication of Documents </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any shareholder is entitled to receive, and the Executive Board is bound to send or provide him with the documents he requires to come to an informed decision
and have an informed judgement on the management and running of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nature of these documents and the conditions in which they are sent or
provided to shareholders are determined by regulations in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In exercising its right to receive documents, each shareholder or his agent may be
assisted by a court-registered expert. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise of the right to receive documents includes the right to make copies, except with respect to
inventories. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>B &#150; Provisions Specific to </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Ordinary Meetings of Shareholders </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 35&nbsp;&#150; Ordinary Meeting of Shareholders </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Ordinary Meeting of Shareholders may make any decision other than one which directly or indirectly modifies the Articles of Association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary Meetings of Shareholders are held at least once a year, within six months of the end of each financial year, to decide on the financial statements
for such financial year, subject to the extension of such period by an order of the President of the Commercial Court on petition from the Executive Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">They are called on an extraordinary basis every time it may be in interests of the Company to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When convened for the first time, Ordinary Meetings of Shareholders can only make valid decisions if the shareholders that are present, represented or voting
by correspondence hold at least one fifth of the shares carrying the right to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When convened for the second time, there is no quorum requirement if
the original agenda has not been modified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary Meetings of Shareholders make decisions on the basis of the majority of the votes of the shareholders
that are present, represented or voting by correspondence. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>C&nbsp;&#150; Provisions Specific to </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Extraordinary Meetings of Shareholders </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 36&nbsp;&#150; Extraordinary Meetings of Shareholders </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An amendment to any provision of the Articles of Association and, in particular, the transformation of the Company into another form of company may only be
decided by an Extraordinary Meeting of Shareholders. An Extraordinary Meeting of Shareholders cannot, however, increase the undertakings of shareholders, subject to operations as a result of regrouping shares in a due and proper manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When convened for the first time, Extraordinary Meeting of Shareholders can only make valid decisions if the shareholders that are present, represented or
voting by correspondence hold at least a quarter of the shares carrying the right to vote, and when convened for the second time, one fifth of the shares carrying the right to vote. If the latter quorum is not obtained, the second Meeting may be
adjourned for a maximum of two months from the date at which it was convened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Extraordinary Meeting of Shareholders makes decisions on the basis of a
majority of <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes held by shareholders that are present, represented or voting by correspondence or participating in the Meeting by video-conference or another method of telecommunication in
accordance with statutory and regulatory provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By statutory derogation from the preceding provisions, if the share capital is increased by the
incorporation of profits, reserves or issue premiums, the Extraordinary Meeting of Shareholders may make decisions at the quorum and majority required for Ordinary Meeting of Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, where an Extraordinary Meeting of Shareholders is convened to deliberate on the approval of a contribution in kind or the grant of a specific
benefit, the shares of the contributing party or beneficiary shall not be taken into account in calculating the majority. The contributing party or beneficiary cannot vote either in his own right or as an agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>D&nbsp;&#150; Provisions Specific to </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Special Meetings of Holders of a Category of Shares </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 37&nbsp;&#150; Special Meeting </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there
are several categories of shares, the rights attached to shares of any such category cannot be modified in any way without having been duly voted upon by an Extraordinary Meeting of Shareholders open to all shareholders and also having been voted
upon by a Special Meeting open only to holders of the relevant category of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When convened for the first time, Special Meetings of Shareholders can
only make valid decisions if the shareholders that are present, represented, voting by correspondence or taking part in the Meeting by video-conference or any other means of telecommunication in accordance with statutory or&nbsp;regulatory
provisions, hold at least a third of the shares carrying the right to vote, and when convened for the second time, one fifth of the shares carrying the right to vote and for which a modification of the attached rights is being proposed. Failing
that, the second meeting may be adjourned by a&nbsp;maximum of two months from the date at which it was convened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special Meetings of Shareholders make
decisions at a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes of shareholders that are present or represented. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE VII </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FINANCIAL YEAR &#150; ANNUAL FINANCIAL STATEMENTS </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPROPRIATION AND DISTRIBUTION OF PROFITS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 38&nbsp;&#150; Financial Year </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
financial year begins on 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> January of each year and ends on 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> December. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 39&nbsp;&#150; Accounts </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts of
corporate operations are kept in due form in accordance with the law and usual business practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the end of each financial year, the Executive Board
shall draw up an inventory of the various assets and liabilities as at such date. It shall also prepare the balance sheet describing the assets and liabilities, the income statement summarising the income and charges for the financial year and the
notes to the financial statements which complete and comment on the information provided in the balance sheet and income statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Executive Board
shall present such documents to the Supervisory Board within three months of the end of the financial year, for the purposes of verification and supervision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It shall prepare the management report on the situation of the Company during the preceding financial year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All such documents shall be made available to the Statutory Auditors pursuant to the conditions specified by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 40&nbsp;&#150; Appropriation of Profits </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income statement which summarises the income and charges for the financial year, after depreciation and provisions have been deducted, indicates the profit
or loss of the financial year by setting forth the difference between these two amounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Five per cent. of the year&#146;s profit less previous losses, as the case may be, is allocated to the
statutory reserve. Such allocation shall no longer be necessary once the aforesaid reserve reaches one tenth of the share capital, but will become necessary again if for any reason whatsoever the reserve falls below one tenth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributable earnings consist of the net income of the financial year, less previous losses and amounts added to the reserve in accordance with the law or
the Articles of Association, plus retained earnings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the Meeting of Shareholders may decide to distribute amounts deducted from the reserves
which are available to it, expressly indicating the reserves from which the withdrawals are to be made. However, dividend is paid out in priority from the distributable income of the financial year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except in the case of a reduction in share capital, no distribution may be made to shareholders if shareholders&#146; equity is, or would become as a result
of such distribution, less than the share capital plus the reserves which the law or the Articles of Incorporation do not allow to be distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After
the financial statements have been approved and the existence of distributable income has been acknowledged, the Meeting of Shareholders shall determine the part to be allocated to shareholders as dividends, in proportion to the number of shares
held by each. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, after the allocation of the amounts required by law to the reserve, the Meeting of Shareholders may decide to allocate all or part
of the distributable income to a retained earnings account or to any general or special reserve account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any losses are deducted from profits from
previous years until such losses are extinguished or they are carried over. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Executive Board may decide to distribute interim dividends prior to the
approval of the financial statements of the financial year, pursuant to the conditions determined or authorised by law. The amount of such instalments cannot exceed the amount of earnings as defined by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 41&nbsp;&#150; Dividends </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;The procedure for the payment of dividends is determined by the Meeting of Shareholders or, failing that, by the Executive
Board. However, payment must be made within a maximum of nine months after the end of the financial year, unless such period is extended by court decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders may not be required to reimburse any amount of dividends unless the distribution of dividends was in violation of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Claims for dividends made more than five years after they have been made available for payment shall time-barred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Meeting of Shareholders convened to approve the financial statements for the financial year may grant shareholders the
option of dividends or interim dividends being paid in cash or in shares issued by Company, in whole or in part, in accordance with the conditions set out or authorised by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE VIII </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SHAREHOLDERS&#146; EQUITY FALLING BELOW <FONT STYLE="white-space:nowrap">ONE-HALF</FONT> OF THE SHARE CAPITAL </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 42&nbsp;&#150; Early Winding Up </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the
Company&#146;s shareholders&#146; equity falls below <FONT STYLE="white-space:nowrap">one-half</FONT> of the share capital as a result of losses recorded in the financial statements, the Executive Board must convene an Extraordinary Meeting of
Shareholders within four months of the approval of the financial statements which recorded such loss to decide whether to wind up the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If it is
not decided to wind up the Company, the share capital must be reduced by an amount equal to the recorded losses, within a period determined by law, if shareholders&#146; equity has not reached at least
<FONT STYLE="white-space:nowrap">one-half</FONT> the amount of the share capital again within such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In either case, the decision of the Meeting of
Shareholders shall be published according to regulatory conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reduction of share capital to an amount below the statutory minimum can only be
decided subject to the condition precedent of a share capital increase to at least the statutory minimum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the provisions of one or more of the
foregoing paragraphs are not complied with, any interested party may apply to the courts for the Company to be wound up. This rule also applies if the shareholders are unable to deliberate validly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the court may not wind up the Company if on the day of issue of a judgment on the substance of the matter the situation has been rectified. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE IX </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT
STYLE="white-space:nowrap">WINDING-UP</FONT> &#150; LIQUIDATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 43&nbsp;&#150; Winding Up </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company shall be wound up on expiry of the term determined in the Articles of association, unless this is extended, or pursuant to a decision of an
Extraordinary Meeting of Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may also be wound up at the request of any interested party, where the number of shareholders has
dropped to under seven for more than one year. In such case, the court may grant the Company a maximum of six months in which to rectify the situation. It cannot wind up the Company if on the day it issued judgment on the substance of the matter,
the situation has been rectified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company shall be in liquidation as from the date on which it is wound up, for any reason whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Winding up will cause the terms of office of members of the Executive Board to terminate. The Supervisory Board and Statutory Auditors shall continue to
operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Meeting of Shareholders shall retain the same powers as during the life of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Meeting of Shareholders which decides to wind up the company shall determine the procedure for liquidation and appoint one or more liquidators and
determine their powers. The liquidator(s) shall exercise their duties in accordance with the law in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company shall continue to have legal
personality for the purposes of and until the completion of its liquidation. However, its corporate name should be followed by the words &#147;Company in liquidation&#148; as well as the name(s) of the liquidator(s) on any instruments or documents
issued by the Company to third parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TRANSLATION FOR INFORMATION PURPOSES </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares remain negotiable until the completion of liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After liabilities have been cleared, the net proceeds of liquidation are applied to the full repayment of paid up
<FONT STYLE="white-space:nowrap">non-depreciated</FONT> shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any surplus shall be distributed among the shareholders in proportion to the number of
shares held by each of them. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE X </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DISPUTES </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTCLE
44&nbsp;&#150; Disputes </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any dispute which may arise during the life or liquidation of the Company, either between shareholders and the Company or
between the shareholders themselves, concerning corporate matters, shall be resolved in accordance with the law and submitted to the jurisdiction of the competent courts at the registered office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To this effect, in the case of a dispute, any shareholder is bound to designate an address for service of process within the area of jurisdiction of the court
of the Company&#146;s registered office, any writs or notifications shall be validly issued to that address. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an address for service of process is not
designated, writs or notifications shall be validly issued to the Public Prosecutor of the Court of First Instance in the area of the registered office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32. </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap">08-05182</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REGISTERED WITH THE SIE (<I>SERVICE DES IMPOTS DES ENTREPRISES</I> Corporate Income Tax Department) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CORPORATE INCOME TAX DEPARTMENT </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OF EUROPE ROME ON JUNE&nbsp;23,
2008 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket: 1996<I> </I>Box: 4 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registration fees received
handwritten: <I>one hundred twenty-five euros</I> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J&eacute;r&ocirc;me ROUSSEAU </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tax Agent </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">379758 01 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/59/LH </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL PROPERTY LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by the <B>Company &#147;SOGEBAIL&#148;</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">in favor of the <B>Company &#147;INNATE PHARMA&#148;</B> </P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE YEAR TWO THOUSAND EIGHT</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The</B> ninth of June </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
MARSEILLE (13006) 65 avenue Jules Cantini, Tour M&eacute;diterran&eacute;e, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ma&icirc;tre Annick DOMENECH, Associate Notary for the Civil
Professional Partnership &#147;GIUSTINIANI Alain, ZERBIB Jean-Charles, DOMENECH Annick, and FINO Eric&#148;, holder of a Notarial Office having its registered office in MARSEILLE (13008), 28 avenue Alexandre Dumas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Standing in for her Colleague </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ma&icirc;tre Eliane FREMEAUX, associate Notary in the Company &#147;Nicolas THIBIERGE, Andr&eacute; P&Ocirc;NE, Eliane FREMEAUX, Henri PALUD,
Herv&eacute; SARAZIN, Jean-Fran&ccedil;ois SAGAUT, and Jean-Christophe CHAPUT&#148;, Civil Professional Partnership holding a Notarial Office having its registered office in PARIS (eighth arrondissement), 9 rue d&#146;Astorg. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the participation of Ma&icirc;tre Annick DOMENECH, Notary in MARSEILLE <FONT STYLE="white-space:nowrap">(Bouches-du-Rh&ocirc;ne),</FONT>
attorney for the <B>FINANCIAL LESSEE</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certified true copy issued on 110 pages Sogebail </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Received, in true form, this deed, containing: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FINANCIAL PROPERTY LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>BETWEEN</U></B>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
company &#147;<B>SOCIETE GENERALE POUR LE DEVELOPPEMENT DES OPERATIONS DE CREDIT-BAIL IMMOBILIER &#150; SOGEBAIL</B>&#148;, business corporation, having its registered office in PARIS (9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>
Arrondissement), 29 Boulevard Haussmann, identified under SIREN number 775 675 077 in the PARIS Companies and Trade Register. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Represented
by: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Yasmina OUELAA, Charg&eacute;e d&#146;Affaires, domiciled in COURBEVOIE
<FONT STYLE="white-space:nowrap">(Hauts-de-Seine)</FONT> La D&eacute;fense 3 &#150; 18 Avenue d&#146;Alsace &#150; Immeuble &#147;Les Miroirs&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN LIGHT OF</B> the powers entrusted to her by Mr.&nbsp;Claude MAINBOURG, domiciled in COURBEVOIE
<FONT STYLE="white-space:nowrap">(Hauts-de-Seine)</FONT> Tour &#147;les miroirs&#148; B&acirc;timent D, LA DEFENSE 3, 18, avenue d&#146;Alsace under a power of attorney under private seal dated June&nbsp;6, 2008 at COURBEVOIE, the original of which
has remained attached and appended hereto after mention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;MAINBOURG, himself having acted under the powers granted to him by
Mr.&nbsp;POUGIN, following a deed under private seal dated February&nbsp;13, 2006, the original of which was filed in the minutes of the Notarial Office located in PARIS (8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) 9 rue d&#146;Astorg
on February&nbsp;24, 2006. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE AFOREMENTIONED</B> Mr.&nbsp;POUGIN having acted himself in his capacity as Assistant Managing Director,
to which position he was appointed under deliberations of the Board of Directors of that company on September&nbsp;17, 2002, renewed in his position under the minutes of the board of directors&#146; meeting on April&nbsp;8, 2004, a certified true
copy of those minutes having been filed in the minutes of the notarial office located in PARIS (8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) 9 rue d&#146;Astorg, on February&nbsp;24, 2006. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">That Company hereinafter being referred to in the body of the deed as &#147;<B>THE</B> <B>FINANCIAL LESSOR</B>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>AND</U></B>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The company
INNATE PHARMA, Business Corporation with Board of Directors and Supervisory Board, having its registered office in MARSEILLE (13009), 121 Ancien Chemin de Cassis, identified under SIREN number 424 365 336 RCS MARSEILLE. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Represented by: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Herv&eacute; BRAILLY, acting on behalf of the chairman of the Board of Directors of INNATE PHARMA, domiciled in that capacity in 13009
MARSEILLE &#150; 121 Ancien Chemin de Cassis </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Appointed to that position under the deliberations of the Supervisory Board of that company
dated June&nbsp;13, 2005, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specially authorized for the purposes hereof under deliberations of the Supervisory Board on
March&nbsp;13, 2008 in Marseille, an excerpt of the certified true minutes of which shall remain appended hereto after mention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also
appended hereto is an excerpt of the company&#146;s registration in the Companies and Trade Register issued by the Clerk of the MARSEILLE Commercial Court on June&nbsp;5, 2008. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The petitioner states that no event has occurred that should be mentioned in the company&#146;s registration nor that should appear in the
appended excerpt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Which Company is hereinafter referred to in the body of the deed as &#147;<B>THE FINANCIAL LESSEE</B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>FOR THE SECOND PART</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties, prior to the agreements covered by this document, stated following: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>BACKGROUND </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- I
- </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> wishes to have, for the purposes of its activity, but without assigning ownership thereof, a building
for use as industrial and activity premises, laboratories, located in MARSEILLE <FONT STYLE="white-space:nowrap">(Bouches-du-Rh&ocirc;ne).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the financing of this operation, it has approached the<B> FINANCIAL LESSOR</B>, the purpose of which, defined by Article L. <FONT
STYLE="white-space:nowrap">313-7</FONT> of the Monetary and Financial Code (codification of law number <FONT STYLE="white-space:nowrap">66-455</FONT> dated July&nbsp;2, 1966) relative to financial lease businesses, is the leasing of unequipped
buildings for professional use. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- II - </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The<B> FINANCIAL LESSEE</B> has asked the<B> FINANCIAL LESSOR</B> in particular to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* acquire, to that end, an existing building located in the territory of the Commune of MARSEILLE; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* finance the development work for the building under a project management delegation agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* lease the above to it as a whole, under a financial property lease agreement, for a term of TWELVE (12)&nbsp;years beginning on the effective
date of section A defined below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> has granted the request by the <B>FINANCIAL LESSEE</B>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- III - </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Building permit </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The building permit related to the development work was issued by the Mayor of the Commune of MARSEILLE
<FONT STYLE="white-space:nowrap">(Bouches-du-Rh&ocirc;ne)</FONT> on August&nbsp;31, 2007 under number 13055.07.H.0127.PC.P0. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
<B>FINANCIAL LESSEE</B> declares that, in accordance with the provisions of Article R. <FONT STYLE="white-space:nowrap">421-39</FONT> of the Urban Development Code, the aforementioned building permit was displayed, namely: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* in the City Hall: and on the land, as shown by the affidavit prepared by Ma&icirc;tre Fr&eacute;d&eacute;ric ARLAUD, Bailiff in MARSEILLE
C&eacute;dex 02 (13472) 9 rue Chevalier Paul, La Joliette M5, on October&nbsp;22, 2007 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> declares and
guarantees to the <B>FINANCIAL LESSOR</B> that the aforementioned building permit has, to date, not been subject to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* any contentious
recourse by third parties; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* any administrative recourse (voluntary or hierarchical); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* any cancellation or withdrawal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An attestation prepared by the City of MARSEILLE on December&nbsp;20, 2007 shows that this building permit has not been subject to any
voluntary or contentious recourse. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Amended building permit </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An amended building permit was issued by the Mayor of the Commune of MARSEILLE on December&nbsp;18, 2007 under number 13055 07 H 0127 PC M1.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> declares that, in accordance with the provisions of Article R. <FONT STYLE="white-space:nowrap">421-39</FONT>
of the Urban Development Code, the aforementioned amended building permit was displayed, i.e.: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* in the City Hall and on the land, as
shown by the affidavit prepared by Ma&icirc;tre Xavier TITTON, Bailiff in MARSEILLE C&eacute;dex 02 (13472) 9 rue Chevalier Paul, La Joliette M5, on January&nbsp;8, 2008. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> declares and guarantees to the <B>FINANCIAL LESSOR</B>, and it is additionally shown by two attestations from the
City Hall dated April&nbsp;30 and May&nbsp;26, 2008, that the aforementioned amended building permit has, to date, not been subject to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">*
any contentious recourse by third parties; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* any administrative recourse (voluntary or hierarchical); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* any cancellation or withdrawal. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of the following documents: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">building permit decree dated August&nbsp;31, 2007 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">affidavit recognizing the display on October&nbsp;22, 2007 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attestation of nonrecourse dated December&nbsp;20, 2007, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amended building permit decree dated December&nbsp;18, 2007, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">affidavit recognizing the display dated January&nbsp;8, 2008, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attestation of <FONT STYLE="white-space:nowrap">non-recourse</FONT> dated April&nbsp;30, 2008,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attestation of <FONT STYLE="white-space:nowrap">non-withdrawal</FONT> dated May&nbsp;26, 2008,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">have remained attached and appended hereto after mention. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- IV - </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Classified
facilities </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> declares and guarantees to the <B>FINANCIAL LESSOR</B> that the activity it plans to
perform on the premises covered by this financial lease agreement does not fall within the scope of application of the regulation on Facilities Classified for the Protection of the Environment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- V - </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under a deed
received by Ma&icirc;tre Martine AFLALOU-TAKTAK, notary in MARSEILLE <FONT STYLE="white-space:nowrap">(Bouches-du-Rh&ocirc;ne),</FONT> dated this day (June 9, 2008). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> has acquired from: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The city of MARSEILLE, territorial collectivity having its seat at Quai du Port, MARSEILLE City Hall, identified under SIREN number 211 300
553. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existing building covered by this financial lease agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This sale was granted and accepted in return for the price of ONE MILLION, FIVE HUNDRED AND FORTY-FOUR THOUSAND EUROS (1,544,000.00 EUR),
excluding value-added tax, paid in cash under the aforementioned deed, which contains discharge therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the costs, duties, and
emoluments for the sale have been borne by the buyer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the aforementioned deed, the parties have made the standard and usual
declarations in such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The portion of the price related to the <FONT STYLE="white-space:nowrap">non-amortizable</FONT> charge,
i.e., the land, is assessed at the amount of SEVEN HUNDRED AND <FONT STYLE="white-space:nowrap">SEVENTY-TWO</FONT> THOUSAND EUROS (&#128;772,000.00). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the aforementioned deed, the following has in particular been declared and is reported literally below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>NATURAL AND TECHNOLOGICAL RISKS</U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>THE SELLER declares that in light of the information provided to it by the Prefect of the department or the Mayor of the commune, THE
PROPERTY covered by this document has a prevention plan for the following foreseeable natural risks: </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>plan approved on October&nbsp;20, 2002, hazards: land movement (collapse), </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>plan stipulated on December&nbsp;12, 2003, hazard: flooding, </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>plan stipulated on July&nbsp;6, 2005: land movement (withdrawal - swelling of clay, drought),
</I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>plan stipulated on April&nbsp;8, 2005: forest fire, </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The PROPERTY is not located in a zone covered by a stipulated or approved technological risk prevention plan, or in an earthquake zone
defined by decree in Conseil d&#146;Etat. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>A statement of natural and technological risks done within the last six months has been
signed by the parties and has remained appended hereto after mention. (Appendix 13) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Likewise, it declares that to the best of its
knowledge, THE PROPERTY has never experienced accidents resulting from natural or technological disasters. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the
aforementioned risk statement has remained appended hereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- VI - </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under a deed under private seal dated <I>June</I><I></I><I>&nbsp;9, 2008</I> in MARSEILLE, a precarious occupancy agreement was regularized
between the city of MARSEILLE and the <B>FINANCIAL LESSOR</B> authorizing the temporary occupation of a strip of communal land, a copy of which has remained appended hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expressly agreed between the parties that the charges and obligations resulting from that agreement are transferred to the <B>FINANCIAL
LESSEE</B>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREFORE</B>, the agreements below covered by this document have been reached. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE ONE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PRELIMINARY AGREEMENTS FOR THE RENTAL PERIOD </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These preliminary agreements will govern the relations between the parties as of this day and until the date of completion of the development
work of the building, as will emerge from the provision of the premises established between the parties as set out in the project management delegation agreement analyzed below, but only as it regards section B. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAPTER I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1)
<U>Delegation of project management</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By deed under private seal dated this day in PARIS, a copy of which with the special technical
specifications will remain attached and appended to the minute hereof, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereto have entered into a project management
delegation agreement, which in particular indicates the following: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The work shall be done at the liability of the <B>FINANCIAL LESSEE</B>, acting as assistant
project owner, in accordance with the stipulations of the building permit, as well as the plans and descriptive quotation, the references of which appear in the special technical specifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The cost of the work has been set at a maximum amount of FOUR MILLION, EIGHT HUNDRED AND <FONT STYLE="white-space:nowrap">FORTY-ONE</FONT>
THOUSAND, ONE HUNDRED AND TWENTY-THREE EUROS AND EIGHTY-SEVEN CENTS (4,841,123.87 EUR) excluding value-added tax, including any accessories. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The cost of the work will be reimbursable by the <B>FINANCIAL LESSOR</B> to the <B>FINANCIAL LESSEE</B> over the course of the advancement of
that work upon reports equivalent to invoices. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The work shall be continued without breaks so as to be completed no later than
December&nbsp;31, 2009. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The recognition of the proper performance of the work, covered by the project management delegation agreement,
will be reflected by the drafting of a letter signed by the <B>FINANCIAL LESSOR</B> that will be equivalent to provision of the premises on the date of receipt of the work reached between the assistant project owner and the companies that have
participated in that work. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The assistant project owner will be required to obtain the certificate of compliance set out by the
regulation on building permits, at its expense, risk, and peril. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that the FINANCIAL LESSOR is the sole owner of the structures for
their erection, the FINANCIAL LESSEE notes the following points: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* <B>The development or extension work</B> will be covered by open
coverage subscribed for by the SOCIETE GENERALE from AGF IART via the firm GRAS SAVOYE, i.e., a Builders Risk Insurance (BRI) policy No.&nbsp;213,203,000, a Renovation Works (RW) policy No.&nbsp;213,200,000, and a Property Developer (PD) policy
No.&nbsp;213,202,000, with the understanding that the Property Developer policy is subscribed for both on behalf of the FINANCIAL LESSOR, Project owner, and the FINANCIAL LESSEE, Assistant Project owner. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The Civil Liability &#150; Construction, both for the FINANCIAL LESSOR in its capacity as owner of the structures over the course of their
erection, and the FINANCIAL LESSEE, Assistant Project owner, will be covered under Civil Liability by Renovation Works policy No.&nbsp;213,203,000, both on behalf of the FINANCIAL LESSOR, Project owner, and the FINANCIAL LESSEE, Assistant Project
owner. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The loss of advance rents, resulting from material disorders affecting the constructed work, will be covered in part under a
Builders Risk Insurance policy No.&nbsp;213,203,000. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A notice stating in particular the main characteristics of the terms and covered limitations, as
well as financial terms, has been provided for information to the ASSISTANT PROJECT OWNER for all of the aforementioned policies, with the understanding that the ASSISTANT PROJECT OWNER is still free to complete the coverage of the policies
subscribed for by the SOCIETE GENERALE, going through the insurer of its choice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ASSISTANT PROJECT OWNER remains solely liable for
the effective establishment of the aforementioned policies to cover the construction operation in question and has undertaken to conduct all diligence to establish the guarantees, and in particular to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complete the &#147;builders insurance&#148; questionnaire at its sole liability. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide GRAS SAVOYE, at its sole liability, with all useful information on the technical conditions of the
operation (contents and value of the existing and adjacent works, worsening of risks), both before beginning work and during the work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitor and obtain the issue of insurance certificates from GRAS SAVOYE. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">send GRAS SAVOYE all of the essential documents to draw up the policies, listed below: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1) <U>BEFORE THE SUBSCRIPTION:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) the presentation questionnaire </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) the Technical Inspection agreement </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">of at least type L for work sites with an anticipated amount below &#128;1,000,000 excluding tax.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of a type L inspection, the ASSISTANT PROJECT OWNER will be required to pay an extra premium of 50% of
the premium rate on the RW/PD policy. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">type LP for work sites with an anticipated amount exceeding &#128;1,000,000 excluding tax. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">type LE for work sites including an intervention on existing structures. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of an <FONT STYLE="white-space:nowrap">LE-type</FONT> inspection, the ASSISTANT PROJECT OWNER will be required to pay an extra
premium of 100% of the premium rate of the coverage for existing structures under the RW/PD policy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) The initial report from the
technical inspector </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) the blueprints of the work (mass, cross-section, elevation) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) the technical description of all building trades or estimated quotations for work </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) the <FONT STYLE="white-space:nowrap">ten-year</FONT> Civil Liability insurance certificates and capitalization for the architect, project
owner, technical engineering firm, and soil study firm (for work sites exceeding &#128;1,000,000 excluding tax) </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These certificates must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Be signed by an insurance company or a broker </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Be valid on the date of declaration of the opening of the work site </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expressly target the work site in question </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Include the list of covered activities, these activities having to correspond strictly to those appearing in the
contracts or assignments held by the company. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) the declaration of opening of the work site </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2) <U>DURING THE WORK:</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a)
The interim reports by the technical inspector </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The technical experimentation notices, if uncommon techniques are used by a company </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If these notices are not provided, the insurer may apply the proportional reduction in compensation in case of accident. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3) UPON RECEIPT OF THE WORK: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a)
the list of all participants in the building act </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) the <FONT STYLE="white-space:nowrap">ten-year</FONT> Civil Liability insurance
certificates in capitalization for all builders participating on the work site (except subcontractors). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These certificates must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Be signed by an insurance company or broker </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Be valid on the date of declaration of opening of the work site </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expressly target the work site in question </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Include the list of covered activities, which have to correspond strictly to those appearing in the contracts
corresponding to the lot held by the company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the <FONT STYLE="white-space:nowrap">ten-year</FONT> Civil Liability
attestations for companies holding large-scale, foundation, enclosure, breezeway, ceiling, or fa&ccedil;ade lots are not provided within three months after receipt, the ASSISTANT PROJECT OWNER will be required to pay an extra premium of 50% of the
premium rates on the RW/PD policy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) the receipt reports and, if applicable, the lifting of reserves </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the receipt reports are not provided within two months following receipt, an extra premium of 50% of the premium rate will be received on
the RW/PD policy. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) the final report by the technical inspector. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this document is not provided within two months following receipt, the ASSISTANT PROJECT OWNER will be required to pay an extra premium of
50% of the premium rates on the RW/PD policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also recalled that the reserves not lifted by the Technical Inspector in the initial,
interim, and final reports, may cause exclusion from coverage for damage resulting directly therefrom or an extra premium. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) the
definitive closure of the accounts, lot by lot, including technical fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this document is not communicated within six months
following receipt, an increase of 20% will be applied to the cost of the provisional work, and consequently to the BRI and RW/PD premiums. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All extra premiums are founded by the fact that failure to provide certain documents essential to assemble the technical file constitutes a
worsening of risk for the insurer. The amount of these extra premiums will be included in the amount of the final premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of
the premiums will be paid by the ASSISTANT PROJECT OWNER, upon direct invoicing by the insurer, with the possibility, if applicable, of incorporation into the financing base of the financial lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inasmuch as, on the market, insurance policies do not exist that are able to cover all construction-related risks, the subscription for this
insurance may not in any case exempt the ASSISTANT PROJECT OWNER, even partially, from the results obligation that it will have contracted with respect to the PROJECT OWNER, or from any other obligations contracted as FINANCIAL LESSEE under this
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ASSISTANT PROJECT OWNER shall, in case of accident, personally cover any difference between the cost of complete
rebuilding of the works and the amount of the compensation paid by the insurers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, the <B>FINANCIAL LESSEE</B> will verify the
scope and validity of the insurance policies subscribed for by the various participants in the construction, and in particular by the project owner, engineering firms, technical inspectors, <U>coordinators</U>, contractors, in light of the legal
obligations for which they are responsible and in particular as coverage for presumptions of liability emerging from Articles 1792 <I>et seq.</I> of the Civil Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2) <U>Performance of the construction</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The coordination of the work site, in terms of design, study, and development of the project and the performance of the construction, shall be
entrusted to one or more coordinators&#151;within the meaning of Article L. <FONT STYLE="white-space:nowrap">235-3</FONT> of the Labor Code&#151;chosen by the <B>FINANCIAL LESSEE</B>, after verifying its competence, and which must be suitably
insured. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will represent the project owner on the work site and must see that
the constructions are erected according to the contract, the regulatory stipulations, the obligations of the building permit, the general principles of prevention in accordance with the provisions of the <U>Labor Code</U>, and all regulatory texts
applicable to the work site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is agreed, due to the strictly financial nature of this agreement, regarding the role of the <B>FINANCIAL
LESSEE</B> in the field of designing the work, the choice of its location and operators, and the monitoring of the construction, that the <B>FINANCIAL LESSOR</B> does not intend to participate in the design or technical and safety monitoring of the
structures, or the prevention of risks, nor will it bear any liability to that effect. With respect to this aspect of the financial lease operation, the <B>FINANCIAL LESSEE</B> assumes&#151;with respect to third parties&#151;sole technical and
<U>safety</U> liability for the construction operation and undertakes to guarantee the <B>FINANCIAL LESSOR</B> if it were to be sought out to that end. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> undertakes to provide the <B>FINANCIAL LESSOR</B>, if the terms set out in Articles R. 238.1 and 238.2 of the
Labor Code are met, no later than one month after opening of the work site, with a copy of the prior declarations set out in Articles L. 235.2, R. 238.1, and R. 238.2 of the Labor Code and in accordance with the decree dated March&nbsp;7, 1995. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, the <B>FINANCIAL LESSEE</B> is expressly required to provide the <B>FINANCIAL LESSOR</B>, aside from the receipt report, the
declaration of completion of the work and the certificate of compliance set out above, as of the end of the work site, <U>with the subsequent operating file on the work prepared by the coordinator relative to health and safety pursuant to Article R.
<FONT STYLE="white-space:nowrap">238-38</FONT> of the Labor Code</U>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAPTER II - INVALIDITY OF THE PRELIMINARY AGREEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document will become null and void, if the <B>FINANCIAL LESSOR</B> deems it appropriate, if the anticipated development work is not
completed by the agreed-upon date for technical or legal reasons, not imputable to the <B>FINANCIAL LESSOR</B>, such as refusal by the assistant project owner to perform his assignment, recourse against the building permit, material impossibility of
erecting the structure set out in the project management delegation agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The same will be true if the development work is not
completed in accordance with the project management delegation agreement (building not usable or not operable in its condition, serious breaches of the stipulations of the building permit, etc.). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In these cases, this document may be terminated at the request of the <B>FINANCIAL LESSOR</B>. This termination will take effect one month
after receipt of a formal notice sent to the <B>FINANCIAL LESSEE</B>, by registered letter with return receipt, containing a declaration by the <B>FINANCIAL LESSOR</B> of its intent to activate this termination clause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This termination will cause, automatically and without any formalities, the payment by the <B>FINANCIAL LESSEE</B> to the <B>FINANCIAL
LESSOR</B> of compensation equal to the total of the sums disbursed by the latter for this operation increased by an amount equal to one percent (1.00%) of its amount, except in case of force majeure. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This compensation, the amount of which is expressly agreed upon between the parties, will serve
as lump sum monetary damages to compensate the prejudice suffered by the <B>FINANCIAL LESSOR</B> due to the nonperformance of the financial lease operation and will be payable on the very date of expiration of the aforementioned time frame. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the advance rents, regular rents, study costs, commitment fees, and any other financial charges stipulated below for which the
<B>FINANCIAL LESSEE</B> is responsible, due on the termination date and actually paid by the <B>FINANCIAL LESSEE</B>, will definitively remain the property of the <B>FINANCIAL LESSOR</B>, which will not be required to return any of them; those due
on the termination date but not actually paid by the <B>FINANCIAL LESSEE </B>will become due immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Likewise, the <B>FINANCIAL
LESSEE</B> will remain responsible, with no ability to claim the return thereof from the <B>FINANCIAL LESSOR</B>, for all of the costs, advances, and any other expenses that it may have incurred, on its own behalf or on behalf of the <B>FINANCIAL
LESSOR</B>, for the performance of the financial lease operation or the fulfillment of the obligations for which it is responsible. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE TWO </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FINANCIAL PROPERTY LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAPTER I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 1 -
<U>Financial property lease</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this document, the representative of the <B>FINANCIAL LESSOR</B>, in an official capacity, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grants a lease and rents out, under the provisions of Article L. <FONT STYLE="white-space:nowrap">313-7</FONT> of the Monetary and Financial
Code (codification of Law <FONT STYLE="white-space:nowrap">No.&nbsp;66-455</FONT> dated July&nbsp;2, 1966, as modified and completed), on the financial lease, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In favor of the <B>FINANCIAL LESSEE</B>, which is accepted by its representative, in an official capacity, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The real property designated, after completion of the work, as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DESIGNATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the commune of MARSEILLE (13009)&nbsp;Quartier du Redon, Route de Cassis <I>(1)</I>, a building for business use, industrial premises, laboratories, with a net floor area of approximately 2,838 m&sup2;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Land Register Section&nbsp;851 M, numbers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">34 locality route de Cassis for 96 a 48 ca </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">39 locality route de Cassis for 02 a 99 ca </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38 locality route de Cassis for 02 a 39 ca </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">37 locality route de Cassis for 04 a 64 ca </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Or a total of 1 ha 06 a 50 ca </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 2 - <U>Term of the financial lease</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This financial lease is granted for a term that begins as of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regarding the investment part related to the acquisition of the existing building and related costs (section A),
on the date of acquisition by the <B>FINANCIAL LESSEE</B>, i.e., this day; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regarding the investment part related to the cost of the development work (section B), the first day of the month
following the date of completion of the development work, as it will result from the provision of the premises established between the parties as set out in the project management delegation agreement analyzed above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">And will end, for both sections, TWELVE (12)&nbsp;years after section A takes effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 3 - <U>Termination ability by the FINANCIAL LESSEE</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article L. <FONT STYLE="white-space:nowrap">313-9</FONT> of the Financial and Monetary Code (codification of Article <FONT
STYLE="white-space:nowrap">1-2</FONT> of Law <FONT STYLE="white-space:nowrap">No.&nbsp;66-455</FONT> dated July&nbsp;2, 1966, as modified and completed, the provisions of Article <FONT STYLE="white-space:nowrap">L.145-1</FONT> of the New Commercial
Code (Codification of Decree <FONT STYLE="white-space:nowrap">No.&nbsp;53-960</FONT> dated September&nbsp;30, 1953) granting the lessee of the premises for commercial or industrial use the ability to give notice at the end of each three-year period
are not applicable to these lease-management agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, and subject to what will be stated below regarding cases of accident or
expropriation, the <B>FINANCIAL LESSEE</B> will have the ability, as of the end of the seventh year following the taking of effect of section A, and on the condition that it has effectively obtained the certificate of compliance for the building, to
terminate these agreements, subject to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* six months&#146; notice given to the <B>FINANCIAL LESSOR</B> by registered letter with return
receipt sent to the registered office of the <B>FINANCIAL LESSEE</B>, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* the simultaneous payment to the <B>FINANCIAL LESSOR</B> of the
lump sum termination compensation stipulated in article 28 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In all cases, the termination may only take place at the end of the
calendar year in progress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The termination thus requested may be recorded by a true deed that will be received by the Notarial Office
named at the beginning of this document and published with the competent Mortgage Office. The costs of this true deed and its publication will be borne by the <B>FINANCIAL LESSEE</B>, which will have expressly agreed, as needed, that if the
<B>FINANCIAL LESSEE</B> does not sign this true deed and pay the cost thereof, its termination request will be considered null and void. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 4 - <U>Inventory - Bringing up to standards</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Inventory </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By express
agreement, no inventory will be prepared upon entry into possession. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, the <B>FINANCIAL LESSEE</B> will be considered to have
taken the building covered by the financial lease in a perfect state of upkeep. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The signature by the <B>FINANCIAL LESSEE</B>, in its
capacity as assistant project owner and future lessee, of the report for receipt of the work set out above, will entail automatic recognition by it of the compliance of the building with the plans and quotations and the finishing of the work
according to the provisions and stipulations of the aforementioned quotations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the <B>FINANCIAL LESSEE</B> will take the
building covered by this financial lease in the condition in which it is found upon entry into position and may not make any claim in this respect against the <B>FINANCIAL LESSOR</B>. It is prohibited from exercising any recourse against the
<B>FINANCIAL LESSOR</B> due to faults, flaws, or defects, visible or hidden, even if they prevent use of the leased building. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
<B>FINANCIAL LESSOR</B> will not guarantee the condition of the building even due to construction flaws and the like, whether visible or hidden, or the state of the soil or subsoil due to digging or excavation that may have been done below that
building, presence of asbestos, askarel, party walls, or errors or omissions in the designation of the building or the contents of the land, even exceeding one / twentieth (1/20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>), irrespective
of the date of completion of the structures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the <B>FINANCIAL LESSEE</B> undertakes to inform the <B>FINANCIAL LESSOR</B>,
within one month of noticing them, of all defects or flaws that it may detect in the structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B>, to which all
powers are given to that end, must immediately, at its expense, bring any recourse against the companies, the project owner, or any other relevant third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall keep the <B>FINANCIAL LESSOR</B> informed by sending it a copy of all useful documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, if the management of the recourse against the companies proves unsatisfactory, the <B>FINANCIAL LESSOR</B> will have the ability to
request, at any time, that the <B>FINANCIAL LESSEE</B> abandon its proceedings in favor of the <B>FINANCIAL LESSOR</B>, here having specified that the costs resulting therefrom will in any case remain the responsibility of the <B>FINANCIAL
LESSEE</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, the <B>FINANCIAL LESSEE</B> may ask the <B>FINANCIAL LESSOR</B> to interrupt the proceedings to avoid the costs,
inasmuch as the <B>FINANCIAL LESSEE</B> will personally see to the repair of the observed defects and disorders. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Bringing up to standards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall comply, in the context of its activity and the management of the leased buildings, with the requirements set
out by the national and European standards, in particular regarding safety and health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It must ensure the compatibility of all supplies
and materials located in the building with the same standards, whether it involves personal or real property by intended use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It may not
claim any modification or work from the <B>FINANCIAL LESSOR </B>to bring the building or a piece of equipment of that building covered by this financial lease up to standards, even if that upgrade results from a legislative or regulatory
requirement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>* Asbestos:</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall satisfy all regulations, and in particular the research, verification, periodic inspection, and work resulting from decree <FONT
STYLE="white-space:nowrap">No.&nbsp;96-97</FONT> dated February&nbsp;7, 1996, as modified by decree <FONT STYLE="white-space:nowrap">No.&nbsp;97-855</FONT> dated September&nbsp;12, 1997, decree number <FONT STYLE="white-space:nowrap">2001-840</FONT>
dated September&nbsp;13, 2001, and decree <FONT STYLE="white-space:nowrap">No.&nbsp;2002-839</FONT> dated May&nbsp;3, 2002, specifying the rules for protection against risks related to asbestos exposure: the <B>FINANCIAL LESSOR</B> transferring all
of the obligations resulting from this regulation to the <B>FINANCIAL LESSEE</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If applicable, it shall also prepare an asbestos
technical file within the time frames set out by the aforementioned decree dated September&nbsp;13, 2001. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>* Termites:</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall also comply with the provisions of Law number <FONT STYLE="white-space:nowrap">99-471</FONT> dated
June&nbsp;8, 1999, which defines the terms under which the prevention and eradication of termites and other wood-eating insects are organized, in order to protect the buildings, and decree number <FONT STYLE="white-space:nowrap">2000-613</FONT>
dated July&nbsp;3, 2000 implementing that law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the <B>FINANCIAL LESSEE</B> becomes aware of the presence of termites or other
wood-eating insects in the building, it shall declare them to the City Hall, in accordance with the provisions of the aforementioned decree. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Building covered by this document is located within the perimeter of a contaminated zone, defined by the competent authority, it is
specially agreed between the parties that the <B>FINANCIAL LESSEE</B> shall, within six (6)&nbsp;months, check for termites and undertake the necessary preventive or eradication work, and provide proof thereof to the <B>FINANCIAL LESSOR</B> by
providing a diagnostic regarding the search, issued by an approved entity or an attestation delivered by the approved company having performed, if applicable, the necessary prevention or eradication work, in accordance with Article R. <FONT
STYLE="white-space:nowrap">133-1</FONT> of the Building and Residential Code, subject to the application of the penalties set out by Article R. <FONT STYLE="white-space:nowrap">133-1</FONT> of the Building and Residential Code. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In its capacity as guardian of the Building, the <B>FINANCIAL LESSEE</B> undertakes to comply
with all current or future provisions regarding the regulation relative to combating the spread of termites and other wood-eating insects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is further specified that in case of total or partial demolition of a building located in a contaminated zone, as set out in the texts in
force, the contaminated wood and materials will be incinerated, or if <FONT STYLE="white-space:nowrap">on-site</FONT> incineration is not possible, treated before any transport, a declaration having to be made to the City Hall by the person having
conducted these operations in accordance with the texts in force, and in particular the provisions resulting from Article 3 <I>et seq.</I> of the decree dated July&nbsp;3, 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> may not be sought out or bothered in any way to that end, regarding compliance with all of the provisions and
obligations resulting from the text currently in force and any subsequent text, the <B>FINANCIAL LESSEE</B> personally covering any liability in that respect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>* Legionnaires&#146; disease:</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall comply with the stipulations resulting from circular <FONT STYLE="white-space:nowrap">No.&nbsp;98-771</FONT> dated December&nbsp;31,
1998, supplementary circular 2002.243 dated April&nbsp;22, 2002 and the subsequent texts relative to the monitoring and prevention of Legionnaires&#146; disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall assume, at its expense and without any recourse against the <B>FINANCIAL LESSOR</B>, the cost of all work
that may be done to meet all legal or regulatory provisions, all such that the <B>FINANCIAL LESSOR</B> is never sought out to that end. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 5 - <U>Liability possibly resulting from the use of the leased building or its structure</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the decisions pertaining to the choice of the location, nature, configuration, and intended use of the building covered by this document
have been made by the <B>FINANCIAL LESSEE</B>. The <B>FINANCIAL LESSOR</B> assumes no part of these decisions and is limited, at the request of the <B>FINANCIAL LESSEE</B>, to ensuring, within the limits set out above, the financing of the
operations made necessary by the decisions in question. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout the entire term of this agreement, the <B>FINANCIAL LESSEE</B> will
possess the use, management, and oversight of the leased building. It is then considered to be the guardian thereof, and this building is placed under its sole liability, this liability having to be assumed in full without it being able to exercise
any recourse whatsoever, for any reason whatsoever, against the <B>FINANCIAL LESSOR</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> alone will bear and
satisfy all obligations for which the building owners may be responsible through any national or European legal or regulatory text. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Damage that may be caused either to the <B>FINANCIAL LESSEE</B> or to third parties, due to the very structure of the leased building (in
particular that of the floors), which it should be recalled here have been chosen by the <B>FINANCIAL LESSEE</B>, shall be fully covered by the <B>FINANCIAL LESSEE</B>, who may not, as in the previous scenario, bring any recourse against the
<B>FINANCIAL LESSOR</B> for any reason whatsoever. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an activity is performed on the premises that may cause risks of pollution, in particular in
the subsoil, it is agreed, as an essential and deciding condition of the undertaking by the <B>FINANCIAL LESSOR</B>, which is expressly accepted by the <B>FINANCIAL LESSEE</B>, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The <B>FINANCIAL LESSEE</B> will assume the burden, in strict compliance with the current and future laws applicable to the type of activity
and installation done, for the elimination of waste and the collection of materials so as to avoid any harmful effects and so that the <B>FINANCIAL LESSOR</B> may never be sought out due to damage caused to others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The <B>FINANCIAL LESSEE</B> will inform the <B>FINANCIAL LESSOR</B> of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any formal notice by the Administration seeking to obtain the backfitting of the Building with national or
community laws and regulations and international agreements (subject to their integration and applicability in French law) relative to protection of the environment, and in particular relating to discharge into the water, soil or subsoil, emissions
into the air, noise, waste treatment, storage of flammable or hazardous products, PCB (Polychlorobiphenyls) and PCT (Polychloroterphenyls), asbestos, the rules for protection and safety of workers within the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any accident or incident resulting from the operation of the Building and that may have harmful consequences for
the environment or that may create a risk of damage to the environment and must be subject to a declaration to the classified facilities inspectorate under Article 38 of Decree number <FONT STYLE="white-space:nowrap">77-1133</FONT> dated
September&nbsp;21, 1977 implementing the Law dated July&nbsp;13, 1976 and any subsequent text; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any judicial decisions or injunctions following complaints filed by third parties or by an administrative
authority seeking to compensate any injury whatsoever to the environment or seeking to end any annoyance resulting from the activity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation to repair all or part of the Building following a temporary or permanent cessation of any activity
or following the modification of any activity conducted in the Building. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The <B>FINANCIAL LESSEE</B> will be
considered the owner of this waste, if it exists, and waives the right to any recourse against the <B>FINANCIAL LESSOR</B> in that respect, undertaking on the contrary to hold it harmless in any disputes, and that the aforementioned <B>FINANCIAL
LESSOR</B> may never be implicated, in case of subsequent sale of the building (whether it involves an option exercised by the <B>FINANCIAL LESSEE</B> or any assignee, or a sale to a third party following the termination of this financial lease).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* All of the expenses necessary for the implementation of all laws, all regulations, and more generally, for all consequences of the
activity of the <B>FINANCIAL LESSEE</B>, will be the responsibility of the <B>FINANCIAL LESSEE </B>or its assignees, if they are claimed from the <B>FINANCIAL LESSOR</B>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* In case of termination of the financial lease for any reason whatsoever, if the activity
performed by the <B>FINANCIAL LESSEE</B> may be considered to generate pollution, an audit will be conducted so as to determine the condition of the soil and subsoil, at the exclusive expense of the <B>FINANCIAL LESSEE</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* All fees and costs that the <B>FINANCIAL LESSOR</B> may incur for the foregoing under this article and to comply with the conditions stated
therein as well as any deposit to which the <B>FINANCIAL LESSOR</B> may be subject will constitute a charge for the <B>FINANCIAL LESSEE</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* When an option is exercised in favor of the <B>FINANCIAL LESSEE</B> or any assignee, the declarations made above will be reiterated by the
BUYER with respect to the <B>FINANCIAL LESSOR</B>, having become the seller. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAPTER II - TERMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This financial lease is granted by the <B>FINANCIAL LESSOR</B> under the general terms and conditions stipulated in articles 6 to 15 below,
which the representative of the <B>FINANCIAL LESSEE</B> undertakes to perform and accomplish subject to the penalties stipulated in Chapter V below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 6 - <U>Occupancy terms</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Allocation of the premises </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The premises covered by this document are intended for use as industrial premises, activity premises, laboratories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall give them the same intended use throughout the entire term of the financial lease and is prohibited from
allocating them, even temporarily, to another use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Enjoyment of the premises </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> must enjoy the leased premises as a good administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> undertakes to comply with all current or future regulations relative to the activity performed by it, and more
specifically with the safety rules, in particular those relative to the protection of persons and prevention of risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expressly
prohibited from using, for the intended use set out above, the building covered by this financial lease, until it has proven to the <B>FINANCIAL LESSOR</B> that it has performed the required formalities, as well as any authorizations that may be
necessary, in particular set out in Article R. <FONT STYLE="white-space:nowrap">123-46</FONT> of the Building and Residential Code relative to protection against fire and panic risks in establishments receiving the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of persons and property, due to the premises, covered by this financial lease, falls to the <B>FINANCIAL LESSEE</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall, both on its own behalf and on behalf of the <B>FINANCIAL LESSOR</B>, obtain a subscription with any approved entity for periodic
inspection visits, when it involves satisfying any law or regulation. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The inspections done to that end shall pertain to all of the buildings, elements, installations,
and equipment subject, on any grounds whatsoever, to any regulation regarding the safety of people and property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C - Operating
authorizations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will personally see to obtaining any administrative authorizations that may be necessary
for the exploitation of its activity on the premises covered by this financial lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D - Easements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will bear any easements of any nature that may affect the building given under the financial lease, without
recourse against the <B>FINANCIAL LESSOR</B> for reduction of rents or other financial charges of the financial lease. It will benefit, as compensation, from active easements for that building, if any exist, at its sole expense, risk, and peril, and
with the burden of participating, if applicable, in the repair and upkeep of the equipment from which it benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 7 - <U>Work
during the financial lease</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Upkeep - Repairs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> undertakes to maintain and return, at the end of the financial lease, the leased premises in a good state of upkeep
and rental or other repair (in particular including repairs and reworking of enclosures, doors, windows, floors, ceilings, locks, equipment items, toilets, etc.). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will further be bound to perform, on behalf of the <B>FINANCIAL LESSOR</B>, at its sole expense, risk, and peril
and without recourse against or claiming back from the <B>FINANCIAL LESSOR</B>, all major repairs that become necessary during the financial lease, in particular including those that Article 606 of the Civil Code in principle makes the
responsibility of the owner and which, incorporated in the building, automatically become its property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall
in particular keep the equipment and installations necessary for the normal use of the leased premises in a good state of upkeep and operation, in particular the heating, <FONT STYLE="white-space:nowrap">air-conditioning</FONT> facilities, the
elevator(s) or freight elevator, the sprinkler system, when the leased premises have such equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this respect, it is expressly
agreed that the <B>FINANCIAL LESSEE</B> may not, without prior written agreement from the <B>FINANCIAL LESSOR</B>, finance the replacement of the aforementioned equipment under a contract that would grant temporary ownership thereof to the financial
lessor (in particular under a financial property lease agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It will also be required to perform any repairs that may prove
necessary following flaws, defects, or faults in the construction, whether visible or hidden, even when no external sign has revealed the need to undertake such repairs. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the performance of the work set out in the previous three paragraphs, the <B>FINANCIAL
LESSEE</B> may not claim the benefit of the provisions of the second paragraph of Article 1724 of the Civil Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the
<B>FINANCIAL LESSEE</B> may never ask the <B>FINANCIAL LESSOR</B>, during the financial lease, to perform any work, developments, or repairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above work will be handled by the <B>FINANCIAL LESSEE</B> without recourse against or claiming back from the <B>FINANCIAL LESSOR</B> and
without it being able to perform any compensation of their amount with the amounts due to the <B>FINANCIAL LESSOR</B> on other grounds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is further specified that the obstacles that may affect the terms for coverage of the costs of the work by the <B>FINANCIAL LESSEE</B> may
not prejudice the principle of that handling. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Equipment work - Enlargement - Extension </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> may, at its sole expense, risk, and peril and without recourse against or claiming back from the <B>FINANCIAL
LESSOR</B>, perform any equipment and installation work on the leased premises necessary or specific to their professional use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It may
only, with prior express and written agreement from the <B>FINANCIAL LESSOR</B>, perform, in the building covered by this financial lease, within the limit of any administrative authorizations that may be necessary, any enlargement, extension, or
raising of the structure that it deems necessary or useful for its needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall also perform all work that may be required by any
legislative or regulatory provisions, and in particular, work relative to the safety of persons and property, and consequently it shall perform any work that may be stipulated, following inspection visits, by the entities or the various affected
administrations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The work targeted in the previous three paragraphs shall be performed at the exclusive risk and peril of the
<B>FINANCIAL LESSEE</B> and under the oversight of an architect or a technical engineering firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will
subscribe for any insurance policies that the nature or scope of the work makes necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of such work, including the insurance
premiums, architect or technical engineering fees, will be borne by the <B>FINANCIAL LESSEE</B> without recourse against or claiming back from the <B>FINANCIAL LESSOR</B>, which will not be required to pay their cost, or to reimburse building
occupancy expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The property additions resulting from the above work will be considered the property of the <B>FINANCIAL LESSEE</B>
throughout the entire term of the financial lease. However, notwithstanding the postponement of the accession of the <B>FINANCIAL LESSOR</B> to the ownership of the works thus produced, the <B>FINANCIAL LESSEE</B> may not, throughout the entire term
of the financial lease, remove, destroy, or eliminate the works thus done by it without express and written permission from the <B>FINANCIAL LESSOR</B>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, these property additions will automatically become the property of the <B>FINANCIAL
LESSOR </B>at the end of the financial lease; consequently, the <B>FINANCIAL LESSEE</B> shall, upon its departure for any reason, and in particular due to the end or early termination of the financial lease, leave all work, embellishments,
improvements, or structures of a real property nature that it may have done in the building, without being able to require any compensation to that end or reimbursement for its building occupancy expenses, and without being able to perform any
compensation with the sums it owes to the <B>FINANCIAL LESSOR</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, the <B>FINANCIAL LESSOR</B> may always (except for work
expressly authorized by it) request, upon departure of the <B>FINANCIAL LESSEE</B>, the return of the premises to their original state, at the expense, risk, and peril of the <B>FINANCIAL LESSEE</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conversely, the equipment, materials, and installations not permanently fixed and which, as a result, may not be considered immovable by
intended use, will still remain the property of the <B>FINANCIAL LESSEE</B> and must be removed by it, upon its departure, it being responsible for returning the premises to their condition after that removal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C - Changes in distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes in distribution by demolition, drilling of walls, beams, or floors, shall be subject to prior written authorization by the
<B>FINANCIAL LESSOR</B>, and potentially, the obtainment of a building permit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The work set out above thus authorized by the <B>FINANCIAL
LESSOR</B> shall be performed at the sole expense, risk, and peril of the <B>FINANCIAL LESSEE</B>, and under the oversight of an architect or a technical engineering firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such work constituting development or improvement work, the cost thereof as well as the premiums for the insurance policies that the
<B>FINANCIAL LESSEE</B> subscribes for on that occasion, the fees for the architect or technical engineering firm, will be borne in full by the <B>FINANCIAL LESSEE</B>, without recourse against or claiming back from the <B>FINANCIAL LESSOR</B> and
without it being able to perform any compensation with the sums due to the <B>FINANCIAL LESSOR</B> for any other reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, in the
event such work, due to its significance or nature, is taken into account by the <B>FINANCIAL LESSOR</B> for fiscal or accounting reasons, the coverage of the corresponding costs by the <B>FINANCIAL LESSEE</B> will assume the form of a specific rent
supplement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D - Liability of the FINANCIAL LESSEE due to work </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B>, having the initiative for the aforementioned work and the liability for its legal qualification, will alone assume
the financial or fiscal consequences that its performance may cause for the <B>FINANCIAL LESSOR</B>, irrespective of whether it has been authorized by the <B>FINANCIAL LESSOR</B>, even if it results from a legal or regulatory obligation.
Consequently, the <B>FINANCIAL LESSEE</B> undertakes to reimburse the <B>FINANCIAL LESSOR</B> for all costs, taxes and fees or tax adjustments, insurance premiums, or other charges that the <B>FINANCIAL LESSOR</B> may bear due to the performance of
the work under the <B>FINANCIAL LESSEE</B>&#146;s<B> </B>responsibility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Likewise, the latter shall repay the <B>FINANCIAL LESSOR</B> the
amount of any necessary work that the <B>FINANCIAL LESSOR</B> must perform following a breach by the <B>FINANCIAL LESSEE</B>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E -
Monitoring visits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout the entire term of the financial lease, the <B>FINANCIAL LESSEE</B> must allow the representatives of the
<B>FINANCIAL LESSOR</B> to visit the leased premises at any time to ensure their condition, and it must provide, upon first request by the <B>FINANCIAL LESSOR</B>, all supporting documentation that may be requested from it demonstrating the proper
performance of the terms of the financial lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 8 - <U>Decoration</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The leased premises must be decorated, at all times, with material, fixtures, furniture, and goods, in sufficient quantity and value to
guarantee the <B>FINANCIAL LESSOR</B> the payment of rent and the performance of the terms of this financial lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 9 -
<U>Pledge - Audit of the financial situation of the FINANCIAL LESSEE</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Pledge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> is prohibited from pledging the rights that it holds under this financial lease agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this clause is violated, this financial lease agreement will, if the <B>FINANCIAL LESSOR</B> deems it appropriate, be terminated under the
clause stipulated in article 25 below, without prejudice for the <B>FINANCIAL LESSOR</B>&#146;s ability to seek, if it prefers, the invalidity of the pledge granted in spite of this clause. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Audit of the financial situation of the FINANCIAL LESSEE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will be required to provide the <B>FINANCIAL LESSOR</B>, annually, with a copy of the balance sheet and income
statement for the past fiscal year as well as the text of the report by the Management or Board of Directors or Supervisory Board to the Ordinary General Shareholders&#146; Meeting called upon to rule on the accounts for that fiscal year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These documents must be produced within one month following their approval by the Ordinary General Shareholders&#146; Meeting. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 10 - <U>Subleasing</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The building subject to this financial lease may be subleased to natural persons or legal entities, in order to perform the activity specified
in article 6, paragraph A above, on these premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subleases may either be total, in favor of a single natural person or legal
entity, or partial, in favor of several natural persons or legal entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">They shall be subject to prior written agreement with the
<B>FINANCIAL LESSOR</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of termination for any reason whatsoever of one or all of the subleases, a new sublease may only be
granted after the <B>FINANCIAL LESSOR</B> has agreed, under the terms defined above, expressly and in writing, to the person of the sublessee as well as the draft sublease agreement and in return for the irrevocable undertaking by the <B>FINANCIAL
LESSEE</B> and the sublessee with respect to the <B>FINANCIAL LESSOR</B> not to alter the terms of the sublease agreement throughout the entire term of the sublease agreement, without prior written agreement from the <B>FINANCIAL LESSOR</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any case, the subleases may not in any case be enforced against the <B>FINANCIAL LESSOR</B> for any reason whatsoever. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The sublessee(s) shall comply with all terms and conditions of the financial lease agreement, with no exception or reserve. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The sublease(s) shall not in any case last longer than the financial lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall be expressly stipulated, in the sublease agreement(s), that the termination of the financial lease agreement for any reason shall
automatically cause termination of the sublease(s). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The <B>FINANCIAL LESSEE </B>shall inform the <B>FINANCIAL LESSOR</B>, by registered
letter with return receipt, of the names and capacities of the sublessee(s) and provide it, within eight days of signature, with an original copy of each sublease agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The leased premises forming an indivisible whole by the mutual intent of the parties, in any case, in the event of partial sublease, the
sublease(s) shall not be enforceable against the <B>FINANCIAL LESSOR</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> undertakes to assume, with respect
to its total sublessee and/or its partial sublessee(s), the payment of any compensation of any nature, in particular that which may be due by the <B>FINANCIAL LESSEE</B> to its sublessee pursuant to Articles L.
<FONT STYLE="white-space:nowrap">145-1</FONT> <I>et seq.</I> of the New Commercial Code (codification of Decree number <FONT STYLE="white-space:nowrap">53-960</FONT> dated September&nbsp;30, 1953) on the commercial property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> undertakes to see personally to any relationship with its sublessee(s). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall reimburse the <B>FINANCIAL LESSOR</B> for any amounts that the
latter may be required to pay to any sublessee, in case of its own breach, as eviction compensation, or upon expiration of the financial lease agreement if the promise of sale that completes it is not exercised, or at any time in case of its
termination for any reason whatsoever. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(1) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sublease agreement shall include the following clause: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>The company INNATE PHARMA, hereinafter referred to as the </I><B><I>LESSOR</I></B><I>, hereby grants a sublease to the company
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, hereinafter referred to as the </I><B><I>LESSEE</I></B><I>, under the terms of this agreement.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The </I><B><I>LESSEE</I></B><I> declares and recognizes that it has been fully informed of the fact that it is occupying the premises as
sublessee. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The </I><B><I>LESSEE</I></B><I> declares and recognizes that the sublease is not enforceable against SOGEBAIL in its
capacity as financial lessor and owner of the premises. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The </I><B><I>LESSEE</I></B><I> expressly waives its ability to assert,
with respect to the aforementioned financial lessor, any rights that it may have under this sublease. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The
</I><B><I>LESSEE</I></B><I> declares and recognizes that if the aforementioned financial property lease agreement is terminated for any reason, this sublease will be terminated automatically without legal formalities and without compensation at the
responsibility of the owner. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The </I><B><I>LESSEE</I></B><I> shall immediately vacate the premises as of denunciation of the
termination of the financial lease done by bailiff affidavit. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If it refuses to leave the premises, it may be forced to do so by a
simple interim order handed down by the District Court of the location of the subleased building. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>It is expressly understood that
if the </I><B><I>LESSOR</I></B><I> exercises the purchase option contained in the aforementioned financial property lease agreement and thus becomes the owner of the premises, this sublease shall become a primary lease as of the transfer of
ownership.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the aforementioned sublease is terminated, one or several subleases may only be granted after the <B>FINANCIAL
LESSOR</B> has agreed, expressly and in writing, to the person of the sublessee as well as the draft sublease agreement and in return for the irrevocable undertaking by the <B>FINANCIAL LESSEE</B> and the sublessee, with respect to the <B>FINANCIAL
LESSOR</B>, not to modify the terms of the aforementioned sublease agreement throughout the entire term of the financial lease, without prior and written agreement from the <B>FINANCIAL LESSOR</B>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 11 - <U>Assignment of the right to the financial lease</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Assignment of the right to the financial lease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> may only assign its right to this financial lease, in whole or in part, with express and written consent from the
<B>FINANCIAL LESSOR</B>, subject to invalidity of the assignment granted in spite of this clause, and even termination of the financial lease agreement, if the <B>FINANCIAL LESSOR</B> so decides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential assignment of this financial lease will necessarily and automatically cause the transfer in favor of the assignee of the benefit
of the promise of sale granted below to the <B>FINANCIAL LESSEE</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the right to the financial lease is assigned, the assigning
<B>FINANCIAL LESSEE</B> will be jointly bound, with its assignees, by all obligations for which it is responsible hereunder, and in particular the payment of rents by their due dates and the full performance of all of the terms of this financial
lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, all of the successive financial lessees, even those who, having assigned the right to the financial lease, no longer
occupy the leased premises, will be jointly bound to one another with respect to the <B>FINANCIAL LESSOR</B> for the payment of rents and charges and the performance of all of the terms and conditions of the financial lease, such that the
<B>FINANCIAL LESSOR</B> can act against all or any one of the successive lessees, jointly bound for the whole, without being able to have the benefit of discussion or division enforced against them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the assignment will not release the guarantees from their obligations with respect to the <B>FINANCIAL LESSOR</B>, such that they
will remain jointly bound with the assignor and the assignee, for all obligations for which the <B>FINANCIAL LESSEE</B> is responsible under this financial lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above stipulations apply to all cases of assignment in any form and the contribution of the right to the financial lease to any company in
any form, whether this contribution is done to a new company or a <FONT STYLE="white-space:nowrap">pre-existing</FONT> company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
company assignment or contribution shall be done in the presence of the <B>FINANCIAL LESSOR</B>, or the latter shall be duly called thereto by simple registered letter with return receipt sent to its registered office at least fifteen days in
advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assignment or contribution will be recorded by a true deed, an enforceable copy of which will be issued at no cost to the
<B>FINANCIAL LESSOR</B> to serve as an enforceable document for it against the assignee(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assignor shall provide the assignee, as
of the assignment of the financial property lease agreement, with the technical and legal documentation related to the building covered by this document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assignment of this financial lease agreement will lead to the collection, by the <B>FINANCIAL LESSOR</B>, of transfer costs, the amount of
which is set at the sum, excluding value-added tax, of THREE THOUSAND, ONE HUNDRED EUROS (&#128;3,100). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assignee will be responsible for these costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Bankruptcy or liquidation - Dissolution of the financial lessee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assignment of the right to the financial lease as part of collective proceedings may only be done in accordance with Article L. <FONT
STYLE="white-space:nowrap">620-1</FONT> <I>et seq.</I> of the New Commercial Code and after having been duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of
dissolution of the lessee, the assignment of the right to the financial lease may only be done under the conditions set out in paragraph A above and subject to the provisions of Article L. <FONT STYLE="white-space:nowrap">237-5</FONT> of the New
Commercial Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 12 - <U>Obligation of the FINANCIAL LESSOR in case of sale of the building</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the provisions of Article L. <FONT STYLE="white-space:nowrap">313-7</FONT> of the Financial and Monetary Code as modified,
the <B>FINANCIAL LESSOR</B> undertakes, in case of sale or assignment of the property covered by this financial lease during the term thereof, to require its buyer, assignee, or agent to perform all of the terms and conditions of these agreements of
the financial lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 13 - <U>Contributions - Taxes - Fees - Charges</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Contributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
<B>FINANCIAL LESSEE</B> will pay directly or reimburse the <B>FINANCIAL LESSOR</B>, in addition to rent, for its personal contributions, occupancy tax, professional fees, and the like, and will pay all city and police charges to which lessees are
ordinarily bound, all such that the <B>FINANCIAL LESSOR</B> is never bothered in this respect; it must provide proof thereof to the <B>FINANCIAL LESSOR</B> upon any request, and especially at the end of the financial lease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Taxes and Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the <B>FINANCIAL LESSEE</B> shall pay or reimburse the <B>FINANCIAL LESSOR</B>, in addition to the rent, for: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* All taxes, fees, and contributions, property or other, of any nature, to which the leased premises or the lease itself may be subject, as
well as all municipal taxes or city or State charges and any royalties, based now or in the future on these premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL
LESSOR</B> tasks the <B>FINANCIAL LESSEE</B> with sending the &#147;Tax Declaration&#148; form (model U, P, or CDB depending on the nature of the building), duly completed and signed, to the Property Tax Center to which the building reports, within
90 days of the date of its completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will send the <B>FINANCIAL LESSOR</B> a copy of that form, completed
and signed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is recalled here that the information must be accurate and truthful and will serve as a basis for calculating the property
tax. The <B>FINANCIAL LESSEE</B> waives any right of recourse against the <B>FINANCIAL LESSOR</B> to that end. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* Any taxes, duties, and
royalties that may be created later in any form, in addition to or as a replacement for those set out above, irrespective of the taxation mode and even if these taxes assume the form of taxation on the capital of the <B>FINANCIAL LESSOR</B>
represented by the premises hereby given under the financial lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* More generally, any charges of any nature that are or become payable
on the leased premises or the lease, all such that the rents set out below are collected by the <B>FINANCIAL LESSOR</B> net of any real charges, to the full exclusion of taxes that may affect the rental income due to the <B>FINANCIAL LESSOR</B>,<B>
</B>and<B> </B>which are and will remain the responsibility of the <B>FINANCIAL LESSOR</B>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B>, which ultimately owes the taxes, fees, and charges affecting the
leased premises or the lease, will have the ability to contest the amount or principle of any taxation for which it is directly or indirectly liable, but it may only submit this dispute to the relevant administration or collectivities at its sole
expense, risk, and peril on behalf of the <B>FINANCIAL LESSOR</B>, which hereby delegates it, as needed, all useful powers to that end. Any claims or disputes that may be formulated by the <B>FINANCIAL LESSEE</B> with respect to the <B>FINANCIAL
LESSOR</B> shall be considered inoperative, the <B>FINANCIAL LESSOR</B> not intending to personally assume the burden of any disputes with respect to administrations or entities. However, such a dispute may not result in delaying the due date of
these charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reimbursement of taxes or fees, as well as any tax deductions that may be obtained, will benefit the <B>FINANCIAL
LESSEE</B> exclusively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Free zones: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> undertakes to inform the <B>FINANCIAL LESSOR</B> if it meets the conditions allowing it to benefit from special
exemptions for free zones or any others benefiting from a special specific status. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the administration has not taken the specific
exemption regime into account, the <B>FINANCIAL LESSOR</B> tasks the <B>FINANCIAL LESSEE</B> with filing any tax exemption request with any competent administration. The <B>FINANCIAL LESSEE</B> undertakes to keep the <B>FINANCIAL LESSOR</B> apprised
of the requests and responses provided by the tax administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any case, the <B>FINANCIAL LESSEE</B> shall reimburse the
<B>FINANCIAL LESSOR</B> for the amount of the property taxes paid by the latter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C - Charges for audit and inspection visits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The various charges resulting from the audits or inspections to which the building covered by this financial lease, and its development, as
well as the installations and equipment that they contain, may be subject to the various regulations applicable to them, and in particular those on the safety of people and property, shall be directly and fully assumed by the <B>FINANCIAL
LESSEE</B>, which is solely liable for the premises safety covered by this financial lease and their use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 14 - <U>Value-Added
Tax</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By express agreement between the parties, this financial lease will be subject to the value-added tax in accordance with the
regulations in force and thus exempt from any lease registration duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of the value-added tax affecting each term of rent,
at the rate in force on each due date, will be borne by the <B>FINANCIAL LESSEE</B> in addition to the rent and other charges stipulated below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 15 - <U>Expenses - Duties - Emoluments</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the expenses, duties, and emoluments under this financial lease agreement, and those that are the result and consequences thereof, will
be borne by the <B>FINANCIAL LESSEE</B>, as well as its representative, which agrees thereto. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAPTER III - SAFETY - INSURANCE - ACCIDENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 16 - <U>Safety</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of people and property, due to the building covered by this financial lease agreement and its use, falls to the operating
<B>FINANCIAL LESSEE</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the leased building constitutes an &#147;establishment receiving the public&#148; within the meaning of
Articles R. <FONT STYLE="white-space:nowrap">123-2</FONT> and R. <FONT STYLE="white-space:nowrap">123-18</FONT> to 20 of the Building and Residential Code, the <B>FINANCIAL LESSEE</B> undertakes to comply and ensure strict compliance by any person
in its service with the regulations relative to the type and category of this establishment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To that end, it in particular undertakes to:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* see to the maintenance, upkeep, and inspection, at its expense, throughout the entire term of the financial lease, of all of the
equipment and facilities with which the leased premises are equipped, at the times and in the manner indicated in the texts set out above, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* not make any change to these premises that is not in line with the provisions of those texts, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* open and keep <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date,</FONT></FONT> or have opened and kept <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date,</FONT></FONT> a security ledger, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* throughout the financial lease, have the inspections set out in Article R. <FONT
STYLE="white-space:nowrap">123-43</FONT> of the Building and Residential Code carried out periodically, by the entity of its choice approved under the conditions set out in the aforementioned article. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, following noncompliance with the above obligations, the <B>FINANCIAL LESSOR</B> is sued, in any manner whatsoever, the <B>FINANCIAL
LESSEE</B> shall reimburse it for the amount of any order handed down against it, as well as the costs and fees incurred for its defense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 17 - <U>Insurance</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>I) Content of the coverage that must be subscribed for.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1) Insurance for the building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The premises covered by the financial lease, and all elements and installations of an immovable nature with which they are equipped, will be
insured, for an indexed amount allowing them to be rebuilt or replaced identically at any time, and covering them against any damage, in particular caused by fire, lightning, explosions, storms, hurricanes, snow on the roof, crossing of the sound
barrier, hail, falling aircraft, impacts from land vehicles, electricity or fluids, including damage from acts of terrorism or sabotage, strikes, riots, or popular uprisings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This coverage will be completed by an &#147;Indirect Losses&#148; coverage of at least 10%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expert fees, demolition costs, and backfill costs following an accident will also be covered, as well as the amount of the premiums for
the &#147;Renovation Works&#148; insurance policy, which will be subscribed for upon the reconstruction or repair of the buildings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2)
Insurance for personal property, materials, and goods. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The real property, materials, and goods located on the premises under financial
lease with the FINANCIAL LESSOR will also be covered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3) Lost Rent - Deprivation of Enjoyment insurance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Lost Rent - Deprivation of Enjoyment Insurance policy, covering at least two years of financial charges under the financial lease, will also
be subscribed for. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation that the FINANCIAL LESSOR may receive from the insurance company to that end will be handed over by
it to the FINANCIAL LESSEE inasmuch as the charges stipulated in the financial lease agreement have indeed been paid by the latter, in accordance with the financial lease agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4) Civil Liability Insurance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Civil Liability of the FINANCIAL LESSOR as well as that of the FINANCIAL LESSEE with respect to third parties, including, if applicable,
sublessees, will be covered against: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The pecuniary consequences of the civil liability that may be incurred by the FINANCIAL LESSOR,
owner of the premises, and/or the FINANCIAL LESSEE, due to the building covered by the financial lease agreement (Art. 1382, 1383, 1384 paragraphs 1, 1386 of the Civil Code), for the minimum amount of &#128;4.5 M for bodily injury and &#128;4.5 M
for material and immaterial damages, including &#128;1.5&nbsp;M per accident for immaterial damage, irrespective of whether it is consecutive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The pecuniary consequences of the civil liability that may be incurred by the FINANCIAL LESSOR, owner of the premises, and/or the FINANCIAL
LESSEE, due to the building covered by the financial lease agreement, due to fire, explosion, or fluid (Art. 1384 par. 2 of the Civil Code &#150; &#147;Recourse by Neighbors and Third Parties&#148;), for a minimum amount of &#128;4.5 M for bodily
injury and &#128;3.3 M for other damage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>II) Terms for establishment of coverage.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* Pursuant to Article L. <FONT STYLE="white-space:nowrap">121-10</FONT> par. 2 of the Insurance Code, the FINANCIAL LESSOR, in its capacity as
new owner, tasks the FINANCIAL LESSEE with proceeding immediately with the termination of the Multi-risk policy that has covered the building thus far, if that policy was set up by the seller. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* All of the aforementioned coverage, outside the furniture, goods, and Civil Liability of the FINANCIAL LESSEE, will be insured under an
&#147;All risks except&#148; policy subscribed for by the SOCIETE GENERALE exclusively on behalf of its subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The coverage
regarding the furniture and goods as well as the Civil Liability of the FINANCIAL LESSEE will be subscribed for by the FINANCIAL LESSEE with an insurer of its choice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* All of these policies will include a mutual waiver of all recourse clause. This waiver of recourse by the insurer will also extend to the
respective insurers of each of the parties to this deed, as well as against authorized sublessees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The amount of the premium regarding
all of the coverage, excluding furniture, goods, and the Civil Liability of the FINANCIAL LESSEE, will be reinvoiced to the FINANCIAL LESSEE at the same time as the rent, by way of charges. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>III) Liability of the FINANCIAL LESSEE in setting up the insurance.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that the FINANCIAL LESSEE cannot, in light of the factual elements specific to each of the buildings that it gives under lease
management, decide itself on the amount of the capital that will serve as a basis to establish the aforementioned policies, in order for the coverage set out by this deed to be obtained, it is expressly agreed that the covered amounts will be
determined between the insurer and the FINANCIAL LESSEE, under the sole liability of the latter, and may not be lower than the amount of reconstruction at new value, including costs and fees. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The brokerage firm GRAS SAVOYE will establish a relationship with the FINANCIAL LESSEE in order
to allow the latter to assess the risks precisely. Based on this information, a pricing structure will then be established by the broker, based on the coverage appearing in the notice prepared by the insurer, defining the essential terms of the
contract. The FINANCIAL LESSEE recognizes that it is already aware of this notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FINANCIAL LESSEE will see, at its sole liability,
to the issuance of the insurance certificate by the insurer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inasmuch as there is no insurance policy on the market able to cover all of
the risks for unlimited amounts and with no deductibles; if the amount of the compensation awarded by the insurance companies, following any accident, is insufficient to provide full pecuniary compensation for the damage caused by the accident, in
particular: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in case of error, omission, or reticence in the declarations made to the insurers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">or because the amount of the capital covered by the subscribed policies is lower than that which would normally
have been subscribed for in order for this compensation to provide full reparations, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">or because, this amount being sufficient, the insurance companies, for any reason, would only pay compensation
lower than that to which the aforementioned insurance would entitle the holder, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">or because the deductibles were left by the insurer(s) to the responsibility of the beneficiaries of the
compensation, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">the FINANCIAL LESSEE will owe the FINANCIAL LESSOR the difference between the amount of the full
pecuniary compensation for the damage caused by the accident and the amount of the compensation awarded by the insurance companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>IV) Maintenance of the coverage over time</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the &#147;All risks except&#148; policy subscribed for by the SOCIETE GENERALE on behalf of its subsidiaries is terminated by the insurer
and in the state of the market, the FINANCIAL LESSOR is unable to find equivalent coverage on the market in the form of a group contract for all of the buildings of which it is the owner, the FINANCIAL LESSOR shall inform the FINANCIAL LESSEE by
Registered Letter with return receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FINANCIAL LESSEE will then have one month to offer equivalent coverage to the FINANCIAL LESSOR
to cover the building under this deed, as well as the Civil Liability coverage related thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the coverage set out above,
excluding the personal property and goods, shall be subscribed for by the FINANCIAL LESSEE, acting on its own behalf and on behalf of the FINANCIAL LESSOR, owner of the premises. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The various insurance coverage indicated above will be subscribed for by the FINANCIAL LESSEE at
its sole liability with one or several companies known to be solvent, it being responsible for maintaining the validity thereof throughout the entire term of the financial lease agreement. It shall regularly pay the premiums for this insurance,
increased by the related fees and taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The insurance companies with which the various coverage described above is subscribed for shall
expressly undertake, for each of the subscribed policies, to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">notify the FINANCIAL LESSOR, in writing, one month before any cancellation or reduction of the coverage requested
by the FINANCIAL LESSEE, without the latter having simultaneously provided express agreement from the FINANCIAL LESSOR; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">notify the FINANCIAL LESSOR of any delay in the payment of the premiums and only suspend the coverage granted for
one month after receipt by the FINANCIAL LESSOR of that notice; notify the FINANCIAL LESSOR, with one month&#146;s notice, of any termination of the policy to take place at its initiative; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay the FINANCIAL LESSOR alone, except with express authorization from the latter, any compensation related to
the rents and property damage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not assert, with respect to the FINANCIAL LESSOR, any omission, insufficient declaration, or inaccurate
declaration by the FINANCIAL LESSEE and, consequently, not enforce against the FINANCIAL LESSOR, the invalidity, or coinsurance clause, or forfeiture in case of breach by the injured party of its obligations committed after an accident; the
insurance company nevertheless retaining all recourse against the FINANCIAL LESSEE, subscriber for the policy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive any recourse against the FINANCIAL LESSOR in case of an accident damaging the personal property, materials,
and goods contained in the building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not assert any clause limiting the compensation to the cost of the materials if the building is erected on land
belonging to another. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>VI - Obligation of the FINANCIAL LESSEE in case of accident.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The FINANCIAL LESSEE shall notify the FINANCIAL LESSOR in writing, within five business days of its occurrence, of any accident suffered or
caused by the premises covered by the financial lease agreement. It shall also, under the terms and time frames set out by each insurance policy, make all declarations to the insurance companies: the FINANCIAL LESSOR henceforth gives it, as needed,
a mandate to make these declarations. <B>The FINANCIAL LESSEE is prohibited from any proceedings or action against the FINANCIAL LESSOR relative to the accident.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* It shall also take the necessary measures to obtain, from the insurance companies, the quick payment of compensation, and in particular
either on its own behalf, or on behalf of the FINANCIAL LESSOR, which henceforth gives it all useful mandates to that end, to take all measures, perform all formalities, obtain all expert assessments, assist therein; in case of difficulties, bring
any proceedings, constraints, and diligence. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* However, in case of judicial proceedings, the FINANCIAL LESSOR shall be notified
<B><U>beforehand</U></B> by the FINANCIAL LESSEE of any action undertaken, as plaintiff or defendant, the FINANCIAL LESSOR having the deciding vote relative to the choice of attorney, who may not be appointed by the FINANCIAL LESSEE without its
agreement. All duties, costs, and fees of any nature, including the legal fees and those of an architect or engineering firm appointed by the FINANCIAL LESSOR to monitor the court-ordered assessment operations, that may remain due because of the
performance of the obligations set out above, will be paid directly by the FINANCIAL LESSEE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The FINANCIAL LESSEE will relieve the
FINANCIAL LESSOR of any orders that may be handed down against it due to the nonexistence or insufficiency of coverage by the aforementioned policies, and more generally, in case of total or partial coverage refusal by the insurer. It will further
take responsibility for the costs and fees that the FINANCIAL LESSOR may have incurred for its defense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* In case of an accident involving
the construction insurance policies (Builders Risk Insurance or Renovation Works Policy), the FINANCIAL LESSEE further undertakes to reconstitute, at its sole expense, the coverage such that the amount thereof is at least equivalent to what it was
before the occurrence of the accident and to allow, in any case, full reconstruction of the premises covered by the financial lease, and to provide evidence thereof to the FINANCIAL LESSOR upon first demand by the latter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">*<B> </B><B><U>In any case</U></B>, the compensation paid following any accident will be collected beforehand by the FINANCIAL LESSOR, the
latter being responsible for subsequently passing it on to the FINANCIAL LESSEE, upon justification of the full performance of the work and presentation of paid invoices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall also pay the <B>FINANCIAL LESSOR</B> the management costs of the accident, in the amount of ZERO point FIVE
ZERO percent (0.50%) of the amount the accident, not to exceed TWO THOUSAND, THREE HUNDRED EUROS (&#128;2,300), excluding value-added tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 18 - <U>Accident - Reconstruction</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Partial accident </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By
derogation from the provisions of Article 1722 of the Civil Code, the partial destruction, even by act of God or force majeure, of the leased building will not authorize the <B>FINANCIAL LESSEE</B> to request termination of the financial lease, or
the payment of any compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will be required to repair the premises having suffered the accident, at its
sole expense, risk, and peril, after having obtained the necessary administrative authorizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> will pass
on to the <B>FINANCIAL LESSEE</B>, upon provision of supporting documentation for the work done, any compensation that it may collect from insurance companies or any entity whatsoever, after, however, deducting any taxes and fees that may affect
that compensation. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the repair of the premises cannot be done for lack of the necessary administrative
authorizations, the <B>FINANCIAL LESSEE</B> will have the ability to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* either request the termination of the financial lease, without
waiting for the expiration of the minimum time frames set out in article 3 above, and in return for the payment to the <B>FINANCIAL LESSOR</B> of compensation equal to the entire price, stipulated below in article 32, of the sale of the building set
out in article 31, determined on the day of the termination, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* or realize the promise of sale granted in its favor, under the conditions
set out in article 31, and in return for the price stipulated in article 32, even before the expiration of the minimum time frame set out below, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* or continue this financial lease on the usable part of the building. In this case, the <B>FINANCIAL LESSEE</B> will pay the <B>FINANCIAL
LESSOR</B> compensation representing the depreciation of the building determined on the date of the accident by mutual agreement between the parties or, otherwise, by expert statement designated by the most diligent party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of the rent will be reduced in proportion to the amount of this compensation (net of all taxes and fees that may affect it)
relative to the price stipulated in article 32 below of the sale of the building promised to the <B>FINANCIAL LESSEE</B>, determined on the date of payment of that compensation. The sales price stipulated in article 32 itself will be reduced by the
amount of the collective compensation (net of any taxes and fees that may affect it). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These reductions will take effect as of the date of
payment of the compensation by the <B>FINANCIAL LESSEE</B> and not from the date of the accident. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In all three cases set out above
(termination of the financial lease, early exercise of the promise of sale, or continuation of the financial lease on the remaining part of the building), if the <B>FINANCIAL LESSOR</B> collects compensation from the insurance companies or any
entity, it will forward that compensation to the <B>FINANCIAL LESSEE</B>, having deducted any taxes and fees that may affect it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
compensation collected from the Insurance Companies by the <B>FINANCIAL LESSOR</B> and passed on to the <B>FINANCIAL LESSEE</B> will be deducted from the compensation paid to the <B>FINANCIAL LESSOR</B> by the <B>FINANCIAL LESSEE</B> in the cases
set out above, i.e., the termination of the financial lease or the continuation of this financial lease on the usable part of the building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall indicate its option by registered letter with return receipt, within one (1)&nbsp;month of receipt of the
letter sent by the <B>FINANCIAL LESSOR</B> requesting its agreement regarding the amount of the compensation proposed by the insurance company and asking for the selected option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no response is received from the <B>FINANCIAL LESSEE</B> within the aforementioned time frame, the <B>FINANCIAL LESSEE</B> will be
considered to have opted for termination of this agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Total accident </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of an accident causing the total destruction of the building, this financial lease will be terminated automatically, but only upon
expiration of the time frames stipulated below in favor of the <B>FINANCIAL LESSEE</B>, to optionally exercise the option reserved for it and except in case of express and written waiver by the <B>FINANCIAL LESSEE</B> regarding the benefit of this
ability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, by express agreement between the parties and by derogation from Article 1722 of the Civil Code, such a termination
will cause the obligation for the <B>FINANCIAL LESSEE</B> to pay the <B>FINANCIAL LESSOR</B> compensation equal to the sales price of the building, as stipulated in article 32 determined on the date of the termination, increased, if applicable, by
any repair costs for the land after the accident (in particular destruction and removal of remains). In return, the <B>FINANCIAL LESSOR</B> will pay the <B>FINANCIAL LESSEE</B> the amount of any compensation received from the insurance companies or
any entity, after deducting any taxes and fees that may affect that compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, and notwithstanding the preceding provisions,
the <B>FINANCIAL LESSEE</B> will have the ability to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* either realize the promise of sale under the terms indicated in paragraph A above,
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* or (by express derogation from the provisions of Article 1722 of the Civil Code) continue this financial lease by having the premises
rebuilt at its sole expense, risk, and peril, after having obtained the necessary administrative authorizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL
LESSEE</B> shall indicate its option by registered letter with return receipt, within one (1)&nbsp;month of receipt of the letter sent by the <B>FINANCIAL LESSOR</B> requesting its agreement regarding the amount of the compensation proposed by the
insurance company and asking for the selected option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no response is received from the <B>FINANCIAL LESSEE</B> within the
aforementioned time frame, the <B>FINANCIAL LESSEE</B> will be considered to have opted for termination of this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
<B>FINANCIAL LESSEE</B> opts for the continuation of the financial lease, the necessary administrative authorizations must be obtained by the <B>FINANCIAL LESSEE</B> within one year from the date of notification of its option; otherwise, the
financial lease will be terminated automatically under the terms set out above, unless the <B>FINANCIAL LESSEE</B> prefers, within the same <FONT STYLE="white-space:nowrap">one-year</FONT> period, to opt for realization of the promise of sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irrespective of the option chosen by the <B>FINANCIAL LESSEE</B>, the <B>FINANCIAL LESSOR</B> will pay it the amount of the compensation
collected from the insurance companies or the other entities, having deducted any taxes and fees that may affect that compensation. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forwarding to the <B>FINANCIAL LESSEE</B> of any compensation that may be due to it under the
provisions of this article 18 will only take place after the effective payment by the <B>FINANCIAL LESSEE</B> of any amounts that it owes to the <B>FINANCIAL LESSOR</B> under this agreement, the <B>FINANCIAL LESSOR</B> nevertheless reserving the
right to automatically perform compensation between these amounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C - Rebuilding authorization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In all of the cases set out in paragraphs A and B above, the <B>FINANCIAL LESSEE</B> is required to obtain any administrative authorizations
that may be necessary. It is specified that the <B>FINANCIAL LESSEE</B> will also be required to obtain, if applicable, the authorizations resulting from the coownership agreement and/or documents governing the zone on which the building under the
financial lease depends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D - Rebuilding - Repair </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In all of the cases set out in this article, the rebuilding of the building that has been completely destroyed or the repair of a building that
is partially affected by an accident will be done by the <B>FINANCIAL LESSEE</B>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* based on a work quotation and plans prepared by the
<B>FINANCIAL LESSEE</B> at its expense and under its liability, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* and under the oversight and monitoring of an architect or a technical
engineering firm approved by the <B>FINANCIAL LESSOR</B> and whose fees will be included in the rebuilding or repair costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E -
Provisions relative to rents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In all cases of accident where the <B>FINANCIAL LESSEE</B> has opted for the repair or rebuilding of the
leased building and therefore for the continuation of the financial lease, the <B>FINANCIAL LESSEE</B> will continue, during the period elapsed between the date of the accident and the actual rebuilding, to bear all of the rents, charges, and
accessories stipulated in this deed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In return, the compensation that the <B>FINANCIAL LESSOR</B> may collect from insurance companies
under the &#147;Lost Rents&#148; coverage or the &#147;Deprivation of enjoyment&#148; coverage (or any other equivalent coverage), when this coverage has indeed been subscribed for by the <B>FINANCIAL LESSEE</B> under the terms specified in article
17 above, will be passed on by the <B>FINANCIAL LESSOR</B> to the <B>FINANCIAL LESSEE</B>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAPTER IV - FINANCIAL CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This financial lease is respectively granted and accepted in return for the financial charges (study and assembly costs, advance rents, rents,
and other royalties) set out below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 19 - <U>Study and assembly costs - Commitment - Management costs - Advance rents -
Interest on the value-added tax</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1) Study and assembly costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A lump sum, excluding value-added tax, of FIVE THOUSAND EUROS (&#128;5,000.00), or the sum, all taxes included, of FIVE THOUSAND, NINE HUNDRED
EIGHTY EUROS (&#128;5,980.00), has been paid by the <B>FINANCIAL LESSEE</B> to the <B>FINANCIAL LESSOR</B> as of this day. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2)
Commitment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> will receive a commitment commission set at ZERO POINT ZERO FIVE PERCENT (0.05%) per quarter of
the amount of the investment excluding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This commission is calculated, <I>prorata temporis</I>, as of the date of the financing
offer, or January&nbsp;7, 2008, until today, on which date it will be withdrawn in a single operation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3) Management costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> will collect, from the <B>FINANCIAL LESSEE</B>, if applicable, throughout the entire term of the financial property
lease, the following costs excluding tax, in case of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs on rents if withdrawal outside Soci&eacute;t&eacute; G&eacute;n&eacute;rale rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">55/par</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management of a dispute related to the construction or an accident</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Modification of the agreement at the request of the <B>FINANCIAL LESSEE</B> causing the
preparation of an amendment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of the early option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quantification of exercise of the early option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract management costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">115/year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4) Lessee advance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> grants the <B>FINANCIAL LESSOR</B>, which is accepted by their above-mentioned representative, a loan in an amount
of ONE MILLION, FIVE HUNDRED THOUSAND EUROS (&#128;1,500,000.00), which will be pledged by the <B>FINANCIAL LESSEE</B> in favor of the <B>FINANCIAL LESSOR</B> throughout the entire term of the financial lease as of this date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cashing and repayment of this loan will be done as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <B>FINANCIAL LESSEE</B> pays, this day, to the <B>FINANCIAL LESSOR</B>, the amount of the loan, i.e., ONE
MILLION, FIVE HUNDRED THOUSAND EUROS (1,500,000.00 EUR), </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <B>FINANCIAL LESSOR</B> will open, in its writings in the name of the <B>FINANCIAL LESSEE</B>, a special
account corresponding to the amount of the above loan granted and accepted and intended to trace the relations of the <B>FINANCIAL LESSOR</B> and the <B>FINANCIAL LESSEE</B>, on the occasion of this loan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This loan will be repaid at the nominal rate of the contract applied to the
<FONT STYLE="white-space:nowrap">non-indexed</FONT> rent element decreased by 0.20 points. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The repayment of this loan will be done by compensation with the rent excluding value-added tax due to the
<B>FINANCIAL LESSOR</B> by the <B>FINANCIAL LESSEE </B>under this financial lease agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It will be done over the same duration, i.e., TWELVE (12)&nbsp;years, and with identical due dates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The repayment of this loan may also be done, if applicable, by compensation with any other amounts due on any
grounds to the <B>FINANCIAL LESSOR</B> by the <B>FINANCIAL LESSEE</B>, which will then be imputed to the amount of the financial lease payments as they become due. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <B>FINANCIAL LESSEE</B> recognizes, to the <B>FINANCIAL LESSOR</B>, the ability to modify the terms for
repayment of the loan defined above, in case of default, bankruptcy, or liquidation, subject only to being informed thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <B>FINANCIAL LESSOR</B> will be considered to have met its obligations in the capacity of borrower, due
solely to the repayment in full of the loan no later than upon the conventional expiration date of the financial lease, if applicable, in a single payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <B>FINANCIAL LESSEE</B> waives, in advance, the right to claim the repayment of the loaned sum before the
expiration of the financial lease agreement and to invoke, for any reason whatsoever, the provisions of Article 1944 of the Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In case of termination of this financial lease agreement or in case of realization of the promise of sale before
the conventional expiration of the financial lease, the balance of the loan will be repaid by the <B>FINANCIAL LESSOR</B> in advance. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5) Advance rents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advance
rents calculated on the basis specified below are due for the period elapsed from the first disbursement by the <B>FINANCIAL LESSOR</B> of any amount excluding tax under section B until the effective date of that section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of these advance rents will be calculated at the Mean Monthly Rate (MMR) of the Financial Market for the past month increased by
0.80 points per year on the amount excluding tax disbursed by the <B>FINANCIAL LESSOR</B> for the performance of this financial lease operation, by way of cost of the development work for the building, in principle and accessories, as well as any
royalty, costs, or other amounts paid on the occasion of this financial lease operation. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This amount, increased by the value-added tax affecting it, will be paid at the end of each month
directly by the <B>FINANCIAL LESSEE</B> by withdrawal from its account open with the SOCIETE GENERALE, as will be stated below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6)
Interest on the value-added tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During an inclusive term of four (4)&nbsp;months from each payment made by the <B>FINANCIAL LESSOR</B>
under this operation, the <B>FINANCIAL LESSEE</B> will be required to pay it, in addition to the financial charges stipulated below, and as additional rent, interest calculated at the Mean Monthly Rate of the Financial Market for the past month
increased by ZERO POINT EIGHT ZERO (0.80) points per year on the amount of the value-added tax credit corresponding to this disbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This interest, increased by the value-added tax that affects it, will be payable at the end of each calendar month. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 20 - <U>Basis for calculating the rent (investment)</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rent stipulated below will be calculated based on the following elements, representing the sums invested by the <B>FINANCIAL LESSOR</B> in
this financial lease operation, and which will be expressed below using the term &#147;investment&#148;: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The price, excluding
value-added tax, for the acquisition of the existing building paid by the <B>FINANCIAL LESSOR</B> (section A); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The amount of the costs,
duties, and emoluments, excluding value-added tax, borne by the <B>FINANCIAL LESSOR</B> on the occasion of this acquisition (section A); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">*
The cost, excluding the value-added tax, of the development work for the building, as set out in the aforementioned project management delegation agreement (section B). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of this investment will not in any case be higher than the amount, excluding value-added tax, of SIX MILLION, FOUR HUNDRED ONE
THOUSAND EUROS (&#128;6,401,000.00). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No excess of the maximum amount specified above may be required from the <B>FINANCIAL LESSOR</B>,
even if that sum proves, for any reason, insufficient to carry out this operation. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 21 - <U>Financial lease rent</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Determination of the rent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rent under this financial lease will be due by the <B>FINANCIAL LESSEE</B> to the <B>FINANCIAL LESSOR</B> as of this date regarding section
A and the first day of the month following the date of completion of the development work, as it results from the provision of the premises established between the parties as set out in the project management delegation agreement analyzed above
regarding section B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expressly specified in this respect that the term &#147;rent&#148;, used in this document for convenience of
language, must be likened to a financial royalty covering the amortization and remuneration at the agreed rate of the capital invested by the <B>FINANCIAL LESSOR</B> for the performance of this operation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, and except in case of an expressed legislative provision targeting the financial property lease, the rents agreed upon below may
not suffer any modification or revision for any reason whatsoever, whether it relates to a state of affairs depending on the <B>FINANCIAL LESSEE</B> or legislative texts regulating, temporarily or permanently, the amount or the rate of the rent for
premises for commercial or industrial use, or any revision based on the provisions of Articles L. <FONT STYLE="white-space:nowrap">145-1</FONT> <I>et seq.</I> of the New Commercial Code governing the relations between the lessors and lessees of
premises for commercial use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rent shall be made up of a financial amortization and interest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* The financial amortization makes it possible to amortize all of the investment over the term of the financial lease agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amortization rhythm selected is one that makes it possible to obtain, for each element of rent before indexing, constant charges
throughout the entire term of the financial lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rents will be made up of the sum of the following elements: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1</B>. First rent element calculated on 80% of the investment </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A first, <FONT STYLE="white-space:nowrap">non-indexed</FONT> element, including a financial amortization and interest discounted on the
financial amounts outstanding remaining due after amortization of the period at the following annual nominal rate T: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">T = TEC 10 + 0.85
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TEC 10 = Yield to maturity of a fictitious value of the Treasury, the lifetime of which will, at all times, be equal to 10 years,
published daily by the French Treasury Agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The value of the selected TEC 10 will be that published on the third business day
preceding <I>the payment of rent for each of Sections A and B.</I> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2</I>. Second rent element calculated on 20% of the investment </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A second indexed element, including a financial amortization and interest deducted from the financial outstanding amounts remaining due after
amortization of the period at the fixed and definitive annual rate equal to FOUR PERCENT (4%) before indexing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This rent element will be
indexed in full on the index of the cost of construction published quarterly by the INSEE, as this indexing is specified below. Irrespective of the variation of the index, the amount of this portion of rent may not be less than the amount of that
rent element before indexing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Terms for indexing of the first rent element</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indexing of the second rent element will be done annually based on the variation of the Quarterly Construction Cost Index published by the
<I>Institut National de la Statistique et des Etudes Economiques</I> (INSEE). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The revision will lead to the application in full of the
variation of the index over ONE HUNDRED PERCENT (100%) of the second rent element for the year in question, before indexing, as defined above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variation of the aforementioned index will be taken into consideration both in the case of an increase and a decrease of the index;
however, and in no case, will account be taken of an index lower than that the base index agreed upon below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual indexing product
will be calculated by applying, to ONE HUNDRED PERCENT (100%) of the second rent element, an index increase coefficient determined using the following formula: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:2%">


<IMG SRC="g751960g1213113437809.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this formula: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I.C.b.: represents the base index of the Construction Cost </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I.C.c.: represents the comparison index of the Construction Cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expressly agreed that in no case may a variation period of the index be taken into account longer than the duration elapsed between each
revision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">*
the number of quarterly periods separating the base index from each of the successive comparison indices taken into account to calculate the indexing product is determined below, so as to represent a duration at least equal to that elapsed between
each effective date of the contract and the date of each revision in question. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* the duration elapsed between each revision of the second rent element is determined below so as
to be at least equal to the number of quarterly periods separating the comparison indices respectively taken into account for those revisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1) The single base index
for the entire term of the contract will be that relative to the calendar quarter preceding the effective date of this agreement, and cannot be after that of the second quarter of the year during which the contract takes effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2) The indexing beginning one year after the effective date of the financial lease, the comparison index will be one year later than the base
index. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will owe, as of the starting date of the indexing, the indexing product related to the period between
the start date of the indexing and the end of the calendar year then in progress. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3) The revisions next taking place on each
January&nbsp;1, the determination of the indexing product for each of the subsequent calendar years until expiration of the agreement will be done by using, as a comparison index, that of the second calendar quarter of each of the preceding years.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of cessation of publication or disappearance of the selected index before the expiration of the financial lease and if the
<I>Institut National de la Statistique et des Etudes Economiques</I> publishes a new construction cost index intended to replace the one currently in force, the rent will automatically be indexed on that new index and the transition from the old
index to the new one will be done using the necessary linking coefficient. If the <I>Institut National de la Statistique et des Etudes Economiques</I> does not publish the new index intended to replace that which has disappeared, the parties will be
responsible for reaching an agreement regarding the choice of the new index reflecting, as accurately as possible, the construction cost on the national scale or, otherwise, in the department where the property under the financial lease is located,
on the variation of which the indexing will be calculated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If they do not reach an agreement, the replacement index will be determined by
two experts chosen by mutual agreement or appointed by the President of the PARIS District Court. In case of disagreement, these experts will have the option of adding a third expert to break the tie. This third expert may be appointed by the same
President upon simple request by the most diligent party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no case may the effects of the preceding index clause lead the second rent
element to an amount lower than the rent element as determined above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Disappearance of the selected rates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, for any reason, the rate(s) selected above is (are) no longer available, they will be replaced by the rates officially substituted for
them. If no officially substitute rates exist, substantially equivalent rates will be chosen by mutual agreement between the parties. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 22 - <U>Payability of the rent - Definitive financial table - Summary statement and
tables prepared pursuant to Decree number <FONT STYLE="white-space:nowrap">95-617</FONT> dated May</U><U></U><U>&nbsp;6, 1995</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
rent thus determined is payable quarterly and in advance on the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of January, April, July, and October of each year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, the first rent term payable upon taking of effect of section A has been calculated <I>prorata temporis</I>. Likewise, the first term
of rent payable upon taking of effect of section B and the last term of rent will also be calculated <I>prorata temporis</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Regarding section A:</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Decree number <FONT STYLE="white-space:nowrap">95-617</FONT> dated May&nbsp;6, 1995 implementing Article 57 of Law number <FONT
STYLE="white-space:nowrap">95-115</FONT> dated February&nbsp;4, 1995, the <B>FINANCIAL LESSOR</B> has prepared: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1) A summary statement in
particular including the price agreed upon for the acquisition of the building at the end of the agreement or the information making it possible to determine that price and the price of the <FONT STYLE="white-space:nowrap">non-amortizable</FONT>
elements and amortizable elements appearing in the assets of the balance sheet of the <B>FINANCIAL LESSOR</B>, as well as the acquisition cost of the building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the economy of this agreement would be modified due to changes in the situation of the <B>FINANCIAL LESSEE</B> or property subject to the
financial lease, a modified summary statement would be prepared by the <B>FINANCIAL LESSOR</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2) A breakdown showing, for each term of
rent, the portion of rent relative to the amortization of the capital taken into account to determine the sales price of the building at the end of the contract or the information making it possible to determine the sales price, as well as its
allocation to the respective financing of the acquisition cost, the amortizable elements, and <FONT STYLE="white-space:nowrap">non-amortizable</FONT> elements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary statement and breakdown will remain attached and appended hereto after mention. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#149; <U>Regarding section B:</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once section B takes effect, the <B>FINANCIAL LESSOR</B> will begin rent for that section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>First scenario:</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> then has, as of the beginning of rent, all of the supporting documentation necessary for the payment of all of the
investment under section B: it then prepares a definitive scale regarding the actual total amount of the investment, stating the due date and amount of each term of rent. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Second scenario:</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> does not have, upon the beginning of rent, all of the supporting documentation necessary for payment of all of the
investment under section B: it establishes a provisional scale on the contractual amount of the investment set out above, stating the due date and the amount of each term of rent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will have a period of six (6)&nbsp;months as of the effective date of section B to produce the supporting
documentation necessary for the payment of all of the investment. At the end of this period, the <B>FINANCIAL LESSOR</B> may determine the amount of the investment for section B at the amounts effectively disbursed on that date, after notice sent to
the <B>FINANCIAL LESSEE</B> by registered letter with return receipt. It will inform the <B>FINANCIAL LESSEE</B> that the payments not taken into account will remain the latter&#146;s responsibility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, pursuant to Decree <FONT STYLE="white-space:nowrap">No.&nbsp;95-617</FONT> dated May&nbsp;6, 1995 implementing Article 57 of Law
number <FONT STYLE="white-space:nowrap">95-115</FONT> dated February&nbsp;4, 1995, the <B>FINANCIAL LESSOR</B> will then establish, upon the taking of effect of section B: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1) A summary statement in particular including: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* the date of conclusion and the term of the agreement, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* the price agreed upon for the acquisition of the building at the end of the agreement or the information making it possible to determine that
price, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* the price of the <FONT STYLE="white-space:nowrap">non-amortizable</FONT> elements and the amortizable elements appearing in the
assets of the balance sheet of the <B>FINANCIAL LESSOR</B> as well as the acquisition cost of the building, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* the location, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2) A breakdown of showing, for each rent, the portion of rent relative to the amortization of the capital taken into account to determine the
sales price as well as its allocation to the respective financing: acquisition costs, amortizable elements, and <FONT STYLE="white-space:nowrap">non-amortizable</FONT> elements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> will send the <B>FINANCIAL LESSEE</B> a letter of amendment to the financial lease, to which the summary
statement, the breakdown, and the final scale will be appended: the <B>FINANCIAL LESSEE</B> must return this letter of amendment to the <B>FINANCIAL LESSOR</B> after approving it, within ten days of its receipt, failing which the letter of amendment
will be considered to have been approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the economy of this agreement is modified after the financial lease agreement takes effect,
due to changes in the situation of the <B>FINANCIAL LESSEE</B> or goods given under the financial lease, an amended summary statement will be prepared by the <B>FINANCIAL LESSOR</B>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 23 - <U>Payment of the value-added tax and charges and taxes</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will pay the <B>FINANCIAL LESSOR</B>, upon each due date of a term of rent, the amount of the value-added tax
affecting that term of rent at the rate in force on the due date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will directly pay the insurance companies
the premiums for all insurance subscribed for covering the leased premises as indicated above, including those payable for the policies subscribed for on behalf of the <B>FINANCIAL LESSOR</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> will provide evidence of these payments upon first request by the <B>FINANCIAL LESSOR</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the <B>FINANCIAL LESSEE</B> will reimburse the <B>FINANCIAL LESSOR</B> for the amount of all taxes, fees, charges, and expenses
of any nature, as well as, if applicable, the charges that may be due for a Zone, a Lot, or a property management payment regarding the property subject to the financial lease, that the <B>FINANCIAL LESSOR</B> may have paid itself, relative to the
leased premises or the lease, increased if applicable by the value-added tax that may affect such repayments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All payments, the
value-added tax, and in general, all amounts due by the <B>FINANCIAL LESSEE</B> to the <B>FINANCIAL LESSOR</B> under this agreement will be recovered by the <B>FINANCIAL LESSOR</B> by withdrawal from the account of the <B>FINANCIAL LESSEE</B>, in
particular open: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the <B>SOCIETE GENERALE</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Branch: MARSEILLE ENTREPRISES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under number: 00020294991, RIB key 57 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 24 - <U>Late interest</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After expiration of a period of fifteen days from receipt of the rent invoices and any other requests for payment by the <B>FINANCIAL
LESSOR</B>, their lack of payment will cause the <B>FINANCIAL LESSEE</B> to owe the <B>FINANCIAL LESSOR</B> late interest calculated <I>prorata temporis</I> at the overnight Mean Monthly Financial Rate (MMR) increased by FIVE points per year, not to
be less than 9%, from the due date until the payment date, increased by the value-added tax at the rate in force, all without prejudice to the ability of the <B>FINANCIAL LESSOR</B> to seek the termination of the financial lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, nonpayment of any invoice will lead, on its due date, by way of management costs for outstanding amounts, to the collection by
the <B>FINANCIAL LESSOR</B> of a lump sum, excluding value-added tax, of EIGHTY EUROS (&#128;80). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAPTER V - TERMINATION OF THE FINANCIAL LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 25 - <U>Termination by the FINANCIAL LESSOR</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of nonperformance of any of the obligations for which the <B>FINANCIAL LESSEE</B> is responsible under this agreement, the financial
lease will be terminated automatically and with no judicial formality, if the <B>FINANCIAL LESSOR</B> so desires, two months after notification to the <B>FINANCIAL LESSEE</B> of an order to pay or formal notice, which has remained fully or partially
ineffective, and which contains a declaration by the <B>FINANCIAL LESSOR</B> of its intent to exercise the benefit of this clause, having specified that any offer of payment or performance done after the expiration of the <FONT
STYLE="white-space:nowrap">two-month</FONT> time frame shall remain ineffective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this case, the expulsion of the <B>FINANCIAL
LESSEE</B> or its assignees may be ordered by simple interim order by the President of the District Court, provisionally enforceable, notwithstanding opposition or appeal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> shall then be required to return the leased premises to the <B>FINANCIAL LESSOR </B>immediately, in good state of
repair and upkeep, and provide proof of the payment of all of its taxes, fees, and services, as well as its insurance premiums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to back rent, it shall pay the <B>FINANCIAL LESSOR</B> the termination compensation stipulated in article 28 below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article
26 - <U>Bankruptcy or liquidation - Dissolution of the lessee</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of collective proceedings against the <B>FINANCIAL
LESSEE</B>, and subject to the enforcement of Articles L. <FONT STYLE="white-space:nowrap">620-1</FONT> <I>et seq.</I> of the New Commercial Code, this financial lease may be terminated at the request of the <B>FINANCIAL LESSOR</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of dissolution of the financial lessee, this financial lease will only be terminated if the <B>FINANCIAL LESSOR</B> requests it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In all cases, this termination automatically causes the payment by the <B>FINANCIAL LESSEE</B> of the termination compensation stipulated in
article 28 below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 27 - <U>Failure to obtain the certificate of compliance</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> undertakes to perform all diligence in order to obtain, within two years of completion of the construction work, as
stated in the project management delegation agreement, a certificate from the competent authority confirming that it has not issued formal notice to the <B>FINANCIAL LESSEE</B> to bring the work into compliance pursuant to Article R. <FONT
STYLE="white-space:nowrap">462-10</FONT> of the Urban Development Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the issue of the certificate is made subject by the
Administration to the performance of modifying or additional work, the <B>FINANCIAL LESSEE</B> must perform that work at its expense, so that the certificate may be obtained within the aforementioned period of two years. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this <FONT STYLE="white-space:nowrap">two-year</FONT> period, the <B>FINANCIAL LESSEE</B>
will owe the <B>FINANCIAL LESSOR</B> a lump sum compensation for each month late at one percent of the rent in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to issue
the certificate may not be held by the <B>FINANCIAL LESSOR</B> or the <B>FINANCIAL LESSEE</B> as grounds for termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, if the
termination of the financial lease takes place for any other reason at the request of either of the parties, and in particular for failure to make payment by the <B>FINANCIAL LESSEE</B> for the lump sum compensation stipulated above, the amount of
the termination compensation will be increased under the terms set out in the &#147;termination compensation&#148; article below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In all
cases, the <B>FINANCIAL LESSEE</B> will personally see to the payment of all tax adjustments for which the <B>FINANCIAL LESSOR</B> may be responsible if it is considered not to have fulfilled its commitment to build under the conditions and time
frame set out by Article 691 of the General Tax Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 28 - <U>Termination compensation for the financial lease</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The termination of this financial lease before its conventional expiration for any reason, and in particular in fulfillment of the clause set
out in article 25 above or for any other cause, irrespective of whether it is provided for in this agreement, including termination at the request of the <B>FINANCIAL LESSEE</B>, will automatically and without any formality lead to the payment by
the <B>FINANCIAL LESSEE</B> of compensation calculated based on the sales price, which will be discussed in article 32 below, determined on the actual termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an essential condition of this agreement, this compensation, related to the specific nature of the financial lease, will have the nature of
lump sum monetary damages to compensate the prejudice suffered by the <B>FINANCIAL LESSOR</B> due to the early termination of the financial lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, no compensation will be due by the <B>FINANCIAL LESSEE</B> if the cancellation of the financial lease has been the result of the
realization of the promise of sale granted below by the <B>FINANCIAL LESSOR</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Likewise, no compensation will also be due by the
<B>FINANCIAL LESSEE</B> in case of total or partial expropriation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of the compensation will be equal to half of the sales
price in all termination cases. It will be increased to three quarters of the same sales price if, on the termination date of the financial lease, the certificate of compliance of the building has not yet been granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is observed here that the provisions included in this article do not novate those stipulated in article 18 above for cases of accident
affecting the building, the provisions of article 18 expressly remaining in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All costs, duties, and taxes, in particular the
value-added tax, that may be applied to that agreement, which is stipulated excluding tax, will be the responsibility of the <B>FINANCIAL LESSEE</B>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAPTER VI - EXPROPRIATION - REQUISITION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 29 - <U>Expropriation of the building</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Total expropriation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of total expropriation of the building, the financial lease will be terminated automatically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, from the order bringing about the transfer of ownership and until the date of effective taking of possession of the building by the
expropriating Authority, the <B>FINANCIAL LESSEE</B> will owe the <B>FINANCIAL LESSOR</B> occupancy compensation equal to the amount of the rent payable during that period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the expropriation compensation awarded to the <B>FINANCIAL LESSOR</B>, after deducting all taxes and fees that may affect the collection of
that compensation as a result, is in an amount exceeding the sales price defined in article 32 below, determined on the date of payment of the compensation, the <B>FINANCIAL LESSOR</B> will pay the <B>FINANCIAL LESSEE</B> the difference between
those two amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Otherwise, the <B>FINANCIAL LESSEE</B> will owe this difference to the <B>FINANCIAL LESSOR</B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Partial expropriation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of partial expiration of the building subject to the financial lease, the financial lease will continue to bear its full and complete
effect on the part of the building remaining available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rent will be reduced in proportion to the ratio of the amount of the
expropriation compensation, net of all taxes and fees that may affect it, with the sales price defined in article 32 below, determined on the date of payment of that compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This reduction will only take effect as of the date of cashing by the <B>FINANCIAL LESSOR</B> of the appropriation compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The same sales price defined in article 32 below will itself be reduced by the amount of the received compensation (net of all taxes and fees
that may affect it). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C - Dispute regarding the expropriation compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of the amount of the compensation that may be due in case of total or partial expropriation of the building currently given
under the financial lease may only be agreed upon by the <B>FINANCIAL LESSOR</B> in the presence of the <B>FINANCIAL LESSEE</B>, or with the latter having been duly called. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> shall indicate its position in this respect no later than eight days before the expiration of the time frame
granted to the <B>FINANCIAL LESSOR</B> to accept or refuse the amount of the expropriation compensation and, in any case, no later than one month after it has been informed by registered letter with return receipt of its intention to accept the
offers made. This notice from the <B>FINANCIAL LESSEE</B> must be given to the <B>FINANCIAL LESSOR</B> by registered letter with return receipt. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> may not oppose a refusal of the offers accepted by the <B>FINANCIAL
LESSOR</B> except in accordance with the stipulations below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of dispute regarding the amount of the compensation, the
<B>FINANCIAL LESSEE</B>, to whom all powers are given to that end, shall exercise any useful judicial recourse and keep the <B>FINANCIAL LESSOR</B> apprised of the progression of the proceedings by sending a copy of the exhibits for those
proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of total expropriation, the <B>FINANCIAL LESSEE</B> may only oppose a refusal of the offers accepted by the
<B>FINANCIAL LESSOR</B> inasmuch as it has paid, within one month as set out in the second paragraph above, to the <B>FINANCIAL LESSOR</B>, an amount equal to the residual value defined in article 32 below, determined on the last day of the civil
semester during which the payment has been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case at hand and for the duration of the deposit, no rent or compensation will be
due to the <B>FINANCIAL LESSOR</B>. The amount deposited will be pledged in favor of the <B>FINANCIAL LESSOR</B> as guarantee for the amounts that may be due to it under this agreement. The deposited amount will not be remunerated, its remuneration
consisting of the abandonment of all rents or compensation by the <B>FINANCIAL LESSOR</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regarding the partial expropriation, the
dispute of the amount of the compensation offered will always be reserved for the <B>FINANCIAL LESSEE</B> under the terms stipulated above, without any deposit or other obligation, but it of course remains that the reduction in rent set out in this
article, paragraph B above, shall only take place when the <B>FINANCIAL LESSOR</B> has in fact received the amount of the expropriation compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 30 - <U>Requisition of the building</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of requisition or total or partial occupation of the building currently subject to the financial lease, by any competent authority or
entity occurring during this financial lease, this financial lease will continue to produce its full and complete effect. The rents agreed upon will continue to be payable with no decrease. The requisition or occupation compensation will be paid in
full to the <B>FINANCIAL LESSEE</B>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE THREE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNILATERAL PROMISE OF SALE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 31 - <U>Promise of sale</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article L. <FONT STYLE="white-space:nowrap">313-7</FONT> 2&deg; of the Financial and Monetary Code on financial lease operations,
these agreements must allow the <B>FINANCIAL LESSEE</B> to become, if it so desires, the owner of the premises currently given under the financial lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To that end, the representative of the <B>FINANCIAL LESSOR</B> promises the <B>FINANCIAL LESSEE</B>, which is accepted by its representative,
but only as a promise, to sell it the building covered by this financial lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This promise of sale is granted for a term beginning as
of the end of the seventh calendar year following the effective date of section A of the financial lease, and ends upon the conventional expiration thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The realization request must be made by the expiration date of the financial lease or during the financial lease for the end of a calendar
year, via a registered letter with return receipt sent to the <B>FINANCIAL LESSOR</B> at its registered office, six (6)&nbsp;months in advance; it shall, subject to invalidity, be followed within three (3)&nbsp;months by the deposit to the
<B>FINANCIAL LESSOR</B> of a sufficient amount to cover both the price of the sale and the costs and duties caused by the performance of the sale. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(1) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This promise of sale
will become null and void, if the <B>FINANCIAL LESSOR</B> deems it appropriate, in case of nonperformance by the beneficiary of any clauses and stipulations of the financial lease, with no exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale will be granted in return for a price determined on the date of the performance of the sale by true deed, pursuant to article 32
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This price will be payable in cash upon signature of this deed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the sale is done, it will be recorded by a true deed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer of ownership will be subject to the payment of the entire sales price and any amount remaining due on any grounds whatsoever by
the <B>FINANCIAL LESSEE</B> to the <B>FINANCIAL LESSOR</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The entry into enjoyment will take place upon the actual and effective taking
of possession. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale will take place under the regular and <I>de jure</I> conditions in such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, pursuant to Article 1627 of the Civil Code, the <B>FINANCIAL LESSOR</B> will not be bound by any guarantee, even for hidden flaws, by
express derogation from the provisions of Article 1641 of the Civil Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The costs, duties, and emoluments of the sale will be borne by
the buyer. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 32 - <U>Sales price</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A - Determination of the sales price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The price of the sale promised above will be equal, upon conventional expiration of the financial lease, to ONE EURO (&#128;1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the prior years, the sales price will be calculated as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>For the <FONT STYLE="white-space:nowrap">non-indexed</FONT> rent element:</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sales price on this rent element will be the updated value, on the date of the sale, of all amounts due (rents and residual value at the
end of the financial lease) until the expiration of the agreement on that rent element. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any case, this amount may not be less than the
financial amount outstanding remaining due on the date of exercise of the option on this rent element increased by THREE PERCENT (3%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominal update rate will be equal to the nominal rate of the agreement on this rent element decreased by TWO (2)&nbsp;POINTS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>For the indexed rent element:</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sales price before indexing on this rent element will be equal to the financial outstanding amounts remaining due on this rent element.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This element of the sales price will be indexed in full on the INSEE construction cost index on the same index as the one used for the
second rent element, the base index being the one used upon the taking of effect of the financial lease, the comparison index being that of the second quarter preceding the sale, its amount, after indexing, can never be less than the financial
outstanding amount remaining due on the second rent element. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the sale is not regularized on the expiration date of the contract, the
<B>FINANCIAL LESSEE</B> will owe the <B>FINANCIAL LESSOR</B> quarterly occupancy compensation equal to the financial lease rent due for the last full civil quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any started quarter will be due in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These values will be calculated based on the effective date of the contract such that, in light of the cashing on the due date of the annual
base rents, the sales price applicable at the end of each calendar year ensures an annual rate equivalent to the actuarial rate of the operation. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expressly agreed that the sales price thus determined forms, in the minds of the party,
with the rents paid on the contractual due date, a whole for the expression of the financial terms of this agreement. Consequently, if for any reason, the <B>FINANCIAL LESSOR</B> were to be forced to grant a reduction of the contractual rent for one
or more terms or deadlines for its payment, the sales price would be recalculated taking into account on the one hand the amounts actually cashed and their payment date, and on the other hand the rents that the <B>FINANCIAL LESSOR</B> would have
received on the contractual due date without any reduction or payment delay, all such that the <B>FINANCIAL LESSOR</B> receives, through the price thus recalculated, the profitability resulting from the strict enforcement of the provisions of this
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of Decree number <FONT STYLE="white-space:nowrap">95-617</FONT> dated May&nbsp;6, 1995 pursuant to
Article 57 of Law number <FONT STYLE="white-space:nowrap">95-115</FONT> dated February&nbsp;4, 1995, the <B>FINANCIAL LESSOR</B> will prepare a summary statement in particular including the price agreed upon for the acquisition of the building at
the end of the agreement or the information making it possible to determine that price, and a breakdown in particular showing, for each term of rent, the portion thereof taken into account to determine the sales price set out above as provided under
article 21 of this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B - Any increase in the sales price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If applicable, the sales price, thus determined as specified in paragraph A above, will be increased by the amount of any sums that the
<B>FINANCIAL LESSOR</B> may be called upon to pay to the Tax Administration to regularize the deduction of the value-added tax having previously affected the amount of its investment, in fulfillment of the provisions of Article 207 II of Appendix II
of the General Tax Code, as modified and completed in particular by Decree <FONT STYLE="white-space:nowrap">No.&nbsp;79-1163</FONT> dated December&nbsp;29, 1979 and Decree <FONT STYLE="white-space:nowrap">No.&nbsp;95-1328</FONT> dated
December&nbsp;28, 1995. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In return for this increase, the <B>FINANCIAL LESSOR</B> will issue the buyer the attestation set out in Article
207 III 3 of the General Tax Code, which will allow the buyer to deduct the value-added tax, the amount of which will appear on the attestation under the conditions set out for the acquisitions of property constituting real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This potential increase in the price will be applied in all cases of sale of the building, subject to this financial lease, as set out in this
agreement, whether in fulfillment of the promise of sale above or in fulfillment of any of the other provisions of the agreement, in particular those relative to accidents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore and by express agreement between the parties, it is stipulated that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1) in case of partial accident causing the reduction of the rent and the sales price, the <B>FINANCIAL LESSEE</B> shall pay the <B>FINANCIAL
LESSOR</B>, in addition to the compensation representing the amount of the depreciation of the building, the amount of which will be used as a basis for calculating the reduction of the rent and the sales price, the amount of all sums that the
<B>FINANCIAL LESSOR</B> may be called upon to pay to the Tax Administration in fulfillment of the stipulations of Article 207 II of Appendix II of the General Tax Code, as modified, as set out above, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2) in case of total expropriation, on the expiration compensation that will be paid to the
<B>FINANCIAL LESSOR</B>, first the amount of all sums the <B>FINANCIAL LESSOR</B> may be called upon to pay to the Tax Administration for the regularization of the value-added tax having previously affected the investment will be withdrawn; only the
balance of the expropriation compensation, after this withdrawal, will be taken into consideration to determine the difference with respect to the sales price set out in the terms of paragraph A of this article, the difference having to be the
profit or loss of the <B>FINANCIAL LESSEE</B>, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3) in case of partial expropriation, the amount of the expropriation compensation, which
will serve as a basis for determining the reduction rate of the rent and the sales price, will only be taken into consideration after deducting the amount of the value-added tax that the <B>FINANCIAL LESSOR</B> may be called upon to pay under
Article 207 II of Appendix II of the General Tax Code as modified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the last three scenarios, the <B>FINANCIAL LESSOR</B> will issue
the <B>FINANCIAL LESSEE</B> an attestation that will allow it, pursuant to Article 210 set out above, to deduct the amount of the tax paid by the <B>FINANCIAL LESSOR</B> under the terms set out for the acquisitions of good constituting real
property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expressly stipulated, with respect to all of the provisions under this paragraph B, that they will apply, if applicable,
both to the <B>FINANCIAL LESSEE</B> as well as its assignees or future beneficiaries on any grounds, and also any assignees, even when the <B>FINANCIAL LESSEE</B>, its assignee(s), economic beneficiary or beneficiaries or transferee(s) could not,
through the attestation issued by the <B>FINANCIAL LESSOR</B>, benefit from the right to deduction of the tax thus paid, for any reason whatsoever, even not imputable to the <B>FINANCIAL LESSOR</B>, its assignees, economic beneficiaries, or
transferees. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE FOUR </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GUARANTEES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 33 - <U>Pledge of the financial lease agreement</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To guarantee all of the debts that may result from this financial lease, and the performance of all obligations resulting therefrom, the
<B>FINANCIAL LESSEE</B> pledges, to the <B>FINANCIAL LESSOR</B>, which is accepted by its representative, the intangible elements resulting in favor of the <B>FINANCIAL LESSEE</B> from this financial lease, together with the right to the lease and
the benefit of the promise of sale, with no exception or reserve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through this pledge, the <B>FINANCIAL LESSOR</B> will have and
exercise, over the various elements of this financial lease, all of the rights, actions, and privileges granted by the Law to pledge creditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Civil Code, the effectiveness of the privilege resulting from the pledge granted will be ensured as follows: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the appearing parties request that the undersigned Notary only issue one copy of this deed; this copy will bear
the note: &#147;Special and sole financial copy subject to the pledge contained in the financial lease dated <I>June</I><I></I><I>&nbsp;9, 2008</I>&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <B>FINANCIAL LESSEE </B>undertakes not to request any true copy of this document. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This stipulation cannot, however, hinder the issue of the enforceable copy to the <B>FINANCIAL LESSOR</B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 34 - <U>Pledge of the positive balance of the Lessee Advance account</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To guarantee all sums in principle, interest, and any accessories that the <B>FINANCIAL LESSEE</B> may owe the <B>FINANCIAL LESSOR</B> under
the financial lease, on any grounds whatsoever, the <B>FINANCIAL LESSEE</B> specially pledges, in favor of the <B>FINANCIAL LESSOR</B>, which is accepted by its representative, the positive balance of the account indicated above in article <FONT
STYLE="white-space:nowrap">19-4&deg;)</FONT> (lessee advance), under the terms and according to the provisions of the Civil Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
<B>FINANCIAL LESSOR</B> will exercise, over the sums thus pledged in its favor, all of the rights and prerogatives set out by the law in favor of pledge creditors. Furthermore, and by compensation, the <B>FINANCIAL LESSOR</B> may still directly
withdraw the amounts that may be owed to it by the <B>FINANCIAL LESSEE</B> for any reason, under the financial lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pledge will
continue even after the extension or termination of the financial lease, until the liquidation of all accounts between the parties relative to this financial lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representative of the <B>FINANCIAL LESSOR</B> declares acceptance of the above pledge and holds it as validly served. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TITLE FIVE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MISCELLANEOUS PROVISIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 35 - <U>Powers - Relative effect</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties, acting in a mutual interest, grant all necessary powers to any Head Clerk or Assistant Clerk of the Notarial Office named at the
beginning of this document, in order to prepare and sign all additional, amending, or correcting deeds relative hereto, so as to harmonize them with any mortgage, land registry, and public records documents and make all additional tax declarations
to ensure the publication thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is specified that the <B>FINANCIAL LESSOR</B> is the owner of the existing building given under the
financial lease, as shown by a deed received by Ma&icirc;tre Gilles DURAND, notary in MARSEILLE <FONT STYLE="white-space:nowrap">(Bouches-du-Rh&ocirc;ne),</FONT> on <I>June</I><I></I><I>&nbsp;9, 2008</I>, a true copy of which will be published with
the competent Mortgage office before or no later than at the same time as this document. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 36 - <U>Evaluation</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To calculate costs only, the parties declare that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* the amount of the investment by the <B>FINANCIAL LESSOR</B>, for the performance of this financial lease operation, is evaluated at the sum
excluding tax of SIX MILLION, FOUR HUNDRED ONE THOUSAND EUROS (&#128;6,401,000.00) and the sum including the value-added tax of SEVEN MILLION, SIX HUNDRED FIFTY-FIVE THOUSAND, FIVE HUNDRED <FONT STYLE="white-space:nowrap">NINETY-SIX</FONT> EUROS
(&#128;7,655,596.00). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 37 - <U>Declarations</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives of the <B>FINANCIAL LESSOR</B> and <B>FINANCIAL LESSEE</B> declare that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Companies they represent are French companies having their registered office in France,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they are not subject to any action for invalidity or dissolution, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they are not nor have they ever been in cessation of payments and have not been subject to any of the measures
set out by Law <FONT STYLE="white-space:nowrap">No.&nbsp;67-563</FONT> dated July&nbsp;13, 1967 on legal settlement, liquidation, personal bankruptcy, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they are not subject to any collective proceedings or any of the proceedings of the same type or having the same
purpose set out by Law <FONT STYLE="white-space:nowrap">No.&nbsp;2005-845</FONT> dated July&nbsp;26, 2005 for company safeguards. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 38 - <U>Forum</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By express agreement, any disputes that may arise during the performance of these financial lease agreements will be submitted to the competent
PARIS courts, to which exclusive jurisdiction is awarded as needed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 39 - <U>Data processing and civil liberties law and
professional secrecy</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The personal information collected under this agreement and in the future is intended for the <B>FINANCIAL
LESSOR</B>, which, by express agreement, is authorized to keep it in computer memory, to use it, and communicate it for the same purposes to the companies in its group, to its brokers and insurers, or to third parties or subcontractors for
management needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of access and the right of correction may be exercised with the <B>FINANCIAL LESSOR</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> authorizes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> to obtain any confidential information regarding it held by the entities in the GROUPE SOCIETE GENERALE and/or
brokers, which are consequently authorized by express agreement to provide that information. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> to communicate all confidential information regarding it to those
same persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of course, all measures will be taken to ensure the confidentiality of the information transmitted to the <B>FINANCIAL
LESSOR</B>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Legal note</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the &#147;Data Processing and Civil Liberties&#148; law dated January&nbsp;6, 1978, the Notarial Office performs computer
processing to carry out notarial activities, in particular formalities for deeds. To that end, the Office is called upon to store data regarding the parties and send it to certain administrations, in particular to the Mortgage Registry for property,
accounting, and tax publication purposes. The parties may exercise the rights of access and correction with respect to their personal data with the Notarial Office (SCP THIBIERGE et Associ&eacute;s, located at 9 rue d&#146;Astorg in PARIS 8<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> arrondissement, telephone: 01.40.17.86.00, fax: 01.42.66.54.29, <FONT STYLE="white-space:nowrap">e-mail:</FONT> thibierge.associes@paris.notaires.fr or via the &#147;Data Processing and Civil
Liberties&#148; Correspondent appointed by the Office: <FONT STYLE="white-space:nowrap">cpd-adsn@notaires.fr).</FONT> Solely for activities relative to property transfers, certain data on the property and its price, unless opposed by them with
respect to the Office, will be recorded in a property database for statistical purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 40 - <U>Election of domicile</U>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the performance hereof, the appearing parties in their official capacities elect domicile as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSOR</B> in its administrative offices at Tour Les Miroirs &#150; B&acirc;timent D 92978 PARIS &#150; LA DEFENSE CEDEX </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <B>FINANCIAL LESSEE</B> at the registered office of the company that it represents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Article 41 - <U>Issue of enforceable copy</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties ask the undersigned associate Notary to issue an enforceable copy of this financial lease deed to the <B>FINANCIAL LESSOR</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>IN WITNESS WHEREOF</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepared on <I>fifty-nine</I> pages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The substitute notary read this document to the parties, obtained their signatures, and signed this deed. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document will be entered in the ledgers of the Offices of the substitute and replaced
notaries and will remain in the minutes of the Office of the replaced notary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Referral (1)&nbsp;page 26: The FINANCIAL LESSOR hereby
authorizes the sublease in favor of the company &#147;INNATE PHARMA FRANCE&#148;, simplified joint-stock company, having its registered office in MARSEILLE (13009) 121 Ancien Chemin de Cassis, Immeuble le Grand Pr&eacute;, identified under SIREN
number 502 563 679 in the MARSEILLE Companies and Trade Register. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Referral (1)&nbsp;page 52: If the FINANCIAL LESSOR has not
received, at least six months before the end of the financial lease, the request to realize the promise of sale, the FINANCIAL LESSOR will ask the FINANCIAL LESSEE, if the latter intends to exercise the promise under the indicated terms. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Referral (1)&nbsp;page 14: and whose mailing address is 117 avenue de Luminy. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">APPROVED NUMBER: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of
referrals<I> three</I> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of crossed out words <I>eleven</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of crossed out lines <I>none</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of crossed out numbers <I>four</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of barred blank spaces <I>one</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">/s/ [Illegible Signature] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">/s/
[Illegible Signature] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">/s/ [Illegible Signature] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">/s/ [Illegible Signature] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">/s/
[Illegible Signature] </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">51364902 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/138/ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Account&nbsp;No. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO PROPERTY LEASE
AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by the<B>&nbsp;</B><B>Company &#147;SOGEBAIL&#148;</B><B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">in favor of&nbsp;the <B></B><B>Company &#147;INNATE PHARMA&#148;</B><B>&nbsp;</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE YEAR TWO THOUSAND AND SIXTEEN </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ON </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN MARSEILLE (Bouches du Rh&ocirc;ne)</B> 28/30 Avenue A Dumas<B></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ma&icirc;tre Roselyne&nbsp;<B>BOTELLA</B><B>&nbsp;</B>,&nbsp;a notary in the &#147;SCP THIBIERGE ET ASSOCIES, Notaries, members of a private professional
partnership holding a Notarial Office,&#148;&nbsp;with headquarters&nbsp;in PARIS (eighth district), 9 rue d&#146;Astorg, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the participation&nbsp;of:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B></B>Ma&icirc;tre Annick&nbsp;<B>DOMENECH </B>notary in MARSEILLE&nbsp;Lawyer for the Lessee,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established in authentic form this deed containing <B>AMENDMENT TO LEASE AGREEMENT</B>,&nbsp;between the Parties
identified&nbsp;below </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. <U></U><U>IDENTIFICATION OF THE PARTIES</U><U> </U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>L<SMALL>ESSOR</SMALL> </U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B><B>1/ </B>The Company called <B>SOCIETE GENERALE POUR LE DEVELOPPEMENT DES OPERATIONS DE CREDIT-BAIL IMMOBILIER - SOGEBAIL </B>,&nbsp;a
Public Limited Company whose registered office is located in PARIS (9&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">th District</SUP>),&nbsp;29 Boulevard Haussmann, identified by the SIREN (Syst&egrave;me informatique du r&eacute;pertoire des
entreprises [French Business Directory Identification System]) number 775 675 077 RCS (Registre du commerce et des soci&eacute;t&eacute;s [Trade and Companies Registry]) of PARIS,</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Represented&nbsp;by: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.
Justine <B>KRAMER </B>manager, with professional address at COURBEVOIE (Hauts de Seine), Tour les Miroirs, 18 avenue d&#146;Alsace, under the powers granted to her by <B>Ms. Fr&eacute;derique BEGNEZ </B>Director, with professional address at
COURBEVOIE (Hauts de Seine), Tour les Miroirs, 18 avenue d&#146;Alsace, pursuant to a power of attorney by private agreement in COURBEVOIE dated September 23, 2016, the original of which is the Appendix. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(&nbsp;A<SMALL>PPENDIX</SMALL>&nbsp;1:&nbsp;P<SMALL>OWERS</SMALL> <SMALL>OF</SMALL> SOGEBAIL )</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms. <B>Fr&eacute;d&eacute;rique BEGNEZ </B>herself having acted under the powers conferred upon her with right of substitution, by Mr.
R&eacute;mi <B>DANIS,</B><B>&nbsp;</B>pursuant to a deed established by Mr. Herv&eacute; SARAZIN, associated Notary in PARIS (8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP><SUP
STYLE="font-size:85%; vertical-align:top">District </SUP>)&nbsp;9 rue d&#146;Astorg, on January 23, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Said&nbsp;<B>Mr.</B><B>&nbsp;</B><B>R&eacute;mi DANIS </B>who himself acted as General Manager
of&nbsp;&#148;<B>&nbsp;</B><B>SOGEBAIL</B><B>&nbsp;</B>,&#148; a position to which it was appointed and that it accepted pursuant to a decision of the Board of Directors of said Company dated December 15, 2014, a certified true copy of the extract
of the minutes of which is attached to the deed of January 23, 2015, referred to above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Said company hereinafter referred to in the body of the deed as
the &#147;Lessor&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>PARTY OF THE FIRST PART </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>L<SMALL>ESSEE</SMALL></U><SMALL></SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The company called <B>INNATE PHARMA, </B>Public Limited Company with a Board of Directors and a Supervisory Board, whose registered office is
located in MARSEILLE (13009), 117 avenue de Luminy, identified by the SIREN number 424 365 336 RCS of MARSEILLE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Represented by Ms.
Ir&egrave;ne <B>BERKOWITZ</B>&nbsp;Director of Legal Affairs, under the powers which were conferred upon her by Mr. Herv&eacute; <B>BRAILLY</B><B>&nbsp;</B>pursuant to a power of attorney by private agreement established in MARSEILLE
(Bouches-du-Rh&ocirc;ne) on September 22, 2016, the original of which is the Appendix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The said Mr. Herv&eacute; <B>BRAILLY </B>Chairman
of the Board, domiciled at the registered office of the company</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Having himself acted under of the powers which were granted to it pursuant
to a meeting of the supervisory board on September 7, 2016, a certified true copy of an extract of the minutes of which is the Appendix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is observed here that by deliberations that took place on September 26, 2008, the supervisory board of the company <B>INNATE PHARMA
</B>decided to transfer its registered office to MARSEILLE (13009) 117 avenue de Luminy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A certified true copy of this decision is
attached. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>( A<SMALL>PPENDIX</SMALL> 2: D<SMALL>ELIBERATIONS</SMALL> <SMALL>AND</SMALL>
<SMALL>POWERS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>COMPANY</SMALL> I<SMALL>NNATE</SMALL> P<SMALL>HARMA</SMALL>) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Said company
hereinafter referred to in the body of the deed as the &#147;Lessee.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>PARTY OF THE SECOND PART </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. <U></U><U>DEFINITIONS</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To simplify, certain terms
will, over of the course of this deed, have the definitions below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Deed of Sale or Sale</B><B>&nbsp;</B>:&nbsp;refers to the deed established by
Ms. Martine AFLALOU-TAKTAK, notary in MARSEILLE (Bouches-du-Rh&ocirc;ne) dated June 9, 2008 and by which the Lessor acquired ownership of the Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Appendix: </B>refers to an appendix to the Amendment and which is an integral part of it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Down payment: </B>refers to the amount made available by the Lessee to the Lessor under the conditions agreed in the original Lease Agreement</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Amendment: </B>refers to this deed concluded between the Lessor and the Lessee</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Financial Expenses: </B>refers to amounts owed by the Lessee for pre-rental fees, rent, and other charges, as specified in Chapter III of PART II.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Agreement </B>or <B>Lease Agreement</B><B>&nbsp;</B><B>: </B>refers to the Property lease agreement between the Lessor and the
Lessee&nbsp;pursuant to a deed established by Ms. Annick DOMENECH, notary in MARSEILLE, on June 9, 2008, replacing Ms. Eliane FREMEAUX</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Lessor:
</B>refers to the company&nbsp;&#148;<B>SOGEBAIL</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lessee :</B> refers to the company&nbsp;&#148;&nbsp;<B>INNATE PHARMA</B>&#148;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Effective Date: </B>refers to effective date of the Amendment which is today&#146;s date </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Reference Date: </B>refers to the day that will be taken into account to determine the rate applicable to the Pre-rental fees namely: will be the
day of disbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Disbursement: </B>refers to any amount paid by the Lessor in respect of this transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Financial Amount Outstanding: </B>refers to, at a given date, the amount of the Investment, less
financial amortization applied quarterly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>EURIBOR </B>(Euro Inter Bank Offered Rate) is the interbank offered rate in EUROS between major banks
in the Eurozone. It is calculated&nbsp;with three (3) decimals using the average of fifty-seven (57) quotes. It&nbsp;is&nbsp;published&nbsp;by the F&eacute;d&eacute;ration Bancaire de l&#146;Union Europ&eacute;enne [European Union Banking
Federation] (F.B.E.) at around 11:00 a.m. (Brussels time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Building or Property :</B>&nbsp;refers to the Property that is the subject of the
Lease Agreement and the Amendment</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Investment: </B>refers to the amount dedicated by the Lessor for the financing of the Amendment </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Business Day: </B>refers to any entire day (other than Saturday or Sunday) on which credit institutions are open in Paris in order to perform
banking operations and transactions on the interbank market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>TARGET</B><B>&nbsp;</B><B>Business Day </B>: Refers to a day when the target
PAYMENT SYSTEM is open. The European real time gross settlement system, referred to as TARGET,&nbsp;connects the European Central Bank to the national central banks of the states participating in the Economic and Monetary Union via their respective
real time gross settlement systems (hereinafter RTGS). The TARGET interconnection system&nbsp;is open every day when at least two RTGS are open, except Saturday and Sunday. It is closed&nbsp;according to the TARGET schedule (currently January&nbsp;1
and December 25). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Rent:</B><B>&nbsp;</B>refers&nbsp;to&nbsp;the financial charges&nbsp;due by the Lessee to the Lessor under the Amendment </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Parties:</B><B>&nbsp;</B>refers to the Lessor and Lessee together and where the context so provides, all those appearing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VAT</B><B>&nbsp;</B><B>Pre-rental fees</B>&nbsp;refers to the financial charges due by the Lessee to the Lessor for any disbursement by the latter of the
Value Added Tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Work or Development Work</B>&nbsp;refers to the development work carried out in the Building and financed by the Lessor </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Residual Value: </B>refers to the Financial Amount Outstanding remaining due at the expiration of the Agreement after payment of the final
installment of rent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>These definitions are not exhaustive. </B>Other definitions are given in the body of the Agreement and they have the same
contractual power. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. <U>SUMMARY</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1. IDENTIFICATION OF THE PARTIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2. DEFINITIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3. SUMMARY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4. PRESENTATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LEASE AGREEMENT OF JUNE 9, 2008</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5. PRESENTATION OF THE PROJECT - FINANCING AGREEMENT - GENERAL
PRINCIPLES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6. AMENDMENT TO PROPERTY LEASE AGREEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART I</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PURPOSE - DURATION - FINANCIAL CHARACTERISTICS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CHAPTER I</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PURPOSE OF THE LEASE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DESCRIPTION&nbsp;OF&nbsp;THE&nbsp;BUILDING</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INTENDED USE OF THE BUILDING</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CHAPTER II</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DURATION&nbsp;- EFFECTIVE DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DURATION&nbsp;OF THE AMENDMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EFFECTIVE DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CHAPTER III</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCIAL CONDITIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FEES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.1. COMMITMENT&nbsp;FEE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.2. STUDY AND STRUCTURING COSTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.3. MANAGEMENT FEES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PRE-RENTAL FEES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.1. PRE-RENTAL FEES ON THE VALUE ADDED TAX</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DEFINITION OF THE RENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DETERMINATION OF THE RENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>9.1. CALCULATION OF THE RENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>9.2 DISAPPEARANCE OF THE SELECTED REFERENCE RATES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SUMMARY - BREAKDOWN TABLE&nbsp;- APPROVED BASIS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 11.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RENT DUE DATE - PAYMENT - DEFAULT INTEREST</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.1. RENT DUE DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.2. PAYMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.3. DEFAULT INTEREST</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 12.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SALE AGREEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>12.1. UNILATERAL AGREEMENT TO SELL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>12.1.1 Conditions for fulfilling the sale agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>12.1.2. Implementation date</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>12.1.3. Procedures for exercising the option</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>12.1.4. Sale fees and taxes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>12.2. CONDITIONS OF THE SALE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>12.3. SALE PRICE UNDER THE AMENDMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>12.3.1. Sale Price at the end of the Agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>12.3.2. Advance Asking Price</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART II</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TERMINATION OF THE LEASE AGREEMENT AND THE AMENDMENT&#151;TAX PROVISIONS &#150;
INSURANCE - CLAIMS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 13.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TERMINATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>13.1. TERMINATION AT THE REQUEST OF THE LESSEE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>13.1.1. Conditions</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>13.1.2. Compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>13.2. TERMINATION AT THE REQUEST OF THE LESSOR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>13.2.1. Conditions</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>13.2.2. Compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 14.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONSEQUENCES OF THE TERMINATION OR FAILURE TO EXERCISE THE OPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>14.1. TERMINATION OF THE SALE AGREEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>14.2. RELEASE OF THE PROPERTY BY THE LESSEE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>14.3. INVENTORY STATEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>14.4. DELIVERY OF DOCUMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 15.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TAXATION OF THE AMENDMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 16.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INSURANCE UNDER THE AMENDMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>16.1 CONSTRUCTION INSURANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>16.2 ALL RISKS EXCEPT INSURANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 17.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LOSSES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.1.&nbsp;OBLIGATIONS OF THE LESSEE IN THE EVENT OF A LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.2. INSURANCE COMPENSATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.3. PARTIAL LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.4. TOTAL LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.5. RECONSTRUCTION AUTHORIZATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.6. RECONSTRUCTION - RESTORATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.7. PROVISIONS RELATING TO RENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART III</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GUARANTEES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 18.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PLEDGE OF THE AMENDMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART IV</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MISCELLANEOUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 19.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COSTS - ASSESSMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 20.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INSEPARABILITY OF THE CONTRACTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 21.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>POWERS - RELATIVE EFFECT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>21.1. POWERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>21.2. RELATIVE EFFECT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 22.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>REPRESENTATIONS AND WARRANTIES OF THE PARTIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 23.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>NOTICES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 24.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>ADDRESS FOR SERVICE - JURISDICTION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 25.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>DATA PROTECTION ACT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 26.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>ISSUE OF AN ENFORCEABLE COPY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 27.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>LIST OF APPENDICES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.<U> PRESENTATION </U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Acquisition of June 9, 2008</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under&nbsp;a deed established by Ms. Martine AFLALOU-TAKTAK, notary in MARSEILLE on June 9, 2008, the Lessor acquired, from the City of
MARSEILLE, the building whose description is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the municipality of MARSEILLE (13009) Area of Redon, Route de Cassis,
whose&nbsp;postal address is 117 avenue de Luminy, a building used for business, industrial premises, laboratories, with a net floor area of 2,838 m&sup2;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Registered in the land registry in Section 851 M, numbers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">34 locality known as known as route de Cassis for 96 a 48 ca </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">39 locality known as route de Cassis for 02 a 99 ca </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38 locality known as route de Cassis for 02 a 39 ca </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">37 locality known as route de Cassis for 04 a 64 ca </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a total of 1 ha 06 a 50 ca </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This acquisition took place for a price paid in cash pursuant to the deed which contains the discharge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An authentic copy of this deed was published in the Land Registry Department of MARSEILLE 3<SUP STYLE="font-size:85%; vertical-align:top">rd
</SUP>District&nbsp;on July 10, 2008 volume 2008P number 5846. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><U>Lease Agreement of June 9, 2008</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a deed established on June 9, 2008 by Ms. Annick DOMENECH, notary in MARSEILLE, replacing Ms. Eliane FREMEAUX, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lessor granted to the Lessee a Lease Agreement on the Building and the financing of development work as part of a&nbsp;contracting
authority delegation agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement was granted: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For a period that started to run on June 9, 2008 for Tranche A and on January<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>1, 2009 for Tranche B, the two tranches ending twelve (12) years after Tranche A takes effect, i.e. June 8, 2020</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For an estimated investment excluding tax of SIX MILLION FOUR HUNDRED ONE THOUSAND EUROS (6,401,000.00&nbsp;EUR)
definitively approved for the amount of SIX MILLION FIVE HUNDRED FIFTY-ONE THOUSAND EUROS (6,551,000.00 EUR) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It included the following
guarantees: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pledge of the lease agreement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pledge of the down payment </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It&nbsp;was&nbsp;also&nbsp;agreed to under the obligations and conditions that it is unnecessary to recall here, as the parties declare to
know them perfectly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. <U></U><U>PRESENTATION OF THE PROJECT - FINANCING AGREEMENT - GENERAL PRINCIPLES</U><U>&nbsp;</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U></U><U>P<SMALL>RESENTATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>PROJECT</SMALL> / F<SMALL>INANCING</SMALL>
A<SMALL>GREEMENT</SMALL></U><SMALL><U></U></SMALL><U>&nbsp;</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Lessee wants to have, but without taking immediate ownership of, premises for
industrial uses, businesses, laboratories located in MARSEILLE (Bouches du Rh&ocirc;ne) 117, avenue de Luminy </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To finance this transaction, it contacted
the Lessor whose purpose defined by Article L.313-7 of the Monetary and Financial Code is renting unequipped buildings for professional uses and asked it: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To reimburse it for the cost of the Development Work that it carried out on the Building, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to lease the whole thing to it under an Amendment to the Lease Agreement, for the remaining duration of the
latter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This work consists of&nbsp;development&nbsp;work&nbsp;to transform an office space into a research laboratory </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Work does not require the issuance of a building permit or a prior declaration, as established by a certification from CCD Architecte dated July&nbsp;1,
2016, appended hereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(&nbsp;A<SMALL>PPENDIX</SMALL>&nbsp;3:&nbsp;A<SMALL>RCHITECT</SMALL> C<SMALL>ERTIFICATION</SMALL>&nbsp;)</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee represents and warrants that the Work does not change the classification of the Building with respect to the regulations relating to Facilities
Classified for the Protection of the Environment and the activity carried out in the Building does not fall under these regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Work was accepted on June 16, 2016 as is clear from the Acceptance Report attached </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(&nbsp;A<SMALL>PPENDIX</SMALL>&nbsp;4:&nbsp;W<SMALL>ORK</SMALL> A<SMALL>CCEPTANCE</SMALL> R<SMALL>EPORT</SMALL>&nbsp;) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessor agreed to this financing request within the limit of an amount excluding value-added tax of <B>EIGHT HUNDRED FORTY-SIX THOUSAND THREE HUNDRED AND
THIRTY-SEVEN EUROS AND EIGHTY CENTS (846,337.80 EUR)</B><B>&nbsp;</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessor repays on this date as is clear from the accounts of the undersigned
notary, the sum of EIGHT HUNDRED FORTY-SIX THOUSAND THREE HUNDRED AND THIRTY SEVEN EUROS AND EIGHTY CENTS (846,337.80 EUR) excluding tax plus ONE HUNDRED SIXTY-NINE THOUSAND TWO HUNDRED SIXTY- SEVEN EUROS AND FIFTY-SIX CENTS (169,267.56 EUR) for the
value added tax, for a total including tax of ONE MILLION FIFTEEN THOUSAND SIX HUNDRED FIVE EUROS AND THIRTY-SIX CENTS (1,015,605.36 EUR) to the Lessee, which recognizes and agrees to this and grants it good and valid discharge. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>FOR WHICH DISCHARGE IS DULY GIVEN </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U></U><U>G<SMALL>ENERAL</SMALL> <SMALL>PRINCIPLES</SMALL></U><SMALL><U></U></SMALL><U> </U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U></U><U>Risk transfer</U><U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Lessee acknowledges having perfect knowledge of the legal, technical, administrative and environmental characteristics of the Property, having chosen
it to meet its own needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It acknowledges that the role of the Lessor is limited in this transaction to ensuring, according to the following agreed
conditions, the financing of Development Work </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In these conditions, and although the ownership of the Property&nbsp;is legally attributed to the Lessor
for the duration of the&nbsp;Lease Agreement and the Amendment, it became justified for the Lessee to assume all the risks and obligations of any kind, even those resulting from a force majeure event, which would fall, according to general law, to
the builder or the owner of the Property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U></U><U>Responsibilities arising from the ownership, use or structure</U><U>&nbsp;</U><U>of
the Building</U><U>&nbsp;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All decisions relating to the choice of location, the nature, quality and intended use of the Property were
made previously hereto by the Lessee. The&nbsp;Lessor took no part in these decisions and agreed, at the request of Lessee, to ensure, within the limits set above in the Presentation, the financing of the Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is hereby specified that in the event of non-compliance with all current and future regulations applicable to&nbsp;the Property and to the
activity carried out in the premises,&nbsp;the Lessee shall bear all the financial consequences, including any compensation for damages so that the Lessor is in no way either sought or disturbed about this matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if the administrative or judicial authorities require the closure of the leased premises, the Rent
will continue to be due with no recourse against the&nbsp;Lessor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee shall be personally responsible, without recourse against the&nbsp;Lessor,
for obtaining and maintaining all administrative authorizations required for the activity carried out in the Property, the occupancy of the premises and their opening to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee also shall be personally responsible, without recourse against the&nbsp;Lessor, for easements of any kind, as well as current and future
regulations that may change or restrict the options regarding the use, layout and consistency of the premises without being able to claim a reduction in the Rent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It will bear at its expense and without any recourse against the&nbsp;Lessor,&nbsp;the cost of work and/or any other measures and obligations required by the
relevant authorities and that would have to be done to meet the current or future legal or regulatory mandatory provisions set by national or European standards rendered applicable in France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the duration of the Lease Agreement, the Lessee shall hold the use, management and control of the Property. It is therefore considered to be the caretaker
and this Property is placed under its exclusive responsibility, which it will have to assume or have assumed by its sub-tenants in its entirety without being able to exercise any recourse whatsoever for any reason whatsoever, against the Lessor.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Lessee intends, despite the acquisition by the Lessor of the Property, during the period of financing, to maintain full control over the
Property from a technical and economic point of view. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the duration of the transaction, the role of the Lessor, owner of the Property, is limited,
although it is the legal owner of the Property, to financing the Property within the limits agreed between the Parties and subject to the Lessee exactly fulfilling its contractual obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any damage that may be caused, both to the Lessee&nbsp;and to third parties, due to the structure of the Property (including that of the soil), will be fully
supported by the latter, which may not, as in the previous case, exercise any recourse whatsoever for any reason whatsoever against the Lessor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this
spirit, the&nbsp;Lessee shall assume alone all the rights that could be exercised against anyone, particularly with regard to non-compliant defects, constraints on the use of the Property, easements... </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this context and because of the Lessee&#146;s responsibilities under the Lease Agreement, the Lessor gives the Lessee all powers to conduct any action,
take any initiative and if necessary conduct any proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Lessee will be solely responsible, at its sole expense, for any proceedings that may be initiated and
continued, though it will keep the Lessor informed of these. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Lessor, if desired, can always intervene regardless of the status of the
proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Lessee agrees to keep the Lessor informed of these actions or proceedings by forwarding the documents or exhibits concerning these
actions to the Lessor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is in light of these introductory statements, which should always be referred to in order to justify as
necessary the distribution between the Parties of the charges, obligations, responsibilities and risks and to seek their shared purpose, that the Lease Agreement is concluded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. <U>AMENDMENT TO PROPERTY LEASE AGREEMENT</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Lessor hereby finances as a property lease, under the provisions of Articles L 313-7 to L 313-10 of the Monetary and Financial Code of Act No. 95-115 of February 4, 1995 (Article 57), of Decree No. 95-617 of May 6, 1995 and following texts, to the
Lessee, which is accepted by its representative, the Work which is the subject matter of the Amendment </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Amendment is divided into four parts: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <B>first part</B>&nbsp;contains the purpose, duration and the financial characteristics of the Amendment
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The<B>&nbsp;</B><B>second part</B><B>&nbsp;</B>relates to the termination of the Lease Agreement and the
Amendment, the tax system of the Amendment, insurance and claims. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The<B>&nbsp;</B><B>third part </B>contains the guarantees afforded to the Lessor </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <B>fourth part</B>&nbsp;contains various provisions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PART I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE&nbsp;- DURATION - FINANCIAL CHARACTERISTICS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CHAPTER I </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PURPOSE OF THE LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 1.</U> DESCRIPTION&nbsp;OF&nbsp;THE&nbsp;BUILDING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the municipality of <B>MARSEILLE </B>(13009) Area of Redon, Route de Cassis, whose&nbsp;postal address is 117 avenue de Luminy, a building
used for business, industrial premises, laboratories, with a net floor area of 2,838 m&sup2;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Registered in the land registry in Section
851 M, numbers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">34 locality known as 117 avenue de luminy for 96 a 48 ca </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">37 locality known as avenue de luminy for 04 a 64 ca </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38 locality known as avenue de luminy for 02 a 39 ca </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">39 locality known as avenue de luminy for 02 a 99 ca </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a total of <B>1 ha 06 a 50 ca</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 2.</U> INTENDED USE OF THE BUILDING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Property is intended to be used as industrial premises, laboratory activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This intended use will&nbsp;not be subject to any changes without the express written agreement of the Lessor. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CHAPTER II </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DURATION&nbsp;- EFFECTIVE DATE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 3.</U> DURATION&nbsp;OF THE AMENDMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Amendment is agreed for the period ending on the same date as the Lease Agreement, which is June 8, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 4.</U> EFFECTIVE DATE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
leasing starts on this date </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CHAPTER III </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FINANCIAL CONDITIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 5.</U> INVESTMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
investment by the Lessor is an amount excluding value added tax of <B>EIGHT HUNDRED FORTY-SIX THOUSAND THREE HUNDRED AND THIRTY-SEVEN EUROS AND EIGHTY CENTS (846,337.80 EUR)</B>&nbsp;and is as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cost of the Development Work </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No&nbsp;amount in excess of the amount excluding tax of EIGHT HUNDRED FORTY-SIX THOUSAND THREE HUNDRED AND THIRTY-SEVEN EUROS AND EIGHTY CENTS (846,337.80
EUR) may be demanded from the Lessor, even if said Investment would turn out to be insufficient for any reason whatsoever for the realization of this transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 6.</U> FEES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.1.
C<SMALL>OMMITMENT</SMALL>&nbsp;<SMALL>FEE</SMALL></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Lessee shall be liable to pay, from the issue of the financing offer, i.e. June 14, 2016,
until the Effective Date, which is today, a commitment fee equal to zero point ten per cent (0.10%) per quarter of the Lessor&#146;s maximum investment excluding tax </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This fee, plus the Value Added Tax, will be payable by the Lessee quarterly in arrears by debiting its account as will be described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.2. S<SMALL>TUDY</SMALL> <SMALL>AND</SMALL> <SMALL>STRUCTURING</SMALL> <SMALL>COSTS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A lump sum, excluding value added tax&nbsp;of TWO THOUSAND FIVE HUNDRED EUROS (2,500.00 EUR) for an amount including tax of THREE THOUSAND EUROS (3,000.00 EUR)
was paid by the Lessee to the Lessor before today. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.3. M<SMALL>ANAGEMENT</SMALL> <SMALL>FEES</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&nbsp;&#147;<B>SOGEBAIL</B>&#148; will invoice the Lessee for the cost of the specific services listed in the schedule appended hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B>(</B><B>&nbsp;</B><B>A<SMALL>PPENDIX</SMALL></B><SMALL><B></B></SMALL><B>&nbsp;</B><B>5:</B><B>&nbsp;</B><B>P<SMALL>RICE</SMALL>
S<SMALL>CHEDULE</SMALL></B><SMALL><B></B></SMALL><B>&nbsp;</B>)</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;costs set out in said schedule are valid for the current year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">They will be revised on July 1 of each year and will be communicated free of charge on first demand of the Lessee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any new obligation&nbsp;placed under the Lessor&#146;s responsibility by legal or regulatory provisions may be subject to new fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is specified here that the management fees stated above will apply to all the transactions (Lease Agreement
and Amendment) excluding all those that may be listed in the previous deed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 7.</U> PRE-RENTAL FEES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1. P<SMALL>RE</SMALL>-<SMALL>RENTAL</SMALL> <SMALL>FEES</SMALL> <SMALL>ON</SMALL> <SMALL>THE</SMALL> V<SMALL>ALUE</SMALL> A<SMALL>DDED</SMALL>
T<SMALL>AX</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Value Added Tax paid by the Lessor will give rise to the payment of VAT Pre-rental fees for a fixed period of four (4) months
from each payment made by the Lessor under the Lease Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Lessee shall be liable to pay VAT Pre-rental fees calculated according to
banking practice on the amounts of Value Added&nbsp;Tax disbursed, at the following annual nominal rate of &#147;T&#148;: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>&#147;T&#148;: 3 month EURIBOR + one hundred fifty basis points (150&nbsp;bp) per annum</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rate&nbsp;&#147;T&#148; is calculated on a calculation basis corresponding to the exact number of days of the calculation period of the VAT Pre-rental
fees calculated on a 360 day year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 3-month EURIBOR as defined above, to be used, will be the one published two TARGET Business Days prior to the
Reference Date also defined above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These VAT Pre-rental fees, plus the Value Added Tax that may encumber them, will be charged at the end of each
calendar month and payable by the Lessee within fifteen (15) Business Days of the following month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It being specified here that the 3-month EURIBOR used
may not be less than zero percent (0%). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 8.</U> DEFINITION OF THE RENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is&nbsp;explicitly&nbsp;specified that the term &#147;Rent&#148; as used herein for the language purposes, must be treated as a financial fee to cover
amortization and remuneration, at the agreed rate, of the capital invested by the Lessor for the realization of this transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, and unless
there is a specific legislative provision affecting the Lease Agreement, the Rents will not be subject to any modification or revision for any reason whatsoever, whether they are due to an existing situation of the Lessee or legislation regulating,
temporarily or not, the amount or rate of rent for premises for commercial or industrial use, or lastly no revision based on the provisions of Articles L.145-1 et seq. of the Commercial Code, governing relationships between lessors and the tenants
of commercial premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 9.</U> DETERMINATION OF THE RENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Rent will be due by the Lessee to the Lessor from the Effective Date of the Amendment, which is today and is established as follows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1. C<SMALL>ALCULATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> R<SMALL>ENT</SMALL></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rents will be composed of&nbsp;financial amortization and interest. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial amortization depreciates the entire Investment for the duration of the Amendment </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The chosen amortization rate is the one that obtains&nbsp;constant maturities. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The interest will be calculated by applying to the Financial Amount Outstanding due before amortization for the
period, a fixed annual nominal rate equal to one point twenty-five percent (1.25%) </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.2 D<SMALL>ISAPPEARANCE</SMALL>
<SMALL>OF</SMALL> <SMALL>THE</SMALL> S<SMALL>ELECTED</SMALL> R<SMALL>EFERENCE</SMALL> R<SMALL>ATES</SMALL></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there are changes affecting the
composition and/or the definition of one or more reference rates mentioned in the Lease Agreement or if the rate or rates should disappear, and if there is a change affecting one of the bodies publishing these reference rates or the publication
procedures, the parties agree to refer to the rate resulting from the modification or the substitution, and the transition from the old rate to the new rate will be carried out using the required link ratio, as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there is no replacement rate or link ratio, if it is necessary, it will be up to the parties to agree on the selection of a new reference rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the absence of agreement between them, the replacement rate will be determined by an Arbitral Tribunal composed of three (3) selected experts, one by the
Lessor, the other by the Lessee and third by agreement between the Parties. Failing agreement, this third expert will be appointed by the other two experts or otherwise by the Judge in Summary Proceedings ruling at the request of either party. This
Arbitral Tribunal shall decide&nbsp;by a majority of its members and will make its decision within sixty (60) days of its constitution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is expressly
agreed that the lack of a reference rate will not authorize the Lessee to delay payment of rents. The Rents will continue&nbsp;to be billed when due based on the rate of the last Rents billed before the reference rate ceased to be published or
disappeared. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Rents will be adjusted as soon as the replacement rate is determined. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 10.</U><U> </U>SUMMARY - BREAKDOWN TABLE&nbsp;- APPROVED BASIS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;accordance&nbsp;with the provisions of Decree No. 95-617 of May 6, 1995, taken on the basis of Article 57 of Act No. 95-115 of February 4, 1995, the
Lessor provided the Lessee the following elements established on the amount of the Investment as provided in this agreement, namely: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 / A summary </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2 / A table (Official) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3 / the financial table established and
calculated on the amount and according to the above procedures provided for in Article 12.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The summary and the tables form the Appendix. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(&nbsp;A<SMALL>PPENDIX</SMALL>6:&nbsp;<SMALL>SUMMARY</SMALL> <SMALL>AND</SMALL>
<SMALL>TABLES</SMALL>)</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 11.</U><U> </U>RENT DUE DATE - PAYMENT - DEFAULT INTEREST&nbsp; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.1. R<SMALL>ENT</SMALL> <SMALL>DUE</SMALL> <SMALL>DATE</SMALL></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Rents thus determined are payable quarterly and in advance, on the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of&nbsp;January, the 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> of April, the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;of July and the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;of October&nbsp;each year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the first term of Rent due on the Effective Date of the Lease Agreement&nbsp;was calculated on a pro rata temporis basis.&nbsp;Similarly, the last
term of rent will also be calculated on a pro rata temporis basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.2. P<SMALL>AYMENT</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Rents, and, in&nbsp;general, all amounts owed by the Lessee to the Lessor under the Lease Agreement will be collected by the Lessor by deducting the amount
from the Lessee&#146;s bank account, whose details are shown below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bank: SOCIETE GENERALE </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Branch&nbsp;: MARSEILLE ENTREPRISES </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IBAN (International Bank Account Number): FR76 3000 3012 4000 0202 9499 157 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BIC (Bank Identifier Code): SOGEFRPPXXX</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ICS (SEPA Creditor Identifier): <B>FR76ZZZ003492</B><B>&nbsp;</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">RUM (Single Mandate Reference): 000000100000000000000000005565301 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lessee&#146;s EU VAT Number: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.3. D<SMALL>EFAULT</SMALL>
<SMALL>INTEREST</SMALL></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Lessee fails to pay any amount due under this Lease Agreement, it will be liable to pay default interest to the Lessor
calculated on a pro rata temporis basis at the nominal annual rate equal to the rate of the Amendment plus five hundred basis points (500 bp) per annum from the due date until payment, all without prejudice to the possibility for Lessor to pursue
termination of the Lease Agreement and the Amendment&nbsp;under the conditions set out below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 12.</U> SALE AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.1. U<SMALL>NILATERAL</SMALL> <SMALL>AGREEMENT</SMALL> <SMALL>TO</SMALL> <SMALL>SELL</SMALL></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;sale agreement&#148; article of the Lease Agreement is canceled and replaced by the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U></U><U>12.1.1 Conditions for fulfilling the sale agreement</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the provisions of Article L 313-7 of the Monetary and Financial Code on Leasing transactions, the agreements resulting from the Lease
Agreement must enable the Lessee to become, if desired, the owner of the Property that is the subject of the Lease Agreement and the Amendment, inseparably. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To this effect, the Lessor promises to the Lessee, which is accepted by its representative, but only as a promise, to sell the Property, subject of the Lease
Agreement and the Amendment, to the Lessee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This sale agreement may only be exercised and implemented if the Lessee is current with all its obligations
under the Lease Agreement and the Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The implementation of the sale agreement thus granted by the Lessor may be requested by the Lessee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either in advance from the date mentioned below under Article 12.1.2, </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">or upon&nbsp;the contractual expiration of the Lease Agreement and the Amendment </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U></U><U>12.1.2. Implementation date</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This sale agreement is valid for a period starting to run from the end of the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd </SUP>) year from the
Effective Date of the Amendment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U></U><U>12.1.3. Procedures for exercising the option</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The request to exercise the option may, from that date, be made, for the contractual expiration date of the Lease Agreement or during the Lease Agreement, at
the end of each calendar quarter, by a registered letter with acknowledgment of receipt addressed to the Lessor, at its registered office, at least six (6) months in advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It must, under penalty of invalidity, be followed within three (3) months, by the consignment in the hands of the Lessor of a sum sufficient to cover both the
sale price and the costs and fees incurred by the completion of the sale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U></U><U>12.1.4. Sale fees and taxes</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the price&nbsp;determined below, the Lessee shall pay all costs, duties, taxes and fees associated with this transfer and also all taxes, duties
and contributions that the Administration may require from either party for any reason whatsoever (excluding corporate taxes that may be owed by the Lessor or any new tax owed by the Lessor, as a leasing company). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.2. C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>SALE</SMALL></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale will be granted in return for the set price on the date of the completion of the sale by authenticated deed, in accordance with Article 12.3 below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This price will be payable in cash&nbsp;upon signature of this deed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee will be required to establish at its expense all diagnoses, certifications, expert assessments and other formalities imposed on building owners by
the legislation in force related to Property transfers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The signing of the deed of sale will occur on the expiration date of the Lease Agreement. In
the&nbsp;event that the deed of sale would&nbsp;not be regularized on that date, the Lessee shall be liable to pay a quarterly occupancy fee to the Lessor equal to the Rent due for the last full calendar quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale will take place under the ordinary and statutory terms and conditions in such cases, and in particular under the following terms: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#9679;<B></B><B> <U>Charges and conditions</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Buyer: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>will take the Building in the&nbsp;condition it was found on the day of the sale, the Lessee having perfect
knowledge of this for having had the enjoyment of it under the lease agreement, without any guarantee of the good, or poor condition of the buildings, defects of any kind, visible or hidden, condition of the soil and subsoil, shared walls,
misalignment, errors in the description, and any difference in capacity even if it were to be in excess by one-twentieth, pursuant to the provisions of Article 1627 of the Civil Code, and by way of express derogation to the provisions of Article
1641 of the Civil Code.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Will be personally responsible for the absence of all administrative deeds or authorizations related to the
Building.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Shall bear all passive easements of any kind and will benefit from all active easements that may exist, as
those easements result especially from:</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>property titles, building lease, long-term lease, condominium rules, volume division, subdivision, particular
areas, and any document concerning the Building, </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>the provisions of development plans that will be in force&nbsp;at that time, </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>the Law. </I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>will pay, on the day of signing the authenticated deed of sale, all amounts due which have not yet&nbsp;been
paid by the Lessee, and will make a provision covering the entire property tax (established based on the billing of the previous year), and undertakes to pay and/or reimburse any additional amount that could be claimed by the tax authorities for the
ownership or use of the Building, under the conditions provided in the Property lease agreement, as well as the charges related to the Building. </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Will be personally responsible for the situation of the Building with respect to former or future pollution,
without recourse against the Lessor in accordance with the provisions of the Lease Agreement. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; text-indent:-3%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>&#9679;<B><I></I></B><B><I> <U>Transfer of ownership</U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>The Lessee will be the owner of the Building from the date of signing the authenticated deed of sale, the transfer of ownership being
subject to full payment by the Lessee of the sale price, as well as the amounts due referred to above, to the Lessor and payment of the sufficient sum - assessed by the Lessee&#146;s notary - to meet the payment of costs, taxes and fees. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>The authenticated deed of sale will be established by the notary of the Lessee with the participation of notary of the Lessor. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; text-indent:-3%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>&#9679;<B><I></I></B><B><I> <U>Taking possession</U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Starting on the same day, the Lessee shall take possession of the Building by its combining its status as Lessee and Buyer. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.3. S<SMALL>ALE</SMALL> <SMALL>PRICE</SMALL>&nbsp;<SMALL>UNDER</SMALL> <SMALL>THE</SMALL> <SMALL>AMENDMENT</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is expressly agreed that the sale price thus determined forms, in the minds of the parties, with the rents paid on their contractual due date, a unit for
the expression of the financial conditions of this agreement. Accordingly, if for any reason the Lessor was forced to grant a reduction in the contractual rent over one or more terms or payment periods, the sale price would be recalculated taking
into account firstly, the amounts actually collected and their date of payment, and secondly, the rents that would have received by the Lessor on their contractual due date without any reduction of the rent or payment period, all so that the Lessor
receives, using the recalculated price, the profit resulting from the strict application of the provisions of the Lease Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>12.3.1. Sale Price at the end of the Agreement </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At&nbsp;the contractual expiration of the Amendment </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The price
of the sale promised above, will be equal to ONE EURO (1 EUR) excluding tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>12.3.2. Advance Asking Price </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale price as of the end of the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP><SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP>) year following the Effective Date of the Amendment will be equal to the present value, on the date of the sale, of all the amounts due (rent and Residual Value at the end of the Agreement)
until the agreement expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In any&nbsp;event, this amount may not be less than the Financial Amount Outstanding remaining due on the date the option is
exercised, plus three percent (3%) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nominal discount rate will be&nbsp;equal to the nominal rate of the Agreement minus one hundred basis points (100
bp) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>12.3.3 subjugation of the price to value added tax </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of Article 260-5 <SUP STYLE="font-size:85%; vertical-align:top">e </SUP>(a) of the French Tax Code, the sale price, determined as
specified in Article 12.3 above, may be increased by the VAT, if the Lessor, subject to pay the VAT, has the option of being taxed at the VAT of the exercise of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This increase in the sale price by the VAT will be applied&nbsp;in all cases of Property sale as provided in the Lease Agreement, whether in implementing the
sale agreement above or in implementing any of the other provisions of the Lease Agreement, in particular, those relating to claims, referred to below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PART II </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION OF THE LEASE AGREEMENT AND THE AMENDMENT&#151;TAX PROVISIONS &#150; INSURANCE - CLAIMS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 13.</U> TERMINATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Articles related to termination as requested by the Lessee or the Lessor contained in the Lease Agreement, are canceled and replaced by the following:
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The termination of the Lease Agreement and the Amendment&nbsp;before their contractual expiration for any reason whatsoever: termination at the
request of the Lessee or the Lessor, will lead automatically and without any formalities, to the payment by the&nbsp;Lessee of compensation calculated according to the following terms determined at the date of the effective termination, to which
will be added where applicable exceptional charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an essential condition, this compensation, related to the special nature of the Lease Agreement,
will have the character of a lump-sum compensation for damages to offset the loss suffered by the Lessor by the early termination of the Lease Agreement and the Amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee formally acknowledges that this compensation corresponds to the essentially financial nature of the
Agreement, as the transaction was conducted by the Lessor at the express request of the Lessee out of consideration for the person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.1.
T<SMALL>ERMINATION</SMALL> <SMALL>AT</SMALL> <SMALL>THE</SMALL> <SMALL>REQUEST</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> L<SMALL>ESSEE</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>13.1.1. Conditions</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
provisions of Article L 313-9 of the Monetary and Financial Code, the Lessor and the Lessee agreed, by mutual agreement, the conditions according to which the Lease Agreement and the Amendment may be terminated at the request of Lessee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These conditions take into account the specific nature of the Property, as recalled in the presentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee expressly accepts the consequences of the termination of the Lease Agreement and the Amendment </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee may only exercise its right to terminate as of the end of the third (3&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP><SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP>) year following the Effective Date of the Amendment, and according to the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The termination may only occur at the end of a calendar year, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The termination shall imply the termination of the sale agreement granted to the Lessee under the Lease Agreement
and the Amendment </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Lessee shall notify the Lessor about the termination of the Lease Agreement and the Amendment at least six
(6) months in advance by registered letter with postal acknowledgment of receipt sent to the registered office of the Lessor, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Lessee must be current with its obligations under the Lease Agreement and&nbsp;the Amendment.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It will have to justify, moreover, the good&nbsp;state of maintenance and repair of the Property by the production of an inventory
drawn up by a recognized expert in this field, chosen by the Lessor at the Lessee&#146;s expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The termination of the Lease Agreement and the
Amendment will revert to the Lessee against simultaneous payment to the Lessor of the lump-sum termination compensation stipulated below, which will be recognized pursuant to a deed to be regularized by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation&nbsp;will be due even if the termination of the Lease Agreement and the Amendment was requested by the Lessee or its successors after a
safeguarding, reorganization or liquidation procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee will also bear the cost of any tax implications associated with the termination of the
Lease Agreement and Amendment, as well as the cost of the deed of termination and any publication of such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>13.1.2. Compensation</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation shall be equal to fifty percent (50%) of the Sale Price of the Building determined according to the provisions of the Lease Agreement and
Article 12.3 above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All fees, duties and taxes including the value added tax that may apply to said compensation, which is stipulated excluding tax, will
be charged to the Lessee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.2. T<SMALL>ERMINATION</SMALL> <SMALL>AT</SMALL> <SMALL>THE</SMALL> <SMALL>REQUEST</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> L<SMALL>ESSOR</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>13.2.1. Conditions </U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case of failure to perform any of the obligations imposed by the Lease Agreement and this agreement under the responsibility of the Lessee, the Lease
Agreement and the Amendment shall be terminated automatically and without any legal formality, if the Lessor sees fit to do so, two (2) months after a notification sent to the Lessee of a payment order or a formal notice by extrajudicial deed
remained totally or partly ineffective, and containing the statement by Lessor its intention to use the benefit of this&nbsp;clause, it being specified that any offer of payment made after the expiration of two (2) months will be ineffective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee shall pay the Lessor, in addition to arrears of rent and charges, the termination compensation specified below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It must return to the Lessor, without delay, the Building in good a state of good repair and maintenance and justify the payment of taxes, duties and services
as well as its insurance premiums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The termination of the Lease Agreement and the Amendment shall automatically imply the termination of the sale
agreement granted to the Lessee under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>13.2.2. Compensation </U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation shall be equal to fifty percent (50%) of the Sale Price of the Building stipulated above. It will be increased to seventy-five percent (75%)
of the Sale Price if on the date of termination letter, the certificate of non-objection was not issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All fees, duties and taxes including the value
added tax that may apply to said compensation, which is stipulated excluding tax, will be charged to the Lessee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All amounts and compensation due on the
date of termination and / or because of it, will produce, for the benefit of Lessor, automatically, without requiring any summons or formal notice, late payment interest at the rate stipulated under Article 11.3 above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 14.</U> CONSEQUENCES OF THE TERMINATION OR FAILURE TO EXERCISE THE OPTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.1. T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>SALE</SMALL> <SMALL>AGREEMENT</SMALL></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination of the Lease Agreement and the Amendment or the failure to exercise the purchase option at the expiration of the Lease Agreement and the Amendment
shall imply automatic termination of the sale agreement granted to the Lessee under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.2. R<SMALL>ELEASE</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> P<SMALL>ROPERTY</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> L<SMALL>ESSEE</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to request the exercise of the purchase
option within the agreed time, as in the case&nbsp;of termination of the Agreement, the Lessee, any beneficiary or successor, must remove any occupant and all furniture from the Property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.3. I<SMALL>NVENTORY</SMALL> <SMALL>STATEMENT</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the request to exercise the purchase option is not made within the agreed time, as in case of termination of the Lease Agreement and this Agreement, the
Lessor may have an inventory report drawn up by a recognized expert in this area, who it will choose to appoint. If the outcome of this inventory reveals that the Property is not in a good state of maintenance and operation, the Lessee will be
required to restore or replace the equipment and materials that are in bad condition that are considered to be fixtures, and which are necessary for the normal operation of the Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee shall, at its own expense, remove signs and exterior panels and refurbish what results from this removal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.4. D<SMALL>ELIVERY</SMALL> <SMALL>OF</SMALL> <SMALL>DOCUMENTS</SMALL></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to request the exercise of the purchase option within the agreed time, as in case of termination of the Lease Agreement and the Amendment, the Lessee
undertakes to deliver to the Lessor, on or before the date of expiration or termination of the Lease Agreement and the Amendment for the Property, the following documents (without the list below being exhaustive), namely: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the technical file containing in particular the technical reports, inspection reports and safety
reports,</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maintenance file containing in particular the maintenance contracts, and possibly employment contracts
(concerning contracts related to maintenance and not to the activity of the Lessee). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Lessee agrees: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To bear the consequences of termination of the current contracts, which would result from their non-recovery by
the Lessor </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To submit to the Lessor all the documents in its possession that would be necessary for the proper management and
operation of the Property by Lessor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 15.</U> TAXATION OF THE AMENDMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By express agreement between the Parties, the Amendment shall be subject to the Value Added Tax in accordance with current regulations and thus exempt from all
lease registration fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of value added tax&nbsp;levied on each term of Rent, at the rate in force at each term, will be borne by the Lessee
in addition to the Rent and other charges specified below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 16.</U> INSURANCE UNDER THE AMENDMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>16.1 C<SMALL>ONSTRUCTION</SMALL> I<SMALL>NSURANCE</SMALL> </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lessee states that it did not purchase STRUCTURAL WARRANTY and TEN-YEAR MANUFACTURES LIABILITY insurance with respect to the Work, subject
of the Amendment, which the Lessor accepts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, the Lessee undertakes to assume all the consequences of any kind that may arise
from the lack of purchase of said policies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>16.2 A<SMALL>LL</SMALL> R<SMALL>ISKS</SMALL> E<SMALL>XCEPT</SMALL> <SMALL>INSURANCE</SMALL>
</U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The coverage provided under the &#147;All Risks Except&#148; policy purchased by SOCIETE GENERALE including
building insurance, Lost Rent -Loss of Use insurance, and Lessor Civil Liability insurance will be maintained throughout the duration of the Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The coverage amounts will be adjusted&nbsp;to new features of the property upon partial or total acceptance of
the Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is expressly agreed that the guaranteed amounts will be determined between the insurer and the Lessee, under
the sole responsibility of the latter, and will not be less than the amount for reconstruction at replacement value, costs and fees included. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Brokerage firm AON FRANCE has been in touch with the Lessee to enable the latter to accurately assess the
risks. Based on this information, a pricing was established by the broker, according to the guarantees contained in the manual issued by the insurer, defining the essential conditions of the contract. The Lessee acknowledges to have read this
manual. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Lessee will ensure, under its sole responsibility, that the certificate of insurance is issued by the
insurer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There is no waiver of the provisions of the original property lease contract concerning insurance.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 17.</U><U> </U>LOSSES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The&nbsp;article &#147;losses&#148; of the Lease Agreement is canceled and replaced by the following: </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.1.&nbsp;<SMALL>OBLIGATIONS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>LESSEE</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL> <SMALL>EVENT</SMALL>
<SMALL>OF</SMALL> <SMALL>A</SMALL> <SMALL>LOSS</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee shall give written notice to the broker and the Lessor, within forty-eight (48)
hours of its occurrence in the case of theft and within five (5) business days in other cases, of any loss suffered or caused by the Property, subject of the Lease Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It must also make all reports to the insurance companies under the conditions and within the time limits provided in each insurance policy: the Lessor hereby
gives it, as necessary, a mandate to make such reports. The Lessee is prohibited from initiating any proceeding or action against the Lessor for the loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It will&nbsp;also take the necessary steps to obtain the rapid payment of compensation from the insurance companies, either on its own behalf or on behalf of
the Lessor who hereby gives it all useful mandates for this purpose to perform all procedures, carry out all formalities, cause all expert assessments, participate in them;&nbsp;in case of difficulties, take all recourse excluding legal action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It must, in respect of losses activating the guarantees of the structural warranty policy, use all the compensation paid by the insurance companies to repair
the damage to the structures. Otherwise, the Lessee will risk an action for recovery of undue payments being initiated against it by the insurer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
event of legal proceedings, the Lessor shall first be warned by the Lessee of any action to be taken both as plaintiff and defendant. The Lessee shall appoint a lawyer whose specialty is directly related to the subject matter of the dispute. The
Lessor reserves in any event the right to appoint its own lawyer. All fees and duties will be paid directly by the Lessee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee agrees to keep the
Lessor informed of developments in the proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee will show the Lessor all convictions that could be imposed against the latter in case of
absence or inadequacy of the coverage of said policies and more generally in the event of total or partial coverage refusal by the insurer. It also will&nbsp;bear the costs and fees that the Lessor shall have incurred in its defense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a loss activating the construction insurance policies (All Risks Construction or Structural Warranty policy), the Lessee undertakes to
reconstitute, at its sole expense, the guarantee so that the amount of the latter is at least equivalent to what it was before the occurrence of the loss and enables, in any case, a complete reconstruction of the Property, and to justify this to the
Lessor at the first request of the latter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.2. <SMALL>INSURANCE</SMALL> <SMALL>COMPENSATION</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For losses whose&nbsp;compensation exceeds FIVE THOUSAND EUROS (5,000.00 EUR), the Lessor will only accept the compensation offer with the written consent of
the Lessee, which shall notify its position within one month of receiving the offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation paid after any loss shall be collected first by the
Lessor, with the requirement that the Lessor repays the compensation to the Lessee upon proof that the work was done and the invoices paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessor
gives all powers to the Lessee to challenge the amount of compensation from the insurance companies or any other third party liable for this compensation, with the requirement that the Lessee keeps the Lessor informed of the progress of these
challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In any&nbsp;case the Lessee may not invoke such challenges to avoid its obligation to pay all the Rents, charges and accessories stipulated
in the Lease Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee shall, in all cases, be personally responsible for any difference between the cost of full reconstruction of the
structures and the amount of compensation paid by the insurers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For losses for which the&nbsp;compensation is less than FIVE THOUSAND EUROS (5,000.00
EUR), the Lessee is permitted to collect the compensation to use it to carry out the repair work, the Lessor reserving the right to request any proof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.3. P<SMALL>ARTIAL</SMALL> <SMALL>LOSS</SMALL></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an
exemption to the provisions of Article 1722 of the Civil Code, the partial destruction of the Property, even by an unforeseeable or force majeure event, will not allow the Lessee to request termination of the Lease Agreement, or payment of any
compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee must restore the damaged Property, at its sole expense and risk, after having obtained the necessary administrative
authorizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the rehabilitation of the Property cannot be done for lack of the necessary administrative authorizations, the Lessee shall have the
right, without waiting for the expiration of the minimum period provided for in Article 12.1 above: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to either request the termination of the Lease Agreement and the Amendment upon payment by the Lessee to the
Lessor of compensation equal to the sale price stipulated in Article 12.3.2 above, and determined at the date of termination, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">or to implement the sale agreement for the Property granted in its favor, under the conditions stipulated in
article 12 &#147;SALE AGREEMENT&#148; and for a sale prices determined in Article 12.3.2 &#147;Advance asking price,&#148; even before the expiration of the minimum period prescribed above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">or continue the Lease Agreement and the Amendment on the useable part of the Property. The Rent will be reduced
in proportion to the ratio of the amount of insurance compensation net of any taxes that may encumber it, with the sale price determined in Article&nbsp;12.3.2 &#147;Advance Asking Price&#148; approved on the date of payment of the compensation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This reduction will take effect only from the date of the receipt by the Lessor of the insurance compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee must inform of its option by registered letter with acknowledgment of receipt within a period of one (1) month following the date on which it
became aware of the impossibility to restore the Property for failure to obtain the administrative authorizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otherwise, it will be deemed to have
opted for the case iii) above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lease Agreement will be subject to an amendment modifying the description and financial conditions to reflect the
amount of compensation actually received by the Lessor, net of all fees and expenses incurred by it in particular with respect to any duties, taxes and capital gains. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whichever option is taken by the Lessee, in cases i) and ii) above, the Lessor will transfer to it, on the day of the deed recording either the termination of
the Lease Agreement or the exercise of the option, the amount of compensation received from insurance companies or any other organizations, net of all taxes and duties that may encumber this compensation, excluding corporate income tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The repayment to the Lessee of all compensation that can revert to it under the provisions of this Article 17.3 will not occur until the actual payment by the
Lessee of all amounts that it may owe to the Lessor under the Lease Agreement, the&nbsp;Lessor however reserving the right to automatically offset these amounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.4. T<SMALL>OTAL</SMALL> <SMALL>LOSS</SMALL></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
event of a loss causing the total destruction of The Property, the Lease Agreement will be terminated automatically, but only at the expiration of the time periods set forth below for the benefit of the Lessee, to possibly exercise the option right
reserved for it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nevertheless by express agreement between the Parties and by derogation to Article 1722 of the Civil Code, such termination will trigger
the obligation for the Lessee to pay the Lessor compensation equal to the sale price of the Property determined in Article&nbsp;12.3.2 of the Lease Agreement, &#147;Advance Asking Price,&#148; said price calculated on the date of termination, plus,
if applicable, any costs of restoring the land after the loss (including demolition and removal of remains). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions, the Lessee shall have the option: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either to implement the sale agreement under the conditions specified in Articles 12.2 and 12.3 above,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">or (and by&nbsp;express derogation to the provisions of Article 1722 of the Civil Code) to continue the Lease
Agreement by proceeding with the reconstruction of the Property at its sole expense and risk, after having obtained the necessary administrative authorizations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lessee must inform of its option within six (6) months from the day of the loss, by means of a registered letter with acknowledgment of receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the Lessee would opt for the continuation of the Lease Agreement, the necessary administrative authorizations should be obtained by the
Lessee within one (1) year from the date of notification of its option; otherwise the Lease Agreement would be automatically terminated under the conditions stipulated above, unless the Lessee prefers, in the same period of one (1) year, to opt for
the implementation of the sale agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whichever option is taken by the Lessee, the Lessor will transfer to it the amount of compensation received
from insurance companies or any other organizations, net of all taxes and duties that may encumber this compensation, excluding corporate income tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
repayment to the Lessee of all compensation that can revert to it under the provisions of this Article 17.4 will not occur until the actual payment by the Lessee of all amounts that it may owe to the Lessor under the Lease Agreement, the&nbsp;Lessor
however reserving the right to automatically offset these amounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.5. R<SMALL>ECONSTRUCTION</SMALL> <SMALL>AUTHORIZATION</SMALL></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In all the cases provided in Articles 17.3 and 17.4 above, the Lessee is required to obtain any necessary administrative authorizations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.6. R<SMALL>ECONSTRUCTION</SMALL> - R<SMALL>ESTORATION</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In all the cases provided in this article, the reconstruction of the completely destroyed Property or the restoration of the partially affected Property will
be carried out by the Lessee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as part of&nbsp;a project management delegation contract that will be regularized with the Lessor and under which
the Lessee will, in particular, agree to purchase the necessary construction insurance, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the basis of an estimate of the work and plans established by the Lessee at its own expense and under its
responsibility, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">and under the control and supervision of an architect or an engineering firm chosen by the Lessee, authorized, if
necessary by the Lessor. Fees for the architects and engineering firms will be included in the reconstruction or restoration costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.7. P<SMALL>ROVISIONS</SMALL> <SMALL>RELATING</SMALL> <SMALL>TO</SMALL> R<SMALL>ENTS</SMALL></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In all cases of a loss where the Lessee opted for the repair or reconstruction of the Property and thus&nbsp;for the continuation of the Lease Agreement and
the Amendment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Lessee will continue to pay, for the period elapsed since the date of the loss until the actual reconstruction, all Rents, charges and accessories stipulated in the Lease Agreement and the
Amendment as long as the Lessor has not been compensated by the insurance company, under the Loss of Rent guarantee. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PART III
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GUARANTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 18.</U> PLEDGE OF THE AMENDMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the guarantee of all claims that may result from the Amendment and the implementation of all obligations resulting herefrom, the Lessee pledges as
collateral to the Lessor, which is accepted by its representative, the intangible elements resulting from this Amendment for the Lessee, together the right to lease and the benefit of the sale agreement, without exception or reservation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through this pledge, the Lessor shall have and exercise, on the different elements of this Amendment, all the rights, actions and privileges conferred by the
Law to secured creditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In compliance with the Civil Code, the efficacy of the lien resulting from the pledge granted will be ensured as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">those appearing request that the Undersigned Notary deliver only an authentic copy of this deed;&nbsp;This
authentic copy shall be marked: &#147;special and single authentic copy submitted to the pledge contained in the Amendment of September 28, 2016;&#148;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Lessee agrees to not request any authentic copy hereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This stipulation does not however preclude&nbsp;the issuance of the enforceable copy to the Lessor. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PART IV </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 19.</U> COSTS - ASSESSMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All the costs hereof and all those that will follow or result from it will be the responsibility of the Lessee, who agrees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the calculation of the costs only, the parties declare that the amount of the Investment&nbsp;of the Lessor is valued at the sum excluding tax of EIGHT
HUNDRED FORTY-SIX THOUSAND THREE HUNDRED THIRTY-SEVEN EUROS AND EIGHTY CENTS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(846,337.80 EUR) and the sum including the Value Added Tax of ONE MILLION FIFTEEN THOUSAND SIX HUNDRED FIVE EUROS AND THIRTY-SIX CENTS (1,015,605.36 EUR). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Lease Agreement will be subject to registration formalities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 20.</U> INSEPARABILITY OF THE CONTRACTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All the provisions of the Lease Agreement that are not contrary hereto, shall continue to apply to all agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is expressly stipulated between the parties that the Lease Agreement and the Amendment will be inseparable from each other and will form, in relations
between the parties, a single and indivisible agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, all events whatsoever that could, by reason of the provisions of
the Lease Agreement and the Amendment, affect either of the two agreements, will apply ipso facto and automatically to both agreements which are considered to be one transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This will be the case in particular: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for the termination of the lease agreement at the request of the Lessee, such a request applying automatically to
both agreements, even if it is made for only one of them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any transfer of the right to the lease agreement which will necessarily concern the subject matter of both
lease agreements, this agreement being necessary even in case of transfer of the benefit of only one of the agreements to the successor in the business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for the termination or rescinding of either of the two contracts under the termination clause inserted in it, for
failure by the <B>LESSEE</B>&nbsp;to perform any of its obligations: such a rescinding would affect both agreements automatically and the compensation which would be due would be established by the addition of the compensation due under each of the
contracts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of a loss affecting all or part of the premises given in lease the agreement: it is expressly agreed
in this regard, for the application of the provisions of the two contracts in question relating to the total loss, that only a loss that would cause the total destruction of the object of the two agreements would be considered a total loss. Any
other loss, even one that caused the total destruction of the object of only one agreement, will be considered a partial loss. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, it is expressly stipulated that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the application of the provisions relating to losses, the termination of the lease agreement or early
implementation of the sale agreement will apply automatically to both lease agreements, even if the request of the Lessee was limited to only one of these two agreements </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the case of partial loss not followed by reconstruction for failure to obtain the necessary administrative
authorizations: that the compensation payable by the Lessee to the Lessor like the reduction in rent and the sale price will therefore be determined based on the financial conditions of the agreement applying to the partially damaged property
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">But however, if the loss partially affects the object of both lease agreements, the amount of compensation
payable by the Lessee as well as the reduction of rent and the sale price will be determined separately for the object of each of the two agreements, according to the financial conditions of the relevant agreement;&nbsp;to this end, the assessment
of the building&#146;s depreciation (either by the agreement of the parties or by an expert) will be made separately for the object of each of the two agreements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of the expropriation of the building: in this regard, it was agreed that only expropriation that
would affect the entire building, object of both agreements, would be considered as expropriation, and that partial expropriation would be considered subject to the provisions for this case, the expropriation which would concern part of the
premises, that part would itself constitute the entire object of one of the two agreements. Furthermore, the above rules established for the reduction of rent and the sale price in the event of a partial loss not followed by reconstruction, will be
applied to the reduction of rent and the sale price set for the case of partial expropriation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for the sale agreement for the premises which may only be exercised by the<B>&nbsp;</B><B>LESSEE </B>for the
entire building, the object of both lease agreements. Any request to execute the sale of only part of the premises, should that part constitute the entire object of one of the two agreements, would be considered null and void</P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 21.</U> POWERS - RELATIVE EFFECT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.1. P<SMALL>OWERS</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties acting in the common
interest confer all powers necessary to any Clerk of a Notarial Office designated in the beginning hereof, in order to prepare and sign all deeds that are additional to, or that amend or correct these, in order to ensure their harmony with all
mortgage, land registration, and civil status documents, and make any additional tax declarations </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.2. R<SMALL>ELATIVE</SMALL> <SMALL>EFFECT</SMALL>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lessor owns the Building, for having acquired it pursuant to a deed established by Ms. Martine AFLALOU-TAKTAK, a notary in
MARSEILLE, on June 9, 2008, an authenticated copy of which was published in Land Registry Department of MARSEILLE 3 <SUP STYLE="font-size:85%; vertical-align:top">rd District </SUP>on July 10, 2008 volume 2008P number 5846. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 22.</U> REPRESENTATIONS AND WARRANTIES OF THE PARTIES </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The representative in his official capacity of the Lessor warrants, on behalf of the company it represents, the
accuracy of the following information and statements: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The company is a French company duly incorporated and validly existing, whose characteristics listed above are
accurate and current; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The company&nbsp;has not been and is not subject to measures related to the application of the provisions of
Articles L. 611-1 et seq. and Articles L. 620-1 et seq. of the Commercial Code, covering ad hoc mandate, conciliation, safeguarding, receivership and liquidation procedures, pursuant to the provisions referred to above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The company is not affected by any claim for nullity or dissolution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The company and its agent have legal capacity and have obtained all consents and authorizations of its corporate
bodies and, where appropriate, the competent administrative authorities, and all other possibly necessary consents and authorizations to allow it to conclude and perform its obligations under the Deed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The signing and&nbsp;implementation of this agreement by the Lessor do not contravene any material contract or
obligation to which it is a party, or any law, regulation, or administrative, judicial or arbitral decision which is binding on it and for which a failure to comply could negatively affect or impede the proper performance of the obligations arising
from the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The representative of the Lessee, in its official capacity, states on behalf of the company it represents:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that&nbsp;it is a French legal entity, having its head office in France; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that&nbsp;it has full power and authority to enter into and perform this agreement in accordance with its
articles of association and any other corporate document; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the signatory of this deed received all the powers and authorizations necessary for this purpose by
decision, a certified true copy of which is appended hereto or to a deed established by the undersigned notary recording the receipt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the signatory has received full authority to enter into all agreements relating to the Lease Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that&nbsp;to its knowledge neither the signing, nor the performance of any provision of this deed and other
planned agreements to said deed violate any agreement, deed, judgment, arbitral award, legislative, regulatory or other provision, that would apply to it or to which it would be subject; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that to its knowledge, there is currently no, and there is no risk of there existing, a dispute, legal action or
claim that could adversely or materially affect the financial position, activity or the property that are the object of the Lease Agreement, or incur the validity and force of this deed and other planned agreements to said deed;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the obligations hereunder constitute direct and unconditional obligations vis-&agrave;-vis the Lessor and are
equally ranked in all respects as any other similar obligations of the Lessee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that&nbsp;it is not the subject of any action for nullity or dissolution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The company&nbsp;has not been and is not subject to measures related to the application of the provisions of
Articles L. 611-1 et seq. and Articles L. 620-1 et seq. of the Commercial Code, on receivership and the appointment of an ad hoc representative, conciliator, legal administrator or liquidator pursuant to the provisions referred to above;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 23.</U> NOTICES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice between the Parties hereunder will be sent by Email (confirmed by registered letter with acknowledgment of receipt), express courier and delivered
personally or sent to the Party to whom it is intended, at the address below (or any other address that they may subsequently notify to the Parties). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alternatively, the notice may&nbsp;be supplemented by sending, by email, a copy of the registered letter with acknowledgment of receipt or by a bailiff&#146;s
writ. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>As regards the Lessor</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Company: &#147;<B>SOGEBAIL</B><B></B>&#148; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Administrative address: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">BDDF/DAI/CBI </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">189 rue
d&#146;Aubervilliers </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">75886 PARIS CEDEX 18 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Registered office address: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">29,
boulevard Haussmann </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">75008 PARIS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Telephone: 01 42 14 38 80</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Email
Address: justine.kramer@socgen.com</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>As regards the Lessee</U>: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Company: &#147;<B>INNATE PHARMA</B>&#148; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Address: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Telephone: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Email Address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The date&nbsp;on which a notice shall be deemed validly made will be the date of its actual receipt by the recipient, that is to say, the date on the notice
of receipt or the notice of delivery in person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 24.</U> ADDRESS FOR SERVICE - JURISDICTION&nbsp; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legal entities that are party to, and participants in the Agreement, for its implementation, elect domicile in their respective registered offices except
the SOGEBAIL company which elects domicile at its administrative address </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any dispute concerning the&nbsp;interpretation or implementation of these
agreements will be submitted to the competent Paris Court to which jurisdiction or authority is expressly granted by the parties without prejudice to the provisions enacted by Article 48 of the Code of Civil Procedure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 25.</U> DATA PROTECTION ACT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Article 27 of Act No. 78-17 of January 6, 1978 relating to data protection, the personal information collected as part of this agreement and
subsequently are intended for the Lessor who, by express agreement, is allowed to keep it in electronic memory, to use it and to communicate it for the same purposes to companies in its group, its brokers and insurers, or to a third party to which
the Lessor entrusted the management of its business. In this case the Lessor will inform the Lessee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The right of access and the right of rectification
may be exercised with the Lessor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Legal Notice</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the &#147;Data Protection&#148; Act of January 6, 1978, the Notarial Office carries out data processing for the performance of notarial
activities, including deed formalities. To this end, the&nbsp;Office is required to save data concerning the parties and transmit it to certain administrations, including the Mortgage Registry for land registration, accounting and tax
administrations. The parties may exercise their rights of&nbsp;access and rectification of data concerning them at the Notarial Office (&#147;SCP THIBIERGE ET ASSOCIES, Notaries, members of a private professional partnership holding a Notarial
Office,&#148; located at 9 rue d&#146;Astorg in PARIS 8 <SUP STYLE="font-size:85%; vertical-align:top">th </SUP>district, telephone: 01.40.17.86.00 fax: 01.42.66.54.29, email: thibierge.associes@paris.notaires.fr&nbsp;or via the &#147;Data
Protection&#148; Correspondent appointed by the Office:&nbsp;cpd-adsn@notaires.fr&nbsp;). Only for deeds relating to Property transfers, some information about the property and its price, unless they object at the Office, will be transcribed in a
Property database for statistical purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 26.</U> ISSUE OF AN ENFORCEABLE COPY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties request that the undersigned Associate Notary issue, at the expense of the Lessee, an enforceable copy of lease agreement to the
Lessor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>ARTICLE 27.</U> LIST OF APPENDICES </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>A<SMALL>PPENDIX</SMALL> 1: P<SMALL>OWERS</SMALL> <SMALL>OF</SMALL> SOGEBAIL </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>A<SMALL>PPENDIX</SMALL> 2: D<SMALL>ELIBERATIONS</SMALL> <SMALL>AND</SMALL> <SMALL>POWERS</SMALL>
<SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>COMPANY</SMALL> I<SMALL>NNATE</SMALL>&nbsp;P<SMALL>HARMA</SMALL>) </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>A<SMALL>PPENDIX</SMALL> 3: A<SMALL>RCHITECT</SMALL> C<SMALL>ERTIFICATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>A<SMALL>PPENDIX</SMALL> 4: W<SMALL>ORK</SMALL> A<SMALL>CCEPTANCE</SMALL> R<SMALL>EPORT</SMALL>
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>A<SMALL>PPENDIX</SMALL> 5: P<SMALL>RICE</SMALL> S<SMALL>CHEDULE</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>A<SMALL>PPENDIX</SMALL> 6: <SMALL>SUMMARY</SMALL> <SMALL>AND</SMALL> <SMALL>TABLES</SMALL>
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>IN WITNESS WHEREOF </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pages.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And after&nbsp;reading, those appearing signed this deed with the undersigned notary, named above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ms. Justine&nbsp;<B>KRAMER</B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On behalf of&nbsp;the <B></B><B>LESSOR/</B><B></B><B> SOGEFIMUR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">/s/ Justine Kramer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ms. Irene <B>BERKOWITZ</B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On behalf of the <B>LESSEE/ INNATE PHARMA</B><B> </B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">/s/ Irene Berkowiz</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Participating notary</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ma&icirc;tre Annick&nbsp;<B>DOMENECH</B><B> </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">/s/ Annick Domenech</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Notary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Subsidiaries of the Registrant </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Name of Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Jurisdiction of Incorporation or Organization</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Innate Pharma, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Innate Pharma France SAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">France</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g751960g1213113437809.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g751960g1213113437809.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? $(# 2(  A$! Q$!_\0
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3NQ>1C[W_ -:@!XZ"BE'2B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g752656g01o95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g01o95.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[3I24&AO=&]S:&]P(#,N,  X0DE-! 0
M     #\< 5H  QLE1QP"   "   < E  #D1R;W)Y+"!*87-O;B!,' (W  @R
M,#$Y,#8P-1P"/  +,C,P.3,W*S P,#  .$))300E       0L1HQY>*]HNDU
MWZE*3"VNK#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              *@   %8          $
M 0             !6    *@                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   *@     4F=H=&QO;F<   %8    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      >WP    $   "@    3@
M >   ))    >PP 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X
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M&+35B9#L0L<QSG%NYQ:T?S1A]>W<J&!A%^5U/"S7^NVRC'KM)T]IKM8]N_\
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MTJ[-WI;V[HWZ[)Y_E;%D=/'U9'5,O[&:CFFUQNY@6S^G%&[]%ZOJ[_M?V?\
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M2222E))))*4DDDDI_]D .$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(     $DI-30 J    "  /
M 0   P    $!8    0$  P    $ N0   0(  P    ,   #" 08  P    $
M @   1(  P    $  0   14  P    $  P   1H !0    $   #( 1L !0
M  $   #0 2@  P    $  @   3$  @   !X   #8 3(  @   !0   #V 3L
M @    \   $*G)T  0   !X   $9ZAP !P  " P   $WAVD !     $   E$
M   1[  (  @ "  5^0   "<0 !7Y    )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C V.C V(#$Q.C0P.C(X $1R;W)Y+"!*87-O;B!,
M $0 <@!O '( >0 L "  2@!A ', ;P!N "  3    !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                               )D   !P    0P,C(QD ,  @   !0
M  FVD 0  @   !0   G*DI$  @    ,P-0  DI(  @    ,P-0  H $  P
M  '__P  H ( !     $   %8H , !     $   "HZAP !P  " P   G>
M #(P,3DZ,#8Z,#4@,C,Z,#DZ,S< ,C Q.3HP-CHP-2 R,SHP.3HS-P <Z@
M  @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                              8! P #     0 &
M   !&@ %     0  $CH!&P %     0  $D(!*  #     0 "   " 0 $
M 0  $DH" @ $     0              2     $   !(     3A"24T#_0
M    "           _^$23$U- "H    (  \!   #     0%@   ! 0 #
M 0"Y   ! @ #     P   ,(!!@ #     0 "   !$@ #     0     !%0 #
M     0 #   !&@ %     0   ,@!&P %     0   - !*  #     0 "   !
M,0 "    '@   -@!,@ "    %    /8!.P "    #P   0J<G0 !    '@
M 1GJ'  '   (#    3>':0 $     0  "40  !'L  @ "  (   #P     $
M  /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#8Z
M,#8@,3$Z-# Z,C@ 1')O<GDL($IA<V]N($P 1 !R &\ <@!Y "P ( !* &$
M<P!O &X ( !,    '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M      F0   '    !# R,C&0 P "    %   ";:0!  "    %   "<J2D0 "
M     S U  "2D@ "     S U  "@ 0 #     ?__  "@ @ $     0   5B@
M P $     0   *CJ'  '   (#   "=X     ,C Q.3HP-CHP-2 R,SHP.3HS
M-P R,#$Y.C V.C U(#(S.C Y.C,W !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    !@$#  ,    !  8   $:  4    !   2.@$;  4
M   !   20@$H  ,    !  (   (!  0    !   22@("  0    !
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M%3$6(D%1%V%Q(S*!H? 8)#5"=9$S-C>QM$5V=[;!_\0 '0$!  (" P$!
M          $" P4$!@<("?_$ #P1  $# @0#!@0%! (" @,   $" Q$ ! 42
M(3$&05$3(F%Q@? 4D:'!!S*QT?$(%2/A0E(D<C,T8G-T_]H # ,!  (1 Q$
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MX:NQL*X]O?7_ *;FM2*;%39ULDRXY$>;;8RS2 \5$SY!0,3.,A"IBWU/+?\
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MG)!2&]<Q+9*RJN^ONHQM[9O//YJIJ_.,8XYSP1?N,8QSSG.?TQC&?MGCWZV
M4"HH@R #MIK)T\@-:ZWH(D@3U.W+7I)T%*>X?_279_\ ^/;E_P#KLCU:E/6'
M_P"$Q?\ TX+_ .,UTI2#?KE$:ZI5KOM@P3]#IM=F;/+?(L?-'*CH*-)DRT!C
M>3>'REL"N)&9RM.'GLH;YQE?.,3KB6@E1![RTHT G7U'3SZ:U9*2LP(V)UK-
MC?W>YIS8?:KW+#K:GJ8*7V][QC/J5Y9AX.-8M\;4GH61HQ+^)<EP>RB&VFN^
M"7&$Q1ZY5 T;)&&!20X>=3:D#-W>SRYN>;4$_E@CD9.8Z[Z&:QN*#<9N9$1K
MKO\ 3?TFF)\1^VS<;H?5&O*MN:+U+-;*=9CY'! ,VB6M=?#J2RS8*&FH0*35
M#.D%Y #*(-5%"%J,89?F0VU*9*\U_$E]UW!L-M&+_P#M5Q?W *"I+N9X-M%;
MC(<:!++I)3E4K30@D F/JO\ I0P:RN^+\=XFQ;@6Z_$2WX0PVW?90FYM&['"
M+R_NNRM[R[M;M#OQB$MLOK0&CVC9:+B&W%A(JW?8AMG5NQ>WJL!:MMUJO$5K
MK#.OI:;MS<RJ<?G82- >*2\1-,#D%#>D6Q\@0UA8:Q<LH'<4E.,=;_@[$;#$
M,':187;]XFR4;-^XNLV=RX92@NJS+4HK'^1)S$A1*N\E)) \^_'SA7BSA?\
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MH:-RH)0L)@ZFJ,&["^%$GN4_'+=<F9B.E-KS9LU9GH7:DO %]P$G::Y+05A
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MQ@1AQ+@^06VW7,L,-Y<<RVOA2EYSC\N.?OCC<6=NW;7:T)7NVH1E3KE*(DI
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MZ*M8=5T%V_;,T_-UF8L0E@<US<-ZU+9>S(?8:F!XL=N!B(VLW!^4"2E$Z++
M9D<*9D8Q"8^OVW_BIK?7J:5\W,9RGC">><XYQSC'MC/[YQG]<8^WOQ[XSC[X
M4K+#>U3+=[U-;EPA$E"&*&UK8FY#.)MFJ2#^+7*1EI9FVVZ!:P[5)%5B%C8R
M$!%N>O\ -/DEA31RY,:04ZU6S*VG;M1 [%MEL*A6LN%T#NE22H'))@$ 0#H0
M:EX_^.TF=2\H1ON$@'8Z[QZG6N'N_J-:NW=CV^1A4-*'V" $K5I:E_2EY>-A
MHUF_O,)2+&0^H-F)@Y,POS<=FY:PZZ#.0  L*:*_#)CD1%JE N+EP?F;0A*I
M@:OYU(*29V#:IG0:0(T%+@E2&D :Q/@0--8YR9 @?>M.+':X6E0)U@L9) L7
M')840\)'24P4K)1 H0K0L7"BR$L>0086P.R,"$0^MUQ.$M^*T9591$ZZ@GS_
M %U/R\]ZE , ;D:>^6FWI5+.X#>6J-OZ/L3&MKG'VQ<1?NW"0-7'CR+0^ 9C
M?-!0"6(6:$*+)#Y( / *>C7BVXZ5!,B)%0LF*^(W*DJC2/F#\HG^-:2/?A/R
MVG6KY.>OX8PRA"L^7YO)S*.$YQC/MG"%<_?G],_SZ)$3.G2!/D#)'EMZ5"B=
M,J KS5DCQ'=5]O.H'[F!<JT5L!M><.^<:+A27E)6E6%28.,LX2K&/)*L_ERG
MWRI.5?ESSGK5XNDKPR_S-Y\UJZCLTB90H *T$SIK'41.M:G'6BK!L1;0%+6J
MW66@HE0+@*<H4 )*=](T\JH?MC5_9YH,;>=JIS-+H&XNX?7TA ,0XL^U',VE
M-):2J7'JM.;DOI8[PKC39,QB$C1G7"65Y(7DOU\YZSB-MA&&8=<,,]C;W=W;
M+89:?4&D%QI3?:B0"D%:W$R,H)5H!-=;QBSX>PQK&'$.6MO?<1V^5=HZ\EM-
MR]8R'2AHA63+\3WM725'8:"M&B9V(CK3(@EF"M/F#5P<;)+R&WWW>)?' Z,^
M[CR.4X0GR3G.7%)\N<XQGL/Q#36).L.J2'"FWRJ<A.;L@]GRG<JEP =23Z]P
M3<L,7D+6R,QM4)[1P"5'MP -/0Q.^E*\2:.;;I,D5Y)+#L'$L)>9SZC?JM%R
MRG486GG'Y.4X5[XSA2L8SQ[XQRF5(-VZ$*S@LM)S @@%*G)!@F($:>/K4-J2
MN[6M*T+2NW9$MJ"DRE;\B1IH?+]W7-3<;78>2GI<C(L5$@E2<@3AEXA0X0;*
MR"'$CC-NE$*0TA2D#C,O$O*X:8:==4A"N65! )5.JCL)Y@:US@)VJD/</W!Z
M@V?VR]T59HMP:G9Y/;;O8QV+^D6",)'Q$T:8CY@$M,Q%1Z1)N%+/!9FZ\2IJ
M>AE&B9DXT5)0^7,B96,R?2=/IO\ (>M0=-#'D=B>FGOY5;>LQRS:=6VGD->D
M]6H="F\\+Y\XX?.5J5E.,*PI"EMJ;RC'*7%\J]^.J:[*;0X'<WQ&=4I.?\W<
M*3G!))@J$U(43D7)9+9#K:&"4*9?29AIZ9"4G0+[,& # T 2KR$8Y3K)%BQB
MUOKJ4\&$, GUW7R"(LD88=A*4,^6,YSA/IIPG//II3GVZXUPK_#=-=FLH;9)
M80&_\2@E*X@YM%*T[@2<NO>5FKCW;ERFWN7VD*?N7;6["R9==+[@"D'M"$EP
MK4#F)RF8WK\U=>^)V$Q:8"EU_M#CY3N+K<F%VV?66A)Y_99>I(N#R!/F(&;I
M:9>.F!9D%XS\,/EO<#_-+4G*&B7L>:M<37 <=<;PUI=\XR&VKC/KD*EI-GD3
M+A=SH;4IS+D03E*2:\*:_$)'Q[5BWPQDXC92WA*W$N+<N'L.@_$@H3:M+;*'
MVK9612W$B==JW;C:JPC4.F/QE%S6 :KJNN!3(@:<"R84L!$U_P F3&'ULO,9
M'P"]@EI:5*0YC*/3XY\>RW%HAW#,)N<5;>2JVL(?;MAVF1U2+=2OS]F2D=DK
M6 28TKUAQAMRTPTWC;R+1FR:+H:'^1MU"63JDJ1W04D'69&VE2;KH*#E99=K
MJX$B-%S LVZ2^>A*/4)DSHLA&&L?,D+_ "I#<PI.,-H_N9]\YXQRL+["^7\?
M8MN(9=:N@2\D(42\];K3H"J-&U29Y#?<<O#FK4OKNK8.AIX/**EB"MQU;9$#
M.J-$JD<B !SB>&$Y2C.,_?R5S_+W^V,_KQ^_Z_MUV>MSS/BHGYFO9:,.83C/
M'Y585CG'E[XQG'\OW^_3S]_0TDB8,3H?+W%?#(_Y/%*$8RE7DG*L>>.<Y]\\
M?EX]OY]$A())&^\=>M1WDIALY2=SMY['6?&NOI4T=*4=*4=*4=*4=*4=*4=*
M4=*5\W.?'/VX^^<9]N<8QG/WY]N,XYSGW]L9QQG/55#,-#$\]Z@ S,R#RZ>_
M2J(C:R[EH+NIL6SH\VHSNI;(0[&&1TSMO88DC'UIRN:["COI>MU428HXLM5;
M)7+P>.5'3,2=9F;X^W+RX[<4&SC#:#LF,0;<)+KGPZVU0=$ /!:#,$"2# D*
M(DQ%3=2M5NMM("4PE2=-QJ2"#J8@:ZZQK&D+]VZEQ7==V]6'$37Y'U0H2"%&
MM$"X85-$%[(BG'0-9GBT^9PW<H=E],U8 YVRU*-Q!9".%?)>#+*C<ML/\V('
M_P#AUD 3ENM]=>1V(WD;&KNJ$-IYP>9/=&7-UY1L8TTUK1;9.OX_:]%GJ-)3
M=GK<?8AVA"YBH2 \3/M"H*')?9"+. DV&AY%EE<9),O O-FQ99P3B,LE95FQ
M$Z&??I[VYU1)V(\]8\_?C5#>XOM1T]K[4)T^%$&3TH+M3MU.@W;*Z 8-5#@^
MX2K2I!=2C@(V,C:X[+3EKLDW)(C!&&/FY9P0!D"%"BHH"Y43S]^_GSJ  -OY
MK35.,83CC]O_ ']^JT&WJ?U-15O&H.WW4E_J+'SWKS=:DQQDQJPT'N%M#K*#
M9$6>VZ&A]\MAEA"R6U,IRYY.>*<96G5XU9)Q'"<1L5=K%U:/M?X" \2I!RAL
MD$!95&4D:&N#BEJF]PZ^M%I<7V]LZA*6E)2XI>4J;2E2@4@J6  3I)UK\J7;
M5K=S8.UM=]N4K^$^WZ^ZWOUAL-MH&XZS&6?:&(W9 ;I=F&U+?"H9AHJ1EH 6
M&DLA MQI8*)-N29.D4C&Y,\BL,,NKE-O@-ZZEIESX<-NW326;Q?:) =+:"TG
M+_C804H6V@J</<4@#*/GS </<O+RTX0=ND8<J0\;/%$I<Q-:;TJ<>1:.K$@H
M#*4H#B%J! =2YFK]3VPJE5Y@ Z5E8YETZ/CG2$FK;0E]I3"'?05Y>/EA7DXM
M3:L*QE.48RC*5)PK'JV+8=A]TT;BY6E"@D(2[ V4"=)(U$=?T%>_8C9V[K:[
MART3G2VZM*X *5,@008D07-#N")D$:.JCT2NTF.R)7V%-#ON.$K6XM3KKCC_
M .?.<N+RK\B<YSZ:,>V,9SSSG*LJY&%X=9X>P$6?>;6I3F<D*S*<@DSK&VP/
M,S)DUGL[%BR04,-Y$R3!)49/>F23H)TC[FENTUYNTUJ>K+DK-02)^'DH=<U7
M#DQEABD20CP:Y"$DE,$8CY41+V7@#<,.Y%)0T\E"LHQCK8J2%#7T/2N:--:S
MD[D^S;3-1[5.Y,Q\:<M_T_MLVVRR';RXHR*5)A41PENSNQ,5"PT;FS.(J55&
M=DT"MX5B &.2PB8.FY*5NE60::>/WZ3XT.IGQGR\JT9I_P#Y2J__ -NPO\O_
M *:-U4;#R%0/N?U-=QK;:G$J6ZTC./'P2MOR6M6/+Q2VK*T^_P";.<8PG.>?
M^_5$R'M5@@I #1W!'_*<W/IEY;])*U@)2EWL@I1!5, S C<3H.72LW0ZW&U[
MXF"Y&*T "&Q=NW.5DK-O)N1#]66EHZSU\86/?B'6\._,1C+(48X^+ELDI$N*
MZ0ET,#R;ZFVVQ;<3N-_ MM!RT==0Z$R'5J<9"G0<@0G1*4JRG,><C4].#+#/
M&RD?V9&=[!W7U8T0DEQQ-Q;-!C+V9RYD3)#J3_C&9$*!K2!]IO()6'$8RA0[
MB7$YPE:5(RWGG"T\8QE.4^V??QS[XXZ[:O5"@0""E4CE$'J#/J*[>L@H(4GN
MA)&6-(B2.8U\?K3?H#3+-6A$"H2AE0 ZLX0A*,>6649^R,8Q_/[8YYS]^.N%
MAB$(L+<-I@=DG3028\-*X]B$BU:RZ=Q)@  :I$[>^5/;K85RJ.E*.E*.E*.E
M*.E*.E*.E*.E*.E*.E*.E*.E*.E*H/OC0.S;KO6E[5J5<ITMFJQ<9%1A4Q9*
M4 R*P'."V):9B-N';]M>=96W+-/.-2NN[?2Y5\!0PCOHG1T?+,*>]JO:"DQ
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MP?\ &)RU+.EE MRC=C1=DQ@;$8[$HK#KAJ)5OKQL+]O&QB*G4KMC:+MTH!4
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M4HZ4HZ4HZ4HZ4K/SORWKNO3D-KZ/U%7R%N7FQ.PAEP#%#E3XLQ(V5!UV(C)
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D2O/2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g752656g01x34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g01x34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2]64&AO=&]S:&]P(#,N,  X0DE-! 0
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M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#
MP     $  3A"24T$)@      #@             _@   .$))300-       $
M    'CA"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              -D   $6          $
M                     0             !%@   -D
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   -D     4F=H=&QO;F<
M  $6    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   #9     %)G:'1L;VYG   !%@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $    !#A"24T$#      D
MS@    $   "@    ?0   >   .I@   DL@ 8  '_V/_B#%A)0T-?4%)/1DE,
M10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-
M4T94     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M
M$6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M    %')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0
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M
M      !865H@        \U$  0    $6S%A96B
M6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M       DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C
M+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                 &1E<V,
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@                            !D97-C
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0                                  =FEE=P
M    $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %
M  !7'^=M96%S          $                        "CP    )S:6<@
M     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #<
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M.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_XD C0&1
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MK[LKJ+F8V-2V^NZJNG]7W^EZGVBW[57BI</]8J='..;]CN^T-I;4&.+W![Y
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M7XJK;4"T[S[28W:'0<E4NGU_Y-#*:'8#GA\,=!<QQ+OTA_>]WZ177$-!<XZ
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      7Y-30 J
M"  , 0   P    $!'@   0$  P    $ VP   0(  P    ,   "> 08  P
M  $  @   1(  P    $  0   14  P    $  P   1H !0    $   "D 1L
M!0    $   "L 2@  P    $  @   3$  @   !X   "T 3(  @   !0   #2
MAVD !     $   #H   !(  (  @ "  5^0   "<0 !7Y    )Q!!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C V.C V(#$Q.C(P.C0W
M  20   '    !# R,C&@ 0 #     ?__  "@ @ $     0   1:@ P $
M 0   -D         !@$#  ,    !  8   $:  4    !   !;@$;  4    !
M   !=@$H  ,    !  (   (!  0    !   !?@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0& 34T *@
M  @ # $   ,    ! 1X   $!  ,    ! -L   $"  ,    #    G@$&  ,
M   !  (   $2  ,    !      $5  ,    !  ,   $:  4    !    I $;
M  4    !    K $H  ,    !  (   $Q  (    >    M $R  (    4
MTH=I  0    !    Z    2  "  (  @   /      0   \     !061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-CHP-B Q,3HR,#HT-P
M   $D   !P    0P,C(QH $  P    '__P  H ( !     $   $6H , !
M  $   #9          8! P #     0 &   !&@ %     0   6X!&P %
M 0   78!*  #     0 "   " 0 $     0   7X" @ $     0
M   #P     $   /      ?_A04IH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED(C\^/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A
M+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q
M+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ
M1&]C=6UE;G1)1#YX;7 N9&ED.C8Q,49&,30P,44X.$4Y,3%!,S9!14$X0S(V
M1CDR1C%!/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS
M=&%N8V5)1#YX;7 N:6ED.C8S,49&,30P,44X.$4Y,3%!,S9!14$X0S(V1CDR
M1C%!/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/D,T,T-&13<X-$0T0C8P.3%"-4,V0C5"-3!!1D4Q,3A%
M/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV,#%&
M1C$T,#%%.#A%.3$Q03,V045!.$,R-D8Y,D8Q03PO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-BTP-E0Q
M,3HR,#HS,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M
M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z-C$Q1D8Q-# Q13@X13DQ,4$S-D%%03A#,C9&.3)&,4$\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,3DM,#8M,#94,3$Z,C Z,S$K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV,C%&
M1C$T,#%%.#A%.3$Q03,V045!.$,R-D8Y,D8Q03PO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-BTP-E0Q
M,3HR,#HT-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S
M9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z-C,Q1D8Q-# Q13@X13DQ,4$S-D%%03A#,C9&.3)&,4$\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,3DM,#8M,#94,3$Z,C Z-#<K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX
M;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-C(Q1D8Q-# Q
M13@X13DQ,4$S-D%%03A#,C9&.3)&,4$\+W-T4F5F.FEN<W1A;F-E240^"B @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-C$Q1D8Q-# Q
M13@X13DQ,4$S-D%%03A#,C9&.3)&,4$\+W-T4F5F.F1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^0S0S0T9%-S@T
M1#1"-C Y,4(U0S9"-4(U,$%&13$Q.$4\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O
M97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO
M<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO
M=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @
M(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#$Y+3 V+3 U5#(R.C,T*S U.C,P
M/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P
M,3DM,#8M,#94,3$Z,C Z-#<K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @
M(" @(" \>&UP.DUE=&%D871A1&%T93XR,#$Y+3 V+3 V5#$Q.C(P.C0W*S U
M.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M )$ N0,!$0 "$0$#$0'_Q  >   ! P4! 0             '  8( 0($!0D#
M"O_$ $40  $$ 0(% @,%! <&!04   ,! @0%!@<1  @2$R$4,14B40D6,D%A
M(S-"<1<D@9&AL? *)5)RP=$8)B=#\6)WLK3A_\0 ' $!  (# 0$!
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MI59Z+-D]++AVT74&>^[=3X^ZZZ_4>/3%GB0.K>O6K>D-C,Q#%]-K;4=,:P'
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MYV\](D,+-O\ ?;[^'&.6W-1FE3,UC,/!;SU25M'2T]_:U$DH06-Y!&3UI62
M/8R6@1%CQ2&8\H7DC*C'.5%VH2RF%PX.@>[-QT\=VLT2$GAK^G&WI?7RUFGU
MO.0@WN*][U<URN5[W.>JKY<Y5W<YRK[JJJJJOONG&=/Y1^@8.P:]M?.XT81D
M#L+'SUU^FUMN8CH[H[E>1T98\F!.N*IYAM'ZF!*FUSRL16O:-3QR 5PW%:U_
M0\G:W3K<U7<%A!#D/9P  ^Q;0\O9HJI+@$N /JP#Z:6=^8T ,?5_]G+S@2=>
M*D^B>M-I%N\NI:Z*_"I\X!VR\LJ(48Z64*Y.BNBS;2N ,#QED,&>QBN,4C3R
M8Y"/Y.*X938I2JDU$E,V4I*D39*FR39:TY5RUAF"9B"4*+6<EC=X0O*06T+^
M>Q\1Z&)::K7?,K@&;F%HAH]39OAT:'5D'2H.AQ>'(&^JL33Y$?*I%D^4EM\=
M#652U2X^\ Z>9,M6R6R(@!R=.@P3"L-EI11X92T\M("0)*DRS* &@E]FI4\:
MAPN43;4AC*Y\]=C.5EW22>]?<.Q&@;[1C1=8N<6R7TIN73'\.4!,C":<3,!9
M.&2(&-YR2CE1&C911X979;5X7"D1Y;Y8)=;DCYL:4&/$EEB=(JDR)94XER4
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M=33$S9*BL=HDBRI<Q<M8#$@Y5H4DW!!!@I#$@BX^1OHPXGB\>U;IKJ!=N_\
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ME5$1S4]>J8@LQ<"S!W-@S\KV\[WC 2_D!USZT>.C^O7V0>!YI@,6DTFU*R3
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MLB-,42M9+595='*PQVD,)1JP;VL>1K]OX9^&\,P^CH:R322Z?$)V'T:JF9*
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MGPB3UOMPCG)J+R5\TFI66:EKD4W3&QPC7C4[$,XR6GOZN3F55A=?IQJH-N)
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M>S7(U%V1%=61&JOE=D<LC9-_=6^%W\<:4T!592#*H&2)TQA<C,@RW60+)47
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M!(TAP<;<887"$"_5_'I&0X6;T;3$G4-K393$CQTZC2WT%@&>:(-O\1)4-DD
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M)<PU 0 Y,NE@H*HBE5SAR;FP(R)5C,QBH10-E'::2C5ZO3A,Y%1$\0D"6A0
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M'G??VXE;6<&]@;Y4G5U'0"VI;Z13P:P_+9SR =R>0!\H FK>$:=ZCRL5@Y%
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M'/6WFCTLY?[O&J'40]W$F9=B.I&841J^K29!EQ-+X5%89!4NFODQP OIL.^
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MJ3+L<@G.E2&[K^S<2.^)_51]2]$5$;'8BJUHMEXHC!*0$3)T^MJEYLV:HF(
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M]>H_6H 7J5CHYHO4(Q$,HD>Y[D&K]U8CE5R-5-UX]5($XRDB>):)A S]BG*
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/%PA"X0A<(0N$(7"$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g752656g05q01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g05q01.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2:B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  Y$<F]R
M>2P@2F%S;VX@3!P"-P (,C Q.3 V,#4< CP "S(R-#$T.2LP,# P #A"24T$
M)0      $)%+QEI:[VD<'\QHCH/!2L$X0DE-!#H      .4    0     0
M    "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M    26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R
M:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M8@            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 !
M \     !  $X0DE-!"8       X             /X   #A"24T$#0
M!    !XX0DE-!!D       0    >.$))30/S       )           ! #A"
M24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      S4    &              &!   #)@         !
M                      $              R8   &!
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   &!     %)G:'1L;VYG
M   #)@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   !@0    !29VAT;&]N9P   R8    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     TX0DE-! P
M"R     !    H    $P   '@  ".@   "P0 &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( $P H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M7>G[7LV_X2MZLJ37/Z]CM]7(;=2T%H#[&!H!:?T;6[F_F./YJHO>YY!=V :
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M))3M%22222E))))*?__9.$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(     $DI-30 J    "  /
M 0   P    $#.0   0$  P    $!DP   0(  P    ,   #" 08  P    $
M @   1(  P    $  0   14  P    $  P   1H !0    $   #( 1L !0
M  $   #0 2@  P    $  @   3$  @   !X   #8 3(  @   !0   #V 3L
M @    \   $*G)T  0   !X   $9ZAP !P  " P   $WAVD !     $   E$
M   1[  (  @ "  5^0   "<0 !7Y    )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C V.C W(#$Q.C,X.C4X $1R;W)Y+"!*87-O;B!,
M $0 <@!O '( >0 L "  2@!A ', ;P!N "  3    !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                               )D   !P    0P,C(QD ,  @   !0
M  FVD 0  @   !0   G*DI$  @    ,R.0  DI(  @    ,R.0  H $  P
M  '__P  H ( !     $   ,FH , !     $   &!ZAP !P  " P   G>
M #(P,3DZ,#8Z,#4@,C(Z-#$Z-#D ,C Q.3HP-CHP-2 R,CHT,3HT.0 <Z@
M  @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                              8! P #     0 &
M   !&@ %     0  $CH!&P %     0  $D(!*  #     0 "   " 0 $
M 0  $DH" @ $     0              2     $   !(     3A"24T#_0
M    "           _^$23$U- "H    (  \!   #     0,Y   ! 0 #
M 0&3   ! @ #     P   ,(!!@ #     0 "   !$@ #     0     !%0 #
M     0 #   !&@ %     0   ,@!&P %     0   - !*  #     0 "   !
M,0 "    '@   -@!,@ "    %    /8!.P "    #P   0J<G0 !    '@
M 1GJ'  '   (#    3>':0 $     0  "40  !'L  @ "  (   #P     $
M  /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#8Z
M,#<@,3$Z,S@Z-3@ 1')O<GDL($IA<V]N($P 1 !R &\ <@!Y "P ( !* &$
M<P!O &X ( !,    '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M      F0   '    !# R,C&0 P "    %   ";:0!  "    %   "<J2D0 "
M     S(Y  "2D@ "     S(Y  "@ 0 #     ?__  "@ @ $     0   R:@
M P $     0   8'J'  '   (#   "=X     ,C Q.3HP-CHP-2 R,CHT,3HT
M.0 R,#$Y.C V.C U(#(R.C0Q.C0Y !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    !@$#  ,    !  8   $:  4    !   2.@$;  4
M   !   20@$H  ,    !  (   (!  0    !   22@("  0    !
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M==-M6(Z18;3X74XCBV/44K&:,8AARIT^>144AJ32F>DR]L;*5I42Y"BD6#D
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M8[B?1Y:KA-%%5=9<J2"")UU53JF*1)-(GI%C*'N!"%23*<YU#&*CU$SF])8
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M&GK" 0   1$0 0*8!M<MC:E^D540L)+' 0$;@   =8Q"F<+<>SP:]X0Q(4!
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M^TVX$6??<Q6FOQ11(35SB0F8I@;LA!6-,ULR1OS81""IQ&W6*&M@&P@'>(B
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M7N*D24A_^#FSFQ#=I( ?@_#.*/RAB@ /UN=<$EG.P0_LJ]G,Z,XOG$(JJZ6
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M'_)CS^49'Y:KO\97_IQBW-3]:&9&O^?M8^^H9'X8\4>F9_XW]++?^7\9W?\
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MSV=<MQECE46=K$!J1%P)$694!:M@3/=(Q1 ,54U352YLE1*B%&:%!G!V-H)
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MTGF1643E]3LW4L+6#2F(JD&C%VHQC*>%19<T\:/2D!5D'KM0P,%GBY2J-0;
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M?4/=MR^&&BOLJ)UT.9[[^EH@Z?:3V^\-;?"-MN@L-^DYEX/_ ':L.W_,R?\
MNOQ'PQ]K_@^V^E_HN/\ T>-Z-_YL8GV;MV@WQ@8I^@[P'[%GA\>ZT="?E5/Y
MNCIA?V)53^ZWQZ61ST?FF:7-?NW#:_VZ\!#VX0AWWWW"X\[^P TMKW:CN*$+
M3GKW:V'M*(\==AW"P<,(0:<0U$>X+Z"(<_;<.(;V%"'>X6OKMK\>8W ;<!'?
M37"$=5,L_D?ND[FOEA%9P4M7G1C3HB1@*8J)\]F<^*:C'-*MJO;MU8%E6:!F
MZA*6EW1U_5"QLJLW<"]34:I@HJ !A".:-:4G(4+5]4T7*.HN0D:2GIFG)%]
MR*$Q#.WD(_<QSMU$238?1R4<LNV.9D\0*9)TDHFHF'T^KA"+7$>K8 MVZA?0
M?1CIUM@4N0>MU+?R9@ 4UDC'0@,.UP-<;#;JB6]^J!;=<" /7ZY 3 #?2!5$
MPB4%DS'0C,>7V0N9^9M YM9H4I3X.:$R1A8&<S&J)T_9,&4,A5$TG T\S2(X
M7(YD9&6>&65:M6*"_P#@;)^Z6432;W.A%MYC4&KEQ4)*=4JZ@:W,>*BY0)S+
MBJF=64V 2C0'18\TPV300++,0'T,DPZ@G9N"G04,*J9BX0BP0&_ VP 4?SNL
M)A-8 %(3AUA @&T$;@8I;]?K$ _RA$10$XE*7Z1S>C I0 WTC'.!"$#Z.ICF
M$.J4+G&R@B4/1' K?R\(Z14%\EATEJ_S!5RI;3N2=)9C(T9EA6YZ5KS-2)I>
M9]#FU'JR=)P#1J]:F-(U:1LFD:4@8\7KB.4>L2'%91P"81IQW<6RA'0HV1?R
MO@3%,=!B%SJR(J20GLC<P<N%"TU)9*U)55#Y)T-*4_$U+EQ6N<+?+XV;%,PS
ME]5T9"1E)O:G2&3Z[J+39-T&KEVUGGY>7=Y1''<^7.OK''?*CH8=(G.O/^H.
MC3EY0BLKFG2$W4T36C)Y),8>$HU*C)A2#JF;J:H)=1FPBX2&?$4*LZ6-ZT\,
M";>*9/GR[9JLB8S?FU\EYTH<FWF4BE1&RLG:/SHS'@LI*2S-H3,ZGZSR\;YC
MU&_%C$TM4,Y!BX>0SUP( Y,Z6BSQA&H**"_%5L\1;HA\^$:09DY>5;E)F!6>
M5U>1AH6LZ J68I&J(I0Y%/4IJ#>K,'Z*2Y/Y-TW%5+KMG:(F1=(&371,8AK@
MB8LK3;M$ X#III;?@',0TX:H0N[D-P&][;"%Q&V_'[+"A#]O'A?7@( /B(VX
MC_HX0CU\_P %[_0GIH;_ //N2=[[_P#-F:V_A;$I]X?:#-VCS>*5^XK[*O0Q
MZ%^EK^H.I?Z72_;_ )R1W$-_9?GC;X%_?:F^V=&T/+:=\<9](GZJXA]NA_M4
MB./!#&3$IB"(& >L @8Q1 P6ZMCD$IR<P,00.70Q1 0T^AJ8DO8"PMF'+V[>
M+=IC\VH6JG8R@2?>=(N,K6Y\8JY*AJ!&05E49F6))KI^@5D22;]-^LA_)616
M?I. >+(_R")127553.0@%.40*&,=<NDL)L@+869)"0ER68, 07.[7.\9\C&<
M81/$^5/F))&RM14-M6GM$W9B V5@,H;BHZD<E53<5!-+D72;(K@M*/E"*H-C
M^E015*982J)ME+>K%$+(% 0)]$1 (3)HU%D2=A1R+-?7A>XS>*JS$\;K%,JK
M7LD!_;L0BZ7_ '@,VNVD2U9V>7%T*\W*N!?))H//323PQG+=&XH-W1BK@+I!
M$3&%-%QUTD] *341&OZI)L2$L,MP[._<VO9%DXAB\P*E?6ENH!*_;#+ T5EM
M#)A=H2DU-KLVT>XEY)PP9"0[)BN_=J,VAR (%%LW%;T;42 )B$.W!,Q2G.)1
M*-L1]4D DC9=7O'4]IS+<8OKQ;&)J$29M2K8ELE(VALAK.P##)W !CY';MY(
M.#NGSQR]=*]3TKEXNJZ<J>C(4A!4<.#J+*B4I2E#TAS"!0 M[  8D29" 4V%
MW#$L!E;0991BK-;-F==,JC,F'-2E[1+"SFZK6#GPC[%9V>73437G)=9-9J@Q
M735D7:J:S-!03I,U$U%3)JM$1.IZ%J<@HE$P")1'%(HI3[;"Q)!8."1>^8?L
M^,7EUV+JEJE"KF%*MA!_.,"B6IPE3YI#>Z;:,T-S.3;QNLT=2TDY;.4FZ3M%
MS(/ET7*;0+-2+)*KBFH5J ?X-Z7TJ:'6$J:)2@4N HY&8"7NV69W;BK5K]L7
MI]?BTV091JU*]D O,!<)'LB_[K^R^5F(BYHUKF5.HP3B+"KI9LC)"QITS=Q(
M*H-)1DS2<>@B1,N4Z3QFP](J)F8-S)(*&3OUKIXQ"K"I*E!4I(.:@0H$N=ES
M>X=QI<1GTR.D-0953+E8U,2W4R]FI5L[:4)/YM)J+%F4  ^S=Q%PM<L\](Y^
MI--*3S"8RKDRA5I!JVDT7ZIGG5,J8[PBA9%45U2IIJ',NJ10X!<5  W5MU-7
MA4ZC"$&4DB>QEG@E)VF-F+B^=M&C(3T<Z9T/6XAALO&4U=2HE<D5*.L73S+J
M42J>002%!S<$911(6"S0-4$ZC ,:Q+5$=ZT:I!CSRK:::)G5Z[Q236050?)%
M772.L<RRMS&2*-U^LDL3)5-PP2Z=4\H7**&8@D*.S[+9!5V(X<&C'IZ+I%U\
MY-%18PG$UHFJK)XJ6*%,KK4J4:@I"B0I(R<\7BH,,O<Y)6&*M&TO73J F54Y
MTIV;>0.PDE7R8G3E[%,*2ZZR*_6(^6*HX&Z:AE1&PELS*["$*(2A.T+,=H%B
MU@^6F>; GAD4V =+JBBG?64XR2MRG_A090&64^[Y/Q\+6E/RTB5S2\LI4$<Y
MJ5!\S5?.G;]%S--&9R,'[59Z*WIWB*"Z9&3M%P<Z:9FZ9?1"F)<790IIK)2$
M #94$@#V2?:%L@64X9G8EWSU,Y?2"EFS<5FSIJ$XC*_)X6M2-I?5CZN0HAR2
M-AE7<GRI;*=G(U!LU93,FS;M'!W;9%I(NVJ+9RHF9,[AN@DKZ)!8Y#F(=9N1
M!0Q2V$WTSXR31R57('M  NY<;CGM![L7%]\8TBNQFDE"GEU2PF6M2_94!LKF
M .I.1"F;W=(EL9>8BW*CV*E)"/>KD52<.V3YXS<JE6,)U05<-%VZZH&/](>L
MH FZPW,:X]:#2256(219@;@D&Q8@WXC4>%:*O%*:8*F35*$UE E*DA1$RR@2
M6)S[3ZPC*2H(.6Y9)\1N[<>NNVY7*OH';WK&4!VY2OZ%9P582JE<G0,ND<A3
MD/Z4#*&GZK*)<[).AS(=K7;-AEF.P077XI/!2NK6D+(*D=8R"4^Z6%G2[A[B
M[7L/L7J2HG*:A%YZ97(JX;NE4UY5^L0SIJ"14')@,O<[EN1N@""P@"B8EZQ#
M%,4IL1]4DAO=&8 R]DE[96)W&VD5JQ/%EC9^N++D;1ZP':4D;(*B<U#($N6R
M-K2%9J:<E?$<R<@Y3DE$UWY%Y%^J5\X1T15>E46-ZX=,O5%,[D53(G"Q+@ 6
M?5)-FV UAP'J P&_L+13]?Q9.V%5<P]8HJ6\P':9KJS"E/D_$ZN)JL_42SAD
MZ5G9E9Q&E#YO67DWZJK(Q;@46JJC@RS4"@.S=5,@?LIEP%))%AL %]ILB]G(
M8.^O#?E XGBI*5*JIBE(8)45N4@%P$D^[LFX:P)?,1)&7F#% II>2 H2@3(%
M!ZY.7YV  *$J!553=63(4!*1]<SSJFL+GJD3*0:21ILDLV@MN?=J!QB?REBH
M&S]:6VUM@!?[9'OL+;0U4P.5VB1(2+^5="[D7KQ^Y%(B8KOG;EZMZ)(#E3**
MSE51003 QBD ! .H8=KXNTTH29ZD@ !,M18#ORR&_M [8Q*ZNJ:Y2E3E+6V%
MU(6I9<G914#,WSRBG8QNN'\[_H_*.98[CX&,5YJV_C0S(_V]K"WC44AK;7C[
M,>'_ $Q+],.EC?\ /^,^ Q6H^^V[>[QZ)4G\61;]D:\$N.\;OE%@[7'81[QV
M[-!]G8..9W:@99#YC*]\[C,7OYL,P.P9\;CQXB& ZCV=@6U'3<. !B)B4S"E
M2A=@'22EF _<(\[VO Y [_D >X[MVX07N/:/ +:<_L'\1Q6"0 ,PCW2OVR-6
M!6"0]CG;5W@7;@/.S#RO^+07L'Q#A[]!\\<-M@IP&4%D% "%%2DE(+H90<D
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M )0"/=V2?:*RY)OI';XS4U5'A'0[\FU$VG15IGFL*9BU*FK$W96=I949;;
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MK"2;JZM%\V%MGW0!9V<DP!XWM;?A]^*&''Q/SBG9#O[3Y>\IO!V\GA^W7O\
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M > !A" 1XAKIRVWN-NP=+\+ZWUPA!<.0B.H::WTYCROO;NN&$(./9I?73:X
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M^?/+$%_A]W'U[A$<\[XAU'CIW" _$/AB3O9M<P1GI:_.Z*CY]H(]"_C#\]_
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MV\=O/L#;%R3^FF_Y)7H. YWYQCJ_E_Z+J?\ :(E8US#<OP$:)U;QXIC%>:H
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MK+;SX#YQI'/[P_TA_NQBO-7]:&9'^WM8AS"_Y12 <!M]?OQXC=,OUPZ6V_\
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M/7U_!?/T)Z:'9.Y)<;__ %9FMB4V4/M VMJ.7BE?N*^RKT,>A?I:_J$J8/\
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MM8I\>7C7XB/^#]X_^8?&QCH1\JI_-T],+^Q.J?W6_+7'IA'/Q^:7Q'3C<;"
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M4IF-?E7CUB+/X^*I"/DUFL@Z1>29CK/I$RK5R#HS5LB51  . XK J#DJ8Q*
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M/"(@PA!A"#SWX0@PA"\[<A\V]H80A^?N\\L(1+#0>?T1X?\ :'ABY*_3S/\
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M/._P^S3"$&$(JZ-/SS@#&0A)=<"=03BC&O% ("A 53$PD1,!?2)B"A+VZQ!
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M!-A<Y  NT1LB6=HZERW=;Y[]^HMM6M*-;LGLDXJRF$8Z-?C%/Y!:=C$V3*3
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MXU-D#G+2#FGF4UEW5(/*HR[@,UXEHQBG$NX/E_4Q'"D)4CLD2D\]28ODFQW
M>N>@6:)&33?)M7!5$E$(M>(RZK"9<"W+3\VQ2+'H2CB0=04Z+-K&OH]R_BGZ
MYV48_7(VF4D!"%<':"TD3F*9)P9 BQR(12YBCJNIYDPDJ@I6I(&.E@,,4^F8
M*4BV4D!"D4,+%R^:((.^HFHF8WH#J=0#E,8 ZP70BV[["-K<=M0]P\NP;[<!
M0@'6X (:;:CP >/L'@&_(1PA &P?G &G"X;Z#QWOL :#W:(1Z^OX+Y^A/30
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M0K[>S34 \[80A!^=_NCS_P!(?/+PQ<D_IYF[JE?U4[M,FOEQC'5_+_T74_\
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M>^K]T7I>_P  ]X\;WM<;<]\<Z4I"CL*V_<VG>RA+0A0)M9QOU8M%P@C/3O\
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M?H5TT?Z]R2[=XO-;$INH=H]8I7[BOLJ]#'H7Z6OZA*EX_P"%TO\ WECM<;;
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M99;N&K?-O'C#\/-O//$:*R'L*'EX:7RWQ&H^TG^L,HVVZ"XWZ3F7EMO5:O\
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MW0I&3$UL4V%$; EK5>__  B:;@;)#F9D0FZ<M6>+AQCI9*4)ZC(EEI8"CA5
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M_P#$\]<SH\="/E5/YNCIA?V)53^ZWQZ6QSL?FF["/:(; (Z<]M[ZWVY7VPA
M !<-.T>5^'(+Z\-NT,(1#IRTVORO<>>MM.%_=A"([\A"XA>X\OJMKIKS'M0B
M#6V^^N_$;\@O?3GPMQMA"'XWO8-QOK<;#PON%A$>%[!NA#&X  V#M[/-]^&H
M7$1OA".C70#RBROJ%;,3-W/:EZ1JS+"CC4?EPR@JYS%I/*^)>55FG/(M9.;B
MYNL:JI&/DIF@<MHVNZTB8=K(*.W%1,Z<.JFBW/B+>!\^3X\81?#KY/ZBJ,G
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M0<//W80B /SM.0_O#Q[<7)7Z>9J>I+EOYH[.?&,=7\O_ $75?[1$K&NOO/\
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MN@%\P->&MO6 1(".J09@)(-MMBQ>YR]/F^J6WYUOH@4! Q@$"A>Q0']D OH
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MX:^'SN;-WVDW%CF!NYOOC;;H+#?I-Y>?T:K_ '49/]GMY<,?:_X/O^%_HO\
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MW-_O  .0:7MKYL/9[<"20IS^RJV6A;MMW]UX.20Y_:0]L_:#=NEXVXZ"X?\
MI.9><?\ !JOU_P#!<^/?]7/77'VG^#[_ (7^B_V,;[O^+&)_?X[K1K\4?J-+
MD/JWMO;XQT)^54_FZ>F%_8G5/[K?'I;'/1^:6-OI;<0$==Q[+WT&_9QMIHA!
M_P"Z ;!W;COO<+A?B/MPA /'37CKQ'30-;[VORVM8,(06X#8 UMVV&_'A?70
M0'OWPA!?:UQ'EIKN(?&_*W(=D(-!&]N^VV_'7781[@N(6UPA!QY7Y#?6][#M
MJ&VG.U]0PA&Z.5G0.SPSAZ/0=):BSTJ\R^;YYT_D1,LC/9H:HIN;J3\GD&=6
MSD:V@'3!.@FDC5,+%24DREG,XRD7Q"*00MC>LIH1F^I_DF^D+1[URO4U:9-0
MU$PJ>>KRN,T9&HJP9T!E['9"YA*Y85 [J>2<T$C)G<UA5(IM<LH* AYVI*K.
MHW(,,BLD\;BOSSW^3PC2Z=Z-/2$IRA$LV)7)#-MKE$_3BW41FN\RTKN.R]EX
M^=.0("2C*MDJ<8PZC&?3<LSPQG"Y%'*BI4NHH<#$)'K?G+33?"-PF?R4W223
MJBC:7K";RORU)5&0</TBY^?K6=J1*(RQHRI*OD:"@(BORP5'SLLVK"1J=B1G
M\PTU$5*G$@^:#.2K 64X2.GG[LX1AS(OH,9P]([-C.[)K*F:RXJ2LLCJ,KVL
MI+YOJES*P%>LJ FF5/.H[+.H(&'F6-2RM1R3YL%,J.C140^2<(*+2+05D$ED
M(RI#?)9=)NILOZ8KJEC494[BK*1R6J^&H>)>5,2N?5,\\P*SRZIMB_8R-)LX
M9@^IZ3H:9EJQ4=S3:*A:?0/)%DWWHW*+5"*1!_)W53*R59F>])#HO4S05(YF
MQ62:.<=05A7R.6-89Q24:25=Y?4/*1F6<O.3"].-5"*5'5;BGVN7\>B=H\_+
M%1J_9JN$(JK;Y-*OFU"-Z_K?/SH[Y>1KVK\TJ*CV,N_SDK-Y(2V4$RG U>XC
MY;*#);,ND',3Z^X;*0\@M4C9O),%P=D4 B:YTD(YP;:B.FM@#3B/.WVC<>W"
M$(0T';;N'LXZCIR#LY80@#;<0&]KA[;\-[V[=.S"$(1U"W;;F-^W74>RVO:(
MAA"& VMOMS#A?;<;!K;PN(6PA -K:!L-QX!?F%].[PTL.$(]?7\%[_0GIH<?
M_+N27_"\UL2G,:>T/6*5^XK[*O0QZ%^EM^H2I?Z72_=^DD=Y]F-M@/\ ?:E/
M\XZ_S2]N>Z.,^D3]5<0^W0_VJ1''D/J[_?\ 7QQ]#5[ROM'1M>;1^<QD.P07
M\Z:[]W+%,3#\^;^>6$(7X]O+S[,(0_/GS]6$(+?;A"#"$'OMY\^W"$&$(,(0
MK]H80@TVXVX\OK#"$/SY\\,(080@PA"[?9KA"']6$(/CYOA"#"$&$(A#\[73
MZ(\.T;<.//QQ<D_IYM\Y2NZP_"[9-&.K^6_HNIX?\O?X\8DXUNT>2KYQH>]/
M^C__ %C%>:FF9^8^@_IY6'+_ *PR'+3\,>(G3*_3#I;?_P OXP#_ /NM1S]S
M1Z(4G\61I[(]$=^F[6+#\^?/OQS-_$?=KX1>YYY\H6M^SX=OB/G?$L.-QNSR
MT?OW.[9")LW'UX=PYR@YWUTY?"X<>(7'E@.[/?\ $6M=CJ]H;FM??ZL=-"PW
MP=GAOK</KTP?M!W9 <.QG\3F\-YUSRM=O)CZ0:6]_P!>(=VRW9? > 80U\M^
MC?A /GA:]@Y;\N^V)'=OM?+*[FV]VL'S@.=79SORW]CP7VUW[-^>F_?RXZ7P
MWEM.;LS\B[&#9VRXY;KY=F_2[0#S^H1^'G6_.[>[EKY_.]\^-AF1#AX9#3CS
MD-0RYV[+#;A\1XCXAA=[]X?LSW:#@V5HG<_%P^OH-!W&'V=;X7\Z#P^&'%O,
MZZEWX:Q''9]6YN-?6%RMV=F@Z:?&U_J##(D$VR[Q>_?9VO?B8G>_'C<7OZ.W
MQ,.XZ^',?LOWAXVP:P/:>)XO?P.IL[VAA;OW#YMV'N> .S;SMV<?-L#QN=_9
MYOIIOXP/'/G/CIR\&_U?#OXZ[< YX99AF_%G'<V>;Z"&7Q]>S2V>IW0#M>_V
M?5\?LP&;'[][#,=KCP@,V;Y_'T^< <//=M8-NS[X-]+_ !UL;^?W#KSVYN<^
M/W'+3VZ^=;<_KPWW[&RSW=YL6^;??PMS9]WPA#K;:_;:W;V^SQQ(MO;>+%K]
MV>]^$2+/FW!WX</'N@MOKW6X;ZAJ/NM@]LNU]>VV\.;Z^!\K=KZY6-AYO##C
M[N[W^WV:6P.1T9"O0]@?*WC=XI.EKNFW':&>7.=WC;?H+"'_ "G,O.?JM8>Z
MC)\/>./M7\'VWTP=%Q_Z/&_/HQB9Y_%\'%/T![1_\SP';KE'0GY53^;HZ87]
MB54_NM\>ED<['YIEAZQM!]W*X<^SXCK;"$&FPA;ZA$- \ $;WXZCOA"#AIQV
MVYZZ#[[#;GI:Z$ ;<;!P -[^T.-NK[>6$(!TW"_(=N8[A8-[=M[\PPA""W/7
MF%M0'A81"_VV\4(! =QO[QML-[\?"P7XVPA'37HF_*+2G17RWRPR_BJ'6J%C
M2_2"JC-#,1JO,-$(+,C+6LJ)IJC9O+5Y%KQ+P[%XG^3K6:C*@%PY%A+LXIXR
M:M3LBV<_,PC9NLOEE1K)=G1$KE%,/^CM5LUTJ5\\LG9&L8ITEF+&=(:NY:M*
M7<L)L*4(> J[*1Q()+TY4:;150TJ@9X@@S0<.&RKGGGUL;QB]JI^4XR2R0RY
MR.:9(4>^SAS+9=#K([)^<9YDU9(2F1U'J45685HY@:KRE;T[3,A4M?QCR,8H
MNZCA:WC*96;2)B1K-JZ!X=TYO]_:S6@WSY]>V+:0^6J5E:C@I>H,B5J*,^R3
ME<L<QJLR"S0K++[-5Y.+YORF;\?+T)7E7OLR5:=IQ*9D'",G#3$?4,Y)+U#5
M+H]4$8*04)"H1II3G3ZD*5SUZ9.?5.T4I2=2=)ZFJXC*2;4M+-XY#*NH*GS(
MI7,"'GT5/FV\L> 7IL$Q;MB1/KKY;UPRJ ^L LY\(1NC6_RXE<OH"5DLJLNG
M64.;,SEIT?Z.>5C3T[#KP*<[E9F57.8V8$BTIA>EP;MJ>S+6KE_#FIX#F1BH
MP[MF91XR<%:IH1KS4O3BZ*>9!*XHK,7HJULEDM46>K;I-TS0^7.;L+2$K2.:
M$W2[*G,SZ2+,OLNJA9O<G*T/',GT= 1\5!U;2OJWJD76'H%R@W<\_AXPBOTU
M\HQE4RR1A,F$Z7Z7^25/TU6F==01%/=$_I9%RFHY]3N;<^SE6%)5I&S^6M<2
M=;M:+C&1(.*?RTFFY<LG<J*P%4DCJ)(1R$5%,55!1 Q414.9(%#>D4*EUC>C
M!0P 4IC@4?I&*!2F, B4H:!A"(!$=[:>(#S^Z^XCV#;"$+EIV<[#>^HC;GIP
M$1'>P70@VVX#OP#WB-MM-M->("A!OQ !V"W/AKKH(7Y<NS"$(+[;AM^=MYY@
M&U^&H(1Z^_X+W^A/30_KW)+_ (7FM;W=_?B4'V@=RAY&*5^XK[*O0QZ%^EJ%
MLA*E_I=+_P!Y8[SV!;&VP'^^M+]H^AUU[/G'&?2)^JN(?;H?[5(CCR&P<]/J
MOCZ&KWE;MH^IC\YC(=@A^.F*8F%YY?#R&$(>^$(//X>?JPA!A"#"$&$(,(0>
M?/G7"$+;SKA"'Y\\,(080@PA!A"%Q\^?L\=$(>$(,(080A;>0\Z80B +W'_5
M'8;".H^SM#X<+DK]/-_R2F_T1Y-D8QU#]-_1=3Q_Y?S^,2\8&T=X\O\ ?C0L
MG?YG_<C%>:OZT,Q^7Y>UB([:?XPR-N5N.H7^O'B%TR'_ !PZ6?T_C/&_Y5J&
M#7X6XY1Z(TG\61O8<=$?&+"\]M_ACF.>#>1^/E%[G@WK!R\W\^1P>YLV>5N[
MD;X;^6YY$ >_3S>P7P/=KEVZA[0/E?EG+06UX6\[>W?3QWP?>_.\]P87W\(/
M;5^<_#*_=E!IM]V#D=^_GB1N\++Y_?!KKS#;D/OQ.@?(^-C?LWV^))-EN/)T
M@V]O+S]P:=N([C;3OYW7-MT,_#?S]YOP@\0W_#\.>)/ $.!X:^G(,.XY?C^.
MZ#;S]6_QQ3RQ^=OA#/GXY>D'D>[S\<5!F=[W\6MOSXC31KN1V\^D'Q[?NQ![
M&[/-OEX6,/3A]\+OWXAVA8?</*X:\\2;/\='?3B-2/A$FV7'NS'B1O8VAW_
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M'7?C>X=E]0OQWOA"%:^_6'4;7$3 %P$P@F!K]0#"("8I  #=4HFOU0PA$6G
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MCPPA!I?CW:";CSUV -./;?5"#6VFH:!N&]O.@B(@(!W80@MM?WCMOI<.' =
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M S//[2HBQ"<CVI]8@9'[?Q$0E_:_UAQ&O^;_ -B*AD.P>D,=O$/B& R'^?\
MU1%",A]H_P!4P\5:#[2?ZHBL9GM^ @Q S7V*]8A7_95\(@3W3_\ O2_$,53/
1<5V19U'VD_UA%;QA1T$?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g752656g07h45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g07h45.jpg
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M Q$!_\0 %@ ! 0$                 " <)_\0 '1   @,! 0$! 0
M    !08$!P@# @$)%O_$ !<!  ,!                   ! @/_Q  F$0 !
M P($!@,            ! !$A05$B,6%Q A*!D:&QT>'P_]H # ,!  (1 Q$
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&?.GE?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g752656g13f27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g13f27.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[33J4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #\< 5H  QLE1QP"   "   < E  #D1R;W)Y+"!*87-O;B!,' (W  @R
M,#$Y,#8P-1P"/  +,C,P.#$X*S P,#  .$))300E       0W^ZS;NEK 9>3
MYKG]*T%7,CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              4@   0X          $
M 0             $.    4@                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   4@     4F=H=&QO;F<   0X    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      9>     $   "@    ,0
M >   %O@   97  8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ ,0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ [ZSZV_5VNZVA^:UME%AJM!:^&V!QK=6Y^S9NWL<M''R\
M?)I;?0[?6Z8,$'0[7>UP#O:X+#/3.H9&;DOJZJ"P6$,/V2AYKEYN?C-N(]_I
M?HOI_P#G]$'2.O-8ZNOK)J8WVTMKQJ0&M ]LMT;['_V-B2G4RLX46TTUU/R+
M;7M!;7!V,<=KLBW<6[*F?]/_  :0Q\Q^[U\HB7.VMI8&#:2=C7>IZ[][6?2>
MU]?]15NH8Q?B665[ADL:7[ZW.JWV-;M_2^BYKNW[Z;'Z=BY>/3DTY.4VJUC7
ML:W(L VEHV_G;OHIVB=&W]B_=ON:?'?/_1>'L4++,K#K?=83E45M<XM8PF_0
M2!772-M[G?N-KJ5Q)"^Z+:0ZHPN.RFRVKU32VZG;:P[=HM>[T7.=6VF_U,>Q
MMGZ3U*;/8L#I_P#C&Z7U#)IJJQ<AE=UOI"UVR&R0VJVUC;'/8RQW^8LWZ].Z
MKTUM=E<_9K_6;=F8\U/#'6MR:NGMK:_TOTD/^T9/\]E?\%^D]3B<-N)@L-E3
M_M <(%=8EP:?;OL:[;L;7N;O2-=$Z/M]&3C9+"_&M9<QKBPNK<' .'TF$LGW
M-15P?U$S,;"S']/-1;;GG<Q[!#-U37/?O;^;N9^<N\00I))"=8[UVU< M+R[
MQ@ANT?YR2DJK9.8VDFMK2^X@%K8(:2X[&[K8V,]R*7#\XZ?&%6NQ\4&S(R-U
MOMX,G:UNU^RMK?S=[-_[^])3#)ZGE4W655]-R;]@!;:STO3=(:887W,L_.V^
MZK\Q6</(LR,=MUE#\9SBX>C;MW@!Q:QSO2=8S](S])]-$INKNI9?69KL:'L/
M'M<-S3JHO=>=:@R.VXG7_-'M24E0<B\T^F159:'NVN-8!V"'/]6R7-=L]FW]
M'ZEG_!J5=H>YS""U[(W-/@>'-/YS4KW5-HL-VM08XV Z^V/=_P!%)3A9W5*&
MT5/ZMEW=*]9EGHNK_1"P7^JVEAKM9;E,S<''95?D?HV5XV0__"L6MTG,KS>F
MXV56]EC;:VDNKL%S9B'AM[6L;;M?[=^QB\G^L?U@MR;Z!313CU8M7IXN.UI,
M4:-:RUQ_D>WV>FM/ZA_6O,Q\C$Z4V@6X=[S6:*:]KZ;;'OM=D^I/Z;%_TN[]
M*SZ?^#]-$F_))?_0]-HQ*\8V&LG:]SK-FAASB7V;?Y+WG?[E&VYE0&XADRZ+
M#MTY=_65I!R,3%RFM;DTLN:P[FBQH=!'YPW)*<W*8[-OQ\;9<<:\/-]S)8PU
MAOT-[3N9ZS_39_IK*_Y"NYN?@=)QF/O(IH!].MK&D@;6NLV-96/;MJJ>I9G3
M\?,V.LW,MJGTKZG%EC-WTMEC/S7?GUO_ $5G^$K5?"IRJ:<FSJ=IR-SR*VN#
M=*F?HZ997%7KW_SUFQE?\[Z>S]&DII-^LG0<FAE[[&V/L;8X5O:\P*6^KD-:
MSTW?S3?I6;5+%^L/2'W,KQ+7$AS*K,8,<=OJ/^SUV-]OL9Z[O3?_ (-77L+0
M*Q9JR QC'-;M 'T'[FNW>T?^8(F*'^H]MH8',B&LU&O=W[EB2GGNN^E];&4X
M?1LZM_V:P6Y5+@\,?6YKJF_I/3^G2YWJ;%PW3L#+L9=:,6^CT+/3M8&N=M.[
MTV>IL;]/=^8O9  .!"Q?K)D68_V5U5N71:7.#'XM)O:20VO9D4_S;OI_H/4_
MPB2FC]1^G>GCW9F1C/JO-AKJ=<W:[8 -SF-<-[-]CG;_ -_8NI7+X'6,S'R/
MUK]J9S2"P,=@MK#2/<;7/J:SU?W/8N@P,VGJ&'5F4!PJO;N9O$&/ZJ2FPJ6/
M1DMRLE]_O#W U/!T%<>VIK?S',=]/_2?]1=224A<X5@EY !.A/$=E4S<JREK
M!2UMEES]E;+#M&YPAI)&[;7^<[VH^7BW65!N'<,6P'Z>P/!'[KF2S_JDF].Q
M-U-MC!;?CR:[GZOW$;'V3^\YI24CQ,%^)TJO#+S<^MFUSCI.NY[6C\UGYE;/
M]&GS<?(R?3=CW>FUIDQ^<.['?R5=5?)KI@%U37O<X-:".Y/)_JM]R2EV-W62
M'&&-V2/&?_,4K<2JS$MQ=6LM8YCB#K[A'TB@VMPV6-::PZSEKOSM/W'?FHK*
MRYYK>\O%1!'F#]%MG[^R$R0UXA$2D/2/#B^;5-'KH#J^5#I>5U&UV'CTO=D5
M[A91M >T,,.%F_;[6O\ Y2W?J9T3K?2?K" _"->'9CN&1?9H026O8VIS7;'>
M]FWTUT_UBMOK^S?9_MPM!>YK\)@M:-!7LR:K'"IV[U=]/J?GU(/U?R,F[,NK
MOR,YYJJ:[T<RFNJ!8YVRS=2T.LL_0O3T/__1]3]2L:%PD>85/-Z?TS/>RS)E
MSZP0QS+7UD D'_ 65_NJS4&>F) Y/AXE80^K_6Q8YX^L%YEX<T&MIAH=N].-
M_IN]GM_F_P#P/]$DIM_\WNAZ?SL"=/M5\:^7KH^/TWI^(VS[*2UUNTN+[7V:
ML.]G\]99M_LK'ZI9E=/LHQ[.MW4EU AE>']H_FVMILO-VW(O;ON>V[]-?8_^
M6J=?4\JISO4ZQE%SZ&"ICNGEX8ZVNNVBYSZFV^I=2RS?>WU/I_SG\VDEV[NC
M] ?EW9MF.!EY32R^P;RYS7!M;F_HW;?>QC&^W_1U_P"C5GI?3^F]-98W#K;C
MLL()9N))(&W<[>Y_YJY_]J6V,>:NN9'Z .M>_P#9Y(-;?1IL@>DQMFVZ[=7L
M_P RST4/]LDDUCK]]A9K9LZ?[BQFVR_^;JW-]COYQO\ -?\ ;22GL?5J_?;]
MX2]6K]]OWA<==U1YO?;7US+9M+AZ8Z>YS0V2[TF5NJ]UWLV,O>VQ:XZ5UU[6
MN'77;3#OZ-4TD<M;IMVM=_A$D.UZM?[[?O"CD96/C8UN7>\,QZ6.LLL.H#6#
M<]VG[K0J_3\7+QV/&;F?;G.<"QQK95M$1L J^E[O?[D'JV#7U#I63A/Q69M=
MY+'4O<&""?YQECF6[+:OYRIVS^<24A=F]1>[T\6VJUF>/4P;]1M9&]^[VN_,
M_F?YSW_3_P"X[-<$L8WU' D !SN 3\RY<X['RNF].JJQ>FUX->"PMQGU6BPL
M+C[MN,S'_3/R'N_2^W?9ZG^D_2+6P+L[(QJ+.H8[<:\O,U@[I&QWOV_X/=_H
MMSTE-SU:OWV_>$O5J_?;]X69E]*ZM=E76X_57XU%GI[*&TL=LV?3V6./^'=N
M]5"_8_7]Q=^W'"0  ,:J!H).WZ._?N>DIV/5J_?;]X4;#2\ ;VR"'-,C0A9M
MW2.K6EY'5K*]S6,:&4U@- #1D.'_  N0]N]MG_:;_!+GZ^JY'V4%G6<T%H]H
M?T\.>6D'Z7LVW65;=OTM]CZK/YU)3UK[1N_FVN=^]O;'X^[_ *"+6YC02Y[=
MSM3!T\(7,U965U;/?C].ZUD4P#;2#A 5P-U;MUUK&-NV^K7_ #G\[_.4K3=T
MOK<Y KZML;98'T.-%;W5M-EMEM W_3;Z+J**K'_0V/22ZOJU?OM^\)Q963 <
M"?B%C'HG63!=UFPN;N(=Z0;RYEC?;4^MCMNQU7O;_-6?H_2^FK&!T_-PZ+OM
MN<_J%EKVO#WL:P,T8QS*F,]K*O9OV)(?_]+T6S^<=_6/Y5%?,Z227ZBQ/H._
MK(M?T3_6=_U17RPDDA^IW_29_6_@Y-^>?C_Y!?+*22GZI'"SW_2=\5\S))*?
MIA7,7^8;\_RKY;224_52KYW\T/ZP_(5\NI)*?I-.OFM))+])K6[KY6220_46
M;_,_,*@OFQ))3])J5?TV?UA^4+YJ222__]DX0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     2
M2DU- "H    (  \!   #     01B   ! 0 #     0%P   ! @ #     P
M ,(!!@ #     0 "   !$@ #     0 !   !%0 #     0 #   !&@ %
M 0   ,@!&P %     0   - !*  #     0 "   !,0 "    '@   -@!,@ "
M    %    /8!.P "    #P   0J<G0 !    '@   1GJ'  '   (#    3>'
M:0 $     0  "40  !'L  @ "  ( !HBC   )Q  &B*,   G$$%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#8Z,#8@,3$Z,S(Z-#@ 1')O
M<GDL($IA<V]N($P 1 !R &\ <@!Y "P ( !* &$ <P!O &X ( !,    '.H
M   (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                              F0   '    !# R
M,C&0 P "    %   ";:0!  "    %   "<J2D0 "     S<U  "2D@ "
M S<U  "@ 0 #     ?__  "@ @ $     0  !#B@ P $     0   4CJ'  '
M   (#   "=X     ,C Q.3HP-CHP-2 R,SHP.#HQ.  R,#$Y.C V.C U(#(S
M.C X.C$X !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M!@$#  ,    !  8   $:  4    !   2.@$;  4    !   20@$H  ,    !
M  (   (!  0    !   22@("  0    !              !(     0   $@
M   !.$))30/]       (          #_X1),34T *@    @ #P$   ,    !
M!&(   $!  ,    ! 7    $"  ,    #    P@$&  ,    !  (   $2  ,
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M 'D +  @ $H 80!S &\ ;@ @ $P    <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    "9    <    $,#(R,9 #  (    4   )MI $  (
M   4   )RI*1  (    #-S4  )*2  (    #-S4  * !  ,    !__\  * "
M  0    !   $.* #  0    !   !2.H<  <   @,   )W@     R,#$Y.C V
M.C U(#(S.C X.C$X #(P,3DZ,#8Z,#4@,C,Z,#@Z,3@ '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                   & 0,  P    $ !@   1H !0
M  $  !(Z 1L !0    $  !)" 2@  P    $  @   @$ !     $  !)* @(
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M 0$! 0$! 0'_P  1" "X ET# 1$  A$! Q$!_\0 'P !  (" @,! 0
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MORX@\,9E1P @AQ6.( N,10X,NPV1M,@10V*V;L=82)+PD4;=^DEF+\KEUO\
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MAAG;)V68-_SH?[0VG:$8.]9;-NF&.5+W(X[0:'<E/&?<2),FQPBTV@";$_\
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MOO*.1%NZ<&,F5(5T_9F;UPFHF54K1P(%2/1$P9O52*KGBUV6+C!C\5HOZ)U
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M60H%#.@9!51$I"$$G ](%'L/3Z  C\P[\=N0YXUK^I<UY')M,5DG>  OQO\
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MG05-\919RB<S8J)EJ82+PVJ_C/BEU5<@[HIEO*2,)D6Y2-TA$P&ZBH@4@G
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MHBH]+R4Q'[P)(99+HCW-+K+>L*B0036CDQ<*2($,?DIURS"[\JGE\="9$0.
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M/ :"."(F&&.$Q"IA$0) S(!<#B:/1.AZ@CMV[53K*)@* \B/(AV'^CQSR/H
M]_0>XZF_"8MT.35R 3"#"S@Q ;HBJ/I)<X"A:L6?EZW<[L%#6XN]S.,<$Y9R
M#76R+N<I]%L,]&I.%011*Z8,%%2+J'$B@&]D#EV5$Q!!P9$$!$H*"<NU%\#F
M5+?:LBV^>M5IF)*RVBR2:[V3EI-P+J0D7BX]1E5E3 0O/'0 $3(DW0(4J:*2
M**94R$5)LO/ZK3D'"UC6D)!V*8F.TCUD4"(F$!$I/,506.80[<B8 $1 >.P
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MO3$N_+FLG;KE<)%4 !*(A]HH]A*/S 0T6P7 U=18:^*,': ES%X93K9M'NG
M '"#UF=4S7SN [$<(J"BFH/(%.D!#?AEX*' AZ5Z8CV+=JKOI ICIE$IQ, %
MY$?J'_C^?COWU1CR/LZQ%<>A!%U7[EN .?'#Q<$07 J@_9.81[^IO7T[\?3G
MUY] X^?,RMXF(8Y _?1N2*4]=WB:EL?3*F8N 7,=/6;%HJ\<JIHMT$S*J**#
MP4I" )N>1 . Z2CVX[\>NND($$+$W.1?BQ?GQ+YU61"11F[</N.:Z=6::38Q
M!FIA,W9)DG7"G'24B9VS@D6D;Z*NSK%=D)V$C= QS=S$ #U?KG7]W>JVS<R&
MIZL^#94X#"H.7H8'3U];YHPIQ4255X!3#QU@CRJ!0+P/)N2@4O?UX^7(#8#?
MSH ;ZL'+4XW=76Q<V5%0=GC_ '-;VYF8C,<OHG'&'(&9=U:;R+,NCNUG$@Q(
MT/*QU;@&1S2$NZCBN2MEE'*\+&^U%43"0,!1*;<3!P6PIVH.%+[PUURKW#-;
M=MK&UO'FU'&K:@4<'$D\<NU)>V7"40:IS]PGU^OSI*6.V(4H)HD-[-',2G41
MCVB::1#JJBNX7Y'6O=%9?1$T1-$7"D9%G$LG,C(+D;,VJ9E5EE/P2E#T  #[
M1SG-P1-,@"HJH8J:93*'*42**)BE*9.6:.[61=&MMSE<1]844,5%8X<&1>S#
M<!\MTZ[%4205ZDF7/24@N"G6,UZ_;6*G+''E[Z+YR%$U6OP:)4(Z,9MB%*!"
M@1!(O8/0H<%#@ ^10X /ISR(DR>_Y7;+Q[!T42+LVRQ>.G@Z*9@X^@<E[<:(
MPJU'6'S>,Z58&RC23@(]=%4>3%,V2_" >HIB\% 2F(8 ,0Q1 2F # /(<Z(U
MU3AK7P%!EQ;Y=PCY5II*S[*..6)BFM&/Y90'-MAXHG'GR=%G%E2+.E&:(&54
MK\VLLT6 O2S=QB7)TFM>URM<=>ZL%1[O6LBUB,MU2DT)6$EDA4;N$O,(HBH0
M1(X9/6RY$G+&09J@9!ZQ=HHNFJY#)+)$,'&B++=$31%5#?-F^:VX[2,]YIK+
M<CFTT;'LR_JB2J1%T"VAX0D57W+E%0!(JU92S]H]=)&X!5NW43$?M]R+^;9@
M[--]S!8LC#EZ>E[3?)FP2-J?3]@>K2$O.*33DZTFX=N'ASJ*KMGQRF,4.022
M=H%2 $P$H3KC3[<=9(LXM6/1445601Z@,8P\<%$0Y#CD0 /KP(>GS^O?E'_;
MM]]7_"Z0FC78ORKU%*MFS8J,CTA4B@AY7</4/+'^WY_7](>NLK30OAE[7>FG
M7>QE/5,8G"?/VO3IZ>?[/E\N_P"L=$<,U[7W$#B<_<X*8JW5SMQ*<0,F;@O8
MGV>0  [&$H (_GZNKC\VM0?V[^VLEF(N*74#OB'IQP+Z$R0\88PE*!>!$2^O
M #SU?4./[N._U]>RYJQ>/JE)34E%0<,Q<24M,/6L;&L&B0K.7LB^<)-V[9$A
M.#"JNJJ5-+I 0 P\J&3*7J$B^U[;!@6OX Q%2J6RBX=*QL*^P);)MBR:$=S,
MZLF+N36<R"20.'J!'KA9)H*JABE;I) F!2]M%+^&OG@K%Z*IHB:(FB)HB:(F
MB)HB:(M3._G</=661:=MOQO/O*Z:8KY;7DR;A5#MYL(.3>K1L-7(^13'SHPL
MB1A*O)59L=)^=H+!-NN@19<5"G;[7'\X8*?-LD-6Z77T(^.;$:^8Q!$RJ90*
MH=58H =0YP*!Q.8QA$>1$1,/4;D>!T%]V5::S9Z7J&ZZ[ED17@>ZM4TCNDQ>
MC[XF(ATB/<0[#QS^@0X$1Y]!'6C7$,]^)<7MTKQ6!<0+VX,W-\1K%90V8B
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M,/X(B'(^@:#D_!8B%>)Y7T9W^*W\5RTBI.VPD6.B\25*'5V*=,P#W]./UAR
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M"S[=,X0CO&.:H!<H "W%1L)6HV./(H4Y4YRHN9Z%7 HF3?=^DI+K]:T7OO<
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M"*&JY;)@[^H4>VS)E7I9%AGI=!-R8HF;QK7E9^80#\'RP 2$ZN ,!USH%Z1
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M!43#D>H/EWX$>?IQP'?U[<<^NB+W 0'T'G_O]-$7G1$T1-$31$T1-$31%X$
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M6;RT;'@<Q"G="B=)XBVZRBZ.R*@F"CA1(AP )#]\E &6BNQ;\O<<@\B+"$W
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MMM3MM6@SK1*EPQ0ON10P$15+.8C$YI@P&5%)G2 <\<ASQZ?F_C\]?LNZ& %
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MXM-VU0FZG/T[)5IW'WN)OLG#X_AWTS4!PI@ZC52(QF[<0MM-#SD6TC5O.AA
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M/>]WRYRI0BZBSEXJD15),I/+12 B*8)% I>W( 0J8<DZ0 0 .?3CC]'L1Q!
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M<,%7#4[)=5FLH4RC919HHHU6.D8AE6ZAT5!,F8Q1(P7LPBXV*:)1\8P:1S!
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M74%KN6*ZA6.GT$Q30]S+JF .'#Q6132()>0*8629505\OD3%3,_3,43F*F<
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MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+I9NO0]C9BQF&1':(&\Q(_4HBY:K@
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MS9_R-Y(_:F(?YJZ(GQS9_P C>2/VIB'^:NB)\<V?\C>2/VIB'^:NB)\<V?\
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ME<[]:W'NUU.R-!BZPRF9N'*9?-#V91U$^-5"2V&L89?3V]RB2.2M@.XC?>E
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MVYI^-9NRE4B[1,-CE6T3EK6?NMD6B)HB:(FB)HB:(FB*-LR?\TF3O^@%N_\
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M?YJZ(GQS9_R-Y(_:F(?YJZ(GQQ9_R-Y(_:F(?YJZ(M=6;/#OVYY\S'8\YWK
MFXY"[7%[AR9MC>K9IK-7J=ELN IIM-8GM<[48K-:$%*V"GG:IL8YP]9KLP8B
M85&)WW0](4;H,J-[++*_LAP36;'0[1%[>LV!)XWW'Y:W65@'-_QJY9H9BS9
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?:KA$HG\A1U%R+)W[.<?-0!<$5N%B*%*4Y>I;X*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g752656g14i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g14i22.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2(^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  Y$<F]R
M>2P@2F%S;VX@3!P"-P (,C Q.3 V,#4< CP "S(R,SDP."LP,# P #A"24T$
M)0      $#\'0_C8YA 1Q<?=C0[ZMJ X0DE-!#H      /<    0     0
M    "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M    26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R
M:6YT97).86UE5$585     H 00!D &\ 8@!E "  4 !$ $8       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 8@            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 ! \     !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  ")   #)@         !                          $
M R8   ")                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   ")     %)G:'1L;VYG   #)@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    B0    !29VAT
M;&]N9P   R8    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     XX0DE-! P     !JH    !    H    !L   '@   RH   !HX
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M0Z;@L@"AK2TM(.LRP[FN=K]+_2._PO\ A%83<F2)TA$"][C&_P#FI 8=6_\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B     !)*34T *@    @
M#P$   ,    ! ST   $!  ,    ! )    $"  ,    #    P@$&  ,    !
M  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !    R $;  4
M   !    T $H  ,    !  (   $Q  (    >    V $R  (    4    ]@$[
M  (    /   !"IR=  $    >   !&>H<  <   @,   !-X=I  0    !   )
M1   $>P "  (  @ %?D    G$  5^0   "<0061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.3HP-CHP-R Q,3HS-3HR-@!$<F]R>2P@2F%S;VX@
M3 !$ '( ;P!R 'D +  @ $H 80!S &\ ;@ @ $P    <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                "9    <    $,#(R,9 #  (    4
M   )MI $  (    4   )RI*1  (    #.3D  )*2  (    #.3D  * !  ,
M   !__\  * "  0    !   #)J #  0    !    B>H<  <   @,   )W@
M   R,#$Y.C V.C U(#(R.C,Y.C X #(P,3DZ,#8Z,#4@,C(Z,SDZ,#@ '.H
M   (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                               & 0,  P    $
M!@   1H !0    $  !(Z 1L !0    $  !)" 2@  P    $  @   @$ !
M  $  !)* @( !     $              $@    !    2     $X0DE- _T
M      @          /_A$DQ-30 J    "  / 0   P    $#/0   0$  P
M  $ D    0(  P    ,   #" 08  P    $  @   1(  P    $      14
M P    $  P   1H !0    $   #( 1L !0    $   #0 2@  P    $  @
M 3$  @   !X   #8 3(  @   !0   #V 3L  @    \   $*G)T  0   !X
M  $9ZAP !P  " P   $WAVD !     $   E$   1[  (  @ "    \     !
M   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C V
M.C W(#$Q.C,U.C(V $1R;W)Y+"!*87-O;B!, $0 <@!O '( >0 L "  2@!A
M ', ;P!N "  3    !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M       )D   !P    0P,C(QD ,  @   !0   FVD 0  @   !0   G*DI$
M @    ,Y.0  DI(  @    ,Y.0  H $  P    '__P  H ( !     $   ,F
MH , !     $   ")ZAP !P  " P   G>     #(P,3DZ,#8Z,#4@,C(Z,SDZ
M,#@ ,C Q.3HP-CHP-2 R,CHS.3HP.  <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                      8! P #     0 &   !&@ %     0  $CH!&P %
M     0  $D(!*  #     0 "   " 0 $     0  $DH" @ $     0
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MDA3ZW\]+6>.*@!^8VV9OX\8^!K37?2]G?6YU(TOKJP$9(:EK #UN#,0UW?\
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MX_A\H^;X $.X" ]>@@(" 9Z9 >N<8SG B/40 >@4(+D\@06WLUN>WW@QEAJ
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M&=5+ EMK#?A\GU#=3%Q>\6WJ"/(F_+J&>W\&'!#3X6T;5@]]N)?SA#4Z=/H
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M;*Q\+N79GW@/;'</35@2D,DY1P%A[!&,G,23<J.91-RH\23J>9O#6FR>"?\
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MAC_D)8.V?)_"_'/?UZ>OEKZ!_HX7[=SCJ?Q/5W_U2]MOGK'-Q/[%/[7W1?\
M\M_T^3,W^_\ %=GO[;]OM?<Z-9?6;\%QQ4^M_I'P$? SJ"S#;?3;0?5M1P#9
M(:EAL[E^K @Z6+EG&FOF$-#Y/RT&E@&WZD:EALAH;A]>/)WV?4]=1P:$/7N
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MTA$X'W?:']^M2W!'M'W1W'3P3[__ *QKD..<V?YQOCYX'(=1^&0ZZ_BUB/\
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M_DWRBKMVKX0)-@474,;P&R*1 2123)J7-V.I^_1^64&S^XQ(#6$6^'3J'3(
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M4SSR2KTE8*D&GRC1-.;D:,;J5;4/TCB.><@@'T<]1Z9+DQ<B&0''0!$3% 3
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M"SN-..@9X0$//MU].V//. QUSTZ?5H"^^@.I9W>_.S:FWOA >_P''7 8^/\
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MUU(T-FXZN& REN6I#\^$(@0$.@Z%B_ D!V9K&]]GYOMHSHW=X _X<W?3_P#
M=@Z]>_MT+G.?QYZ^@/Z.'_+J<^OXGK+<LTO86\]XYN)_8I_:^Z,@?+@?[,S?
M_P#\5V=_MOV^Z>7?MWU]SHUE]9OP7'%3ZW^D? 1\#.I#6OQMQ#CF]PPO9AYQ
MDAJMW 8M^K>X^9ZVMY0AII<7>S'4NQZN+7\P80U+ EF%^!?J[;MIJ'XZA#2W
MF--#8.>?5CM8$@PAHYW%^=M0!\&T9N-X0U =K#6Q(>VG-FZV]@A#0,_M^%[.
M&WWZ;0C8KADX<)[BDW(8;5U+<':VC6^:4:M:NUW/F+'$(6N7>+^ A"5\U<JE
MK67E.7F<'*\08M4VY!.+HQ^5(T@>1YBXMY:\"]AP$03E#G2-G*'\E[O?NE>M
MQJ)M;N5L'N*;:BM.9J[6JNVZZ?DC%V!"3F6"&VJ<A,;<QCY[N"[_ "9DY!O$
MM(Y2)5CD3N59EN?E+JX3TMMSM;?2Y!=[^1@K :QOTTXZZ>_E%D\/7R>F[O$C
M0*MN'6K]LO1XZ^;C2VT^W\-N7:[+7[%?KQ"0J4XYBJXTB*988TRBC9P*1'DG
M(1@&?)N"G(B00Q#$\ _/9W9FYM8A]X%3%F)L]A8"^I\H_"O_ "?.\2M7=7/<
MV[;,\.]9"[3VW<!*[Z7UQ5B7:T5:37A+*E26==@;._EXF(EFR[%]9G+1E5DG
M(% LLGR&*$,3R;2X]UGLJVUM(9AH'/0:6>_M$1&<!=Q-MJXW9N6^_#-MO2!W
M(O.UD!+7"^V=RTN-CV_P$VZJ$C3MOKC$34$X3636BIDSY%!P@H4Q2&$2 ,@;
MN&VWV;6S\/<;BS,'9B[.PY\;QW+1P#6.I;$PG$-)\1W"RI0[,A/(55!A<=S%
MY^U66KQ)9.<I4 Q6VH(R<V-D)B1X^-+IPYY,X(FG01$[H!##8 DB[C@+>6K\
M>!, IRS%[';?SC0O57TLQXE@PWX#5_E?2T-1H;$=;6WL/FP#\(0T9V;3</\
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MQFR63D3-2M%1+FRSF+LI*4>J%#O&26.64I  RY7_ $O/_5SL"\0(A^D)@,(
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MW$BMKW2S*]R%;?-*ZZ:JBW?H.5P*1P:,<%DX7P)@6 NBPZWSQ$@E*&:'&38
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M?)&U^>0M+5_4:V#:.8TU&"4AS)#A)S*>CK,<[,U=;4R15244%70=F\,I*4*
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M2D)'   >X#[HN']GX[A^/L#7*LP))N+\[W \];_$M:-W> /^'-X&>GY"6#W
M(^W0F?+W^[M\-?0/]'#_ )=SW_[GJ[.Y >7K_)^,<W$_L4_M?=%__+@?[,O?
M[R_UKL[_ &W[>^_'Z]?<Z-9?6;\%QQ4^M_I'P$? UJ/?U(.G(7:U^(&PC)#3
MR&C[Z-\SYOHUH0U8<[[EMSKMO=B".%[B$-5NY''V[MOHVK6;WH:G5R#P'%]A
MJ/;Q!N-BAH18;AM]=';:UQYV<.T(:.XU]VKAR.3%S[QH(0SY>7?&H<<7YMRX
M<[/RM<0AC[\_7UZ_'J/VCZCH/O+:CV-9^(-H0R/K^,8^X<?#2^]VOJ^GPY[V
MVA#_  _5U#[!ZAZ:'</;@'X C1QR<D]=(0U;?5N/&_5M-N&N7>$/\_K#&!^K
M ?8&HU+O\].987N1MJ.4(>[RZ_KZ#]OGI[=1<<-&!U/(;-Q$(8^_F^OJ.?CD
M1Z]^H^HZ;D=0X'.]N@/$!_8AJ.)U#LVMB00UWY]1?>$-39@+7WUU#<>F^MR
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g752656g14p44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g14p44.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1N@4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&Y8
M8D         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/
M     0 ".$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             !C0   DH          0
M               !              )*   !C0                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !C0    !29VAT;&]N9P   DH
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    #.$))300,     !(?
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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MJ39Z;TWIU50MLL,SBVY/46]18[[+]'-R_LV+5C^E;=;5_@UHX-77:L=N)TW
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M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
M0P!3 #8    ! #A"24T$(@     !+DU- "H    (  <!$@ #     0 !   !
M&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "    '@
M '(!,@ "    %    )"':0 $     0   *0   #0 "4*Y   )Q  )0KD   G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#8Z,#0@,#8Z
M-3DZ,C4   .@ 0 #     ?__  "@ @ $     0   DJ@ P $     0   8T
M        !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H
M  ,    !  (   (!  0    !   !+@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0$P34T *@    @ !P$2
M  ,    !      $:  4    !    8@$;  4    !    :@$H  ,    !  (
M  $Q  (    >    <@$R  (    4    D(=I  0    !    I    -    /
M     0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HP-CHP-" P-CHU.3HR-0   Z !  ,    !__\  * "  0    !   "2J #
M  0    !   !C0         & 0,  P    $ !@   1H !0    $   $> 1L
M!0    $   $F 2@  P    $  @   @$ !     $   $N @( !     $
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M=GFVN?_$ !0! 0                    #_Q  4$0$
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MZ4-+-<<DB3HGD]R3Y(1\"AX7!?$I+0\[6HD#^Y,AA32B"UJN/%;XU*F82(W
MN"^26AL()"1L:RA*VD3PJ+"$(=:<I')H\\2%V%OVZ$(QT=%9HQ[$8,8C!C$(
M(==3>!'A^W="LOF"'D^/[K.+%G.E3](\B)_X.N47E!)8S&_<I@L)-8H5-8LM
M5A))DS2L:$;NYM0E2%&_MOW)HQADSP]]I7'U52=MU=U4W,[7V5Q->4LY8Z8'
M'R )(_-91"RDI\<MZ.(R24Z=*PV='U)3J4%*G1H#G=$]*FEN;F4]L1DA;E@8
M,Z=IEEZ*YQOFA)$42:RW+4%BUHN^X![RR 3.)NK 6M#KVBV$YO/7%+DQH-?(
M0H3E'%>AA8=Z#$?CGM]ZOW@CC>Y).::?*["YLIV03 T\7N4#F1\&9B9=M2+W
M"]5.I(0Z:4?S"UH[0]:$+6O=L)GX# 8# 8# 8# 8# 8# 8# 8# 8# 8%97F.
MT83XVNFGO18C4\):ZXLMT+T#9@1,-6W)7=C2+Y2]:WLU.%BB[B)25^VC4^C2
M]B!H6Q:"S$HTH\HL\DP!I)Q8#2C2Q:&6:48'0RS"QAWL(P##O0@B#O>A!WK>
MM[UO UX],;=TS]20^I+.+*=(WX[^"(E,*#B#EOYD".VNC)H>DF=NMZ([^J,<
MT$.3IX7]UHHW[-00TK"CB%R-,( ;$& P/$659,"IV 3"T[1EK'!*[@$>=)7,
MIA)5Y+:QQZ/LR4Q:Y.;BL/$$!9*=.4/>@!]YQYFP$)RS3S2RQA1GX%VZ46^@
M[^\C;Y'':'13R*=A2"SJ)C[XB-;G=7SG6+*17-3S1T0'Z+.0N$S3IWI<8G$7
MLHY&E0NJ-0J0N:4[8; >!U[JX)&EK<G1P4%)$#:WK'!:J/'HLA,D1IS%"E0<
M8+>@EE$DEC,,&+>M! '8M[]-8%<OAT1*TGB[X=4K$YB0V14!#YN4E.+V4:G0
MV !3.&TDPK?\Q8RVZ0)0B+'Z# +6PCUH>MZT%E6 P& P& P& P& P& P& P&
M P& P&!BN]*FCM]TG;]&R\'R16Y*PGE6R,.@Z$+3'/HLZ15T&7H6MZ^4M&ZG
M&%"_M :$ P[T(.MZ",?C4N9WN?C>I#9KO1%PU"A<.<.@6@?N J9;ZY\7G53:
M!*A,9O9R5.]R&,G2YB =L8E,7DC$X%FJ$ZTE0:%7GF\K*P>1'9G\X_+TYCD/
MO+D6M4E97O6LV*'J =3\R26PV41E7O2U.>2J99@P2=_,>(.[)0'J%3H>D2!U
M]VWM!8PV!:_EI$_@<)G:5O7-*::Q&-RU.U.8-%N381)&9$\E-[@7K]BUR,M:
M%,K!K]@GEF!U^VL#UV!K+^?=P@*SHSQ.P;LQY<(UXO93?]E+.J7-0<X(JS>;
M:C<+;7/F6(7<Z(=@+15N\2K4B-<BW8\EC.2)G5>ZB*(9M.#:&Q_!U4*60R**
M:W4Q=77QD>9_T0HA)S4HAQD4 @(+8/TL<Q"&RCCX6L"8#1MI%MNT@"0%'_B^
MB]8'J<"N?RIV))8GQK/ZTK=1L%U]7.+#Q_1Y!/NVJ!8712P4 -DI00;T/22M
M(2X3"UGL\(@_:Q^#.JG0PB*#ZA..M8#':IKJ U=$$VT43K:%Q:!1A'OV[$EC
MT/8T,>94XM@" .Q$MS<F+%L(0AWL.]Z#K7[8'M<!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@4F];V,S^)V^9OWZ^@<0\/=%@C3%VFQQQ":YN517TSH4L3J3J".QE
M)Z'O+;9#.F8J/NAN:"AO!K@WU%,RDZE.U2T\00WISG#IKSDR^O\ KSOI,^4;
MXW6.3L=I<B^/-,8!(_WJU-Y@76 W=V*M*&I*=&U[2FI'^-5<B/&V;0J$_O\
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M];U^V];U^^MZ_MP,%7UT_P Z<MP];/>C+OJ^E(BA3F*#'FR)FQQ8M2$O6]_
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MD_[&-P^-HS3(XPJI5)E9/VK.QMX#7I]5E[*2)E9^MZP) 8# 8# 8# 8# 8#
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M;.\*-96FQUT@^U?XRHFRDF?O)-<P.O3Y"FCFPM*^=.A)VPJ0H B]V[X][?\
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@MN_*?-[_ ,*W?'[3 M"P& P& P& P& P& P& P&!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g752656g14z14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g14z14.jpg
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M 0$! 0'_P  1"  B  \# 1$  A$! Q$!_\0 &0   @,!
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g752656g19q99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g19q99.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C24&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             <    3           $                          0
M           $P    <                       0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   <      4F=H=&QO;F<   3     !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   '
M     %)G:'1L;VYG   $P     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      .6P    $   "@    .P   >
M &Z@   ./P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ .P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MC^2FB-'^Q?.9D -:'S6>+BDV*?6V?IMNZ3&R8C\WZ2(DDG+%)))G$@$@20-
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !?DU- "H    (  P!
M   #     03V   ! 0 #     0'I   ! @ #     P   )X!!@ #     0 "
M   !$@ #     0 !   !%0 #     0 #   !&@ %     0   *0!&P %
M 0   *P!*  #     0 "   !,0 "    '@   +0!,@ "    %    -*':0 $
M     0   .@   $@  @ "  ( !UM#   )Q  '6T,   G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#8Z,#8@,3$Z,#<Z-3(     !)
M  <    $,#(R,: !  ,    !__\  * "  0    !   $P* #  0    !   !
MP          & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V
M 2@  P    $  @   @$ !     $   %^ @( !     $              $@
M   !    2     $X0DE- _T       @          /_A 8!-30 J    "  ,
M 0   P    $$]@   0$  P    $!Z0   0(  P    ,   "> 08  P    $
M @   1(  P    $      14  P    $  P   1H !0    $   "D 1L !0
M  $   "L 2@  P    $  @   3$  @   !X   "T 3(  @   !0   #2AVD
M!     $   #H   !(  (  @ "    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C V.C V(#$Q.C W.C4R      20
M   '    !# R,C&@ 0 #     ?__  "@ @ $     0  !,"@ P $     0
M <          !@$#  ,    !  8   $:  4    !   !;@$;  4    !   !
M=@$H  ,    !  (   (!  0    !   !?@("  0    !              /
M     0   \     !_^%"$FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0$! 0'_P  1" #? ET# 1$  A$! Q$!_\0 'P !  (" @,! 0
M          <(!@D$!0$""@,+_\0 8Q    8! P(#! 8%!0D)"@X# 0(#! 4&
M!P ($1(A"1,Q%!8B01515V&7TA<C,G&!0I&AP? *)"4G,T=2A[$8-3=%=Y71
MU_$F-CA#9X:6HK2V&31$1E188F5R='6"M^&2PM;_Q  = 0$  04! 0$
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M2S)!88@WNX0I51.:>_OD30Q$R(JB87Y6Q2@D?XA*0PEO&CJ\0/\ -*H"H=B
M"%WY<GAT>F)0/I9C<3WG0X#;G;W&JC;<* OHFYKF"KB>:)NO^68.8,XT$@;J
M-2!JN\AYB)GF;27A9%C+1CU,5&4C&O6[]B[)^L*8S9TT77:KD*9,X=2)Q !*
M8.1$#:IEAE@E=#,R6*6,_E(Y6.8X;PT#@YH(X@X&"-,\5D05-/51,GI9X:BG
MDST4\$S989=TD'HRPEKMTAP)UX'' X[K5"OKKI:3CX:.=RLJ]91L:P1,Z>R$
MBZ09,6;9(.M5R[=N3IMVR") $ZJRQRIID 3&$  =5-9)*YL<4;YI9"&1Q1M+
MWO>[0-:UNI)/)6IYH::&6HJ)HZ>G@C?+-/-(R*&**-I<^2620AD<;6@E[W$!
MH&2NNB;%!S#ETUBYJ*DG#$&QGK=A),WRS0C]L#N/.[2;**':E>M!!RS%?RQ<
MMQ\Y(#IF$VCX9X2SIJ>:,2;YBDDA<QCQ&0R0M>0&G=DS&<:[PQC )5N&JI:E
M[VT]53S/B$3I(XIXY)&">/I(7/8QSG,;+'^4BR 'QD/!Y+(M4K)31%^:H])!
M'ZN/ESQ]_P!W[_EIW:]7:GCQ[<+IXR<BY-R^91LDQ?KP[HT?+HM'39RM&O\
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M6:B>&E@EJ:F:.GIX(WS332O:R.**-I?(^1[O5:QK 7.)Q@#B%723W>;;8O\
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M^6^H0]>XAB(/BXX'L/3SSK,Z7:$_YI9#U_[XUW_A?#M_%<UYMY*!G-Y\H?\
M]L[-Y'L_E9\,]8RJ\&7N4OOQVTHV./IK#*U?P/N >9C+C>9F9RN,<;S=DHC7
M&+24E)V$@9$SB1M+&1?1K-Y%H&*X932C Z[1-=8=9OU$FTMJ$T=+%6QVZX&K
M\RGEJ(_,G.A%.R5\M/3'_*<N8W<WAJ0=W4]FV*V4ODBVW-!+<ZC9RMVJV8;L
MU-?:*FH;B^_P05+[])3045;74[6>C3#'+(*F1IB:UCHVR@ ;.C%*<HE.4#%'
ML(&#D!_@.NO7A2J?F?"TFC,MLQ8@60@,H5Y)0ZB8%$(^U1@ !W<)--DA)[:S
M>ID%-9,WZTAA3=-#I/6S=4L$@:GAQ...G'X!,..C1D\!Q^D>&<=95*Z+M/@\
MZU:#MS*S(Q1U8>\4/,^/9>(<.FCNTKY4A;F@9TW2?)^R/V%9;OZH]D0(8+17
MGU2?*E0:PS1EKE:C9=LO0M=4;T9A<R9IC:YLSGSQSA[]1G=B::=PP=]I:#@-
MPO<Z'RTST4M>]MJ.^;A25-JJ/.'LGM?FMMFH:B%CMT[S9*J1MP@+2WH*CI-T
MN$N6SO/;2;VQA7E?H%XH9JX1C9L>Q-3R)3K!8J\VPK8IB)L\/4#!7+;4I9.2
MQM/MY:/I3IE)HQBE*=L*_*1ZCF-0E!K]#31L,=+4TW1MAGIH(GP[S6T$YWZ>
M$X>WUJ2H:YT3Q@/C]0@;C2M$WRAT%6\37:U5[JDUE%>:JMH*VE@FGVAI:62B
MK;@Z.JMU;3NAO%*Z(U<3XB8*MDE5&Z7I3"W%EMHV8I$SRB/LO4B=Q:TQ33L&
MQ"JT':D,H5.CLX"LQ%]5BI5"W'K+"V9$)&RJ\E8%H1Y*-FCN"8MUQ:0Y_;:W
M6BJD)9+6TX@CI(::-K8YM^(EL;*E[?RNZ)*A@>-\C.HR2,YOP[>V6E-/<(]G
MJZ"Y/N]9?YPV>C9;;A<'RU<EK=,UM"R:2CM#Y8/-:2%\<'2,F>YC75!,=J<(
MXG2V_P %>($MUE)ZEN[@_N<(\O$NZDYROHR\7&+6AM,VB46.:51<65K,V!)V
MN*(M2RZK581(V(<=G;Z!MOCDA;*Z:.:=\[<ESBUTH:Y^I<3@R->\'3&\<#&%
MQ6U6TQVIFMM=-14]'7TMNAMM8ZE8RGI:KS265M)+%!&TMB='1/@II '.$CX.
MD)#G%03)AM8O%MNMJC\Q[?Y2\>_]6R2:PH3E*D[/5ZY0HJIM9F+4DD98\F@R
M4;UF2.X=%5;M&:,DL59N<B:WG;)<MRUS\/NT]QS\ETV(X.H[G<?UNKH9^Q]D
MRAXEB5J<*^!Y&>KLJ+XU3;T]@:TR![++KE\RO*V!-9HV39,I/Z4.)2&1;"42
M<?'<?!Y*5+GMP=/X2D2*TG1K)8:P)7MQ7S''VB\42=<MZFK75)AC5G]L2CJF
MN3K/(G^AS-&(JF4.NBJ8J:A"D>,X^Y:-O'WWWX]HNS.O[;,;6;&USN&17<9'
MVQ?';Y@\@:+"4I5DX40B63&0DC0BDE*)(QT8T<.E5V4*W?I\G4,DH$'@>XJ6
MYSJ#ICY_P[^6FJ^!J2G'CI\*I53]76/(@8PB/_XA >?X#_VV%?X\=>M31CV=
M?HJH_K5/VB]A,;TX'[P_?J1Q'>/FJ3P=W9]^?AR'/X+8OB:T.52H(*G,8."B
M3D1'@>PC\Q[=Q$=7U95U*I=;70)",R!0YZ5K%JK[A)TRFH1VJQD&P\"F"R2Z
M(@8!+U%(<!Y*=,QB* 8/0BK7NYN&YW<Q</TG6?-MTM=D;-T&Z,%.RRA:ZDT:
MI%1*VA(]H1O'02BA2 HL"#0$GCDQUG)BJJ'6-&O+X\O'>IT\>/'SRG91N:S9
MA"^Q%A@[#.5VRP#QN9VV,X<)I/$DE2"ZCY5H*@(/V+D@"51!8JB2Q#=1>H!(
M8'C7V>.?W*%]J>Z*/NF_SPK,V5_#D&TDLC[@MO-FKM7KCJ5CX9FI<9-D>/4C
M%IB6<-8Z/;_22"Y".W[E%!-'RS*J%YU*+5IOEV!;^[@]W?5;!&%<?Y*JV\K:
M'M$Q7(VR9S+7:.^Q9<=MDC(N+'"+UR79*GM2UK:2!DJ[(L)-C"M7!1/+2;9,
M@$7)XX'Q[>"RP_A494L6X23R7=\%XTLL;*^+E6MSDE,SC['\S(2&V:(V]C3C
MJOBO%UW[MLA?A 241P!GQU0&6"(%+^^=$4'4+PO=Y>%:7@>QAM?PSN5=U?!V
M\G;E*[>,A90ID!!XL/G7<';<C43,M5E)2-LM-?LEZ?*1]?N<+$"SMS.'39,(
MDJJZ3INU>.Y.OQR5Z_#U\-/)NV7=!6K]F>*J>1X[&GA[[:]NU/RPNZB)I^CE
M"AVNZRV0&=9829E+7"1D='R-=CXB?<,H\\A%M4&Y5?-3<H$(I,\1C;#GB\[A
ML+;C,3[<,4[S:_4<$9XP+9=O&7KI7:5!QDAEU>K2$3E./>7",DJ^_;M2UAQ5
M+A'H"SLR]<ENF 7,H9QY3J\>/9\D6N?,/A1;H+MN;5L\CA:O26)<VU+9>UG6
M."LYXAQ76MJDIMVB8.-L%6JCC)VW;(65)&EUV6B/>;&@XA<TUP_77>1MJ8)
MY%\!%8JG>'ONAA]TE%R<]IT26FP/C"[D]W$A)FN=86=EP7D7;Y(T"IV?V(DD
M#Q>3?V9=)DXKJ3?Z<9D,9ZZ8(M %71.?C&G\?@OHDT1-$31$T1-$31$T1-$3
M1$T1-$31%'<O*+V66=U*$7.1JP*0+3*(&$HMQ7*!DH-JL4/A>N$3 L]4(/6T
M:G(0H@NN HE'W]?=U=76LBB*Q$PC8J#)HD0"%#@"$*4 $ #TX /J^?\ #3X<
MM% !T)X]7?[>6NO,*G&_"F6JQXUQQ<*E5GU[-@_/N*,WV;'T,B#B:N]3HLA)
M!8(>"8*<(2DXQ;3);/#Q;D?)D)& ;-4P,Z51*/,[4PSRT5+/34[JMULNU'<9
M*5C=Y\\-('2/:QF/6?&")6L;ESW,W&>LX8]6\D5UMM%>[[:[G<(+.W:[8S:+
M9*@O=5+T-+9KI>8H#25=3.0>@IZMU.ZU5,YPV""ODDD<R)CW#6W9\G>_V/\
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M4*THFJF(E-P!@ .P]N0 !^K_ &_5WYU(XCO"G&A[>/NQV?=[%=[%\6JDX;F
MINDG B/?O^_L'?\ J[^FKV=<?=X[?EQ5GY=_?W8[.&<*Y34.BMRAE ^ L>Z
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M1&J0"34Q1 .>@2 (DY'L!ONTY^/Q^Y0?O'S"N (**+J' PB!C"(<!Z_Z/'W
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MJZ)G:*9%7*";<S9-8Q_(5,3@A>6M-_J:JC#WVVLJG12RTYJ:2%C8)^B<6])
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MDS;L6B2;9JT00:MD$B@1)!NW(1)%%(A0X(1-,A2)E ."@  'IJ->6OC7X*>
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M"QO18=9LG+2$K&*-7WO&Z6<%43CH* =E9G>O#)**.%EDF#1,ZJRAT*7' RI
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MVB+SHB:(FB)HB:(FB)HB:(FB)HB:(FB+\ED$7**C=PDFN@L0R:R*Q"JI*IG
M2G343.!B'(8!$#%, E$!X$.-$4./<;66ON#/<6V[W?;"')J9/M#3-0,;GD2Q
MO0JC*5\IP^$$V2[J.0#CR(LG \D^]8K(73<7%=2"^'82P]ND'=8N<6+=0!Y+
MU&1L!H)TF)@^,Q 14 @#T]1N!'3EP]BC':>KE[^'L^Y4TF<*OGMQ<7@-D4(:
MRFE ESO@?4@S9>6(KYH2AX\+,$4J\\\//]K4CQ7,N +F,*H <-:;50/FZ=U,
MPR YSC3>_P!;' G.#O$;W/.5R;]A-CYJX70[.T/G[JCSAYF!\U=4C)-8^DB<
M:1TSB3Z[XM_>.\7;VH['*&9-S=.B8]0^*XVMOIA\Z80Z4]8X]S[2:+B7TW("
MBRK:LN[ ",(Y1!)PJFDV&3=QK518#NB ?(JYC2PM<TDDG!P=0 ,DXXDX!T'/
M3B0K^U-]?L_2024\5+4UU3411QT[GR"!T-/$^>H+#&UTO2Q1QG<:UI8Y[HXW
MN&^"?9.2"?C$[1=%I_+K!*?H<4@PB7#"K8R<KVV6HJ"J)DBRI[)85HZ-N\>Z
M*673:P,H=N[:F8%!+SCFU@<P.BB;+G< >< [KC&"1O:C#9&D>KUYX+$DVM:^
MG=56^WR5<;YK:P/8]D5*[SJ:AZ=D6^\2[\$5?',#(QK)'M?'O##E.D1NXH;6
MKPBS6K3RCT8X!5K\:RB&"L8V)%Q$O"E3CRS"Z94YZ&DA?5Z/9+2#A5K&2B(]
M*L>L4MMUPA#20'9#00W'/=:YHU=_68<@ DZ8(R,#'.W%OC@WW4M9).UTC9*9
MO0](UGY-\4N#* YM5%)OTX8'/D$4K=T.:Y<Z W6M)L043ILRLG(O5F]::M5(
M@'$DP,HH=C)NG+Z8:)1YE6B*QEF2Z(*HJ%( *' 0+JW%<&R$#HW .>6MQNY(
M#R,\>+@-[=(!':K-)MW!4[W^]]23)4/CHVL= >FAWGB.:5[Y6MA<YC'N?&[.
M-W#2XG"D3'N?Z_D>>B(J"@+"BRG8:3FHF??A%HQ[P(1*LJ2\?[,G)K22#IF>
MTM$0,LR*V65:OA1742(@HXR8:J.=VZP'@3DXY8R, [PXCB..>];FV;2TEVJH
MH*:GJ.BECFD@JY.B;#,^E%,:B)K!(96.C-5&"Y\88\AW1N< ";!F]!_</K^[
M62NF5.FNZ2(+=[Q6W<2+B-C7J4/17,4N921M4NRL\129YBH+P&\5'^3:IU@V
MCUA?="S%)_(.110;".L%E>TRRL+<='((F@C!>[(8=' 9]=P&A(XD8 )7",VT
MIC<[G1.BWX87"&W/A<1/6315D5OJ8G"7<B9BLJ(A#(UY:^'>E<<  <M]N90B
M+.O&V2HRT%"H/H9HI(+K1+E9BG(Q%?>NWDUY,P*<>U@WL^W2D%D D$1:%4>(
MGZ$5!U2+@WI#&^-S<8P1@C5D3B20=-WI<<#P.HQ@W7[8Q4]=+3UM')24[9((
M_.))87N#9*6CJ7OG:QY%.VG?5QL>[+PYIWVN :X*'LS[D:[DW'EJQ9"U:P&>
M9*K;FJHNGYXM!JC&6A!E"R#\RB,@N"3Z*+9(QV6)=&;O7":INM% H%$\FX19
MPP..=W!( &'.8W4Y)X/'J_2',:K#FV]IS+'2T=OJIZF62 !CS UH@=)''4RA
MW2N8)J43PO,3CO.WVN P-?@>R1M-L5+R,_>))_1$K#RP/1\])R@[:%$BKYJX
M @-Q\TBZ"1#E!$ZGFIN$! #I*]>L5UQB']5PR-"0<$Z<\@$:Z<,\..5DQ>4&
MDD,8;;ZR66NF=34C>B:P3U5.Z@CFI6;VZ8PSSVDD+I-P.W0(SO DV3CXEP\C
M0*](F5XV3$KWHZO9RJ$)\:J0JE3-Y"A0%0H'*F)2CP< $!ULHI>GB#^6,C]W
M #3'QUURNKM%<R[6Z@N5-%-3MKX1/%2RNW^AA+ILCU2]H($3R-<ZC7!"HO<=
MS6/XRUN:ZPA7,NDU<F;'E <E0;KJ)&$JID$2IF4\L#\E(H<Y?, .L"% 0U',
M+::G.3UYX8Y\]#II\LGE/-">53(#8B\:0[-R8A3 @L)%"@(\CW-T@8 _D]7R
M'U#60K/CQX^*D]M6"M51(9#I.F;I,!N.P@(\AQQW^KY<\A\AT4DD\3E96QB!
MY*!2<^G[(?O#O]0 !N!^78/X%"S9BT08]*BPE$X<<\^A0#C[N._?Z_X^NB*W
MNSTN-;=N-Q#3LBJ+GK,Y<8EO)M6O0/M!C. "/9O#&[DCG\@+9M(F)^N^CCNA
M1$JH%,!%]M"**3=%)NW231003(BBBD4J:2221 (FDFF4 *1-,A2E(0H 4I0
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M31$T1-$31$T1?!S_ '3E7+C=MWE90<B\- UK%U:;5M'E3V4J$@N^?RBR)/\
M)]:TF=9-=0  3BW3(81!,O%#^'M5;.)[O'O7SSXOH+^/D4!%)0! P?R1#GG@
M>/0/F'U:MM^D-/'LSWJL\"3V:=WM/'AI\5MDHD"HXISV/>DZR?1*IC </V5"
M)@HAW'OV4(00^8:OJRL-6I[<J_E& "J"4Q@3'IZA* A\7 <CP F$!].X<:C
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MDW-J.EBCSN%PR,:;@!!W,C#6-: =P:M )YDY.=-1[)6VBDBD@EJ@]C7138=
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M=8JW"0%3*4HZW:J\0WDFLM%DM]EJ12R;L-.^9U%+5$.,4SVY)9'O;F619<6
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MCK=I#5ROO,DM8&J6>,HM/GZN9S)1R][<NBLV;0AE4TI6*23\\AVLC&LG!ET
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MFB)HB:(FB)HB:(FB*JNYK-HXZ:UB@5U<Y+_DURX81*Z/ J5^!:&0).60_(&
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MY^-8& =_H"S7=&X8W@XTQT>1H>L8R3G "[:/F"N4)!OU=2I&YER$#]H2\<'
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MQ*(& #!6QN^<<N?N/X*ESL:^[(]A[N.0J.7_ #VUK!3M6[A%DT;\ID;(<(I
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MPYX<QIWL[RFIEN7PLYR-(8K->8MK<(QP+)5D_(NQ9+2"92BK&LI=RFG%NGR
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M3;5:3MGW'NYVL22&=-OACKJT$)>*C)MY8H"X4&(*UJ\NTG(>,;*LD(U*/<2
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M1/<+,GV]K_AE3OSZ(GN%F3[>U_PRIWY]$3W"S)]O:_X94[\^B)[A9D^WM?\
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>,9/$];ND,8R-[@U@QG+03AK6Y.\R37U>6.OGI__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g752656g19r54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g19r54.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2!(4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             =@   +H          $                          0
M           "Z    =@                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   =@     4F=H=&QO;F<   +H    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   '8
M     %)G:'1L;VYG   "Z     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      5T@    $   "@    9@   >
M +]    5M@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 9@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MAS.*76O,+I89QZ7Y-I)53G?NUD_$@?DW(%N=D$>QK6>>KO\ R*,N8QCJ3Y!
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MBVVS]L>EO)I?BA[6=MP?M<__ #7M65?=UX9=[7G(8P//H^C6U[-GNV^[8_\
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MTV7MGB(CZ:U!U_[Y:?=$L8C*IF1H@\/]7YFQB6OLWUV#9;5 >P&1!_F[:_\
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MW_F[YG^SZROKY520EOU_PEV+Y?T?^I_*_522^54DUD?_V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %^34T *@    @ # $   ,    ! NX   $!  ,    ! C@   $"
M  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !  ,
M  $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (    >
M    M $R  (    4    TH=I  0    !    Z    2  "  (  @ &;0R   G
M$  9M#(  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP
M-CHP-B Q,3HQ,#HP-      $D   !P    0P,C(QH $  P    '__P  H (
M!     $   +HH , !     $   '8          8! P #     0 &   !&@ %
M     0   6X!&P %     0   78!*  #     0 "   " 0 $     0   7X"
M @ $     0              2     $   !(     3A"24T#_0      "
M        _^$!@$U- "H    (  P!   #     0+N   ! 0 #     0(X   !
M @ #     P   )X!!@ #     0 "   !$@ #     0     !%0 #     0 #
M   !&@ %     0   *0!&P %     0   *P!*  #     0 "   !,0 "
M'@   +0!,@ "    %    -*':0 $     0   .@   $@  @ "  (   #P
M  $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ
M,#8Z,#8@,3$Z,3 Z,#0     !)    <    $,#(R,: !  ,    !__\  * "
M  0    !   "Z* #  0    !   !V          & 0,  P    $ !@   1H
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M$0$#$0'_Q  ?   !! (# 0$             !@<("0$% @,$"@O_Q !E$
M!@$"! (&!04'"A$*!P ! @,$!081  <($B$Q$T$4%2)187$)%A<R@9&AL<'P
M"B,D)4)2T28T-4955H65X>48&2<S-D1%8F5S=824I;+4\1HW4U1C9&9RM,5#
M=(*DM</5_\0 '@$!   ' 0$!              $" P0%!@<("0K_Q !1$0 "
M 0($! 0"!P4' 08#!0D! @,$$0 %$B$&$S%!!R)1811Q(S)"@9&A\ @5L<'1
M%B0S4F+A\4,)%S13<I(E8X(8-51DLL,F)T1%@Z/2T__:  P# 0 "$0,1 #\
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M$U?G/#_POW&\5>$L>\_$Z2-^JU/J\H: J;9U,TJQ;HF3?V*4:/UXV*@J/79
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M[+KIH"5&!A6S9FU4&5=R=21>=4U5:R:JFK+I56'EEDDR6OR&)!V!AAS*1XP
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M?)JJ&HI(5?ZWT4D,<DA2SWC#H0POCC:>!&,W E]M['N'O+<;5=MF(RQI[/6
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M4YDC"7OXI"&[!W ==6R?B/(L^7GY/FN79G#=CS\NJXIHA_HDY;E=?8AA<&X
M!QI59EM?ESM'6T=52.MKI/$ZL ?=E%AWV]<*_6P8L<&F&#3#!IA@SCOJ!('4
M@?/#&JDY:-C$2KOY%@P0!0"G6>ND6Z1<D./4ZJA"E'IGJ(=,ZM*JOI*2,RU%
M72T\2-](\\R1JHL21J+ !MK[[  DC%1()I3ICBD=C]4(K7/RL-_8>N&IF]]M
MLX8!3^LB$\[]K^"5ILI/.,D$2@14S BK9J;F+@#/'#<G81.4 $0YWF_BWP!E
M>M5SN'-9D\LL&0Q_OB9'5K6G2DYHBTGKJM;J>AQLV7\%\2YAH9<KJ*>&0$K+
M7AJ.(CU5IPNH$]+ @]+]!ACK/Q13"AE&]5IR#1 Z8@$C:'Q5'1!QTY8:)443
M,&/(\PF(#[)DA]H"\MSOQ[SA^8O#_#,,<%F"UF=3M*9%L0&6@HBLZ$W!"S&W
M56'?&\Y9X70G2^<9L 2 324*Z3JO]0U4]DW%Q=$/78[;QVL>\.[\P*@.+M)Q
MJ'0"-*ZFUKZ)"@(B8I5(\H2'4.A@6D%CB!2X-WUQ//O$GQ&S8GG\3YAE]*Q_
M\)DMLF5 >PGR]:>J(]IYFZV-[8Z-E/ W"=&49,F@J'1;%J]VKPQ&Q+)4ZZ,D
MD=H0OH!W8N8>SCT!,_F9Q^8#"/B/9>0>*CD# ;G4=.%3'SVP81'^;@!$-<KS
M:HSFM_\ &9IG>8*;DK4YI65())ZGXB>0$Z202?OQN%-E65TS7BRFBBL+!J/+
MZ: @;6 *1(#:PZ>7:_IA+)OY>-4(M'R\LP6+]T[.1>M5$ASG)#H+I^&.0Y@.
M7VRB!1 0$!'6LK-F65.9\JK\QRV9+F]#52Q3+8Z@+PLK:K[];_?C*/E>45:V
MJJ*DJM8N(:N&"5U/8%2I:]K[=-K;8?;;+BRW&H[]LUM3UY=ZV!RI.&\HN*TX
MT0$0*=>/E5LKKJ)EYC%:R)U45A $P6;CE374. OVCN..#:M$XAJ*[BG( X^)
MI<SE>3-H(F*AIJ&HFU2%H552D4SM"P,BHH=A;1.)/"?AW.HG?*EAR3-[$TZ4
MZ%**4@=*F(MIC$NZAHP@+"YU$8M8H5U@-P*VQM-;?IOXN03*<ABCA1LN7)7#
M1TD(B=N[;J!X;A XY(<N2Y(8HC]$>$.*\DXTR2DXAX?S!*_+JZ-'0A@9::6U
MY::ICN7@J(F.B6"2S1L+:0,>7\WRBOR/,*G+,R@,%932&.1?L/:VF2)K /&X
M.I7 W!%]\+36SXQN(K;C_P"S2:Z?W.Z^_P#BECJ%]_?IU_7\#Z?)A$:AOWZ6
MW-O38W_&_I\^[!I_SON0?D#Z;#[K7PQ"+B?1WVD-PMO(G:Z6W$A*D;9_B2F+
M,^HL>S61/N)!Q%#=;-M)5\YA951%TM,.+"I#PZ2C4+ *#UF_1D61'+0:99H1
MF<ZC5/19:\M&#YA-605=/*B:3</,\"R TNXT[Z=\5UY;)E\,AL)LVAIZF4DJ
M:>AJZ2IA9P]QHACJ&B;XK;S;!P=.(A[@7;CJ6I-Z?UUGO$PWI5A+X]C("*H*
M:^VK2@?Z&21E*?(5U\O5'4:ZW02WO]6HH5KUH[N9K,H^A'D K1"-SC>3PP+6
MP0(X:C;-$IZN:5@S+2?%P#4NH$&$H9%1+%)H.:\VO2"M"F+\N-ZA-#/#1E+C
M2PJ8%D-=%86L?A.:UOK^4%-.^)-P3OBK@(_B#@XUK*6N-AFL<\V_LFX+YZQM
MX'E=EJ[)2B-%2AZ$^CKLX:;D#.^%&22T0VC9548%!8D>DWCX^RGDF^ JF@,H
M>*7/*:ED346F@A91EEF)+20.;@2-JN+@FR@BO2&*.NI'G TPBAGJ4(72A5F-
M0@4 );3INHLMKFPW)CM&2W'5"36S48*FXTJ,QMGPQ3'I\[%R[YJI?IF;5<\2
M$?N<A%[=+5V&!I%&;M#L;3;MOV]9BC)O-NFLU:4W40->H4BHS"*A5!\.ZQ4"
MLP>BDI8Z*98C%S T7-D=A*-'T[U"1P(5#$-0B"FFRY*FYD56:J,0/--2:N].
MRM?4YC0K99 T: -(^Z A)UX_$I%[FPN[*\3Q"O+1&T3AB@=_'LMMM,.&'BQ_
M$'/O]\:KM?'LJ>1>VP,=5YE>5.CM\A.M%ZMZ&ZK3]U,&E"GEA*PU52T::Z.2
MN#RO+K,\SGAC-X5-1S3S 8LUEIO+)O GTFD:1:Y8LT=/'* U;2PETT:=!-/F
M=%5MI LAEEIJ:569/+(Q4&_7&QH]EXYIIS<[=,#ODP)7YC:>0H=6F*2A$L)R
M,G..KB"@+RTF8A:LI2,D5KPR,ML3O6ZCDBT#5%H.SE*VDG:<H:EE:LE#EBUS
MLU:U1D%'7EVNP6IH8!F52[,/)(*QY==38/&Z+9T(!,<Q$!>I%#I,<=)G<M$B
MDNDM53OS<OBY=RLZ2)&T8@</'.CO'(KQNR%'R:W%6UW"@MQG=9W[?[GH;2KT
M#=^5;TB>"F5!]8.)+;UQ8D-LGL/MW,R5HKC7;UI(R)0VSC;%-/*NQ1?1#R+N
M!IN0850$++%.0::>=&GF8V<K3P22D2:3\0_-GA7FE&%/&66+2L+,IEG>)9JD
MQ!;TU96RP0 J8C#+')2II_Z$>BGD=TV#2*NAB9"IPL:)9>.F80ND[/EWI9*T
M2NT)7;^%<T<T/'W5\7B[WJK\VK-1,E7U9N8=N>'R-H"THP<2 O&D ]C+6Y*E
M-.TI)*:E=R*)JE09ILQX:IJT, "E'407SVH\@%WBJ+22N1:CD&J,PLHM+5)"
M$J4A9KP9?Q)6@@GZ6LIG6HRN$ZB2>?(I0J=RK$2!HP1B=O!G6I^G;.2=;M+6
MX,Y^/WDW_6=HW-"93>J-)G>6[S\&_B7<PV;EE:_+5R6AY6/E(I1[$N3O')&[
MM1RD\1;RQ KEV30N;U4&0T$56;;M414H^))/<FQN=][[]L4:@ZJ[,9D&FFGK
M:N2D7J%IY013A1TL#8@=K@#IB6?E_3\M/PN-^O4;_EWWN!T]\"1U[$[??C.H
M_C_OT%O0^G3KAAX-GO[*R_\ R>EU_P"<E_;\-!_7^/I^K=[G#$@-1PPQV\W]
MK7SF/T1>H'WZ?S&X_GAB&V_-LL=$V3W>O%0+'J6JF;:7>TUTDMXHQ@S$#6Y&
M5C_3BHHN%3M2NFB9EDR(G%4G,D8HE-D+6MD=*69U8Q_#IS=8(NSZ@% O8'3?
M4>PM=QH&+JAC6>MIHR 5,G+FC(VDA92TC&WVE2_+[Z@  >ABIM=QAVVQR.W\
M?:-OH5.&L.Y\)L#+V2,MC]Q8B[M'V@3W1EI5M3%:9&M0V^4\!Y'-)@T^UEU4
MU&LK]748U05"96HC05DT<2<D2S9S)2H!=(H,AJIXZA)+$%#6QP\^,/=B\@N=
M1.+"E>1Z6FF:74R4V13S%_+SOWQ##-$?]4L!E'. -Q+KO]4XU&Z?'A)[0SF[
M\C9-IV<CM;M)N@.TSF9KMU>R>X<S.GV+:;VHR+2@?4Q&.2ARMG)X!T8UQ4<M
M2E/-G;ECF[E)OBXI^=!S8UYBS+Q$((I"%2^13R\QYR1IC>H5#I+!E+DA@=0&
M+_X6/4\90>6#*DE%MYAFD2"-;7NXB0A' L0HV/4X0&Y7';NA2+;1X&5V_JT*
MI!6RN3VZ[2KVF1O;6;VJM/#;Q"[QQ<=3)9Q2*ZJ:ZM9#9A\1U'G8(-E?"A$V
MDKZOLSMU%74[+2SUSR%GI\O3,8IU6UGGI*2EJ(ZBG,G1 E0CW/GC<E&<,A!I
M)$U9!%(I5Y\SCRT4W,)M"LM;+0:9E ##_ %P"OD(ZN#?:P7T@&X5GL5"HL1L
M,R:7&^R,,=@>U6/<NCU1I V':'=;=5DN1_<=CX2R2LJS-M6_@'R<955ZXX)-
M1<U$6B2(#J/0KFG*RU4:2!7I9\S$S@;/\ M.3RPS-.$J%G!;FOV;F W"XMFE
M_N\<K;:S3<L$C4#5U4]'*'(\I<F @:3H(\JZ64@-_#_2(7-S(M]PY^NQ,3M)
M9&^S<[58A&R,V4O!1]VX,-VN(Z=B[B^?T:33E6I)VD-89HM R$._*H+!ZBL9
MLWDZW.6^JQ8@[#]Y,FQ/EI*&BJ:;IO\ 5JD-NHL\8 2, 731E6CC[QK34;#;
MZS9G6T52#<[$24K@W'U@0Q,NLG:6+Z0K<6,<-9-]M:UK$=MO>;XSWCK0NK,O
M8YNIP/"K.<0D)]5(^S4"KV"+EW9$6Z2L=8(B$=F=12"(N/5TLNZ1J,IB%4UK
ML:?,FY9T*9)J9H8X*H:E:9(>6T=D),@ZECI :FB\Q8$U;5=1E<ZNNI^735A=
MYHE,96/_ !$D!T!8R045=8D(DKM]Q06G<O;#?667I#[;RW[94,+1%KN8R[IQ
M3PM@HTK8X%RS;[G[=;:SCM>,?1SEM)I*51Q .TDV#R.EI)M(&188_.GDHLMJ
MZB%X:9J%IH',JZV6IO&]/66?4R03\S2J3'6MM "E;8GRUHJO,<OAE3FFN@@J
MX6&DB!+RQ\O4@Y?G,1)*:DN?(1TQ739_I ^(RL;85F'L4DR8[XU7A<G-V;ZT
MKU0A'K7<8CZW\.J.V6Y]-BY5HHFFWMU8OETAY"O-5$8N+OS>PP1?%2@8=^?)
MN V=2TS03&D@S3*:6:FT7$=:^95E%41,#J9&J*:""IHDUCE03(\861V8RQHA
MH:5P=+F.KD2:_D,,=!#54IU6LS4\\KPR)]8HB@D@+:Q?8O?VSVB@;[[M;FG?
MP<WMU+W!*P<.R,7"A9=EHVC,'TG&0TT_9>D2%JMFX]6+$7I.6"24JR\98H)E
M445&+5[,SEG*\=)EB5:2\XV;G5$!#4S&&H:C:GIW(\XC:$I-)J)GD5Y[VD&)
M43GU7(Y:J5CAEC@E!MIF@CE2J'8<Y&L-5Y(](AF8U$4N&DFN/BZP"%+C9#9F
M$>W*]T9]NQ#0U.N]UW%8LMNF=1K-E)]8B;>;06>W5JU/7UK9P[1&8I;.EN&K
M23F4[L#1ND@XKS:H:BIB=5CGRN3X?,8(5TP2.\G(_NK%K(YD76IG8SJA!U<I
MH5$_UA\5&Y:FLS4Z2?7@0!2D;;6*(I&KDA:=I"P*\Y925#PZ<3%^W@XB[/77
MCQ=KMRZKEFL];K,E"0[&;A6P[<<']O@H^3>-&X/E'L4YW?NQ'I%7BY5%Y$J"
MIUDXQ@*%*D#'XI9YOBZB"F;552+](Q3BWBS*HU0L XC6CRNC@TD#Z2"0N.:9
M6::JB$45&1<EJJ9"2;D"7)\HS%P=]V-373DMUTZ5O90!8MJ;\=B+_P .FW8]
M1V'MBCB;3?\ K=#_ (E+_L%U-ACNTPP:88\Q\@<V.7FQDN2X#  '03#T'KGY
M![L:IE@";[M9BH%[$ "Q/:X)O\L+7Z?C;\OOMBL?BFW_ 'TW,2&VE,D!0K[
M196F28K&*K,R &-Z3$)+)F_L4S]A)]X8@9X\\=HMELU,DY\&?M!^,M=FV9UG
MA]PK7?#9-1.D/$>94T@UYA,?I*BACF0EEI:?4B5**5^)9VB<,BD'TEX5^'L"
MQ4W$.;TXJ*RHU/EE'4J1%1TRJICS!A<!I9'YBQ7%DY>L>8JR0[8-R%$"@3!,
MAT[9  *&,?R?Y/0 Z=/GKSG1TZJJJD:H0J6=1;5$02E[;(5\S"(66,,OE&LD
M]BGJ%0M&FI@&,;2-]61AL=&_U5!%B+#<]SA9L6YA,'*41#/7W  CGJ&,?+\^
M!R.MEIX@;#I8#UZ@@="21U]=[;8QLDA6[#KZ^UNE^XMZGOOTPN6+ ^ #E^\(
M9 1P/3Y=O=GI[_/([514@,>XU=/+W[ [CKTOWMMC!U4[MJWTCMV('Z[#OWOA
M4MX=JHN@NHW)Z0ECPG)#"DZ2-D/:1<)\JZ1L@ \Q#%-DH" EQG6=3+:9ZJ&M
M9'22,)I9&:-T<;J4="KQNIMI=65D-B#>UL34S2<HQ,4EB86>.11)&XMNK(UP
MP/1A8CVP[D#=MQ8'E&-NLRX2Y0*#*?,2RLQ*0   %24\242#&< WDT '.!*(
M 4"=!RKBWC7)F+4/%N8RP+:]%F3?OR'3UL\^:K5UL8'<4E1$ +CMMIV9\-</
M5C:ILK@II'Z&B/[O<$#_ *5-%HAE/IJB<F^'1;;Y[DE2(FK!4MRH!2E]*!S.
M,BJ#@ ,;T "O_#SWY ?F 1_E  :WN/Q=XY*C_P"'\*-L/.5S=2VP\VCXNP)O
M<JIMO86&-9DX&R(.I%=FR(=V1HJ=GVW(#<M;=0-T-COOC*V[.ZSP<I.*?%IB
M40PA 2CU4,_^U=3Q$Q .O^U0'MW#5.;Q0\09@?)PW1Q'9'HZ:LGFM;J165,T
M=[]M!';$/['<-IN)\WE(^LLA@0=>Q2G!]!^/L,:5Y;]S9 I2KWN1:DSDZ4/&
MP4:4PCY>,:*=/2%#RY7A1QW$1ZZPDW&/'M4Q!XPJHXR"&@ARW**-@>^B:GH(
MZG20; \T&X-C<;WJ9!PU&MERM&(L.945%7(S>YC,XBW]%4#";>)3<BCX<K9K
MA*)AS"<CNU3IVYQ/@1,=DD]19F#V< 06_AE*(E GM"(8BJ_?=8+UV?<4SAM1
MTGB7.Q3R:K!]5,U::;38  )&!U!'2V1CBRR+2M-EV6 )]8KEM(91V'TPB,K'
MKYG=C?<6WPDE*C")J>*2(8"J01,191LBHX*8<9'Q52F5R(@ B/. CT <^> D
MX<R</\1-EU$9]5_B5$,M<QZ@23"]0T9ZL'8KJ52?,%.,U%F%0J+''/,L8%A"
M:AS3H/5*?5RU8; ,J[ L/M''0JR$ Y0(!>4!P4  "ACI@  ,8 ,X_)VTEI[)
M_P"6J#RI>U][=#Z#\!OZWNHS*+.7N=S8>_H?:^]OEZC"9?,@ZY( F#.// CW
M#MT^&.H?GUBJB$V/N".Q[?[B]]NWI:]2=^A^6X[^O??W'R^23?,0'G#E#)@#
M Y]V.@]/<.0QUZ>[6N5=)?I?_58;^EQWM<VMTW/IC+4TTA_#KT'Y^_X^]\(6
M29G*..@8\LY'W9QY>>?/(=  ,CK4ZRGTN??MZ;]OD3\K'?K;&P0S:P!M?^!V
MO_7W[=[HN1;_  ]H $!QC&<Y[!Y#U]^M>JH#>4]B?PL+;[?\W^_%_%-I= 1[
M&QN1ZCY#TM]^V$DZ;AS" ]A'K@<=ASG/7MUZ_F[:T[,:971NS7/2_KMUZV-O
MU?&>C"R,-?U0-M^VUK]N_P#OB07"YNPXVUW":P,DX'ZG7-RWC9--90?1V4HH
M/A14N0#"!4Q!V=)F[.8>4&:_.H)O1TPUU;]GCQ-FX!XZI,IKY0O#O%<L65YD
M'("4M:P9<LKMR%4+.WPTK]!#4MJ&PMSCQ6X)AX@X=DS&C6^9Y*CU2+L7FI
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M^M0Q/G9G9OD6)7\K>WXXJ.J(Q1.B (.GU$&F.UNV@"WMB0>HXEPQ^\W]K?\
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M\]_5Z?\ ]23I^& #S^>B%F&HJJZBS6%@%)8W4 =$7ZJ ;*H"CIB0?F+ GUL
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MD0Y!$-6SGAIYPL24QE+4TTG,:E=9I98^67:)EL[HUV,DA+@%8K[-OL=!GL"
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M;7MUN?E_/&>IV5@/\VXN=K7%A<??UVZ=.F$6^(7 CC(AWQD//ITR.1SV'O\
MH#0\U1M+7)"OY&MU*ZU)W&_4#?K8E>A.,A&P"D=VT)?VYL;D#TN47<=AIZ&V
M+:.")X9QLH5L8  D=:I]L@ !@ 16,VD,?$16>K&,/83&$0#N.OHI^R15O4^$
MX1VN*7B;.Z>); !(E:F<(+ "P=W;UNQ)ZX\G^,]/'!QK+RUTB7+J*1M[EGM(
MA8D[]$"CV%NVVVW)P-SF@[X&-Z?X*8#U#X_D$.X]\>G" 2H/^93UM<A@0";_
M %20 U[J0;-<7&.4 V((MMOO:VV_?;:V*5>("I<:3VQ[HUS;5OO,Z:RV].Z]
M[I]MKNXS*%K;/;:;X!;C1J3462J]ZC9F-,PXFU(:485M"&2BXJVC'[@IF9G2
M&63DB!:D2/S"05&:J2;#7&\O,ID*W-XXD*L@8 0S(@47Y;8K)H2H1QN6_<@C
MW/E1*A'K6!)_QI53ER2CZ3E-+&7Y<KHR&W%V#XT2/&J&U\A?S/8"HL)JI6V]
M;D.[Y*UV]V3AYM%5W,0AI6Y79Y.LW<G8R1["'9(RT77HRV3 3$:[AF"CR3;5
M?\.:I&_)T04D(&D6I*GB;AVLEB).[(*2BJPMVU+J+(R.%82TI!I8&-N=JE8,
M=_IHZ&OCB-C<?7F M8J6LS*UL<+AMQQQ+45Y$PTAOHXC'DINS)T\(:SV.O7R
M >_9C1(VA0DNK*\64W:5(>6W%1O4W'3MQWCO,-!EY6;_ &]+#R4$2NI&,:I/
M&Y-33T]:*=-.I3.:NGJHH3V;ET=/.=T,LEQ )1(ZAH0B-I.60%C:IIHW8FUH
M'IZ@S,%L?HVJ13K:X5%)F"\I)!CU;B;0<6%ZAK]6'T'N];4]Q*%#(6?ZUWQW
M7HVH6%)QME(.&>W32%WJG=OIIJJ^CITD>];[:[;7&N$9R4D^LLR[?-T'Z5(O
MBXQ"3R8<URFI!))T<CB'*:B1P/JZEHTJIR=MX0IO<C$E.76D!FNTC9?F,1!4
M#4\F5UT,:G?RZJAX*86 .F8LI!52)#;@;)[JVCAKXQ]E9&(L]VBK-=)&(V<A
M+I<W5VE;!MG+UC;5T_CEK+=+%+2[J.-:E[\S20M4P5TW;)G9MR$B21Q!HU\?
MQ$66<Q 9:7/\N:1%)53EM'Q'054P.C3=H:!)9!(#K?0%8D$C$](X1ZD:V$;Y
M&\2N-F%56Y354H47Z&7,98$#&[17O&5L#B(M_P"#SBK?;NO*G".)M"@U*3X.
M:WM+OI$RE9E+?$[74'>C>"Z3Q9)A:GBBJ]XV:KUR9P+67D8^7;V*+:5BPBE,
M32]@AV=2%)9:Z6=I-%349K6?$U"+8FG_ +*9[EE/6TT8.BE>OGJX:=EA5! T
MQDB"2*K"K')'%!31I]2*F&F)[R()!G^4ULU%)JWECI$I9)69]330J\6HAC>:
M-7I.^>W_  <[G;35N@GB]WJ.C9JG6K)4)YG$*;R&>&9/OMLAI<9=I-L[M;&$
MJ^E+6SL$Y6[$[W+83[-I<H]B\B+V$T[B:/+N6H@CCJ:."KB4!EIX8ZB%*N.,
MW4O2PTG/:GN?+&I0:A]:WCL&S)W8NSQRO$6)!EF6GF>E5K#:1JD1QR,!9"X8
M!<1*C]F^-J<^U!L\EN(J.@H.B<52^RYU=Y['5YI_<9.A</#[9$\TW:;V7.6?
M"CN(TW>2K,=?+C9F,3' ^93GJ^&DF\6>HD@%.U0^DU=."R+I L:7.-=/&;C2
MW_P\)I=PUE)M]4XGD(>H2.Y^&J.4E2P+!M%3E4BUCH5(=#\6W_3T-J :^JQ#
M^TG;#?)WQ/;677<BL[HR\A4MQMZIV7O#N^).]FXW;ZV[8O83;N*JU#6OCYO#
MSC-5TT@)E6'HL:_4F64W(RLB\C9".?NY8U$<E<-FYU#3H6 TJ]6*RGJ97T'=
M4EC1F6$7BB"E0@8@XD0DI"CG2(HZ:,);Z@6D9#Y@ &*MI1FO>1CS3==L2B8T
M2V)<9EGW+4AU"T9YPR4BBM; +ED9NO:XK=7<*??Q -0<>L2K-H>:C7QUSL@9
MJ$=F(BZ4<@LD2G1#EQ9N&_\ YG,<NF4DF_\ =Z2:(Z;FX'G <"P8VU:CTGJ)
M-7[NM:\-)7\SW=ZJ!XBQMYF41DJ6\P[6ZF,._5'XL).Z;Z*[7J;L%N,[&N4]
MA+A![H-:_LI3ZTILZ\BG$;;Z#(3JK"9NP;H>LI./=A4&\L=66J3Q+<"+A(:4
M9MJ%.)=$D>HK(9\R:K9-2Z\K>:\%+%H(Y#+3AHDDI^4_Q#I,6U*,5F:%9(Y=
M-UY.7)2"]^5F)E6&HG:]^8CZPO*D#QA 8%4%]HX6WAUXK[I7RA*1MXN,8UD+
MVG58FY/#M+#764M6]H$%4%'-WWVWNL;F-F;)!V5Y'DEMP'IV3MM*JM(^(AWD
M.BK=1JJ55-4OI$,53E#&P C1*/B[+\S)9E/+U0TD#R1EU9XPH"M<7- ,!3U$
M(N6>*O!:_P!I\BK(!9NBZI67I8$[FXN!.GA?K>]-8W)W3:WE+<R9I+]ND^AK
M?NU99-2?"<^M%D.%?B*HVW;W3HAHE.%>HN2V2D1.U+ C$D!!O:E)NVAW<3"G
M;ET=*AVDCI8%?5J;Z181&Y.NY<M<W)OJ;SVO;$TY'Q$[*+!IY&4"P !8D  ;
M  6 &P VMBT+9T,2LO\ \GI>8_\ K!?Z/VSJ5=M*W\J1HBCOI06&H]2WJ3NW
M4DF^*-@+^_7$@=38CC0S=9AK%Z,,NT,Z]#\;T?#ARAX?I'A>+_6ZR7-S> E]
M[FQR],9'+#&B^S6F_P!RC_XPD?\ O>F&#[-:;_<H_P#T^1_[UIA@^S6F_P!R
MC_\ 3Y'_ +UI8?CAC [:4W^Y1P]P^L)'I\?Z[T_X(/0CN".X.($7!'2_<=?N
MQP#;*G (9C%#>6!?/PR&,!G#H,XZ?CJ32?HKLS&*,1W-O.%C$8+[6+!0!< >
MIWWQ$;&X 'I8;#:UA\]V/^HD]SC(;94[(CZL4$<B(?P^0# =@+T=!D"A@ SU
M$ ZB.IB+ECW90K_Z@%5#?YJH![6]3O@  J+86C9F7;?S$D GJ0H-E'8  =,9
M#;.G (CZL4P(]O3Y   ,8QT=9]P]\Y^>H[WN"19D;L1= % L=B"H 8'9NK7.
M!N>^Q!%OFJK_  7YB^Q&UL_9G3/*),'_ #^1_+_77EJ!%U"WM:UCM=0.P)W&
MVWN-C<8?P-]2]FOZC[ON&PMC [9TT1Z19P[Y_A\@.<]LY=9Z#H;D@DW'0K8:
M6'10P[Z!LOH-AMAN +&UMP1UZW._O_$D]SC(;:4T QZJ./\ S^1#]#K]NOOT
M L+=?GZ=A\@-@.P &'<GU-[#H/EC/V:TW^Y1_P#&$C_WO4<,'V:TW^Y1_P#&
M$C_WO3#!]FM-'_<H_;']D)$.GX.],,+DI0(4I"]"D*!2AD1P!0P'4>H] [CU
MTPQRTPP:88J5XT3'6WK1%0XG!O2H-ND01]DB)7TVZ H%]XKNU3YZ#S8Z^R(#
M\Y/VH4>;Q<@/,'T'".1JB7W,9S'/)&0WZ(79FVZW._3'JWP8!3@FH9 MVXAK
M69OM'519:FD]/*O)! O?SO[#$=8LA1 1QW ,=.H8YOV#7(LM%R\AV+*=2_95
MELA '720H8ZC?4QL;$8Z/5FQTB^P!/S<<TC[B]AUV_$[]ZGF.. %R4',<94.
MF/!!\V\0!^'*/M8[AS /0>N3KP#E;J1J4STQFCZ*R),I.HBQ*JP5K7VMWOC%
MQ..>M^OF N;7.DDG8^O?Y8<U2G(7K;^WTD[X8PEQJEAJYY(C<'1X\MAB'D2=
MX5J=9N5R+0CP%RMS.4"JB0$_&3$_,7L'!LPHVH*U&!--/!5'8'FU$54)&B?J
M0B4_*(T%9 23J!ZZ/Q&2RUD<ES'(DD;[D'3*CQ6&DCO(#OL+^IQI9+@Q<SU@
MI$U%[LO("-@*OL%6[3#$IS.3/;T.'J[+7BK.6DDI.-EZR,D]D)%I*I(MI,YD
MEFRB2I?1%2.?1>4\0\N2N;X82/4YSF^=TB*\J\LYM200S/&1):RA:<QA]0W8
ML+V...5N72I3TM,LYC$%+#E[$I%KDA@D@DIU9RA;8TTR@JPOS.I-KIR'^C:V
M]JK*",I>VR;F-CMGHHLLUID5!2[AQMC>;U<9%\RE4)E1U'2MY3N81+UPV5.Z
M9D@V;_Q9'V&K7,GBF5EH!=@Z5%3,(;/)K1<LRC+VAD&K2T?/H)*BQ6QFGE+7
M788@4!=9"SL'J#*K:B55"<T^.BW&EO*KR4][@Z2H&^-96^!"M5%]5YN3N\7;
M25FP;?R;1@TVYKE>K\I7MMZ=?:I5&DA&1LDY9/+*J7<!Y+35U4\1:47BXI!&
M+8(-T10UK/>+:PTSQ4X^&E>#-D=Q).)5?-&R2&01R-(7BB@3)(7@IHRE,K5-
M4#$0X V+*<I6216$\DD8S*GDC34--J<9B[ABB@R*TF8E'YFJZTM/O<2%GCDE
MO5]IK[],YBBUG(MP8Q1'VDP>)%<DQ@HB5=N91(P8 >0PE  Z8\RYQ*U)G5#4
MB0K+!F%&5J 0)9'J:ODSL]@%\\+&(JJA A<!?.^KLT,0J,KS.!B2'H7?L C0
MPRLN@= "RC:VW;$U$4@$>7D#.,8QCMCICIV#I\\Z]&!0UCT!Z =AT%O:PVVQ
MQECW^IT-A:PV'<W_ %WQZ/ _]G[_ )#[_,?S]?SZCH'J?R_IBGK!O](1TWO:
M_H;=?<=[;CI<=*R0%*.2XS@ [_CT_/GKY?#4"M@+"_W7M;^OO?TQ4C-S];4!
MT(Z]]M_?:WIUVQX#DP'8<>?0!^0>_P"77Y#UU3*W%R/;O_Q_/[L5U;MU! V[
MGWM['T_&Q&-4\1 >4?RB& Z#\!_']>!UCY4&L=?U?U_6YQ?PR6V'3K[_ *Z#
M?_A./$/O>\![=,^?X>73J.!UB*Q "?3?]?KMMC*1MWO8^UNHW^72_7IZX0\D
MW O4W\K(9#'0>H=L!C\.GZ-8">-3\C>PV-OEU]O2^]B0;XR4+&VYO_R=NWI\
MK^N$#))8(?ID<=,!U[A\,_ 1$<]\ZU6NA)+)TWW]Q<];>@V_IC.T;$V)-K[;
M7]/8??MMU/R;N82#D*;EQD??C/0V?B(!@O3'8<XSWTRNA56E!.X8CMTM>]NG
M0[=#C/TLAN+=[?GN/GWZ^N&]D2!RGZ>_R]PY'(?''7W!UZ8UJ58 8W[D'^)_
MY'IUQL-.YUVOVV/W@?SV^>V$+($*(FQG(#Y"/4/,!ZXZY#O[O+OK0\UC9HF*
MZ?+T#="Q:R@#:XVWZ&WJ-L9M2"P!(%N6=NALZ]?E?TW/N,6O\$S$[398C@V.
M22M5@=IB 8 2I':L1 OP*LT7(/Q)Y=M?0S]D^A>B\*@S@CXOB3.JF(]FA8TL
M:E3;<:XW'< @@=,>4_&>H6?C60*0>3EM%%(!]F3Z60C_ -KJ?D1A=W>F6:6M
M$I(1T69PT<"R\)8'3)(#@E'-4%/95=$5 2K)G)[28= Y@$0$!UZ8_7_!ZCYC
M<=00=\<G!M?W##\01_/"3^SBY9#^)38#L'IL=^GTO\W7SZZ$DL3:UQ;H+7-K
MG8BQ) (V&FQ"V#OJB#;E_P#RU=1_JU@@:O\ T ^4"POV[8S]G5SP #"&''_O
MT=W_ .E_^&G50I%["U]KBR.@/S&O4+=& Q(JZ2FDD!).8!V/^DCII.]]KV/S
MN?9S<_[BJ#[@]-C>G7(#_7><]LCG.,_C#[0:VXMTV(LRO<$$$2EE%Y@>;:Z\
MRQ-YCN?G<$>J'8(?](0L@[@,=\'V=7/N,*H(_P#YV-]PX_VW^'NZYU%39672
M/,6):P!N1L0!ML=QZVL=B1B-R7+DWOV[6M8C[Q_ 'KO@^SJY=_4A_+'\-C<Y
M^(^F?+L/7'7/0-0&UK[V()OWM>YZ[:C8M;KL"+7PO8@V L;[=P&#!3VLI4:>
MXM>]]\8^SFY?W%/G A_7L=^7J\'OYA\?>&HBXW!L2H5V!\SKJ5G4G:P?3I)6
MQ52=.D[XA<C3I.DK8H1L4=/,CBQ^LDFF0$WNRC5<;8/LXN61'U(<<ACJ_CQ]
M_7'I8@ ^?3IGKJGRUL@%P$@EA5025^EL==B=.I2+J+6ZBUB1A_E  54^JHN
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M#(-0((<EA9B(QC&)6M$6BJ$62G+BP-B57<7 /?K;H/PWV[.XNX0Y6LXW6BG
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M ,>O3/3 X]_36P4<Q V!W_$7[;>]_P"'MC$RQ[V^8]-NA_#U^??"N;K!S$,
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MO;1"'%R"OU9"C%59%1SGT7UBM)GFN7&2^+ZP\3E'[W-[06!\9^*-0_N^5Z0
M+?#S^;?>["H!+;6V]>EQ?&Q)^P%X++1B UW&3U&D UK9O3<X/IMK$0R\4PWW
ML8=(L+"Q-[;N"+Z5^E<2M@8;7[H0#';+=23RG F:.7#RF7)VF4ZQV44Y<E%W
M"RXHI*+(Q4NJY3=@!D6$HZ=B5N;JG!OB;E_$T\>6UD'[OS-E'*367@JF5&,A
MB>PT-L6$3_9V#N;@>,OV@/V/.(_"2@J>*^'*^HXLX,IV9ZV62G1,VR*$R*(9
M<PC@M#54EV"2UE/#%RWLSPQ(VK%O91 Y1$_0PY$1YN<,8,/7'O* 8#L'PZYZ
MBQMOJTA#O<=1;<6[>I/7U]O%XL>JWU[E0U]K#38G<W["]NN*DN#J1E&G&GQ
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M3TL)TR)*]*T32S5* LLDA(0M:,* !CW-G.^[AMM"\2XB]R/1MSTY)1SRW:Z
M>G(Q;E0'*CY/U^/K$BD8BK(-2MP;&<'079D %">*-.63A2&;B&*3@W);Y"81
M"!EF6+^\WD501%_<CR^542Q0/S3,;R*VP%L3PMQK+1<,U-)QMG<J\2/**PMG
MN;-^Z((I9%$CVK5,C24T$M4JTC4UM#J0Y!8IU>5XJ#2RT3%[H;H2YAFE(B-\
M+=68;/7_ #64]292)(9U;2RK6+?38$:)R+EL1@FJH4%'94N98+R/^P)A66?(
MLAA I_BIS^X*5HX'%$]?+3FI2C,9GBIXG;DH6FLOD0E@,64C>(HJFAH>)^*:
MB5*D9?2)_::N!K(6K(J"*J-$U8.9&]34(@J9+)J(#.54G&L"Q\4XKIMS[G;E
M%]):G=HNOMG=!&JHDECP)R>M_K>,4+@LPD>/48&>>F J0?X.).41K&#@,J;Y
M!D[&.41\M.'(!4ZS :@:8!0B<JU-]-K*<MHU+:ML6JYEXA1U"K'Q/Q"O.HZB
M9IZGB6LFR_Z&KBI7C><U[4\$HGD6%%2TL,CK$P.LD>R5L?$;$L&3EQO'ND@X
M632))(/-RI:(:0K]2PW6N^KGTE)7%LF1R"M*>K)J(I':J@J+4[A%1-$7EM1+
MP563SPQ\,9'HC#F+E9)23RU<,<%%.L\,%/E[/RW2N0;R![#6 ZZS%=5%;QW1
M4-/6S<4\2TS&:H#_ !O$&90)03+555*89Y*K,C3EBU,TB(:9HXU(5C&= DZG
ML]Q7QSMLR7W)W0](=+RK5 C7>!Z^3,YA:^QM<HW,X86YP@DHTK\DS?J%65((
M^D%;$ SQ-1N6M"OA]4+*R9)D:<E:=I(IN'($=14U;4%.0LM#K<2U2F)=)(!L
M[6C97,L\_B-3O&).(N(YPYG1*JDXJJVBDY%'^\*E&$-8D"-#2D2F\*,=)0$L
MK)CV+R'%PAD%MQMRB\JB!#HDWJ66=E<*PX6))F5HE=#NCR"\((232-*@,@[1
M X-VRQTQ#5*-_#QE#)D>2.K, 7_LW"L?*-0M(\IE:A""&.9M$DP8)&Q6[ LM
MZDO_ 'F+(%/$/$R.RE$7^UM23SGIFJ84,25A=YFB!DCIF75. R6(O;E R?%%
M*G1\;=G<F,:+LI9=NZ/NO++ID?1]8?VQM&2!4K:!X1>08QYP34F?04FX&456
MZ-5P"%0O E-$S)PWDDO+FIH^6F04J:H*G,(,O>I@;X+34Q123#4L.MR!H 4N
MN%)/XB5C(O\ :CB6$50J)8I)>(JTL&I<JJ*^GIY:<U6FBEG@IRUI- +'6UPK
M80LEO!Q!UF010D-VMT&KPK=I)-1)N189-FX:.TP<,W;9=O.OHU^U52,"A%$5
M%VQP R9LF3.0N<I<@X/S& R0<.Y"\3-)&P.34D$B./+*C(U/'-#(N^H$(Z]1
M;8XP%7Q1QOETQ@FXKXI$B!&C9,[JI8Y(P08)(Y%J'BECE90(R"ZNQTN2 5%T
MW GQ V7?#;Z:;753TNU4=ZSCGDT0A$ FHU\@JM&NW22)4TBR)/1G2#HR92D6
MY$U^4JBJA2^8O%'A"CX5SFD.6ZTH<R@DECIF;7\/+$P66-23J*>9&6XN-174
M=L>N?!_C:OXNR*J&:NM17Y5+%!)F*H$6OBEBUQ3-&@"+("&5]*B_E:P+&\[B
M="E[]@[CD>WF/G\]<SW[_ECKP%@!Z;8Y:88-,,&F&#3#$=N)[9-#?K:N7I /
M$(Z8*Y:S5:D'!3&1:3L:"OHX..3]\*V>MUW+!P=,!.DBZ,L!%?#\,VT\&<2R
M\*<04V:A#-2Z)*>NA!TN]-+IU<L] R,J2+?8LMCUVTSC[A2/C'AJKRC6D57J
MCJ<NFDC$B15L.KEZE/V)%9XG(\P5R1N+&CV-X4>*"@7"+E&FTDQ+O*S-,Y5F
MNP5CI:&>JQKPKA 1=Q\B4RK98$4Q,0QFSLB:G*HF@L @'J23CW@7.<IJ()N(
MJ>E3,*6:FG28&GK(4EC:-@.9"=+@$V8!@=CYACQPOAMXB9+FT+1\(5$ARFKI
MJBC-#))59;-)'(LPE*0U$2%5E\[Q=>WEZ86\?MWQAQJB+AILM.I/FT0PB&[K
MU?E8AHFSP]D9OC ,F**KQ-.OPL"(J)BB$-'H) D#HOI6L//F'AO4,RR\4TIA
M>>HJ7C%0MBU71-33HK<CF)$\LT]7H5["HF9MT.C&=CRCQ3@03TG"&815T=.E
M!!,]/*[K2P9F*F,LCU#0R314L-/2+(4+&"(+L]FQY5=IN*@*V]J+#A_EHFNJ
MNF[UO'H-';D6+I&P(3[A1%P]FG+E3TQ=HU9JE<++E(S:(E3Y7)EW*U6+B#@&
M*LAS.?BZGJJ] T1J)G@4S1O1_!PQM%3TL48Y49+H512TK$R:ELHI5/#/B1-2
M5N40<&U])E58S3O!3+*!%5MFLM?/)'/4S5$@1Y&$?F9@E,$2(I]8J-U3N+ET
M:944V!ETU)IXJZ=$1"638(G4W!1W#4.A#A8O5 /%99LDR6D56:L@I%D\(7!5
MS*K'Q4<OARHI@.+X1'3I#$EY:5Y"L.6+E:"6=Z0U!7D*&Y7,6,2C4J7 &,M)
M3>*#"LJ7X(K355@J5FA05II4:MS>3-*@4U+%61T)Y<CF".I:G:<TJJK2$,2=
M$[VEXGI*-?QS[AUF%32+&-B'4DU"092*L3$N7;Q&*,NC-?V/6D7 /7;<I0!Z
MZ9L#NQ6!HD!+JES/@.E^$$''"1I2O+4PQEZ2:,U,ZKKJ"DE&=4XC^B21RS1@
MRE2KR,395N1^(E6*O7X=3,U6\=,TE\TII5R^*:1XZ96I\SC7X<RDR3QE2*R%
M:<S\S0"-@MMOQ8JP\[&%X>Y1%>RHBG,RQ6\B=Z\6"GO:4+HJ:T\HQ;G/'OEG
MPI(M"(^L1$P$%H;T0)8Z[P[CGI:D\8T[-12*:6(M3B)43,FS*-"12B9],K,M
MVD+<I[$Z@IQ4_=OB68:JG;@*N=J_+:6BJLQ/Q0KN9#DT.7/(J)5+1)UD\JTA
M3FK?18D8\R.VO%LDZ5<FV'FN952#.<4V[QJX;GK]%<T1HHQ=H3)'<>Y%@Y%\
M#QLL5RC($ 454VHF:C7ES3P]F72O%],K(:QWO+ ZR-79HV<,LD<M,Z21)4L5
M2%E,90692WF-M3Y+XDTDT;_V'S*10,J@9N75,X@R;)H<@@E61*I.1/-1TZ-)
M)3&-A(24TJ%0;1_1N+*34CWG^AZE4Y*&=LW\'*@69<NXMZRJ474478B\L;@L
MDX]$B&C]525*[,M(D%4XBW.=L:A3U_A_3++$O&<)AJ4D2M@)I%2H6HKZG,I(
MBJ42F!>?5R*HI&@(ATI<6!%]597XD54D4PX$K%EHIM=!*K9F7@Y%'!EU/*K3
MYA+'4,::EA9OBTJ )P[@;Z<-C1N![B'MM@914E1'M-BA<)!)3UB58LV\>S,)
M1473;%=C(22Y$@,*39HB<#*\A5EVY!%8N<S?Q2X.RRBDJ:7-H<TJ"I$-)1HY
M+NH(57D*Z8H]>Y:0C[6GLN-=R3PDX[SC,E@K,AGRFGU"26OS&>-EIPY D:*G
M4)S9N6   I:UM36-\?03MW2HK;JD52C0I!5C*M"LXAHNJ!?&< V)RJNUS%#
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MBO(\BUZFLX<. >J\X/2-_1DCI'.?59(&CR:?.#+(5AJH:5J:: QM+K5YQ(A
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M677465565!,"IE10)LE%Q]P+D]-5 <2I6O/5SUT\BPRM4RS5-]6F.&&*.VP
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M+5M550S30U:M'1FG1+O4PFZ<HK%<I.%TG!% 6(X364(L14I@,54JI3 <JA3
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M@YE35.\LV9U\2!-3S2R("J1R/($,*V$4NO0%+@8VMUA@A%PL8F8C-D@94Y2
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M#-NR;-VK1($6[-NDR;IEP4J:#8A$DDB%[ 4I"E*4 [%+@.FO<='3T])34U-
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MPO)R(JB1)>0COK>)%F("2H,([;XT@%\I)X@ICRH6ZM&BRIE$YSOPF&0LBD*
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M4W27 WO=NOQ W.P[DW:02HK2<7]1763E(V;MLM +>$NUAZG$1R+2(I;)HA_
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M\;F\:Q.C BHU22K[,5)!%!T)$W\B1BQ 3@Y.!>'<;\1GA;(9JVGB9ZER*>E
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MZ@J$03G57AT6ZO:.%?%7*,]DCH\PB_=-?)94UR!Z.=SI%DF8*86)+'1+<
M2,3CP)XT?L3\;^'E/59]P952<<\.4_-EJ88J98.(,KIDYC\RHHXG=,RBCC5.
M;44:P2:F+"B6-2PN33<E52*JF=,Z:A043.0><BB9@#D,02F$!*;F*(& 1*)<
MB&0[=5Z]/8W[6./$S*R,592&4D,A&EE*FS*0;$$'ZU[$=".^.T" H4!-D!-U
M' \OPQT_/W^>H"QWM^._\;@8EM]W?8_S%KXY F4N>7(9[CG(]!R 9'(].OY1
MU'[_ ,A_(6_+  #_ '))_$[GKWQUJ()G !,4!$F3%]DG0>42B/W?,!$/D/3&
MH;[6)!!!N#UL0;$="#TL0;?6'F"D#Z];7(![&Q%P18@V)W!!L2.A(Q\_'TY-
M2K59VCV+"O0<7")K[EVQTLE%,6T>BNZD:\BX?NUT6::*2KMVLW24<.E"&<*G
M)DZAM<<\=JJ>JR/*)JJ::IECS6*"-YI7D:*$4-81$A8FT8TI93<*%LND%@?H
M3_V<-+2T7'/B)3T=-3TD-1PM35=1'3P10B>J_?-,K5,O+0%YV$K<R0G5*=)D
M+%$(^=>J7N[T1^64I%PM-.DR 8"R%6L$M7WH <,'+Z3$NVBPE.'0Y!.)#AT,
M40Z:\VT>;YGE[ T.85M)9M0%-53P+?W6-U4W&QNIU D&X)&/JMGG"/"O$\7)
MXCX<R//H@ND+G&54.9:5O<!&K()F2QL0492I *D$ XL$V)^D[XS:A9:567>[
M1[E6'%EA6+V.OD! V-TNT?RC1N[!6SK,$;>)O1U%"$,:P&*D41Y" ( (= X=
M\3>+(*^AI9ZR*OBJ*NDIW^-@220))41(Q66/E2:BA()9FN;,?.J,OESQ._8_
M\"<PX>XBSK+^%9^',UH<IS;,XJK(<VS*")JBDR^IGB1LNJZFMRM(FD5=8@HH
M9"OE615VQ]E"2*?)D,^T0#!@1]@3AD1+@<Y]PY$<#@!P(Y]9@]=AN5)[W+
MFY]ML?$1AI+>UQ;H-OE;K;KVWL=SCU:GPP:88-,,&F&#3#!IA@TPP:88-,,&
MF&#3#!IA@TPP:88-,,&F&#3#'$Q@*&1U FV^&,"H4 SU'X '7]6E_8_E_7#
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M'/"LN;<1YYD,.<UTKYQG-$A3-I9LQR^T&69A21(T.65-' ?*"W+U2 RL[&.
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M]!#.0QYYU[T.RZA=O*FRC>X-[;D#I[_=C\TK_7DZ>61P3?[(8@-VV)('?'N
MP"'-Y>>?+4V(8"FYO(0_1^'OT.UKD;^^( W['[Q;' RH%$,E-CS''W>^1'X!
MCKY_#4 ;FP]OD;X$V%_X8Y$.!PYB]O(??J.^X-A;T-\ 01<=,<],1P:88-,,
M&F&#3#!IA@TPP:88-,,&F&#3#'$Q@*&>H_ .^F%][8ZSKID^\.  O,(C@  ,
MB&1$1#&,==.]NYZ#N<.F_;O[#U/MAI+GOIMC3/%0D[*@[D$C 4\5!E&7DBF
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M8!=$G+\IY9"MKW!3;;4#<VW.*D\7,X=OH.'Z4^56*M+42.%:Q#$*$TK8WN;
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M$>,<BI\VH@\\HY4%;2U%8?B*>JN-<4D<*0Z=>_+;<2(0UU.V/A'^TGP5XR^
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MHB6P 8$'<B]K;]\>?,_X\XBXA=XUJ&RS+R6"4- [QF13?>IJ">=.VD@,(S#
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M]/5S4Z\HKI4ULB(&1K%(T)=EU-&,1":LLFR!E51.8RBJBYA45564$3'6544
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M0A/_ -]GYK1!B>W7GGV]_P L!PA&>E>U_>$#_P#:'\/?&!_=/>XA@$H\)M(
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MBO;)+(-ET%O#YDG*!" HFMK?O$O/*/.*[*5H,R3,Z>ERS0U2B",1S&8ZHC&
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MX'M>1IL?D/3KO[7M^8QZO#/TZF#';'-_2&I;>Y_]S?UQ5 ;U ^0'^V Y#F#
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MSA3OU4Z+D$BVZC[\>Z/NE7LW.G#S+-PX$HB5H<QF[SH "/\ !G!4EN0 R(G
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M@P:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IAB)/&
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M=P38$G^&,?F<S5=:*923%2Z0!V:21 QOV\JL%O<VU-WPLX*'(J4AP3 "GY1
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>F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g752656g24u24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g24u24.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1O<4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             <H   -(          $                          0
M           #2    <H                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   <H     4F=H=&QO;F<   -(    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   '*
M     %)G:'1L;VYG   #2     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      19@    $   "@    5P   >
M *,@   12@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 5P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M8VMWC;L0@VB[JO4:GGTVBNCU'M>6N).[;N&GT=GL_ML358>/C9^'Z%UES2;
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M,,:\LWND_0'M:]_TDE-9EI9TC!#1)>RD >.UHL _M.9L6?;D,N#,6IX)>WT
M_72N8LMC_AMEUS_WZ_00<K.L.+@-QZWEM&.'6V656"MKMC!+O8/4V,%GM3X]
M=.,T%[-]H(!>]MQAQAFZUOV<;_>[;317_GO_ )Q3PX8Q!)%[U?\ TF&?$9$
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M]C@^9IQF[&@B"7 >G^B9_(;^B9_QEO\ A5?-P96UUFCW<,;[B3^ZW]Y8F/\
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MY5224_522^54DE/U4DOE5))3]5)+Y5224__9.$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M 7Y-30 J    "  , 0   P    $#<P   0$  P    $!X0   0(  P    ,
M  "> 08  P    $  @   1(  P    $  0   14  P    $  P   1H !0
M  $   "D 1L !0    $   "L 2@  P    $  @   3$  @   !X   "T 3(
M @   !0   #2AVD !     $   #H   !(  (  @ "  7;#8  "<0 !=L-@
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C V.C V(#$Q
M.C,X.C,U      20   '    !# R,C&@ 0 #     ?__  "@ @ $     0
M TB@ P $     0   <H         !@$#  ,    !  8   $:  4    !   !
M;@$;  4    !   !=@$H  ,    !  (   (!  0    !   !?@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0& 34T *@    @ # $   ,    ! W,   $!  ,    ! >$   $"  ,    #
M    G@$&  ,    !  (   $2  ,    !      $5  ,    !  ,   $:  4
M   !    I $;  4    !    K $H  ,    !  (   $Q  (    >    M $R
M  (    4    TH=I  0    !    Z    2  "  (  @   /      0   \
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-CHP-B Q
M,3HS.#HS-0     $D   !P    0P,C(QH $  P    '__P  H ( !     $
M  -(H , !     $   '*          8! P #     0 &   !&@ %     0
M 6X!&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $
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MLD?(CS/Y?A52"V/'C!42>82M#9\_XG$_>1@"I*I*D.0H@H4_//<!Y >!X]0
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M*5K^>7ZW3^^9GCAE/R36HUS&ZLS+PK90H1[E^J<R)5'28D4,=9$7K Y3=1.
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MU)^"J%,9,#D'T,7K*(E$?B+W,'-?3^QO02/&VMT1SL:@J&0/%! '0YD^>1!
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M )-=)#M_'^G2H'YG\34_=*FO@CP'/X>GWCQJ"=HD^GWF/SI03 'Y"/;[N_\
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MG@2O<1!.(XDU.#7CJ]C32E-*4TI32E-*4TI32E-*4TI32E-*4TI709PF0>#
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M]<5[@$!]._\ J[:D&1(JE-32FE*:4II2O"]'A!3E,5P%!3E'MPJ/0/P#U"!
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M$,"Q5N>DAR&#T'HW2+6YT$7B+*WMWT:Q;L;F4E'[$L+4I$%2AME 4(,R5="
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M+MJVA1/G^U<QM@[4ICDDXQW9F=Q2VW/%[)T0[FE5MQ:)MJDB"YC@+:.CRCX
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M0OS#\>?]6O,H.^%'JF(Z>TJNR/93Z)'U_7[NE=:K%(P',81$QC%-U"! $/C
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M#VB[F[U>ZO\ M*VV0'"-#TE!X986.[4I C:.YMMX6L [=REQ.1Y5*&-.8MM
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M!CWJ'PXSBK7H6ZK$&1;--5>#DYABYB64M*M):QPCNO5RSPT#8!JDY-5.<D_
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M20! R:QP:HHZP)2$73;X]I"7!UX6TMO_ /%@]*R.J4NW<9C"BG'GM6E0,?\
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MW[C\(>H^H_O^?U^>E.>:^> CW_5D[AP/PAZ?V$0_#MZ:@)2,@ &9P.I 3/R
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MK)>M>MNFE*X>&3J$W07J'@1-QW$0  #D?GP  'X=M5"$!2E!*0I9!4J!*BD
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MT65ZK-S@F5*4JQD7+OJ28@J!0ZR1R#0@@(AT](B UJ?PQCIBLE@' <?Z/ZN
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M %41D$ ^'.>?2GQJ_P!/<SN^5Y%/V>EZ,4/YWZ?\&E >XAV \Z01[!SZ=@$
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M&Q<SXD7"LR'>2TB*+?E!L1RX2P*(^U6*2=J7+@MN&8VMJ0I2E$\)2%)2"HD
M$I!R16PRWW@7(D #KS)/O_RGUJCX:W26ZYYLAZ<K7J<AC"\V+.-3H1J^H\&S
M0ZV"Y%O&2,M9N%C1"L7;BG![#$CFC4(U%1@BJZD#/2J$NPA2@IQ4C]BMQ4B
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MJ &ZR X9G=LV3HS!T5=B9RU2<';G632424KG2L(XIQW:;/=:90ZU7+7<A/\
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M"TBGUV7FYZ"J]<AIRS."NK%,1,)&QLI/N$P,5->9?M&Z3N463((%(J]57.4
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M5@H%O5:W5:I6+(SHUXKKVS/'L189TE%NA6L9;U;(LLQDT_(-D2XVB!?-)6/
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M8GS^[\*EK%SD/-%6/$2<?*$;*B@Y/'/6STC=P!$U!07.V45*DN!%2'%)02J
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MAG%N,M-3$55'DFZJ<HSA:E>YP94D30+F_<$($!;7RD)))),%DU6R:J*)'+U
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M'$XD_,DQ_<^@O3<%MQN>;;5CB3CLKIU>ET5TXD9'&<I16%PIUTF"NFCJ&F;
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M""?B#GXD&M,3&?,CY&N[4U--*4TI32E=*INC@W4(<%4[!S\0@7J_@!1'Z^O
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MLF3L8W2/ CP(&YX#@1^7WA^>HW"8G/E2($]*Y%4(;G@P#QQ]W8>>![^H#P/
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M*01[QC)Q,XR *_08 <#Q]"E#^G6/J?</SJU<M32FE*UV;1/\++VF/^7G#?\
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M*8\@\;MF;X_ZAFQB)SW?#OA42B!<HI)*#LVR0+=2IYB9] ?2/AGI6&Z$72D
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MI8Z(3@9DK5^BXD&BJK)OG,%%N4D!;K-BXJ?9"KJ]M;9R.H2VV^M8DDA21N)
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MB(&K("="7D#1CJTSC=M(1Q4HQ1)T9=+,V.]WP0-DS/6/* ?A,"JK_9A(,G>
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M@XY(!,+3N24_[P ,CG'I7S]H%QU F2JY0E/ "BX1$1&"".(&9%8DVW-O!Q+
M/#=U)UU.V10?YP_:"=D99/K$>1$P).R!R(]^.0 ->-_1@ KL9I5URJ_%S>+5
M,E2W;IY)),#(2A*3Y0!S7INVA_\ E#>-#V;9+%ND#A(;8;E(]Q/OSFLVO5RM
MFCAP<2@1%$ZIA,8"E "%$PB8P]BE[=Q'L =QU[M]P-,N.$A(0@J*E$)2D 25
M$G  &23@#->62DJ4$I!4HD!*0)*E'V4@=5*5  ZD@"L$8*3!Q1GMLX44=7BU
MVBVE,<A@549R,JNG%&#L G*:);,?#$I +T"7H 0[F\!^CYLO:;<:K<([NYUC
M6K^[6IR4EQFVN#:LO0L#<@MLA25I\!24[?"17JNV3@3J#5BVO>WI.DV5FRE)
M![M:[9-R\T )A:;FX="TY6'-VZ(@>7-ZY)4,;50I^L;+E2M [22$IE#L:\F_
MM3CQ$^1'P2J0B**YND03!8.K@1+J.V]P4_Z.Z8ILN(U/M9;V;C<%4VYMKVY*
MB ,MDVZ1N&)@@UG[(,?_ #_J8<[I6E]FKZY:<)* ;U;]G9M6P62 'W&KI]:6
MOWBD-.*VE*%D6QB1F6UY9S)E _BN6Y)&)QI4W!$Q%N2/JC,_O]RT73$R2R:M
MF>NVZYRE 4EXY1 QN4CD#E=B6$:KVK[8=I74=ZPSJ36C:0YMW-!G3&&["\^S
MJ'A6&KRV>9?*">[?0XTLAQ"Q6]VH'ZJ[-]F.S[;FQ^YTU>M:H@F%-W5\Z\_9
M)=3RTI=@JW<;0J%.M.M.I!2XDU*EJ!BI@0X&ZP*43', AUB(F^8^HAQ\7XA]
M=?6S[1\NGN_#^G6OGC<A(!F8$R(DY^_&?A7IU%7II2FE*ILF#0&3T[TJ1FI&
MRYG(+$\5$6Y43F6\5$0,55/PP'K3$INH X$![:Q.^SZ 'W#R]U$X4?4@>_'3
MK//'PK65M^W&;7KEFD(.D[;4L;V"QV*:K]7R<.-\>0I+B=I6AN;:7))UX%+#
M'L[? I2$A&>^&K)=T$>KYM)NNNW3+G:3O92XG@3&WK.#!$21$G\N#1SPN.)7
MA7A\))23DP8.<R?QY,UL-N>/*G?F$0RM,065;P=@@;3%HBZ>M2M)VN/DI"(?
M%%BY0,<63M,JP(*F5:J\="Z*I/AU"?"^A\>V@.0>HWH6A6?4*..)S1P%5NM@
M1L<+94GH=CB'!YXE(/P\JP2[V6;=WSV<DW=,F%Y*:7.[2?J7S(1G]5<'L:-N
M%3'CW[3^9QT8;*@E,B%'5K_+I,O84B@F%$*4VVY .Y1)\U9'3'N/!S.:E7B6
MW(D)'6=IR>?P_*NRO[.]O55L-7LT%0'3&1JCF.DHU,;3<W,:ZG8<)#W59[##
M.9]6)M-OCQF)0S.U61E*3Z*[Y=<D@"XD5)1,MAP@*EH@-B#X@3'A Y 'D)'/
M0T<EY2"L27/$N8 ! P%8$0,#@].M8;V@%*7='[2H"I@D ;A,2])"AT@4/Y,>
M)1 . XX]1'I^7(AK+,P>I )GF2),_$GXT3Q[BI(]R5%(CT@8]*V(:5:FE*:4
MJS[E8&U=K4Y.NE4TD(B(D9%THH;I(FW9L'#I0RANW2411 O/8.H0#GG@!Q-A
MQVXLF6T%;EQ<M,. ).YM+P5!< $MC<E(E12)@&MBU;[RY80 5DN)(2G)4 H;
MMO).))(!Q6%=H<(M&;?,<NW[<496SQKV[2H@4Y/&D+K+R%L=.3 ;MRX4F3*!
MT@4G!@\,I2 0"]OM"X'-8O$)E3;#HM4'D);M$)MD)!' 2&HY,?$UTNT#Z7M4
MN"V?V: RVD R)0PTE0G/"DP<\CSJ3(  "/ <<\<C]?7^C^O7(ZGX?0KB^M?=
M32FE*:4KB)BAZF*''?N(!V^O?2?NY]*5$3=(Y"S2F$,0-@3<FR!DR.G9M(I?
M&%O5<8*-+S(NE0)U"D@M*,8&+,JITH_WSX$PFZ"&[FC#N6=3U$JVIL[%;;:I
M 27KT*M4IDXPVMYP]1W9R/:'I.SX2RG4+]6/L]JI#2B8!6_N04I)PH[020,\
M>8!E$P.<IT2>$<J9SKAU"4>. ,L*8]0@ <'(1,2\<<@(#\]><0L^'JE3SH"N
MA2"O8H'@I4$C:<@R""<5YM)EL+5A:W%$I,3D%4D<C/I$GXU6N0#U$-9I Y('
MQI6**UDV)M-YOM$C$'@OL>)5T)R0.F!617UB:+R#:,16YZE'C=@FW=NTA(7P
M2/F8@8X+!Q>YL7;:QM;J-ZKHN%I(E3BDM+"%K( ."J0#SX2.0:W7[13+3;JU
M%*7/9)$(,C^$F-Q'$CS$Y-96+^R'<1^\?7D.P_QU45I1&,_'FN6E*:4II2FE
M*:4II2O@CP'(B ?>/IJ"8!,@>IP/C2K.NERB:-$*SD\H[)'$520.=G'2,FIU
MKGZ$@!M%MGCH0$>1$Q4ND@!U'$"\CK+:6KMT[L2XA."1O<0A.(R2L@1)CGY=
M->YN.X1N[MQS.0AM;A^2 ?KW@5A8=T&,>W]VV$/PI=S-V^\ @1'L')OEQQW[
M=M=K_175SPK2?_:5A@$8G_6OKRKF'M%9<=S<9Z_9WS'R:^N:SI6+)'6RM,+#
M%G7-'R2*JC8SIJZ8KB5-=5 ?$:OT&[E$P'2,'2N@01XY HD$!'B7EL[9.N6U
MPIH.M$!19<;<:\24J&UQ"EH7X5 DI41NQR"*ZEM<(NF47#84E#F[:%I4A0VJ
M4@RE8"AE)Y D9&"*T-N,Z[QK3FS.*.)[]N1M5AHF[93'E>QZCA;'[C:\SQ5$
M2=/+8V=ERFXIC.?9OV-:D)U^L^0NKF8:2A&K9M&/S&!NGCB4MR(!M[AP',*6
M@(V)G@J,JV"?%T$BMI(PHXP@D>IW1&<2<XD2/C5G;8=XFY"3O&#I"S9ARY/I
M9@F=P$!/-,YX?J= P&VD*:TOCZB1V*,F0M,JSJ2F =UQFW6:R-AFB/Z]'S\D
MN)'#0JZV*T2?L5HM0*7CV>TNX<23"TWSPLS<L+2J%"X:+CY>8("V@A6Y(V&+
MO(3]I,06@Y=#<GV80^4M&<X6B"V9A284"<5*K9SG+<";,]5HVX[*>1VMROU#
MLDR^QEDC$U0C*)/V.%6BGRDYMNS#CE D!.U")C7*QW5=LLG/V5Y!NVDX"J!V
MSOJSLC<F58/DJ02><<3C ^'&)UWO"? ) R"D @ ].L9YC@&I,V+>R:O[R*AM
M9'%.57[6Q4"=LCJYL<97!W#H2\?/5:*9K-)M-H2(7J*3>?<FG;"4ZS:)?(,F
MRZB7FN!K;2ZU+G[-8_G\,_!43Z1GTK(X D2"%3_*9.>//CU'/G,"T-SF^^X8
M"R5<:/7L%.<D16/<>XRR/<[&2_Q=579QF3,@35 BHF%A'M?E!EYA-Y#*OC%=
M24.S49>*(O$E4R%5JTH*N%H) 07F;="B0-]PZE'=,).)?=+B>[:$K7N3M!D
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M?3\,.0$QRFD!,4H"7GI_: .=>&_2)="V[+7:2?\ :KK2K$^Z_P!6LK/X_O\
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M.TC@Y^['O^^OCUTBR07=N#E30:H*KJJ',!2IE2(94QC";@H%*F4YA,(@ =/
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ME/D>>.ALE(+;Q,@H0%IXC"@DR?\ B!]8]*UZO=ZV>1L<+%EO=38-,BV:;B;
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MN[=\G8.IAJFHS;$5.@R5</2"#7LZ_P!I[;M%;7K+3UYI>@BW%E>:]+MJS=(
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MSE:7#B5H]DF!,>XX/J#7KU>JTTI32E-*539(Q!9/2G.4A?++ 8Z@J%2(443
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MLQ&6O-=K3=-K5FF6)9",G)1(K 4QJ@#2DUY--4#JH%;P_$H[2ZBE]Z2[\PD
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M^[SZ_*ME9"B4H /'/ <\>G^G\]$@B9ZF<56NLRY2D,?I.(%$0'I+R(\&$HB
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M=KR&SQ<W2EQ:V\<*2M84XX 9[IEP=:KHEN@+N;V\"56]@&WDGH]=$NFU:1N
M"B2A2E@[3"<2"2*9?YT,24RB8 PE&,0R-9HQ&NX_C5"^-'5B!B"MDYV]6=0A
M@.6/@&(*O#',(K3,\=E&$7%=_P",2UJD:FZ_J^I=XJS:=#UVH;0Z\\ZHEJW:
M!4 %.J$F#^R9"UI22D)5DMFU7]S=:SJI4;5IP*<2GQ..**TH9MV4KVH46U*0
MI8*PD-H4I.X@).<L0XKA,24QC5845GBHKN96>G7XD-+66QR8E7FK#+K$3 '$
MC*.Q456./PID\-!+H112(71U&]?O[E3RPA*% -AI$A%NRV-K++"<CNT)&W,'
ME1W$DURM0O7;^X+SA_=CNV$S(0VGV0?(]3$\\UE;6K6E32E-*4TI32E-*4TI
M32E<3& H"8?0/I]X\:4KCXI.KIYY'Y\?+MSW_/[]5W)XD3Y=?K\\<U$^GX?U
MFNKS2?\ BG_(O_\ UJ9/D?N_K4Q]2*Y N40YZ3@'<>1 O'8!$?YWW=M <*)P
M$\S'E,B">)S,4ZI'\WN@>_K]U1(R!OJVUXRO$M0K9<99&4K#N'8W:9BJ;;)^
MF8]>SY4#Q#;(%VA8=]5Z:N\1=-%P3GI1D9!LZ0<.@004\0,:7DK*0 KQ;H,8
M(1MW'F8&Y/ ),X&#!7A7LY4(F.D@D?.#GCUJ52$NP<IIK-U2K)*I LBHD9)0
MJI#I>.44S$4$#]27QAP/ E[\]PUD_B4G:?"5!2L;04KV1,Y*CE, XY@XJ$J"
MRD P5;8GKO3N'G$ YG[Z[$))LY 3(FZR@8"#TB0P@81XX-TG$ X^??GZ<ZIN
M*29B-_=B//'G&,^_TI.8^_I[13^*3\*Z6DY$/W,DR92#-T\AW*3.7:-W3=9S
M%NUV3:20;2*"2IE62ZT>]:/4DG!4SJ-'*#DI1163.;(,B1D"<CC'.:@J ,'!
M\CS_ $^_WUVFE61 ,)UB% O6)A%1'X03 O6)@\3D"EZR=0B'!>HH&X$Q>8"@
M1N&4@*5N&1"09SZ$$>\'IFK=0"()4$P>948$\Q//NKJ&98@!!$QNI0.LB8^%
MXIP #B)BD\3DW )F'D.P@')1$ ,(4+@!@A0\6R<1N@DB0>0!)]XBJA0(2H?Q
M;8'7QD@?^Z:AE-^T.VVQ*\$S9OLDVQ[88FV3S-I0\/Y*O+EG"4BX2%#LDK-(
M5:M2JL&S86F*D8SKE"-3+&:++I$,W+XNLA"BUWJ8@M-/ D@>!YH/H\^6\QQ\
M(- I.\MG!%P[:G&.\:4I"O\ AE!@]1!BLIT/=I@;)D#;+/1KNC88&DT:OY(L
M,HRCI+RC:H6>!=62'E&ZBC4@/A<1#)TLHT:>,[:K(F9N44G8>#K&MP-6:[Q<
MEEM2TJ*1*BI#:'%!*< ^%:8,Y,^59$)+CZ;=(_:+"2 >/$M2!)_WDF<8&:M:
M-WMX*G;U!8]KRN0K),SM=IEK]Y5_%=_EZE!0608L\W4WMMN+.!5K54"4B4SR
M )STFQ4;M2BLY*DG\6LC@4VZ65)4%CO)XVRT 7!,_P ,BL+;B7&DNHG80DB1
M!A9(3CWBJ1#>T VNSD=;Y=K>)-M&4^OC:Q>RE.M<4C;:X,V2L)3..?/Q*"F0
MF#JRK-J\S7J))4KN7>L&;?Q#R#+Q\0="FU.!*C!0$H@;W.\C9L$P=T@ J*8.
M#%9BDC?_ .;;?>7Z-6S*WWG/]UMM"U'KX2 ":K;O?%MGBL5I9DG\B(5>E'N"
M./5!M4;)5RQM;\M,MH *4\J4PV:61O9TY5XV;K0YXWSB2:H.SI@S 7 9B"'K
M=B)7=*2AH@IVE1"C!5(XVD*B8/IFJC*EIP"@IGR.X>$@CD$=:ED10IP((<_&
M0% Y[#TCQZ]_7N'/].J!8)">I3O^$@?G2N>K4II2J?)F3!DOXG)B^$H)B$*"
MBAR 0W4!$^!!01#L!1 2&YZ3\E$0'"ZI.WVAP5<YVIY5[DDB3P#$D3-63[0^
MNGYUH=V0S$C3,P8C915LNPX8RC-959XKQP7<TKDJ8IZD.YGI213RABQQ18PE
M?BU5B/U&I(RTN4J9**14(_366?%23O;C<R%) 4C;NW#*849201C((*3,$'RY
METCO%"1/AD B<I3TYSZYK?8J8X<= ";D#<\!SVX[>GIW]/7GCCC^<4HG&T$S
M(QG\/Q\_2:I6@^7KV=8;)&4',6ONHN>/K-D1S.YW=3$'E:L6*DU4,U-%DZ7@
ME"'G';&TUM_4';\QGF,FBLTRKL.@9!]'J21XPE&I4L)<2K80L#D0K8KNR2<0
M%[9^A55D[?# (@<9VR-W'7;@?"JKB",W3EOE*)866>TK6.2JBKB9Q8"7Y>B,
M]KXN;06P-\NG663KQ;V$4")'J-S$]_5<#609'*N#HZ6\RVV''%.%,[EFX,B'
M$]RR$!J<*5*2GPSD'J#6%_V$[$R(_P!7$&4+/)<&#$D'Q<YS%2+]GDWRHUW
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MND6(F;LTE.5W7CAX&O+L]IG;[7F].M+-YZRV$N:@VTM=I,*,"Y 4T3(!@*3
M(F9QUW=%%CIWVJXN&FWW""BU+B3<08RMJ=S:1QX@%*,P,&<U:]=7&JG2WA>[
M'X+D441\FZ\9-(H'5.EY=3Q")D$0 ZAB<@0HB &,( (@ ZQ.\? _A4CD>\?C
M6B+91*2E+S5BN+8VZZ'Q#E23RZCB_':>YP^3)"H^X5IV7?)Y.Q@ZHL.G6V2A
M_-E8-82P/4*3*&:5R1 RP(&6V;=)^SR 3 $JB8,GX9CTXK'<X> /(Y!$=(\Y
M]!_6M\RPF(W,8@&4,4A1   PG-P)>>Q0$>>.1X !'G6!9,2F3[I_('^WQ-9$
M $I"L#KQC'P'UBM!+^MY]@<D9$6BG>Z:Y4"PWU28ST_EJ_E"NV6EUDN96YC4
M_"R<+.R"-GKSRF.5%_.XN9N)MI7HI R,B51\ZC S, $'<=O/M8,S,B>?+GK/
MD:H^8/A$\1MR,X@@>?\ ;SBO8?8;I2Y II9UEG]"Q$RE25,0NK(C?UZ0QVS>
M)9RVE#+:*RJ-<^UZ;!9D5RG=%CWU9T%<18J%63>J!5F%>W@9^T!1@N*S!;DY
M@\%'2">:R+*8'Y3R((Z2?KUJ1_L\T,I-LZ^T;0S#(4B5OI-QN-/>C['L5-PM
M659'VWXH-$E:1]@D9631>HQWA)R9U7ZR+AX!G#<C=-3RR4K@*(293 V_[L#:
M#!.0("O(@@YJM;41$ ]1X_'5:5:]RL\+4*M/VB=D6T=#P$8ZE9)XNNFD1!FR
M3,NN/6<Q0ZS$3,FD4!ZU%1*F0!.(!J[+2[EU##0W.NK2V@")W*,#W0<R>()Z
M5GMF%7-PU;I25*>5L2!,RH'Q8S"1XST"4DG -1,P<>.CTK)N RQ+1]/M>7%V
MTFR:6=^A$GJ^.HKQ?L=4O%DU&I2'08'&:FDDBATR\N]%P8_2F)>QJ?>/_9])
ML$./,Z:8*F$J<1<7BS^W?E((4%*"6D9([MM(3@Y[FI-ONIMM&T]AVY1IH)=<
MMVUO!]Q<[B>[!W',1YIP,2<>5[VH6T.PV]K2V&17#EZ\DDHE*67KTLTKR3U=
MZO'I^9FEFB;!LU%= .E\Z539*%<-CHN50<%*7;<[ ]JF;95Y=65NM"&R[W:7
MF^]VA"5G:R%E:U;2? D*6"E7A&VLQ[(ZJVTI6U16 3MVJW$#,"4 SCCSQ@"L
MCSV9\CY%M\K4]O#>E/8>J@1.YY+MZ4C(U-.;63152J]62B3MB3TM'-E?,SKA
M*3(UB5@2C%NI\HJFASV-/L;&U3=:TS<,.W.XLV>G[4W:FT*VI?N"0M3;;D?L
MDE&Y286!L$UA9TFWM6^\UD*=*B>[M$*_UA&?"7&T^- 6"%(W)E25)4,<QRKU
M5N.3KQDVI1ES"<DK*\81V><XPL2I#Q,96H5!5)EA;$Z17TH<#'3=/PM,PA*.
M3P[M^[<*G4G7!6;'N+N+>QM;*Z>MTLH;;6[I6G.K27ENJ45#4M25M02$2 PT
MM">\VA  9W*/=>N;2PM+2_6Q#5F'?L5BL'<5/["MUY$).Y!;;V)4!,':(!-2
MP/F7%&+G*N-HU1%-EC?'[R<FHV C5/<]#K\!%F,R;V-ZD5-M$/IA-$$(:'6$
MTH_6354*W$B8*F\RG2]5U)7ZQ>)3;7=SW3/VA2FKB\NWEE+KC:5[5.L-A14I
MS]RC"I!VBO-IL+O4UF^*Y;O'D=WO4GO%=XL2-A\82V"3,!( !D $#'..;#7<
M-X,OVXG,[U.LNLE2<CDZUJ2"GA2,5&R+=LQJ-.;$,J*RSV*@6L;%HQK4QQ<2
MIGBJ"91<*$UTM1M7-6OF- TY"G6K9@::PIH$!:DE2KBZ*N ''2XYWJN$!$D;
M01T-0MW-4U6ST.R"EAEI-KM0 1O$J<?61/ADY6K   Z F.^'L27_ 'BY(C-S
M6XV*D*]C*,.9;".%Y0BB %BTG!5V-EM3 >D!</Q*F](T6*"KP2MSKAY!HT04
M[FJ:E9]F;+]0:(4OWKD(U35& %=VI2?&S;* .U"2-I4GPC.V5%2AT;V]M="8
M=TS22AR^*-EW>-DJ;5.%;EY2%3 2@D!!@D;I-3(H.67F0LG65O6W46RP]1F;
M^%:2R@AYK(%T0<HIV!6N*G4(4E6HX(+PKYZW340>3;ARW(HBC%=3OR][IR=.
ML[?[0EQS4+Y;:G&4)6LV[#R?V"GPD$-N/I5WFV1L;\1"5&3Y]6GFUL=RPIVX
MN5$OX4HV14LJ;#\ EKO4D.MA<%;2DK3X2DFR\1R+*YVG*NYJ=<F:UEPT7IV-
MC+' J<?CBEN7 S]B0%4033)<["@I+INBB9%W#1\"KXQTQ)SL:BA-HSI_9UI*
MFWTJ-S=(3.\W;X3L;(,F;=M26R()2XXY(!-;5ZV?LFGZ$P I;SBGW'D>+>\K
M9W"I0,I;27!U WR8Q-S[9XIS:GMLW"V)HX6E\P2)U:0#M(PN*_B",,LG1(TA
M!3+Y$DNPZ[4_3 I3GD9P4U3'\!("-<>%K]FT=@@MV+8%SL\27-0<2%W;BU#!
M2VL?9FU8$-"(W9Q:U<AEJTTED[4V2$B[V2.]OR"'W5#JDD0E1Q '$BIB"'!?
MA#CY\!Z]QY']_P!=<)4D")F>D_7/I7G:Y<A]0_/5YZ]*5]TI32E-*4TI32E-
M*4TI7P>>.WKJ#,8Y_OG[J5C;)4'>9VOJL,?7 E&GSKME"3RE::68B:)%.7"'
MNU\NV;G%=/X"JBH HC\8%,(@ 9+9RTMG.]O+5=VC@MH6X@R>"%(0I0@3,#,\
MB)K:M'&$.2^V5C(\A'W D]"9Z>XQ_#$V[H/^^MB?H C@RHCQR(<\@#LHB''(
M=C%_QN>.P]PZGH!'_P##[WN_6=Y^:('WXKK_ &SLYG_P(]_]N>__ #?UJ2-+
MBK5#U.-B[K9?MC9VJ3CWG9$(5O IR2HKKJ)'3B6 >5: 1N9%OX:(B"ADO$,/
M4<=<"_+-X;G[*TJT:5A#)<6XI'A$@..>)>9DGW<5Q[EVV7=;K2W-M;D@(:4M
M3I1"0%*4XJ3XE;E9. 8!Q6J:>QON"QW4=W^WNL[?9O*0;DKOE.R43+",U46E
M$;,LUQI63XN4??,HWL,0KCU==TBB6*A)T9>*C8T(XK=90$2:S*%*:8;)+:F0
MZA2E)F>\4V0O(.Z-IP))!F">-<G8^ZKVDN=W&WQ1M"YXXY@Y_(U'MIM-W0XY
MRAD.RUW&-BO6/TL-VC%F+:A(W]U%H-<W0^)H"L3FX)\V8S[(\5$YJ2AUJFP2
MCI-*8K[IFE.>%$+VJ7>-\YN"479[M25K?WM)V$PE-ZVE208\06D]^%9\"8!
MQ6!ALBX9650$AF29 '[':1F00%$SY8ZBI.>S>P?F?$UPW#*WFD66@8^NS/$4
MK18J1B*Q56J5A85N7C+ZO'U2M6RYEBG82(,/-R<S).96?Z$))XY<G-SJQ [E
M!QO^T%2DQ_#M;B1Y2.D<9K(?WA/DE($<?OGC&!'$<'(/29K/6VO9S;L$9ESW
ME&;SSE;),=E2T14S#5JVS[&18HH,Z%1ZHH_GD6U8BCKV%DXJJS2'=-7@M&\
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M@E4/XQBII%9HM1Z0,"11_$W8KMQV/T/0-8[:=K%?KOMIKUTON62I)7:M6RG
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MK8"[6*@B<YC@F $.83F]"%( "<PCZ  !]1 /3GMI!/'NXG)X_P NM %*4EM
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MZ>@&S9\2?:4!*UJF"I2A/BS'D!'O.+RN*V8BS=LUDH5%=V!1EO,J3)21PI)
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M_P#E2:Q;,Z!::2-1NTWEVN6]+99>5;7$E(W7,)%N[""2A+BE*!&U(G%?I/\
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M)@J]7HMYV-[7]GK=A&GL%MEV[=M]+[2VMI97=B^7G5 V>]M+;?>$AT*M77'
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M3"8X:+_4;9IZW9NKINTN D.,6[CJ&W$HG:+E"%)2X$[SLWA6V5Q$YKI7381
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M0P#^R(ASR \\>H\B( /8/"H]D>!3?^%2@I0]2H%0.[VADX(!@XKPH  @*2L
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M6P8>K[F"C(2JBE&.H,(J=Y9.G,E(/FKR.$THU39/RR)?!HR2A85'!<(D'_I
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M9R"_'NQCFLY$]EGOT(T*P);,/$9$ "D:DW$WPJ)"AZ 4H;4 XY]![]P#6O\
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M4DI F#,P<].>@\XG/%5GF ).9DGS \_CY?.MMA $"$#U$"E#N(]^ #OSQS_
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M VGRS'PSMIW!9\/A P3!,[N(!/0U1<)[H,AWS<-&5>1DZS)U"XVC/U>:TQA
MK1MGQHSPS)M8ZO3\\^7?*2"YKXR=@NNSE8QGY([F/)'"!3NDS;B)+)5 !* H
M'/ <"(]_/!B()S@:A4H/)1&/%.>/"?S' _M6RSO] _,?]&L?C_P_?6:M=&\[
M..8L066E.L>V2@P=&K]9F[[E2,E'L&MDZSP498:U$IQ>-ZY-H*H3+P$I!\58
MA%6AW$@YCF2;Q!RY:%<:Z7%!T-$ E77IR,DG/7&*0.3/U]<>GR\NU?<QDK*N
M2HB)M;^MR4%?*9E6WM:S#PIHZ:Q&XQMEI''<76K,Z][/UGCNRQ+@TJ)I5JR=
MIRD=*H,Q49)I ;>=;+2RVHI) 3E))'B2%#D \'..9I'Y?U'XULBUCI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E6G"4.E5J5FIVOU2O0LW9%B.+#,1<0Q8R<ZNER"2TN^;()N9)5,!
MX*H\46.'R$-50GNT[1@&20*'Q$$Y(P#Z5=FK4KR/4$G#=1%=N1TBLFHBL@H3
MQ$UD52B15)5,0$JB:A1$JA# )3E$2F 2B(:0%8/NSZ\\T)(!*9D"1'F"!^?D
M<3@U:)L=4%28A)H](JXS%4C@B*Q,^X8X92 C/"*D#"$D/+>:C&A$A,D5!DJB
MF1,3$*4 $0&  @A:1"@($<QP1\IP>10^(*"N)B/.842/2?OJ]B)D2+TD 0 /
MER8WH''\X1'_ %]_70GE423\SUJ  D0.*M"[X\H.2HE*"R)3*M>81%XE((Q-
MM@HRPQJ3]!-9)!\FRE6SIN1V@DX<)HN2I@LD1=4"'*"AN9D<SCSJ:Q*,WM,H
M^0X&JFGMOU1RM$1S*O5FM'FL>P.0(V)>_KHZ$A(0SMK86L>\!7K9QS%J1NY(
MH'@HG(8-0DA9A!"R%AN$D*(<,0C$^,@B$^T9&,T4-@E?@&TN2J4C8"0I<G^$
M$$%7 (.9%2'!= 0Z@62$.>.04((<C\N>>.>X=M 09 ()"MI /"OY3Y*]#FG0
M'H4[@>A3_,#_ "^O%6O:J92+XQ)$72M5NW1J3A)ZG&V*,833)-T@811=D:/T
MG")%TC"()KE3!0G)B@8 $0$0%8(GC'K[0^[/N]*!02000#F,^L'Y$P?(GUK@
MUH%$9V ]M8U"M-+2K'(Q"EE:0\>WGE(IOQY>-/,(($D#,4   0:&<"@B7X4R
M%*(AJ1X< 1[Q_6H("^<^XQGX&KPTJ:H\Q%1LPT682L8UEF#HJ9'3%\V3>,W"
M952J 5=LN51!4"G3(< .F;@Q"&]2AQ4I\07,%)2H9ZH.X$=00<B.O0FH)/LQ
M(./^\=JI/E!SZ52(JCTZ+GI2VQM3@8VTSJ*#>:L+.(8M)V61;% B"4E*(H)O
MGJ:)2E!(CE=0J? "0"CJPGCHG"9F8Y.3R)/SFH ',03$\_4^=7?I5JM*PT2E
M6Y[$2%JJ5<L;ZNO"2$ \G(:/E',,^+Z.XM9ZW649. '@?%;F3/R4@B/)"B%$
MCQ*)&9P?G_6E=D)1Z;6Y6:G:_5J_"S=C436L,Q&1#%C)SBR/()*R[YL@FYD5
M4P'@JCM14X  !U< '%@ D;1@<QZ^=*ND XT @12FII32E-*5\$ 'CGY#R'X_
M[.0'Y" B ]ATI5JP]%I=>EIJ?@:G786<LCA)W8IB*AV$?)SSI$.E)S,/FJ"3
MF373+P4JKQ18X% I>KI*  I5UZ4KH<H(.FR[9RBFX;N$5$%VZI 52715()%$
M5$S )5$U"&$AR& 2F*(E, @(ZA0"DE)$@B"/0XI,9'(R(JRBX]HAIB#G#T>L
M#,UED$76IDU?C?>=?C 3!,&$+("T\U%,P()B>69*H(B0QR]/2(EU*91[*CDJ
M5'.5)2A6#C*4)Z# 'QJ0%F5"8,=>!"QZ>TI7Q!]8OS2K59=VQ[0,CQA(3(E,
MJEWAD'2<@E%6Z#B[!'(/4"'(D^392S9TV2=(IJJE3=$3*JF4YRE. &-S6!NG
MJ>/ET'7%. 2< <GH/>:Q.TG-I=5R+$U!G.[?*]EN#C6U;@ZPA,X\B\C1,0X(
M#EE!1<,5TC9F3!9)8%FL:U;)H'26ZT4135$360OO@.[/>#QA)1"@2V)< *9!
M+8(*P/8!!5 -%CNB X.[*DI< 7*"I"RH(6 J)2LI4$J A128)*3$ABK(<?"L
MD(!P'/B%'Y=N_4/R#YC]^J!QLA*@M!2H@)4%)A1. $F8))X YJ2"!)! SDB!
MCG/IUJV+;3Z1>F"<1=ZY6K7&).47B4;9(R-F62;M PF;NDVLDBX1(Y2-R*2Y
M" J0>H"F#OJ%MH61N&2=@XDJCV1UW01CF(Q0+*/95ME.[!Y3GQ?[O.>*-*'1
MV-B6M[&I5MI:G$<C#K65M#1Z,ZI%-R)$0C32R:!7PL44T42)M?'\$A$DBE(!
M4R &8J5P2<>O'U]<53:G!@'RZ^E76 %XX#]GOV^7?UU69]:M'2J9*0\5+M5&
M4K'-)1DKTBJR?-R/&BPIJI+)^*U7*H@J)%$DU$_$(82'3*8G!B@(8W)P0"2F
M2(GG'03/N_*I!(X,3SY_/FJ1'T>F15DE+;%U.OQUJFTTD9FR,8=DTFI=% G"
M*4I*(($=OTT ^%$CM94J7?H HZL%*DI@A(P.8R-QCIR,D8D1S5=HD*Q/W^7Y
M_(_*[-6J:M.P42E6QW#/[14Z[8GU=?$DX!Y-P["4=0DBD=,Z;^)7>H+*Q[Q,
MZ29B.&ATE2B0H@;MJI0G<%QXAP?+UQ2D+1*57969GH"IUZ$F[&NDYL$O%1#&
M/DYQP@ @BO+O6J"3F153 1 BCQ18P%[ /  &K;BK*IG SS P/N I5V:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4KK-^P'W<?Z/Z]8_^C^O.E?G[W*R6$"Y,]I'0
M[]3T['F?)3+&#3 L(UQ],S5VL%J/@N$C*>^H]@8P:YV*T3>$D%3RK24;)5]=
MFH]?NV::0F2PM3W#)MS+WZV:[ST\36TGJ/#',#TJRS+[P?PT-+=*2< B'=R>
M,Y(/G\JM6"S/NRLN?(?%4'D/)M=F))EF/%-C1G"-W+:LVBE88=/Z3;V]1;X[
M7B*O$S%X@R2=;M<[?'<E?(UX^!M$E2<>62V1"FKP(*3<,HU"YX\(<878!)/F
M VZ\0 .??-87$J0NU,;6GCI]LG//VC[7,YSEI$Y^%4*U;K-TMQQ_1=PR5QR#
M38"\S5L;PN%X5%.MV*1/C1G4Z@Y3KEB4QW<H.<GYN\1UX>LL<V<(&-O;)XQ7
MCI9N6.,JID9*"^T&P2VYIJM1;)/+5Q=MBP$1 7]A>07#_/,8YEX -O3 6UJ3
MNG',982\7L3,!QHCWS,'G]&-8>KR5?AG[EL\9N'L9'NUFLBDFA(-E'+-!=1!
M^W2$4F[Q$ZADW*"8F316*=-,PIE*.H<@*5Y?*/KFH:]@?Y_7T*KVJUDII2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4KR.NY#ASV\%<!]../"-\A^?KZ
MAQQV$.^J9[UH])/GZ<_=%4<_=N?[BOP)_*OSLYW6PX\L_M$,<2U*2L.Y2^9<
MIRV!VC#'LM*WUU938DQFWH]FK%J:0+H8B-KEM9B]=SR<JT8024>^7?';D*MX
M^I8J?1:6QMC#GZSO#,@?L]EL7LS@;2)/$8W>71U3N>^L^\B/U3IHP>N_4 //
M$YR0!Y&9-37S?NHN.YMUBJFY"R=6U)V2W!8PEDY@A'L95I6BXJE97'5I95)'
M'X1-4@9.ZUY->O6^6OTC)7N(D5?&CBBL)6>[M84+Q:/]G#879Y@=XB_85!(P
MJ+=+N1[X K2*7(LQC]HU;I<,9*U6</#G_KE$G, XF15C7+=7NMM&.J1N++=\
M@4V#R!.V\]?PI"-#5RPN$L<Q=4J"C6MV4^/+G!ST_,W6,ODO'X]LRD(WN+"5
M8*1TZDM&I)EN-BKIA'M#;]J@Y/,#I$>$?/,$5C<A$B<S]FG!(),\8/\ %'^5
M?H]K[Q5_#Q;M9!TV7=QK)VLV?I%0?ME7#=-0Z#U$G*:3I(PF3<ID,8$URJ)@
M(E(!C0YRKZZ?7P^50W,9,Q\1_7\N>M5@G[(?O_I'5$>R/C^)K)7+5J4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E. XXX[?3Y:B!$0(\NE*\YFC4
MYA.=LW,<?4YD4S&'L(=S"41'L(AZ^@B'H.B4I3.T!,J"SM $K'"S'*A A7..
M:$;O:\7A*,Y\!Y3G^$R93QGBJ#9JM"VF"EJW+-E/=D[&2$1(#'.W41(%9R#)
M=DX%C*QBK22CG8-UU2MWS!VU=M%!*NW7353*8&U/B,"5I6E9C*DN0%I4>H7M
M3N!PJ!,P*?R?X%)4C_ I!E"D_P I222DB"F200:I]&Q]2\<U"L4:FU]A"U>J
M13.'K\8BEXI6#%FB4J)?&<&6<K+GZ/&<NUUEG3MT=1TZ66<*J*F !.TI 24-
M(81 C8PV$A#*8]EI 0D(;$(2$I  "1$'Q;BOQ%QU;[A.=[[I4IUY4^TZXI:R
MMQ4K65**E$J)-Z@ %#@   ^@!P'Y!J:D #@1[J^Z4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4KB8A# (&*4P" @(&* @("' @/(=P$.P@/80TZ@]
M1P>H]U.00>#@CH?>.M><&+(#"8&C4#&$!,8&Z0&$0#@!$>CD1 !X 1[@';TU
M5*4H "$I0 5$!("0"L +( B"L !1'M  &8%%>(RKQ$)2@%62$))*4R?X4E1*
M4\ DP,FJ/8ZO#6> FZY)H+IQU@C',-)'BWCR&D18OD#M%BM):)792<>N"*RA
M4';)V@Y;&-XB"A#@ Z!" D("4A F$!(VB1!A,0)&# XJ258\1\/LY)VGS&<?
M"J?1Z%4<>5"NT2GPC.'JM3C&D- 1:1!5(R8,DP(@05G!E5UUA^)19TNJHX<+
MG4764.JH<XVB#NZ[=D]=G.R>=LYV\>E5(GD G=NSGQ?S9_B_Q<U>(  >@ 'X
M!QISSFI@#@5]TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
:TI32E-*4TI32E-*4TI32E-*4TI32E-*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g752656g25l94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g25l94.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1>^4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      ]P   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    "@!!
M &0 ;P!B &4 ( !0 $0 1@      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#
MP     $  3A"24T$)@      #@             _@   .$))300-       $
M    'CA"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              K    28          $
M                     0             $F    K
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   K      4F=H=&QO;F<
M  28    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   *P     %)G:'1L;VYG   $F     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ 7@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M 0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q
M@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87
MTE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=W
MAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4
MH;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B
M\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>W
MQ__:  P# 0 "$0,1 #\ ]522224I))))2DDDDE.?U3%???@EIN#1<1=Z-ME8
MV&NUWZ7[.^O<WUF4_3_]&++Z?E?61EV#CY#7/KA@MM?4X%VZNNRX6O:U[:WX
MSGN:RRRRGUG_ */]-:NB=8UD S)X !)_Z*CZS/!W^8[_ ,BGB="B =.JJ>?^
MT_6.MSGUL<:V/?%+JG.+@'T!OZ5[W6?I&95S_P#T$_1_GJ1S?K#C ^H'Y (<
MUI;CD$/VW"GVU.?[++?1WO\ H5+>]9G@[_,=_P"12]9G@[_-=_Y%'W!^Y%%.
M$W,^L;,K&8]A?5;8UUCO1<  \U;\<[/5V,HJ=?9Z]CJ?TM?\Y_@+D_JG669[
M\;:(NR?0QRZHM:&D66>HS>ZIU_H4XSGW>F^RM_VBO]/5^DQL;=]9G@[_ #'?
M^13%]1<'%I+FSM.QTB>8]J7N#]P;*IYJOJ'UD)JLV6[K!6U^^EX9[7Y/N:T5
M>I7]H_05V^M3C^G5Z;_T/])6CTF[K;\N,^32^MSH]+T]KMN+:UN_<[\[)R:/
M_07_ (Q:OK-\'?YKO_(I>LSP=_FN_P#(I2R WZ0+521)#]9G@[_-=_Y%5,WJ
MS,-WO8?3]HW$/G<[U(;Z;*K'_P"!4:6^DL4_6?"#6.Y#Q(@6R(.S]*TX^ZKW
M?Z16\'J;NH5&[%K:YC2&DO<]ADM;:/:ZG]RQB2F^D@;\S_15_P#;CO\ TBF?
M=E5M+W55[6ZF+'3'_;*2G__0]50_7H]3T_4;ZG&S<)G^JFO>YH:&Z%[@V? '
MZ7_10WOBP4"H&OO(]OFDD"VRFD3'=4[K+*J'L83[26M<3)VRP3K^[OVHS +<
M5A+M2T'U.X,?2256EIU%MC'-#FN!#N"%2.:PMH/N%QK;8\B16UK^]SOYO^HW
M^=5E[VM?,#CW$#6/WI_K)(6>;79-8J]-U;-PR"7'>TEH=6&,:US7;OS_ %',
M]B,2!J= J.!:PX[[*JR&6.-IO]I#R3M<_P!KO4]C6[?TC/S$9A'NN<X-<9()
M.@8"-VDH$TILII 5)]KZO5I8'/&ZMH</S39H]SOW6,_G/[:M%T> 14D252C)
MMLSK:6M)HKK;N=$!MDNFL$_SFZLL?_P?_74SWO=-A#H:0=1[8! _-=])C_>D
MIM@@\:IU2JN<<ED&=Y+71W ;ODQ^=7[6_P#75=24I4+[:Z^H,+WA@ 83-@8(
MC*;+FG^>;O<S]'_UW_!J^DDIY+*;EMON])^6]KK'/8ZOJ-36P7%S!6R[WLKV
M!GZ-_P!!_L_F_P!(M$],PB6G]L90(:UNF4-=H;#B(^E[?<MQ9.?56[HO4&.$
MM<;BX21)W'S2&LHQ_>ZJ)T)[-C"?A8E)J^W&^7%V^^UKW"?S-^GL:IY&7B/H
M>UMU;G$0 'M))^]6TDE/_]'U1S0X055%E[\E^/#V,K /JFL;73VKLW?2;_Q2
M+]LQ 2/7KD$@^]O(T(Y2^V8G^GK_ ,]O]Z2FM;G]-!./980YFX&6O_-!]3W;
M-J S*Z:6.I]=WI.)=8T,L!,#WM<YS?H^WWJUD.P<@M+LK863'IW;.8^EL<-W
MT5!K<!K&L^V$AO<WR3)GW.+MR25[<C#MQZLXV'[+42=NTP73Z37/86^I^B=_
MZ45:W,P;G G*>*Z];&!CX<R=K6>YKMWN]MGYZT?MF'_IZ_\ /;_>E]LP_P#3
MU_Y[?[TD+XQJ=CUFIQ?46C8YTR6QINW>[_.5 9_36/.R][""1L-;SM=.TAK7
M,^DKWVS#_P!/7_GM_O60ZJW>X,R:MF[V$Y=P.T'VAU;7[/ZVQ)3K89H=0VR@
MES+)=O,ASCPYS]T.W*KE9F%ZOI.R+*'U/!L 8[73=LW/K=[7?Z2G_/1L7(QJ
ML>NM^0PO ]Q-N_4ZN_26N]1S?W=ZKC'Z:"=N98 7%VT9+XUGV_SGT4E-K .&
MZDV8?\W8]SW&'"7D^_2SW(&3F8%&5M?:ZF\ $@,<0X&?Y#F_YCE/%.#BM+6Y
M9MW&2;KO4/RWN]J/]LP_]/7_ )[?[TE(<&[#R'6646>J]GM<X@MV@Z[6 M;[
M?ZJN(/VS$_T]?^>W^]$8]CV->QP<QP!:X&00>'-*2F22222E++SO^1L[_KW_
M %3EJ*AE8U]G3,JAC9MM]78V1KN<YS-4H_SD#V_]!0?E+?22222__]+U$X^.
M22:F$G4DM";[+C?Z)G^:/[D5))2+[+C?Z)G^:/[DOLN-_HF?YH_N14DE(OLN
M-_H6?YH_N5;[/?)_08\>.W6%>20(OJ1Y*:#L:R6$8^.7C=JYH!Y_,_K,4AC7
M$@&FAH[D-!U'/]ERK]0LJ;U[I+'&'O&3L$'6*VEVL;6K50X/ZTOM3:%F+1M&
M^JO='NAHB?)"=COW';CXY;.A)@QY_HBK:2)'B0AI_9[?^XV/]Y_]))?9[?\
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  0P!3 #8    ! #A"24T$(@     !?DU- "H    (  P!   #
M 030   ! 0 #     0+/   ! @ #     P   )X!!@ #     0 "   !$@ #
M     0 !   !%0 #     0 #   !&@ %     0   *0!&P %     0   *P!
M*  #     0 "   !,0 "    '@   +0!,@ "    %    -*':0 $     0
M .@   $@  @ "  ( "&1P   )Q  (9'    G$$%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,3DZ,#8Z,#8@,3$Z,34Z,3,     !)    <    $
M,#(R,: !  ,    !__\  * "  0    !   $F* #  0    !   "L
M   & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@  P
M  $  @   @$ !     $   %^ @( !     $              $@    !
M2     $X0DE- _T       @          /_A 8!-30 J    "  , 0   P
M  $$T    0$  P    $"SP   0(  P    ,   "> 08  P    $  @   1(
M P    $      14  P    $  P   1H !0    $   "D 1L !0    $   "L
M 2@  P    $  @   3$  @   !X   "T 3(  @   !0   #2AVD !     $
M  #H   !(  (  @ "    \     !   #P     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$Y.C V.C V(#$Q.C$U.C$S      20   '
M!# R,C&@ 0 #     ?__  "@ @ $     0  !)B@ P $     0   K
M    !@$#  ,    !  8   $:  4    !   !;@$;  4    !   !=@$H  ,
M   !  (   (!  0    !   !?@("  0    !              /      0
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M  (1 0,1 ?_$ !X  0 !! ,! 0             ' 08("0(#!00*_\0 :1
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MFOO?NI)I/A=)ZZ<5?[_ ^L%T#$!4JR1DS% Y5 4()!((<@8#@/:)1 0$# /
M@/MQSMSXVYVZV)NN-_/#XG KMJ=4R!7+<RQ"@<Z)5DQ5(01X YDP,)RE$?0#
M"  (_/AII;S5HW:N]%=<5?A=<UR'.W/C;G9<7[CDDY;N $R#A%8I3&(84E4U
M *<OUQ!$AA #%_NBCZA\X8>EKZ72:OI=.UFK\4[JW>A]G'L.[ & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MW!3]+=*FWOVNVDBJ6&F\PCBKP=/U5T&O:<U-U-^]K);MEQWM'R,\,TTOA@#
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MCZ/^_G_;A1LDKO3SSO\ XZ@H!>.?7V^SGCT]OLXX^G"C:_3EIP?%]]W;P!4
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M:'T?>^CT_:R=WM?NTMX>>/N%<J P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M(-J-6]S7V?)[3@AV+?$35FP.NE>^K[&ZG][5R.N<Q7K%LRMMM:H.K;MAJ78
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M1PZOC]]ON\"[E[I)HR:,7\!;2(N$N4Y/_D88@BXE'M17<$E3NR%[^ ,J1BH
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M.#JKJF.JH<PR27'@%LMY,RT9)6 J9UTTT7JL>BGR<RK1D502^&4OJ*CU1(5
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M#7.I%.;WR31[JF/8]9Y5)BSQMD+*(NFJ@0;F.0=LGC(6C=1N=4L@51LLBNZ
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M)-__ )?/OOIYTZ$ZBT5NE]/"]N!R86^L[!1>U60:*Q\BZ:+&]ZI0J!P=HE*
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MWFU+I8:--X"CECPEG*]*>/PD:V+FG>[E6G)N4GJ[]IN/SD)T\8 P!@# & ,
M8 P#&J ;HVKJ'V!8WWRT=<PD#2X<@B!BI*O6:-EE7) #ZU9PO,MVROM$Q&"
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MFT6J;333LTTTUQ36J:[CXH6"AZY'(Q,%&LXJ-;F4.BS9($00(=8YE%3@0@
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M_P!7T?G2=HO]&VP%G_\ :=HNS5YK7^!H62?EWMK_ *C(?^7T[?4;+\YL;Z,
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M(%F@DXN"A[21]+H2;*HR)8ABC-0TG!GA7Z2[*4G54':,B6;/%OEF[,X&2W&
M, <?Q8!3@/H#^?I_!@#@/H#\& 5X#Z, IP'T![./VOH_8P"N , Q=ZL9#8,?
M1*HIKUU;&*Z^QX)M9W=-9V1[+(50\/8U'ACEJ%3NUC09&EDH9-=Q%UUZH0YT
M2+&;M5%UR 8HW?J'ZO8U:2AZEJ>4F(,%7<2RD2ZQV6I:BI*A=(J(*WDG+J/B
MY!^M%Q-.O\I:W;>#:1:-L<ULL%)V6#<1B\:]/K[_ -WCV ^R^]275WKV L\[
M(ZVA'36&K%ON<>X)K2]F9'8QZ7]#5Z;DFUJ<-XE_5H=M)W64G'OEFUR2;)5"
M#BH>6<H/U9!XTEM3K9?A).F5:E7$+/6.PHP:L3K2TUN9C(ZJQ%3:PEA39S$M
M*K1L#L,DG(3)*K.1ZLO!R[.0:*3#LR!V3(1V<//O]]N_M,X.FF\[)V'JB)LF
MVJS\$[TI(3#.6BTZ[.U9B8C-\HFT=Q<59W"MA"/5;B1-%U+MXUV[4167][6J
M1T^\23[@# -/]AVYUV4FQVYQ'TJV6J*K4ANEM5#2% D+!"VLMIVE O\ 71I5
ME6S1DZ1E1*@TE:Q$O(TSA=TRERRKR.EA;&6('GS[[$H.-_=7CCWU?MJ SB(N
M/3D%I-L\T3LZ6D8%XO.,V$+"1Q&ER9.-@>!'D*O*3M=C6<>(6)N^(FW:U6:3
M< 6_!]1'5W:TB7>+H"2T+6B7I.:K4?K*VK%FW[38]1J(5"(,\M3%28L=2BDI
MBQ-+K'NTZS8TW,U"(Q#16)=2<>'GSI[^-_<6"'6AU=F%"MIZPK(;',PG7B]3
M7UKL\KE.LQ]T;Q3#9*K-I)NYQNQ>PCM)(U%)!NIPZI$[,VE%()VB@#SYT'OT
M\\3/3IKV1N+8;380[CI"5+DX"Y*QU?08P%FAXMU J-2*H)-W]K\I(6-XP4*=
M.1F6<+&0BZBR)8I1^B4RY0,FL 8 XP"G ?0& . ]/0/3V?>_8P"N , 8 P!@
M# & , 8 P!@# & , 8!0?8/[ Y#X/N9'-=S^PQ&Z*_74DR?[)L_81O7V_P#E
MH0]<XO\ (.[[%XUVM?:S:9V__L)+["_S#_M"[*-'_P!-,RZSM)8FM#I__MD7
M7S_DMTY?ZOH_.D[1_P"C78#_ &G:+_FM?X&A9)^7>VO^HR#_ )=3-E^<V-]&
M , 8 P!@# & , 8 P!@# & , 8!U*(I*F2,HFF<R"@JHF.0IC(JBFHB*B0B'
M*:@HK*I"8O BFHH0>2G, AY\_N.W & , 8 P!@# & , 8 P!@'@VD9$M9L1H
M?Q_?8L'+#%@U*)G(R(1[CR0-R@ ]R_F?"\(.!Y/VA]\ ?!\^SJ:A=>[@ZZ:A
M"MX-#7UVMC5:,GY5M8M@:TVJ_>$<$UMYU% [F2;GN:'O9L.+68K0L]"^^$H$
MR*U)^$T.XCXV#>?/GP!>1NI3K&5=46(G=5K1;V[NFT>YKTAIBV>*9^2J3LPA
M749$EP=QY&=N0CVDG9+.HDXC=2 X<0-G;.GQ!.U \L-C]>M49KO750G++)U/
M4=32;.4]=VYQ&VZRRLIKUY+@[K$9*33AY;(2.E+7#>98*,TG#B/7>S(L62*S
MB, VW1RSAQ'L7#M!1JZ79MEW+94A$U6SA5$BBS=0B:[I,AT5#&3,0CEP0HE$
MI5U@ %# ?9@# & , ZTDDD" FBFFDF!CF B9"D(!E#F4.;M* !W'4,8YQXY,
M<QC&$3"(B!T P8@^-)@S:A(G;$9G?@W1!Z=FFH=8C4SKL\<S8BJAU2("H*15
M#G.4H&,81 ^O & , 8 P!@# & , 8 P!@# & , 8 P!@# & , XF]@_L<?AR
MF6D7YXZ Q'Z*1YTX^'Z=D;!'GZ?^75/7_9^U].<8^0=);$XJTE*^U&TC;7!-
MYE4TU[+/WEYCG>O?_P NFOT8[OV7,NL[269K/Z?Q_P#M(^OGZ?@KTY<_?_I?
M,>./^_[^=)VC?_T;; *SOZQM$^JTS2OW_=;P- R/\N]MN'^9R'AQ_P"[Z=OM
MO]O$V89S8W\8 P!@# & , \%&SP#BS25-1E&JEHAX.$LTG"E$_G6<#9)"?BH
M.46+V=@-9*0JUA:-S%.8PJQ3D#E( $$X'O8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P  @/LP!@# .(D(82F,4HF((B0P@ B01#@1*(^I1$!$!XXY 1 ?
M0< Y8 P!@# & , 8 P!@# & , 8 P!@# +=MULKE"JEEO%QEVE?J5.@9>T6>
M=?F.5C#0$"P7E)>4=F3(HH#9@P:N'2PIIG/X:1NPAC<%$"X0$# !@]0$ $!^
MD!]@X!7 & , 8 P!@# & , 8 P!D-7X@LRB4"KZV@SURHL58^)/)R4N9NL\=
M/CB_EG)G;Y7QWBJRW:JN8QBI]_8F ]I"E+Z9A-GMG<KV7R^669/1E0PDL7B\
M;*$YNI)XC&UI5Z\G)I.SG)[J_BQ2BN!Z5*DJLMZ5KV2T5M$7GF</,BNMZ8U[
M4]H;$W'!Q#AK?]J-*RQNTN>4DG*$FVJ$:2)@2(QCARI'1XM&)")'.P;-SN3!
MXCD55!$PY+$9OC\5EF7916K;V!RJ>*J8.DH13A+&5I5Z^]-+>FI5)-I2;44[
M+0QU#*\'ALQQ^:4J<EC,RCAH8J;DW&4<)25&BHPX0M!+>M^,]7J2IF-,B, 8
M P!@# & 0ALSIOTCN&;C[+L?7T59+#&17O$SFS.I>*E"0H.UWZ<4L^A)&-<.
MX]N]=.W;1H[4709N'CU9J1$[QT94"._B,]*WW)VGXU7K]*, ?$9Z5ON3M/QJ
MO7Z48 ^(STK?<G:?C5>OTHP"OQ&>E;[D[7\:KW^E& 4^(STK?<G:?C5>_P!*
M, ?$9Z5ON3M/QJO7Z48 ^(STK?<G:?C5>OTHP"OQ&>E;[D[7\:KW^E&!9=!\
M1GI6]OZD[7GZ?A5>_P!*,"RX6TZ#XC/2M]R=K^-5[_2C MRY%/B,]*WW)VGX
MU7K]*, ?$9Z5ON3M/QJO?Z48 ^(STK?<G:?C5>OTHP!\1GI6^Y.T_&J]?I1@
M#XC/2M]R=I^-5[_2C L/B,]*WW)VGXU7K]*, ?$9Z5ON3M/QJO7Z48 ^(STK
M?<G:?C5>OTHP"OQ&>E;[D[7\:KW^E& 4^(STK?<G:?C5>_P?\Z, L^C^YY]-
M=3B'\;,5F8O+IY:KG8$9BT72^.Y%C%V>US%@AZFU4&U&[(*DQ4DSJ-;0Y#R\
M#"QZ(E*)! !%NQ>;?=]2+P^(STK?<G:?C5>OTHP2/B,]*WW)VGXU7K]*, K\
M1GI6^Y.U_&J]_I1@%/B,]*WW)VGXU7K]*, ?$9Z5O9^I.TX_RJO?Z48 ^(ST
MK?<G:?C5>_G]O_I1@%?B,]*WW)VOXU7O]*,"Q3XC/2M]R=I^-5[_ $HP+%?B
M,]*WW)VOXU7O]*,"UN ^(STK?<G:_C5>_P!*,$671?X\2GQ&>E;[D[3Z/^=5
M[_2C!-OO'Q&>E;[D[3\:KU^E& /B,]*WW)VGXU7O]*, ?$9Z5ON3M/QJO7Z4
M8 ^(STK?<G:?C5>_THP!\1GI6^Y.T^G_ )U7O]*,"WW%?B,]*WW)VOXU7O\
M2C 'Q&NE?[D[7\:[W^E&!8I\1GI6^Y.T_&J]?I1@ >A?I/4X*YTW"R+<3$%9
MC+3-LF(MX0I@,+:1BI2P.XV29*\=CEA(-7+)TD8Z#E!5$YTS 99@ ![/3 &
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M ,BVS\U?P95\^OR?_P OGG]7,X[OYJ1ZE7Z1_3C]X^.YT_\ V\L_XBVS\/\
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MRK:"\P=FZ>RCA>466=PLI .5W\@<?&>+*QTN\*)UA$06,17VD+E_C-F,MS'
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M^P(_O2?\G]K_ +\>KX?^;T_U%+^P+OJ_%E/+-_L*7[TG_)QZOA_YO3_44O[
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M,GKRF3-EB[?*5R*D;%",U&,1)/6B3A6-056\PH+(JI3)-U3J"(F<IIE<< !
M5 @"7,3B-FLBQF:8;.L3E."Q&98+#SPN#Q-?#TI3P]*K/?J>C>XU%R?%I77)
MJ^E2J347%2:4N.O%="\R@!0  ]  . XS/I))))))626B]R*"N2!@&DW;'NC6
MTZ-UFW30$'9=*R UWJ&T/IFF]/SC5VUY+=>V*_LRAZGNUYN==VE"6Y37M=4H
M41>[=9%F,]1SL$:_07BDS+1R#\DF@!X>F_=#.HW9NO-^W^O2^HMJW;76OMV6
M.J]-=&Z;^H.N7)&9H%_<T^OE>[:F;O.4O8J:35LF[E*W0:VA8K,Z>D:5H6RS
M19-0"T9#W3S:R55U>'Q@NBZNA;=J;8I<ENNT:QW+%5;R="U73K[&5:SZ'GMF
M5?:6G=HN9VPRU=>UJV6*=<N8B*B[1&1QT[$A&- Y<->GV$C5_KWZQMI:GN6Z
M*%JW3]#C.G#0FN-M[[UWLYE?E+9L2W6G7RFWK)K_ %K))R=:5U?'QVKCP$W7
M;1?*O;G\E/VUI7YFK0B4!*2;@#Z-:>ZFW*];%MVLWNN8&(G?C80] U$9=1^B
MCM+ISEIV5I[VULC*R(E8;$J%VASUZV,E3FCHU">J$PI&D:6! I (3:^ZG]0Z
M&I;78[5-].]0V RM'3G#6*KS6G]]QUZZ;9;<&SE*/=Z3M#1$O9HS8NVF-*9G
M;&JVX-;R4%4+_+MY="-A6[9LR4>@;D.E?8EBVKIF O-FOM,V4_F)">(E;*%J
MG8>EZ\\9Q\LYC4FZ5!VE8;/<HYTR4:+-W3M_*"WDCD!XP;HM%4NX#(K & ,
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MQT/AB022;@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# -/\
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ME5> @1!*S146Z,E-F7CD0,K, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'FS$Q$5Z*D9V?
ME(Z$A(AFXD9:8EWK:.BXR/:)F6=/I!^\41:LV;9$AU7#EPJFBBF4QU#E*41
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M%@C[O',9TR[@J(M# 6;L'W+K0^Q76R#2-SVY$Q6X(NMQ&T("%G:HE&7%K0X
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M+<-.#J956IQIR4E;&4'!0JUZ.KO&EBXU:4N6XZ,OXS9F. \@ _2 #FG&UE<
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#R+! P]J@9JL6
M&.:R\!8HF0@YN*?)$79R<3*M%F,BP=H* )%FSMHNLW63. E.FH8I@$!' -7?
MN8ON9U:]S[2WR\)(-+)8ME[*ERU><[05D(G2\*\6&@5QZY.DF?WX4(Y<R5E,
MCPW<OO)$*!@8IF$->?9Y[C:W@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M=(^(F82*I&.D8P)KHG 4UD%.U9%0#)JD(<HE 2>M@# & , 8 P!@# & , 8
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MZKMZ:OIQO:Q\.HE7:VJM;*OP$'AZ)4Q<]W=R94()B!SCW !@%00[Q P=P=W
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MP%+(3CANH=JX?I)IH-&IUF$?W(KO'3Z//GRR4DN_W?82-@D8 P!@# & , 8
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M_)K_ +ES7_C,/\.!H&RS_P"L^W?^WY7?IK2Q:T]QLDSFRX+N7P.@#) P!@#
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M/6T>T%_,2+6(B&(.':B2(O)66?,HN.; ?QGTB\:LFQ%7+A)(X'HX P!@# &
M, 8 P!@# & , \V.F8>7/))1,K&R:D+)*PTPG'OFST\5+H-VSM:*DB-E5#,9
M)%J]9N56+H$G*;=VV6,D":Z1C >E@' RB9/0YR%'V\&,4O\ "(8XJ_):-\D^
MA#:6C:3[64\9+[*G^[+_ !Y-GT?@R-^/YT?%?>/&2^RI_NR_QXL^C\&-^'YT
M?TE]X\9+[*G^[+_'BSZ/P8WX?G1_27WCQDOLJ?[LO\>+/H_!C?A^='])?>/&
M2^RI_NR_QXL^C\&-^'YT?TE]X\9+[*G^[+_'BSZ/P8WX?G1_27WG6;RISI*'
M\N=1$3&14-X9CI"<@D.*1AY,F)R")#"40$Q!$H\@(ABSZ/P8WX?G1\5]YR,=
MN<  YD3@!BG #"0P 8A@.0P (B &(8 ,4?:4P (" @ XL^C\&-^'YT?TE]YR
M\9+[*G^[+_'BSZ/P8WX?G1_27WCQDOLJ?[LO\>+/H_!C?A^='])?>!51'T%1
M,0'T$!.7U_TXL^C\&-^'YT?TE]YTMR,FB)&[4K5L@F @F@W*DBBF B)A B:8
M%(4!,(F$"E#D1$?:.+/H_!C?A^='Q7WG=XR7V5/]V7^/%GT?@QOP_.C^DOO'
MC)?94_W9?X\6?1^#&_#\Z/Z2^\>,E]E3_=E_CQ9]'X,;\/SH_I+[QXR7V5/]
MV7^/%GT?@QOP_.C^DOO'C)?94_W9?X\6?1^#&_#\Z/Z2^\>,E]E3_=E_CQ9]
M'X,;\/SH_I+[QXR7V5/]V7^/%GT?@QOP_.C^DOO'C)?94_W9?X\6?1^#&_#\
MZ/Z2^\>,E]E3_=E_CQ9]'X,;\/SH_I+[QXR7V5/]V7^/%GT?@QOP_.C^DOO'
MC)?94_W9?X\6?1^#&_#\Z/Z2^\>,E]E3_=E_CQ9]'X,;\/SH_I+[QXR7V5/]
MV7^/%GT?@QOP_.C^DOO.!E4N0^JI^PW]V7Z/V<C=E>^Z[)/D^J(<XZ>U'CU7
M1]IK@Z-#%-U3^Z-]IBF[MQ:Y$.TP#R'P*D/9Q[?;\V=(VT:_R2^39<UDN:Q:
MYI^NT%9KD[Q:MQT?1FA[*K_K-MU+6TL?EEGR=J&*;L^#LI1;MRDNJOLFSFRX
M+N7P-_&2!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# +-V!K^H[2J$S0[U
M$C-U:?3:$DH\K^3B7 J1[]K*QKUA+0CV.F8B4BY5BRE(J6B)!C)Q<DS:/V#M
MN[;HK$ QX-T2: 3 .?U<N/0/3JNZKS#\P!SV[H$?G#V_-Z^P!'!#:2;Z:Z)O
MB^22N_==\ROQ)= >S^GASZ^GQL.J[GTXY]/U:?OA_/G%UQOIPOT?1].',77G
MSK[CC\2;I^YXYWASZ_\ K7]5X_6^WV;I]>/O8]ZXVXKB3?X7X/S?LX]AR^)+
MH#GM_IX\\<_V5_5?[/O#^K3P/X?9P/L$!R+KRG?PX^_@!\230'/']/#GV?V5
M_5=[?V?U:>,D76O9:_OX'6KT0Z 4343*IO)(QR'3!4G5CU6@9,QBB4#IB.Z1
M+WD$>XH^H=P!R ^S'[WHK\.O3WD77^.GAU+;I/0/I>K4ZJ5J?M?4/>YV!KD+
M#S-WG^JKJ>;SMPE8R-;,I"T3*$3M]E%-Y6>=HJRC]"-9M&"3ITJFS;(H$(F6
M&TN+^WSY1/GA]O N?XDW3^(\?T\N?3T^-;U8?.'/W:/H]OT#Z#Z^F3YZ>>SK
MR%_-GS\^[F<OB1Z!#[N'S?\ K8=5WS__ +T_\/GP+^;/SS\V9Q^)-T_^O_3C
MZ>WGJNZKPX]>/7G=(<?>Y]OS<XOY6OP'GAT\^_BM /1+T_EX 1W> B'(?^-A
MU6^SZ?\ IJ]GICNN^Y-^?/0775+O:13XDW3_ /\ OQ'D0#TZKNJ\0Y'U .0W
M1QSZ?[/;CSY^[CQ?)D77GW^'!ZDZ:NU/0]-5M:IZ]B7D5$.IB2L+\\K8K-;I
MN5G9@Z:DC+35GN,Q/V::D' )((^:EI=XLDT;-62!DFC5N@F)XDC8!B=OOHRT
MKU(V6)M>S6=P<2T)#%@8\];O5EJK8(XCUU(%(X9PL@T;N7 N7K@1=*IF6%+P
MD>_L2( ;3D&V.=;-X?$87+)814L36C6J>LX.ABI^DC&,4X3JQ;A%**O%.S=]
M#6\ZV6RO/L11Q&.]:52A3=*#P^)G0BZ<GO-3C'24KMVE:Z6A!X>Y4])' <QN
MT@'@.?Z<5_\ ;\__ )Y^G,^_E4VK=[O*&^;_ (&P%WVW]%>[YOB^9A/FWV=?
M_P!Y]?\ O3$+ZEI[EI[BOZU3TC_:W:7Y8K_^><?.IM7UR?Z%P'[(?-OL[_2?
MTIB1^M4](_VMVE^6*_\ YYQ\ZFU?7)_H; ?LA\V^SO\ 2?TIB1^M4](_VMVE
M^6*__GC'SJ;5_P!#_0N _9#YM]G.N9_2F)'ZU3TC_:W:7Y8K_P#GG'SJ;5]<
MG^A<!^R_QYCYM]G?Z3^E,2/UJGI'^UNTORQ7_P#/./G4VKZY/]#8#]D/FWV=
M_I/Z4Q(_6J>D?[6[2_+%?_SSCYU=J^N3_0N7_LA\V^SO])_2F)'ZU3TC_:W:
M7Y8K_P#GG'SJ;5]<G^AL!^R'S;[._P!)_2F)'ZU3TC_:W:7Y8K_^><?.IM7U
MR?Z%P'[+ZA\V^SO])_2F)'ZU3TD?:W:7Y8K_ /M_^>/Y_>Q\ZFU?7)_H7 ?L
MA\V^SG7,_I/$^[S\1^M4](_VMVE^6*__ )YQ\ZFU?7)_H7 ?LA\V^SO])_2F
M)'ZU3TC_ &MVE^6*_P#YYQ\ZNU?7)_H7+_V0^;?9W^D_I3$C]:IZ1_M;M+\L
M5_\ SSD?.IM7Q_\ <_T+@/V78/FWV=_I/Z4Q(_6J>D?[6[2_+%?_ ,\Y/SJ[
M5]<G^A<O_8CYM]G?Z3^E,2/UJGI'^UNTORQ7_P#/.1\ZFU?7*/H; /XTA\V^
MSO\ 2?TIB1^M4])'VMVE^6*__GC^?T9/SJ;5]<G^AL!^R'S;[.=<S^D\3Y\\
M1^M4](_VMVE^6*__ )YQ\ZFU?7)_H7 ?LOK'S;[._P!)_2F)'ZU3TD?:W:7Y
M8K_^>,?.IM7UR?Z%P'[+SQXCYM]G.N9_2>)'ZU3TD?:W:7Y8K_\ GC'SJ[5]
M<G^A<O\ V0^;?9SKF?TGB1^M4](_VMVE^6*__GG'SJ;5]<G^A<!^R_QYCYM]
MG?Z3^E,2/UJGI'^UNTORQ7_\\X^=3:OKD_T+@/V0^;?9W^D_I3$C]:IZ1_M;
MM+\L5_\ SSCYU-J^N3_0N _9#YM]G?Z3^E,2/UJGI'^UNTORQ7_\\X^=3:OK
MD_T+@/V0^;?9W^D_I3$C]:IZ1_M;M+\L5_\ SSCYU=J^N3_0N7_LA\V^SO\
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M*K4G5J.M6J3D[WG5G[<DN$4W[*T1.685::&9& , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MYESY0>XP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
-8 P!@# & , 8 P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g752656g29k88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g29k88.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2"<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #W    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    * $$ 9 !O &( 90 @ %  1 !&       /<')I;G10<F]O9E-E='5P
M3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U
M<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU9
M2P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N
M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MP     $  @/      0 ".$))300F       .             #^    X0DE-
M _(       H  /_______P  .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              G8   ($          $
M 0             "!    G8                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   G8     4F=H=&QO;F<   ($    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      5]@    $   "#    H
M 8P  />    5V@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ H "# P$B  (1 0,1 ?_=  0 "?_$ 3\   $% 0$! 0$!
M  ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !
M! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($
M! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*2
M0U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M6]KZB-P>TR(C=V6.SZW],<X@ML#9T.V20&LNL?M:7?S+'_I/_ _46X&AH@"
M. -$-F+C,^A4QO'T6@<3';^4Y 7U3I>CE_\ .KI<V-;O>YCPQC6AI-D@>ZEN
M_P!^QQV?Z3V)K/K=T>O>2YYK88%FWV.,[?T;Y]VWW._L+3.!A';./4=GT?8W
M2#N]OM\E(8N*&A@I9M;$-VB!'$"$4:.7_P YL?TO6^SW;/0]?\SZ7J?9?LO\
MY_.^M^?_ $?_ (9):7V+$B/1KC9Z<;&_0G=Z?'\WN_,224__TO54DDDE.1;_
M .*S%_\ 3?D?^?L-:ZHOP+7=;IZB'-]*K%MQRS7<76646M=^[MVT.1>H9=F'
MCBYE1O\ TE;',!@P][:MS-';WMW_ ,W^>DI.]C+&%CVAS'"'-<)!![$%8.7T
M'(MZEZE(KJH(>VNP,K)J:^NO>&U>D/5;9D4UV_I+/99[_H?HE/'^LQ?@YN;;
MC>HS!J%SVXSP\N;[]]E?VC[*ST_3K^T4?I/TV-_+_1K=24XW5>B-OPFTT4U.
M=J,@;*V"UNQX<V75V>FYUOIOKV?S5OZ3^0GKZ/;]AO%QK?EVU?HG-JJ::K=F
MUQ99Z;FV?I_TN^RK_K:V$DE.'TSH3Z;;'9-=(K-MK_2%;7!^^'^KOVM]/]+Z
MC_2V/_XQ#MZ!D/ZJ+F"MF.'.VOV5DMJ(I?9B^D*F[FVY%>ZMV[]%Z5O\Y]H]
M-= DDIQNL=#;E5M;B4U-: ?4JTK#R#795^D95997;6^O]%<S^:6EAU74XS*\
MBWU[1.^V"W<22[1KG/V_YZ.H65UVL++&A['<M<)"2F0<")!!',A4*NO=(M8Y
M[,NLM:0TF8!+AOKV3_.>HW^;V*W3BX^/2***VUU 0&-$".%2/U>Z0Y^\X_N$
M?GOCVP6.V[]N]CF[F/\ S$M5#Q7=]8.C,J-SLRK8TAKH<"03VVME:#7->T.:
M0YKA+7#4$'N%G/\ J]T=_ISCP:OYLM>]I;'T=KF/;MVQ[5H5ULK8VNMH:Q@#
M6M&@ &C6A)3)))))3__3]54!=2;32'M-K1)KD;@/';])37+8]&!_SB-SFLUR
MK&T7>GD0; Q[KJFY3[&XS;_6%_J5[+<9_I>G_2/T-:4W7YMY^L QS?Z-+"&F
MMSZYL+FA[&T41ZNW=_.V>]_^C]-;BPLG*NJ^M&-59<YF.^KVL-@96YSO48W]
M&3^FMW[/_ /2_P *MQ)3G_6/_P 3W5/_  GD?^>GK0' 7*9F9UQ_0NJC/H>]
M@P+A(8*R7$/;ZC/4=5[=KKO4H?\ I*J<6FS]-]I_2=6. DI=))4;\RRS-/3,
M=KVV^F+;,K;-=;"[9L:\S6[,?_@JG_F?IW[_ .9M(%J9#JN$[(OQJW/LNQ7-
M9>QE=CMKGM%K&N<QA9_-N_>4*NJ/LK>]V%DUACGMA[6 NV$MWL_2_0MC]$B4
MNI;NPL2&^A M.I+2[])^?_.W6;M^]W_&6H&)53>QXQZW4T.>\/>X'U+"2=]E
M3G_1IM^FV[_"?X/TTTS%U$<7B3UCOLDBM[!.HC71A9UC(?T[[9BXI;N8+&C)
M<&:.C1_V?[4]KO=_K]-:BK,Z9@LH;CBEKJF -:UXWZ-U;[K-SG;58<P.:6DD
M3W!(/WA(&74 ?W;WZ[H^E?6V2IU]8Z9:'.9DUEK"UKG3#9<"]OO/M^BU_P#V
MW8S_  :L44MIJ;4TN<&@ %[BYV@C5SUEV?5C!.([&JLM8&ZX\O+VU.'N#JZ7
M'TW_ *;],_U=_P#VU[$5-I_6^DU[S9E5L;67-<YYVB6--ENUSO:_TV,?ZCF?
M0V*\L["Z%A8;V/K=8XU[-@<Z6M#&6U!C6?1V?K619_7L_P!%7577HI*4DDDD
MI__4]56!5T++9U@9?IXP:W)LR#E  7.98QS!B_9Q0UC-FYOZU]K]7^<L_P"U
M%M:WTDE.$W)_[)S0S';7N9-E[F-WV;6._F[!9N?7_-?F?H?0LK]+]+ZK-U<[
M?<P_6ZC8[U&BOTWL;M(%@;<[>[<YONKI?^[]HV6?J_Z&O/71)*+G?6/_ ,3W
M5/\ PGD?^>GK0' 7/_6A_4*\+JEFUS\$=-O&UNR/4+7-G:8MWM;^?_,>C_PB
M61]8NCY/3L=UF737>\TOMQJLVECZW$M=;6^]MK&6-J^B_P!/^=_P2!-"TZ==
MO#5V,S-KQ@RN6NR;R6XU!<&NL<!N.W\[96W])<YO\U5^D0Z@VC]498'YELVV
MO,;C,-?>YG[G^"I9_P 75_-UK'=U7ZNUY&.^J_&.QSRZQN3C&)86;K;K;#E>
M[Z/Z%_\ QB*/K'TKU_29E85%>S<<AN30XS,>BUF]ON_/]1WZ-"4B10!&NI[_
M -U5Q&]GZ=?%UK&AVW#KD B;7=PP_2]W^DO=_P"C;%9    T X"P\;KGU>IN
MN<S+Q&.>6E]SLJEQMANW>?TCG?H_YOW(U?UIZ*YI+LW%:0YP#?M-!) ,-=[;
M=OO1 1KN=W747V,K:7V.#&#ESC 'S*R3]:>C^B'_ &S$%A )J=E4 @F/:7"Q
MS/:M<@'E%2'$SL+-K]7"R*LFO]^E[;&\EOTJRYOTFJJ?K!TD7-H]:;'&(#7Z
M#W@63M_F7.K]EW\V_P#1_P"D5O%Q,7#H;CX=->-0R=E530Q@DE[MK*PUOTW;
ME7=T7I+P\.PZ3ZAE\L&I)<_W?VGN24B'UCZ07[!?K) ]CR)!+7#1GM]['U^_
M_",]-6.G]3P^HL<_%>7!A@R"W0_0L;N WU61[+&_^?*[$W['Z5M<W[)3M?\
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M%=>POV5M+"VMK8_1O;D-+G7>HW]/=[/T7I?9?YZZE-^U_K ; QO3-()<XN<
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M  %^34T *@    @ # $   ,    ! BX   $!  ,    ! I@   $"  ,    #
M    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !  ,   $:  4
M   !    I $;  4    !    K $H  ,    !  (   $Q  (    >    M $R
M  (    4    TH=I  0    !    Z    2  "  (  @ &\G\   G$  ;R?P
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-CHP-B Q
M,SHU-#HP-@     $D   !P    0P,C(QH $  P    '__P  H ( !     $
M  ($H , !     $   )V          8! P #     0 &   !&@ %     0
M 6X!&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!@$U- "H    (  P!   #     0(N   ! 0 #     0*8   ! @ #
M P   )X!!@ #     0 "   !$@ #     0     !%0 #     0 #   !&@ %
M     0   *0!&P %     0   *P!*  #     0 "   !,0 "    '@   +0!
M,@ "    %    -*':0 $     0   .@   $@  @ "  (   #P     $   /
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#8Z,#8@
M,3,Z-30Z,#8     !)    <    $,#(R,: !  ,    !__\  * "  0    !
M   "!* #  0    !   "=@         & 0,  P    $ !@   1H !0    $
M  %N 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @( !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!3 $0 P$1  (1 0,1 ?_$ !X
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MKT([C&,U*U9>YP$9#6IO"NIJ)3F4J[*RCN)"19J2#9LBN10;+ANH%()B57D
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M]=]<R^=H]??_ /-[N3]7ZQ$ #U$0#SR"<#/]3C^?RI6;+WRUXXZUVI!Z4O\
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M4IBE,4IBE,4IBE,4IBE?*\8LI%NHTD&;5\U5#PJMGC=)TW5+WWTHBN0Z9P[
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MQ>IM6($66SCDCDZ:EBH>TAOHYB2$-M<6@O82S$XWR0,K@$[L$>Y Z%@E99G
M_P NYFLC&?MFZM[N*TF55'.Q)9% 91M.1SYJNVY<ZN-]&K_VLF[-=GE=39TQ
M\]EJEIC==[;1;78D1$3E)5ERTC7\^M#C9F,Y%EBDI--JLX?N@B03"5279IW\
MP:-",O).]O'C!4S1L$==QP/*3SWW $C(Y&/VH^H,%-K,S>R*I))]@,=^U5[-
MSEXS5%G6W<O>)M0;<\EXRKL(/6VT+/.3DE"WU]K&0CHZN5RGRLZYD$[S&NX)
M%B$=\2\52!XR3<1RJ;L]'8)*87_S1';RD!O*L=[87VJ6[%NRB2RTR[GRWV!'
MM_> )2&C$H/D+RH#D<M#=6=G*/\ X7%];(?7SYQ@'%HLO:*\37M/<7AE>;I*
M0B)85T5&+TCO62L+V+GZU/V^+L<34(_6[BV2]-7KE5L\HI<XV%>55JG7Y=%W
M+H.6"Z);N"CA#NWO,T 3E2)$6)BISCIX2:)@7PK!P5SFI4.5+%>%B65O<*9)
M(23\^K%(N!ZJ?2O8TKS6U/N#:EYT^S?OHZZUNUSL16$C0EO/6KS7X6K4^VFE
MX"]/:M&4:0F@AK>RE)"F1%DEK#%PW@EW;<K)0QV]D5F7.UM\<<KS*58='IW<
MED0W;=^M5%SR=TB@D9YH652N&&)&B5<\$M+ +E0 ?>-9C[D12'' SNCBKTQ2
MF*4Q2F*5%3[+;^?>TC_M2N57^"UUBE2K8I3%*^"4DF,-&OY:4=MX^,C&;E_(
M/W:I$&K)BS1.X=NW*ZABD10;()J++*G,!4TR&,80 !'*2.(T9V. HR23@#T[
M^G-2%+$*O))P .Y^78Y^X<^U8BTGOW6O("%E+#K64F7C."EB0LPQLM4MM&GX
MYR[AHRQQ;EW6;M#P,ZE&SM?F8B=K\L:.^6SD+)-)&*=.FJOO,N5*GD]@$8<9
M650"T9'HRJX+CN#MSZ"J ]L@^;SH?1HF+!9![JS*55AGLWL<:A^S*NU-G]1[
MRK4!;:U-V2F<SN:Q+? 1$]%R$U55)[EAN:3@R6.,9NEWL&>8CRG?119-!L:0
M9D.Y: JB4R@#V_T[_A\_;YU;GT&3]^/Y^E;=6C>-!J>Q*[K*8EW2=ILL.]G(
MUBT9NY%0R+%RDDFW50C4W3PKB0 KM1DFFV6*JE'/3"8@%#Q_"ZM_B'X8T/Q1
MI7A'4;]H]7U6PFOK:%8C*"L3B..*0(&E6>XVSM BJ=_P\F.0N?KM-\"^)-7\
M-:CXLL;$2:+IM[#975R\RPJLLR&0NKRO'$(83T4E9G 5KF%=IW$"W=J<C:AJ
MNF3MRF8VY&91:0)M$EZO8(A.1D%RF*P9(R$O&-FZ)GBW0>]6$Q4B$.J;Q$*8
MH\/B[_$G2?"&@WNOW-IJEQ:VS])52RGC:>ZE_P F*.28817?:H8Q;4R25(4@
M[>&O ^H^)-7LM)CU#1K(W<A5[FYU:PZ-G#$-TMS/TY\[44-A=^9& 13E@:]6
MH3LSN"N0-N;S"U?I-E8-9:,CH)^(V&18ND2G3),3S?PA"CXQ51<1D%X'[9='
MP*SH&%9HETZ+>ZCXTTC3M:-U)I.B:O917,5GITLAU*1945@;C5%Z4EF3RIBL
M8[>1'#9N&7RCFU2TM?"VIWNE;8-6U*PFFM)[V>-3IT<J.%+V-KYEO47:QCNK
MHF.5'!%JN%=K*@(SCKI*=M;BF)-&=PG'PQMHA:W*35JM,Q+((HS96*M?+(2T
MDO)E;S36147%HFHW:RQ72[E%FY.H;GT'PUX#\&7^K7F@6L5IJFHG&J16L]S>
MWE]<1RK*%>!I99&N!+<K()"J8:Y+LXZSFO*\2_XD:MX@M+'3=>UV35H="9[/
M3].C$4]Q8B2S@S#!:VD9F11;+9EH]H1%:)R K;CBC=4'REVI9M8JU*OTRJZH
MAK9'SMRJEPN;]*PWF-0=D,,'9(R$B7T2E'IM"*/TX7YG+(+OR-_FIE$T!:AK
MK<'BK6+K2FLK6"VTJ&1)[RTN+LJ]Y'N!$5]"(]K+TSN%J6GC64$R;\*!^0^)
M;/QQK%[HATR'2[30+;4(;S5[*_OIQ>:E;(X3X6YBM+66WB@Q^M$37$@DF$8G
MR%*&0 $DBD((D*/A(4._" ^1>A#Z?> "'D  (!Z=!GZ" ./4J, X&>1@]NV<
M<X^[M7Z0>>#SR#^(P1^6!^0KL@N@X236;JI+H*D*HDJB<JB2B9R@8BB9R")#
MIG*(&(<@B4Q1 2B(#DTKL"A!.*8'**A2E.8@" F*0XG AC%]2E.*9P*(] 82
M& .Q*/2E=A,  (CY 'U'R#]_\?=YXI3L!\__ $_OQ2NB:J:Q1.DH10H'43$Q
M# 8H*)',DJ3LHB'B35(=-0H^9%"&(8 ,40Q2JF*5U'OL.AZ]?^7TRC$@CS8'
MJ,9R/[?7W4K$.T=9.=A5N?AV=PM%/E)J.",2F(>;F0;1Z*IRD=J)0:4HTBW"
MCEF*[10RZ0_FN#'$3&3)U\=XP\(OXGTS4[*UUW6M%N;^T-I%=V6HWD<5LLK(
M+DBQCN$MI^M;B2$B52%$A9<,#7U'A3Q./#>IZ??W&B:/K4%E="YDLM1L;647
M+1H_1!NV@>Y@6.4I+^I==S1A6R#FO-TYJ!?5M6@:^[NEHN+NO-UF#>2DY>8;
MM5V'B4*Q:J0/S5W$D)'M3)M&PIH ()H)'_\ $*)AX_ W@AO!ND:9IEQXAUK6
MI--BE@6>[O;KHR6YD+P0FP,[VD8MT/35XXU9U4;\\YZ?&7C >*]6U#4K?0=&
MT2+4'BG-I865L&CG$:K-*+XP)=N;B13-(KNP#R';Y< 9AE6*$G'/(YX G:OV
MJ[)TF F+[UNZ2,@LGXBB!@$Y%#  E$I@ 1$! 0[S[BXACN;>XMY@6AN87AD4
M,5+12QE)%!!!7<C,#@YQG%?(12-#+%*I(:-U=2.VY2"I(.<\XX.?GD9J+B"]
MG=?*P\UU8(#DF*=ITU$U2@ZUEI/3\2_9,=34C6NX=;URMV"(;W./">MR;7<,
MI-R-V0>Q#1_)5^"33I[-D:4:2&C[IIKII0'^-^,^-;&WJ-=QV<("A?L".*RB
MW!< LS !0H I&%BCB2--HMVMG@P2<&UDN)4<AB<L6N&0-R3&BEBSL['[*'[,
MVHZZK5EIU9V1-$K\S7J;6H=!_!MG3Z&AZ5<Z7;8Y-9\641"4<JHTMM%N7 MF
M! %ZH_30*9(C8TR,SFV!08MKW0+N.,,>F%T*XN)4PFW:K3K<F.1@,[(L?OM6
M*Q;!+YN9+/6K<L1YF;68[=)'=FR6: Q-L+9^V%\JJ /%2]F;**3<?)2/()S(
MQE75IT)18@NLH]K\AUY4;-N25-6Y9ZC;/?6&Q2D%NVPU\]O!.(2:K0M>F"5Q
M44)"/D,%M]MC!8%F98K6ULS*>9&CL]*_1,#ENVX0QPR #RB7?M58RB)Z"7;)
M<23HHW27%Y=E6&466[U6VU1BJGD - L&1@F+&27#,WS0GL[MPP+^CR#3E+7)
MP*;8*-.&A+?Q]&3JDPXU-KR)UQJET_AH7<5:<+R508,9*S&7=RKV+?WB6)9&
MT)%C!5UC%ZD[C&VU"RI.ZOC.VZN'C#RKQPBP(T-NAW&(.Q5MV".;A8WA7<L9
M:-=F[.8$9V:,\_ONR&8C"NJ*FW;NS==:]G9*QVT:7L"8WHXG(76UYG;;2*<C
MKF.B4XUI9=LV7<$Q$R4ZE9G+B9<FL=KD8UM+&8LR(0$?#M_EAI%&1E)2'C9I
MII,LIE6&+<#C,5KH^NZ3;H?WM@@U[('H]DI_?\LLRF*.)$542.0,@ P9;C4=
M%O[B7M@,T^B(2>Y^(D)/?-CW?V5J%M@:_6D-W.V<*PU-K34D]$2U!0L%:L\3
MKRG;4J"4U*5D;?&1[V=3-LT]AK!)HTW UJ=@VKMY"64JY$V>LQ$DYG*\_&2W
M4:<$(TL%I"^T8P&'PB\@#@D9]Y60[6!49:&*(G][]7=W=RW(P=K_ !.&![[%
MR/;.>D.$3O4EZJ=AF-OK7*N4&8F;72:N2BLZXYC;?9-65O4<Q(R5A2L,LK+Q
M8P$1*.HV'&-9K,9&QO#.)21;L(U!O<2LS2,^"TD=Q%@_^7/J"ZF<?^V9$ YP
M/;.W;B\:L8CSF-E<8]"EO+:)\N([A@.Y&U!V#AI"<K6E,4IBE,4IBE14^RV_
MGWM(_P"U*Y5?X/76*5*MBE,4K&>Z*2ZV5J':&NV+PD>^O>OKC3V;]03E38NK
M)7I&&;NU#)E,H5-NJ\(J<R93' I!\("/6<M]"UQ:RPJ<,X7'?!VNK;3CG# 8
M..<&M8)!%-%(1D1N'(_]O/'S/:M.M%ZVY,1,'O6\(5ZC:<VW?T-15^BP6Q%!
MV?5(YOJVBP56EK):&>M[;7%I%K9'8V5.O,HRWQTDWBFM<D)LC-R=] -NO=GX
M@C<1=ZI?ZGR/\E;F*R@2W)'!9!:LSE25+2@QY&XUQQQE/A1G/PVEV6FX_B>V
MFOKB289Y(;XI44GDA#FM0/8H\16FC:OS.WU-6YU9=L\IN86_76W6\2P2B->1
MD_I;?^ZJ(P5US".OF=EB(>60>.GSIE9+3:':2H(E1D$R J"E&Q@[C@>I]N:V
M/XGV SD^GOS6_.RN%E#VAO*!WG9[?<224'\B02JC!U%LZV]:P@J"#-U[N.3E
M5$GXKK"Z7!^#M,#@1FZ:D10!'X34_P##[PYK'B&W\4ZC )=3M3;&.4&,");0
MDQ;9NFLZ*,L6"2*<NQ#<UYEU9:A<W0D'BCQ/:Z8T?1E\.6FJO;:#<I(I69+B
MQC4+,;@M^M9F,C;4V2)M7'I[CX9ZKVK2W-.06L])0?.FZKZ5K$R^<O'C)N*O
MO8IRC.JR[(6#T%""Y*#4JJA4"IBJ5(ZB:G;K/@O1M:LI+.5)H5>5+DRPRR2%
MFA.Y/)</*A(.&7:N=RJ5)/!\+6/!6DZM9-8I<:GI>]T+7FEWT\=UM0YZ!>5Y
M1TGSAP%!*@@MM)!]>C<2-5T^GP5;=$LUI<0;,&1K#.6>?"7DDR',*"CU"+?,
M(X#(HF(V(*$>F4R""?O"'.)CFZM,\*Z1IEG;V<,$DJ0QE1----U?,2W*!UC&
M,^4*BJO<9-=NF>&-+TRQM[,"ZO3;(L9N]0N);J[GZ8VJ\KEMI; 'V(U''(SD
MUBSCSPM5T7>MEW%;9D[,I[%5076:MNXEPBJUDI!ZS%S(D577=)M6TBY9)I)"
MS2$@)F,B(I( C30_"NG:!>WVHVDMQ-<:B LRWDJ2QKYS(#&P0.2&+%3D*/52
M0-OG^&O ^E>%M1U?4K&[U.:XUIM]ZMY/'-%)(KRR)(A6-65HNLZQY('3VJ0V
MQ<9RV+H1]=K)1IV+V9<*LWI,I\Y)&-WTI)IR[U4BC1P+IXYG$'+1-6*7>1?_
M +![E8K61?>%<#+%]W]4N%W<?;&T_=^/UV]J^T4LJD XRI4\#E3C(;'?L#]X
MR,5?EIU:TL%<F(-A:KW7W<JP78I3;*[VUT[COB">[4<-FS^;79'6!(QR)^_1
M4(0QP.!1,0,@<<>U/;_G^?\ >O#UEI&.UU2X>FJ6^]6-"$35;,7[RVV.)62C
MQ4,=I'D9PDPSCTT&!#"W:^Y;D\*!$T_/P 85*MZ#X_.(;:]AV6?9]\?LK#'H
M1:M17F9@C)JRCR_^Z$DY<)H\HX^6KJ/7"/Q1UB">3DOS"_$ )+;N -J_?C)/
MYYJ/P&>?H_1[5WVYJ#8%RBXJ/U]MN>HRC2;92[Y:0,XGRNR1:R3R/:)"=PV>
M)I$?(IN')57JR+HB16ZR*B1U %D<Y4'/X8J:R6-$4<0YF;RTVX955B9(TLVL
MLRS%N^.AX/BFS1@[8M3)HKB*R*"R)B&*4J:WO $PC'X<?/Z_I4?7UG^>,?+O
M5N:4U&?35;D:R2Z6*Z-7TX^GDG5E^%,]9NI0P+22::[<@*+)O'HJR"HKF.87
MB[A7OQ+J",4Y]_Y?7?Z]ZS)BIIT'_+]6*5U$H&]0[ZR  ,_.E (4OF =?3U'
MZ?I')I7(@ ^N1@$YQS[_ (YI]?G7'A#[O7^/^_W_ %Q@#\R?Q/>G_'Y=JX!,
MA?0H?4/O]?7UQ@8Q]?GWI7($*7T#K_OWZ?IQ@9)]3C/)]"2/ZG\..P%*%(4O
M\DH!^_\ OQ@>WY<=J4\)?N#Z^GEZ^8^0>OZ_^>-HSG[_ %/J03Z^X'T3ECU^
MO7_4T\)0'OKS#O\ ?Z_AD;5RIQRN=ORSP?SI77W1/]GT'OU'U[ W?K]X /ZL
MG SGU (SWX/)_H/R%/K\JJ9-*8I3%*8I3%*BI]EM_/O:1_VI7*K_  >NL4J5
M;%*8I00 ?(?,,4KIX  ?$7R-UUWV80Z\O+P]]?3R\O+L>O4>X QGOYCN.23S
MC'&>V<<X[GDU'M\ACCVS_;T]AG%1;:DXQ<_-'0EXJ]#Y,<34JC8]S[SVS&-;
M9Q5VM8YZ-2W'MJX;05BY"<B^6%08/3QBMJ.R!1" :$*1 ">)UX?B51(4%FSM
M&2<>W^W?\*D G@#D\ ?,\>A_+Z%82LG(GG7 [PT+KD.6/L]W5$WS6ME*UO9Y
MN/6Q4&#J^T:TTFKQ% @8@_-4SBS25I>V:81;.HUV5%J_KRD8=)R[D&Q"4 +.
MD3_YQC$HCQD312*75UX[A<8&$)!R X!Q4G:C2\]!9# [D\QS ,=K>I[-EAY4
MP-V >=DF*W/B8M\U0(WE]P5?7*MMFKR?K37B+M]65B&[U%JX;+/FB?-856Q5
M6SZ/< 10/>$;OX]90")/FIEK!E;++]A,1MSP7W/E@?3.TQ^VZ-L#(-7(QM/(
MW[L>@.Q4W#OSMZL;>^"N3S@>M:(KVA=+KLW;+?RRX,UNL5N,>S<]/S?$7;\;
M$0\1&MSNG\C)OG?-E)LT9,VJ2JR[A=0B:*9#&,8  1R"PC5BW.2 O)SR< ?>
M3@?WYH 6*[=V0/-CN<#S'[ORP*U\UQM_V@=WW3MO1\QR<X%UBZT:5B'E @U>
M-6S9"Q;/U?):[U]:UMGQM90YHI2,9!-+3;IJD>X<@Y4.XK"LJ"Q6LBW22L00
MSQJ3F/<)1@9@Z3PB0X ((7XB!&!^R9X,[25ZU"V5B?)"RB-XB"0)EF2:2+OZ
MLMO/C&-RP7!&=C&/82(CO:&V!S/LX/EEP;EG56F?L[9&\?Q$V\Z5@Y[Y9&S0
MQ$H1'FL<6<B6)F(J0,R7\"Y6DBS7,4"+IB:%8,HD!\C;@I(X.UC&Q_\ W5AW
MP".1QBK'OMQAE*;L]R"H/S'FSD8]*\N<6Y^U^62KLMR_X&QEC<UR?MS.$D>)
M^UV3YQ6JN>/2GY[X=QS934)"PZ\M&(2<D8 :,E)!J5PN0RI ,W "9BP"0A>J
MY(Q"CGB23M@D JH[$CL>30*S&%5!+3/TXU&,S2!6?IQ#&6PBEFQD@#.1P*UW
MT)R&YS[<XM:OY,6GEEP#H$=<ZA5I*XQ(<:]G62/UY>96-:'LFO)"RQ_,Y)E(
MS%4G57<$_51;-_>K,%G?PS9N/1+-F-D212'E?I(A])0SQLOH>'B=<')ZH9>P
M $;E83[&#*BJXD7D+$4$HEQV)DC92@)V[&# 'O6VB%+]I8X11<(\G>%2R"R9
M%4E2<.=R'(JDH4#IJ$.3FJ)3E.4Q3%,3R,40$/7&-I(;/!(/H1CCGOCY_CV%
M3D'D# .,#.?Y_/O6IW(_?G/O0]#F;JQY2>S_ +66D[CU#JS9[1QQTV364M=I
M;(L](9S,M8'DAS1=)MG]2H]WC]A*UQ8J4E)P9FID!;IR"#DE-R["Y8@=0J#Q
MC<J*S1'@^4(>L[9W*@<Y"*3'=5);9M.[9U./_*+%!(.#_P!1&B7T9W0 ;BH?
M/55F.=5XEI2#IW,[@-99>%8Q$I*1\+Q0VS*N&<;/M$Y"&?J?!\V3%%I(L5D'
M35<GB34;N&ZOB\*Z0GN0<MP5VR.C*>3&ZL0T1XSE>W.&]3608'&""&19%(_>
MC;[#CW##U&5]C@BKLEJW[1V"CG\Q-<I^$<7$Q;)U(R<F_P"(6WF,?',&2)W#
MMZ]>.N:I6[1FT;IJ.'+IPH5%!!,YU!*4HF"K.(QN89&0"/OXSQ_"<$C.2H91
MYBN+J,L@] <MCNR@J<=N/*&&1SYL^@-8#UIR^WM <B>/U2W%OCC#M#0G(G2%
MBV13K]J70^T-;KIV!W9-=1&I6+VPV+>VTX6-AMH,K395:V]L$1!HS4K72042
M\6EG:30UG!266$CS19+9*YSL>01C&=\G3C>0J@)"JSG"*:H">G')G.Y^D5QW
M(*KO4C!'G=4Y&W. !ELU*;1+]4-DU]&TT:S0UMKSARZ:(3$$[3>L5'#%8S=V
M@"Z1A+[U!8@D4(/1@'HW7@.01A<E58CAU61#Z,C#RL/D<'N<@@@X/%2.[*3D
MH[QL,8(9#AE(/J#P> ,YQ5Y9-33%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI45/LMOY][2/^U*Y5?X/76*5*MBE,4IBE,4KQ[#!Q=G@9JMSC4KZ%L$5(0LN
MR,HLD5Y&2C15D_:F5;J(N$BN&JZJ(J(*I+$ _B24(<"F#.5%>-U894J<CGD#
MG''/IV]>U65BK!AW';[Z@G3X][+IM.J^NX/2MM0C[M1$=44(M:K;=O Z<>U;
MF7:-@IR4^**C4*)6@H$Q7+= R**";-TE14HUIU+C7V+V"K2W*.S%F_2GAO4'
M8^42VNE&YDNHV8>5"5DCCZ/VI<A.<$TF9.G)L)6)K+7;41 G_P"XU&R@AMY<
M9SN26&1@>=K.>1N.90=1\5ZWJ#;5^VE 6>VR)]@HD&2B[+-RUE?#(C%4R(7>
M2MJL,K*SMA19LZ1&EK;:26$]<"6M"#5VZ92S5K%V1>G'-'G()7I'U6-;F\N\
M$C!)ZU[,"W<QB*/&V-<T<EVB8\$-/*X'"]6XCMTDVKCRIMMH@J [5(+#EJ<X
M]5,]T\2N0>OUZ>6^R,IJ:_+5:JBU,_/*75G5I9>G%:1_?NWTDA82L%XE!8BJ
M82B31<J0K(HG)SWJLUN^S.]&B=>_[LBD\#D\ \=JZK)E6XC,A 0B1'..-I1@
M>^<?(\'G@C-:31>D[]/[\A:=+TC9,%%?Z0)-^2NTH5>8JT0.KG/ ^/X^?9B*
MV-7I..F(J[I;3533^S,>Z:RK>+@1LA_=,O@5EO1,D9N;V0*4$5OJ<!;G]NDN
M-8TV^C,8&<HUO (R1_\ P(QP'%>=&K)::<A D=X-/1@1@V20:??02'&<%TDD
MX+9/_>,F,E6Q(7H?041H9KL%E#VZWVQO?[Z[O[E6XJP;J1CI%_ P$*];DD8B
M$AW4M\4>!)(N92>-)SCMT[6.^D72P&64Y40+!'"!A8^H5R23F69[ALD\G]9(
MQ'L#M' %=#>:1I.Q<+D 8'D4*N!V' Y]^Y^>F7-;C)/[)O-[L6KZ(5U>MA\'
MN5FHGUQ3*5L9]/3GY*RZWIK^=7."<6A(KIV8\:W!9LU(8TN_4 3D76S%66VE
MN',77C>*.]F@/(N9+.\L9!;=LD2QQ,@4G #/MY8BM2=T=H5<QRV]\#%(.\$;
MV=VCRKZ@]1T!(Y.1Z54H6AK;N=/D9?&R^Q=#QNX=K04C5*K=X>PQ_O\ 7\-J
M[4='N3.SZF0ME=:13JY3=$GXU&P O'VYM6'R[B'E&32;*8_:<+'8;GWRV]U>
MS2$X.2=6O[B%5<Y\LT-PDY8#<K,!G*FL481M.JH@!MXHAD87?\-%"69>-W01
M!&@SA=F1S@5)TP;$:L&;0A4B$;-4&Y2MT0;(%*@D5,H(-P,<&Z0 4/=H <X)
M$\*8&,!>QH3NR<GS$GOD\DG&?Y4 P /8 ?D,5#_-Z1F-/;.VKL*K:5M,EKZ)
MY[1.\92LTBLJ3D[>8.X<'&FK[%>82%%47EP70W#9A6GE"&</$UHR:D *K\H$
MA> J1'=1LKD2?I.VMUP=HDO;71VBG;W5/@KNVWG./BW48!:NMRKRHZR ']'6
MBR<X_6KJ.H"12!V5+>2"X*X^U&KX) SL)P.XHRF@]<ZYF+?)R87+\DU;@9.G
MNTV!D*1+2</4%[C#!*,U5C39$)*HP3./.H<Q(I-@^;M73YJ]3.C[%TZM/<;"
M'#W,LO5 VB0NQ.57T'?&>2,$@5P)ENF^WI[84A$60=BQX &?7 'X?.MY;36X
M2W0LE6K/#1=CK4VR6CIN!FX]K*Q$LP<=%68R4<]269OF2Y>R.&KM%5!=,3$4
M3.01#.&8?JV/<[HB![%9 =P^8(!_ 5LK88\XRCCC.<L N/Q5F!^\&H78+C'R
M"KU?T/2$M72:GVET/P/U_9[&WE*4K#Z0GN*^WY+95V+;&;RRLW\BUDH.9^%J
MA:2RLJ<G9(E2/DQAX]=O+CH<27A&XQI%K#ZL)\ AHI-(_1Z6T7JKK.F\[L@+
M(3_%4W*PGKM&NZ,QRVP@W,"T7QBRHP;^(QEP''F7:!P2#4L&B-:RFJ* VJ4W
M8FEPF@E9>8F;>W@5*XYM$M-O5)"0FI6-/-SR:4H\<JG.Y*R=M8IN4$F,+$0T
M0T8QC605,<*JH01Q+'M';*D@L!Z;SYR!P&8XJF/UD[_^;/)(J\^2-CF-,GOL
M7"Y.20!DDUF7%33%*IJF$A.P^\ _COR_;Y95C@9R%Y7D]OM#/YC@?,T'<#WX
M'W_7XGL.:^%.01%<S4[EM\6F1(ZC7WJ8. *N"HHG,D!O&4B@H+@0WAZ.*"WA
M$?=G\-=Y+.H&2C!>/WL*C-CY ,,^HJN>%.0. 6Y[;N%^[D$#GGT[5]GO  !,
M)B@!0['ORZ\A_'T[#S[]/KUDAO,1G/(!&.Q/V1\]U6/ S^/X#O[?GV_*J+5X
M@[2(NW72<(+$!5!5 Y%454S%*<ATEDQ,10ABF 2F*80, ]ADJVY0PP0RA@0<
M\, R_FI![C/<>4@U&>2">02#QC!!Y_+/KR.QY!HL[1:)@LZ=-T4?&DD*JRA$
M2"JNJ5%%,#G,4OO%ECD123[\1U3D3* F,4!G/(_]3 +]YX ^_/&#S4>8#OV&
M6X[#.<_<%SSQQ7U@(#Y@/?Z, ]QC&#BK5SDTIBE,4IBE,4IBE,4J*GV6W\^]
MI'_:E<JO\'KK^/W?3%*E6Q2F*4Q2F*5P(=AUCOP:5T]T7L![-Y?3RZ$>P'L>
MP]?+Z=!Z^7?GE=@^><YW9.[WVY&,+P/*, XY!YR^L<8^_MW'H?2N_7D(=CY]
M_O\ H'X8V\$9/))^[/H..U*X @!]1_CZ#Y9.!G/RQS[5&/ZYKI[DOB.;LWY_
M0"'?YO0#WY!]._K]_8Y!&<<L"/4'W*'V/\ &!@<GU.1.![>F/P&[_P#T?R7V
M%5<M2NOA#S^\?4?+^[KK[OIWY>>*8KI[DO91\_S0Z#T^O7?GUWY]>?[NLKL'
MEQD!5*@ G&#MY(]2-HP3VY]Z?WQSZ_7-50#H.LM2J9DP-X@$1Z-UX@\A >NN
MO(P"'TZ'KKL/Q\\J5!//..<9XSG(/OP1QSCY4^OP]1]Q['^U=BE H  >G\?=
MT'[  ,D #MZG/XFGU]8KMDTKH8@'Z[$0Z].NO^8#_'XAWD8XP22/G_KWX]*C
M'X?=]^3_ /MZ_*A2@0.NQ'S'S-UV(C^@ #\/3O &/4GV^0]ACT_G[FI]?3Y\
M?7]*U_W=M#9^M:W:+#3=2/=C$A8DCA@RAI%VXG)*2<G(U;MF=;C8:2D9%-%T
MLDJ[^&4(*;$CAP<Z)$3&SPM=U/4-*LKFZL]*FU0PQ@K%;EC+O=EC3$,<<LTX
MWN&=8D!6*.1LCBOG?$>KZEH^F7U]I^C3ZQ+:P[XK2W=S<W$C'8D<%O%!/+,>
MHRER HCCW.QP"5\C0&W-M[2J-4GKWIYYKAS(-%T9]";=R$5+-I:/]XW=&1J4
MQ#LY5I'OG2)G$<HN\<A\O<(*"NL<%/#CX>U?4]6LX+B_T:?2G?>KI<=1'+QL
M48BWFBBGB1^'C+A@4.-Q(S6'A?6M6US2[*_U'0YM%FGB_:+2[:6.YAGC8QR9
MMI[>"187*F2!\OOC="2#FMCW@B#54X?RR)'.7H.Q X)FZZ >_/OR .C=^@@(
M=Y[UQD03%1EA&Q '<D#.!D$<]L$%3V8%20?JTQO3/;<N><<9Y^NX[@@@5^8J
MV7+E.G3-0[/E-I[6G-L?D:UGM".LB6N=>,IAUM_8G$_GBK7:4Z95W5S0DK#H
M;%0I57JU4FDGRC.4GD6?Q)Y:P@LO$F8KV>-!U((+J]ACDX;K0F'P[(9W(*EM
MV+Q%=2NV-) 0_35*D,C10AE4=6&V^(=00T8%Y>@&/+$*&$L0.5<EU4J,D[M@
MK%S,W/==TLW>I]FWB0T>^Y"0M>MSV/U2P=P]3XYGH'&IY)[)CI:P0$5+-@6W
M!9)>B)2KE&PI'J=^V!;6T8LVURS=Q>L"8NI.OAK=I-4,  P9+P7$":-;K*#(
M$CN"&4#:1-"6D$T)[T8-\*P7 FCM]-:X:0KNC4V=Z^K%(E96D6&)4D28'8MR
ML=N8G9U"VG0]E<N9>H13B,W/LNA1C1C&5>/J-2UGJ6,@H]C%>S_K^]C/(YE(
M:M?KM'KS<2:T<X307)%MF3F0K,?'-%#-C-.:US%'"'V,4T-+[8=R[9K6VT*&
MW@D=>Y9YKUI8D"NZ&&.)H5@8-U3K&]PO BANM4EMY7)STQ=ZUKT;NHRSCIVU
MM!LD<2 ;#,_4ZN#B78_*;?VV):6@+3?-BU:BODZ',6MB:I0JDEJJRZ[Y'\1%
M8NX0-/:Z5<FKK!Y!SEXN5:=W':6QE[S6R*7!?7];@8U%F6UMF:YL"T;-&\FE
MWT@!5-ER]ZT4]G+YS\.\<*AY+(&X,*D2/>-N(&-QB.UO-A E6#4K./.&WPK8
MSM%=)@AIPTH3]H"6Z_\ 36W)8 3N\.;??;KI-A,7V:D[:L2[;2B:E>YR)80<
MU?\ 6D'L>SQ&L;Q*1L5%P<6#JTT9G"2WS&,A(>-FT5DIQA&M&DF@B7IW&18Y
M"%1I$+NJ#R!NM.HVC)*AH%@D\Q)!D*]Q7.H*/+$-S1QLJQN_+,OP]NS%N ,B
M9YT& !MC'&<D[3XK2F*4Q2F*4Q2F*4Q2M".".BME:.=\TE=CPS:')N3G=OG>
M-!%M+Q<M\UUQ>VM,3K<PN$8Z<C&.7AX=^"L3(@VDV?N@%TU2!5,3J5OOBE:_
M<G^0,1QATU:-PS-2M]X:UPJ!25NE0[R5E'BJXG,*SMPW;K,J_"L6Z+A]+V.;
M5:1$:T;F!5P=XNR:.LI)1'):(1Q<WMK9E_2/XF41"1O_ $JS#C]XD(,%@1HD
M;2+<,I7,%K<7.TD#>+>)I2BY[NP4A1[UKCL_V@41JRZW>#F-3V>0IU8EY+7L
M#>HZ>@/#<MWL:# [&:ZM85URJB_C0FH6?381-ND')8D\]%3<>_0CT6S![)S&
MS2/'  OQ5U/-;V$.<&[DMYY()@">(MC1DY<G<GG&%QFI "/*6 CMX[:6[9N!
M;K=Q"6VSC.XRAE "\J2 W(;;L'K'D1"6O5MRV/LIC%Z6-JV9NT!MUE;;="+5
M[7SR@@=W/2<E>1&.@3U<L 9E9TK"Z^6MTH1\DM(HL%DG**-HF$T%M<QG=%<1
MR2(Q!4D17,]G+@$Y 6YMI54D890&'!K/=B22,XW1LB/MR0K26\-RJY]3TIXR
MW'E)P>:NW3&_](\C*Y*W+0FV->[EIT+8WE1D;;K&VPMVK*%FCX^*E7\*6?KS
MQ_$N'S./FXMRY3:/%RHE>HD.8JOB(%JG_0>GOG_3M67\5-,4IBE,4IBE,4IB
ME,4IBE,4IBE,4K@0[_</[,4KH9,IO+T#OOR^_P ^_/U#OOZ>7[<@C/\ QGT(
M_O\ B,CL33YUR1,""/7U\_/KO]OK^_H,  ?R[<=OE]?RI]<G/]:X.F!P$.S!
MV(#V _H_^W[\C;PPR?-G\,C''U[4]0?O_'((_O5(&J8!U]/(/0O\D.^@[Z[$
M/,?41]>O3RR0 .WMCL.W QGVX[4_V'MV_P!^?O-= 9D#KHY@Z[ZZZ#H!\^NO
M00#RZ_0'U\\,-RE23@@CY@]@P/<%?0CGYU&!G.!_?G.1\P<\J>.![5W%JD/7
MEY@)O"/EV7Q=]]?M']?G],C:.!Z E@/F<\?=SV.1V_A%3D^AQG&?8D>N/?OS
MW!9CZFN"M$BF,;S$3==_</0=>9?0?+KZ?C@*!C'&#D8)P/? [#/.3W.><T/.
M<@'( .0.<=LGZ_/O5(D!/J(^8B'D ==]?< ?<'K]WZ<D# QGC.1Z8YR1Q[G)
M_P#D1VP! &.?KT'] !GY9]ZJY-33%*8I3%*8I3%*8I3%*8I6&.1&JEMX:0V;
MJ-O,(U]QL&I2M90FUV2DBC&*R2 I%>*,4G#11T1+OL42N43&[\C@.92IO, S
M@)=6DYP 21:W,5R5Y[;^CT]W==VX9( JR/LWG&=T-Q%WP/U\$D!)]P!(21^\
M!C(SD:7;@X"6;;5RNRZNV8B$U_*WE_O"EPJ5(<O+-6]Z+ZVK>N8F7DYH]F0C
MIFBPJ<$[L05U.'CY60DY]TS5G$&4>R R$&&>&Y4_M-C<SSV4QY"-=7#2RB6,
M<2KTV,2C<O&'+<;35@DD,D#KF"ZCLTNHP0ID^!B$=N4;!,1!1';AMV".-V1M
MYH#4D]JZJV9*[6&&M=WV#?K7LB\2=>A'4!65)RS':-4XZ$AI*4G'[:*AX**A
MH= 7\F\=.Q8G>.#D.X,B2T2"*WMK<$E;5)D1F^T4FO+N\"G'I&;MHU]U12>2
M15 BB:XF48^)>&1ESN"M'9VUHQ4\>63X83;<>4N5!(&3KKP7231V%[1A)(A4
MTR<_+,!2$*4A2]\8^+8] 4H 4OF/?0  =CW]<O5ZD&Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2M>>35A@ZOK4
M\Q:Y*\1-/0F6*=K=Z^OD)K>P!#K).DS%):I.Q5&6:M?C19G6:TNS1%R>BF1O
M#J/"G<QKS-R-T2>LLA0<\C$;OPH!9_L<JBLP&7P0N*G'ED?TC4,01P<R)& 6
M.%7+.J@NRJ68)D%@1'KQ060V%ONRFHJ5_I]%KZ\U-1\H?D-MJ:GY&-9SL<6G
M.+QKG:6Y+NO92;'KBTB]F!L^EJ6\J1R>XAK/,.EF,PIL@*HY8[CLCD5<']_.
M0<^9"".-ZJS*0=JY K*0C>BKQYG5CP1E H)&!M8;LH2K, RD%C@U,@'F ?3\
M/NRHY /O6E!\P$/OQ2F*4Q2H_.#?](WM&OZ_ME_RQ<6L4J0/%*8I3%*8I3%*
M8I5+WGYPEZ\P]/,/,>N^@#U_=YC^'GF8?G!&/09(&YL9POO@<GV(((XS4X^O
M;G%4G#M)HW6=.3I((-TSJKJJK$3223(43'.HJ<2D3(0H"8QSB4A0 1$P &-[
MGA8S)(?*L49WNTA.$C48'F?(QG'XU!('<@#/+-P /<Y^CZ5;U/O%2V!!L;/1
M['!VZM28+FC;!6Y5E-PS\K5RLS<BUDHY9=FO\.Z06;K DL<4UTE$3@4Y# &]
MU#<V5TUE>VMQ:72#<\-S"\+H-JL"ZR!63<&5E#*"5(;&"*JCI(H>-T=3V9&W
M ]QY2,@X((.#@$$=Q7TV&UU^HQR\Q:IF)KD.V.U3<RTW)LHJ-;G?.4F3,BSV
M06;-DSNGJZ#1N0RH&6<KHHI@950I1B"*>YE6"""2>X97=;>W4S3%(U+R.(U&
M\HBJ2Q53@ DX .+' !)X4?O'&W.1P<$D=QW&.?QJW;-MG6E*3*K<KY3ZL50O
MC0+/62'C%7)1\/0-D';Q%9RH(J)])H$4,/O"= (F ,Z;33]0OAFSL+RY'&6@
MMII5&2V S*A"'RG(8C!!&>#52Z*<,ZHWJ'=5(/?G+>Q!Y]ZUK<\V*HZY'::X
M_P!5H-_L#/:Z%Y74VN\K5EJ^O(=6EU>9L9HV'EIZO-F]UDWH1 HKE@W01T>V
M>M'OS)X<YF9?I!X0N8_#^JZ[=W^GVSZ:UDJZ4MU;7.HSB\N(H.I)#!<,UI'&
M)=QZRF1BCJ8T WUR_&*;F.W2&=U8.7N!$X@C*CRJ7*@'><!6!VY[$GBMU2'
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MXOEK6=48ME)=M'^-T^/\$B_%RDU\3QV;W($\3E8>U#;-MR=N=OIZ?=_:LU!
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M/F1948DB><W$@]3*[;WPV,@,Q(< @.OE(( (V(02*EXP+X?"(@( 7T*'70
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M2!D XR5(.[[>W)P3@'T!'F/ /<B<>O\ 3WQG'^OM7(*"(^0=>GK]XCZ#T(@
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M !*?%*W!Q2F*50<N$6B"SIP<J2#=-1994X^$B221#***',/D4A"%,8PCT %
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M?@3_ "_N*Y,<OF7H3=^70=>??_(?^V,@XQZYP><<?7M3W^7I[_=[U1Z2 ?\
MPR^?0>O7?7?K^ >?K]>^@[Z[=\YR,#)Y/;CGCW]/4BF1W]P![YQ^[G/./F<<
MU6*J4P]!XOK].O0.QZ^_[OTC]WGC/)&#P<?(\ \'L>^./7(]#3/;Y^GK^/MC
MUKJ=<B8B!_$'7GWY=?A]>_/T]/7RQN'/I@XYXSZ\4S_3)^0]_P"WWUR*I0$
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M=A!V"9J<T\J5@BK VB+377QXZ>KDHM%.G1&$Y#/T5&DG%.Q2>LG >[<()F$
M&I7)[^W\F#?VIG_3G_?Z]JO0"@'0=!Y>GW_Q]>_J.2!@ =^PR?E]?SIWKG)I
M3%*8I3%*8I3%*8I3%*8I3%*8I6B6ZK+[2N.V1/M./.H>%UJU(DG$#6)S;N\]
MS4R_O%5(:/4G2S=<J.C+G ,$VU@-*-8LS*QOS.XA%B]=%:.W"[)NI6*_ME[9
M7_<![.3_ (G.1?\ TR8I3[9>V5_W >SD_P")SD7_ -,F*4^V7ME?]P'LY/\
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M]9U3<>]+PUY%VO8FX9"':ZJK6D'[[CEK+9DU=&%JE+/=4]H-K>UM%QM^UU:
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M5[LW:$_K.[,#'3?P5\6<-$8]>:C\_?ZQ_3^U?K%XP2O(Z;T5KN3Y:5;6=,Y
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%4Q2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g752656g36n86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g36n86.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2KZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #\< 5H  QLE1QP"   "   < E  #D1R;W)Y+"!*87-O;B!,' (W  @R
M,#$Y,#8P-1P"/  +,C(U-S$S*S P,#  .$))300E       0\JXB:144JMR;
M+LVLQDQ:T#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              38   )X          $
M 0             ">    38                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   38     4F=H=&QO;F<   )X    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      /AP    $   "@    3@
M >   ))    /:P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 3@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]522224I)!<W)EVU[ /S9:21Q_*0+LT8@<_*M'IUQOVUN)]VC=*_4^DY,XZ(
M!B1Q'A'RZG_&2!>S=6=UGZP=)Z'779U*\4^N[92V"YSR/I;&,#G>W\YZG^VN
MF0\OO%3:]7NM!K:T3MW.?<&-:W=[%YA]<?K!D=<R\;(QJ'8M6-ZM=>^/5/OA
MUCH_F][6,_1I]*H]7NKOK'B=2R*L7I&66Y=1]7TGM=6VX>E:ZJC=8S:YEF1Z
M._\ F_8RWT[5<QNN7-RVX?5,4X=MG\R\'>QYEK-FYOT'[K:_WZO^%];]"O/.
MD7Y# W(<?TU$/KL(!(+??W_-6_T.SJ/5<U^'U.YG4L6X.M:W)K8X5O;[JW"N
MOT=S-YV>FS^<I]CT:0]VDLGH'4K,JJW%RB?MF(\LM#BTDB8:_P#1,II[.K_1
ML]FS_KEFL@I2R.MV]69;2WI^13CM?79N==MC?NH]-^Q\/>QM;K_YO_"OI]1:
MZJYG2^GYQ:[+I;:6" 73QN9=V_X6FNQ)3F8^=]9,C'KOHJQ+ZW3#V/<6N$[0
M]MGL_=_2?H?^_P"/5L8WVG[/6<K9]H+0;17.P./+6;O=[?WD"C$QSCUUX\TX
MC9+*ZR6 @G=NW-]^QR88.+)%%CF.<#(%A<"/H^ZI[GL24V+LFF@@6N(+IB 3
MQ_5!3^M7Z7K3^C+=V[R.LK!OG#;8+@\.H+26T576!S7>VJRIPO\ S=NRS?\
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MN-K7#5S_ -STG>STUJ5VY.,1;AO-=]9!K<W6#P0 =V[]U5Z<>AK6OT;NB-Q
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M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
M0P!3 #8    ! #A"24T$(@     22DU- "H    (  \!   #     0+2   !
M 0 #     0%B   ! @ #     P   ,(!!@ #     0 "   !$@ #     0 !
M   !%0 #     0 #   !&@ %     0   ,@!&P %     0   - !*  #
M 0 "   !,0 "    '@   -@!,@ "    %    /8!.P "    #P   0J<G0 !
M    '@   1GJ'  '   (#    3>':0 $     0  "40  !'L  @ "  ( !+$
M$   )Q  $L00   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,3DZ,#8Z,#8@,3$Z,C<Z-3  1')O<GDL($IA<V]N($P 1 !R &\ <@!Y "P
M( !* &$ <P!O &X ( !,    '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M              F0   '    !# R,C&0 P "    %   ";:0!  "    %
M"<J2D0 "     S@W  "2D@ "     S@W  "@ 0 #     ?__  "@ @ $
M 0   GB@ P $     0   3;J'  '   (#   "=X     ,C Q.3HP-CHP-2 R
M,CHU-SHQ,P R,#$Y.C V.C U(#(R.C4W.C$S !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            !@$#  ,    !  8   $:  4    !   2
M.@$;  4    !   20@$H  ,    !  (   (!  0    !   22@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX1),34T *@    @ #P$   ,    ! M(   $!  ,    ! 6(   $"  ,    #
M    P@$&  ,    !  (   $2  ,    !      $5  ,    !  ,   $:  4
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MZ@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                "9    <    $
M,#(R,9 #  (    4   )MI $  (    4   )RI*1  (    #.#<  )*2  (
M   #.#<  * !  ,    !__\  * "  0    !   ">* #  0    !   !-NH<
M  <   @,   )W@     R,#$Y.C V.C U(#(R.C4W.C$S #(P,3DZ,#8Z,#4@
M,C(Z-3<Z,3, '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M   & 0,  P    $ !@   1H !0    $  !(Z 1L !0    $  !)" 2@  P
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M 1$  A$! Q$!_\0 'P !  $#!0$!              @%!@<! @,$"0H+_\0
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MRCW';R;TGA$P60W=6%-7K90\J=>0TJ;=KDM!?IN1GPF4'4+1Z1*?.04R9)(
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MY]M3-X@^5N^<OGR4@$Y G>;&P.4\%H'VC[*_=!/ZR?;CY$'W!'//RU >UQ<
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M!LNN\I[1P1K#V;R3[N<G,1>^>5_BD'<,X]>O18'J?IJ>BK(KA=737^463")
M:1:0:V Y =0'.T2D*3;HD*CCPHI])2E(/'IJYXT%)][9>LSQ0@_7,'EDJKO[
ML/M[U9XGG?4GTV[E;NUNXM]M.]A&2TFP>Y5)MI-WSI:5FTM,5V[SJWOZ+(8>
M-6$23<VM=2YK!8@9%CT'(+01)Q:]-H5+2TP;>GKZ?@H^=QYY[N\WSMP5,Z%>
MB'J#Z<Y&$YAF^_\ 'HZ9K$8^)3>E'!Z-B7L1MQA55%D2,9QG!;.VF)R1W,*:
MUGRK+-]SK)$FWSVP<D&=%BQ&X?95/6.N9$^*];D.MN!"D*"DN)"T+204K2>2
M"DCP>0.X?>/.BE<FB)HB:(FB)HB:(FB)HB:(O+;K!Z;]U<LZFMH>H;%=@=H>
MK;$\6VCSS:*TV<W<R^JPYO!KG,,KQO(F-U\,?RC#\WQBQFRJVF>Q7+(DF# N
M13M5YI),M+T^#IUUG\%%^OAQY[E#I[Z.3J!B]8.9[BV>$UN<XEF74(.HG%=V
MX6^6/X/-VR8E;85^$2-K+K#!LU<;@996T#$&SQJCJ:#<>BV[R/&[F"FYI\=<
MC6HDE/#KQZDJ3_T?71IO1TW9EBMWN4SC2(-1T/[!; RS1W+=DI.>;=9[NMD>
M1-H92U'0]4MU>7TJ(EB&D!^1\6VT@-MC1.NNLRO5BXO:;':^3:WEG"J:V(E2
MY,V?(;CQV@ 5E)<60DK[?*6T\K4/T4J.B*(ESU4W%S-D56TFV5UE/H^$9+D+
MBJ2@62#P[$;")5I+;'!))98_<CGCG3XJ/IG^/XW5AS=R>M!Z/)FPJ3;.$VA!
M4(KU)D$P]@\@AY=HPE?(/:1Z#/D=WGG@1/K^/T4]1UUZ*WJ;JKZD,:EMKW#V
M?HL@IDJ]*9(PN995UT@!0 >C0+-N77O) )*VERHZE#A*7>=3U^KR4>ENO+O"
MEUC6^^%[@XMD$O"Y,F3E%32393N%3F37Y5&G(A/+CPWJU]Q#BE+DH#"9$=QV
M*M7YQN0IHH<55^T&/+1+@UQ:)B7 &!.Z3 G<L.)=5;AZ[J-,U:S:-4T:0/O5
M*@8=A@)L"]T 2=^><0LQW)NL^EQ6VQC(*R>,KC5]Y<565MU+>7,6LZQ<D6D*
MG0MH44:O^HHR_JUM;D-;EBOX>&J4MU'JJZZ:FEF2QX:UP!+2'M>7$P8DO]VQ
M/O01/N[I7G>!Q^NM.BZEB]'/I56,#A4:'5Q6>[9?V;G ,;2[,;5]D[3ALB1L
M1=-OG/55 9RR,O;B/DU4J3:V-"Y-IV["6['78-UM=3R*QZP<3WI6ZW=N+0UZ
MC5,'&6VB[';6Y;M])!E1I92?,EA?68UQ%VQLEQC,$WMW&5M8C%ZWL[9HT;2K
M4BYSJ+ZE-M=SFSL!KZ9)[(.)%2),-);>"5;5=>]5J;RSEQ<!IXXL%,*8B.XE
M!54UT&938K-?A+<BW$4WCK-@B\KTR9?HOPW''4*9> '?K,?I=KR12HAKIF*]
M)S0#$ P[WMX,F01G)MJ-KZYNJDLT;@&LJ$#WL+1 IM(I.C_+-[2YJ4KQ&R'&
MYMESI_W9SO-=VLSQS*\>J:)-71^K81J^L#2ZVR^MW(M16N7[4Z1'MUO4++=B
M_&^'C/075EM #2@D;FB<97J[5-[*;2+N +-H.F -H&7>Z9$Y9 0N<T)I/'XG
M3&)IXFA0HM;AY>*9IDTJS33:*3G,)VPYLN!(:1!:T0"5,2W:EO,!$25\*ZI:
ME^JJ/\5Y*5)0AM)4A(<[N%<E7CGR"-9=/4L?7PC!H_2&'T;6:X@U*N"^W5*H
M+'-#,.T8G#.HUMIP<VLTU-B#[N;EW7#&G3>_M*7;@P[8<_LVM$WOLD96BQ6'
M[+:5C)E+>RO),MLTA12(:[@MP E)*REN(PD)0!W$\**BKP"H^$Z^?=/_ +'/
M0OM!K5L3KQK7K]C>R>]OV!FMV-J:'.R-MS&Z+<:]!C3M?Y,2#8"=_/T=/NP8
M'V/1F!M!DT@'7,7.Q+\H)X=RWU_3UMPEEI\5DUWO0AQ*9%A(4/M '[3*R V>
M/)0 GC]'@<:X[17[#SV&X.I@M)4- XZOBZ0I5J6(Q&*HBHQX <UP:[ BI3(/
M[G::6W%LE>KKAK!6!IG%"A2DAE*F*@;38+-8P-JM:&M$-: T 18"%F2MJ!61
MXD-@CX:$T66$<$*2T$A*$=_>HD)'C[7)X_5SKZ9T;HG":*P6&P&&:XLPK!2P
M]6H=NM3I- :&=JX%Y!:UK3[P! RR"ZW5JUJ]5U6K4VR\ES@6SM.XR7'*=X)5
M90GM^1'/R*N?UZY)K=F\DG>29ZR5">/PCX+P0^G7^DJW)Z%-J,.Q/99IF%N9
MNK]9=F52(XEJQ/'ZY<=B3-KF"I*%64I]],=AY\A#/*E-E3R/L7#7N;(;QWBT
M;\OU;]TR 3)Z'RZNOEFVC^D&ZJ-\HTW%MX-X=QLKH<C9^&MZV=FF2_!2&'%^
MDIE<5%HTP8[B5=JF"DM'D @I&KACPX$V@@DS>(F>?C&=XNIV2(-AZ93\AU=8
M1W3WDW/Z4MP'<>@26,KPJYALWN/UN2*?>5'A*<<:D0V9B?MM&.^KTTI0%-*2
M"M14L(YS&HP@$Y]Q^EQOX<^,YB;6F=U_G.[AE/"@N?2(9[;0G(=1B&,8]+>0
M4(L$2)]DXRI?@J1&DM--(6D$=CB5K*5> G[/D"SB1WV.=]W*+7Y#-2&9&?CU
M8]WANQ_6[G7]_9KM[FTEV$^:ZER5(?D..K6I//"$=_V4(')[4I "0!V\>^K;
M3<LB+2!N.1WF)&4QQ$96@[@ >(M(L>![HR[U)[",TD!;"_67V*2D'N))"5>"
M024^0#X(/@^??@";&1?:'?NR-NN"KLF(&[*^?//>9X=]E[_]/'TOF^6W>W53
M@5CC6*;@HH:N)58_>W\ZSK[F'$ALMM18]E\ T_'LFH[2/10HK;>[0V>5 *[<
M-1A)D 2!>+3$"8\<^2H6D&_IUN7OWTF=8.W_ %2X@FQIW6J+,JQ#362X;-E1
MS/B/ED*5+KVPOU)E2XKDL2&TJ* 0V]VN I&(M<!)%N*A3 U5$T1-$31$T1-$
M31%QK[O/;_<GCCWYY3_FUCJSL.V?OQ[O'G'AFG?DK,SE=^,<M$XZQ\1=.1O2
MKDAPM]DEX)9#Y/:2&XY=4\\4\K#:.$H4I0&NKZXC29U>Q3=%![M).:T4!3VM
MO:(<"1L#:M(F!S6UA.Q[5IJ?=!.T#$1GYY;LR28M,<&(W4'%Q:17*>=,^"\Q
M71YJ&(]E86$5B'(=<MTSI)07'Y#XAQBA<:*I"@\KA06%(^?L+3]M=/5FI3<^
MO2QS7N92#,-5TW4J4]IY[05:@IO$@-$07,LVY!78JIT*YX=3V02S:)+]AK7^
MZ TL&RT ^]<P+=RK5Y7[S3\;I6HS#T:4Q;6\B=\/-?9LK"I6U.#4%]I: BOD
MR%>@B$MN1,:;<4AU;:$#@;NF]&>UO2&IFA*&&;CZ6F6:6Q%7&UL-I#&8#%.P
M+L/4:RG7P]!FW2':'W1M%H.P6@$;2K@JFAZ=>LZN6%AIL:P$ M#]H&01&U$G
M:RL#*M"%B^]0:FOSI60MF9$D,Q(_UA(D38\@0*T1')#35E'9?:$CXTN",6'&
MW0ZMUUYHMI3U_1VIWM@:T5,3B].G/W7:P:3,  ;.V'$9W$QM6N%MU<1H7_H^
MR(!:3[K=D7(,&" 2 (DW&7O+N"!NXF.Q):BY>S:MW7K7#2+!R5!F4;;\5;,*
MI[I 0'TI2H.._P"M4]B76RMP+"]<C3T?[2L+2PH-+69^/;I^I^47=KI&O1?H
M-M:@&=E5)V:C@P5B*C '.! F%C?4T.YI]^@X=FP, :UKQ5(.VYTB(<"+':,R
M86:< 5D4C+,HG6=?DU54OMPFZN'=K]5EQQL2%RID?ME2$QDK]5MD1@E"?S(=
MY4M9[?7=4/RZ[673-3'TM-4]#NP^&_)'V\8L4]L]L<6:G;G9VC^U=D+P!8S*
MX+&##B@P4W4G/! <60+90!G-AM& ;<"LS:]27%IHB'P.?Y_ _AT16/N)N3@F
MTV)6^=[D97189B-%'<DVM_D-E%K*V(TVE2SZDF4XV@NK2D^DR@J=<5PA"23H
MHGD<X_'N7S ?3"?2N;5;N]+ESMATRY@YDT/+I\FJS>]@,N,Q'JB$&WVJN-*!
M/K1;)[TE2EIY2IA(9X[U*[+LR)\/KR^G)9&9_#Y]9^$KX?,@LIDZ6M/)[E'M
M5VH/:D@\GY^?/MS[^3^ M:\FP/K:?7*/62LAB\FPS'K],O59'P RV%M@E7'*
M//:> /P')XYX]_E[ZG='H.?X^<=X4C+JW)>BVT-W*CN0W LA0+:#R#Y!'W?A
MQ^K]AYU=LF3!BQG@1M'+T,^D*#^KO]?@O2'%Y?Q<-D.<+0^T._GGCN(') 'M
MQR!]QX^7MJ6_>B+$9>$]?5:[]\97$93YWXVS[U86X>)P<RKYV-WL=N=7J2$+
MANCEMXJ[@AY2>X'UFTD>FYW%3:@%((\#1MH)M<W[HL1'7@K PH-CIZN]K<@1
M<8A)L)E EY"W:YY2W9U4WRI9$9U/:78_<$C[:4A 4$D*/!&0.X@<)!!OT<L^
M$[K3:+>/,1N[XC=\/HC^B5WIRK$]X<3Q(27U4>X8:IK:O4^L,NNI:=^%E>GR
MM")$52RHD-I4Y^@5I[>=8:N9GA;E?B?"8X^5#O \['Z=>2]8_I%]O'=PLLZ<
MXF[DG*!T45E[GMQU.PL<N+3'ZIDTN*+OL!N]TKJIF0I$/:6GL*^V7DH,B-$=
MLGJ46#SL+\PO74=QO:_=>+9?&ZM7Z-???I,=O-P=E^FS>C,LGVTL\CLK_9+
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MAH);':>.UT!2>2..*TI@Z.$Q [-[7-_FDGC!Y@<3OLNHZ;T+AM'XC9PF.HO
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M-IMJ.,"'/>T[-Y@-,.D_G W&:E+]7P9@9DO0VW7ELCL=/=]EIY(44!22. H
M=R>.#P.>=874V', \X$^OP6$TFOA[Z;=N +EQ@;Q/RRF^Y=6+5-08S<:'"8:
MC!9*(WI (:0>>0G[*E-DJY/"5<<'D>^M.M2?BOLKQ1P[A3+@\8RC2%0,$AH8
MUM*H&DQ)AS9$$NDPLK*>'PU/L:%)U-D94W.V9)).;[#(P-]H6[X%4;M4U$0M
MY3Y6GA3Q:0/3*1WKX*D@\D$A"CY')/R4<*QI+ZU*GM,K.JTA08UNPYU,4R0
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M31$T1-$31$_;Q_I^.H(G>1W(M..002?/ZO'\FHV;$23/&Z+:$ #CE7'M[_\
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MV?!X*DH?+:!'96H>IZ;*4CE1\^>-:;G3RZX\MWS603W^$*16JDQ<J5UWI*&
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M+> ^7ED@D" 3YKJLU5<Q(^):CMB00L%\_;="%\=R4.**E(22!RE)2#Q]PXT
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M?939Q6I]O)A1&84=^=-?5':DVUDIDOO!L)5(D+<+;?![04$C?OW=_(?'R5X
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M;3B?T5M)EN/(;4/O0E)]_/.N1D\3YE8UGQ*0D> !^H<#]@^0\>!\M0BW:(G
M'/ XY\G\3]YT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1==]'*>0#RE:5'R1W #RD<>?(]Q\_/@ZU<6VH:
M;#2DNIU&U2T3+VLG:9:9VI B#/!6:0#?N'([CX*/^[M+C4>NGY9/C)=L8M/+
MHH,=9'I2GK1:/30LK4"7@Z2&^WEQ*>_A20"D?*_[)G5O4[!ZOZ?]H^F]&8/2
M6FL!JW6U5T1@<73I 8S&Z5J4\7AFMJNVJ@Q#/L[VTW4Z52LRCVNQ:6KMNJN(
MQF)QE'!T\0^A0JUV/JU65'-[)E(ASW!K2+^X+S()V<W!8PEP<MOJ>7B5996J
MZ[!J"OK5L43C0>ML@D-J6XRY8$J68\-APMJ92OP6PGL44DGPS2FAO:'KMJOI
M'V=ZN:;UE.B_9;H/"Z/QV&U=&(JXG2NN>.[/2M# ?EK#%ND:NC\+H;2K:=6B
M^N6M[.A_B8EKV]@IUM$X>O3TEB:&#(T]B<00*[ 6X2A0>&FI3I@M#:KRPMG9
MF7.)M"O[;3 \WH7H,FW<K*:!'92M5145+#S\IY:05/VEA(:3-4\CCM2EM2N%
M'W6>>?7_ &%^R;VIZNMT=6UFQVK.@='4F4Z_Y'T7H31N(TMBJCV#:JZ6TMB=
M'X;2K<42 RHUV(J!K@7@AQ(7!:=TI@<6ZJ:#G5@9 =5J$;,'W12@[.P+0 UL
MC[Q)LL]3K.+7Q9,^<ZU$B1&%N///OAA"&VT]RG%%SM2E!X/:I1\GQ\N!]6:7
MTQA-"X+':6TC6PV"T=H^C4JXC%XW$C"T6TZ3#4<XNJQ1@@$,<ZHT.,"1FNI8
M>A4Q#V4Z8<Y]1X:T,!=))R$>HB8$Q<K#NUEO,S&7D>>6:Y":Z9.538S$*5(+
M=17N*4)?'* HRG%$K< 4%%OL*U=IY\$]A&M.E?:1B-</:7CL5B':$TCI2OJ]
MJK@JE$4Z#M"Z'Q%6M0TE3ILBA4J8@8L-J8BF*I?V18ZN\4PN8TQ2_)AIX,4V
M;;1M5';()+G M()() <9<P"+.$#(K/;/D%7>5A24*3]D)X21RGV)Y\>YU]'T
M0X-O4[0&'-.PU@V7"1&S8V_5=<%;,")SO/6?#U7-K,B:(FB)HB:(FB+I64^-
M55T^TFNI9AUT.5.E/+/"6H\1E;[SBCR. AMM2CY^6B'+Z9J%'2;CCM^[E6[]
MNT[];9YD5CD*E/A/J-L3G5&!$!23PS"KF($=A'<H!"%*YY6>0XSR\#R[M_-1
MF8CGX@]?J*G&"#['G_DT4JF7,A^/7251'6&9KJ"Q!7( 4U\:\"B,%()'J#U"
M"4#R4A7@\<$H)B_AE/<K'Q'":_"H+W)^.N[.0]9WUP^I3\NRM)9[I+JGGNYU
M#"#]F.PDAEM' #8X'&JXBF"3>>%]]AUWA;33VA@"/P FPX\YW75RJL$\A/<>
M>?GV]H \\\#@J/M_<_(\^PUJ?;&3$/F<@T7_ /CGN6U]E=%@T"!>7 VY;,?1
M8]SZ@9LX\')*P,PLMQ>4W94]LF/S(<9'*+"JD.)0HK@6<-3T=YASUVT%:7@W
MWH21L-?V@!:8.Z;3O(B_+>?BL#J?9F'"Q%X.4DQPGR@SO67X;JGH<5XI"5NQ
MV7"CDD)4MM*BD*)42$D\ DDD#6XW(=P6F<S'$_'P7%9'B!)Y_P"XK! X/GL/
MCSQ\^#S[ZD9A5/W3:=UOCUOLHU=+RE)B;PQ>Q;;3.\-T\RA0"0$S<<Q>2ZI#
M8)2VEV0MYTH0HI[UJ5SRI1(=<?&PZ"MU\>OUJ3RUE*Q]GP3X)/ /C^4_(#]?
M[<+W'M&M \7?<B)MG)\+QG9.N?R]/C91PWCM9%1:U<Y$R^I514EQBXBLM3J%
M,E9"?A[F%SWA! !1)#7"5<#GSP?D3]DII]NK>.T-I:EI;6G0.*P3V8BEIC X
M+"8K5S!U&TWBF_2YQ-=P;0VB&U"<'7:'.:-AP,CMVK^&I8BF^G4;0K-=:IAW
MU#3JN8<S3=83,D P#^<)OP83O)-MX<5G(J&9%L+*+8.TDYAII57?IA-.^H6'
M/42XR^0WWF.4#A+@(^T#VZOLG_9)Z=UCT'HFAKSJ?I?1NGM8]'XO$:M:;PV
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M$WOW_7KXK8XRA?DI'=\C_I_I]^L->D*U/8<)@R.1B)$*19VT,\IWQ\E2H-)
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M:*[W@O+W.I$@$\J3AM,X#!:2TA-?%.UAJ82K5^Z:F'I83#8JHUP;LLGWW?=
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M777'_@\; _Y1N5?T&:=P]?PX=7M%^7E^*U_+GKB_P>=@O\HS*OZ#=1?@//\
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M>W )'C@D?P'C[N/;12HB;C_VV[K>.?\ I9L?=_\ M!Y'W_=Y]OPU^=OM=_\
M2][>O_\ A&K\V_\ [#I#?N7INA /R/JQP.GZT>#8,;\O/U4@]LO[0\6]O]AH
M/MX]F0-?7/L)_P#0W[-?_9#0^?\ V9JZ1I[_ ,]Z6_\ 6&)_XA5]Z]97$IHB
MVJ]B/D?!_ 'W/\&H)B_,3W(J!=2TU5?-M>PN&#"D.!LD)2OLX<Y*O<#D<$CD
M^_@ZZ[I[2'Y!T1I'3A <S1NC<97<T[PT]MR_,@W&?BLU&D,1693) +WM\;$<
M">%MZMUJPSB2TU(CU5(&7VFG6P]82_4 6VE1[NQCM\**N./'&NM4]*^T'%4J
M.)T=HW5ZI@L12I5L._&U<>W%%E6FQ_[<VB_LP0YQ V;;($WE;CJ.!82QU6IM
M-,&+"W#W3;AR6_XG/_WJQ_\ C"=_\C5OMWM._BK57_;:4_25>ST?^^U?3]'Z
M)\5G_C^M5!_&$WV//_@/;W]M3]M]IO\ %>JG^VTI^E\4V-'_ +[4GP_13XO<
M#]ZJ'Q_]8S?!'_\ 9T^V^TW^*]5/]MI3]+K=)LG9Z/\ WVIU_HI\5G_[U4'/
MWFPF^_W?V'GGQI]M]IW\5ZJ?[?2GG][KN3L]'_OM3T_13XG/_P!ZL?X]^/K"
M=_#_ &#_ $\:?;?:=_%>JG^WTG^G*GL]'_OM7T_1^2?%9_\ *JH#[^UA-^[_
M ,1^/^@T^V^T[^*]5-W_ $^E-_<[S4;& _?*G7^BGQ6?<_[%8_\ QA-_@_L&
MH^V^T[^*M5?]MI3X[4>J=G@/WVIU_H)\3G_O]54 'R/UA-_G]#Y_+4_;?:;_
M !7JI>/^FTIO_P!+S4]GH_\ ?:OI^CUP0R<__>J@Y_\ .$[]G_:-1]M]IW\5
M:J_[;2GZ2CL]'_OM2.OYOS02L_/^U-!_&$WY_J8/OYU/VWVF_P 5ZJ'_ -]I
M7YN"=GH_]]J1UNV?FGQ.?^_U50?QA-\__<:?;?:;_%>JG'_+:4_2^";&C_WV
MIU_HV3XK/_WJH"3\OK";S_[C3[;[39C\EZJ=_;:4C_>38T?^^U.O]'Z)\5GX
M_P!JL?\ 'OQ83O\ Y'CS]_SXU'VWVG?Q5JK_ +;2GZ7Z]R=GH_?5J^$?HA/B
ML_X_V*H/'WV$W[__ !''G]?OJ?MOM-F/R7JIPGMM*1_O)L8#]\J>8_1Z@\I?
M%9^.>*FA_'BPF_M!_,#3[9[3OXKU4'_O]*?)Q3L]'_OM3K_13XK/_E54'ZQ8
M3?'_ -QH,;[3C/\ ^UZJ6XU]*7[O>3L]'_OM3K_16GQ6?_O5C_W?[(3?V_\
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M^2L?9QD7F;&USGQ/&5-"E0W]252PAL*5 AI4KM3R0&$<<J^?@#P20 ./.OU
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M^L7R9=>E[</UF5Z%=J3[I3[]WL/TN..[]?'CGWX\>VBE:A*020 ">.2  3P
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M5G:TAAL)C*VBL1CZ?8N!^VT*9HN,.FX![#IW7K0NKU$M[=V-Q@$.PV'):&/
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M#=PSZY+I4?1ITM8WCJ<1H>G[:6HQA$7)X7U' PJCBPG(V9KI',I0\AF&"_\
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M6_O)0?QV]]W_ )J^_C]FGY2]I7\C=4_ZVXS^[B?9]'_PW%_T%G]H3XG+?/\
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M4U$#@+9*9/$WS32!P"2>)34J$TCZ)/U32!PZ&7DDGCT<_--('#+))/'/--1
MX#R4R>)\TU,?11/U340. \E,GB?--(' ))XE-(' >023Q/F4T@<!Y))XGS32
M!P'DDGB?--(' <4D\3P34P."B3Q32/JD_1<O]W^!\?A]A.M=9FW>V;^ZWXA=
@;@%QSD<^&_\ \&L&#_RN-_Z]O_"8JU0#L2!D?B5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g752656g59g66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g59g66.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X8.%:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S4Y9S8V/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!5;G1I=&QE9"TQ)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,3DR,3 T)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" P-BU*=6XM,C Q.2 Q-#HP-SHS-B8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" P-BU*=6XM,C Q.2 Q-SHP-SHS-B8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R:6%L350F(WA!.T%R
M:6%L+4)O;&1-5"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @
M(" @(" @("!G-3EG-C8N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @
M<G(Q.3(Q,#0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(# W+4IU;BTR
M,#$Y(#$Q.C0P.C,S)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(# W+4IU
M;BTR,#$Y(#$T.C0P.C,S)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R
M+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A
M<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P
M<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N
M=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[
M)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D
M;V-U;65N=#HF(WA!.R8C>$$[07)I86Q-5"8C>$$[07)I86PM0F]L9$U4)B-X
M03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<U.6<V
M-BYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C$Q-C Q-"8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,#<M2G5N+3(P,3D@,30Z,SDZ-#4F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#<M2G5N+3(P,3D@,3<Z,SDZ
M-#4F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C
M:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R
M92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M)B-X03M!<FEA;$U4)B-X03M!<FEA;"U";VQD350F(WA!.R8C>$$[+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X
M03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S4Y9S8V+F%I)B-X03M5<V5R
M;F%M93H@(" @(" @(" @(" @(')R,3$V,#$T)B-X03M,;V-A;"!4:6UE.B @
M(" @(" @(" @(" P-RU*=6XM,C Q.2 Q-3HT-SHT-"8C>$$[15-4(%1I;64Z
M(" @(" @(" @(" @(" P-RU*=6XM,C Q.2 Q.#HT-SHT-"8C>$$[4V-R:7!T
M(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N
M.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R
M:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E
M+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P
M97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A
M<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R:6%L350F
M(WA!.T%R:6%L+4)O;&1-5"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I
M;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B
M/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#$Y+3 V+3 W5#$U.C0W
M.C4S+3 W.C P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO
M9&EF>41A=&4^,C Q.2TP-BTP-U0Q-3HT-SHU,RTP-SHP,#PO>&UP.DUO9&EF
M>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#$Y+3 V+3 W5#$U
M.C0W.C4S+3 W.C P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X
M;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @
M(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP
M1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @
M(" @(#QX;7!'26UG.FAE:6=H=#XQ-C@\+WAM<$=);6<Z:&5I9VAT/@H@(" @
M(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF
M;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T
M04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!
M0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K
M-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%9
M2D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-
M5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%52
M1E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!<4%%04%W15(F
M(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!
M=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!
M=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE2
M27A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V
M16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I2
M1E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A
M;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU
M4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#
M05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF
M(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.
M94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH
M2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T
M95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C
M;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T
M<3=&5DYB:3-A9&]&;%%Z;T$F(WA!.WIX0FAZ0VYO4W95031Q<5EQ-T963C=M
M,VIM:FAE5D5M;35E:D=Z04TO159B:7 S3D(Q<&EQ.'5O64E33U)"25=U-4%P
M53 Y<6I&5S@F(WA!.U95-4QM,VE%:&ML4D)%;VML3$U">%$Q;WI6-D0T5'8W
M67$S.5ET*V%*-G%C-5%7:EAK2W-O-FQ2,T<K2W(X5E%C.35C,C9'4V1B94LF
M(WA!.T5%1#%*2GEO,TY"5W-D3GHW-'$S1F188WEI4T),95=&=G-Y3$]X0F]A
M2'!'4BM/2W)(=C5L=6AA:C9T.5E98VQH831):TDS,S1E;50F(WA!.RMY8U9E
M9C-V-5(S9#%Q5CEQ5VTK84Y9<T=V-6)H-VU/,#%)<$8V:W-S<F)+241X.4EY
M.$9!3S-%9#A653=R.'1"9'=3>%A(;3-5-W(F(WA!.S9P0VM->E,V;4-95VEU
M4')";&(Y>E)8640P,DI(,DYS2W(W=CAO9%AU9E1L8GIJ<C9V2$I.2W!85D=5
M0EIL;T9&24MF04,O13!R.%@F(WA!.U=G1T)53&)F;&QQ5'=X5'(K64]T>7-X
M:FE$<G%Q=$4P<6AA0E$P1&=L-E9+;71A-'$Y271V<F1H<#EV0DPV4D5+4G=#
M5U=C,6-G0D8F(WA!.S5-67@X5$@X8U9226952T=S14E086MR2"]M6&EQ>C8S
M8VE4,&Y7,U=5,$%4,7IY<5%3=7AJ0C,T;C=S5E)-6FM+07E+1F8X06%64U<F
M(WA!.T@S:TPK<D96<S%Z8G=C4%=L4TPQ6$5C9DYG=DHR*WEQ,39S97=X5F5R
M<7A)56=L5%)Q1W1$,6]C5F)X5C)+<DIR:4-"43 P:7A+>#0F(WA!.W%864M#
M971"6'9T:7$U,U)%6C-92VEG<WI-84%!8FMK;D962S1V<DLR0W1C,T55068W
M0FMD54(S03(U165)>%954V%*=VA2,5E33'HF(WA!.VIO4653-V9%4$5B:D98
M0U=)=55$<5A'>%=O<G-!96YY65EQ=7A6:44S-6PV56A:;'1,;5-!35538TMO
M5G%E1E1M;VPR>&I(.$UQ-S,F(WA!.TA/;TAC;FUM-GED57-O<C-4-#!E1G=1
M=VQD;S)6=V0Q24-/3G9N;7@P*V5/5T%L2&LS46M*0W=X<GI8*U9N;&IZ5F-Z
M6&5S-E!"4&4F(WA!.WI+:2]7,75P:VQ14C T*VUW:BM$<'9X-CDX=5I*9'!N
M-4@K5$Y/=G1.,4-$4WEB,U-J0S%P3RMO6%9E9'4S3D=:47%O>'(Q<7108D8F
M(WA!.UAO2'%A;B]Y>G<O.&IN+S9P67%K9FUR>6A:96%B5T\R,7%W:FYI:&)L
M2'=U<&]I1'E6*W-C86YR1W5+<%@U4R]+,WDY-54Q5U169$@F(WA!.S Q27(U
M-%I,8C%'=3575EE*6G9836%2:4E)<6@K;$8R07!I<DU053%0+VQN:"\U2% O
M,5-X5F@S;D@X<69,2&Y$554Q2%@Y2E,U=30F(WA!.S1&=&QD3#8V:$AP27IU
M;TMX2VEM:E-T=5(S>%9+;B])3'E!.$17-3!24D%Y<$=9:'%.,D)X:DI+:G!8
M=CE09D97939B6C-/;39D838F(WA!.V1A5W-35VQL1$AB,C9T8U-/4DA%;U)!
M5V%-<W@T:G%46$953G(K:%)E64Y.8E1D6# K,W4W1C-2,V=A95%+>&I936]B
M:D=+:6\S2%$F(WA!.S1Q<390<&MU:C9:8C9B65=S561N8DQW:%)R:5)Y1G%4
M5&LP6DHV-'%L1W-E461',6988F98<C-426TQ:3!A2G)A.5,W;FIK5#!E9D4F
M(WA!.TM5455".5$X:#,R<C!'2W!X<%=M=G!.;6)05#=+0T,R.5=E9C!H3S5!
M:W5:;FYL<%=,64=35FE",$A18EEQ>'4U+TMV>3%C87!E87$F(WA!.V1,5TQ5
M3E%J;FEV6C1B-C5J37%84DQ30G=Q9TAC,5=O*TAA;4MS<5=#-U<P1FU,5T%7
M-&HY15)I6G=/05AJ5&%,=WA6:75M9FQ6-5DF(WA!.S!S:C9H<$5D=6XQ;3%V
M=E-7.'505$YZ6E4Y1U5O57!Y*T=R2#ER=E=P>%9K1W0V3"MM<E9,6%5B3TM3
M1T]26FM#,TUS6D1Q0U!T2D<F(WA!.W S5FE$-TA&5T)X+S@T-V9L>$5N1U!1
M*TY66DMJ57(S;S9L5S)P5&-(=WA63CE(+T%#:3AQ85!Q,6QQ=6XV4VM.-7 S
M*SAR1RMU5U8F(WA!.V%X:4QD5U5H=FA59&-66G(V;7 O.',X4"])-2\K<5=+
M<$PU<3AP,E!M=E0T.5 Q,U1O8G$Q:6M-,&%F5UIO*TUH:6MH-4%P1W!Q16TF
M(WA!.V%N9V0K;WA6:G1V*U-N:W$S=C=7+VHP6E!R1FY,1&-1:S,Y,%8Y4S-9
M=D=747)X8C1M2DY2=C-X5FYN<6%N+WEZ=R\X:FXO-G!9<7 F(WA!.WDS;#5%
M>4Q*2&)Q,'!):E5Z=%9I<6QJ465L,E938U9E9BMB9DYV-65E6DY':G-T6G59
M,G,U2F5C3%)V95)U2EDP<E5&8F%V,DIE*W@F(WA!.W)H5FES=FMV.&AH1F$S
M53!+8U520F)4=&4V:T1X3'56+W=",3=K<W)D9D1W>%9D2#5!+TEP<EIO1TU-
M,7),-FPU1D,R<%AL145#17DF(WA!.W-H0T)Z44E347A/+U1&5G-N:V8X9VUH
M2WE244Y$-GI%;CE)86=&.5%L:CEO24\Y861J:7).4$IF-6-E561-=DEF36YL
M>3%2:D]':V@F(WA!.VTK=E1Y>'-S9UE(6C1Z+W9X*W4K+W-+0E=D97!Q9CA!
M>7IW+SAJ;B]!3W%72W9*-W=!951.4#A!=%9A-6M/-TQX-D5B2TXK,V9/4GDF
M(WA!.V8T=$@K<UA8;C9"-S)C+VQV+WEJ4R\X04=A5"M'8G9S:BLU*TIC;E0O
M4WEJ3FTS=7A6,DMU>%8R2W5X5DMF37%E6FYS;U(U96MG:G8F(WA!.U!70FU.
M>4-5.4AI,5%+03<X=5 P67%K4W=F;79Z6"]33DY%9E T=W=C='<T=C T;V]R
M.6XV9F)B0W)-.$-V169/1GHU:UAZ4'%3,C@F(WA!.W0T24)-,W!I3G!1;%!A
M;3)C.7%P6E!%;%8Q9FTT=51I=$-A6&9A;W-R+W!.=%5K:4E!45%34W%W4$E6
M4'A6+UIR;&5/8W(Y6$=I2E F(WA!.U<P9DQC,GE"5$1C83E+83!94T5O0U!4
M8F8T4S,K-T]/,65L8W1-:#!/4FPX,$9Q,35Q2F10,%A,<6]J1F52;F%8:U)T
M>"MY858V-5@F(WA!.VML3"M(:BM,1U)04S%8>7IC*V54<F1S3$HW;5-B;'5T
M=UI$1'<O83E4;'1X<#E0:'9H,#AS,T=+=C0X;&AX5SEY1F%#=EAV5$]J8W0F
M(WA!.S)+=7A6,DMU>%8R2W5X5C)+=&-L-6-A:FQ3=DAV5'AW5TQR<6UU<7E7
M4U)744I%6D%X25IG5D%50E-15%4Q,TEP=&A1.&=S3DTO36$F(WA!.V%784]E
M>3%A,FA7,TLR-T,X<VI29T$V.&8S04%,;%%P.$\O<U92:T=N96,S='!&;',Y
M950P<4)%83ES4WA%<$-%<GA12S-"1U R:G0F(WA!.S=(9D955'!.=C5R=$IO
M3'4T,&)69%)K:#5Q:V1Z95=:04%35E!42VA9;$M397%#9CAP1C=$1E=15&59
M9&)G:VQJ:#AM,TPP54]H5U,F(WA!.S%!9'8S9%9Q1TE"2'%.+W=0>F]Q;6UH
M-GAR3C=C3D1E-D9.<&M!475K.&MS3'%4.$Y%-&]E46(T:C)P.$HS-EE&5')&
M6&IL,G@O=V@F(WA!.UEJ,#9+3&U4.3558FUH,G!X2&%N-U)Z:TUH+W=E4#A!
M5U T-69P9&-F;T1/+W=!="]W1&Q';"\T>E-F=WIE9&MF,U!X3&QA9C95=D(F
M(WA!.R]/6F)92E122&TT56%1;31R>DQ%17)3:3=,=4MR;3!B,7E3+VY(-DY$
M1&]H:U5%07-B:7)(;T0X2F]013=F9&ER2W1(+U-V-DQT=C F(WA!.W8V6#93
M-$0V,3E8<C984"]!0V57*T)5<SAY>"MD;G5B52M8<&)+3S)(*SEI,U%F;60O
M,D-O661-5E$R9W@O;4MM<' K;7!B1U14:$<F(WA!.W=M15!)4T=1;&ER4C=$
M64%+0T<X8U9:2$UT,E=":&MJ4F4T94YN3F9M2%0Y5TMP1B]J1%%7,UAZ1'!I
M9TMR;FUY:EHV,$\X>3EA9$TF(WA!.U9B=5!.*VE1;UI$<G5N.$9&5TLO=F%B
M;U R2E0S;%@W>&EQ=G S;4-X,5-E4S,P,U9R3S9N:$9:56E5>55!;T,S=WDY
M2VY9-'%M4E0F(WA!.U5/3S X4$QX.4IQ9F0V;4MU-&%H>"]V-&58:C9452LW
M,4U68T4Q1&EA>G<X=7@Y2G%F9#9M2W5#86A1.' T4V4Q26U(+TUW-'$U53$F
M(WA!.T-V>%1W:V4P5$0O;5EC5F-S96\Q*TME16IW14Q$+VU98U9C23E2-6)Z
M=VQF05%S1#DO<5EQ-S Y4C5F,SA02'504F%V,RMP:7)J2'$F(WA!.TYD<#1A
M9'@V3&8X05981EA.2'%/,T=E165.65=0+TUW67%H9&1/=G)P3"]O6EE:3E5Q
M;G K<U-K5D%W3#$K,&0Q0D$Y.%=Z1G<X6'$F(WA!.S5-5&UU=GIJ8WE)3$MW
M:FEL6F5%,$Q+6EEL-&EV1EI82U X045.=S%/-$(V149Y9TY0,VQ'43-V-7)%
M,&PP+U1!;V%N3#%*0V5)-S F(WA!.T1!1W8K>"]O1T)J9S<U23-13E X>"]8
M23E1,5%*8C-%<UHK=7AX4'I1=E5H55-V2VEG54DS>E5W,%=33W)/44@P16(K
M9FPU04XR8E F(WA!.VI/3&='.6-V,2LY:TUI,TIB.3%):7)4;WE&:E=V5V]:
M8S)Z<FU(9CAQ<C!!;U5B;#9:5E8T3$QD<71%57%O2VDT-&M52C=D5%A$87,F
M(WA!.V@P;E(U9$MS:W-B4U=*8F%-=7E+63-*0FMC>4YU6F8U;4]"55HV96\X
M=C<K2&HR2&]T6#<O57A6>&HQ2&QT4$-&.$1#>% S*W!I<FDF(WA!.VUO8W1P
M-%%V9UEM2BLO,4U68WEA:%@T6C114&5*:B]Z34=+=E!.0E=X3VAA94QT27EN
M,6E7:VLK.%DK1G9H2W5/1F9#:'IN3DQW*T8F(WA!.TAI<C9J>C5F8G,T94]U
M15=Y6#AV9BM59E!4+V5I6#=.2V1E,4YQ6G-E>78W<C1L=7=F4WEB3FLS3WA6
M,DMU>%8R2V]85EER-EA43'$F(WA!.T]W9%DW,6]N1G,X9T)14V-4>#5G:'9H
M<C$R-EEQ.#%V=DLS;4]Y9VUU-3E".'-'>711.',X:E%3=$HV8T-S9E4T<497
M<$%R441#<54F(WA!.V%295A/=%@P;&IP1VDV1VMH:E5Y4E114TQ6-#%I.596
M641I63)E1#14=5%"=5)T:7),4$HK9RMC9$DQ<$AU=$HP5S-S<FQP1G5R:E0F
M(WA!.VMA3V%/2E5,4G!U5C56:W R3S-81E=)96-,;GI)=FUF56QT-6)W44-:
M=E1%8E-H2V4Q3G,U,U93>65*2W)Q+TYX8VY&871&9#)C9W(F(WA!.U!,<C!,
M0D-!26U,:&U!1D0X4C(S<G1H16=E9FE*=C-O4S5V3&XV<$E,5U16+W))-6E.
M<%AK-&ME<CA"4$4O-S8K,2]L6D-5:E<S2&8F(WA!.S=F,4E*3F17469L;$HU
M>&LQ85%Y=$LK;4)F.$%3:F1L>4LP*T@P*U<O3#A+9&4R6EA:-7EM5R\P.6):
M675+,W%E8FQY2%EQ-T9867$F(WA!.S=&6%EQ-T9867$W1EA9<7-C>BMP1TDQ
M57AK;C%I>$E)6&EA8U%!86YL5'%2=&ER131B<C@Q:&-W0V5X,&AR675I,T1X
M>E1H=VAP>F0F(WA!.U9952M'=&%6-UE65DDW;C@P1$M1.6YP26IO<$1E<E O
M04I02F5N=3%$5'-02$%R53 S-7!M2TUW,C)J4GDO2#9I=DIC>4-G2315244F
M(WA!.V1$5#4T<79U<G8X04UT6E=3,C W4S-J-&IH33EX34%7*T-T5C1603-F
M<%AP.39Q-D<V+TUK.&I.<"ML045!;T9U<#9G;# R8CEZ,E0F(WA!.VYU3SE-
M5E@V6F-F;4<R;U<V-G!A85I&645S3&PW86%E4U@W2DML039)4'150G(O1&16
M-2]D4%AY:%I+=C)28WEC=#9N;E$Q,C5(8FHF(WA!.W@W1$]1;68X2&HO5TQR
M:CE!.3=.=GDY5S90;'A$1DI':65R2E5/:%DQ<4\T9&8Q6G9/>5 W;C1L>710
M.4Q*:DAQ3F1P-%%V9UE7<B\F(WA!.T%-;DTR8F4U;SE2<CA-.$E(=D-X+W=#
M6F=X5GI*<4@W33A).&%X368K6F=X5GA454M#:SA)4&5S5$@O;5II<FEM;V-D
M<#1E6&HV5%4F(WA!.RLW,4U69'<Q1&HO9G<X=D@P;7 Y,W%9<3<P.5%+:TY.
M0U-F*TM7<%0U97!I<3%,93A7:#E304UO-'%6:%E553=K9C-M2W)L5%5++T8F
M(WA!.U!#4C=235 K6FAX5GEX-FI8-' T4U!!47-0.$%M66-68TDY4C5B>G=L
M9D%1<T0Y+W%9<3<P.5(U9C,X4$AU4%)A=C,K<&ER:DAQ3F0F(WA!.W T861X
M-DQF.59C5F,P96\W8UHT4C0Q:%DO.$%-=UEQ-6LQ1&)J4$-01W-42"]M64U6
M8U4Q0V=P4$-$,TII62\X>DU69'<Q1&HO9G<F(WA!.SAU-3E*<69D-FU+=31A
M:'@O=C1E6%DK:S%0=3E41EA"3E%O87IW:SEI26U(+TUZ1EA+;6]B.' T5#15
M:5EF.$%-=S1Q-5DY4C,U5'<F(WA!.VYW<$-W+S5M2$980U!583=Z=S W1#!7
M+S9Q-'%T+S W,5-G=5E+9V-U2'!.>4-N;V8W,RM'1&E&,64V84Y7=4UE;SAT
M<#11=F=95THF(WA!.RLO,4U+2$Y(<4YF:&YH03A$0W@O-6U$1EA-;6]6*T=E
M140S:5DO.$%-=UEQ-'!Q1D)X;FA"-S%I62\X04UW67$T<'%(155N:#5D>C8F
M(WA!.U15*S<Q359D=S%$:B]F=SAV2#!M<#DS<5EQ-$IQ2$AE94AL-"MK,5!U
M.51&6&LQ,&A(:W%X67-#1&53,%AE;RM(-3!Z:UIJ+T%!85 F(WA!.SE9=790
M.3)097IN.'0O.$%L1VPO-'I39G=Z9#EK9C-0>$QK-F8V54ID4B]M,%,O;WEA
M4W$K;DU5-&E8;#9J16U)5EE%2&=T0C!&5'4F(WA!.V,R:F5T,"M4.#-7;DLS
M8T]K<$%#>6-Y6F52-#$T>4QW2BLQ='-F=4=+<W P8V%O3DMT0G%X:F)5:$5V
M,71O9C=S>54K3&HP-S1&4V(F(WA!.WI7,VXV3S9G;#AT3%IZ5WEX:U1W6$Y1
M>E-&,4%)3E8R0VMN-U$W*S)+<65L+W=$2WEM;G-V,' K:D5T,&U)=F9Q-6Q,
M=D0V8E5)-6DF(WA!.VY,;E1P5#=S5EI4:7%!,7-A,F).4F\W47)D*V]N27HQ
M-"MN6#1H<T0K<G!7;3E-5E-$5#50>EA.>F)$54ET1E<S36EF5S)G3GE8158F
M(WA!.V9J-&-J5&QX-E8R<FA6;#)"6&HR=6%0<55N;7I66G)J5$Y2=4Q/4GHY
M6&4R:FPT.&EY+T950VA8:GDV6F]C,DM2>7E*:DEJ>6-A45 F(WA!.T5D:6YN
M-5HV8C5O=&(V-V%D2G)B4GE44S-U,5I:1V8Y;&M6<49A1#=2-DAP.'-N<R](
M:VI),UEH-7-S44XK5#!83G$S=7A6,DMU>%8F(WA!.S)+=7A6,DMU>%9,=&9'
M=4A3-48P37A,<5)+*VLX-2]D9T)G6')13C%51694:3)9=4AI.5A*:6LS+TLU
M6D=L:B]!3GAC54UR2U9M='DF(WA!.S-R=VIG065!;5=33G9J1E-(2%-O1&1#
M<#)C:V9L+S9336AF.#)U5DI5,%AI1W!8+T%%;7!553=H<590>4AY>%EN=U V
M6#))>E%D2S@F(WA!.W=R9'@S*W%T1$9D4TEF<GE7>G4P8E-624%13T-19U=N
M53%Z57@P330V;S519E%2=G9U9FA824XR6%4T>FDT05!D="M.,E-:=%A83W@F
M(WA!.U8R2W5X5C)+=7A6,DMV;4\K+U!(>35+-W=X95=B:')*6DAA,VI/;RMM
M04=*,SE-44]%<C1":E1X>D%L,EII:TLS<G5V6G!/1TIE,&8F(WA!.VQJ-6AT
M9DU8;$,Q,412;T)P<T%:-'!R5UE'9&A-:"M)*V]':35!,4<O15IL-&--8V-E
M1U!*<VI%055%*W9D5VIS5V1B-U9B2S$T0D<F(WA!.V-Z<C9906Q,:$XS;4$K
M3#!M<#AJ;&I*1%$K84Y,;G4T3%,S,7I4-VDU=5-21$9#4%9,1E)5+UEM86XP
M-'%M,W V;B]Y,%$O.&E8+S8F(WA!.W$T<6<Y5#%--EAB:30Q0R]T<F5&;31"
M,VAE:&)I5W!T2V8R5DHK:D961%-V34YR<3 P:T]N-G!A,T4P4VAP23%H:T1+
M1#1G>41X,S@F(WA!.T\K2W!N-F5P+W=$3%)$+WE*9CA!-G$T<6MN;5!Z6F%E
M6%AT5C%A*VEG1C-Z.4IX87EU=C=S<4<U8UI$5&528U93=50X,'9,:5=59#@F
M(WA!.V155#9R2VAD6E!Q5G=.-G%!=$,T2DQ&=3(S:5)H<%=55TYX95@Q:F(S
M='9C46U#-FE384EM0G=3:VEH;'%05CA$9U8U,S5M+T\K,3 F(WA!.T188GI2
M-VDR96%A>F-).&MC431K;%$R,5HV.3A.3&%79CE$1S9D+WEW>F8X:6PO-G(T
M,&DS9CA!47AU;F8X<TTS+TEP9BMQ*TY,870F(WA!.UHO.$%/445&-4XV3G)P
M<SAS;U9N2W)%=&5+2U=9+S,O04=55GAP3F\R5#@U9%-35# R.'8S-68P>$M!
M=')Y<D=:4%-$:FI-87%:1'@F(WA!.W%/*TY+-"]N3'%O2D(X=#9M0T-Y:V95
M;G)60E9H+V4O<V=B-#!Q0750*V-H8E<R;FMT-3E/;FEN:&1O-5EN:%5-<G%A
M37!";C))27@F(WA!.W!B52\K:&ID3R\U65IV.$%K578O0498>'!&=2\V1TXP
M-R]L:&TO-49,+S%8>'!B5"]W06UF;D9P;FUF52]W0D=*24Q#-V-6=&QU660F
M(WA!.W!4,U975UDO1C=(<FI38EHO=T-N<68X07DP42\X:5@O04]Q=4)896YQ
M9CA!>3!1+SAI6"]!3W%U2W)5*W9V>3185G4S16Q7-'A-84TF(WA!.T]O3DIE
M=4MR=E0Q4"]L;V@O=T-23"\X05981E=I;7!!9T<T9T)/=R]C='5E=BLO8U93
M<51Z4G!%4V,U4$U/;$EL95!*;E%#=$$Q2VTF(WA!.V9R46<T<794>DAP<VAI
M165V85DU;D9947)+4S0U8V%R4V9F-'1T=2M+<6IA,6))4T<Q:E0Q239G,$9.
M=U Y+RM,0694:7)M,74Q5U<F(WA!.TM&=%HP-%-Z;&QH:DY!>G-P05E+4%AQ
M>$))<E1&56)(.69L:E=33S9T,VIC0FMD66U+<W!&45%23'5$:7$W,#E4+S5A
M268X06M3+R\F(WA!.T%&5GA6.$8U2D0V;B]W0V-C6%IF>3550TYN2#$R9F-C
M861&.%--0E,Y03%044Y%,4\T4V959$IJ=DI50W%R>7)'.4%P3$%B=#),2#<F
M(WA!.WHT-$95<EAY=#5A<W)Q3S9T3D1T-&)M33AO-6\T;U9:4U%2<V%G.3A6
M5&-Y>41P0S4K4E0K3%EQ:&12<V),55E"0F8R075O4659:FPF(WA!.T5B04Y1
M:71#,U=J15EQ;V%B;V5J-EA*2DYP,FU,8E-Z0E9L84E)<%E,,'(X6&)&57@Y
M5U-L9E)E=FA62R]W1$5S5E-$>DPU86XQ>&LF(WA!.V1,-B\P,&]N02]62&I2
M:CAA=E5'<&]F:'!I<5)R*U8U15I183ER:6=(:W$O5UDV0FDO<4TS16)63&=(
M-31B5FUT:VML=F%15WA785@F(WA!.S!9,&HY859K6C,T<48U3U$R-T=L5&=6
M-&8U-#AS9FQZ<4AM,U5R=E5V37HR1CE,3"]P1G(V4W0V8G%O57)53C=946A)
M:#5*+TMI=% F(WA!.SA9=4(T*VEV+TY71F%D+V=N.'%+,"]X:3E02#!6+S5Q
M>%=L.%AL1#AR-%@U42MD6EDR24ML:VE65%)H46I:<U942DY/.&UF5VML5#@F
M(WA!.WA,<WIK:FDU049$.6MB<S1!<"M'2U=8="M53W)34V970C5T,58S:UIP
M5$EP459A4F5,3G1+4'1+869,0F%P6F-F.#0W,F,X>C-%,G,F(WA!.UAK<SAZ
M1C5884M)<WI-87-72FLS2D].;W!:+S!,:'!T2R]P5S8K6'!1+SA!5E1',7 S
M+U%U1VTP<BML8G(U96Q$+S%5>'1A6D(U2B\F(WA!.TIN479,3W$O<%=1>F%J
M9'A$+U)"37-3<D4S9'=O9'%T-$4Y4&YJ86%E:6E743E96$AZ2V9W8D%R:$Q)
M9CDP=5!M52\U<7A64V=J:6<F(WA!.TUN;S)F<$=6>DI+545A.#-05FUO,C50
M:6-65F96:W)4,%AP-#%4+VUR1E9/46\P<V)08D9N4FHV3&XP>5%3<$)+,6%O
M*T=V5'1I<D8F(WA!.S5,3#AS-W%*>#E7,#)A1U5",S135S-"9V%!3G,T1R]P
M:D-Q-7),.'19;%-B-G!P9U,R5G5$.')52D=N3G$P<31!2%!L.4YC5E5J;U F
M(WA!.S58<C9T>"MJ=$UP2U9N:VMR8E4O96A3:F)V44LK>%=M,S,T<79';69L
M<$U)<E575VU3<WIS65E1,7%Z:#-P>31$;E5F6D=Y*T=+<#$F(WA!.UHV;F]6
M;EE7='1A>7=X5VMC87A7:UEM:' V8V%,>$-K>6)G2E1V,'=+:7)05F)3.5)N
M<S-7-59$>&-W>5)354Y+,$I6>4)I<C1D8E$F(WA!.TY96%)%,3%R5GAP36LS
M,5I,>F)G6F=#,T1R5W1":VM0<'8X035X=2\X;'50*UDR9CE364-L;G5R96)0
M3&5K6%-7;7 V:$9A6$5K9G$F(WA!.W!(25-#54))-61+57%-0W))4$]8;&5E
M.6IS66139VMU<%<T>'A+,5-396TT,C-R=#0T<6Y/2W!2<79M-WDQ<$UX9S%(
M54ER8591<DTF(WA!.VIK,4%C,%5M9TY+-'%S<V9/9FQE*TMI,3%'3U5V26M+
M9V-G4SAH2V].=T]R06HU-V1C5E)7=C)%5W V5F1A6DI.3F)I-VI-6FYT=S,F
M(WA!.TYA.7=10U!N-UEQ>&%(.'9P3&0P.4QZ3G)9:E=6-694.5=4:7=L8T]Y
M='A69F5H.%1H5EI,*UA.96%R-6LQ=4M*<&UN5T]+5G=O-78F(WA!.WI)66-3
M1'8S.&-B5DUT2CAP4'!U<%$S-V$O<D8V<UIC=&%857-K<TPX,$MG36Y(.6YL
M564T>%8U>#5O+TQ(>F1F83-R;'IB5T]N6$8F(WA!.VYQ9'<X,$TQ>7-N,6A/
M46]P5FQ136Q/=$LP4&5U3G%P2BM7=FY"84TS;#=1-4%$37=$<DU+3DTT64=I
M2VQ21T8T<7!Q3W4R*TYQ:&PF(WA!.R]+<GIO8E8T,C!84FUK34-7-&YP3W)J
M9W1054%52W9Q1VQ786TU>'1#22\U5FPU<61*969L;E%Y-RMQ95EA-U-J4W1Y
M0D-Q44M29VLF(WA!.TM&;T]M3G!5-S<X<69.;6]14S(V-D9O,6=:4V=7-6=.
M,')X:&%$8FYZ0G)3<#)R6'948D<P4%E02U=J>&%"-69S=$A7-&YU+W%I8U F
M(WA!.UAM4C9K:S%.2VHT5D9A2W99645P=4QI36UL2'(O<5 O045X5C,Q:4]T
M2U!8+U5F*VU+=4YX2%=L2"\T0B]W0VU+=4YX1T]Z+T%%234F(WA!.R]H:7)J
M8U)J<4@S.$5C+W%'2W5.>$=!1%(Y+SAH+S99<6]7=U=$,5=-,#AW;&MA44-6
M4V5!8CEH3TM+94DW5GA66"MS4C!R4B]W1&<F(WA!.T@O<&EQ:DQW;&UG;$$R
M9UIM4$]&;6)D0W9W36%C5#A7-7 P,GA6-7I&*U='<$=R6$8Q<'1Y-6DY3GI*
M;S!A,$EJ.4Y3=D%*-$1A;E$F(WA!.UEB5D5R-4(Q:%I9,V=N,'E&66]6:E-(
M.45G<7160FQ!6G9I2W1.5BMV9D961G9Y,S%33C)L=%HY33E8:T)X8E-E04UA
M04Q'3V%%148F(WA!.U(T0VY48GA686LO3$Q5:G%&=F-*939F1TDS4G)V:&\P
M44UX5U)N-45S<C!92W=!;V0V9'-B5FLY=C5(.&UP8G=X6$=J,C X<4Q34B\F
M(WA!.W%L16%2=V=K:T-"94%,;4U(8D%Q8F%B<#)J851'.%=N5V$R:V-J1C5&
M:&A:45=08SA6>%8X=#)U9V%J<F8U6#9*0F)U23 O4W1Z1V\F(WA!.TM3>599
M>$8K46IT>%!--3(T:W)&='1V:%AO.6LO=T-C8VLT9FPR57%'-#,Q=T]1<E$P
M-#=I=$1G2W91-S=1=$5V-51.9E=&=F13;5 F(WA!.S!42DY%:G0V9DQL=W%W
M4'<X=#99<6]1*U903$U&,49D=V%887<S34(U47EX>$EJ2V%5,DMG9'-65%A&
M579V9DPR:%@P-6YV9%!T-VTF(WA!.V-G2UI:66MD:6\V0W!&8U91.70U3SAR
M5W,P53ET<&1V1$Q!,T]*,%%+5F)X,GA63TU64TQ6=%,X,5$V-UHR96TV5VQX
M<&,S<'1D-FLF(WA!.SAI<C98>'-*1CE/;UIJ=T%+;G R>%9+,S%R.'E1-G5.
M0W1V44E8.3!*9UI185(Q0E!)3#EP,D9E,T=P.3%756%:8S-&>G Y=F-8340F
M(WA!.U=T>$EG86$S96Y*2' X43)*-S1Q*V%V>D,X.&5C8E!Z=G)6<F%A,65W
M5S!.,#9247AZ>4MI<4]G54$P1U-#0U=0<"M96&YK=6]B>D0F(WA!.W%#<5-/
M5&972E1195!81VQT;%,K65=M0FM4.'ED470P-4921DY(9$Y*<U<K26Q'-&-3
M04MB,3,V1$973U@S;C-Z:$9*1TQB>DYQ17DF(WA!.W1&1SAJ9E=*4GAK6E%8
M5&-J-THR+W=!-C0P='%54#5G+VU!,#!A>&$W<41Y;&=),$4X:CAM2C)(1W!R
M53ES85<S,5 U5G5.9'503#DF(WA!.VI.<C!#5S)R4$=$9%%X;6]$9&E2*WEX
M1S58<V1S:6Q.8U9D:7)S5F1I<G-69&EQ:F)46$5P;3EA,V%$:$EY4FQM5G95
M461(2$5M9U F(WA!.V=D.%96<U95-6\K8GAN,5=J-&LO07!50C9Q4E$Q0D\S
M,G1V1$98:71V3').-T1$0RMR-FMI4DPV<VQZ6C8U8EA$5F5&1T%904HX0W,F
M(WA!.VA5,6)U5T<R1E51.3$U;60W5S)J=715='!!1&)Z*W9Q.6HV;D-24U)-
M-'!*,$5O64UO2F]"+W)9<7EY3%$W47=P0U!05C@X;GAS2D8F(WA!.W4W8FM1
M,4]7>%9Q,#1';CAU*TMR2G10,&U+.6AA6'HY9%)V4$-%:&=E.71G2D-)+U$Y
M4D9O2VMS<DAB.75P-FI&569:951D5"MR>6HF(WA!.R]&=7!81G)C4DMS1'$P
M6$Y63')*>E=8:7A9<V\T.'9!-$9:8T%!04(P1S(U<69V3TMV:R]Y8C5J5'DO
M;T]H87IF56TP>3-U<G4S1G F(WA!.T5:0S-R<VAB,5A1>FA$5EI!;CDR=7<W
M-%9E<F9K3F-',R]+*S9V25).37-&,653<$)'<2MP2G=5349#,&8T;3950GA6
M:T58-6@S<'8F(WA!.W)#,75T0S%3,&$K;5-,,5I%:CE+3EA-641S-5@O:3!6
M2&)P,7A61#(S-7(R,7I0-E5E;#9O>$HT>&E'2TM2;5!+4F1L07(O=75P*VXF
M(WA!.W<S859L9FPW5DHY6C!Q3R]E1S4P-3-E4D1A,T-Q<V<Y3GEG2D)4.7)J
M6$%Q2&XX-"M5-%A-8S)V,CA-:78V8DDX<U-S1W S5FA7;BLF(WA!.U8P>%95
M+WA6-5AR=T]V,FET=%1L8U<V:S%.05)8<4-D<6IV:7%:5W-K9#%A>%A.=F1.
M3$)/:7EW>DQW25I(2$I72'<Y0T1I<7DK=3<F(WA!.U=W9T4Q-V5M0TIN5TY:
M2#1$-&U.04(X4# O3&9P:7%#="]-+VQM9#!J9S$K,&UE4FQ33E5U3%II>DUA
M2W%H97!9.4)I<6%I2U%D6FXF(WA!.U!Z0V9W6$98;&UR9FY,<6QN-6PQ4%),
M3%%*=%)F5$=94U-*8V]L55)L5756*W)T>$97038T859-+W=!=B]W03),2'I8
M<54R;#-%374F(WA!.VPV<$AY359Q.&E3<DMQ1#0K3&E+4#1L<'5T3VXP-&M+
M.4$Y2U-T9E=E;FA24"MA8T-U355L9C<U+VQ24"MA8U9C67!$+W4U>#AG;B\F
M(WA!.T%$5&ER:D9)96MZ:C5"4#1R:7)J1DI11#%N2'924#A!;6Y&6&5L2E-N
M<E X-DHO>E1I<G93:W!4,6XK9$4O-7!X5G=I:V]2-GIN,V\F(WA!.VXO3D]+
M=4559S9Z3V9M12]G=4MP9&-A-V]L<5I28V%V1D=9:7EY0C5)9U9:0V]92&)Q
M1$EO4'IY=UEP;FM#:FE#-E!73DIK=D9S-#DF(WA!.U534S9K-4)95F%*;7%N
M3&M.;#=C1RLT-$1J:T):1WDR151B4WA825HT3'!P1E)I:F=C4&A99%9)-#%"
M*V510G1K4E,Y-U)8:U-2;DHF(WA!.V5);&]Y5FI*56M&5'A*5V]Q1%1&0U-F
M.'$K.&YJ:G@P=3)89W!685%1,4-S=D5I=D-T2T=M3G$U+W=!=F9+1# U85IB
M;6EO9TII:DHF(WA!.S1X;TDP1E-P-DE!36)6<30O3'IY9&-)5FLP=3,S8WEL
M:$1%1S5T4W)"9W9)5C1J;V-B5F8O9TAY;#9K56\P>3)75T)G.%1R0D-#<%8F
M(WA!.VDQ4E)+1#1I4V9(1E4V:7121D-K355J2DA'07%+;U%!2T)1041J4V='
M2W)V4VMP5#%N*V1%+S5P>%8X55@O;5='8GE0<&YL>4U%=&$F(WA!.UA5,35-
M>E)+=$AL<6]#>6AY5UAG1D\V1&8U1$I)9E%V+T]/2FQ(-6-R=U93=C$R97!,
M14AO=G-C0E-Z8GI0;T]G870Y5F9865E74S,F(WA!.UEI,F%3-&5':D]566=5
M-#%*.4U91E%U:&559DQM;&%W.3=P4W Y8SE)>%!(.5I:-DM/2R]:25DO0T%&
M+W1X5FMX834W26@K8FMF.$$F(WA!.T=U2W-F,4AY<C50:VLY4R\P;E143DM7
M679-141-6')Y,TM63E-C5E=F-%HX:S-%<U-$4W1,;&U:05E9>#9:2E)'<E9!
M139"=D%9<6XF(WA!.SET03%T87A7,79"2$9$06EX=WA+>$-Q:41I<6HT96=!
M>%92,4,S=')M,CE056)E,VMG-6]1:WI65&YY050W4S!Q5TY"-#E-5E%&<#4F
M(WA!.T\X=%=S<U4Q=F]D:$),07EV0SAC87%66E1534-)>%%G.3A65&M.8SDP
M469*>68X06I81EAI+VU#=R]+8RMA.55M=F1:=C=45TAL2G8F(WA!.S1R43-"
M0W-(5FE09W1(2$5/<6XW4C-P:%9K+S57868K6#A,,SEZ-59N1V]88E!X=F)Q
M-654-GEO8F9J>&MH:%E+5S-Q0G5E<#(R4W(F(WA!.S!(;&,Q+W4P<#0X>B]W
M03 T1F-7=6$W4G!4+UA0+TY/2W5,6%!A3D0X,TDO-#%X5GAA-3=):#AA=5(O
M>')I<FDQ>E%54DLY+VI0.$$F(WA!.WI4:7)U5GI4-T-6.$]:+S5P>%8S2S5P
M.6A+*TA-+SA!3D]+=4183D1617(R*TTO.# T<31.8SDP465&2$HO-#%X5DIR
M<GEH;T8U3% F(WA!.TQD851A>5-82C54<U-A=3-1,2M%9&4K6%(Q17AY4$II
M64%Q:6573D=357E*<&1Q:FM-3V%K9S!93W!'>6IB:DMW*UAY1DLX:WI/2FHF
M(WA!.TDS13E%9T%,9$9I,#-4<FDU,'I4;VQ6>DDY>F-L<&YK6G!:1#A437IH
M;4QD2S<W6FI$6%%Y6E1J=C%22#1$8V102TU"3W1I;35A-7(F(WA!.W1';%!(
M;68K86-V86Y&<FUU,&%%93=K9CAA-'$T=&,Y:U$O3GE0.$%J6$981G)N<VE(
M-75F*V%C5F-7=6%B26QE-#5N+VUN1EAC<FTF(WA!.VXR17(T8WI4+VE/2W4U
M6$Y0<TI8=S5N+T%*<'A6.$1:2D0V;B]W0V-C6E94.'560D1%;3EN-DMZ1&]V
M8T$T0VQN*W4V2&]7=4I$1G$F(WA!.W1S,7EK1$=32E-S;T%9<E-P-#!R.4]"
M54QO;FQ(>79O5CE*96%:85-15'EI44]16C-7:W!1=G,S240K-50W<U94,#-%
M639H+V]2>BLF(WA!.V]9<6M8;4QY:#58.'<S3G1C-G9A4UA%='%R3$%16C!O
M2#8Q0T919G!X5E$P=GE(-5(P=E999%=S-U-:3#)%3T5K6G S,VQ"1$5Q>% F
M(WA!.VEF=G=Q>50V>$A3=$AP+W%06#=Q64915W)A9'!E<C)G='(V2U-31EA7
M44%#5D1Y6#-503E#4FER2'1/+TQ$>4A96$9V8U=L:$UK;'(F(WA!.TEK,%)A
M4S590U--;&Q*1$4Q;V-.<7DT6$5:-D(O<%)X*W-91F5#95IF3$8S1C5Z,6Y5
M-TAZ5'!M;E-8.')#4T-:<%)+<4=26E!4:U@F(WA!.S!M<#A567%0-%E6<&M8
M-50K4F)(4TY3=69-5GAQ<6%R9758:6I/;6E:-V1E93AN<4951E=.9&Q);T]V
M:%)*5VYQ<'8T04%E33%$-%$F(WA!.WEN+VI807)V<CA(2&QX;6]F*TM:82]D
M>'A6,S$K1&IY-'I52"]&371F=30T<318.$)"4$=A9SA96E(O>')I<FQV-$=R
M4EIT=D='568F(WA!.W)81EA,9G=.5VEZ8F(W=U1$.6%9<318.$).3TTS+TEI
M8B]M:D989E@T3UA(:DY58F8S13%0=C15>%9,.65G:#%85'!D4#EE-W,O55HF
M(WA!.U-B:3)I;$5G-$U(2$8K0D$S558Y<U=E3V9#8G$R2U,O;"]5>4Q,-6HQ
M;6%/63%U24I5;&UI:R]D:5 T;%I'-TM#1W)Y0D%)3E)81&(F(WA!.VQF;D(O
M3FEI53AM6$5,2V8X5#8V,T9I4W8W-'%25557:7!11"]6<"MR1FED4U U:U4P
M,&938DQ4;G1J4&585B]D,C!:6#%:;UI':UDF(WA!.W-45U(V25=Q959+-7(O
M>5=0.'@T;"MO1&QT=&98=EI:3EA+541%0V]K+V=*.&(K04M'-'I54#A!>%1,
M6#=U3UHW:$\K=G=C95A'86XF(WA!.R]'1U=V,V-A-'$T6#A"6&QX;7 O>&AL
M<CDS2$980R]G24I#>F)E34UO-F9.8U9C="]!,U):=G!H;$@V,7A6>3,X1$=G
M5V)X,V=M2#8F(WA!.S!X5G=V-$-A8UIQ*SA%=T<S=G=X5CA86% U82]M1&(S
M171U+VQV56UE2FEJ3D9A5%-O4W!P5EA25U9H-$5';5-1*VHO04UL=$EV.$$F
M(WA!.WDY*UAK9&AR2D=L,SEZ2DYC4E%Z;%9L4DI!06I-:D5%2#1A.%0Y3U)+
M5E4V1C5X14US0RMF62M-:6XY*UEO5$ER:5)7540T=&AX-4$F(WA!.VM%9&5N
M9U96-4Y%.'E--%EE949#.%98:'=J041!,4Q616Q46#-X5FMU9U12,D]J,G1P
M<4=R4E@Q-T5P13DR,&DQ:UEK;74U2C<P=TLF(WA!.WAN54Y*.#-3,T1V62ME
M66)A07E.26M,45%V>"]K2$UT56IP5F5N-G-+<C5.4#@U*V]$1C4U=&Q7:2MO
M1W1B6G%S1RM):7 K149D<40F(WA!.RLS1E=686)E,C%V<#%R0F0V;$1C,U5-
M36-D>&,X,$AQ4TMO1'93=3-*=#A#<4=T>G)E5V%W-F9R14YH3TI%8WI":V5Q
M<6%L86-H*W8F(WA!.V9O9&EC5E-$5#=0>FA$8U<W,W9N93)U;T5K4C=I25=L
M<D=:23%.6%%-0V5026)6=W%Y+SE+85HO>3%W+SAJ12]R9U8T2#5H.&QA+U F
M(WA!.S4S,7I61C!E,3%7=W9P5TYS6DPV,6IO1VM2=E5!36]A=D)756-H,WE6
M;U1Z.&]02BMV-D)R,35Q5W!88T]L869)1U5A5W1Z0E V,6$F(WA!.VQ/4FID
M,4%J<G-F=&925V]*55!94#!P<&XO3%A$+WE-5"MU0DQV,'!P;B],6$0O>4U4
M*W5+=2]3;6UF.'1C4"]!0TU4*W5+=2]3;6TF(WA!.V8X=&-0+TEX4#8T<3<Y
M2V%:+WDQ=R\X04EX4#8T<3<Y2V%:+WDQ=R\X:D4O<FER=C!P<&XO3%A$+W=!
M:D4O<FER=C!P<&XO3%A$+WDF(WA!.TU4*W5+<&9R=7%82#9-:T=I6&1N*VM3
M5CE*<FE64D=!1T)B;%-P,U5%1$9S>#A.*W)K>$]85G9Z5%HU12MS-D5S16A&
M2DE:4TIO:'<F(WA!.W X2'%&,&(T.3)$1'!50FAS5D]Z:VHX=B]34F-/<R]M
M3'EB,4IT0316*T%E<DQY-#!&2VYN46YR,D=,16I"+U,K>$<V1CEE1C5(<4<F
M(WA!.W$S=&Y$9%-)9G)S9'9/1VI:-FM!2TAR.$E7;F5U86U/:&Y(5DA+1#9#
M3CDK9G=R:T<W3'%-6GAC04A,;"M/.6MN-E4P>B]L<F@O-4<F(WA!.THO6$YQ
M-C4S-E4P>B]L<F@O=T-2:68Q>%8S-E4P>B]L<F@O-4=*+UA&6&9P5%10*U=U
M2"]!2D=*+UA&6&9P5%10*U=U2"]K66XY8U8F(WA!.V0K;$Y-+S5A-&8X06M9
M;CEC5F0K;$Y-+S5A-&8K4FEF,7A6.#!89C9E:W1H<3EZ3$DX3C-+=RMS1U5%
M=$IU5W%!,TEF4TTV;5!"9D,F(WA!.T]J=TUZ;4UF14I.4U!/,W5F-5989'ID
M95-B2C=I5G!85G!9,5IZ53A5:TE55E!G3G,P5W5I0FQ.4%<Y:WI-=%!%:S-Z
M*SE..5<X,F4F(WA!.U<Y275K=$Y4,4-+,'5*22]64T]1:T5O0U)Y-E5P55IH
M=7A5.5 X-F569%)V27)+>#%/0V4W;G(V54MT.%155#%$445F>69&.'-65'(F
M(WA!.T952G%7<F%D<&M#>C,Y=VQV0WIC1F0K:&%H86XO07%4.4=+;V)34$Y(
M;#=72G!)9$UV-&)U5TI&:VM32G%L5F)P6#E22%DW2$95,'@F(WA!.U9G=7 O
M;71B869F,U9L2F\Q+TDY=%!*0TI),$)J9%5)45-+,V<P:E4O=T$V66%69E K
M84YT85-8158S;VUP1U,R;&5'4G)A151X5E$F(WA!.VM!:5%M3W9)3%5B9$UA
M5FM(;&YZ3EIE66)'4S=T64HW65)31TM31S914GE!.%%W4$5--&]1,C(K0E=,
M83<K8T=N85)Q.3%P<VUN5%,F(WA!.W9A=5DR:U8Q04I(8T$U<TU86CAP>$5R
M-75N,4AB14U5>D%X3WEO+S5O6&E&9BMD6C%"=5,K;W!18W=6;T17<6<Y:4U!
M,$DO;GA:;G0F(WA!.TUJ+TIZ55IF>F--3G4Q>DYO1C5&071E5'5Y<E1J2C94
M9%)8850T5#<U261N,F%%9W=L,G1594EW;%AW-S8K.4U02V8U;S9*-6AV>EDF
M(WA!.V5K.6QD34MW2DM626MP,4-K9G1$=WEV56%'94U8>D1B<$\Q8V5A6$-0
M4V90<7I,34HR8G-69&ER<U9D:7)S5F1I<G-65W!*1R],9W<F(WA!.V)I4W)C
M4T12:#%"<#-X5F1I<6Y,3W-B27!6,DUH24A&4W=&1DQF15)S=E-M+V9&5TIT
M*UID;TE96E)O3W1/2GEW5E9S=U=!54ME4BLF(WA!.U!O9E5!<4\K1VQ65"M9
M9&UQ47E384YQ-E)42GHY43)B14EF:6]J:%=:9W@T949/;FIJ4W$T."MA95E9
M<&8P9G%15UIL:E)46GE":3<F(WA!.T8O:#0O87%"1U-A0VQ-0V]34#A!33-4
M1TE",&I7541F6F1R0UAJ=C K259'*T=L6%A(-6LV6$1$2$M.33%76DI!4U!3
M<S-A9S1O=W(F(WA!.W5"=C9I:C4T2U9K,6IE4EAT;&(S:U%:67)M3DI9=S9L
M5S1U;UEC;$\T3D0P>%8X*S-S<% U8C9B2'I*03%'63A#5F]09S=5*TQV,WHF
M(WA!.V\T:CDK9C9R>&51+S1(2"MU6'%F-5-44DHU2',Q9#%6:DI-44-11"]!
M2'):<64P4#<P+T(V2'-F+T8T+T@W,E(S*VPK5S<K67DS,70F(WA!.V%837AJ
M14IE6DDS8C V.&=L5W%E3F0V6FA/>E5B4'DO-5(P*S=7-W1,0WET<G1E4E=E
M3T].2DMU2TUE449A<T1U8U9453-.<T]S<40F(WA!.S5S3591,2]B-E!F4DQ&
M9DI"8U)+=VM26F5,04U!44=&93E#8U953DPP:GDQ<$-S9$UT8E=Y1"]B34-P
M2'ER-&QA5C99<6U(,6TR<%@F(WA!.S%5<#0X:%1&5TQ8;C5D*U),>3EM=C59
M06)I9'!(;6M795%C;6UF;35.2'!V=5!L:%9C+VM(>6)0<#!M;EA!835S6&Q&
M=S!-;'=X06TF(WA!.S1U<E-C9W=B:S1L3F0V67%M*VEA6&]M:C)Z,C)N345I
M:VM-<F=Y1GE88G%A<U0Q=TMX4%=V>7(X=6%X<3%Z<4UU<%1*3F1/6DAJ:F$F
M(WA!.TQI0V9#;TIZ4'AD;U-H15)!1WIQ3E(R4&IY>DUY6E=F8W%7,S5D5SEU
M1U,S.'HV:D5(<4=62C!&83EA9T1!9&)F3T578V5Z2S5:36XF(WA!.WI52F9Y
M<S!Q84XT2G9-1C=*2$M36&IA5TYG4S<K;WAO4BLP+WA(,WE1-U%)3FE-5T5U
M>4EK55IZ;RLW,SDS96U0;%@X=E!++VPR*V$F(WA!.SEI;DXQ9# T=WE4<V@Y
M3W95;T9!,U!J;&5F5WIY0VIS1S-39&PT<T5U25=4-3E'6$<V=&@Q;%%F3FAM
M1S=*>'5B661:549E;%='2W4F(WA!.TYZ8D%!;59!1#!025EQ-S9Z8E5R-G%5
M.&51>%8S,6TR<%@Q57 T.&AI<FAC,GA"26Q19V14>4=+=49Z8DAP2VAP,6]W
M>%9W=7)9.4HF(WA!.U50>5E9<7!19F\R17EE:#9-8E-U6DIE2$93>FYQ>E4V
M:RM*>%96*W17,6%E<6QF1&M-5F-B<3)";UI50CA/47A6261%.' K5TY$,4<F
M(WA!.U,K<UAD3&E33#!816QY.&DX9F@S-'5X2$PY,DXK=C,T<6YX=6)99%I5
M2'I967$T,TYS3W-Q0W9I=WA6>'5B64-P;%-H-DAK359D.5HF(WA!.W1Q5CE6
M2V50255X5C,Q;3)P6#%5<#0X:&ER>%1Y+V]W,79Y:G!&:&-'45<S,3(U2VE*
M4W!*5D-2.%EI;#,V*U!H;3AZ6D]$2DEJ;E$F(WA!.R](3C5F5&%C6G100TIU
M=4DX=C=#>B\X04MH55AY6F)R2%AG2G)G3%AR45-T4W5W>E@V+RLY4'=D=#)3
M04U!<G90,VQ'*UDO4#-L+WDF(WA!.SEF<%DV:5IH33!(,6MM2TIP1E=0:U5Q
M>$A3<D-M66)S:U!O=C5M958Y63%71%-R3C5V<FQX>3E.2&I)2'=2;5$X:E4X
M9FA",D\Y8V$F(WA!.U9L94MP6C5G.'AA8F]&:W0U<4)C474O<')W6&ME6$)N
M.78R54]+;TAY-34X.'8X06U'+W5B2%0S:TYZ87AR3$UK:6-11EDP,DE*0F\F
M(WA!.V8W359:1&EQ0C%N5W)$4C=16&0X>%-&<$9I0E93,WA/9F)S0E4O,C!'
M2W!&669M;C5$,4-E0S-S.54Y5V$U:U-'0D)"8T1L2DEE2W(F(WA!.W9'3W!W
M,')+.$-S279V>D]71%<W-U-,9E-,:3AN<U-F5F%.,$$T<5%#,40R<7=Z3VIO
M<F=*1U%&=7-N,FU":T]-4DUJ2#-)>GEN*UDF(WA!.W5K*UEB>6%W.4HW3%5)
M:65.=DU14S18-UA%:G5V8UI$4&\U67AF34TY2C)J1$Y)>"MM439&;&59:G-(
M67$W1EA9<3=&6%EQ-T9867$F(WA!.V]8,2]:,D9Q.3-E>DQ"8E(X96-R;6EJ
M:W=55E!U>$%X6E)I6D=G;%0K979*>65R+T%,;6)34C10-WE/2U9:6DMC4%5*
M5D5,37=#5EDF(WA!.VQ144%$-$A$5%HK5WEF>E-R2C5U.'%U>%).6G-3-FUJ
M2CE::35+9D%R>7%$-TA!9S1*+WI4.&QL:C5K=#=Z52]Q.$Y*3%=64S%R8W@F
M(WA!.VXQ1FLT:VAM1$M33T\R>'I74C=14#5K-%1%:G4X+S%$.&1826YO*TA&
M>#-V,4AD*S%.6F)I0TIK5U)W<E-K:4Y39#)+<5=.0C=+<$\F(WA!.V).=VU,
M=CA!;7(U0U-+3U8Y5D%35FU21#9&>'5Y<7)%53E/;RM&=V0X85966#AY+TDW
M4&)O3E15=&1H5W1X-E4S>$(U4%-"*WAT.&4F(WA!.S(K3DMI9$@X.2M59%IV
M4EIA6G%C5GID:T9H04$V=%)253=-1C9D.%94-T9867$W1EAH1VYE65HO3"]K
M,U-,,GEU;S5B<')M-#576EDF(WA!.U921T1+4U95:&A8:4-#8S,P.$EY6EI!
M:F%H=3AP:3%2=V%E16]M>EHR*V(P4#AQ3&U,+T)D<5A:23)E5V1G;&%D6E<V
M5DYC,3)V2#<F(WA!.S O0C-06D)V5&<K6BLY;'I4,EI.1VMJ2D\R-5=T3W59
M5'-L<71P.%1657=O>#-Q3TE0440Y47A654YZ8D1R2V<K8D1&5G-K,6UY,&LF
M(WA!.V5.;$\Y1TMK9FII<E5B,D51<D<P4T%G06Q3;W%",$<R2W(O<DYT4W9Q
M<%1X-4-M2W1'93!D9#5),E5%2&-G:6].4BMR1E9I=%E60E4F(WA!.WA65VQ#
M3T\S:&EQ;TQM,E!35D0X;4=+<TDQ2#AT9$=V=%IU=%545TQI,G5,>"MC:7=3
M4F=D47=(4W1/4V<U;E$Q,&]X16%"0618;#<F(WA!.TMJ3$E:.%5G5#-*:C55
M.&QE6&9,='A08W=80G4W*V-N;&14<VI304AC<71+57%E=F,U6&XQ57-G04]W
M8G1*,F9$0U-26FME<%I..6$F(WA!.W1Q,#E62RM(25II=6,T,U9S1%%Y<%AW
M-41&6$<V=&@Q;%%F3FAI<FIC,G<V>6]+.4MS359C8FTR04)-<4%(;V51>%8S
M,6TR<%@Q57 F(WA!.S0X:&ER=G).=%-V<7!4>#5$1EA#-71I0U)+:$$V;FM-
M5E$Y.6(V4G%.<S%T97)$9%<U24Q24V-846MD2V<W67-O>4U465-C*U-V24PF
M(WA!.WE,2TY+<V96:DED2D9207ES3G5123-".3A.='8U;DHO3TMT2#55.&MO
M4T4P,GA"<EA:23EJ<U T1$%J>#AN955B66%F;T=N2VMD:D0F(WA!.V(R-&E5
M<$=S9D5C5G%4>$AG2VY+=D)H>#AD1&HW*W%*6G!Y1D5M:V%B<3)";UI50CA/
M47DQ<55Q85EG5F8S2VA"4D(X06]$5' T9EHF(WA!.T=+=&QR0F%!;4E524E"
M-#=%8FHW<U9A23 P5$I/4D-*:T)73U4X3U%$535!3C$S-S1Q<6TU=&=+;59+
M2&]E47A6,S%M,G!8,55P-#@F(WA!.VA41EAF5V)A;&964VYJ>4=+=FYM*VEP
M*UA/;5-%8G1F>E5.1T<S1'A*-&YF=T=D2$$O=GHO5F5,>40O030O,7DY6"]+
M2"]L0G)0.$$F(WA!.S1Y5&8X;D=Z53EO9C-P*T0P4%DO*TQX*U S<&@U:C@O
M95@O3#$K;&IQ2FU%>E%F5U-9;VUK5EDK4E-R161+<TM::$]Z42MI9FUD-5<F
M(WA!.S%N5EED3'-N;2MU6$)C4G$X4D$K0TUY3GE.5'@R0C)09F)';%I8:7%7
M95E035=M-D):3&5A9UA%3'8V83A&-4AL=UHO8CEL1&EQ1#@F(WA!.W4K9'1&
M,2LV;'1B25-R3D1'2E-*54-G<'DT:W%15T)O,C)+<"]I<4(Q;E=R1%(W45AD
M.'A31G!&:4)64S-X3V9B<T)5+W="=$)I<5(F(WA!.U=(-7 K43E1;F=T-U!6
M4%9M=5I%:&=145A!-5-32&EQ-WAJ<6-.2WEV07)"3'(X>3=X4$U/;V%.8391
M:WHV9EAL3DID:4E-07EP<T0F(WA!.T4R-6%18E9Z4&IO:'=#4FQZ.'8R=7!L
M,FQ,>%I9-'AV:"]P5C-E6&UI9DM(-6LR978V;E!P5GAA;7<Q0TES231V53E6
M6D%N,C9.>%,F(WA!.VA&3VQ/;5(Q1VI/3TEK1%E:-E!T2T]A6F=2=WE(>%IL
M;44W3C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMQ3G1E,FPP6FAB>7))64I':&TF
M(WA!.T,O<WE,,54K-'A65WA663@X36-K8V)U1F59;%EL2C-9:%-X02MG131Q
M>&$U+TY4>49B4G)*4'%G4DAC>'%F475$.&%H4U%127E2<S0F(WA!.W<P<7%V
M-6PK4C)E,U%A;7!A-T-T8FHP<'9I1'EE:T0Y:F(T.70X1DMI9$@X.2M5=%IV
M4EIA6G%55GID:T5I04(Q86EI<#)93#!X5E F(WA!.W-69&ER<U9E0C-F-5IF
M;5!W1FHY6&$U<W):;49U0F-X96QU4V5323AI.&564V9S9S4P161B9S4S4E!K
M.&10<W969E16>$A,8U8X<F4F(WA!.W)E44Y)=F1#.')7;6XV:6Y#-U5Y4$I'
M;%I!=DYY=T):059R5'=/86Y6>D=425I2-5!29&XT6EEC26I,;7E%>7=N<6I(
M='9'+U0W<W@F(WA!.RM%=6)X:CA"66AT56)K:U)6=D52340P<"],-UDX2EAJ
M2#1#<#E9:CA(+S1"+W=#;5!#5C1X*T%T95-",31U:DUV9S!B169I365%<G@F
M(WA!.VHX0GE08G@O66I+-T)F:&I98D-T0G-V87500U8T>"M!=2MS4BM$+SA!
M+SA!5$AH2SA9+T%A86%&:%)L66EO3D1'-3-"<40P-TA(:$LF(WA!.SA9+T%7
M03)O24EI24DV15).=%0O04=/4$-6-'@K07%F5TDO0B]W1&=(+W!J=VQE369G
M34XQ6#AS9DMU<#9N8V%J8TYE<F-83"MP2C8F(WA!.UI+<E@R2'!N37I(<DUK
M66E)<6@K3SDQ=6)S>D1K;5IN:7,O:G544'EX-5$X=2M7>DTK;GA3=%!0<SEX
M37)02G@O;$)#:6=R=FQE9E F(WA!.U!*.59.,FPP;4Q"9D-$6E0O=T-S4BM$
M+T%005 O5$UF:$QM8UDO060Y66HX2"\T0B]W0VU00U8T>"M!-S9X2#10+W=$
M+W="365%<G@F(WA!.VHX0C,Q:5!W9B]G2"]P:G=L94UF9T\K<U(K1"]!4$%0
M+U1(:$LX62]!9#E9:CA(+T%/068K;5!#5C1X*T$W-GA(-% O04U!+SE-944F
M(WA!.W)X:CA",S%I4'=F+T%)0B\V63A*6&I(-$1V<D5F9R\O04%$+T%.365%
M<GAJ.$(S,6E0=V8O9T@O04M9.$I8:D@T1'9R169G+R]!4"\F(WA!.T%%>#13
M=D=0=TAF5TDO0B\K068K;5!#5C1X*T$W-GA(-% X03A!+SE-945R>&HX0E-K
M4WEK1DI)3UEO4E)O;4]X<%AQ=G--945R>&HF(WA!.SA"=71R440P:E%522]D
M3G-2=5 R93)00U8T>"M!,7=S=E=79C!0,WE!<6MV<$YY54XQ06)J559P:G=L
M94UF9TMV,6E0=V8X031"+S8F(WA!.UDX2EAJ2#1$=G)%9F<O.$%W1"\P>#13
M=D=0=TAF5TDO0B\X06=(+W!J=VQE369G4"\Y:ST\+WAM<$=);6<Z:6UA9V4^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!
M;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @
M(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ
M26YS=&%N8V5)1#YX;7 N:6ED.D4Q1$$P,C)#-S4X.44Y,3$Y,C,Q0CA#,D)&
M,#)%03$Y/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C
M=6UE;G1)1#YX;7 N9&ED.D4Q1$$P,C)#-S4X.44Y,3$Y,C,Q0CA#,D)&,#)%
M03$Y/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q
M-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L
M87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX
M;7 N:6ED.D4P1$$P,C)#-S4X.44Y,3$Y,C,Q0CA#,D)&,#)%03$Y/"]S=%)E
M9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX
M;7 N9&ED.D4P1$$P,C)#-S4X.44Y,3$Y,C,Q0CA#,D)&,#)%03$Y/"]S=%)E
M9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\
M+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S
M/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP
M34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M1$(Q-3E#-$(X,#@X13DQ,4(R-#%%-CDW,$8Y-$8Y044\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,#8M
M,#94,30Z,#<Z-30M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3
M-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D4Q1$$P,C)#-S4X.44Y
M,3$Y,C,Q0CA#,D)&,#)%03$Y/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 V+3 W5#$U.C0W.C4S+3 W
M.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-
M.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII
M;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q
M+C O(CX*(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R
M:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C
M(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \
M>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I
M<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R
M86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N
M8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^
M"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXV,S N,# P,# P/"]S
M=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XX,3 N,# P,# P/"]S=$1I
M;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N
M:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \
M>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4/"]S=$9N=#IF
M;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^
M07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z
M9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R
M:6YG/E9E<G-I;VX@-2XR,CPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M
M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE
M/F%R:6%L+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M3F%M93Y!<FEA;"U";VQD350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A
M;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\
M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B U+C(R/"]S=$9N
M=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M
M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86QB9"YT=&8\+W-T1FYT.F9O
M;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @
M(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'
M<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*
M(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP
M,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z17AT96YS:7-&;VYT4V5N<V4](FAT=' Z+R]W=W<N97AT96YS:7,N
M8V]M+VUE=&$O1F]N=%-E;G-E+R(^"B @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93IS;'5G/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP
M92 M(%14/"]%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#X*(" @(" @(" @
M(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y!<FEA;#PO17AT
M96YS:7-&;VYT4V5N<V4Z1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/C \+T5X=&5N<VES1F]N
M=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93X*(" @(" @(" @(" @(" @(" @/$5X
M=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD^36]N;W1Y<&4@5'EP;V=R87!H>3PO
M17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3X*(" @(" @(" @(" @(" @(" @
M/$5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^-2XR,#PO17AT96YS:7-&;VYT
M4V5N<V4Z5F5R<VEO;CX*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N
M=%-E;G-E.DME<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G1396YS93I+
M97)N:6YG0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O
M;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/C(S-38S-#,T.38\+T5X
M=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B @(" @
M(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XR,S4V
M,S0S-#DV/"]%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3X*(" @(" @(" @
M(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/D%R
M:6%L350\+T5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP92 M(%14/"]%>'1E
M;G-I<T9O;G1396YS93I&;VYT2VEN9#X*(" @(" @(" @(" @(" @(" @/$5X
M=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y!<FEA;#PO17AT96YS:7-&;VYT4V5N
M<V4Z1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N
M<V4Z3W5T;&EN949I;&53:7IE/C \+T5X=&5N<VES1F]N=%-E;G-E.D]U=&QI
M;F5&:6QE4VEZ93X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E
M;G-E.D9O=6YD<GD^36]N;W1Y<&4@5'EP;V=R87!H>3PO17AT96YS:7-&;VYT
M4V5N<V4Z1F]U;F1R>3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N
M=%-E;G-E.E9E<G-I;VX^-2XR,#PO17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO
M;CX*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.DME<FYI
M;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE8VMS
M=6T^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT
M4V5N<V5?,2XR7T-H96-K<W5M/C,V,S8Q-SDW-S0\+T5X=&5N<VES1F]N=%-E
M;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @
M(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XS-C,V,3<Y-S<T/"]%>'1E
M;G-I<T9O;G1396YS93I#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @/$5X
M=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/D%R:6%L+4)O;&1-5#PO
M17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @
M(#PO17AT96YS:7-&;VYT4V5N<V4Z<VQU9SX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 8L"70,!
M$0 "$0$#$0'_Q  ?  $   8# 0$              @,$!08' 0@*"0O_Q !A
M$   !@$"!0$"" D%"PL! PT! @,$!08' !(($1,4%18A(@D7&"-76)?6)"4Q
M,C.8IM78&316E=<U-C=!0U%4=7:UU HF0E)3=Y26M+;3<2B1D](G1%EA8F1R
M@8.2J+'_Q  = 0$!  $% 0$              0(#! 4&!PD(_\0 71$  0(#
M PD$!@0'# @& 0,% 0 " P01!2%1!A(Q06&1H='P!W&!L1,B4E;!X107&-45
M8I*EIM;Q"!8C,C14<Y.4LM+3,S5"4U5UE;0D5W)TL]26)C9#8V2"PN+_V@ ,
M P$  A$#$0 _ /?QHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+YP<=/#MQ-<15YP97<&9HN>!*9'U
M/.Q,BY*J5QR##'K=HF$<7M\63!*;CG-&'GE\LD0=K=I*JM+F6_8NCW3=ZA?:
M1-QTR@P>%D"!6HKHNV7UU'A0X%=2[HU^&'QI2,L1F(H6<RE.6/(^:K1B]Q9+
MAP\N9&B,Y;/?&I9<=P*LC?9Y0\_C64QVWX26*];E'K2PTZN7!_7:E/4CTK*0
M-1)ZM171=4> KAKKCXZ[[;;A\,LC8LCM:AC&/=UI//!U*)8'\APY(2"N*W:6
M7_"1S6DFN!R)T6#=1N'0O$A/Y'<Y9N$?8I1>J+8W?!,LJ609NO"_3LO[].P;
M=>SN.9G\)7:IW+]%X6V<E%T:Q8 O430K369;$5=,WNTAA+.8MU1N%KN$5DVI
MYB+FUO@B#Q_(P<&CC*,I4Y;9VP6:-L;1"9J)&YMU<1B=8U4T4KKK7<K#G_"?
M&(VSUC]/"1N(:Q5VJ8CX.JM0LH*<2:4!A^N7''.?+U)<2LUQ%XN?YFA9G+DA
MDG JU8@G,L?"^6I":E7#9./E:I+QXV.**@MI?32:W7D&E*84-3I&%^A6K%4U
M\,I(UW'1K[5<=PU@G;%8F&1T[0?$W1H3>LU+%U^B)>,4H%FE4K52,DWN+S-@
ME@FU;HWJG5BV8[M4HRDGM2G,CV@H<W5\;[]N IWT-XJ ,"JI_A@UV$'=KM5K
M@PG#U>.J]O@JU.<-4A;X^/5O$1*3TS2:9(Y/8X G,B(%\HRA+%9DX-FABD3Q
M;KS-]8M7%D*^K2E=>F\ZNX75NT=^RHQQD/X7G(MLDJ[,032G(PMJQ?0\KV2,
MK6%VU(I[A9]P=2&4)O!#BVV%]<KN]A*W<N+)X[D+I6YRF+M:OCEG3//6MG*0
MUE*'-U''O_VJ;,-NDW:%DE"G?AF&<M@%K?ZC6I*'E+1CV1S;*,@P&F[K[6=Q
MSPF2N1JT]C8^Y-DW>/Z;>)OC#K$5*4I^XR*:1J.-IQ%[>ZT1&/R03U;_ !H+
M\3\*:?V9SPVQ7PG*N9>'68XG9"</0FV/9MQEUA6E,"Q]=;9'N7#Y@N9=P5KC
M:I-JR\I6<>YS8YMJE,F*BG+2IG*\*O)OIRF/_4VB'-U<<*FGB12NKQ7UST6*
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(M:*4:V'44.7,N0DBG,Y$J1(?$HIH@N\@W*1$Q4QD=42LD
M(J0CVPJJ*F.ULTRH[,Z?-JZ\@;78./-2AQ/#DN24>UD534-F3(2A"*(',@>'
MQ,":I4I*9?*)',GC)-8".6DFPAEA3535+'UV)6;J(2SB>DYIX#CS2AQ\N2IA
MH%P%J+<,X9*!86(M ?!"8;[DK@:ZG"A* 0<4BS[TLH0UN!(S4T;YY4[06 U8
M$JXFKL''FE-IX<E6'I-I.LJH7,%_2(==58C<D1BH4D4U)B*DR-4S*8V.N9%%
MC'O*\F9595R,3.R;A9PK.H0TS$J[!QY^/RN2AQ/#DH$Z/:R"039DR$J!>UW
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M0MI5'X86%N;2IO83 [F593!)";LDO 9:K=AKL#3V$GP:L7:T/8(RO*1]IOD
M;C/J$3=\?@:%-4KE1KO6%K$_01BIQ^3-VC5INQQ_])WC$T^T&BQ31$T1=9^,
MK,%PX?\ A9SKFC'\="R]VQOCV:L]7C+%'NY:#?33(B8,FTG&,+#4G;]JHJH
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MAI773#6X:]?JZ-NE?0G@\XO5^+QKD.?B<8.J+3J*XQ7#-YN3ND/8GUBLV1<
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M$;;Q:&$HFP%@0PD-N((\4%W$2FY"7<7GPJ>Z;:8Q>8<AY&$/R".EV)W#FE^
MWGDM78QH&7<,(V%#%O"-PRTE.V2:4O8@A>):\I'E'C9L#)B1=5;A865*PBV8
M=G#Q*)THJ&:F4;Q;)FBJH0R[$[AS5J[ 7;?_ /E;2"W<6I0 I<!X%      X
MH+N   >P   X5.0  >P #\FEV)W#FI?@-YY+GU?Q;?0)@;]:&\?PJ:78G<.:
M7X#>>2>K^+;Z!,#?K0WC^%32[$[AS2_ ;SR3U?Q;?0)@;]:&\?PJ:78G<.:7
MX#>>2>K^+;Z!,#?K0WC^%32[$[AS2_ ;SR7!K;Q:&  -@+ I@ Q3 !N*"[B
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M/"IR$!#V" ^P0TNQ.X<TOP&\\D"W<6H  !@/ H  <@ .*&[@  'Y  /DJ>P
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M04_E/W;9L$.0EV?)4V[1 >0EY<A#V<M+L3N'-+\!O/)1A;^+8/8& \#  >P
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MMJIS%(2S5\YSF I"%F8XQC&,/(I2E!R(F,81    $1$>0>W03LF2 )N5)-P
MCPB23H &>GI87^\A_EMYK(-;I:B:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(L<?/+4E9Z\RCH*(>5%W&V%:S6!U8'#*9A)1H>&"LL8
MFN)P3QO/-9LCF=-*OG$_!G@O%L00:3(RB@1ZZFW4/.]%I?B M>2ZXA7VV+D+
M"O/R#*TN4TV-$?VRMJ+Q+6-7:M++)L(N35AG$B59U&UEJ*L*W?3;Q&7E)Q.$
MK4I#3F0IKV:Z=_5YU#348NKJVZNO#0,3=?C5BNN=&./[\^DX)Y7[@A>8:#H[
M>B0$QDIL>(D,>TU\G*OEPI2$D-;9W=]8%+A*I4J3D&41&RU<KK5Y/GA7A0 J
M,*7UNUG;IPO[[JH2:'36MU+]7=HKIN5O86SB1>+*F:,42)IVBV,WI+%1)%JB
MW7)C[*;V'C(M9NXC7+JCQ%NAL:"A:4V<V\M)[&^B&DRFJ@=-!ZO=X@UO'&E;
MMBE77^-+J'0?B!C6N-RND9:<[2^&G+E*-?LLCKV2!CH@)"'6BI<*M*9?6KRD
M]+N)*C%@V$@3'28S+[IT!T:N],TY(U1PU=Q\8N-*[.&CGMV*U=3;=WZ>ZFC9
MM6-6;(O$G$3U4JT%09"=187:IQEPGPCCONXK0Q#%Q,O#60U=J=4F$K'(/WZ;
M>7K,!"EIR=8$EEC&#RR,6#%1M]^HT[^[3=MK7N%5"7: ->'RI3=HO5SKV:<^
MR5FJ<.[P2[&OSKZ 0DKB*<Y7FT2V>J)+65=U7[ T3F&!:PD9[$H*20MO4CZ-
M),1B1(F9CDRJ"A];1JQ_;P\$#C4>KY_$:N.I5DAG3)J.28^C-<5R1&J\E(HF
MDG4%;3IR;*-RJO47"L6_2CDXI!FGC]]6<@.+.Y<+UIHK*>G7#LD@IM:LT4K7
MPJ/9KYW4TW%7.-0*>>.KPOZHK7>,R9UK=PLC>$Q1,V*#8R$;%P\?'TZROP5*
M0;<]7DG-H;'1C7:-DCH:!(S?PJ<BRICNR,XZRQ[B2:.4U@#;K^(NT:O'$:#1
M0EP.C@?/1T-JEUK*_$).UNZQ3_'3Z)M\+A1>;AK"YHL]$Q+W++>FUU^:&CXV
M2EG:$^S=6><DHUJQ;/V:J"E3?D,O(MI1JX:J#&ZN.KS'SU*U.'^S71KIUN*K
M"Y/XBVJC6$^+1K(R:SN*CB2CB#L:;)")>6PD$YO4N^:"U@ESQT447\A1F#F*
MG72[CS#06%4;'?"HW37K#&_4:7:[U*NN%+^'>:>7EKWOBNQW2T5%K*W^KDJ-
ME.NH#J(1!V5%)%5%N\;@F#X <F,U(Z\:Y6/M*Z>,'+M-!FFN5BVA !NO"R!)
M%]QZT:5L?4531$T1-$7DHP[%R<QE;'3&(8V&0?#<ZZZ*WJC<KJQE;Q\HVD'S
MJ'2.11$'S!BV<ODEG)>T;=N+EX8C5)8Y?ECDC+3,WE1D_!E(,_'C?ABSXHAV
M7#$6T1#EYF''CQ91KFN9Z:! A1(['Q!Z*'Z/TD4B&UQ'@EG0XD6?DV0VQ7N^
MD074@ &-FL>U[W0P;LYK07 N]44J[U05LCBD:NVV1H\\C'.(J3>5.,=2+,\/
M/P+(KGR<TW*I$Q5NCHFXM6"K9NW4.-HCV\BXD3/W++JP*T.NKV#M+A18>4$
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MR,RO<0T9+915) %;&M$"I-!4F7 '>2 -906=:!N^@SE__P#;1O\  O0CP#<
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MG[+!;%F QCR)^5<T.JV-#/KCP2SC2>E",[/$Q ,(,8'DQ1%88;2UT6 "USJ
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MSV7[4?\ J3_B3^5HX1O]/R'_ .25/WEI]=^0O^^M3_ISO\U/WSV7[4?^I/\
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MU&NHV=IT^6:K$_(UV1J58KK^HH6EW7)& NU;AG0@"M!6[371?=381HK>:XA
M2:5-+Z4IIQY&EP7>C6"S4)R$4(9-0I3D.4Q#D.4#$.0P"4Q3%, @8I@$0,40
M$! 1 0Y:(J&*B(J"CVT3!QD?#13(IB,XR*9-HZ/:$.H=4Y&S)HFBV0*=5114
MQ4DR 90YSB F,81(OFO\()P3Y*XM)G&,C0;+1X!&DQEH929+>\GVJCE2<=0B
M[4S$(:OS93D2+&K N+@S<Q3'2Z95 $XD\?[4.SVULN(]CQ;,G+.E6V=!G8<8
M3SYEA>9E\LYAA_1Y:8!#1!=G9Q::D4!OIUZW+(F+4=+.@Q(,,06Q [TI>*YY
M813,8_1FFM:+YV_R-/$5](N%?ZWO/W"UY7]0657_ !;)_P#KK1^[5P/[TY[^
M<2GY4;_)3^1IXBOI%PK_ %O>?N%I]0657_%LG_ZZT?NU/WISW\XE/RHW^2G\
MC3Q%?2+A7^M[S]PM/J"RJ_XMD_\ UUH_=J?O3GOYQ*?E1O\ )3^1IXBOI%PK
M_6]Y^X6GU!95?\6R?_KK1^[4_>G/?SB4_*C?Y*?R-/$5](N%?ZWO/W"T^H+*
MK_BV3_\ 76C]VI^].>_G$I^5&_R4_D:>(KZ1<*_UO>?N%I]0657_ !;)_P#K
MK1^[4_>G/?SB4_*C?Y*?R-/$5](N%?ZWO/W"T^H+*K_BV3_]=:/W:G[TY[^<
M2GY4;_)7V0X0^$.B\*-&"*B00G;_ #J#=6]7I5N";N7=)AU"Q<64^Y6.K4<J
M)@8, -O<* ,A("J\4#H^]Y"Y"V;D39OH(&;,VG,M8ZTK2<RCX[Q>(,$&KH4I
M"<3Z*%6KC_"Q<Z(Z[M=EV7!LR#F,H^,\ QHQ%[C[+=;8;3H&O2;]';K7>5RB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O)=AR+C)'(< O.!-C!5Y1>WSGI]
M)H:1&'J*![#))D</;724XXJ[2.5;C)(6-E(,SK)J12;R4[-FO\L\DI:6F+>D
M7SOTSZ%(.B6M._0&PC,?1+*ANM"8:U\:U+&; #X4NYGTAEHP9B$7-=*MC37H
M8,3P6SF,?.0G1/2>B@DS,7T6;G^CEQZ9X!?'E@RK6$9XC->VM6!S\UIROB*F
M7=DO4?973^5ED[%48"782\NU7;.9*.<@[!JN7N,FY94." )FCW)#VLJ\?(,W
ML.^AXN0CG:)N4[0)R+:-MP+1B1YJ:;/V5(S4":FX3X<28EX@BB$\9^4F5+G9
M@:8$0&U ^!,0HTI&E)6/+Q6+7MB(Z--,C%[X@C2\*(R(\.!<PYV:?6G9\G-
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M4.GK17R4SAHKYJ03,F-%$DEB6IH9)9)%9(_9RG(Z2\5+S:)P 6(#R/%P,N[
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MBIKBDH3JZI7R"9PNOT_L\%&GES'2JJ:*=G:F465113(#22YF5<2LM!HDYBR
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MS9(1(W+GS%^F)=Q4US)16HQ&]<DR]CA19-!.T-3+*JHH)D!I)\S*N)67A$2
M/9<@$\I RS0!$0 #LCG,()'144M#AM\N83.&.^[S5+\=6+^U[WU:T[4&'DQ6
M[.5V]AZ="V=QR[#=M]/"$GMV]3I?-;.X^9TH<.JT\TJ,>J5\E5GRYCE-55 ]
MG:@JBJL@J3M)+F15O+1,&L0>3(0$22LY%,Q$!$!.\(<!%$BJB:APZO/P*5&/
M5VOQ"X)E['"AB%):&IC'%J!0[23 1%XO.MFWY60<NJO6IQ,.?+D,>H)MI5$!
M54.[KH*9PQ\U(/F?&2;=1T>UM"H)-#/E%.SE! K4D"QLYEA & FVA R3*1Y
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M:ONK25?D+#<!1@&3J2VB4#])$4MO<&(B90X:Z>/14SACP*JCY>QPF<Z9[0U
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MHS6/@TCGT3A&9$8]CH1#CGAS'#-J:5 6;\0,';Z[?"15SE(=_(-H9NFP9P4
MVJ3"#A4)&5;,(M.I,HN':UL%Q06G$F*+!/O&TRWFEE%W,JLLIS.7DE:MGVX)
M6UYF4CQX<G#; @R4C#LN!)2;(\S"@2S;*A2TI"L[/]&Z=; 9!;Z6'.,G'NB1
M)I[W;JUX4Q!FPR8B0GN$,9C8,(0&0H0?$:R&)=K(8@UH8H:&^LV(V(23$).C
MM=+7%KU[T;^\FG_[+5__ '2TU]7;%_U-9/\ RR0_[6$OT%+_ ,G@?T,+^XU9
M3KDUK)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HBEJ*I(D%191-),!* G4.4A $Y@(4!,80* F.8I2@(^TQ@*',1 -81(
MD.$PQ(L1D)@+07Q'-8P%S@UH+G$ %SG!K:F]Q %Y"R:QSW!K&N>XU(:T%SC0
M$F@ )N ). !)N"F:S6*:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+R
M)8X5*AD.AK'8)2I$;G5U3Q:[1S((214YQB<S!9@RB9]X]2>  MU&C2"FG+DB
M@HH1,DJ<C-;Y3Y/.#+?L-Y@-F@RV+-<99\*)'9,!L[!)@/@092?BQFQ@/1NA
M0I&<B1 XL9*3#B(+_ )(@3DH2P1 )F 2PM<\/ BL]0L;#BN<':"UL*(YU:"&
M\G-.U>)J*=Q608\71))/R-5C9!!*8"02DDD#2,PT CIE+8XQ7*,/GF:PH-WU
M22.JV%%\WD'[)XU5#L_:/*Q96WH/I6S#?I%F2TPQLWZ=LPUACS4*D2#-9/9+
MS,#UH3RR''LIKG0RR,R/'@Q83AO[;AF'-LJ'C/EV/ B9X> 7Q6^LV))R,1E[
M31KX%2VC@]S7-*Z[ZZ N'7KWHW]Y-/\ ]EJ__NEIKZNV+_J:R?\ EDA_VL)?
MH*7_ )/ _H87]QJRG7)K65"PDXV59)R47(,9*.6ZO1?L';=XR5[=51!?INFZ
MBB!^BNDJBKM4'IJI*)GY'(8 (K1)7.GPT*]LDO:ZU%5V-421D9^2G8MC"QZR
MZC=)%)[*NG23%JHLJ[:I))KKIF44<MR$ 3+)@91*C%5[2?@I!DXDF$U$O8YH
MDDNZD&DBS<LFR"\:TFD%G#I%8Z"*2T._8RR2BBA2*1KUH_((M7**IU$JKFFH
MFLFFJDH15)4A5$E4S%.FHF<H&(HF<HB4Y#E$#%,41*8H@("(#HBM8V" +.EJ
MYIN(+93QHS)*Z,DR"=/#@X%H,L6)%;OS1H.BF;"^!N+4' "CU>H ET17?1$T
M12U54D$E5UU4T4$4SJK+*G*FDDDF43J*JJ'$")IID 3'.80*4H"8P@ ".B+'
M:Y=*=<&J#VI6RLVEDZ3=*M7=<GHN;:N4F+@C-ZJ@XC'3I)9-F[43:NCIG,5N
MX.1!42*F HT@C2"._:E0=!5^:NVCU,RS)TW=HD<.VAU6JR;A,CN/=K,'[4RB
M1CE*X9/FSAD[1$04;.VZS=8I%DE"%B*@E;! 0:L6A-S<1#K3DBC#PJ,K),H]
M68EW &,WBXM-VLB>0D5RD.9%BT!9RJ!3"1(P%'D17?1$T1-$31%8K':*S3XM
M6<MUB@JM"HJ(HK2]CEX^$BTEG!^F@DK(2;AJT3474$"(IF5 RAQVD QO9HBO
M*2J2Z2:Z"B:R*R9%45DCE42524*!TU$U"")#IG((&(<HB4Q1 Q1$! =$4S1$
MT1-$31%\EOA+N+7-7#1.XD8XFFXF(;VV)MSN;+)5^+FS+K1#R 18F2/(H+&;
M@F1^Y Y4MH*"8HGYB0O+Q#M=RXRAR0F+#AV),0(#9Z#/OF!&E8,QG.@/E6P\
MTQ6NS*"*^H;IJ*Z NL906I-V<^5$L]C1%;%+\YC7U+###:9VC^,5\S&_PHO&
ML[2<KM;- N469 4=K-\=5]9)JF8#B51RHG'F(@0034$#*B4H@F<0'D4W+R!G
M;)VA1 ]S)N5>V&*O<RRI5P8+S5Y$(AHN-YIH.!77AE':Y!(?#(&DB780+JWD
M"ZX$WZ@H5?A2.--!!LY7M-?1;/ 4,S<*X[KJ:#HJ)^FL9LJ=@":X)*>XH*1C
M 0_NFY&]FCNV7M!:UCW3DJUD2IAO=94J&O#31Q8XPZ.H;CFDT-QO0Y26N "8
MD,!U:$P&4-+C0TOIKIH7UAX"_A HOB,:)8WR>M&0.:V"*JC,Z!$V$/D./;E,
MJH]A6XFZ;.PL4"F4EX%(VU=NF>8ARBS+(,8;V[LT[3X&5D-ME6NZ#+90PFDM
MS0(4"U(3 28LNVM&3,-HK'EA<6@QX ]'Z2' [-8MN-GQ]'F2UDXT&E/59':+
MZL&J(T?QV:P,]EV<UGT]U[ NQ)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(K8]FH:,>0\=(RT9'R%A>.(ZOL'K]JT>3D@TC7TRZ80[5=5->
M3>-H>,DI5PU9$771C8]\^4(5JT753H!() )#15Q )#02 "3J%2!4ZR!I*U60
M8T5D:)#A18D.78V),1&0WO9 AOBPX+(D9S06PF.C184)KGEK718D.&"7O:#4
M.'[%FLP;NWK1JXE79V$8@X<(H+23Y-B]DU&3!)4Y3O'9(V-D9$[=N518K%@]
M=F(#=JNH24)K0:+SL%0*G"\@=Y 6+8<1XB.8Q[VPF")%<UI<(<,Q&0@^(0"&
M,,6)#AASJ Q(C&5SGM!HK!88"IPLC8[3.0]:KT.V,\EIZP2;*&A8MH00*=U(
MRDBNV8LFQ!,4#+N5TDBB8 $P"(:K6N<0UH+G&X-:"23@ +SX+.7EYB;C0Y:4
M@1IF8C.S(,O+PGQHT5YO#8<*&UT1[C0^JUI-VA66D9%Q]DR+<3F-[U3<@PC.
M04BG<Q2+/"6N+:RB+=J\6C7$A OG[1"02:/63I1FJL5PFW=M5S)@FX2,?)\-
M\,YL1CV$BH#VEI(O%:. -*@BNPK6GK.M"S(K8%I2$Y9\=\,1609Z5CRD5T)S
MG,;%;#CLAO=#+V/:'@%I<QS0:M(&9:P6S31%\]N(8ERR>RM[ETQ%OCRH,KFU
MA84+,,#*N+55V9G"EML$86/7[PJ*"$E(U*L2$G"K/HF-7G.:@/VK1Q^#>WIF
M5W:1)Y5S,S)&!D#DG)Y7RMCV/^^-UAVI&RFR:E'3$3*JWK-$A&^EM@P8%H3^
M2V3D_:%C1IRR[.BVSG1!/2\I'_279J;$R4F+%A09@1<I;:F+#C3T_P#@D6C*
M0[(M>.(3;&LV;,RST)B1(DK*VS:LM*3T.!.34.0]0R\6/"[68IRQ Y%;R$0V
M2FXRV5%O$M[;7['&*1LM'.7S03MW!P*HY9N6S_H+K-EVCQP!TMBIP3*LB*GZ
M=[,.U&P\OY>>LN7A6S9N5&2T"RY?*FPLH+.?9]JV?,SLJ7P)AX$28E)B7GC
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M /8+I=B=PYI4XLWE/C$XF/Z,<)_ZPU__ +!=+L3N'-*G%F\I\8G$Q_1CA/\
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M->&W[;\G_P /NEV)W#FGK_B\4\UQ?_1KPV_;?D_^'W2[$[AS3U_Q>*>:XO\
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M2[$[AS3U_P 7BGFN+_Z->&W[;\G_ ,/NEV)W#FGK_B\4\UQ?_1KPV_;?D_\
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M;NE)>R0K%],YN/GUJ16QO@G,#HJYD\?6(@-S%2,#EJ1F95XK$5Z>:1;,CQ5
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M,\>HSCUN.^_>F:.N&[X!=E]8K)-$31$T1:QG\45RPVU*XJR%GBY%1"LM9MI
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M(HR0+@<R85<Y3&0\DX7%$%//CM.,6=M'=;8;DY;J2/2$''9(DOQX?M4@(N[
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M[0[DY!7!-#?TBQ5?D@:Y!;=-$31%^M#A'_ QB+_NPH/_ +4B=; Z3WGS6N-
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M$T18X^AI9U9Z_.-K7,1L/$1MA92E/:LX!6%M#N7/#&BY66>O8AU86CJKEC9
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M\]6@UW&NJ^EVGH\$JZ_92E1IW8_)80MFC,Q95*)<3UHBY*5FH!%DDOC%$*_
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MKR .:T='B0"$3<$<DIM/77#OKP:J.C$.3UE<"B<JA0.5W#[R;V;!H!B",&(
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MP_N]4L<4!+SA!Y"CV"AD>?,"FDI$3@<%&P-7@E-IZU:%,)67)5"*#;+4<"K
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M\G/6Y@:'=X6C$ )%16[XE>9#R4C_ *>]_P#%+_\ R:UUA08#<$\E(_Z>]_\
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M*4-BTK.2JQ$PDK)9)($TU9BQ3"J95I&16*4! J+1HBTC6C)DVV;G%Q).DK6
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MCS*<@,1;*%'VE>NF+8??<DT5KUOY>2Y-;4R@8?3UM':"H\BP#H1-TDXY00*
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MTO 6H=BXH;P@G(I&Y2;>,ZI#\^1D!,X!\"OY!C$7#T/FTC!HI78=VVGS[KU
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MX?5;+@7DE;IPR:C>,QA_Q<;]FS!SO-4Z>N0\ET(UJ*+]:'"/^!C$7_=A0?\
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MT# JSR,E='S<(B.L<BM/,%:^N\D9MU(M%919_'0JJ32&4*?V'*O);(S(ZSK
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M77#62+]83$,A--L1XA18U\TDU^*S&QA>!*,F@ =:K(@Z3[=<.J/9E;,3"?\
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MG$B9C$]010[#F9/ESI[@#D;INV[-CN#W3"_!R7YEJMI=BE3AQ%W75%$:9M
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M1[^1:,WT_),XM]-NX^$:.%DW$J^:PL7)R[EHQ3770BXY\_53*T:.%4Z&D@D
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MA]FXLSLZG9,>GOY&W;/(>2W\O>[+L=OS_<:)?L\\*8;>"FCZWZOL&J]#N?\
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MZ(Q\05ZWGI,3#^"^W>Q\I,N8.6%MY3.LB4R?R7LG+&3R;R/MF;M.0BV9&L^
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M5$.HH<QM*4[6NS"0A^AD9UDE!)SC"E+#GY>&79K69V9!D6-KFM:VM*YK6C0
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MA*!PDX\2B4#@8'K;:)!0,Y X#U.0E%L0[@#<^70(97GTRB8"+D96+ 1 9)@
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MK%AS$9)@ !N$>;QN'+8")C<_G/9M*X0,;_,"Z(CR!0FXBY\I&"(%"18B83;
M+W;?F)^L=ML .IS$W<)G0V_EZQ#I<MY1*!%"$O$B4#!)QXE$H' P/6VT2"B9
MR!P'J\A*+<AW &_)T2&5Y["B8"+D96+#F R3 !#=S 7C?V;3(E-S^<]FTSA
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M'#(^36K&*MD/:X:'JT=&1(5ZNXSJ<%76P2<T^<UV-K^)K!8Z?'E2DWTA+/\
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MQ+ 3BL+U*1%83"WW"J,@@B_%01W]ZBDZY]=,AP5ZX>24& W* *K5R@ %K<
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M$"A5 6*<(E@!P6!XK(@J!@;[@4"077? <!W \65<\^LH<XD4L*E5 ("05BO
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MN*@Q+ 3BL+U*1%83BWW"J,@BB_ZG/?WJ23KGUTRG")08"_2H JE7*  6MP
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MX<-KX$RUSWOS6M:Z6F&EQ ,"**PW?$^ R6B=I$&'.1H4M)ORWALFIB,]\.#
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M+@N,25>21>/GR\?G<E3@>'-336&; Q@"B60P *P 8LA3.1@36CTB&*!K44P
MX3>.G"0&*42I1+XJX(KK1B,A?$<>25V'AS41;!-&.0HT:R$*8R93*&?TX2$
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MBLI':/I-O(.XYFY*>3 4'+YI$RKIHBH!5'#>+D5TBF28NC)*' [DJ,1O"S"
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MU=3Y?/%G]*_["XU^YVGU+=F?NU^>;?\ O5/M4]O7OW^B^1GZNI\OGBS^E?\
M87&OW.T^I;LS]VOSS;_WJGVJ>WKW[_1?(S]74^7SQ9_2O^PN-?N=I]2W9G[M
M?GFW_O5/M4]O7OW^B^1GZNI\OGBS^E?]A<:_<[3ZENS/W:_/-O\ WJGVJ>WK
MW[_1?(S]74^7SQ9_2O\ L+C7[G:?4MV9^[7YYM_[U3[5/;U[]_HOD9^KJ?+Y
MXL_I7_87&OW.T^I;LS]VOSS;_P!ZI]JGMZ]^_P!%\C/U=3Y?/%G]*_["XU^Y
MVGU+=F?NU^>;?^]4^U3V]>_?Z+Y&?JZGR^>+/Z5_V%QK]SM/J6[,_=K\\V_]
MZI]JGMZ]^_T7R,_5U/E\\6?TK_L+C7[G:?4MV9^[7YYM_P"]4^U3V]>_?Z+Y
M&?JZGR^>+/Z5_P!A<:_<[3ZENS/W:_/-O_>J?:I[>O?O]%\C/U=3Y?/%G]*_
M["XU^YVGU+=F?NU^>;?^]4^U3V]>_?Z+Y&?JZGR^>+/Z5_V%QK]SM/J6[,_=
MK\\V_P#>J?:I[>O?O]%\C/U=3Y?/%G]*_P"PN-?N=I]2W9G[M?GFW_O5/M4]
MO7OW^B^1GZNI\OGBS^E?]A<:_<[3ZENS/W:_/-O_ 'JGVJ>WKW[_ $7R,_5U
M/E\\6?TK_L+C7[G:?4MV9^[7YYM_[U3[5/;U[]_HOD9^KJ?+YXL_I7_87&OW
M.T^I;LS]VOSS;_WJGVJ>WKW[_1?(S]74^7SQ9_2O^PN-?N=I]2W9G[M?GFW_
M +U3[5/;U[]_HOD9^KJ?+YXL_I7_ &%QK]SM/J6[,_=K\\V_]ZI]JGMZ]^_T
M7R,_5U/E\\6?TK_L+C7[G:?4MV9^[7YYM_[U3[5/;U[]_HOD9^KJ?+YXL_I7
@_87&OW.T^I;LS]VOSS;_ -ZI]JGMZ]^_T7R,_5U?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g752656g61j66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g61j66.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1RX4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             @P   0-          $                          0
M           $#0   @P                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   @P     4F=H=&QO;F<   0-    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (,
M     %)G:'1L;VYG   $#0    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      200    $   "@    40   >
M )?@   2)0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 40"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M:/JEB>UM>W+K]0-T >,UOK^W;6VK]+O]2NMGI5/6CDQ_S?Z@[V2S[8]IMV[
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M;<\>G6_V6N=M_FG?SO\ -K+P@ZOZCU$%H(>US R"&C[3N8QIAN_T_P!]S?\
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MQMV%F5 QZA]2UQ9)#7_1JVO]'Z5OO_F_3]+U?\%T(Z3@M #6V  0 +;= /\
MKB?]EX?A9_V];_Z42L]RKAC^Z/L<#;CAC''#Z@\V D>FY[A(<]FR;?0>QWL]
M3]+55['_ ,A)_P!B99Z?V3J1.X,:8< X[6O]DV?RO_ [%O?LK#\+/^WK?_2B
M7[*P_"S_ +>M_P#2B5GN5<,/W1]C@ XKG;6X'5-VH@R.#M^EZFS_ #E9PF8K
MVXV=B>NS=D"L"UQ.@<^BS<P[F^Z%K?LK#\+/^WK?_2BDWIF&+&V;7N<PAS=]
MECQ(^B=MCW-]J5GN5<,?W1]CF]<^J73^MYC,O*MM8^NL5 5[(@.<_P#PE=CO
MST'!^KE?1>DY[*WONMOW.,21L;(I8RIG^$;5_./:SU+7_P#6JUT22#,<^0X_
M;,CP?NO-]2S,[(RW'%R*_L+JV#[/D8MM@WM<]SW;6T-=[OT7^&_,_P"W*[,G
MK!%MES\,WD TSB9#@QQL:ZUKK6ULWUNH]3^7]IM_G5UB23$\I@9/5:'5A]F+
MC4FQK[ZL;$O#G-AC7M-OI>D^W8S9ZC:EO=,>+/M-K0X,LO+F%S7,)&RIL[;6
ML?\ 2:Y74DE/_]+O<DL_YO\ 4 ]N]K_MC"V'D'?;?7#OLS+KVL]WZ2RJI_IL
M_2+/Z,\'ZGX5@@L^T5%CFL%>YHS&%K_1K_15O?\ \&ZVK]RZ[^=6O3AXN=TZ
M[$S*FWX]M]XLJ>):X"^UWN']9JAU#$Q\/I+,;&9Z=-=U&Q@)($Y%3C]*?SG)
M*;?VMW^B/^<W^]+[6[_1'_.;_>J=ETNFK(H#8$!S@23KN]V[Z#O8@MMS@T[L
MK"<Z!MB0)GW;OTOT=OT4Z@LXBZ/VX;BW8-PVRW>R1NTKTW?G_F)G9[6SN:!'
M,O8(^C_*_EL_SUBWX#,FTVY)Z;<\D$%[7$Z#9K^FV[_3]F[9_P">T-_2,;8Z
MIC.F&GW-8QS2/:YU;GL>:[?W,?&]W^DHK0I-^+O.Z@QK#8YH;6T[7/+V!H=/
MI[7.W;=WJ?H_ZZE]L.[;Z?NXC>V9 W<;OW5C'$#JRRQW37R][S+)!]1_VBT[
M7V.]]F0&WO\ S/45!W3NDU7C'MIZ:[]&P>DVJP_H6%W\TYKWL]1O[GT__ TJ
M5;TK^I5,.U^UA@NAUC 8&V7:N^C^D9_GJ0S9+FA@)9](;V2(_>]WMY7/8=%%
ME#OLS^G-K<XES!6^L>H75W6O;^F%GN?50_\ ZS6G_8^)Z;:FLZ8VEID4@.V<
MM^DUMS6O]M;?I^Q*E7XO0_;#)&S4:GWMTGB?=Y)?:G_Z(_YS?[USIZ+@@D-J
MZ5M)W0YKC[C]/_"_1^GZ;58Q,7["US,&SI^.RPAUH:#[GAONLTN;])__ $$J
M5?B[7VMW^B/^<W^].S*+GM::R-QB9![+*]3J&I&7@F9@$.TTT&EJM8=KG.K;
M=;0^[?Q2[2(_=<YSTJ59MTTEA=>^MN'T/+KQ;Z;+76U^J',+  -Q9'Z1[/W5
M7Q/K(WK71>J/96^BS'98 1,%CFN=26VL^C=Z?\ZS=_X&@SG!E&/W#'T?O/2I
M+%ZQ@VTT,?T['QYW_K%F2YS:ZZ@"ZRX[;&?0683U08SLE^'@5UBH6MM^T%U;
MFD6O<_U#94UM=;?LGN^A^DL_2),=/6I+$Z9B69 8_+PJ*ZGL<[?7<7.W>H[T
M*_29ZM6QV)Z5OK-R_P"<_P $KG2V-KLSJF2*Z\B&-DD &G'>0W=/Y[G/20__
MT_0\'J&!5597;DU5O;?D;F.>UI'Z:WEKBJ_7L_ NZ7;53DU6V.=4&L8]KG']
M)7]%C27.6M5.LR6C@GE$0&H4X9?T?;[?L<[?;I5$Q[>RS S+B77=++MH&UK:
MPW?+2^SWMW>D[])LK_G&?H_IKKTD5/*-=8&&!TTV-8_8;#26N<?3]#UA4QCV
MN8WUO5=5^B?9_P '_-IUN2=VVOHXAT-W$&6Q.X;3^]^\NK223;RK;K!97ZE7
M2G5.L#;!66;FUS[[0;"QOMK_ #/?^D_\#L9[NFG"M;3]G-AV[&UBO<3N9]#T
M_=N71))(>;S'U/\ 3^Q6=/ VGU/5%9,D-](L@;=C??ZK57J-[+&&Q_3K6-V[
MP/1;NC:+=OL]N[Z5/_7/5_P*ZQ))3RPLN%=8;^RR[:/4-FPD.EV[^:].NQNW
M9]'TO_!/T2==?ZL-9TCTR^ Z02&;1[GSZ>[W[_H?\'_QBZE))5O*MMRR0'MZ
M.WQ<#/=OYG]7?_K].QB64VMPW65XU6:;P754>F2T V[=KJB__!;-_O71))*8
MEC'&7-!/B0JM_3J78&3AXX;0,D620)&^W<Y]CF^W=[W[OI)\O/.-:UGV>ZX.
M$[J6%\:\.3-ZB75>HW&O$/+"QS"U\-:7[VM_.;IM:DG5%?C=5R*7T7.Q7U6M
M+7MV6:@^8M66SZHT5G<S&PVO!W"QHO#PX"!8VW[1ZK;?;N]7?ZGJ?I?YQ; Z
MDXL#_L>3#A,;!(TW0YCGAVY)O4RX2W$R="9E@:= T_GO;^\DAK8/3,WIU3J<
M(8E-;WFQS6LM@N( <[W6G]U7,#&OH]=^0]C[<BWU7>FTM:/972&C>Y[O\#N0
MV=1N<0#A7M!X) [^.UQVJ=6<^RUM;L6^O=/N<UNT1^\YECTE/__4]527RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JD
ME\JI)*?JI)?*J22GZJ27RJDDI__9 #A"24T$(0      50    $!    #P!!
M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T
M*@    @ # $   ,    !! T   $!  ,    ! @P   $"  ,    #    G@$&
M  ,    !  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !
MI $;  4    !    K $H  ,    !  (   $Q  (    >    M $R  (    4
M    TH=I  0    !    Z    2  "  (  @ '+*&   G$  <LH8  "<0061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-CHP-B Q,3HR.3HT
M-@     $D   !P    0P,C(QH $  P    '__P  H ( !     $   0-H ,
M!     $   (,          8! P #     0 &   !&@ %     0   6X!&P %
M     0   78!*  #     0 "   " 0 $     0   7X" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!@$U-
M "H    (  P!   #     00-   ! 0 #     0(,   ! @ #     P   )X!
M!@ #     0 "   !$@ #     0     !%0 #     0 #   !&@ %     0
M *0!&P %     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "
M%    -*':0 $     0   .@   $@  @ "  (   #P     $   /      4%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#8Z,#8@,3$Z,CDZ
M-#8     !)    <    $,#(R,: !  ,    !__\  * "  0    !   $#: #
M  0    !   "#          & 0,  P    $ !@   1H !0    $   %N 1L
M!0    $   %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 0P"$0,!$0 "$0$#$0'_Q  ?  $
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MYRL0#%>[?Y^@/A\Y\:Q:G*2;<*4X=9R=3AXJ8_)T]KF7I3W.%-?%C_:!]RP
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M[N4QRQ.D4D3:(F*21RLJ.C ,CNJL Q -C/&H0NZQZVPASG<CTYQT.,9Z;FN
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MBN$6)@1C#2W+RA=QCEJ!V-K\YV-)KREN=0R(,M:V45>J]DXV;NY<J8=;?GF
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M\XSUZ[=.A[]\8]GW3_<PX/[I/!1;W.FUXI:)_P!&\7*KYU;7;#LP2 X9["3
M\XB8ZD^,I5U!'MDP1GS'.Y'&0#*N+#29F-G$NH52OK:B3"E$++*D0)QE2Z^\
M>8&*J42=M;^JMNLJDZ:JKLW+9PKR,I4X/W\/5XU_F9Y4>37%_)#C5[P'C5NU
MO>V4A4G?ESQ$X2YMWQ\)"XW5ATW5@&! T?/_ -<*VN_N6-W_ /"+M%U6O"J;
MNE*:4KK@WB;3,D[@,UX)R)#2T-' L88HW@00^WD1,RR*N"^?,3,(+#EQ*(V/
MEVKD>Q,-%'$D6=O1[EB.JFL,:%W%;FMO)=1-/:\6@4X>_P"#2V%LYQIBN'O+
M6=G?O9#%;L@V.&.1XUT6LRPW/#9V4D67&+>_D"]7@AM;N%HP-@&:2Y# ^ (/
M7>(D Y%[$N(M@^0L18WA,,'[R<G;$9+MCDF7I+DC+\ZB=LZE^*$8Q)E(V1GC
MR5/X%C<Q/$6Y9ZS@<$CMJ@ELTZF(V59M R'9Q'3<O<BS'*M[FZMI'$F#,]O;
MS\^.-Y#EW".-:J790YU@!NU7-9LT+0O.=4D NC"!\1'FCD36%V42:'T%P-1&
M1G#&K$"Y%F$8SR[%);MF'X[VK C^R7,&W3,TTP^D^;9+=Y.R.1Q:J-G468D@
MC@(_;C!T7ER=Y8D7#%F#TL/78"UE%5G(V99>9+QF')%GQ".P-LF=T>VO[N:4
M'#!@LUK-' YWUHH4],U6 O':<(U#5>VES++/*?BNC6*VZX'3*76N< @#4<[@
ME:S3;'R9V:<!8LY0W%Y+)N/):$W*VDA^"F;.,,HB.B[2NW\)A\27ES0!$V](
MJ^IVJ1$.P\6LDXUO'1K<HBY<EBI)C;CQ!WON&16C BX2XO93,=E"SWGG9B0I
MN(Y 06V'+D^"4<L"KP$0WZW()Y @L8FC(U,S6Z%-;9)RZG(7)[8;F2'76%YD
MY,'<!*L?8\BD%F6(TB,LY.J-\G9N%5DQ26(-8I%VSH ^+Y:Q(H,B!)2=&F%B
M4L$C81+$,>,B]I4*==RT+<(>!">\T@DO[V?2X@O>(67$6;*\R.7A\RRQ0E<D
M:)555U Y4@X#*VV-HOFMI9+G5=</@OH54CX&1+V$1!RV58-"XUXPP<=DZ2 3
MM5+:1O D/*$1W<)ER)[?\H;?<-7,(KM8"J;B,F1XU@6++@&X69Y34PREMD*Q
M3(>=99UM=ND2+9F#B(['54P(=U8O8J77F.8\V]N78I<WDD[2S#M<JVE9F\TA
M7.(UEW\ZD :1QA2 !H:TJ#D6EM&"T5ND.(G"CG7,0&+B9A\;E'_\.@ 53VB"
M3D=SR5>*=GBYO%Z*\/%2FL5Z#PWQZL[?5CU=*TKZ:M2H+[W_ .S=F/[NC"7[
MP9%TI4Z-*4TI32E0BS5\N[L<^A+=K]JF+M*5-W2E-*4TI32E8I//U#S/Z%)%
M^]#S4'H?5]^NU*\ZB_ZW5R/5?)L*Q1_ 9MJIXN?Q^+7\=_[7'_JWR*_ZQXU_
MY;A5>UP3^7E_^6/TUI77\25[HZ#U"FE332E8]+>R.YDSV(,=&W782G8XED_7
M%.WBU:VT3M;$FMZ;EBNG=P53<MU$W"-UE+T+J*TLK3NX2JMQ2S#W,5HC3H#<
MW"0O!$,'/-2X(@>(]'$I$6">8=(8U#[QL N6P<$'!SG/48(]8.?"M.$7) -A
ME9Q.P60LB/&Q1NG='!T?=JR(I8H=0M%"WHR*O#;TG&F*=Z"1Q\16+*DPC5^Y
M.-W]SA5DM]@+>&;ROABX5>>3O 8WB?-_-Q&TNN%6K+:OSKI;BX46T5Y+I=[:
M"'0L5R\0MF1 L@Y(F>.&02K)(ISI4$EO2#C)T[CKG(ZCN..$#4@AF.L,,64A
MF+3NAGI 4?>B(.6?RAF%<Q;),IJ#!Q28QE](TAH(B*&" M7D87+V1L8V4N;*
M(*J*7=\=KP_B/E#Y6RRV?![A;'@T$U@L_$K:+ADUXG$. V/GMW>\-NXK)KB\
MMY[J>Y2*\CMO/KAHTE5U05S\QUM8G42QZBXT,3J&))3VM08@!1G?) 4/C$3!
M\43+[FE1-2[X8Z5D[4X/:#X[='8_<#:V7;=53+TJW?\ :ZCOJU<KNE@RSRA_
MM<BZONCJ2B3:]7J^\Q>0'GK6<<L$?"Y+6Z+WZW,WGC+_  V@MK>&13*T9"<
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MY#I)2ELA-)@FUHGN;-#*7(N54%[%7'93Y"E$:6VUZUUR_JOT/"ND;%&SCO\
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M.#&.PN.\<B1>)\6YPDV,9&YOC\JR@^L;EQ# 0T>-!@R0'7<DONLN:I,E72Z
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MC18;&"LBD+@!<6<GN#.I.3Y!B$8)1UN[?Q6.=M&RRJQ"6-&HIUU^A<,:(,"
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MWHL223I:FG9;XK;+:4IY-3++)/*\T\DDTTC%Y)97:21W8[L\CDNS,>I8DFH
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MP*>Y7_0GA?TKO_5T\\N_SB3Z1^WU_?K7P>FTGS<27X9\Y?E*Y_:T_ I[E?\
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MO3S5_NB^.G3Y=2!C&-L'(QW$YR1Z=SOZ33]>WS>%/!YXYZ>^$WX<?W=&YO\
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M1JV4D#;'+;MMOX,Y*8^2GBJ+J&")"8/D4HK-'D72MBD9[M)(%'3)G'UHD>F
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MS(TB, VP$IARPZHFM2K+.D#I,"A!R%J)/)WC<?G',@>(681IB;N!]6M#,%C
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MG$\@M%R]JJBS563J&?[(?O+:Z7$+M=2%21;LXFB3'1)P)M!/7*ZRND]E.T@
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M:+6T7.(,U)'I632?M32Y5.8=PKI]D68!&>/WQ'(69)"B[<M J:;DDB>C4Q@
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MI&E>;R?H^;V:<*T\5::<VVU9YR#((&XP <_%WSU.1Z<4\VN<*/-I,+JTJ(I
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MN2JD[4XIUNZB^SFGUF-VBVE2&1H1U!DT'0& W9<@;;=>XFM8I2F8R3RI603
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MVP? 'BK\5/\ ;3GIS5U422][M\VGZCC?NWVJ=6PV7OVQ]_N*=Y!LN]:'M@^
M/%7XJ:G7)\LY_P"SX[=W=C/IQ4:OZJ^RG>0;+O6A[8/@#Q5^*FG,DP3S&_\
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MK!(\ "'&HLVG"/DG&F,L1J;N&L#/4:0RDTIM!VF\:T[V#;Q3A_@3QIY.-/\
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M%9WSI).G<C [MCW=/K]'2K<L@X+$; ]>[V=:=Z%M-];!MXYNG])3&O3T\_\
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MO$X!U7)MN5;<.(F)6WM^'K);<1?S<2R1K'*&5T<25S(R#AJ2YRUEPZTND U
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M7$9C$AE(: AG4(&>+ O FMN%"12HN9+)+O4"K+YT80^%P>7IYC*A!D#!1(2
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MCQJ]_C%0O8!?.8\O2O9JDL?"2X:M:U9M%[J<-9V9TR<3F8ZXYX8([8]0LD;
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MT<:<U:]'BY_9T^"_)?\ B_=4X]+>C?N/S;??&33ZW-Q\?&OB\?N\W-I\%O\
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MM:]52E*=-.IXW<W#C7C2E/T/L5Z>;A7Q::8U)62-5*@,Q#ZPH*ECJ("[@#8
M=H'/0$T*A<ZC(%(8Q'&6<*<=I<]@XZY)P=CXTZOA6G&VE+>%.->-:UI6M:6T
MI6E.>E*]5T\:4IU//PY^%1RCH)C5$=7D#DMM&KQQ@$:<"0NY5XP6*$#=M8TV
MT 8+.Z]G<=2KDX7(R/@V&&678Z=1T +VJ4OK6O#J:5X5K3CQKPK2G/3A7A_7
M?UM+J?H:4XUX775I6FH1HFT@Q:6*R,ZEAJAT,B\M\94.HDC+C/9,B :U)=7*
M.2 S8499BVD')( 7/QCNNI3I*G6I&J)A7TKQ\E.;Z_L\*^UQIT>YJ?@_R8]I
MV^_IS\_?F!OC+CPR3O[1X??K5>'&G'A3TUZ.CQ=/#R=%.?W=3\%^2'JU?NS3
M Z:F]&Y)_1Z^O3%.'-XO:Z:>ST>+CPKQKQZ/)P'E=T7M)^_U_O8WW+9/3M'&
M_P WC@8QMG/C2E*\_-QX>SP\7II];CZ.;4?!_D@/^U^[[^-3@#&689\3^[].
M*I3CY.CGZ/K?6Y_)PKZ=#R_R0'7\;/ZN[ZZ8'RFW_K??'7T=0*K2E>'BY^CR
M^.G\?#TT]C3X+\D!_P!K]U1@>+[==_OTV\>OKJE>;C7FYN->'"O"OCZ/L='I
MU(Y60.7\^=_7]\]:D#8$%^[H>GS]^/\ GBKCCJWCE5S7R8_<<.'-_P (V'3P
MKP\=>;7!=* 0P&-1.W7'3H3O7N<%);FL68X.,$D_?[],U);7'7OTTI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E0BS5\N[L<^A+=K]
MJF+M*5-W2E=:O*D1KE%IEMU:Q/DU9'C^'YHD$M0&2N73D@R%.(]C=P /=M'L
M+($AIA@REMQRV/MFCU86Y69,5R#IC5L^2;NT.:1)'EC761 0_-520S[*$&>J
MA3J)(())7PK:)HECE++F8<LP$C*+ACS RX(;4N  =AOD'85Y_MENPGEN=D#\
MW-H%M!Y-;)F>)BLZ=S[<QG#,.:LC9UFSQ\I<J\6(3%_-F]@ANZK6VCD?%QX-
MD\HFBH_1=N$Z+U[1)RXN1 BV\&%#0P#2KE3G+L<NV3VM+,8PQ)5!7,ZF24S2
ML9I0Q*/*=10$:0J  *H5>R#@OIRNK!KUNX@=91?8PQ\]S.,C 7++J(@5\E!X
M6L[>1 ;.51S>^2L8P[?N'1!P!9E[G:(I=XY7=*L4T5'"RBEUU]:R! Y$?Q,#
M&<9#8!)ST.^1T[^_K5(3*8U,NTFI]6W4:F"8'=A=/CD#N%9%._U#3+Z$Y%^\
M[S5#TWW..[U5M75QL)^4DY.?_%O[2?13Y$D*\GW/]6NVU_&^_A7@\9_X7H'S
M_C=Y_7Z?74S:^+Q<WIX<*TX4^/E\O1KLKPQW]^_Z#D^C/A\W2J5K7GIPYN/-
MS^3CS5X>7RTKXO+74*=1.V .K=?OF@W.>X AFQW[>(\?'IGPZTXU]CFX<W'Q
M?9X^/CJVDG)7M*.K#N[SM]N*@$$K\DY)8]WH]'@,=^-_%QNKSUMYN/#CY>'1
M7V_'3C3F]K3 .-)R"0,],$YQGV;FIP0#CM#!.01L,@#8]-3'"C?OJM.CGIZ:
MTXUYN;V*5Y^;Q>2GCU&W=N" ?#J,]*'(V.S?%.-]P=]^AQN,]^Y&PJE:\.GQ
M\.'1TUK2G-[?-S\U./"NK CHQT@[KWYQM\V_7QQ4A'8C0NK<+L<$!I(XP#G?
MXTB8.W7/K_%;Z4K7FX_H:\*\>FOCIT<W^]Y^CG]&B$I(CXP0C C.[,3E%\,E
M<GU#?KM7K^-D,FO3I[QL5SUSC2V>O; QMFNL*7[=YI;NPGF2#>VN [B@N1IM
MA*1X]RK*9=& Q/;H(QP("CS@Q-N>9$):UHR.CBL[B3;&S DWDT@D+T?++X^C
MUXNXQM0Z8C94C,,E[<2\01,O/!.A$&D!U(GA/P00MI,05M0.0/2FDCEMR8YC
MH>P2U-@^Z--YT)W#'&E8I(V4-.%YJNI13C:HZ2#;!OPGUV2HW,CTN=@#DMBQ
M,^[+9G'R$#.2P+>7BC)L!G&"XTZ=51P4)Q?M^C$M"'HSVMCKF2RI4-UD5+28
MVLM-90QGD\'$_-$5MQ'@TMPI<M($MN>>(70E&D21R"2%4@6./04YB:#73-/:
MQM>F%%#7-GQ2.T90J)'#<P)%:VL\9U-)+%,K.[L^7B<JY*D 7:48 Y1!DS!@
M(Q.,GEFL?DV=A6+S=^X>Q@^A5SK<$6+X2R+G1T0?.B^=H.RP/VI K0H^XF!Q
M)]8HD>C+HR^K)(ZMDOD\TN+AD6\B@M%EE(U0B."2[-ZCQ*1S))[<VS)(&219
M$.6!9FK6\GX29)EME9;:9V$UL/CN[VELL*V\Q!\WC2Z-P91AAR2ICQH"'947
MVHYW8Y9VS9>GAK+D[D$.W&;EY-D!%WN!D:H&*X\G2>0 V)G@>&/)LE%5HH*
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MMC8=/IUYMW\5/[1_57M<#^+-_:^RI*:XZ^@KY**T3IQNIS<>%.?IK70#-1G
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M'#C=6OW>-=3A3U?.0R%@#J*G)Z_*8GMGO 7;:H5F144-C1E1OL$8DE?'&O)
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M#-J+99LY<MC#.[?C,Q[^X8'3-?7:3L)VT;*&TX3P)C&%1 CD&8S*5'Y()@D
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M4O.,\9O9K[B%],99YYF)._1(UZ1Q(N$BB3"QH J["HF;NOED^3#_ '7>3?\
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MMUOWXA9 A0UN99]4MHR='M-/P\2%O@;@?!@(6)YK5S";&1L":WB2&[<:F:[
M@,9F))[,XR8>9@F6W=Q+EBK+;,B\FCC;))[/&4B\7P_3<)+,OQK+6#,W$L:@
M)-+\=.X5CC&L:C<<D;\P)J0/0Y:20PXY.1"UZL&>!I(NJVM:';4GS2B2FV,,
MMDJ)/#>SW<G-+M%=B0J&A=8Y$,2S1L\;N.8\/P<L1,\<<J1$J,(H[AF$*V$%
MDPA RFAIW:6)6&@2Q.\+1,1HDY?+FC: M"=R33 ^;,H91QP>G3[!*42@4TA&
M2Q,J!120W9JB)&-(A7QW&42DCM5(?6'2^0LBZ!Z8*7BB92!&WT*(0I=9Q=(4
MYCY<<[/KF,86_2)HN5;RNEU#Q&U@6X,:".1HH>(<YF$?+>X@A(A55DYN7POF
MPC^",K-87$IE0S1"[MKNQO)Y8$=M<2RRV2E,N\H_XLLQ9F&K\0[7-R8Z"81P
MAE>3X4:8?P;)(9)V[C'M)R9G61'&-R]Q^%C35TD8@ 40'IR%L&-'%!J<D<D+
M1E [2H]%PN^OH0LRP2SC3=VEF(+9H1B-9CP]K R-VPVE8IKH(N3B2?FL69<'
M25F7S^&U)%MQ&^GN9A*0SI'->QW95!H*"<:.6)QI*0EH4 #!EYN-,4[]<68!
M]1&*%]K8PA#\=UA^,<A5*9,*/T3#=\U0'G))&R$)[46VHAE"3OL5NL5;4.)#
M4UVCT9V4G6)FEN(\L[12GDK(L6&66$*!+"7?XO0HLN@DH[_!@G-;.\7G<\J)
MKAFEN9@'VD1Y)':,J>UV>T&D3.'9!G!WK=&"<+9"C^%IMBW+;6!"B<OI)FY2
M4XSE,ODTAE;N7A[V$AG,QDLSCL?(NIV0=+*K=D-F5PUBT;#!PM$>(&L!+.MV
MJ3V\<$*\F.*-UBC4Z4C.L/&JMNQUDEIG/;;XO1\CGM]<<ZSR-K=9X9A)DA@(
MB&$:@8"HI'8 )P#Z *AUB[DZ)UC_ !Y.H.DK@(*4E>)Q&WM2<1L/DLP8,8W(
M$!C?(4R+",@R25 0TJ*QQA6^-P ,S=1 7*JI%2<@*C$&P5M,@%U:FVG!A6=D
M-REM(P*I$"#'!,=$D;RDAN>%!@4\M$D[+C2-W@NC=(P>2'SB6TY@!7SB<,JM
M,@&EHXD=LJI$K,1IEBPVOYLMINY"%'H_AO'A#%JL"";5YKM[0R/-X>>>VIXT
M-Y#L3C5+THZJ$8.\JA(A5-21"%+4H].R3.DB=DP:BRC6RH!OWXP+MFC?B2\#
MM[N:W[&>3!QFU22W0X6.)8&A1X\XB>8R('$(CELC1626I@5I!#<\0FBCG8D+
M)>3V,ZEI5)=F#1W.9 J%$,:*&<\Y-C2_D_'9;$,TQZ)D,9).J[@L=YNA366T
ME"8.2L,>89QCB"R)Y/(1-\"DR+@Z.A!9;NBC3Y=<"\=@#"3$Q08X!N=7G:26
MPN>5%)YK<^4%PUO)V4N/?SB7&KJ5BVE^7)$O$T*DI(LBP+#*"C%SG"HAAO+4
MNP2XMN&6T;KG5 O#%X<ZXCR%:.:>S=>6&401&-HOA%0Q8 =Y/#(;?'T)#XQ>
MX?Q9D5@0R02?Y"QS)-QN.I%CDAD,P*+=DPV21C)7;3*X<74**OD,)R\VK%\B
M&AZ)H@A'6BJT?K<,HGMRSNT45O CL53,\D5Y=WSI/ [2131+)='S5G)>VDYL
M[^</,VDITBX;2-4UU)*L+$M''&UK;V:LDJ\J:-W2 -<K$R+,I2 &..!2^43;
M8SF.1Y#R>:CN1(E!HQD6%9,"RFZ,R7,[-OEDS/,8&(.T<9.PL^EA;!XTZQD+
M\=,"^5(7'V4S,J!41=@T>U>N[KJQL#SB[L@:37'#& T0(O8[M5920%4*KATC
MQ'))(9=$8 2H?#-#V=:HZ2=ML21E86@=$=% =64J8V=!)$F8BTIS*VW;MHDA
MJV-(WR$#_1?=CCS<(M>U2?)NKH]#<48[QV^!6+7-K?Z8'J\,=N&*]]W8*31T
MRL6<67IJIT37!,6D)RV:/C<4A0Z^9'Q:YDEY;Z@NJ-8Y-$B'&O?N)-:6X9;F
MYG+B9I;;A\*"0:%5[".!5D"KJW+1-IQO'K+*=1VC[L>B&XA7,,"5R1CM>%XR
MVV[82VW"(%#N/'V/91)G"DBQ4J*=%$',D/@RCRV/8ZKVVICMP9QN/(W*N(S,
MSZ1SL %T1R<V*]N93IDG%NAC!R%$!490E00I4 B/XL9.E21O7)-&L<EK;PZW
M2*2ZEYK_ ,H[7.IF:4ZFR^MP-0TJ5 (5>A[>.FE*^7_5KC&"!X!0-_0N#]_T
M'-=!&"?63[3G]=-,_OQZ>FV=OG&V>O4U%1VW??*F;H?W.V;/X-9-J?OT/W_?
MMZE?K'/R><^?0CMH_@D2Z-#]^OW]OKI4A]#_ & ^^^3C&,]/G.W=]52#CUYV
M.^VQW&._I\V:ZY2^Q7M;D?(VXO&3N#P[<V8SU3*<6R38%615DV.W$&@,'D&#
M,MD636AD[ Y,+BI*MC1*\BC$S]\<FX-JH="*-W=X)# ;71J5%FN3>PJ>Q<PR
ML'C0MU62,_"1OCL/TU*=J2ISN>)69^9%9+;N2>9:RVR,KO&>ACE#:)8SM-'L
MVG?/&-<G]$\ERN-.,ZQ?$>7L?"LX;D\NDX%.8DUF@9>N:&+5O%[&@Z3!W0VP
M[%EDW"BY2K=!5OUVU44M17CPQMXXHXTBEC!Y7![GAD#Q#3)!SN.S<466%ACD
MD0R+"Q4,3J=-E[5;O*\CR/KT:N(PW930'CEAAX0MCR7!8:0]RJS$ L%T"3+$
MF,\J*;4\P8>Q!7 6+*[;Y7AH!*I.SAN/,MP BJ&4Q5(7 PW'PDF[FV=K5Y)<
M9G*FQXT@L**]W\>[1N)._%RML0D#VS%YULENRLCQVDEI=7!743I:+S>2*$LJ
MAA;\^WE7F1B25A>ZA-(57,"*.2>2&/29I6ERLC1G,L/+G PK:,S'GP,.U @-
MJI:'EB*WP7;5NIP.6L'85F&#3L??X-P7B<E+\J-\@5DXHUB$/*PJLF&0V-IW
M"BXQW9(TW@Z//IP,42L:6BUC%B5*/KKM))+%=12,5>>]GOEN\B2YYTW"^&\-
M#SLRA9YPE@=<SCX>6:6X9$+K%'"XC:VE159[>*:,1G*0JCWG$;I+:!1J,5JJ
M7_(1 /@HXH574(EJZ0K;AN&V\RH7;@-[AB70FS">$\4&'67S4Z!3!9_B=Y/5
MB$D02AT8-B'"LG[MU7ZZ*SAM1N_252LI1O?;?2T;CFW6K,=M<<02[6.(Y>WA
M'#^'\/\ -TD8]LPIP^,Q2ME@&T'X@:DN95AE?>[2.=Y"<B*2[GO[N\DDP"#R
MYVN3*Z]DK(S*FR(YRS%^*MU#+<7(\J9F<8(F,;?.Y2#A9(,;G])7B_&+J^YR
M"B<,BS^)-(PV*G7S(*]R5)W9UR:DSALDCV=4("C0$?2T(ABD1MI981%-<(-3
M2\MV>)%#OF"WC+L1 KOF0\^9II7=C-UB612C,T*#,5O)@)&Y^/(V@ 33N53,
MQ50J 1Q1QHH6KU+ML9^1/\P/FQV/ME,D[HMLN=V*JJ#[K[*/8*7P J6 O[K$
M;J*%2=,1'*!;T*W,T:FF/92R-*O>HS@58[>&V9=DO>)7#3(<3&*_B>( 9V.G
M5EU; )R-6C"5:=VDEN958+SN&V5DB%28U>UN8YVD*Y_&"NH*D'M Y! J,#[8
M#F0WBX?A0WD/%M\$Q+AK*6(L)E!L=D[:6R)ODAF)$-BN6EG3UZ/9W1\$+[$)
MMHPD3I,SZUDJ<*@*MD@=VRR9>.XGB1IUM.'V#1ID6_(L)K67FJ,=F606D?P8
M4(&)(;9 MS)HN8WA9A E[/?]LEY>9,MV.3N0"FJ[<M*3JT!8PH!<M+<AM6$R
MK*&4IK+I-.AX68E<4G(XQQ3F',N%334ACN)%8TY;RLKB.9P5U* 3^I"Q9.-&
MWAJ.K]826?"KG+=!2S.-I(D=QAY??.\XBD+CX%S<VO#H-$K'46D5[$L9C&V8
MWY90AFQBW:CMX2,K#96=H90Q28""2\DE:-P,I(QN$Y<FY4J6&"JU%K&&P2<8
M?R')IK$JX-(DPKW.4GQ7-Y,WRT4FK^4Y><2YP);ST2[E[N#!A<22F+\6=)1
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M:3\49#%A\);OQ948^;H/1Y!DX0=LW:*3ANLFLG9?12IIZ4II2FE*Z_-S</S
M+W';:<W8=QBCEGN#!9R#3"']WD<@#KJ)F#@[((>8OY(E>.>*-%13AH10ZNCE
M5O>PZW2ZUM6FO*TV\'$)#J9);V$NXP"C+:\L-,$[3&1!*@.$^$"1AB-"ZIP?
MOZSO[>\^BLF]7K>+ZPQ_7_E,X<]WAU''7IZAW;X]&_ZJBJ^KSO%]860^J8PY
M]YJU*>KSO%]860^J8PY]YI2GJ\[Q?6%D/JF,.?>:4JS2/,V\DU'CP='8@]15
M+!B@Q)93<OAZJ:2C]BNUL44I9;2_J$[E:7W]3^BZFE:4X5YZ*5&[$VTG=7A;
M'.S(?$@6$Y3(\-;!<&;7<EB9AD^7PYNRF^- 4;0+$8P2CV*)\D?"+OF#]LBN
M[1"K];207M0OM<76I0?G^;;Z\_?]"MW=R^^CS1;7?JD,G_FP<=1COW]6WU;_
M *2>\8I3N7WT>:+:[7_E(9/^[M@U 7?/:'CDC?T;=/LVI3N6WT>:+:[]4AD_
M\V#X^QPU._IW_L_7\WW/2E4[E]]'/^E%M>^J0R?^;!S?'R:G'K'7P\0?3\WH
MVI5>Y??1YHMKOU2&3_S7]1CT-[1GKXY]'W-*IW+[Z/-%M>^J0R=^;!IC;O/3
MK@D>W;Y^OLI5>Y;?1YH]KOU2&3_S7]/I'T]G[?OTZ;4IW+;Z/-'M=^J0R?\
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M:D)U,<* "<#2I7&H #9BJY))T+TJ@32V%.F-0 %  UL-VE95&E&D8DE5+ #
MU'>I&ZSR? _5]M7IJ:4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
..I32E-*4TI32E-*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g752656g73c07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g73c07.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1M<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #W    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    * $$ 9 !O &( 90 @ %  1 !&       /<')I;G10<F]O9E-E='5P
M3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U
M<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU9
M2P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N
M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MP     $  @/      0 ".$))300F       .             #^    X0DE-
M _(       H  /_______P  .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              8H   (Q          $
M 0             ",0   8H                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   8H     4F=H=&QO;F<   (Q    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      0M@    $   "@    <
M >   -(    0F@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ < "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M D 24PW3+G-8/W8W'YNE D#=(!.P2%Q/.JK96!3D@$$U7-UKOK.U[#_)</\
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MZO7]5L;?B5NN=6W:]K!, '_:N8ZA1M(#) : T$&-!\%[#]OQJL>W+O=Z&/C
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M>!^XH)623[7>!^XI;7>!^XI*623[7>!^XI;7>!^XI*?_V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %^34T *@    @ # $   ,    ! E4   $!  ,    ! :8   $"
M  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !  ,
M  $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (    >
M    M $R  (    4    TH=I  0    !    Z    2  "  (  @ &:XX   G
M$  9KC@  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP
M-CHP-B Q,SHU-#HT-0     $D   !P    0P,C(QH $  P    '__P  H (
M!     $   (QH , !     $   &*          8! P #     0 &   !&@ %
M     0   6X!&P %     0   78!*  #     0 "   " 0 $     0   7X"
M @ $     0              2     $   !(     3A"24T#_0      "
M        _^$!@$U- "H    (  P!   #     0)5   ! 0 #     0&F   !
M @ #     P   )X!!@ #     0 "   !$@ #     0     !%0 #     0 #
M   !&@ %     0   *0!&P %     0   *P!*  #     0 "   !,0 "
M'@   +0!,@ "    %    -*':0 $     0   .@   $@  @ "  (   #P
M  $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ
M,#8Z,#8@,3,Z-30Z-#4     !)    <    $,#(R,: !  ,    !__\  * "
M  0    !   ",: #  0    !   !B@         & 0,  P    $ !@   1H
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M;3E3^\Z)>XJ=/4JEU"FPZA;5=J,&?#DSVZ=4X-7PPL2^0L]LW&KV^Y?8!5K
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MQ*4O_P"[/S/N\::O M8L-N8BF&HS?F]CUSLUKE[N;;PAHSDD:OR/A:V8O<Y
MY0AJ3KOD,L_;6A#0#<N?#\6_@=(0TW]7R\?#S#7:$-4D @AK'/H_T\&L=+PC
M;T@]0/O)6<J2KWDJ^1!SQ\M4A+.$J(<W# _*1^TN_P K>/B\22""Z>(J20LK
M)6%EW2HA1("DY)*0&C1* D  DA)!2%85T\8(!(/NGX?#CL -1W?#P_,P2OC+
M,.(J)<*-G23XYAHDJ!"!P_++_P#6%*4H(L'">(DLI0*BE^%R0S-&GEI P D
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M"&I-_J^GEKEX9N\(:C^'\CSMIJ?J80_+/;UQJ#EE^TY:;^\GVT@Y%QG'A?\
M^(5\4=Z;E>(O_D]2JG-9VYVEBMTUBD,/+1"FW1*;]HK-9?0A6'7E!R/3XZUE
M198BX0$E14KFL1J%+F< 40QR>WV!(?TU81V.#4XD2A/X053,\MAZ7MKF.4=
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MA*1T*3P5$\%0(YP22!VPD#7$"44K6M24$3%]ZE02.))6'*26S 8DC4G./7X
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M.JJDD$*P(,-;:T]EH>4A7!UC5*B$$"P(/F+?QX6YY-(GBG#8 GDX:WOZ1?\
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M]1F;78,3=HR7I'B(VAJ+:5FY8T9:N?)G-2HCH Y(6EQGN,9//T[8T@ <^5K
MY[$W\]SK\T1#O+XRJ;8,ZG4BQZ-#KCLJ,W-=JC[BTQ4MO%24(BMA 4\O]7UK
M6X0D< #CETAPOF?>ESXBP'J8L%YF@^*Z$E=QHET&YT1%,TRI0W%.16U)R6VW
MXBO<<:"U85TX44GCE.0>_P#-_+I$V2+9<RWD_P">CQAS)VEK5H714J!4VO\
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M] 0!PF)_IC^F.)U!JL3[!=D:^LGCOZBKJ>S.%3JJ:0$CO)LPT2IDX\-ES"2
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M0O\ ZA;%RW8TT0<Y)937$H /)QT]([8P,#3_ /P;LK,4"<&D\:QQD.4F[W*
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MS(EEA\RI'"O@*@2@*^0@1+6<Y/2$<X"/@!^0Q_J>=;*6>,@L4D?*$Y?*V?\
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MS\+Z[1TN?:V^#"I[Z6Q3-V+/I9JE;M&DNTVY*=&:+DR31&''946H1VTCJ>5
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M_-K(:@[,;9'^2&#;W\X0U/B_/Z>;^[0AJ.ASTNV9.EQK](1IGG &3@'&?0G
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M2[KFTR [22$@+7)0P"2D\9<!95G%"VUW$K6TTY=Q6 &[OVZK[ZJA<5C09;9
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/#2$-(0TA#2$-(0TA'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g752656g77y86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g77y86.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1K84&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             G8   2@          $                          0
M           $H    G8                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   G8     4F=H=&QO;F<   2@    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   )V
M     %)G:'1L;VYG   $H     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      08@    $   "@    50   >
M )]@   01@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 50"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M!W;A^>RKZ.Q$%!B1?AXJN.:+F>@*C3_A=Y<'<CZ&UKF_1W)L&?0,\^I;,?\
M&6*&8,5M]%E]SZGD[:FM>YK2XD'WM9['?]<2PKJ&4EIL:(LM^D[7^<L_>]R*
MUMJIDXMSKV96,]K+F#8YKQ+7L.NPD?I&>[WMVH_VG'_TK/\ ."7VG'_TK/\
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M-IG]+[2S3MOK>_W)J_L+WMI%&T@%S&OJ+1#=C3MW-_XM6*Z:J@6U,;6"9(:
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M?]+\U+]<];TOM#-VW=_,NB)V_P YZGI_V/II*;B2IO\ MC+*V'(9-A($4N/
M+]7-LVL^C^>GM^VU-#G9#(+FMTI<[5S@P?0L_E?3_,24VT+[-5! W &= ]P&
MOP<@VC-KK?8;V0P$Z4N<=!^XRW>[^RG8W-L8U[;V;7 .$U$&#K]%UGM2H*IC
M90S[=1J_^;M_/?XU?RE996UA)!=KS+B[_JRY5*69.0&9+;VR YK2:7-Y,/\
MT;[=W^#1<=][WO:ZT.])Q:\>DYG:?:Y[O=S]-GL2TTT53__4]527RJDDI^JD
ME\JI)*?JBS=Z;MLAT';$3/\ :]JHX3>IBUGVFU[F;?>'5U-!/QINL=O_ .@O
MF5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224_52S:V]5^T NML]+U#
M(-=,;)T:7-NW_1^@_9ZG[Z^9TDE/U4DOE5))3]5)+Y5224__V3A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      %^34T *@    @ # $   ,    !!,H   $!  ,    ! H8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ '*;.
M   G$  <ILX  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HP-CHP-B Q,3HQ-3HQ-      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   2@H , !     $   )V          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
M 7X" @ $     0              2     $   !(     3A"24T#_0
M"           _^$!@$U- "H    (  P!   #     03*   ! 0 #     0*&
M   ! @ #     P   )X!!@ #     0 "   !$@ #     0     !%0 #
M 0 #   !&@ %     0   *0!&P %     0   *P!*  #     0 "   !,0 "
M    '@   +0!,@ "    %    -*':0 $     0   .@   $@  @ "  (   #
MP     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,3DZ,#8Z,#8@,3$Z,34Z,30     !)    <    $,#(R,: !  ,    !__\
M * "  0    !   $H* #  0    !   "=@         & 0,  P    $ !@
M 1H !0    $   %N 1L !0    $   %V 2@  P    $  @   @$ !     $
M  %^ @( !     $              \     !   #P     '_X4(2:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@
M:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL
M;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E
M(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @
M(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R
M9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @
M('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C
M(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HQ,4)!-C5%
M,S%$.#A%.3$Q03 Q.3DW-#DR040Y-3)"13PO>&UP34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HQ-$)!-C5%,S%$
M.#A%.3$Q03 Q.3DW-#DR040Y-3)"13PO>&UP34TZ26YS=&%N8V5)1#X*(" @
M(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#Y",C4Q-3@R-C,T0S4P
M,#(U.3<W1#A!,C!%140Y,S%$-SPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,3!"038U13,Q1#@X13DQ,4$P,3DY-S0Y,D%$.34R
M0D4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,3DM,#8M,#94,3$Z,30Z,S8K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@
M:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYC;VYV97)T960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N
M+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$Q0D$V-44S,40X.$4Y
M,3%!,#$Y.3<T.3)!1#DU,D)%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 V+3 V5#$Q.C$T.C,V*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,3-"038U13,Q1#@X13DQ,4$P,3DY-S0Y,D%$.34R
M0D4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,3DM,#8M,#94,3$Z,34Z,30K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@
M87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$T0D$V-44S,40X.$4Y
M,3%!,#$Y.3<T.3)!1#DU,D)%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 V+3 V5#$Q.C$U.C$T*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C$S0D$V-44S,40X.$4Y,3%!,#$Y.3<T.3)!1#DU,D)%/"]S
M=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)
M1#YX;7 N9&ED.C$Q0D$V-44S,40X.$4Y,3%!,#$Y.3<T.3)!1#DU,D)%/"]S
M=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/D(R-3$U.#(V,S1#-3 P,C4Y-S=$.$$R,$5%1#DS,40W/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R
M:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @
M(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H
M;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @
M(#QP:&]T;W-H;W Z1&]C=6UE;G1!;F-E<W1O<G,^"B @(" @(" @(" @(#QR
M9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI/GAM<"YD:60Z,3%"038U
M13,Q1#@X13DQ,4$P,3DY-S0Y,D%$.34R0D4\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+W!H;W1O<VAO<#I$;V-U;65N=$%N
M8V5S=&]R<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#$Y+3 V+3 V5#$Q.C Q.C$X*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3DM,#8M
M,#94,3$Z,34Z,30K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#$Y+3 V+3 V5#$Q.C$U.C$T*S U.C,P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 4("70,!
M$0 "$0$#$0'_Q  >  $  00# 0$             " $"!@<#! 4)"O_$ '$0
M   & 0," @0'!PL+#0T%"0$" P0%!@< "!$2(1,Q%!5!40D6%R)A<9$86(&7
MH=?P(R0R59BQP='5UN$G-38W0E=W>)*W\1DE1U)35F)TA[.XTM0F*#,X0T94
M9W*"EJ6V1764E<8T1&6$A:2UQ,7_Q  < 0$  P$! 0$!             0(#
M! 4&!PC_Q !H$0 " 0,# 04$!08&#0<&" \! @, !!$%$B$Q!A,B05$487&!
M(S*1H? '%4)2L=$6,V+!X?$7)"5#5%56<I25EM35-%."DI/2TR8U8W2BUC=$
M149V@[*TM2<V5V5F<W6%AY>FPL7$_]H # ,!  (1 Q$ /P#]_&E*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*AGO&WLXXV716*7M[HV7LE3&;,FM,2XZI.%*?
M'W:YSUS=UZ<LR+1*'D+!6DS-QC*](&\1-\LOXX()IM3E,8Z>8<M<Q6T:.\DD
M5S*2I 6..VC625GRP& CY& 3C)/ XEEVV\]T[ 10M"C#!)+SOW<:J #DLW')
M&/LJ(<S\-;M7957!E@I^-]S^6+%G^VYHH%7Q/B[#(S.7ZS>=O9(I7+-0O%#E
M[+ /X*<JB<NW</&S-:634;).7B:HM4@6-7([P11G>K:<-462(CN?8N^%NS!M
MW#)-X#PH)Z$Y7-C&RB7O,1R17:V;1MG<)WC>91TQC8A8D<CCWD;:QY\)YC+*
M>;28)H> =V%@G89;&,;E:V-L312-(P+:<LUMM:ZW3<Q.75S2L]>L$?&/&P6T
M\+5;)!55XH9"8FFW@.3H]"H&[XB2,PQ320K<(P,4S1A2W=9 8CQCJ <^@K!V
M9%A+(V^>%9EB.-PB9G57/D-Q5NN.!Z\5*2\;BZ_C_-M-PY/UN<:LK5C7(649
M'*3J1I\;CJFPV.E8=*59VAW*V5A/M73I.8(\0>,X!]#M&C5PM*2;$..,0ZYN
M]V%]D@BN&]7664Q C /.02<XX'KUNP*^S8RWM-Q)" .2K1PF4\>8P,<9.?=S
M6Q*5EW%F1WMAC,?9(H-YE*>[0CK?&TVX5ZSOZG(N4S+-XZR-(20>N()ZX134
M50:2J;1=5-,YR)B4HCK3:>2%.U6:/=CHR'!4^F.,C/&1\:J''AR1N9%8+ZAN
M01QG'7!Z<?.O&?9\PPUNK[%Y<K8U<Y58QCR57Q:A>ZJID4K%FR._6<FI02OQ
MC*V*T(*YES1H) CPJ)P3Y-KEGN%BM[BX7QK;07$[$=![/&'921C& 1G/K@]1
M6RQDR11L-K3.D:9'U@^<'X=?CBH)[7/A3<9;J;YM]H=5QI?*T]W"84S3FNON
MY]S7U&<%#X7RZMB&7AIDD>]765DYF5;JR\8HR!5HE'>&FZ43='%,O9' \BRR
M!E'L^GZ7J##.!(NK=\(5 V\M$8&W'(P&!QG K%GV 9'#7]Y8+Z]Y9(DCG'ZK
M)("/3SJ>4MG+"]<M,=2)[+6,8.[34Z2LQ-.EK[5(RTRMD48L)(E?CJ^]E$)9
M].#&RL9(%BFK19\9A(L'94!;NVZBF,9,C;(AOEVEF Y($9 D)VY!$;-M)\CP
M<59LJNYN%!"@XX\6=H].<$_CGRG>X_ 36>MM25S3B=2X4&&D['=:<AD6H+VZ
MJ0<&W,\EI:Q5I*7-,PT?'-B^*[=R+)LW;E$!54+R'-'=>XDG!WPPJ9"X\0)C
M.=H(]",?'&*L%;O8H\>.=@D0QRVX'IGKD#/PYJ.F,/A$,$YV8;9K'@U&?RI2
M=S<]<:_#V^ 4K+)MCEW3*Y(V5V7)4%/6.)M<*YD4X\6K",C8.6D^I=L]>,VL
M<X;.5] C=^D)RHDL9;U&YPJQ=RQ7(!Z]^H))"C!#'S%"P$<DG![J[BLW7//>
M3=Y@^F/HF(SCCG/K)>(S_@N=-=D8+,^*9I7&QSI9&)%9$I\BIC]1,RB9R78C
M&75-5%$UDU$C$G08G*9)0I@ R9P"BD-$)58%9 @$G!#ER4CP5\#98J!@YY&0
M!BK'PR=V0=Q8@+R#X0"PP>>-V.G'%:=S7OWVDX%Q;<\R7G.%">4;'MJ@Z/<'
M5,LL+=).#N%BE&T3'5I]#UR0?2"$X"CL';N)41(_9Q;9[*.&Q&31PLG7O #:
M \^VS+%;D^%<MXM[$XV1(A4O*>(]R@_6YG:Q[[ _Y/$TTJ]3M"DA5 Y:1L$(
M@&6/ Y%;G:9[PB\L51I[?+^+%K=D"')8*)4T,@U-6S72#.BJX"9JD$26&4L4
M5X"#A8)"(:O&@I(+'!;I2.(=!1DEFA9"KP'$BG(:/C(#J>49AX@#RRD-62NK
M1QR@J4F7<C Y#>NTCZV/JDCHW%;=TK2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*\]^](Q:.W1B"8K9%=<Y0$.3 BF*@@
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MLG9JM5H5F^NAP0.@_@&BXIIGJA9K6RNB&3VZ0PK&OCE6;QE(957+@-"O?=X
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M.VTRX>22&-CRW?J\HR_/ '0 #"U#6\5G;*V^&SL-1M%D(^DD>\M$M(9&;/\
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M-*4TI32E4$ 'S !^L-*8ITE]P?8&E*<![@^P-,?NI3@/<'V:4IP'N#[-*4X
M>P@ A[N TI3@ \@ /P:8_'W?LI7G-(:'8/).18Q,:RD)M9!Q,OFC%JV>2[AJ
MV39MEY-TBD1=^LW:(HM4%79U3I-DDT$S%2(4H.@P.!DG'EEN6./5O,]3YT/)
M!/) "@GJ%7.%!]!DX'09.*]'@/<'V:8I3I+_ +4/L#V>6E/ZZ=)?/@.?J#Z]
M*4X#W!]GX/WM,??UIBG >X/=IC\?=^RE5TI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E. 'V:4JG >X/LTI5>-*50"@'<
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MS/9BF,;QGKJ-QFSDFXFW2ML>5QS14657G7<; EQ8RGE;!-9.B)E<9$\/,1:
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M%8R"*_Z@H9L4$C-F9TP_6R8A]%[(@EBF$TR+$@00+(ZPD+]7,2L(CM' &SC
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M4II2FE*:4II2FE*:4II2J" #Y@ _6'.GO\_7\?"E4Z"?[0O^2'L\O9[-  .
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M7G_P8[&]?[(MF3C&?X.:UD>H_B_=^ZJ!E[<"4 *7:380 !$0XR[BT Y$1$1
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M*BB_*D[8(=-,0)!+W<YTX30G/UHQ%<7$D9'U>Y5#T%2_A-P=7L=QR!1&-8R
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M1%K'<2O&;G2;SV4LZ*'ETZ8[CD"IDH%2,3J H")3&+U<<=P[<@'L_P!.OJ$
M R.<G.?7///O\OW=!^-'GKY'IZ'X>5=@2%$>1*'/ES]'''[VK5&!UQ^#5!33
M-YD+]G'EY>7N]GNU  !SY_$^?6I_H^XY'W@&M&QT>PI67!K=6P_7X&MVVFR5
MNE\E5UA&Q15[9#6!JS5K5D;,HIL=P\D8VP*3<-(K23A1P+*?24:HBB19SY<:
M"WU(6\&FB*VEM7N)+V$1QQ^TB;8+>1%52TDBR=[OR2P7!QCGZ^\>35^R?YTU
M'M;<7>IZ5K=EI-GV;U&>YN9/S7=Z?/*NJ:<\L\BI;V3:>UC=P+'&(C/IVPNL
MC+'NY$W)>_81$!X[\CR4.XC_ '0^_P!WMUZ@ 4;02=O!)YS\^,\8YKX_D\\C
M/('3XYQ[\Y^SUKGU-332E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI33&/GS2HH[8/[(-V7^-=;_ /-CB/2E2NTI32E-*4TI32E-
M*4TI6A=SM0L%_P!NV<:/4V/K6SV_%%_K=?C!=-F0OYF9K$G'QS+TMZHBR;"Z
M=KHH^.[61;)=?B+J)I%.8/3[.7<&GZ_HE[<RB.UL]5LKFYE*NW=00W,<LDFR
M,,[A%#,%4%N. 3Q6<R[X94 R71EQ@<D@@ D^70'W5\_3;CKWBW--7LV0MK>;
M*,R<[=K-&2!G=JPQ*-99#%$E7[ ^EU&-7RM/@+>L1$U,&:'5:I2*PS"B*"*A
M#* EX_;'L_::"=;_ "CZ=KUEKUMIVGK9ZQI>F1:C;7)M[B_DN+*^9M2M;*WE
M-E$+].ZBWR%97((&U6^+UBZN-"U,=H&TRZNK%=!N+;4DMIK?OD-E<B^ANW@D
MN8X7@M[=[P*RL)@\NU$D+>#ZY(+E521.4?FF3(;Z0^: "!N!$ ,41[ASY_@'
M5HR&12"3E0>3D\@'D^O/-?;Y/4\@GY@G'7G[??\ =V@\@U>III2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*^3F1-\67J1
MDF\495GBE@DG8;T%!D)-J>3AVM2QQ#6N2EE;O/US*[YRVM5ED*XRK\'!R=7H
MJT<ZFSNTT;.I"O8U7&)VD60$%#$AG#\%9T-V+>"VB.<&YG'CVGE5R6"BM)$"
ML,' +1Q!2?&Q-MW\UP!CB"(^#)Y)'(\ZVQCO=]=W%_KM-S-4H?'Z=V5CWE7-
M&HR<R[(RM[F%CZ)!2IF3^219RCMW.,#S,Q)IPQV:SV/CEJFP:O$YW6\:DA@?
MK@D;2>0PY9#UP  =C#(<@@[6\(P9L'<,[,;B2/T,X5_^D2 PP"N> 1AJS_?'
M=EX/;5N$@"4B]3B<G@7)O7/P,7&NZ_&>E5&>:F]9O',RR=("U GI3OP&3@4V
MIR*$\0YO#"*M_1[OC4OHS^ML?_Q%I_S"?U?O:5-=[2E-*4TI32E-*4TI32E:
M^R2U*\JLH 4='(CEF9A(L*BX<QC-.6DXN092<;TNIDQ8ULX8/6S>1:N'(E*D
MY:)G3,"I2"'%?HKVTI-G[>R;&6UW1IWI21)%PTQ6/*.B2 L>&4$>=>YV;E[K
M6;56UQNS<-QW]I<ZRJ7<PL[6[MI;:Z#0V*O=RQSV\DEO+'$C%HYF!\)-1ZR3
MBZ$W"0;19\W;8OS]6XJ(D(B02EF]@M6-D%;0WF6:$FWK<]&MY:"LKBL*MU4%
M78,W:97J:1P7;*]/B:AIB:[;+WD9T[5XA!)#(7CN)K'$XN(R[6\RQR1R]UM*
M!CE201N6OT+LMVRN_P G&J7<-M*.V'Y/]0N+ZTU"V%J]AIG:(C39K O VIZ=
M-=V-W9+?K*DD<*RI)'&QW(4<^;1L_P"<HVIPK#(>UK,TU=F33T2S2]/3Q@A5
MI.5;J'27D(%"0RD1\A&O (1PV1=%!=(JGAGY$O(VLM5U5;6)+_0[XWB I<&U
M%J;=I%8@M#NNMW=L,,N[G!YIK_8CL/+K.H2]F?RC]FK;09IS-I5MJS:ZVI06
MDB*Z07;1:$4::%BT;,G#;<\YK*_NC+^/EM'W%?;B/\ZFNO\ .US_ (CU7[+3
M_>J\C^ FACK^4WL3_P#W!_P*O*<;M$H&PU*(R5AG+&(HJZS2M;BK9?%,=MZV
MA-)P<S8$VKUY"WV:=MC.H^#?@W4.R%#TA-)(ZA!6+SE)KH@:'VO3KZRCEE$0
MGN3:K &[N67#%+AV!*PL,XQDA<@D5U0_DODU*RU:Y[.]K^S7:6ZTBQ&HW&DZ
M0-8;4I;/VRTLI9K:.YTJVBE%O)>0O*@D[Q8]TF"J-C)W%HQ=N/9M*_6,E3K1
MW%$JUY;.\>75>M3Q$)N*E0CV[I>)=BJ[:'8N7@RL,\26;MW7HAW*)7;5LHEL
M\ECK*]S!?RQR1"UO@;.Z$<QC96:/(C8YB.YE(;@MDD$JI' NF]J/R<W4U[JW
M9JPFBNGU70'A[0Z0+^P,UA=P+=M")U01SK- @MKJ!T<KWBHQC=PVQ[+1I"9G
MZ58(Z[6^!/3G3ARYA(N5\."NC1PP6;^K+.Q6172>E\<S=V@^)T/&2S?]3.)%
M5B&[)[:626T>.ZFB6TD8F*.4!+P=V%6.Y+(=PW98E2K>>X9P/G-+UNVLK#6K
M&YT32M0&KVZQ17]U;R>VZ),)XY1=:5+'*JQMW2/"T4B2HZ.>-W(Z%5M&79&N
MVE[:L;P%=L\<J[3JM?89!">96$$6@J,QDILM7C@@!=N^ANH/H$D#=(PN>5>G
MPC1#)?O!(]S;1PSH7:***Y$BR[0Q1&?NDVAN 1M./7RK74[#LQ;W^FPZ7K][
MJ&GSB,:E?3Z+)9R61,@67N;5KJ0W?=)E@PDB[PC:,9R+6UGS(?'#N:>8QKS7
M):2QR-*(ED4'4*Y1]+(FDLM=?BLD#0YV9E70I>H5P(HD1OUF\052$FU!K7O6
MLXENR3_:PN@(]H/![XP\'!SCNC5Y-/[*+V@BL8^T=^_9YM@EUPZ'(+N,LA9]
MNE>V;GVOA WM*C!W>6#8MDJ;AE\/PMOJ:L3:<H2DI!/V$)+DGXBIR,74YZU+
MG7F3,(P9)F)(,S%%R1BT,HX>(B*!0*(:I)?/"VGPW%M(DM_,]O\ 0L)8[=T@
MEGS))M7*E8F4,%'B/(K6'LU;:A;]LK_2]6CFT_LK8VVH127=N]G=:I;W6LV&
MCQBWM=\W=7"OJ"3R1R2,HBBD._(&=A5ZUUNS+SK: L,1..*W++0<^WBY!L^5
M@YEN4JB\5*)MU#G8R"2:B9U&;D"+D(<AA( &#79%/%,THBE20PR=S*JD$QRA
M0S(^#P<,I&<<'.*\"[TS4=/2SEO[&ZLX]0MEO;![F"6%;RS=BB7-N9%42PLR
M, Z;EW C-9-K:N*FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4IJ"<#.,^
MZE0IWF7++M+B<;2F)I2Q-W"-R<N)VN5FO/):2R$W:P;\8J@)2R-#OC"J'L$P
MHVZ)R9;0480[0J#JPQZ2AQ/6,L;J-/"596.'X7B6W R<C VLPZCJ>AYJ6V]S
M(22#T#+RR^I'49^1],5%.N9%WM2->>7!K9K:^"O.0:3U,F,8QL?//+W.U-%[
M;*O5VXU&/+-U+%;]C)'@':D@Q+87SU-C\=+$JV;,'<1$+!"Y8S!EE$3MPTL4
M5C:S">4  (\EX;Z(9(93!%;;,2=XMGQWLX"[1')$[@$,$$E[<PK%&=WC(M_8
M78 D-'/+<AP8PA^C5(R#;+MB6"O-?H[X+#*-A\&JW>55J3M0&LBO&JOG<C\7
M'JS=%\@U&9C3'KC91XR=-!58QQEC)(Z,,;2/-5)&>.>>/A[_ +JR!SGW,16H
M-H#J<>.=TKFR1#*"FU=U=R%_%1TP>?9LSAC;$Q4R(2QXN&,\*=$J:ICC&M>@
MYS)])NCK,JU3'TI32E-*4TI32E-*4TI5HD*/F4!U7:OH//[^N1Y_.E12W([:
M7&?'%5>L,ES>-WM9A,A5=TXAZ_6;&E.UG)<9$Q=DAG[2RLG9&Y#MH9H+=['F
M;OD!,L":Y>H#:]*ROM/CT_6-'U;2+76]+UB&"*ZM;B:XM@H@,QVAK9T+!EF8
M$.2I!Z9Q7!J6GQ:I975E<%TANK>:UE[L@%H9T,<JY*D@.IP2"&'Z)!Y$,J/2
MMZV.(1>F&RMN(GVT!8[BRBIQEC_;?:$Y2 "VS)ZZ\&7N+\;&Y,:#/'E%.3 #
MM3I^A) +9LB.O%M.UEGIT36A_)3?W"6\]]'%+_".XG,MNES*MFX9KVU8J]OW
M;(K1AXTV1O)<,&F?Y#3)]:TBS.GR:3KFH""[O4BO!<:7>=];_G.X:U<S7>H1
M7.?8NY4K/&63E00%&<U V]3C^SW<B/T_(_M)]H?_ 'CKH_AU88&/R1:ACR'Y
M]N.G^MJ] ZUJV3_Y.]H_D.S_ /Q+\>=:\MN<-UN#[9AF9NMAS#:*?:LK-J5:
M8&ZX^VV55@^BGM/N<N"<=/5F:8OF$LB_@V2R"CAV@Q4;I.4EE145134]_1M3
ML^U-EVBAMOR=:AI%_IVBR:C831ZM-<M/<Q:A96WLRQRWT\)9TN'W]Z%" ;MX
M"DBGY^U.-@TF@:XJ#.8YAHP:7"D[8C%J!&XXW#<R*0& )8A3-? V[2EY]L,_
M5X*(G:_,0%0IEX5;3+FN.?3*_?22:L Z:*5^;F4RJ"E%.#.VKHS=TT$Z17"1
M#GX+\SW6M6TTD.K:%J.C,#*L+WIMVBG>WG:VN50P2R =W+@ DX<>),@&N_1^
MT4>KWEU9'3M0TZ>TM[:Y>/4%MU,D5WWAB:%[:XN$8@1-WBL5=-R!ER:E>D<#
MIE,4W6 AQU#YB(")1Y^GD!YUT#H."/\ .!!^P@'GJ#CD<U]""",@Y'K7)J:F
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*Q)U0:,]6D
MW#RFU9VO-N63R96<P$6LK+/(XX*1[J2.HU,9\Y8G #LUW(JJMC  HF)P&@X"
MJ. CM(H'19'^NZCR=_TF'B;S)IYY\PNT?YO3;\".".A\Z]-Q6Z^[<MGCJ#B7
M+MD^)*,W3B.:+.&DFFT%@G(M5E4C*-WR;$19$=I&(X(T'T<J@(_,U4*H.0.>
M>>?/J?BWZ1ZMYYIY8\O3\?=Z>5:'WC  ;2]S/^ ;+'U?V#SGF'D/X=6I4A8W
M^MS#_B37_F$]*5W=*4TI32E-*4TI32E-*5:)"CYA[A]OF'''[P:?C\?;3 K0
MEZK4S3[4_P K8VH;2[76UIT.E7!D_N*E9!.C0$Q-KIR<21:'E&#V5@U+5*/U
M(YPXB2RC(%$PD2N&S9NMX][%-;3&^L+%;RZN&M+:Y1[A;=1:QR2DS NKB22$
M2L1'A=T8PK;@!7W&@WVGZQI\79;M/V@N=!T/3AK>L:1/;:/^=5.NW=G:J+:\
M$=W:7%M:WWYMMK87,*7C0SLC/;F%I)8=S,'S%^V3<L'K=VU4#J1<ME45VRQ!
MY #)+(B9,R?("!#%'I$0$ YX'7JB1& 92K(V=K*0R8YP0RD@CC&>G!Z5\2\$
MD3F*2-HYHQAXI$*R*3T[Q& 92<YVX!Y^WMG6 OEV*'D<0 0'L(^X.KM[2]0
M/?N #JV>"1M/&?K# '4'=Y9]_%9D#TP1^CL)+>HQC=QP<_NKP+)6*Q;V)HJU
MP,+8HLP@J#"=C8^68^D$25*1R1J_1<(D<HE.IX2P)@<@'/TFX$1#">W@N45+
MB*&==V0)$5PK,&0[596!)1F4>?)Z>?H:=J>IZ/<>V:5?WVF7"J5-Q8W4UI(R
M'#,A>!T?;E074G:X # X&(#UV*POM[WG0]281=9IZ&3]N-6@:>Y;FKS !G,5
M6JP)R[1\0IVCU*9FZ[;Z\LW>@W.-A+%2)5%C*L0(/R$,>DZ'VP6W6)+:36-
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MK102$PF$@"8>PF[]0A[A-SSQ]'/ Z>H\CU'D?C]M1@=<#/3/GUSU^-5\)/V
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M($E#][&CKZ#O&=<>W9A?E7]X1FHUN#5"-99*R%'TM9,J#AN"DACUC9V]%DW
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M]L?AJ>GBI_[LG_E$]_\ [7N_A^C7U>Y?UEQ\1^^OPK#>C?8/3\?/W9IXJ?\
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M)-,_U_+_ ,!I\:MP']YS'OXZY7\S^GMO:O\ R?TC_:.?_@%!=]I?/1--'_\
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M5':GMHXY#"..S!R(<A7V0B'<>!$O3Q[O+O[./9H.RW9\DYT6R&.F8(QG'7@
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M$\]37:^0O)7WTN8?+G^MN-O+_P""=9_P?UG_ "PU?_1-*_W2H_@]JG^6&O\
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MBD6@3*L>\BHOUFG/6AJI7($7\XZB[#/>A6C(7O(6R8=K&(9\6XDL,MCQ>(Y
M/AZY^JM9N"P1U&)2WTA.<$9.1C'&<]1[CCKG&)G;UG.-G+[)4VD4IG>I6ZW6
MP+Y_8Y#D(+)=ZQU;,GP]F;8M:J-X7TF#?1N/$W=!C9.PNI2'J!X6%D*8,>X>
M&>PM43Z.V1G*F-D,Q4#$BEV:3WDD$ ?I<'G'2Q.9+@CA)5/=,1D1.8\*&!SG
M#@Y]<\\\5C3O;#NRN$96D+]DB7G6GRAX^DIZK*Y-DO5 8UJDECVR!$+FCXR+
M3F;0C+5Z4:S$\9)NK9Q5=G=*%CYA=B0N5N&F.%5(XN #COX[G297('.%9+:^
M Z@+,!QQ4-AHEC &'6<,>"VR2UU2%.>O#7%D6P0,Q9]]2)SCB#,N3+SB&V5*
M8>4!G'5&5@<@D@[@M$V!DWL>0\/669AXJ7CF8BX\6NTZU1*DNP.R=%\='U<L
MT4=E<(\\D;M.&0C8(9D&[G$GYKUBVA8CGZMY<V<H)_YK)K8.JPRQD9)E# X/
M*B\M)2>OAS!'.I'/UP,Y'&2[5,?9@QO%6B-RVLZL$W99>+M<C;G%T<V1%W.F
MQ[CV"G&S&,>%3&%:N;+$65\5M&-V,23@CANS3&0Z4^I67NB@P +N_:/CGN);
MVXE@!;C<5A=%^58MN,S/^B8K=>,8+1P1H^!Y9=22>I/QJ7.E6II2FE*:4II2
MFE*:4II2K3$ W<>0'@0Y >!X'2F/W?;6!N,84AU=FV15X8Y[BT;BT;2X2DN0
M$FXME6GA^KDWY(M3];KK$ZE61S@)^L#>(4AR\C6-LUVEZT9-Q&NR-S))M13G
M($8;NSGS+*3P,8Q7OQ]J-=AT&;LS'?;=$GF[^6R]ELF+2]['-N%TUL;Q?I88
MWVK<!?#C;M)4TB\84B&N,K?HZ'4;VV;;&9R<J,K,+@Y;G,T,=,(]P_5BV_4+
M%K\]LR1. )<%,'6IUPEA:1W4EZD6+F5=KR;Y""HQ@",N8UQ@<J@.?B<Q<=I]
M<NM"M.S4]]OT6QN&NK6S]ELU:*=FN'9S=);K>2 M=3G9+</'](0%PJ[>.MXJ
MH=1<V-W7X0[%Q;53+6!0TM-O/3U3'=',<"/I%R1H(F>N1_6)6P?J@!QPFGT5
MM].L[5KAH(2ANOX[,LKA_K=!)(P3ZQXC"BKZIVJU[6H=*@U._P#:8M%4+IBB
MULH#; +$HRUM;0O/X88AFY:8^'KRV>I!X;QS6ZO.4R%@%&=;LGI(S4=ZYGG
MO!=MTVK@0>NY-=^V,H@D0G+1T@)>!.7I.8QAK%I=C!;2V<4&VWF+&2/O9FW;
MAAO&TAD7CH%< >6*VO\ MEVDU35;#6[[4>^U/3!$+&Y%G80B 02-+%]!!:QV
MTFUV9OIH9"V<-D<50<-XY&BAC48!0:6"PN AQF9[J\8SX9(3#)^L_6Q@]-$5
MN@7XD !\+I\'A/0:58"S]@[@^R9W=UWT_7=OSWG>=[];^7TXZ "I_AGVD_A
M>U/YQ'Y]*[3>^Q:?MV]R+?;[)[)[%CN0$_Y-_*^MXJK-X<QU8JM!TN8@#NZU
M7#-#0T<$S/-C,Q9-E6C;E\TE$)!R";==4@E=NERJ=74J!S 40M-IME<6T-I+
M#OMX"IB3O9E*E 57QI(LC8!(\3MZ]0*KI_;'M'I>KZAKMCJ @U35!(+ZY]CL
M)5G$LJS2#V>:UDMHMTB*WT,,>W "X7(/:LF*:';7E:?V"%4?.Z@J5:O+%EYM
MD,>J55JL!Q*PD6I'@^(R;&$'Y70#X8@(""B@'M/I]G<R6\LT.][4AH"'E381
MC&51U5^@XD# ^8Y.<=,[5:]H]MJUGIU_[/;ZXCQZI&;6RG]I21)HW >XMI9+
M?*W$PS;-"1OR""J[>:3QA29BW1-[D8=1Q:H) K:*E/6LPB#1$OI724&"#].,
M6$/37/SW+)8X]8<F'PT^A)I]I+=17DD6;B 8C?O)0%'/!C5Q$W4_60^7H*BU
M[4:[9:)>]G;:_P"[T?47:2\M3:V3M*[K$K$74ELUW%D01<13HHVY !9L\"6+
MJ2QMS_(#&)4;7&1:&9.I@)284*HB=%!OQZM5?GB4S>&V0#Q$F2:GZF @?J$1
M,-C;"ZDOD0K=O&T9E[R7:5( P8C)W7&U3G8#QG/)S+]J-<DT*W[,RWHDT.UF
M2:&R:ULQMD1W<'VI;=;QN9'\+7#*=V"#A<8'%TW-L'B"#JD3E.M2&4(L2M5\
MB7"CR<Y%RD>G(N3E,_J[2[Q#U264BC-&JT@%D*B=^BL^*P*BOZ"CRP6NHVVF
MP6RWD;W47#7,UN7[Q,D^*,3J3(1C+=Y@G) &<5Z=]K/9'4>UNH:S)V9NK/L[
M>.TD'9[2]3CM7L9&2/Z.&]DL)U$"R"4JAM00K*N_PY;V[1#YV=UJJM:=?L=0
MEM9^B?'28GL<34_!S8D:IE>A 03/(,$\KX.'8*KMP>SDZ+9N=-L<SA0@N#=4
MJ7K)"(;B&.0%>^9[8R*XXW!%%PG=YY )>3''7'/!I]WV3COM3DU+2-8N]/E$
MGYIMK76(+6YLRS,8O:[EM,N$O=B[%;NX+8.RL?#G"^A;XO,;NP5)S2+G1H*L
M,EDS7:)L-$E;#+SZ .FYUDZ_,LKM M:X=1H5RW34>Q%@!)=9)P<JI$3-U)F2
M],D)@GB2,8$RO;F1G]2C">,)_P!5\>GKEIESV;BLM435M+U.]OY8R-)N++58
M;*"SE[N0*UW;R:?=->*)3$Y5)[8E$=-V7#+<]C,MJY$BY-I<Z4ABA*/%*:I[
MBBRCFYOI$S:0*#IE=T[JUC(]L5VI&K"T5IKPXMFKM#TCQ':;AK+)>&Z1EFB6
MU (>$P$RNVWC;-WP"@/@D=RQ(!7(SD4CN>SJZ!<V\VFZC+VA:8-;:HNIPQZ;
M#;B2(O'+I?L#2RN8EF02#4(PKNC[2$*O'?,4?D!+*V#'L_/5J7J#K<97UJ=$
MPU5D8J;KS4F)LL$DPLD\YL<LSL!G;I1%1JHSA*\1D0QD3INQ.50GAZI'<'4=
M%>1XY(6UR(VZI"5DBC71M4[SO)>\8N&E.5;NXPN[:2<YK])[#76A_P %?RCQ
M6=E>VFI#\F=U'J5Y<W\$]I?32]N>Q1@6SM%MH9+4I%O+AKBY,NTN"F"*FT4.
MP"(^S\@CR'G[?(-?35^, 8XSG'W#D#R_=5VE6II2N!TL+=LX7*0R@HHJJ@F4
M.3'%,AC@4H>TQN. #VCJK$JK,!N(4D =20,X^=!R0.F2!GXG%?*N*WS9I>0:
MUU^(&/Y2DQ3=E,V:4AY1X56LDN570G*E19A!Q+GD?C955 DELA24+$396\8Q
M0=GK%>:NW$A'D8%,E@2)FA!&,3;--@OY)(QGA0+A=F?K)%(3A@5%Y4V7-S I
M)]GEV;B.&"WTMB_/3ZT+-QT9D4;@=P^@E<RU 6?&L;DNO-YZV1#XJJ)4*[69
M8\RN^822\'+(HUUX1&50&/EV;U!RBX+XB!&ZA^M4H <UF!#=>,9]<^F#C\'C
M'&:R!Z_YQ%:7VCOUI=?<Y-J1,U")S&Z.Y/6L?88\\7+I-R8]Q:QZG<>J8RK4
M5%F:PIIJCU&3Z5/V)RZ5:I?Z4II2FE*:4J@" ^6E*KI2FE*:4II2J (#R #S
MQYZ4JNE*:4II2FE*H @/<!Y ?+\O\6E*KI2FE*MZ"^[\NH  \NOXQ\/=2G27
MW?E'^/3 ]!]E*H $'N'?[=,#T'V4JO07W?E'^/3 ]!]E*=!?=^4?X],#T%*=
M!?=^4?X],#T%*=)?=^4?X]32J 4H^0?E'48'H/Z^M*"F4>/,.!Y#@1\],#T'
MV4J[@/=_#Y:C8O7'WGW^_P!YI3@/<'V!IL7T^\_OI3@/<'V!IM7T^\_OI7"L
M7DH=/2'?GD0#C^CGN'V^[3&",#J>>?+G)Y_;3R/KY'K@^M:3P77YFNM,FI3#
M!:.&5S-D:=CDUNCES$2DJDK'/TN@QN6[M$OB)<B!@#YIB@(<!\[V<M)[0ZZ;
MB-HS==H=0NH0WZ=NZ6R1R#T#["<>N3BO!T"UFM8M32:(Q&77=7N8]V,O!<7;
MR0R#!QM="". >>1QSO+D/+GO[OJ'@?RZ^DKWJKI2FE*UCE+$%&S'!LZ_>6,B
MZ91\BK)L5X>=FJW)M7+J*DX%^5"6@'T=(IMY."FI:&DFI7'@/HV1=-5R'(IV
MIL\0<,P(/.,>-"06B?(.8F*J67C)1<GBGD1@>HXZ,,X=?1ER<$>I]:QB8VVX
M>G;'5;7(58YINE/*\ZK;EO,3+-*.1J@1AZ]%%9M7Z312#C'D/'2B$*JB>.]:
M-S/CMSK.79EY PVX%@?3/'PQCWGY<'@# \C!Y]YZGG)R?>>O])KJ;HJT:P;>
M<Z,XN.2<V)]A_(<="+I1",Q(I2+BJRZ<=Z$S,DHJ\73>*D4;LR#^KJB"8!R;
M5J5A"&'MSPM6Y3;NS!PBD''R!8\ Q>$RAQ_7 ! 2^7< $/HU!!\F(^&/YP:#
M&/JCGKU'["*Y@P]N=*!0#=X;@OD X$QZ/LX[\R7(_ATY.<G.<^0\_E3"X^J/
M=XG./3JQZ>6<U>&(MSX  !N],  ' !\@6._8''[8:8]YX\AT_'X&*5;\D&Y[
MD1^Z\-R/G_4"QW_*&A&1CWY_'[^OJ:C'.?=C'D/?_62/=7&KB'<^5,QB[NQ$
MQ2B)0' ..QZA !'C^N(#]@A^_H1D$=,]2.O[L>X@U/ICR&,>1]Y\_L/RK!L6
MT7=O=<98[N-DW3&K]AM='J=CG8(-OE%;^I9B:@V$G)1/@/7X/$/5[URLT\)V
M .4_"Z%_U4IM,# 'I\>?CS]O0?#C#SSU'ZIZ XQD>>?GUK//D>W.\@;[KPW(
M (!_4"QYP "/(]O6/'F'/Z#ICC'EQ\\ C)^.3FH  P>N P'_ $B#Y>F,#W=<
MU=\D&Y_[[TWEQVP'CSGV_P#\1]G(\:8&<_#@9 X+'GX[O%[U!&.<SYY^/'ER
M0<?+&!SG!.23@BOR1;GPX#[KTW;C_8"QW[/_ .HZ 8  \@!]@Q2J#B/= !1X
MW>F$0\OZ@6.^X^P/ZX<:GY_+\<TK ,94O=U<*P[F+!NE&#D$;OD^NI,?N?*,
MAUQ%.R7;:A7I3H>2 +&]>0$%&3?BE#T9QZP\=D)F:B C&#Z_L_=YTK8'R1;H
M/OO3?B"QW_*'L_TZGY_C^G^JE5^2/=!]]Z/X@L=_;_7'4?,_=]G2E/DCW0??
M>#^(+'G\HZ8]Y^[]U*I\D>Y_[[T0_P"0+'?;_P"8ZGY_+\<TK7U'I>[NR2N2
MV4ONF&+;5#(*E6K[@-OE%2]>0A:;39\LQU.9#H7YE9^5C?&9_K3_ %M\(!](
M2<<*5L+Y(]T'WWH_B"QW_*.H^9^[]U*I\D>Z#[[TWX@L=_RAJ?G^S]U*K\D>
MZ#[[P?Q!8\_E'48]Y^[]U*?)'N@^^]'\06//Y1TP?4_=_,!2M>0=,W=R61[_
M %)WNE%K U>#H<C"S7W/E&)ZW>68;7ZZ:>.I(>AK>J0A(SYC7]51]/\ UUQX
MB'+Y_C\9I6P_DCW0??>C^(+'?\HZ8/K^S]WX^ZE4^2+=!]]Z;\06._Y0U-*?
M)'N@^^]-^(+'??\ ^8?O<:?/]G'W?MS2J_)'N@^^]'\06._Y1_!_3I\_V?N^
M?]'%*U\M3-W:>58VE$W2B>MN\?3=I7G_ +GNC#X$W'6.OQ+2'])"0]!#TIA*
M/7O@''TLWH8G)^HD4U'S_9^ZE9^;$.Y\P<#N]-Q[OD"QW_*.IQQC\?CX\4^6
M?Q[L5QAAS<X <?=>&[CR/]0/'GG[_P"N.HQR3\![@!GI\<\YSY=*#@8Z_6))
MZDL<\XP./+@=.<U=\C^Y[GG[KT_/;_8#QX/D' ><CV#Z XU/X_&:'&% &-H
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MVD$VU"GE(1=^^>UM=*;32DYN']:1K*'GI66CV*DE7I5N@G9(^#>K W\1)H8
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MH7'ZVR*2 9\OXJ62,\?5=@,"I!E*4H 4H  %*!0  XX* <  ?0'NU:H QQZ
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M4>JR4HJP8LV:DG(K%(5:0?F;()"[?+%33!5VMUN% 3(!U# 4H!& !@<#TR<
M$DX )QC)SC'\].I!/) QD]3P%!)XZ  #RP ,8  ]C4TII2FE*:4K%*Y1:93S
M2!JG5*W6!EG(/)7XO045">LGA?$X=/\ U8T:^F. \53A5SXJ@=9AZN3FY@#
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M2E-*4TI32E-*4TI32E-*4TI32E-*4TI5.>X!]OV".HSR!ZY^ZF>H].M<0J"
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M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4KB/SW OF;]E]
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MW#/^?K)D#,!*3+T&M[D8I>QP5>HL&RI%C;WNQ5>JLGT_,GDI6IQCPJ:$8Q=
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MA5%Y8L%X?A)-]6;-I>[3%K>G27K'&S#8EO=SY9\9G9,58^XW7"L! 3-'7>R
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MN>H)I(U19PTY+%2+JL(HHH5YY(Q[IS"HH-DHU5L1NB!)B+P2&6%VCF>02R3
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MJIX65<9R!M8X+*6YJ<'NDC#$&.%K>.09$B6[G+PA@0>[;H1G(& " ,5W]_\
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M&Z!?6YO&L,R^T(G>-]!-W6W&?X_9W); ^KOS[J\-.S6J/H'\)5%B=+$IA/\
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M%D'8OOLFF4*U9_""R,N4+957K]-7$$E&)M6,5+MY)624$V<'0R/JX[4CE**
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MD0 P<A[Q$/H]NISD @$\X]".<'[#3CU'X\J' RB8BF8"G,!BD,/(E 0YX$P
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M]<(!6PN&@C87#MC[#*L3W,;H-RC5PI _2D[1-<6HYR RV"*BD8"HY48&17G
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M&^.1XV(SG:2A!V],CIYXJU6-;+^CBNT9+F:](MS+-TU3(& >>43*)F%/C@O
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MEH5)O%,C'/ZN\/P3+D5.?(7<D9OWN+:01VTD:H8(WF>=# DAD2- 78!V:,*
M3X"?/ ZFT33[FW[*1Z9JUM)J>M6UV=4AOKB"RM=)NXM4N[6VAFNIG6*..:RA
M@O&EF9%7O\9P 3S/,V5=CCQGDM: R0I!/E2HI13;&EV=71,QG:S(#.J.A"*6
MEHD"J)CG5<Q:2:;<R;DYBHJIG/+:G EHEZT-[W3]$%E<M.O. 7MUC,R@^I3'
MGTYJ8NR.H3=H).S:7_9X7D4?>&[E[0Z5%H[CN$N L>L27*V$CE'VA%F+=Z&B
MQW@*ULB$G&D_$QLRR2?(-)5DV?MT9-@[BI%%%T@FNFF^C'Z3=\Q=$*H!%VCI
M!)P@H4Z:J93E$ [8Y4DC24;E610RB1&C?!_61P'4^H8 CS KYZ\MGLKNZLI'
MMY9;.XFMI9+6>*ZMFD@D:)S!<PL\,\1928Y8F:.1"KHQ5@:]85"@'///U=^>
M_&KY .#PV,[?/@ GX]17-G/3IZT\0O B'?CGM]7F&F1QGC/D1S4U:*Q0+U!R
M//8 #CGSX[ASV_#J"P'4'/' !)Y^&>GF>GOISY\ =3SQ\>/QZU0JQ3!VYY[]
MA^OM]OG]6ISS@X!\AGG'K3GKCCY=?3\<5R=7?C@W['JYX^;[.W(=N>_E[>_'
MEJ:C/[,^[CRS^/?5.L. $/(1X]W?@1_H_#] Z5.?Q_76-V:L5VW-HUK8H=E-
M(PT]#V>,1?)>,FRGZ^\(_AI5N ?L7D8]3(Z:*A_X-8A3" AR QT9& !*]X,G
MR66"6"0#UWQ2R1,/-)&\ZJQRCH<[7[O<N,[NZFBN$Z9P4EACD7^4@\LUK!QM
MOP>YI@8^#&E6:4P;;-WI.OQK 8MHUMUFD)64L$^Q&-4:.(V1FWLY,FE%F"S?
MTU&6DF;@#LWSENI501W0']X01Q]"!&%V['4C#KMQE6!#$*3R :L&(;<,@E]Y
MR#G>23N&#P=QR".!C@#R]*0P5B5Y4GE!4H->2I\A,L9Y2#8,C1S1O.1HL/5L
MM'#'':K1,A'%C&!6#V+69N&16J)&RB12\"V@X)\15C(&8@X)SD+D\#!8!1X5
M!( \J;B,]1E%C\.>@(V^6!MP.1CIDXXK&7>UO;TY;2C%;$E'3;SOQ3!^5E%%
MC7+@*+ JU:H@#V/.U>-Q@:RX<UYEZ,X1Z8-T[BE/$9/':"T@8.]1]2:2<$KD
M">6-()9<$$%FB1(SY%$"]*@G/#$C,8BQNP>[$C3*G!!_C6:3KPQR.1FM0;D:
MU@;"N,6U_F< L;^V@[U48N'J]2C6B4\66R3D6FQ"[R#:KKMFZJWK4D-*.8I)
M5,LNG$)QB9!(X!$U)%SW9 W>&2,OU[J.X:5YY"O5E[R221E +89BH)J\,1?O
M47 (5[EE)([R6"%=@R3@,8XDCWL0 1EN!FNIBRP[.)7#EL5)5\7P&#F63EHX
MSJ^C 2-/ML^6OUI[%6M5U;1=I.G3N(>QD?$^M5E)-BTBD8Y#P&K-NV2T9F9;
M9I2,R=_' F5)'LU[?0,4(.UD;N&E5ER-C]<MBL8G$CW2QA_H# )RP<<2VMA+
M'N! (Q[3#&0PR)!CJIQDN9LW8 Q?"8$C3P4):HRV7R@L\51%/&#3AZY'R<M%
MTUED5B"*[>,95*LA;XUD5:/*J9PI-,8R-;+'=F,A1@)9N[?=N2VOYFDZ]W'!
M8W$DH/.[,D2/$"/J[P>@S5V81PM)R4DN+2$*!_&327EN(U4XX*OME))P!&<<
MX!\S9Q<\4VHMR+C;$J>)Q>Q=!OY$"+L7YK/0[Y'S2^.YH7#150T.F5I#S+=*
MF<^A54 ,WCP\!YUFN R*ZG/T4Y@D4\E)1;VTS9;I(2D\691G.WN]V(P*F1LR
MJ"P8F%GC91@-%[5<1@XP"H,D<KK%T42!N"QJ<6II32E4$P!I0\ GTKA*N4PB
M' @(<=AX]O''D(^??[/=WT\L_$]?(9_FY^!J <Y\L;<_%AD?NSZ@_&N8! >.
M.X#[=1GG'NSFIJ,6"?[;.\'_  Z53_H[X3U-*D]I2FE*:4II2K1* @/M[]0<
M^P?8/X![ZS* ]<'#;US^M[_A2KM:4II2NF9L85.H3 8HF X@83!P8HB)1#CZ
M^X"(@/ =O/FA4G'/GXB<@X ., <<'!/KYGI@><^OA 'E@9)/KDMY^GW]=Q%M
MW"AE5$&RBH@B7K50(<1306\=),>HI@Z2+"*I.P@53I4 .HH"!D#C:0",@X(W
M9VD$9R/49\\>1JG=QEMS(I8[06V@D*C;U SY@Y(\LG/4"HM53;GDZE5J#J5;
MW+7..@:Y%,8:(8_$?'KH6<='-DFC-MZ2YACKN/ ;HII>.L(JJ@7K4$3#SKXR
MQ[+ZQIUK;65KVJNDM+.VAM;:(Z;8N8X;>-(HE+MDOM1%!9N6(R:^.M.R^K6%
MI;V-IVLU*&VMHHX(8SI^D2;(8D"1IO>R+MM157<QW,!XCFHN7;X+2"N*UID%
MMPN9XA_<+ \M4Z%?LD_789Y8).6),RTF%7@;-%UI!U(OBJ.5S-8I  =J"[3
MK@I5 _2]&[4]L]+-BL^MZ?J<5C9O91B\[.:4]P8A;26]MNNF1Y66UW*R)PK*
MG=^%6)KG;LCJN^20=LM:!=I)&7N+$1;Y,[B(HHH@O4E=I #8)5@"IT!@P\=M
MMN>Z/%MCWN3U09XM4J-Q(PMUEKUX=OV4_59>3?IUQSE"3EYA>205@UT)2#B5
M@*A(JMRK(^D/2'4[-;[*=N^U.B]B]12]"ZC=1:M874NC]G;:&TGDCU3^T9[F
M.&(K;]U:W$4:3,=LBAR!B/%8Z=I.K6L4EFW:^^1K;):9K739I)0[.P+"YMV
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M);'#2:R$O!S"BZSB1D<F7N0MR2C@R!C@QNCR=7L\:D46Y/"28R:":13+%(0
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MC!((./EGC\<4JY%)-!,B**::*212III)% B:9"% I2$(4 *0I2@ %*4
M#4\^>.G/Q_=0 #I7)J:4TI32E-*4TI49=TG]C6)O\9;;O_G3KVA_=^W\?#K2
MI-:4II2FE*:4II2FE*:4II2FE*:4II2N(Q.HP#P7CMWY$#?-Y$ [%Y$.?^$
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MJ3)?H$A>XBW;)#M1!JQ2%$R#=)(44"M4#))(E!)J $$$$Q(3]30 2$#PBB!
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MI?\ M*^S75G):3+!+%>K"DFYHTE5U:&>>*2-DD0AED)ZY4<$_,=K>Q\_9/\
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M*PD6;NB\<FPF)&13X$DZ,[L?K@<GR/ J3FOG:Z*:4II2FE*:4JA@ Q3%'R,
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MCO+)(RQ1QHL[$N\AX5 <;B2 ..N<5LY'/.$ * CEG'@FY-\X;;"<_LA 1_\
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M:4J@E 1Y$._EI2@E >>WF''X-#SQ2@  <\!Y]Q^OL'Z>S2E1BP3_ &V=X/\
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MS=+QS@&<@BW<HK*L79FZ+LK5XFF<QFS@S5RW<@BL!%!;N$%@+X:J9C/('R/
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ME-*4YX[CV#3I2O%^,E=ZP3]?0PJ&EE($I DV0G-.))"NK# 7QN1E4T2F6/'
M'I9$BBH9$" (Z+XMNWG<'*X&=PC+*Y'KL9&#8^J58'&TX$@;L\;-I;/Z(?;L
MW>F[>FW/UMZXSN&?25=M4$E'"[E!%!$@J*K*JD322(7GJ.HH<P$(4.!Y,80
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I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g752656g78x43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g78x43.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  /  \# 1$  A$! Q$!_\0
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%69F\_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g752656g90m90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g90m90.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1?^4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             8    .@          $                          0
M           #H    8                       0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   8      4F=H=&QO;F<   .@    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   &
M     %)G:'1L;VYG   #H     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      -AP    $   "@    0@   >
M 'O    -:P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 0@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M;[YY]*J?\_(6DB@ ?82^8![(^D.3W\T>O*H96&/JKM@DASC!U_JKT'[#A?\
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MYWC_  7_ '__ (+>NM7RJDH\F[9P?+]7_]D .$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M 7Y-30 J    "  , 0   P    $#N    0$  P    $!H0   0(  P    ,
M  "> 08  P    $  @   1(  P    $  0   14  P    $  P   1H !0
M  $   "D 1L !0    $   "L 2@  P    $  @   3$  @   !X   "T 3(
M @   !0   #2AVD !     $   #H   !(  (  @ "  =C3P  "<0 !V-/
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C V.C V(#$Q
M.C,V.C,Y      20   '    !# R,C&@ 0 #     ?__  "@ @ $     0
M Z"@ P $     0   8          !@$#  ,    !  8   $:  4    !   !
M;@$;  4    !   !=@$H  ,    !  (   (!  0    !   !?@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0& 34T *@    @ # $   ,    ! [@   $!  ,    ! :$   $"  ,    #
M    G@$&  ,    !  (   $2  ,    !      $5  ,    !  ,   $:  4
M   !    I $;  4    !    K $H  ,    !  (   $Q  (    >    M $R
M  (    4    TH=I  0    !    Z    2  "  (  @   /      0   \
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-CHP-B Q
M,3HS-CHS.0     $D   !P    0P,C(QH $  P    '__P  H ( !     $
M  .@H , !     $   &           8! P #     0 &   !&@ %     0
M 6X!&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $
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M>KT[^O#YW/AP']:V4Q]D%7OYT_8-/<GQ#\=;?.=L=WP*?=7\G?Q'$OYL#CY
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M]8\].N-]OGSU!Z;8.V?#T4JZ07*;A]MN<I'>W_1:/^40Z?5H,^'CX8W[_2/
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M%4*(AOJ WTKJ;&^E=2IJ;P74Z+D[:F4=6 ([8)V!.D$][89L#Q.E6..N%8]
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MZ7IVV3:[PSF2>,XN,81>&UPGVV4G2)N'1G.^LO\ ;&V8QC'PM*AG4$';45Z
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M;=VHXP!UR>F.HSMU&-6_N#:6-[=*@=K:TN+A58D O#$TBYQO\-1X^JL+Q_Q
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MI&AA\+M=,=<=<';K_P !64>.R1>1<72H5UD7$;59-H[<Y0>.XZMP[5, *H6
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MO=@:Z<,H]G%LF\?'-6S%@S230:LV:";9JV02*!$T4$$2D222(4"E(FF0I"%
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MB%9A13XNEAXY+9BNV.JM:/2)D7A3JL54X\U1Q*\-WH142..6VATLL;-=QW$
M:21P09WE1VPI0K&#J$G2LLGDYPA>%&>5KF:Z>&_NFO;*.22ULY(;LQ1Q%R\=
MLD.E=31R9D9>U&6&*\I# U.1L=K3#">2HYK1FE^3KL&[M+A93-ZU7?5YG'+Q
M A#IRY%D8Z7?6Z?/5D',4\AVR#6*69+%6<B7B%U)#S9+J$F[:R27$9"<.AO9
M+LW$LB]1)"42)5?M+/*';"+O5_)ZPCO[V <+XDD/#8N(/;S&\UIQV6VAB,,%
MJ<<P<P2-.WF8Y;6\9C4ZR:N*>$<+PTW58J?HMJ4=Y%R5B>D^@GMT<Q\IC <C
M4N'G)R/>&3B -*359EI3:/2EFC-4K4J;:>:KN2J"%?/;UTD2*X CAM>)3">6
M/6;Y;"6)(E48<0M(& (V#LA:)F!).1> \'@6TDGL9S+?W? K7S-[R42<*^V-
MO<R3*'7!9X64,JS]M8V,<H&!7YP>&JY'X]O$9%4.?>JSV'\=O$<N.YA,U=E)
MRWYKQ:PD:PP1<QP042_@Q,[@P=IO_239Q"SZLDFHP>%".N]^\\T$L\T=LB\5
MABDLU UM!'PZ:7SG6!JY7,<1G!*EW& "!66/@=M96]_:Q6LMQ)/P&8IQ93JC
MYUUQ*"T-JD,@6WC?E$G5J$PY9?=-6C*+=PUXBJT:QM:]4L7P"+:9X1DH,\G>
M(AO/.<8TUC8:XY)*V^K5F75.I(KNV4W*PT,VK\B4HEAVK=PU7*&I#Q.^D0@.
MLLSV?#VM,,I:-CQB+AZI,@8M^\WTK:)2SX"MLHP=B^\E>$6ZM.;=EBM;CCT$
MT0:[CCN1P[@W$.)VY620 ,ZW-DHFEM5$$RE@-6D5&6YX_P ?,<4AEZ%8K,F%
MW1K-;I\#Z:</35Z\1CE^?)A7"C@XNY)E'QT-&NF)'IA*@VR)"F[1UF(^9]F&
MXNXKZ"Q\XB:>"1[J2Z"'1<V)MT[(&-I/.[J:W238:+$JN<&N5N.'<)^T\W'+
M>&>%+D6G#K.S%T\[VO&(92]W%(SMM9K96XGU;AY.(1#3D;[-H&(\06%W1X61
MKD\O(DP>KEF<&+D9B6E;C-*23F.2KT57(Q(CM*-CF2?IY^G$G-,.DF3XJ*[1
MF7M)ZMU<W<(NWB>/S:*ZBLXXG7#Q&>&RN6N#(PT&'5<R1$GLJY/>I%;O"N$\
M'NHN#PW%K*UT_!+OBEU-"\K2S2PW/$K>&Q2!)%)/(B6=A$.<8DP@RX-9B3AR
MQ9**Y"BJO4[Z:<(1JO7T[NE<*K$0!CT9O8G$<6QQ-9LT7'2[*164>@QR6$41
M:O&8-'+UB_6<2!=1N(\0C6!GD&$:=B(C"QEBMYE4#'8#*RDZ>4&8MN,KG/JI
MY.<&GEN(H[?B&K3:+:+=)<000\U+A6A2>!IY(=,J)/CB*DK" '*&137XP&"J
M-=&\TT6@;#,W):KT L%(2KFXQ500*[P]6YU1)M<*W4[/!1<XTDW*SE1K=T&T
M",,1DB1ZU.HO())[^YMP7@(51->2LJE#+(%FC,>5F*JP",ZCE@.3E=. :O:\
M L+H+#=1W$MYYE80PJ>=YA&QM)^=&9[6(XE$@1V-SB!8QEF#,#6206#:)?[;
M&2<MC-['P T?APAVC*&=7ER23<W*@D>RD\S9U.MS3YP\%2-4C2STB_A:DG(1
MTBYFGLG*NU&Q*/=SQ<Y8[DZ[B^NWC%P8P(((55E37E43)U#2_4X*:>_*O ;*
M\FMVN^'Y6WX3P2-UMWG:"YN+EI(I9$\W0SRJ,/B1'50[DS'X-:[MF$\20"<Y
M2$X2=)98_'V5[HE?'-G5!-NXQ_E:WU2*;KULD;\"6;NH2MB694(H14[A9%>,
M*S4;KE?;-KQ"^G9;@2QQI;S\+C,1C+O,US$QFY1P2"CJ27V3M!6VQC4O/)G@
MMN&X6([B*[>VXW-'?)-(IMX^'W1> B+M0Z&C'+9=Y)-Y$!89K+&_#=CA>^3L
M#(8VR17JU1'%Y0BK I*NILF<$:S%-G44K!12#!C)NWT@T!Q=7)**=PP6JYR1
M[95J_P#@TDXHO$;N.R2020N99$7S=E!:SUW30N9F.6TZ<9Y@ U-GX  K&/)K
MA$G$_M?)87R6]ND\R7ZW+2Q\9:*T@N56"(,"\KR.SXM#@1$H6UKFH@Y[J%6I
M.17D)3F=DC(52(@)0(>UM%64O$/)6*;OG3$[9T8T@FU ZI5X\LH4DH1@NW2?
M@+@BBROK</FEGMR\NDD32J'4H=05B!GE@)JP '*#EEAE3C>N3\H;.SL[\):0
MW%OSK>"YE@NE>*2&25-T2&5GD$)P)(VE8R@-I;H*TR'J^OGM[.G/J/AWCTW#
M>]6_HZ]<^@>O]/<:\*@!S[^[N[O6 >.W3J.^_/O=_P"SZ?0>_P!=,9Z54H=-
M^7T["/4-OR=W+VZC26[]([S^H9]&?5\M"VE3W>LX]O85.;@OX,;-Q/6HLG*E
M>0&):\[3"SV0J?FUY=8ABJ&K5;,J0R:LFX)L#U[V56\*V4\\X(LY59M'/C<9
MXS%PR+EQA9+HJPCC."%!&#(XSD8VT9QJ[0&PS7=>1?D9<>4%TEU<@KPF$YGD
M*GW\G!$$)(P6RN7*YY8*YP6KZA:32ZQCRKPU-IL,R@*U ,DF$5%,$_-H-T$M
M^T)A'=1=PLH8Z[IVN=1R[<J*N7"JJRJAS?-)9I+B1Y97:1W.2['))R=O4.@[
ML5^E;.SMK"WBM;2)8+>% D<2 !5 ]75CU8]6.YWK*M8ZV::4KF9/<.' ;E3B
M+FH;*5CP%GC)3:V9'NRW#WE'Y',D/:S8<B5+!T6\FT,<V)M+ST5(PE?P[#.(
MF54C4GJ+&X3GG7)V3UF"=H"3:PPQ()([2.YTN@U86YXK=<2=V8;#]T7KPZMA
MITCKUB4E3()"4YT]M(P;L[PV LXUWQE6B'-'C)C&1M6Y;EP281NQ,W^EJ]""
M[S/ 5VO)O_BM4UWV.XZL4MM2HA&@N',*JI$)-&C-)\W0 QD&;T %JDBD4B88
M+<- 7T,0S\0;B8D&TIE>*RA9"PP2L8LH@C9S[XV_2HD"OLV"OFXM^4<\L(LM
MQ,"!W:C</J_U5]9QFT<"E"R38YQSEG(^5;]27+Z=E:-0F=H^2P^-)"RW&!OT
M\\KF2L+HX[R^[5/;*Q!O(<\Q?7QX9JS(S3,X*!5$X1-*JF0778N0#V5G6?E@
M?Z$JJVLXDRHU-VCF2Q8JP&V-R._,#6Q8GH5,3E=&ZY;( TX&N8OR>.,8:O1^
M-<;YWR_ 0$4E=JGEZ"=75CEJP9(Q[E"\N\F/*!=K'F!#(EWK[<JTO(M(><@)
MN$L7H2=F'(/UI"2"50V(I>US JF-6C#@C*RS6B,L0D;H&C2=FY>00)%R NG$
M'4B:=]4CO(CG8HDI5',8V!0M$J%AD%D.<L&J<T1C&(B,N73+*$@\-*7/'V.\
M=.XD_P &",91F.)O(L[&/6?92*Z^%OU\D22#[SJRB()1S#X,1)3X296F^F5"
M<B63F$'.,\L1G?T@#;KU-6)#<C"@>;QO$A_T6D$FWH!^<=:U;0^%3A:X?)R<
MRC1\?U;',T:$EF4_;CSDN@@C!OG#>1EP?.)N:<1K1J==BW<N'"A$?,^8 ?.I
MD[0#C:,R0M; $JZ<IE0D91ETZ1W[C;8YZ;U.2&YA^$IYFH]VG+%CW8&Y)Z#O
MZ5'Z \G=5HA:&+(9IRA:(2FQV,:IC6!F6..T6U#Q_B.QR=AI5,9R$!48>4GV
M[,DF,4[GK0\F;#(,6K-5U(G>E<.7.5&,8E4?Y4(LYZ!S';>:Q8&?>S'&27"X
M$CG+ ]*M#(8I5FB 4+EHDR2$+SQW,KAADMS'C73DG0NRG?-8GG'R;&"[GBQM
M%77*-@IL?CY:C6MK?9(:(I&UMKC3#+3#;QY.MK;!O*LI$2E-8J24RZDD&_HR
M6$L@R>,VC8S56DF&E,K,,-SU96.G4MT\;,#G?=XUP1W[ [XJD6I8/-T7[Z.3
M(!8AX1)H; VP%=\J, C<C;(_67\G7PX9IP!'XYI^29!_3&MRI5UQ_>:BICVS
ML(:9QCB:)P$W29M&\"\HDW&JUNOR#>7C!B2-F4V]>^B2PYX]B@TB<,\J2,"L
ML<MY,A96;*<09))H^V!B/"1Z&!#852S-DZHB*A9-+<Q)$BBD(8#+P,Y4G1U9
M7=R0=@21@$;;1J_ !B6D8[''$99+(C7"S%"G'+CX/5XQPH>@T9:E@ EAX*,B
MF2,LW<O)9^#./:MVS]RH#-)!J((:O<2AUE+:85,,X9]2KI1X&@9M3DX$43@!
MB2%Y:YV&*6Q>WD$B,7?FVT@#+D%[:\AO4& !D-- -0[PQ[R*O<KPR1UIQ)@Z
M.@>(*WP\CB:F&K\!FJLM,72#JX8_G:LP@["A)Q\Q4I_'RK&SP$;%/BS,)#,5
MH]['M).)=MVIWC1YAO5:X6]68B%;B*>"XR1RTCDB7F32B3'+D&G7ECH0$@C0
MVFKVQ,"PQ(ID"3V\L*G)DUP&18(8RN"ZA)7CP!K?LL<NN3JJN^3VH+JOU^$C
M<ZWZP8<1K+*4@**:&PY9:<[N[[!KC!A<I!)RN/)UU9496@R3B0^)LT\F\<OY
ME^H_7@'L.JG#DS3.6>=2IA8R7;Q##%K:6^OY.(7&SDDYNIW*"3)C20HA54!3
M%$H11@APP@%R0P(N4MXEAB5B,A-,<%NAY10N8%+ZC))KU!(^1BP;/5*A5BPY
M6R9-+4F1NB;AZ^B\:O(J2IM^5KB\[0XBDR=*?TVB5TBU99NXIO48:/29NY&Q
MN%T7HS D:S&_*N8;E H,4<*M@L&D:"[O+R.1IM7-!$E_)A58*%"*N!&F+$,4
ME0DD/*SHNV$+P00.-&-))6!"2P+9P=P<5)?'/#%B3ALXA<B9TD<TN8B7XB9:
M4K$-CZ;=XSQS3Y2S6J::6IRWCXBKP=27R7D4CJ)<-X"Q3XSU[0A'M@3=R4R\
MF)F5=8EQ)#+8O\*?WTHK'FE(HGADD0*P8*JW(YDR*A'O>0O9)ESJ>.XP +>-
M8=94%1V(8U5G;.-K-0(F;3LPP<8KQX;N VL<.>2W&3HG+F2[B]/0R8RCZ[86
M6/(JMM:8R/"C!K2K2I4JON[/?H]K 144_P G3SY]<K1#LHV.L;]^C&M?-YE9
MDB,) D+X:5R &UA57F($PL>L)IDC0)$Q]\(UQIBKGF,K@X ^!I[T)F)4ZBQ9
M09=418LT?P%.F20-KJ3\G?CZ!R%D?++#B!O..;=D?)$'<J4]AHG#M9@*9DQ:
MR+R45(IU5.B-*EDZVRCV3D*TWDL@0UBM$G$S<DT-)/+!)+SJF&*/0L"+VWMV
MDD5R"6$4EG=V3  '0%-M=RJX QV5DT*R+C)+)S6=B  \4<3+XM!+;S*=9[6%
MDM8SH)T@D[]PV_*<$M4L\796%_R1?+\^N5KQO;[I.RZ%0B).QOL>4XU-*DNE
M4ZW78B,:6"/.LH^)"Q<>9FL)"QWP<$Q,;&(8EU*$4I))Q&8QC)75Q'@\/!94
M#%BP5(H(YE[2DS,P+<KL!J;.<Z2(K6+/WQ6UOY.(QL1L<M+(R-N!H5, $9J.
MV)/)B8KP@HI&8NS]?JQE1N^8S<;:X^#PD:W,L=)1DY3S5=_7G..'$/-0<BRF
MI1!2SS$,YDV\ZFD^AWL<8LBQD-E9G<#X#1L[B\4DZ96F8M&F,@0Y>(LJII9]
M#G+!3B >6[X #-HY'BGF[([E>]MV02:M6G4NP+ F_,_)M8X[*-.99YR6>N0%
M<JQ9;'Z1L;*-S6=EPU6/A68Y E7*-1"V-WLOC9V59&&&70J9[%"J2K2*$YUT
MD<++S)"67('.:%@ #&UQ'#%,$TXZK I&HL>V=\ 8GF>.D$^;%\LW:BM[R:\C
M7.20!/+(K,NG4 !DD&O7=^2=P@KDW(V3&MMLA'.1(6X-E("3IV)+=$0EGO\
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MKWPZ=_7?O'GK%9@>>V?IN[?N(ZS)OOUQW_)TWSAXK_!7%/Y.O<^D"VDVSO\
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M! ,<QALT$#LLAAB'-',[<>LAAV-QU#$8Z[XVWZU*WEPG+Y=Q-"D,/)0HTH!
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M?I6RL[;A]M%:6D*06\*A(XHQA54?2QZL3DL=R:RW6.MJFE*:4KD#:<4W^S9
MRU0X_A>MC>S3_%QC_,-1XFI)'$K*EP--K4CA^9DIR+L*=X<Y6&>:1E2LU<8P
M"5%02E'+H8YZY2KCYX]UCMP%BX:K91K*2[DN"Q+-)"W&>*WT44(C&'\[MKB&
MV<'08(I7SO$%:\A4->8]]%S:<J/&P2=^'V]JDDFOIYG=H)^R/?!"2HP^JL;K
M%.XZL@R.*JI>&>?,<5B&K.!*#EFRM<GU.+F;5,59[F1OF*\UV6J-SG)=O&6I
M);'2B<^<(>WR;!5DNG&Q3Y@<S5$2;B.1E]Z:)-61N/\ H3B ;;(*O]MC:-IP
M<GDL00).76=CHT1JNH37SEAG!BEXWPQ[1-AAM'#%O%.#V$,J#9UUVO,M#\H"
M]I=NJ\"MF15E5LB0V+ZM/4*]PREXN.*FY[]<#9B-OD[$TV_E'7IK%&,YM)7*
M5$M;=_2[A9"#+UV16CK+0ZG$)965Y))4>-?@1BTMY(K69F&"%OI)#/=(0T>M
M808W R,^85>4+^]I'%*I(RSO<RQ-=Q G6/W(%E2VQ@\F0$-&ZU:,753C\H,#
M 7>VX_RA;,@6K'<+6,FL*Y:L:1\W(Y*4X>*[58BZSP/+['UY2-J^1(=^66DX
MJ7EY%BX?A*Q#&;;BHL.5P$2[CBZW#7#VR@DI%/(OD^[RZR,1:HK7B,".(6[?
M9TJDBL=<#][=CGE<LZ<99K?SCC6(0HW=E2>QD:)I$(QKYAD5E&4K\/O&M:"-
MW\UE?B0K[V>9WB'G(VMY9A8F/AXZ'P329&@.X@B*SA1A+O\ .T5, ^FF3@TK
M)(/92&FEAI<BJT5R3:$>00]O6Y>,L#A3'=,8E."!I\U/OB8"3M@2A^6NFD;N
MRA7C503&A..TJ/%^Z&V&H-KP(V#!XL9A9223H/,F,/*59"OF3F7Q?S"XI=SP
M?D"A2=9)9L<K8ZD'LEP^.#U-_6C266/1,9;7F86/F'@J84C5XA])_!IO(UAJ
M9R('M;-&K73.K8DE>5,$\R)5NUT16S,[,$>T#=I7A[1("K(-;9I  (3$P,L<
M6CMC,4NJVN(9#,"I4#68&".DAZX.,UTKP#7>)F*P_E2/;+V6N69?(2KC R/%
MA(M<J6J"I8UBBHRZ627>,[L9>9;O+^WR7)5=HA?EY"/K<E64'#IJR;)PC'#-
MJ*PL.49$+B0HK -:&9S$C#L:KD0E [LS=H N9'#,V",:68,'":(B!G/[HY(Y
MA4Y(6$R '0JH@;7RT12BC'L\84XDLW\)69L2YGFZ19;K;5(-"N!PY-;UB0J\
M*TG8"2<QDB]MF0+._47<&9ORR'FIMA&/X90\:Z9K JJ5>P$.8BX8A)4D8X'W
MK#0<#KIZD'(V!QW5EC=T,Q 4!X)HE'5@9(V&0=L,"0%(P<$@L<X$=V^,^.V
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MO3OX;X&X\=?BO\%<3]'#KX__ $T@J3/ ]^I-P3^X1I_'GVMOC'\)WO\ MC]
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M3_ZIR?MZ^9Y;[;<N73OU'VWX9_&D_.J.I]!/MMTI[B_*OXFO_P N/ZZ?<?\
M%&(?VA,I_P#5*3 ?_P '[;^X.,<,_C4>_P#VJ'YJ>XKRK^)K_P#+C^NJ?<?\
M40=,"93'ET^*,IX=>:&WVVV[M/MQPL_];3\XG?ZFI[BO*OXFO_RX_KI]Q]Q1
M_@$RGW_K2E/5R_S@-NG+I^+3[<<+&,72?+(@_6<T]Q7E7\37_P"7']=/N/\
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M[@K_ '__ )AY0^C]UW&__P!7]-/FYLA_MU<]?OR7\?W9?;ZM/MY;8Q]J+/\
M)7P_V?R4]P=__GAY0_SNX_M?M^FGS<V0_P!NKGK]^2_\\N_UZG[>6WQ39_DK
MZ_Q?C3W!7_\ GAY0>KSNY_M7=5?FYLA_MU<]=/\ =DOS]FUQY?;GH..6P_\
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MYB$<U[_'H&X\PW^C4:2[! <$E<'/09&KO'<#ML#C.>N& 1N<9.#\NWM^G'?
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MNWX(K+OZO\S9<'?G[!]PZZ6U4GR7XDP&R\034>X9%D1GUZ&Q_JGP./FG%_\
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M$X]](E9QZ#FR-DF1'3HZYRF.3[[S/G#XN.7UG<P<-M[.:66.VA96$D>G2V%
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M P"!MMMN_< $/> AI^JHR#CTC(]7L:"(;#S\0]P:JVZ[=^,?*14UR8\K]O\
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M4QC*!P!G4Q0R)G"]^>XD"K".270_+AY?-<(Q5.=JY>H@$#7I;'JWQ7DHV<(
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MD Y[ECQ]@C'M=_Z>_4=,GV.WZ? #]F &?;])_76M^N_</4=Q^KZN7U[[:C?
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MU=!/MAO#'ATJRV?R:'"%&UR>D6M#G$G+"(D7C=0UZN*I2+MFBRR1A(I,&(8
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M0X3WF1*DYJ$(TL%(D&;Z@(V)NI!-<6P#$7<U#.(^M"4L\E'(P[Q1!%R5^=T
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M'D'>/=X;\O;UD*H?6JQ\PL)3)I&=0VT9(SOG.<?>CI4#[S3A<>^,KL[1&4'
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M=C8$ CM=X KZ"FS=%JB1!!)-%%(I4TDDB@1--,@ 5,A"!]Z0I"@!2E* %*4
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M!@_\"Q/\',_7_O/K'WCI2O(L'"D.50D1&%.0P&(8K!J4Q3%$!*8H@D E,40
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IDDY)W).=SWG?Q^>OK@    "J  H48 4      8\!L*_;2III2FE*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g752656g95n92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g95n92.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[3/(4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #\< 5H  QLE1QP"   "   < E  #D1R;W)Y+"!*87-O;B!,' (W  @R
M,#$Y,#8P-1P"/  +,C(T-#4Q*S P,#  .$))300E       0TTHG:\0ZHCWS
M6&A7\_KTPCA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              0@   )U          $
M 0             "=0   0@                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   0@     4F=H=&QO;F<   )U    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $(     %)G:'1L;VYG   "=0    -U<FQ415A4     0       &YU;&Q4
M15A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F
M875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D
M969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP
M90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L
M;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E
M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      850    $   "@    0P
M >   'V@   8.0 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
MT #5 -L X #E .L \ #V /L! 0$' 0T!$P$9 1\!)0$K 3(!. $^ 44!3 %2
M 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I ;$!N0'! <D!T0'9 >$!Z0'R ?H"
M P(, A0"'0(F B\". )! DL"5 )= F<"<0)Z H0"C@*8 J("K *V L$"RP+5
M N "ZP+U P #"P,6 R$#+0,X T,#3P-: V8#<@-^ XH#E@.B ZX#N@/' ],#
MX /L _D$!@03!" $+00[!$@$501C!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-
M!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&
M>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+
M"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)
MY0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA
M"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.
M+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";
M$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,3
M8Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)
M%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W&!L80!AE&(H8KQC5&/H9(!E%&6L9
MD1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H<4AQ['*,<S!SU
M'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@
MQ"#P(1PA2"%U(:$ASB'[(B<B52*"(J\BW2,*(S@C9B.4(\(C\"0?)$TD?"2K
M)-HE"24X)6@EER7')?<F)R97)H<FMR;H)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I
M!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K:2N=*]$L!2PY+&XLHBS7+0PM02UV
M+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^,#4P;#"D,-LQ$C%*,8(QNC'R,BHR
M8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@
M-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\
MXSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_XD C0&1 ID#G02E!:D&L0>Y",$)R
M0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(
MD4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW
M3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5
M=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU
M7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %8%=@JF#\84]AHF'U8DEBG&+P8T-C
MEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW
M:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7 K<(9PX'$Z<95Q\')+<J9S
M 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$
M>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$?^6 1X"H@0J!:X'-@C""DH+T@U>#
MNH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(:8C.B3.)F8G^BF2*RHLPBY:+_(QC
MC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5
MR98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=
MGXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I
M-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP +!UL.JQ8+'6LDNRPK,X
MLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^
M"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\
MR3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N- YT+K1/-&^TC_2P=-$T\;4
M2=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^O
MX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K
M^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9
M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X
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MN]LUC>S9]/\ FM_L?_-*31:^LULQG.L8& 5_:_TA:XMNM_2-<+/T'T7M>_\
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MY?F/SOK@]3^5\MB7Z3^7_P"!KR-): V_3<D[_P"3_8^N?I/Y7_@:?])_+_\
M UY$DE_CJ'_4WUO])K]+_H(N+O\ M>-,QZ],_0_TC/!>/I)D_EE\^Q9,?S0_
MF]P__]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<  @ $, 4P V     0 X0DE-!"(     $DI-30 J    "  / 0   P    $"
MAP   0$  P    $!(P   0(  P    ,   #" 08  P    $  @   1(  P
M  $  0   14  P    $  P   1H !0    $   #( 1L !0    $   #0 2@
M P    $  @   3$  @   !X   #8 3(  @   !0   #V 3L  @    \   $*
MG)T  0   !X   $9ZAP !P  " P   $WAVD !     $   E$   1[  (  @
M"  0+P(  "<0 ! O @  )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$Y.C V.C V(#$Q.C$R.C0U $1R;W)Y+"!*87-O;B!, $0 <@!O '(
M>0 L "  2@!A ', ;P!N "  3    !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                   )D   !P    0P,C(QD ,  @   !0   FVD 0  @
M !0   G*DI$  @    ,U,@  DI(  @    ,U,@  H $  P    '__P  H (
M!     $   )UH , !     $   $(ZAP !P  " P   G>     #(P,3DZ,#8Z
M,#4@,C(Z-#0Z-3$ ,C Q.3HP-CHP-2 R,CHT-#HU,0 <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                  8! P #     0 &   !&@ %
M 0  $CH!&P %     0  $D(!*  #     0 "   " 0 $     0  $DH" @ $
M     0              2     $   !(     3A"24T#_0      "
M    _^$23$U- "H    (  \!   #     0*'   ! 0 #     0$C   ! @ #
M     P   ,(!!@ #     0 "   !$@ #     0     !%0 #     0 #   !
M&@ %     0   ,@!&P %     0   - !*  #     0 "   !,0 "    '@
M -@!,@ "    %    /8!.P "    #P   0J<G0 !    '@   1GJ'  '   (
M#    3>':0 $     0  "40  !'L  @ "  (   #P     $   /      4%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#8Z,#8@,3$Z,3(Z
M-#4 1')O<GDL($IA<V]N($P 1 !R &\ <@!Y "P ( !* &$ <P!O &X ( !,
M    '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      F0   '
M    !# R,C&0 P "    %   ";:0!  "    %   "<J2D0 "     S4R  "2
MD@ "     S4R  "@ 0 #     ?__  "@ @ $     0   G6@ P $     0
M 0CJ'  '   (#   "=X     ,C Q.3HP-CHP-2 R,CHT-#HU,0 R,#$Y.C V
M.C U(#(R.C0T.C4Q !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M        !@$#  ,    !  8   $:  4    !   2.@$;  4    !   20@$H
M  ,    !  (   (!  0    !   22@("  0    !              /
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
M[P(Y P$1  (1 0,1 ?_$ !X  0  !P$! 0             ! @0%!@<( PD*
M_\0 ;Q    8! @,#!P0)"PP+# L  0(#! 4&!P 1"!(A$Q0Q"146(D%181<8
M<9$C,E)7@9?2U? 9)"9"5EB6H;'!TR4G-#<X57)WE-'A\2@S1E-B9&>2MM37
M-39$1TAF=H:'DZ/60V5U@H.BI;*TP\7_Q  = 0$! 0 " P$!
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MU5^-L,#67\FV;3]C1F%X&*44.#J50@VS5S,+M$B[D51CDGC072BFP("Z;AN
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MZ00G)&Q0+M-.SUF=&#CYI^B\A9M^XBEW#4=%7CHVC6?[#J_*(1J!P<C.V;9
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ME !$3&$"@   B(B([    "(^X $? -(0YR;;\P '3Q';[8>4OCM]L;8 ]XB
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M,(.8Q52Z#6G"5-:O;-9<XQ[9U#2-SJ%HL,<5Y7D\:.5%X^/D*9,-G\TC+IL
MK#^,L;)M(2+A2 :T[I_*/'(]US\^9RA>X8<O$<.TWR.5XU>YX]E\@2E3R(@A
M%5@U7K_%)!6;'<#GFUQE%OR-#K5&G:Y/LK/(XUIL\R4%O(/G]>GG.-D96/.L
M]3:N7$<*;H^@V3[QT<<3?,_+E<F)D22" ;9WY,V3#3)NJ-N2'E"IR$EW\2PQ
MCB:7IU<-CADK8W/% Y=6]PA=)ZE5LPOJVKA>1!Q)5QA;D;58P/<7)6\.Q(>;
MEHN6?ECDH$W[>T9WY9,#?B-#&G&KYL_'7/)KNW",>_5-["K*L(>+PGCF3(]<
M0$4H^:\24<D0)RS9-F<4Q;%%&1Q1%]NV7G(IM*G>""!/15XZD1!J]9L8V7NY
MJ2VNMN/.W'O$9*K$#+5NZW8';@]PSQYV[R@#2YP==H43#5>,F<S8]R:W<O:+
MFVSN+WC6\P$+D"/:&CE8?%%>9NF$C,TMP2HSH7JI6A^H9([*L- 0.B%W>+ #
MQ&?&S99<\[QG>[3=N()MPO\ N&D=+<*7$':\IXFD?.L!6V%LQ[1\?.DYA]DY
M6P5>X!8:"PFVCVV7%&JK.*K9VRZ)TL@PZ+&\I5B06_6%GN+8Z3U6%LS<%Q8"
MW#-\WT9\XTQRR/6;@9BW#)KGAI&(<7UZM4 MC[N]XF*,U/C_ "-<XX*?:Y!J
MPL^4*XE53TJGJ6%NG#R=FB7R;VQ.BP"Z+9C8DFB9)"+=HH)-D@8Y]7#/ED,[
M7OI<EX03?YOPS([;MW 1:.*K/EZK+?!T;7OE"B6[N]8E?Y&L]"I4[;(QX]D[
MU 0DGB5[(P3!^PKSQ8SQ[(34?(N&\NX8(QU>:-3)SSQW'0<0SG(9&P/OU-A:
MU\MZ]_#KY]SGN$=8<0\]&J</N79QA:7$,$11[.]:V&OV9U7'\1+1<<X4;G1L
M$0\9O8R1:/R)D$J#I%RW<I@F/(J :B;'3@7X:\O.L+/W:>][Y6RM=[Y:%R1?
MADL'<.+)UDM]7HJ_2V,F65;I7[:M"61E6Y3&MIG$'2UNC'K6;KZ5SR-!5.H.
M[&T>1KX1L#EJD_[TLHF>@,3;C=LKV8-F/+7AIFXUT)MUOEQYZ&VTN'VY2]\X
M=JN\M%G/&6]S0U33,\9]$A88]EO),X"[2"3UEYN8R;N#9L;2121BE(Q=VH8R
MJ0M 5$\+!7;S;MUO[N,#<=>7P.?=EIEG'.U9R*K \.O$E8\79ID;W"MUK9,X
M2EK#>5\C7.$K3.M(I2DHWL$^]G+//L6\I&66Y5<EADIQR>)(T7%,M9=,6&CA
MP>_K')NS)N%@\0:Y7R=LBP[3[W#YQN?A1NAI$N6Z<I<9"ZUNI96""Q59K1;U
M;C8+)75\38KNMF;A8)-1:3M*=4O]JM<2>26DYD(UNBA ><D_,P,6@MIU%K96
ML>8//F.$N;!]&)OGF]N3$<7#G*-4XCSI<+/QA9=KEJ^42HTU'$E/E:O2[O4[
M#5:M756>2K]6_.[6PS,0UC9)[D%JT9RIY!/O"92FCZ97W[I*H2$E)Z(]G,&^
M8S-O?\'.<0%CD;"X[N]^KD;1)PM9$MLUD"S)O[9-W9G-X>C\B9%2L=ED'L7C
M3)A,EWR&]&H]B873*@,I2NQRB)JLP9)HLD:8VE$&#=R^EWLI"6L6L^7,<WS>
M]]"[N( 9,^=[CM/&W#,$@B-0O?*=/3IO6U?Q=C&PN6UVM584DH_B#DHFNK1]
M=Q4]RFC<(F3MF"89Y,PJC*-E(>173K)4&\@DS5B'-C!R/8'''1K@_"]^NV61
MB@'AJXNUV/9ER8N,B(RJ@<5;O.O$]@YO"E3K%'F*?E>,<PI<J/7[VU2D?"8Q
MG"*6'%I8=I$QS>&/89%"LV=1_-2,R@:2( 0[9N1!W@YG47TTOU>=(UH+'33A
MUY=IXM'U;TC4-(0TA$IS<H .PCN8I>GLYA -_H#?<=(1QYG_ ";8JU=8MBQ[
M1&!I6'\HYWDH<; O3F]^F,=JP+: J4S<&[*57AJ<DM*+O;6FWA9,[XR\&D^:
MO8)*8AYDS]_B8ARZPYST9\L_CE',LGY2"=@'4,2P\/Y5VKK#ZN99=W2<AV2V
MHQ<:XQK9,F0;-I)KX>KM=DDG)()C4K!)NK'$J0-AFD.Z0U@@F,A+I:W3PU([
MG^49<=3W+N>&7,/UALHO5JXX<M59*1(C@O#=CDX/$N5,M.TX;BP/)1,E7L6L
M4Y9TWJSNNX'FW,HO.LE$TH49F#KDJDH@J2:BHM$S=RZC'AJW;%<9/9M+6#Y>
MZU^'+#,H\>$X$7? H%7I#BUTI?.%?J$XEG63?PKX:3C^HVN(M#ZJ1V/6\=-J
MS$'<5%B0+DKJ/K]F@U&+*2F6:WG5M=U7 \,O/#YP)#%R-7N>T.W,!FM=LHMB
MGE,+E'.YF)G,)XN?C7Y.SPKZ=A.)YJ\A9->D56KVZ:DXTCO$$3(&9.(6?.V:
MF4BVJ[JS-DH1JP7C%GU@C]A)'(CD'?GU'3M?AAP>!).KL,F Z^-M8R&Q^4LE
M(ZT6F*KF#6LU7J]+,(>-GYO),C4$I-XM:ZK4G!';I_BIS5V!I)2TKSU3<0MS
MLK21KM>D5+"6G/UXEA*S<['[.S,Y<,R=8%5[Z'K[K6N.K_1C;?#MQ67S-N6;
M&RD*UCR Q\UP52+RVBX')3VT6MO<1OF9ZA;0B ''5:1M,&H\HJ##ME)")/"(
M,(28-%K/+B\BJT*6##-]06NW%QY:*_*U[.S,YR#&^77=LA&,J\>EI/#PT@UQ
M1C1%Y=9"P&H7G_B.C(FOO(6M5N4L$FQN\XAC*5D<?Y%$T6,;'T=_5IB+?G6=
MKHWXGFQV@#=^TM[@,^PMQ$''(C0$Z?"W$$Z.=-82_E-[&Q-.+-<"5(64;5;'
M8V?I!Q!-ZY8%DJMC"(RX_93D*3%,DZKDFG6Y!Y"J,61IIPWR"U0@T4%X%S(V
MV%;N9U<9\R+,_OXCG$WLAEGEVWL#WCGI%+G'CFL,]3,V5B.JT51HMA'V%K4,
MEU#.#E6XI=EBJC9CJUM/6VM7J4E6HJ4AKI%QLJ[;V=RT93:;J+CUKBP=.5R:
M0@D\>+V%BW:QXZ$9- EW<,--<P_-GL;<^9BMR#Y07)BLK<:5C/%\.R"C7*J5
M@,DW2YV6'AY%J2SU2 L3R4*.)9>"BVTX,G)/:?,PMBO#>0K:2,Q-LX"1>)PJ
M$$OC>SM;+/O;3M!RB[SVS>V?D<;ZY;ND3R?E%7]S@;]"-L.O:BZ</C4VCV.:
MR18*)$+*23:^J3#BQ7)7&,>]I%KA&%'3DH*.JA+E"SCR=KC%.]LEW$DK#"@I
ML6&O$,-1IJ7?L$-[,]7)[FQR8@:CA<FT=98>S&C&<'M2RO*R[B^R%5Q#'6RS
MD2G G[$^=,X49(2OI$%'SM61>)&(=P]>F=F.E^N00= J(FRWM'1R0_7W]@S/
M$0<,,M"QZVM[S[C>.4[%Y2NVU9LL+S"&-WR[&!R#:WKZ*XE4W-5=0U"H$5D]
MT:KV <,MU+6\DJY(^9RQQ(&+=QM[15@7?+#IN+<UA!?[=,A9W@".[5K<6R#\
MK=5XRZ5\H99&5ZR-#L\+U%Q1**Z@6;2^R>:)EF1VM:+)3ZK%R5B9L\)S$!7*
MQ%/K:E.6^>A;K=5:K4X]S)O(MU++M($S=4-/=&MX:%R?/!N>1X-D(Q6T>4!E
M:_($FEL1UMS98: ED58E#B8DFE=G3L<LP^/GZE4,ZQFWKMJB7(S3&9KUPEXN
M ?KH-I2->HP:#4[IV*%#3D[AKY:Z^^T1QIK>[\1S<L.PMFP:,LBN/ZV3EHQK
M38'#-$EIFW6V\4VX+H9QE5H2HK4+,-MQ3)R<1)QV')!M+PCY*FN+1!+V@,>'
ME&$E'1\>$B^4>JH1CPZ_/'4^X"#\[$GCY(.60>]G);Z=H$$HI@)@ I4R<I"@
M<HB()@0PCRG!+LP#8"I=ERE,43\W.80)(T.J_'C\NKXNU;I%AI"&D(:0AI"&
MD(:0AI"&D(:0AI"&D(D,H4H\H[[[ /VHB&PCMN(@&P  [<P[^J @)M@$-(C^
M>UO/9$"JD,(@',&P!U$A@ 1W. @ B&PF#D$3%#J4!*(]#!I!_AX^7ZHB*A \
M3>T \!\1'8 \/$1'8-(./!_/GX1+VR?7UO#QZ#ZO01];W?A]H@'B.D'\L?/S
MT@"R8B8.8 $AN4=^G7V;;^(#U !#H(@8/VH[(.//GNXZ1,*A Z;]=M]MAWVW
MV =OB/A[](../F_RB0CA(X )#\Q3<O*8 '8W,4#EY>G41*(#L'4-PW#KI\8/
MIYXMP@"Z0B( ;[CV#U _VI@';82CL;<? !*8!VY1T@X=M8F!4@\O40YMMA$!
M !$3<H!OX;B/@'B(=?#2*_RB';I<ISB8 *F!A.([ARE( B8WT  "._M -PTA
M %B"?DW$#=?$H@&X&$NVX_MAVYBAXF*(&#<!WT@_RCT 0$-P'</?I"(Z0AI"
M&D(:0AI"&D(:0C&I>GUB==QS^9KT%+/HDJQ8M]*0\?(/8WO"8I+^;W3I!1=E
MVZ9C$<=W43[8@B4^X:1&YMU=;Y]_?&/+8EQHY%X+G'=#.:08M(Q^<:G!*&?Q
MC!%!LQC7PJ1XB[9Q[9FS;LD' J-FZ#9!%%LDD@D0$&X^<NPY<.R)7>),6.%U
M)!YC>@NGIBM ,[=4ZON%_P!8MA9-/LIXXRPBW9G,S;F$QA0:B#9+D0*"8(C
M79^)L][>?<28Y4D+SP\09LMQI^&\JM@Q=E"O8D1J#+'N&U9:_P!KR)5Z?+5\
MM%$+,V@AB[3!VB)47<7><IJ[1FVDPL;>,9Q3D$:,_?I\^6GSC)L&YM9GOR%L
MGS^,7J4M/#O%8]JF3H/!L?:G.47R-+KE(JN.,<M[W8Y(C.<G+!5W);"_@:JF
M>L0U*M,Q:32UP90A(VH2:D4]DG18EM(ZOD_,/<N;6:^KAGOS>%F< GBUK9_
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M_)I9(%DOCE,&T2\B(Q5Y'NWSWM^V+=^S-;[.;ZW^<3=U>_<Y?EE9QVQL#%/
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MDG*C5P]3E:@$Q('@7!GBQX%S*2 1:S8[E<YGGY=\,^O@]M!IP;A8Y12O^'_
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MG)\\@7Y>6^<.FE#.8GM4(G#BHX80W_V1."=]N41'+=!$1*&X@41&?W$ $3;
M(CL(CMXZWT<S\Q;9_5/"'32?TB/VA$ XI>&$-Q#B)P7ML)1*&7*"!>7KZO*$
M\   ;CUV 1Z (B!0 )N+_-5^R?E$Z:2?\HB_^D.3>X<(I#<5?#,!MPXAL%
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M:DS-$96.6ODY9&]([@&-Z[)V%O+J239U,3EER)E)ZD$6S;-I52&3CV#= '[
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MP &V)U(JF2F8I.*!/M7,[$_:4&L_2L"/S6?(FQML5=<HMOL E1_(!T8DE*2
M"XR#D<#'J9DRYMO,S$/<'<FX^S<.O=R_SC\1UTAB(!$O_M)Q;^^,1&9Y3.'&
M-&;6.3TI#Z;R?D#%!SUXCE1JLG!)N4EFJ2S4Y8XBJ)W:9C,DC(*%[R59YRF,
MD0PAWKE$[7LB%, ]M$M<Y(6)>*;BDD@]/B000'! /2^T;^TRN0*8XS4UH/\
M=2X(!ND@6]FQ!5<YW&\6*"BX-R"/8  ;QT> @'7]8,]P';KX)#U]_4?I'6O6
MJE'L"KJAN>R$FIGN&LQWIF\XRNY?.\9,^=?>*W_*<ZZO8ZO 6##J(1L>([#L
M ,&FYA]P;(".XCT#8!'?V#HJJJBDO5U2TD%PFIG[Q&1  F%3G(;KGA#UB=9E
M+!T+Y'0Y:<^K**%,L*N[<L4&<,J[:E*9RS309*NFA#G5*FJY03!15,BITU4P
MYTTPYFX@ [\P#P&8H)"RC$@A1*4J-1B+**0Z@#TK$@*3U.DD,8UT]<5$"<1D
M1=+L7()S<$ @6'U7L'BN+&L0\8ED&P ( +%L!N4=P!0P"CN!3#ZH#X#[/>%1
M4+!>4K$)*F9*USZ[=YOTDW=OD'&>@>*9U20\R:I2<KE+:$*-K.='X1Z>;H[<
MH>;H\NYBAMYN:F$1$P;\FR6PFVWV$>FW,.V^PEYQ55=AZ[5/D?IYV?)IG$MP
MMWX,Z8_UN69)#\K-J2^CZQ+YO8>)8V/V]8/[!9^)3F#KLD(;[ 'J^SW;ZBJJ
MO#='652LW_&IHZG]OS?MHGJ-U*58\3W..]C;OCQ.WBDE44%6L0DJY,)6Z:C5
MB114X=1*FD8"JN>FWV)N4JA.IC*"'JAD5.*D$BIK&#.14SB$NP2_MC,D "U[
M.Y:!G7 WE.7&9/'1P_4D C-]VT>OFYD)MRQD>/0H=6+8Y0,)P =^5NF!>7KU
M%00#V]0$1XO6L65/"4UE2S#_ #F8H/O7:X.3V*FY1H3BUE&[L"5%M'9AD-22
M+W$>2*,*Z*L=FA#NTT7"[90[=&/6!-9$=ED3BFB8"J(EV.(;\P <.?7-4S<8
M0A_6JM.H)GS XO<!19N!R(U.D1/<GVR?:*2R@UB7!S9LP>IXG*PCM@$(Z/#<
M $/U@TWZA[^QUE%96;B"NLJM[=3O$U,T>TU\E@9OE$5/FN0"HI>V>7=?KUB/
MF^/_ +W1W^0-/Z'6_7*K6LJA_P")G?VD3UB:;NH]K_"'F^/_ +W1W^0-/Z'3
MURK_ %NJ_I,[_GAT\WBOO/RAYOC_ .]T=_D#3^AT]<J_UNJ_I,[J_/AZQ-XJ
M[]<^';$>X1_][H__ "!I_0Z>MU?ZW5?TB=_SPZ>;_I/QS^'?QC8^"FC)'B2X
M;%DF;-%0F8&VRB+5NB?E/1;T0Y!,FF4QB' 0YR#N0VQ1, B4HA]S] U7/.TM
M<F9.G34JHI7LS)JY@#3P7 65"]Q9H]JV2J%_=!<M3M,E@,;BQ)U&GG./TO\
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MLDDDD<.Y,QC8.57875R:?9"9+G'<GRD8<J9(]9%.I51*&Z60)"SO;JUJ6&
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M9GMG?2*Z.R'-SF.LUSKVU]BYCT:Z_@G,&[DV#2$5D*VP<%C85)51=TV09/\
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M-<IQZRC=N?J4^&XC/II\^?@F#2\7DIW</3TN$JDS))Z289DQ'2FGEK1-$M"
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M$?,8:L(:0B<@ /-S"  !1,(B(   &PB(B(AL !U$? H (F]4!$(4[P(Y$W(
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M\BI68'!$.YBWI Q2?)E]+A<Z33SJ.5-I2M-.@+Z62G<FA!+=!,!WY80D64@
ML'CKKJ5ST7F("BR9@&\!O ^VE!U(WDOFQL0S/T8*93]FF0@$(4H@BF [\Q6X
M&3$$NHBJ!.R,4>SY^I#!N(E'7S):E5JBM992B5,[7!)(%R]W%G+CJCKD%)#
MG>)(R!(!8L[[UP<C<@M$-8C4-(0TA&R,$_W2G#1T_P#'*R]F_P#N(O7U?Z-?
M;_0'_CLC_<?^N/8=F"V*RO\ 97[H_3%L7[K^(=?O&/J\5VD(:0AI"&D(:0AI
M"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(
M:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI")3'*40 1V$0,(=!Z@7;?J ;
M;[#OMON( 80 0*800C6^3LGU'%U<-8+4^43(NX3CH2(CT32-@M$\[(H$;7:S
M!H#WN>FY)0 !I&M ,)TP4<N#(,T%W"2)GQRY,7[W;NC3%0Q9;LGV*(RGG5!!
MF>$?)S&.<1(N4I2)HKQ,>T8V*TNP[1G8K\B0_.W5(16(JYE#!"%%Z'G#2#>3
M?OZKV\8ZK(42%$N_,(%*&X%Y0$=OVI2]"@'@4.O*&P"(^(XU7Q8>Z(=.L<N[
MY1\GO*H"/FWAJV^^A</K^2NW;;_IN.OB_IZ_^'E;_OY'N5E'K&UG]X2N'3_^
MA7VQ\KM?@H1\PAI"&D(U[DJ%L,] LF-:._(\+881T]&-L;BKNC0[9V"DJD61
M;@)E <-.T;]T. E4,J54IDUD$E4_9MDZ^@P[%%5&)*G)IS23I0,B0)Z^D4J6
M4>P5)8#=)W@;$ $$$B.:0N2B8%3@Z&(:^=N')]1'/J>.,Z^CYVSAS,N)8(4K
M#M5LO3ZH*OUH>7C#O>U%<IRIM5581<%!/W]T$:"RZ[B07>.G?TQ6U^R2E)49
MN(!EA2@C"I:0IE;S$"8P!4_L@;H!W0-P!([?34+GV%-UKYD?E#E;@.V,V:TC
M([B[QMDGC2;QDPM[&;00=9!G%%6J"[*4;ORMD&\J#$64=V\:W18=@W1?-F9A
M[@FJLNJKXZMVNV829:9,W$F5+4A3X7*4PW]^Q))"E%2@)@*5I3[(5N  14RC
M)&XG=W?K>TKJ#.I087]YO>++:J1F)[:9Y[ K32$6:R3$I &1R?*,VB;5Q&4Y
MI'HN(P3<R;(KZ)L;X\:FJ"9498&"G;M5W26N2FVJV5*$A:J\LC<6^&I=7MS2
M5.9ME +";7W0D@@I!CA5/I0K*SZ*)[+'37*YM86C-T#),NSKR)8]\A/1DO8Y
M23L2V291T91U(52?B(IU7$5!4/7"D>R[<KMM'"T[PW:$*N8Z)"ICB9MCL0B:
MJ1-^[!5T:4%2,(2I!1OR9X2HIG)Z4;\M'URICP8".=$RE4@*]G6Y6H&UM56#
M.;!G\*)W1,TR1F!W22G(TLL)-LD'.07TDC&'B;VVL2KAZV?I.4;(4\:1$(IM
M)F4&"?QJ2T:9 RP')WZ3:KT>(!41C*%*E]$M2<%2@J0)9E$6GIW-Y*U!90QF
M@M,WAF$VC!=@2[AU;S%WU400&L#UQ<U(?(=1P]+,;),6^6LZEQICE@I V&R/
M98Q?2.#3F.QF(Y]*RR#-^@F\571D1=LV:#E0J;-)-,":\=+QC9W$-II)EA!D
M=!,2DU$N7)>0),S="T+4E$N?NV"D_2])=*MXO&34TP2^ZK=WP/9*B'R =).9
M%DGE9S$C3'67F:IE$92>*]0G*XXBE'.6+$]9LH=M)3#E^V<QZSU9M(.&<:]B
M(I8S@ARR9(CO!0(Z6!R7R"]I=G:3%9M/*$GVT5 FF73RT'Z5,M21TJ%!6[93
M!]U ("0$V@BIHWWMQ6Z5)2Y4NX=LMX <"1?,Z164_'V3V,[6WUID)I2*8+M7
M$XW2R;.NT5YA"NE8RLN+0':2KB*FII&/>,Z\+@K6(;,G"!$@0>BW#P6(8_@(
MPC%_5DR%3!TDI"S224[J$K0D(.>_,2DG?JCO39KI)45)28ZU0:5<].XA845;
MR1OS<KLWMGV;)&Z"P L&L9;5B^YVF:R9- $>FVD; XFJ-"F=L"K/'#_'=9Q]
M(OI6> O?&A#-J]WGS0JW=,%BG:&4(91$R1.S1[=8/2X'A%(5JZ,25"<6/L*Z
M91W4NLE:1O ;P9U EMU0([DJM1N*IP@ABX+DGBSFY< V+7-^(S*+J5\6GY^X
M"[B,?2DK7:U5ACF0I64TT2";RW++33QJK"H&?F5F$(9@H=)V*,-&'3<$YG:2
MC7IXMM;L_/%,DIF5"9:IJPZE2$I5,,I]P%:RITH*2DEB5/H7ZBEDK4I(2G\D
MDWLY>P S?=&8(S#/NV"H1]VA)5M,Q=)CUFS>AL*<_-*S+9DZ3G(>SRKJ9EG#
M7N#EV\8NU9%-4BS=SVSLBBH'[8@E(3N8EB6 5E+0 U*4*I^EF[J'F"8F:F3N
MLKI04J2$"6=Y("7-@Y>S9DM2):4I]H!07O,&&\ES=[/J-#S,7B"K]E6G:=.,
MH8C6N,KA?)@J+MXG'/8:'L2 -61FL6*9CJ JX(N[6;@Y2[5LN0# "@"(^'KL
M9PL29J!/49OJ\@!*=^:B=,2^]O3"L;NXDABQ%BA);+KC=)3[.I.MDD$,!_I=
M5P3J6C$LG8JO=@F[^[K:HBRM46*0)+6=9JQ?&4C&<:,<[AS$49BX17;A))3;
ME-=V@""#5JLDD*B2GF-G=K<"I,(ETE9,KY<Y$Z:2F32IJ$%"BDCZ0K!#AQNM
M;5WMY*154\J6I$P$DKWO:<EF  -P-#QLPSO%3Z'Y><2,J_DG$BX:2,L\>3L2
MTR)-M#65L[GI*2CT8Q]VYE*@2!8.V# Z$6=!O*C'J.'*:R[M957L5&UNRTP@
MA5?ORT%,J8<,EJW24^UOI,S=G;R]Y0Z0+*-X!! 2(X)TVFF*)"0+N661PR.\
M,M6SU>,6/CK-1W5X48'=PC2?F@D())ID:7!:,8%%DI*-716CIF22>V,I0;FD
MG*R3^.5CBO4GJ*[Y=13O)VTV6324LHS,269,F4@I5AR=UT)NSK(TR((.H)M&
MTSZ4)"6N$L;D7%LW#E]?'*+Q%X]RTW9D6<RUF4EB7>!D!%YD:3=1[JL1]?;(
M.F;N-+(&9H(^D!Y=^2,;%=-TN\,!:ID[J!D.E-VNV8F4]7*EKQ!)FTTZ5*3]
MSY:;J<H,R8E0*F9 *F"B')?VGIGTP26-U9^T>')5[@6R'4(ZDU\:CH0TA#2$
M;(P3_=)\-'3?^O*RZ^[]@]Z]^OM_H#_QV1_N/_7'L.S'^%97^ROW?./TP[C[
MQ^L=?O&/J\5^D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&
MD(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0
MCS55*D!3&WV,<I.@;CN;PZ:0C366<R1&-D8N,9QKZXY"LBRC:F8[@1(I8+"X
M2 !<.S<P@VAX"- Q335DE3MXN*0,<#N#NC(M'")GQ]W+KMYOEB.+L-3/I ?+
M>8WD=9\K/$UR0C)!-1Q5,3PK\.9:L4ANY-RB\5()4K); ;L9"RJD*)TF[!%N
MU*AII?/4<^#QTH0HEY@$1'<PB&X[[ .VP> >'L#KL'M]@(L1VZFZ^.W\GNUC
M\I8U('N^V(?B/ O'S!\I;1K_ '6%P4O0J';+X:K9$L$A/LJE&EE9&.C9*@66
M%:R*S/MT5!:&DW;9L)TQ.)3+D$2\NXA\T]*NS]7M1LM/P2BF2Y-1.F2I@FSM
MXR@$!0(/1A2W+AO9U>/$XSAL[$Z9$F3,1+4B9ODS IFW2G\E*CKPR<Q\OODC
MSR'_ ).V<OX"*_'_ (_\/TZZ_+/X!]LM#2GFT^XX_P!R[8^?'9K$@2.C=B18
M&['3KTA\D>>?WNV<OX"*_P#7]/P#[9_ZKW3_ .RB?>WB7Z(]WVP^2///7_8[
MYR#;_P Q%?#W_P!G=-/P#[9_ZKW3_P"RA][>)?HCW?;$!Q'GD?'AXSJ ;^)*
M,J41V^/?]]OATUE7H$VR6-TKER[OO255"%ODV]T61>X8Z6A][>)_H0?]I+CP
MB7Y(<[_O>\\[^[T)5 /_ .?[/HUC^+]M@/\ .Y_;45#^,KJ[XGWN8I^KR_V#
M\X?)!G8?MN'G//N#:DJ>SJ/B^W_3KJ'^#[M<<ZJ>6N'J*@^^5%^]O$_T$O\
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MBHE4%(=RF,8PB._+KF1Z"-L42T)"I!*&9Q/8-D K<WF>Y&IS@=F\7)NBUB
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M]?\ ?L'L\==C\ ^V?^J]T_\ LHOWMXE^B/=]L0^23/7LX=LY?P$4_P"OCI^
M?;/_ %7NG_V4/O;Q+]$>[[8C\D>>OWNV<OX"*_\ 7_P:?@'VS_U7NG_V4/O;
MQ+]$>[[8VI@'#>;S<1. Y.3PCE6MPM;R8E/ST]9:N,3#Q44VJ-M9'<NG:CQ3
MEYWD@R;ID*F8YU%R!L ;B'U'T3>BG:'9C:-6*XG,ID2)4D )2)V_,)7DC>EA
M+@7N1:/-X#@=92UPJ)XW$(2;$75O69.EBSN1VY1^B'F+]W_^577ZCCWZ*S2$
M-(13NG2+)LL[<JI(-VZ9UEUEE"(HHHIE$ZJJJJ@E3222(4QU%%#%(0A3&,8
M 1TA&L SOA+<0-F'%I-AV];(-2 0,'VQ! 9<!*<@B',4VQ@ 0';KI$!< Q-\
MNV$/OR8J_&'4?SOI%A\NV$/OR8J_&'4?SOI"'R[80^_)BK\8=1_.^D(?+MA#
M[\F*OQAU'\[Z0A\NV$/OR8J_&'4?SOI"'R[80^_)BK\8=1_.^D(?+MA#[\F*
MOQAU'\[Z0A\NV$/OR8J_&'4?SOI"'R[80^_)BK\8=1_.^D(?+MA#[\F*OQAU
M'\[Z0A\NV$/OR8J_&'4?SOI"'R[80^_)BK\8=1_.^D(R.O9 IEQ.[+3;75[>
M2/(W/(*5FQ1,\##O)U@;E>%BG3PS<SLC5X9EVH%*Y.R=$ Q12$=(C@>?/VZ:
MQF!3<Q0-L(<P;[#N AO[! 0 0'W@(=!Z:18FTA#2$-(0TA#2$-(1YJ*E2*8Q
MO I#']G4"@(F]O38 WW'8/CI V$:M#.V$^H*9AQ8F<HB4Y#Y!J93%,4=A 2F
MEBF#?Q+N ")1 =NND!$?EVPA]^3%7XPZC^=](0^7;"'WY,5?C#J/YWTA#Y=L
M(??DQ5^,.H_G?2$/EVPA]^3%7XPZC^=](0^7;"'WY,5?C#J/YWTA#Y=L(??D
MQ5^,.H_G?2$/EVPA]^3%7XPZC^=](0^7;"'WY,5?C#J/YWTA#Y=L(??DQ5^,
M.H_G?2$/EVPA]^3%7XPZC^=](0^7;"'WY,5?C#J/YWTA#Y=L(??DQ5^,.H_G
M?2$7^LY(H-T<NVE.NE2MCABF"SQ*LV6%GE6J(J%1*JX2BWKI1!,RINS ZI2%
MY@$-]]@T@"_GQ[=(S;2$2'.!"\P]>H!X@'B.WM$-_H#J/L =(1SSE;,TA#S+
M3&6*HAM=\R3#<'C2'6742K-+C#[I^EF2)5L4YX:"1$X*,(U ?/ME7)W&':K<
MRJI$9<>==#[^LG+G<,08;:4923M=DEG-URS9TDPN-^E4R%<.P*J*Z4%7XXIU
M&U8IT4L(IQ%;C3%12 @.Y!9_)JJO3HH&3/YZ^YOC>-Z))]D3EYC'$3&,)C"(
MB(F'?J(B(_#QV#P*!2@4H(L>ND(@ =1'W[:R =XG1OE"/$Z!%!];[7VEV\>N
M_B.^W7<?5Y=Q$!\0ZYF2D31NK2%#M'B"#XPB7LQ^YZ?X0[]/#WZQ]*S;@Y72
MS#+3AW0WDYN?V;=[@1#LS /V@==_VWP]NI]+^8GE=/RX-!T_Z7[)AV9AW]3\
M(F']/T#5^F_,'[2?^7J@Z>)/4DVZ_/SB/9F]I0VV^Z'IM^#_ %_'3Z:WL!@_
MY2?"W?\ 9<Z>*G_V?M[XAV9M_M/HZCTZ>W] ]NI],WU$VT*D\;M[/R[8.BUR
M_!NONRYNX:(<@_<>\/MA'P]OT:K3;>PGG=/+EUZ0=&I/[)OR'7$>0>OJ>'Q'
MK]'B/LT^E_,'>G/N^$7V7L5=J3[[1'LQ^X#V_MO9X#[/CJ?3?F)_:3;P^7"(
MZ>*OV3KVP[,>H<@=/^%_(.GTWZ-/[2?^7AYX'3Q5^R?G$O(/W'N]H^WV?S?3
MH.F_,2.I2?D,HOL\3KDGAYMQB;LQ^Y#VA]L/X?9^GX=/IOS$]Z<^[A$=/$_L
M_;$O(/W'CMMZP_5[? /Y-7Z;/<2?^)/>^[U0='%7:DWZO"W.)@3-]QM_]X0^
M/\^W\6GTWYB>3%//D/=!T\5?LGYQ#D'IZGCX>L/NW_3XZ?3'-">].3]6;=GN
M@Z>)_9U=N+?#G$>S$/VH>'W0^ :GTWZ-/>GY0=/$_L_;$.S-]Q\/MAV\-_J_
MGU?IM4#O3KGIV^'.#IXJ_9,1[,V_VOQWYA_3_7I]+^8'ZTY]WC!TYNK]D_.(
M=D;V%#_G#_HT^E_,3U.GWMUZ=T5TZ[W[)^V'9C]Q^#F'?K_JU/I;^PG5BZ>S
M3SRA[/$Z_D\.WNB/9F^Y#X>N.J\_\P:_E)U[._C$=/%7[)AV9AW]4/'KN8=_
M;_+OO_I\#SOS!R]I/RYGS>#HXJ_9/GB/W0[,0_:?48?H_G^K?3Z9_J!M;I?W
M7U^<'3Q5^P8AV9M_M?H'F'8-O#] T^F_, R_*2_4+?$<>4'1Q5S]F_/J[<K0
M[$3<H[ 02B!@ZG'<0Z;&*4Y.8H@([D-S%$=A$-RAK<O?OO);J*?@-//)8Y/V
MAO/GJB;NC;_>$_\ FAKDA%1I"&D(U/GK?Y#,SB F*(8HR(8#%$2F 0J$P("
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ME3#AXTC;55Z3+X[:6RWP#MVQ<LR2=:B9)J5=%0#' W(F80WGSY[8CVYZ#O\
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MY25[Z8OY,F3(AVZQ_4T:O#0:&%Y,23R-JQ.Z<%7<K9RA6,=9FT)'7F.MIFC
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MD6(&3(?;G(0VW4.8H&VZ@;IN [>L #]( /B&D(FY2@  !0V+MRAL&Q=O#8/
M-O9MX>S2$  "AL4  .H[   &XCN(]/>/4?CI".9ZSZW&/F\#=0+PS\+!B@/4
M"F-E/C$YA* ] $W9I\PAU'D)O]J79$U/4/>8Z9TBPTA#2$-(0TA#2$-(1:YD
MA/,TJ7D+R^;7_J\H<OK-5M^FVW7<=_?N._B.D(T9PAB)N$[A@,81,8W#QA43
M&$1$1$<;5H1$1'J(B/41'J(]1TB#7SH/W]L=#<H=>@=?'H'7?QW]_@'U:18;
M '@ =>GA](_RB/UC[](1**:9@ #)D$ Z@ E*( (E$@B "'M*(E_P1$/#II")
M%R_8CF(F0ZB95#I%-RA]D[,Y0V,8! @G QDQ/MT*<V^X"("A'RIA>/7($1=1
M5R/BU1ACY^R*B8*[(1\F\J+YGD?(E*.^=R)NR-.^?R4]EW.!;L6+EH<SMP+U
M5/L4S;W7.@/,\LS?4GBPYQDV [&U'S+9\3H8NM:\HFM98J6DT,"7F+AHRDGO
M"DO<)II3V2T*[?LH>OF9#;H.!=RB4U(2K%FDZ9-G1#BHY2C32SM!NB_NZ!JQ
M'CKQY6T<%WC!RRS R[ UA:UF/&QS!\X7RCDK9X]O(U?AMO,\NY@X:08LVMK@
M&S^1FY:&M<LA5FL6\CT)1.3<>AEC9-P>-&H+/$(Y+LTA>F*B*&UXGN\=<VC0
M/ 9D!WXN7UN'O>.ZL(Y6)F:F%O4="IQM8D7ATJI)(33&;:V:(;H($5FV2S%)
M(B+,)3O\:@13F.N6/%X4$TG!$R8(;5]>^-"WGS]D;@Y2]1V#<1W'H'4=@#<?
MCL !O[@ / -2+#8/<'AMX>SW?1\-(1 Q"& "F(4Q0W "F* @&Y1*.P"&W4IA
M*/\ P1$/ 1TA$>4NVW*&V^^VP;;@/-OMX;\WK;^_KXZ0CE-RFD?C5(DJ1,R"
MW"I) X(H!>R4*?*\>13MBCT,4R>Y#<VX"3<!Z:1->L'X?/7LUC$SH.^$^4[>
M/(X7X9Y-T3O;, 665P([6$H_U)1(DL<,3K+JJ">- RS>AG.H6/,VKVS6-0U]
MW,-EUN'\F.Q(M\A(H-W;9TF\;KM45T7""B:B"R3DI7"2I#)+K$,!T%$5""!C
ME%%5)1,XD4#=#[??Y?KBZZ18:0AI"&D(:0AI"&D(:0AI"&D(:0AI"/G_ .4?
MM,37< )M7LRI /YJ]4E&+DV=AQ_6)ANI&32<T\6A)#),[ 5U:4;1<=(+MFIE
MGRNY3&.P50,?2(>Y[>>H^^\?.V0XJ&,.G5D\4<1MLCH:.D9"6R.XG\N\&S*V
MY*CGMSISD[Q%9::G4D<EE9OY^)+S+-:Z>AP;UZ+2-F5X)-3F0 4WNSD<7#G+
MAJ>.0R:,'.UFM=KZ9Z=5K7#/&/QW'%>GD3DA>(XF)BQ(HK7& BDI#)G"E4I=
MI*_*+7RX^EZ8H_5,M,1$#3"VSY22R<3VD\S2B0J#M.16%X?6XGN#];D<F;2[
ML7TC+\^J[=[.=;7]P$353C>RX>6K;RQ<1A&B:T9!1T[&K9#X27T"TD'>++_%
MS4[R-KG'S#L&N2DL=2\>Q0>HD=)KSIMP9JH,&K=0-!F#?A;AR=P^8SO>N;74
M?)\@\.IHR=CQLY,"(@6GS@()P^&GNF]Q?KYDX6DGJJ['*$21:1J!5)HB3>[*
MXW<239@C,L%H)S)L%';MDS67;MBS=2UVR)L"&R.?'AW"T5RXSTSU<VMK;-FO
MG>+0CQG9687BM/5>)]G,TE!_%.FL2;(7"<"TM5G>5I9LV;Y%<%M+)TWM;;&2
MS=>S)5D&;15ZVBU8[N3H[YDIQLG3@,\AD'RYO<,?"-N+:OVW%_M[(Z/O_$1P
MY0V?,OVRWW##.=\>9QP[C_&\*UALO82D&]72JCZVFM]4LC.RWF)3CZ];7MG@
M)Y>8B5)GLGL*HDZ:BYBF0E![=X'-S<V-LQ[R+1";&V>>7"_:VAOJQ:.<\O<3
M$O8J[FJE,LY4)6$>5?+=0;U%GF'AME*", Z<0+3"*^)WP6Z&L_GZ(CS!Z>)7
M64[FY2;3#AHFD;S4BGH=EF.1&IT9^P:]9?![7RSZK.^AS<9=0,7>,XT,DOUF
M$>KQ*P[(T;)R"%5GI#*7"JT9SKPF1UE #,K!*R.U4*JYQV[C&T"M25&,HE--
MIQO)'7708*+0A(^P#E:]N;:]MZER]^\E[Y6[KVU[,MPAG^%5S+@;)F5>+XLN
MT)%\0U5GX:QYIX7VT+7P?6.L.L>JVB-K#]FJ:)L-=AE7!'L4\>2RE@B(=%0L
M='K2;9UG1AU'4$W9K==V[>.G87YVR/8QX7+==LHZUP;E+%.1N*>W/L4WZJRT
M62DRC!Q -KCB.>.YD/2HDBZLV.6%#LDG8'%=E7#D\I9):TH'=N%73 B3AH4W
M<@A#>>R_5PT@[OH78$MYXVS8OK'T@2 H)E GVNVY=P,&P&];;E-ZQ0#?H0=N
M0-B@!0  "1J/32$-(0TA#2$-(0TA#2$-(0TA&I\]?VC,S_XI\B_]#YC2$77$
M9BCBG&.P@/\ 6\I8]! >@UR- !^C<!#?X#I =;^<XV'I"&D(:0BG5*!]RF P
ME]41 !,&X;#ZI>7H/,("!RG]00V 0'2(6[>SN[;QSPCPC<++-_YY:\-> V\T
MHZ*_&9;X;QT29/)'[X"C]624K:SL[T22$@4'*RYU0(_?%Y]W"AC(,.'NN+?N
M9V^$J?"7PN-6LE%H<-/#^WC)YDG$S,8VPKCE)C+Q3>3-8V\3+-B5P4)".0GD
MFLZBR7*#9*=;$ER%[Z8# @V5K9WTRR'GCUX54."O$..I/)4]CA!QC^>R&W9Q
M3>:J52Q%%RV.Z>@>+%W0<<NAQ>KYHH\EYG;B^K4R6QM2J'</HT8Z4.D\21.#
M%^S33)OW/>T=45V':UZ'B8*.:E;1D/&LHJ/1*0J?=H]@V(V9-P(41 "H(I$2
MY"\I0$-R$(3U010&Y?'K]_O:+]I%AI"&D(:0CF:L=.,C. CT >&;A8 !'P$2
M93XQ1/M[^4%"<VW@!R;[;ANB:]@^.OGQCIG2+#2$-(0TA#2$-(0TA%MF?^Y$
MK_\ 9KX/K;*@'UCI"-$\(0@/";PP;#OMP\X6*/P,7&]:*8H^XQ3 )3!X@8!
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M83(QJO+L)N1JMHI\@Z4AYR-[R1P>)L+=.)M]?=&8NHV4;,YV%-RHRT',1$U
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M>B?^<Z?ZOQ'_ *6(_JO'!'^[3(_NW^0O,'\GH;]/M_S:GX+MMW_P.K^D4O\
M;?9RA_&"]%'\YQ_5^)?]+#]5XX)-O^_7(X=?O%Y@V#KUW_8;U^H-7\%^V_\
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M7KO.=.'DG"XA4A5:QKPWFM%-XGA9&])#:J22V;D-QOID_<&A8!1)S9N08O\
M/L.3F.#_ "RDY%2M.X=HYE(QSE['9B>/'3%M(-7#ULPEL7W,\6\=(I+*F;(R
M/<WZD<HKL5^BT4,U,KL<"?<_0,G_ -ME*=BBBGD6S]I(+Y-F--8_,7\+%+^C
MFA3F%XO2DG/=(E3<GS8)OP.\,DO'PW,)1,/)N8?\'8?B/3?Q_#L !^#]UI4&
M&\6]W+,#*V;7ZA'\MILJ:%J$E 4Y)3<@L&)R"K7;-B+V>/,!,)@*LT*X1$P
MHB<52E63$0YB&,38Y0,7<-R&Y@W]4=PU)B),R6M"I@.\@HW7%P1E8A_.L=-:
M*M:C)F4;R5J*9Q/2!)EFRCO;K)!!N7]G-XPEYCJHOG;MPM7$R@\<+KJI]]D>
M8IG:14'@)+]N19(KE$A"F A@  +ZOVPZ]?F;(;-U"E3*NBDSIQ2P6M4X%)WN
M"9Z0;D#(VCS]3M=M'-HY6'TR)DNA292*B4CZ5-7*IC+5(ES2J26$M<L3 4JW
ME'Z^\'!B;%V/S<Z@UX@&,+#FY9&7*(A'"@=J/+WX2<Z9FC414%/F.*!!/S&
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M43,X.9--\9N)U#$-S*\AU0,<_(J&VVO;4R9RUIJ52PM:$+ER]]]Y,M1!*?J
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M$M%8O<"=X"0KI<E**0UORTW;V@(M+B/1**JZ7*9!Z! *ERD,4 *(B!0#EY0
M#&$=]S 'L#V#WI4T)EI3N)"T)W%J8@J8;MR2"0PR8<+'+T^?A8]=F3Y$V8J3
M55"JN7+404RU35],Z F6R5%2LPI3&[DWCV8LHV#8]V%)$@F.4Q$^1,J90W%4
M"@4"$Y1*H/-RE#;?F -NNN&6A=0IZ82Y24)4@FZ4DJ.9*=ZS:Z\\CY*LJZ'!
M$31B0JJN;7U<FN4B0),ZJ/0R@E*$B>90*DD!G*AOL-X!FN!6K$Z93)IM"[<X
M@ ;@;F.'*H8=@ >R,!AV$OKC^VZ#KKK74*F)09B 4,RE%6Z"'NK-D'\EF.@U
MCS='2X-2R*G$9=!B!-?*W9XDRJ;IIT@JWD2)(= 57))>H1,6902'02<]57NP
M*13^)*=!B[AET9!)ZV[J=P]:I;)'%Z5/OR":R;<W,=5N)>V5*83D53Y#$/T<
M3QJ9A:Y3(ES%3Y%0M3[ZEM(2DJ(]M W-U8*B=X@-PC&![,;,8_5RJ+%:G:'"
M!(F(%#4T:L.IZ=<ZH4A4BB2J?+GE==53TB532PA*9LWV5*%HMU7RBBL->CGJ
M0'>I%:-"/(]HW;UY$JS=56*;.$%YQ:3[P>.0:K.>4QFX&7*F0P&3.!?'HQ^A
MJ4TAFKE[E8F6%S9!!ERUS.D5N+*E>S/2"=X,I+-[1<@>7Q79*HH*7$:W!Y\J
M55[)8E.JJC#=OU+E[1T]-32:>3.Q"7*PN1T**(SJA$I$Z;-E'I4STJ0!N+5%
MYF*/:J.(@E4GG*Z;YRR!0$8GL73I*:9Q+@S833A3=B60DXPH%%/F* % P;@!
MA5NT4F5,,R5AV-SY*&1TLF1(7+FI0G='1GITNUPZFNJVHCO8%LC6[]9AE17[
M+3JB52T^)&;)FURY&]BB55R4;ZZ<+*P&*V2!O(8+7946]'-12 J0U?>+"BL5
MJX[NBP(HR4<OU8^+(_ \X @JLZ14;H'8<YE!.)5Q(41'7CYFVU 61]Q=I@RO
M:'JM&$@"R@#ZW?>S.^-T$!@\<F#[%8W5>NUR,2V4_%4NAZG$4K*PDJ!(3262
ME)W4I2L*"5%U%[5E@R),HU^MV)DDWK:5A=JHD7L4<LOV+=2'D'Z(I(14P<?6
M1;&W+N.P*#KNXMB@PVED8C2T5+,142Y>[)K9:^FEJ*9:U=(B4M WR%JWRF8L
M;R/9LYCHX)A>)+7MK+VJVCVQQ"3AU!AM?A,K8:JIYU)TE57+1,DUB<5D!1IY
M"$(.[3A"D(1,WEJ0T8FUNEI<D5L\S$4I5M#/:J16(?0TJ$N0)5%OSE;3;B?6
M0[TQ74, ,P@FAE3>H59$QP.7P2,1QF=B-;1I1@"Y%#C.'TLZ;6"M%3)ESPB8
MM<A<N9N)G*EJ,RG,P)19!F@AW^B8C@TM4C!Z[#-H<=ID8ALSB=30T^Q=73"E
MQB1*F=%.H<:DU=+,]8DS9\OU.LE4LPE2.DEHF)+&,FG\DR4@I-2-55@MHN!C
MGTLY%!RH@<TO)$:]W:I(O4G2:C<%^=19P59N8Y#]0$2B'D\2QRJP4XA*E&BF
M(PZ0,1E%2ISF8N8F0H5)2M(,HH_)EE"MYG6 "D^E[([/5&T]?5+V]IIB*3$*
M.5LW3R,-0#4R?4IOKJ%RD8DA<I$U(7T:C](Z4*W9220L7^?NDI".DV!$(-4C
MMD\;"J1O(&4"9\W%DT#.$A=%YD562)^RW#8H[B4?8'GMY4A2%I5,$LTJZB7*
M0QJ@KHE35!6[]'T1F.0WM;A ))<QZS.Q>HQ!6(HK:;#\1)KL/HZ.=1I6N@]7
M$V50KZ<5"DK%5)EB4/H0J62E2MW\DSOKQ*1%-I]D.R 7+Q2!:G.Q:*%(*3TQ
M4Q20!X_02[/=,W4A@4 RFP%Y1,.NK.Q17W.H:HBHF2\1JI::B6@A2I,R;+5,
M8 J&Y9*O96N8Q2"0;QYO"-GJR=MIC6&4=!@-',V=V)KL7HZG$I-3(1/12XAA
MU/T>](0LK 36L%2I4D%"IB>D21[6"JYE54?1CY. =$8AYT[X@NU1+(M^5G&2
M97B"J<YW5)L9N[,FY%VFH!RBF"?(8IC#XFHVCZ.OH:-%)B53Z\9TN>N1*E+F
MR44DH*E%!5/2$]("H+)2O? MNLQ[>SNR.*8Q0*Q.HF>CZ6K9ZKKIM(53<711
M(F8FHRJT5PZ&:L,I"?5#)6@](F8)H42"#?+#P9MP5:O)NVPF;( NE&BD[8.'
M,ZI&-W#Y8]@[%TB)FQ% [D4H\@]""(#OA6TLV5B$V@&'8YN2D'<FBGD], "
M9:E"H"=P[Y)9"3O,'UC5#L1-VEK)^)TH]':*VF*E5,VM5B0PF<A*1[=*44L^
MHZ8D2]U4Q12$"8IMXL/:/S.U=LE0>5E^4HJ&>))L4H\B,BF+<TBJY(BYFSJF
M%ND K W5 !6$-]M@#>4FV\H5**,T.*>N5,R;325SY,AD"0%3'5NU6^E*I:5
M*2DD$,P#MUI6Q=#CI$NLK\%HJ;#,0JEUU)A<Z;+D5"MTR1.DIJ*18F*5/2%O
M,"$K006"G2;]$9@B7:C)J6&GTVKV04BFKQRE$$0$ V,4ZJ9910Q"N$.4X)&$
MWK_8]]M>3E;5RZ\B?(HJI"$KDTRT3)2 LSI_LH6G=J"DRTD;I5[)O9+VCQ])
ML)A6!;*XC75>,(J!15,NI2J342U$TTA2U3)($RD0$3%)!5NA2D.&WQ]8[929
MM";ND6HI)."@<$UB)<X)F !335*3F+S$*!0'8Y@Z; (AL(^S"JJF$HI=2&!*
M0OZPL2^\QN]V?JSCU>5@6S=2D8E+J%2TU2>GE2UKIQNRYP3,3+6.B*0L LI*
M5$>R;F\>J@-5@#F02 "[;;$*'VO:B41$=@$0%540';?8X@!MAUD3*L$ )()9
MV"\[.;'_ &<[6=H[*L/V:W#TE0DIE DH6JF(FCZQ0W1^T"Q#.E]X\;4IDV+E
M3D-L!N@;^KOX>WFW#PW#P'IXB.N1JU"GF35J27^NI1&;, PY@Y.Y%C'1FIV3
MK*3HZ+!Z:5, )3,E4U,""E*E )4F8KVKA3#K&44#VHQDB)4A325.)NT3*J1(
MX$.7E4,8GV$X[\J0;C\/#69E7*21OHES!<$%(4"YL[J&2F(;KTA0;+5$R1/5
M2IF485NJ3-E[THI]M)("TRU@$I*@7"@0;<1<$-TR>;@$>4.8H@(AT$"[="]
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ML%WY'<=XWZK/"2E.U%*$D$% P%DJ!S! JF(Y-$ 17V  <I;%'<-TTN4-^@[
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M@N+9"IM;6Q(ME$03= (&!VB!PW#?D3#;?Q ! V^_7W^T??K.]+UH)AZYW_\
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MTYSS;Z5QD#I[XZ%7L3B>'3)7W&P+9@]*YG^L5F)2RZ%(,L(W):G%U.^5CK:
M<2&,#>KZ0!R^ %"#L0;_ /Z>'\O^<.9.-83,_P OB(/.GD?"=S[8Y487MB@,
MK MC]W5L1Q5VRL],?? .(C%P[B6U+H^'V,D!.B4!V#<0$6 C[1]W3V:YCM+A
M$@B7,DU4]0=IJI:$J4%,6(3. MD+=L=&;L)M=BLPU4FOP_"92P$FAHITR93R
ME(&Z5(7/I5329A&^MRV\2 R6B7YQ.,#;[V]UL'_U!.^/7W1^K]]6#?J=1^PC
M^VCA5Z,]L98.YM#)M<C>#-Q_O/-VY^^/<O$5B?8-[:^$0#<1\P3@;[ /_$=_
M'I] :ZJ]J<*#GU2;<LD"6G/0'Z7@W)WO'E96Q&T00B6O& 2E++65@[Q%G %.
M&OED.31/\X[%'*.]H7,'0-AK\]RF =AV$ 8[[#OUVV'8>GNUP#:K!U*".@JT
ME9W=X2Y9().Z#><Q8^6CM?>AM8A)G2L1I)JY(Z1,F=.6F5,4@;Z9<Q2:4J3+
M60$K*05!))%VB4O$5B< ':;+T]\%8M^O@/1EMT'X^S;P\>\G&\/2FTVO8G23
M(LW_ .;E?*\<*=C=OL2/2?<K8W>+J(F8IBH4";FZ</(S.AN&RSB(\1V)NA?2
M)1';J!D8&P<P= Z !F.P[B'*._@'4.NVNK]\.%RYQ)%9-4Q!3,DR@DN.*9V8
MS#!G#6!C4[9G;D2QAU7)V>H*))25S\-KZV=/EJE@&6A$NHHD(*5EDK)42$W#
MF <1N*0, A:WAO#8#0$[]/L8AL.VWOZ?'IHK:K"@#O4L]@[[LJ7\9MP?#1XV
MG87:$#I$8Q+WGLE2RP[13%\FRN#H8G-Q'XI4VVM;LO+OMM7YSKX>]CX= Z#[
M!$-]<DG:G"9F\)5+/.Z!O;TM  %V;Z8OJ_9G'4&PFTU0J:F=C$I'1WEM-)LI
MW?\ %2/R0V44BG$3BX1#DMSD/ /^X$\'41$!_P# !ZAMT]_M]^NP=JL&0#TE
M'/N-$)X'_O\ KCQ=1Z/]L4CZ#:"6-[V25J&9<!FI+-GJ,XJFW$?BM-,"J6IR
M<1.8>8("=WV$/>+ .H;#MT^GWZZ,W:K!E3"J72U.Z$IL4(L02/TU\QGIEPCS
M>&;%;52<.":K&9,Z;TTU06)A!*%;FZ+4@%KF_;'DMQ%XH.([VMT7?V>C\[X^
M&_\ 8(^W?^7XCRHVNPD !--4/SEHRSS$[RT=!>P>TE1.(.+2D(+;H$QR20Q*
MGI3PT!/O@'$'A82E!2<54.)0$ZAX"P;G-MN8P@#, W,.XCTV\=O'775MO2)4
MI*9N(I2%$)0B5(9 !8)&]--AD'+QWT^C5&XCUC"\%JJC=!G54V?5B943&]N<
ML(0E(7,7O*5NI2')8,6$?G X3Z":9.(;!U]'Y_\ ZIO_ ">(]-3[^*7]8Q/_
M ,JG_M(U^#6F_D3 1D;3Z[Y:N[^$1#B"PEX!,J;=-_V/V#;Q]OZT]OAX?AU/
MOXI?UC$O_*D?VD:'HUIB;8)@1%A_=ZW4MP!\/E#YP6%-P_JRH/MW\PV#?;W]
M6?B/3P^/ATT^_BE_3XF.N53\N$SK\YP>C6G)_P "8#G^L5U@2S_5YCCD7B <
M0.$Q$=IDXA[O1^P>'L#^PP]H>_;Z-/OXI?UC$_\ RI']IKIPB?@VIOY$P'6_
M3US\K,WG2.LN G*>/+GQP<+<=59%5S()9*D%SIFBY)H3L"X^NQ3\RCU!(@]?
MM0*(FW]FW77R_P!,.T$G&M@\6D2YE4M4D2)Q]81+0D 3Y:"$E"EN25@$$,P)
M?0_=?X.FRLG9[TJX#4)P_#Z/ITUE,544VHF3%J-).6D+Z9DA*2@JWDW>S:Q^
1T#MB?'ZM?@CID<^Z/ZA1_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
